2021-01-18 17:49:44 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_comma/checkpoint_best.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out_fp32_best/nl_comma_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_comma', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_comma/checkpoint_best.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out_fp32_best/nl_comma_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-18 17:49:45 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-18 17:49:45 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-18 17:49:45 | INFO | fairseq_cli.generate | loading model(s) from /global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_comma/checkpoint_best.pt
2021-01-18 17:52:47 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.src
2021-01-18 17:52:47 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.label
2021-01-18 17:52:47 | INFO | fairseq.tasks.translation | ./postprocessed/en_comma test src-label 2024 examples
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise ; cardiovascular
H-1900	-0.538489043712616	▁voordelen ▁; ▁cardiovascular ▁system
D-1900	-0.538489043712616	voordelen ; cardiovascular system
P-1900	-1.4737 -0.4465 -0.9065 -0.1177 -0.1876 -0.0990
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse events
H-1988	-0.38882529735565186	
D-1988	-0.38882529735565186	
P-1988	-0.6713 -0.1063
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox proportional hazards models
H-712	-0.4549325406551361	▁co x ▁proportion al ▁hazard s
D-712	-0.4549325406551361	cox proportional hazards
P-712	-0.1843 -0.2144 -0.1141 -0.0240 -0.7356 -1.0042 -1.2111 -0.1517
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.7713203430175781	
D-1451	-0.7713203430175781	
P-1451	-1.3636 -0.1790
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.17637315392494202	▁EH
D-1528	-0.17637315392494202	EH
P-1528	-0.2596 -0.1290 -0.1406
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.5139263272285461	
D-664	-0.5139263272285461	
P-664	-0.8841 -0.1437
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.1138177439570427	
D-133	-0.1138177439570427	
P-133	-0.1654 -0.0623
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-0.7571090459823608	
D-1685	-0.7571090459823608	
P-1685	-1.3009 -0.2133
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.4516439437866211	
D-228	-0.4516439437866211	
P-228	-0.8356 -0.0677
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient ; hf
H-364	-0.5343111157417297	▁ HF
D-364	-0.5343111157417297	HF
P-364	-1.8166 -0.1044 -0.0831 -0.1332
S-949	No major complications occurred during follow-up.<unk>
T-949	complications ; follow-up
H-949	-0.258739709854126	▁follow - up
D-949	-0.258739709854126	follow-up
P-949	-0.8554 -0.2630 -0.0172 -0.0627 -0.0954
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting ; cell ; anand
H-1037	-0.14534711837768555	▁Cell ▁; ▁Anand
D-1037	-0.14534711837768555	Cell ; Anand
P-1037	-0.1436 -0.2505 -0.0006 -0.2646 -0.0675
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin ; injected
H-957	-0.23351147770881653	▁do xor ubi cin
D-957	-0.23351147770881653	doxorubicin
P-957	-0.4155 -0.0171 -0.0111 -0.1693 -0.6007 -0.1874
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors ; blood transfusions
H-1684	-1.1746675968170166	▁blood ▁trans fusion s
D-1684	-1.1746675968170166	blood transfusions
P-1684	-5.5118 -0.0740 -0.0300 -0.7269 -0.4209 -0.2846
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.20559358596801758	▁FM
D-18	-0.20559358596801758	FM
P-18	-0.3886 -0.1517 -0.0765
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse events
H-1916	-0.5587978363037109	
D-1916	-0.5587978363037109	
P-1916	-0.8862 -0.2314
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart failure
H-1066	-0.9009097218513489	▁devices ▁; ▁heart ▁failure
D-1066	-0.9009097218513489	devices ; heart failure
P-1066	-2.7866 -1.0214 -1.0881 -0.1423 -0.1786 -0.1884
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.6498180031776428	▁d XA
D-1496	-0.6498180031776428	dXA
P-1496	-0.3876 -0.1988 -1.8252 -0.1876
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver disease
H-233	-0.3707278072834015	▁Live r ▁disease ▁; ▁adults
D-233	-0.3707278072834015	Liver disease ; adults
P-233	-0.6360 -0.0733 -0.1349 -1.3164 -0.2431 -0.0820 -0.1094
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.6003484129905701	
D-307	-0.6003484129905701	
P-307	-1.0840 -0.1167
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf ; pna
H-1699	-0.5772765874862671	▁ HF ▁; ▁p NA
D-1699	-0.5772765874862671	HF ; pNA
P-1699	-1.5379 -0.2956 -0.2385 -0.2335 -1.5258 -0.1347 -0.0750
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise ; cardiovascular ; health
H-1897	-1.4479132890701294	
D-1897	-1.4479132890701294	
P-1897	-2.7246 -0.1712
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal artery stenosis
H-1592	-0.09840455651283264	▁Ren al ▁arter y ▁sten osis
D-1592	-0.09840455651283264	Renal artery stenosis
P-1592	-0.0675 -0.0438 -0.0260 -0.2135 -0.0112 -0.0180 -0.2844 -0.1227
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective cohort study
H-1712	-0.7107702493667603	▁Retro spec tive ▁co hor t
D-1712	-0.7107702493667603	Retrospective cohort
P-1712	-2.8575 -0.0488 -0.9733 -0.0523 -0.4768 -0.3743 -0.7521 -0.1510
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute care surgery ; heart transplant
H-1279	-1.1857616901397705	▁heart ▁transplant ▁recipient s
D-1279	-1.1857616901397705	heart transplant recipients
P-1279	-5.5529 -0.1845 -0.1041 -0.7678 -0.3282 -0.1770
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary end point ; inhospital ; mortality
H-190	-0.4021010994911194	▁in hospital ▁mortal ity
D-190	-0.4021010994911194	inhospital mortality
P-190	-0.9108 -0.0188 -0.1355 -0.9842 -0.1801 -0.1832
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.11774901300668716	▁molecular ▁mechanism
D-1607	-0.11774901300668716	molecular mechanism
P-1607	-0.2008 -0.0208 -0.1372 -0.1123
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.4810834228992462	▁tertia ry ▁refer ral ▁centre
D-1497	-0.4810834228992462	tertiary referral centre
P-1497	-1.7634 -0.5246 -0.1080 -0.0859 -0.5000 -0.2182 -0.1674
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.5241822004318237	▁no ▁production ▁; ▁ec
D-256	-0.5241822004318237	no production ; ec
P-256	-1.6306 -0.3033 -0.2872 -0.6503 -0.1993 -0.0746
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.31053534150123596	▁ HF
D-346	-0.31053534150123596	HF
P-346	-0.8559 -0.1627 -0.1205 -0.1031
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate models
H-241	-0.2660772502422333	
D-241	-0.2660772502422333	
P-241	-0.3789 -0.1533
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.09184309840202332	
D-1944	-0.09184309840202332	
P-1944	-0.1271 -0.0566
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.3375748097896576	
D-1982	-0.3375748097896576	
P-1982	-0.5473 -0.1279
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.9162808060646057	
D-589	-0.9162808060646057	
P-589	-1.7124 -0.1202
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic breathing ; heart beat
H-1345	-0.6379445791244507	▁breath ing ▁; ▁heart ▁beat
D-1345	-0.6379445791244507	breathing ; heart beat
P-1345	-1.7601 -0.1668 -0.5344 -1.6248 -0.0369 -0.2262 -0.1162
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.4404148459434509	
D-796	-0.4404148459434509	
P-796	-0.7049 -0.1760
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective cohort
H-211	-0.45731666684150696	▁Retro spec tive ▁co hor t
D-211	-0.45731666684150696	Retrospective cohort
P-211	-1.6078 -0.0390 -0.8210 -0.0430 -0.4254 -0.3817 -0.1545 -0.1861
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart failure ; latin america
H-1788	-0.6339327096939087	▁heart ▁failure ▁; ▁Latin ▁America
D-1788	-0.6339327096939087	heart failure ; Latin America
P-1788	-2.5417 -0.3089 -0.7242 -0.2412 -0.1868 -0.2248 -0.2100
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational cohort study
H-811	-0.6387675404548645	
D-811	-0.6387675404548645	
P-811	-1.1299 -0.1477
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.4199736416339874	
D-44	-0.4199736416339874	
P-44	-0.6870 -0.1530
S-422	Heart rate was minimally altered.<unk>
T-422	heart rate
H-422	-0.4006996750831604	▁Heart ▁rate
D-422	-0.4006996750831604	Heart rate
P-422	-0.4344 -0.5245 -0.4478 -0.1962
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.49696582555770874	
D-1846	-0.49696582555770874	
P-1846	-0.7931 -0.2008
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.48386502265930176	▁doctor s
D-1686	-0.48386502265930176	doctors
P-1686	-1.3881 -0.2523 -0.2277 -0.0673
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart failure
H-1356	-0.5519402027130127	▁nutrition ▁; ▁heart ▁failure
D-1356	-0.5519402027130127	nutrition ; heart failure
P-1356	-1.8553 -0.7059 -0.3532 -0.1482 -0.1339 -0.1151
S-1620	SETTING: Northwest United States.<unk>
T-1620	united states
H-1620	-0.7096946239471436	▁North west ▁United ▁States
D-1620	-0.7096946239471436	Northwest United States
P-1620	-3.4610 -0.0108 -0.4453 -0.0928 -0.1417 -0.1065
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.5488964319229126	
D-795	-0.5488964319229126	
P-795	-0.9359 -0.1618
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.11783719807863235	▁unilateral
D-1595	-0.11783719807863235	unilateral
P-1595	-0.0627 -0.1118 -0.1790
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.290241539478302	
D-363	-0.290241539478302	
P-363	-0.4866 -0.0939
S-1683	She is going into heart failure.<unk>
T-1683	heart failure
H-1683	-0.5017428398132324	▁heart ▁failure
D-1683	-0.5017428398132324	heart failure
P-1683	-1.3973 -0.3073 -0.1375 -0.1649
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.6912921071052551	▁INTER ven TIONS
D-798	-0.6912921071052551	INTERvenTIONS
P-798	-0.9769 -0.4445 -1.6741 -0.2813 -0.0797
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.22080110013484955	
D-1249	-0.22080110013484955	
P-1249	-0.2231 -0.2185
S-979	Heart failure in the young.<unk>
T-979	heart failure
H-979	-0.4614260494709015	▁Heart ▁failure
D-979	-0.4614260494709015	Heart failure
P-979	-0.3955 -0.2837 -1.0053 -0.1613
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.2551538348197937	
D-1687	-0.2551538348197937	
P-1687	-0.4201 -0.0902
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.23100773990154266	▁c lin
D-1246	-0.23100773990154266	clin
P-1246	-0.3471 -0.1519 -0.3444 -0.0807
S-1248	Sci.<unk>
T-1248	
H-1248	-0.4499596655368805	▁Sci
D-1248	-0.4499596655368805	Sci
P-1248	-0.2491 -0.9424 -0.1584
S-1247	Trans.<unk>
T-1247	
H-1247	-0.5122601389884949	▁trans
D-1247	-0.5122601389884949	trans
P-1247	-0.4386 -0.9832 -0.1150
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.30057892203330994	
D-1963	-0.30057892203330994	
P-1963	-0.4413 -0.1598
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.49686986207962036	▁CHF ▁treatment s
D-222	-0.49686986207962036	CHF treatments
P-222	-0.1531 -1.6952 -0.2313 -0.3224 -0.0824
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic balance
H-1375	-0.31012722849845886	▁autonomi c ▁balance
D-1375	-0.31012722849845886	autonomic balance
P-1375	-0.5888 -0.2704 -0.3079 -0.2043 -0.1792
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral growth
H-511	-0.8948425054550171	▁Dyna mic ▁; ▁competitive ▁col lateral ▁growth
D-511	-0.8948425054550171	Dynamic ; competitive collateral growth
P-511	-3.1021 -0.1213 -0.2947 -0.2666 -1.4780 -0.0107 -1.5229 -1.0772 -0.1801
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.22649328410625458	▁inter media te ▁fra il ty
D-1005	-0.22649328410625458	intermediate frailty
P-1005	-0.9040 -0.1880 -0.0748 -0.0249 -0.2179 -0.1724 -0.1296 -0.1004
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.42015910148620605	▁ HF p EF
D-1078	-0.42015910148620605	HFpEF
P-1078	-1.7114 -0.2172 -0.0247 -0.2455 -0.2476 -0.0745
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 ; functional capacity
H-702	-1.0754555463790894	▁functional ▁capacity
D-702	-1.0754555463790894	functional capacity
P-702	-2.7411 -1.2598 -0.1552 -0.1458
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end point
H-1763	-0.18415723741054535	
D-1763	-0.18415723741054535	
P-1763	-0.2750 -0.0933
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.3776931166648865	▁do d son ▁; ▁interest
D-205	-0.3776931166648865	dodson ; interest
P-205	-0.6815 -0.0257 -0.0108 -1.5340 -0.2234 -0.0956 -0.0729
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.4568459391593933	
D-392	-0.4568459391593933	
P-392	-0.7786 -0.1351
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv fibrosis
H-280	-0.37763845920562744	▁LV ▁fibro sis ▁; ▁ ANS ▁mi ce
D-280	-0.37763845920562744	LV fibrosis ; ANS mice
P-280	-0.1469 -0.0463 -0.0817 -0.5609 -1.5471 -0.0351 -0.8546 -0.2632 -0.1461 -0.0945
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.26374971866607666	
D-126	-0.26374971866607666	
P-126	-0.4006 -0.1269
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness ; anemia
H-1679	-1.0910507440567017	▁Jehovah ▁; ▁Wit ness ▁; ▁an emia
D-1679	-1.0910507440567017	Jehovah ; Witness ; anemia
P-1679	-0.0851 -3.9187 -0.7156 -1.4867 -0.7924 -2.0423 -0.5050 -0.1404 -0.1332
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient ; medical ; conditions
H-1688	-0.5399848818778992	▁in patient ▁medical ▁conditions
D-1688	-0.5399848818778992	inpatient medical conditions
P-1688	-0.4962 -0.0098 -0.8269 -1.5117 -0.1782 -0.2171
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient ; hospital ; heart failure
H-1960	-1.4181020259857178	▁heart ▁failure
D-1960	-1.4181020259857178	heart failure
P-1960	-5.1652 -0.2309 -0.1368 -0.1395
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended criteria cardiac transplantation
H-707	-0.25590434670448303	▁cardiac ▁transplant ation
D-707	-0.25590434670448303	cardiac transplantation
P-707	-0.3668 -0.1928 -0.3833 -0.2078 -0.1288
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated ; mixed linear models
H-325	-0.5211751461029053	▁co ▁; ▁mix ed ▁linear ▁models
D-325	-0.5211751461029053	co ; mixed linear models
P-325	-2.1139 -1.0082 -0.1911 -0.0250 -0.0414 -0.2594 -0.3553 -0.1750
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty ; hf
H-624	-0.5672968626022339	▁fra il ty ▁; ▁ HF
D-624	-0.5672968626022339	frailty ; HF
P-624	-1.4179 -0.2455 -0.1445 -0.3729 -0.9880 -0.1303 -1.0556 -0.1837
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary outcomes ; quality of life
H-1654	-0.5223510265350342	▁cognitive ▁function ▁; ▁quality
D-1654	-0.5223510265350342	cognitive function ; quality
P-1654	-0.2739 -0.1775 -1.0052 -0.1240 -1.3525 -0.2009
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart failure ; mortality
H-204	-0.2949381470680237	▁Heart ▁failure ▁; ▁cognitive ▁im pair ment ▁; ▁mortal ity
D-204	-0.2949381470680237	Heart failure ; cognitive impairment ; mortality
P-204	-0.2943 -0.0499 -0.2010 -0.0215 -0.1839 -0.0086 -0.3546 -0.8896 -0.6369 -0.6877 -0.0974 -0.1139
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf ; hf
H-1309	-0.9391068816184998	▁con current ▁ HF ▁; ▁ HF
D-1309	-0.9391068816184998	concurrent HF ; HF
P-1309	-3.2004 -0.0048 -0.6748 -0.1626 -0.3992 -2.6940 -0.4211 -0.7579 -0.1372
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up duration
H-495	-0.8548875451087952	▁follow - up
D-495	-0.8548875451087952	follow-up
P-495	-3.6101 -0.2070 -0.0270 -0.3459 -0.0844
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology ; hospital
H-812	-0.8276784420013428	▁card i ology
D-812	-0.8276784420013428	cardiology
P-812	-1.5124 -0.5280 -0.1875 -1.8095 -0.1009
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.4246717691421509	
D-575	-0.4246717691421509	
P-575	-0.7640 -0.0854
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart rate variability ; risk stratification ; cardiac ; patients
H-1584	-0.656924843788147	▁Heart ▁rate ▁variabil ity ▁; ▁risk ▁strat ification ▁; ▁cardiac ▁patients
D-1584	-0.656924843788147	Heart rate variability ; risk stratification ; cardiac patients
P-1584	-0.4920 -0.7033 -0.6859 -1.0358 -0.3068 -1.7914 -1.0407 -0.7211 -0.6347 -0.0127 -0.5916 -0.2527 -0.2714
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote ischemic conditioning ; patients ; heart failure
H-53	-0.5776881575584412	▁remote ▁ ische mic ▁condition ing ▁; ▁patients ▁; ▁heart ▁failure
D-53	-0.5776881575584412	remote ischemic conditioning ; patients ; heart failure
P-53	-1.4301 -0.5226 -0.0454 -0.4323 -0.0082 -0.1190 -0.4471 -1.4166 -1.8251 -0.7430 -0.2240 -0.1760 -0.1205
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air ; heart failure
H-1805	-0.18914905190467834	▁air ▁pollution ▁; ▁heart ▁failure
D-1805	-0.18914905190467834	air pollution ; heart failure
P-1805	-0.2115 -0.2067 -0.1773 -0.2377 -0.1540 -0.1576 -0.1794
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.6661176681518555	▁de script ive
D-1399	-0.6661176681518555	descriptive
P-1399	-0.6693 -0.1181 -0.1324 -2.2588 -0.1520
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.41545000672340393	▁Sham - opera ted ▁animals
D-1339	-0.41545000672340393	Sham-operated animals
P-1339	-0.2898 -0.1095 -0.0181 -0.4268 -1.2807 -0.5518 -0.2314
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.47485122084617615	
D-885	-0.47485122084617615	
P-885	-0.8277 -0.1220
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.17519229650497437	
D-311	-0.17519229650497437	
P-311	-0.2543 -0.0960
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.9335862398147583	
D-312	-0.9335862398147583	
P-312	-1.7793 -0.0879
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-1.05495285987854	▁Comp liance ▁; ▁treatment
D-749	-1.05495285987854	Compliance ; treatment
P-749	-3.8692 -0.3221 -1.6745 -0.3079 -0.0899 -0.0661
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.5107236504554749	
D-1754	-0.5107236504554749	
P-1754	-0.8882 -0.1332
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-1.1293359994888306	▁tax ono my
D-1125	-1.1293359994888306	taxonomy
P-1125	-4.2650 -0.0661 -0.9699 -0.2201 -0.1256
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.5196547508239746	▁CHF
D-673	-0.5196547508239746	CHF
P-673	-1.0496 -0.3638 -0.1456
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart failure
H-1886	-0.8658890128135681	▁Heart ▁failure ▁; ▁uk
D-1886	-0.8658890128135681	Heart failure ; uk
P-1886	-1.7569 -0.7069 -0.6364 -1.5273 -0.3409 -0.2269
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients ; followed up
H-825	-0.2842613756656647	
D-825	-0.2842613756656647	
P-825	-0.4723 -0.0962
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients ; cardiovascular disease
H-247	-0.4412378966808319	▁cardiovascular ▁disease
D-247	-0.4412378966808319	cardiovascular disease
P-247	-1.1978 -0.2706 -0.1499 -0.1467
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf ; mi
H-1101	-0.7921854257583618	▁ HF ▁; ▁MI
D-1101	-0.7921854257583618	HF ; MI
P-1101	-3.0214 -0.2194 -0.5653 -0.2861 -0.4917 -0.1690
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal support
H-1296	-0.2607068121433258	▁extra corp o real
D-1296	-0.2607068121433258	extracorporeal
P-1296	-0.4230 -0.0066 -0.0986 -0.0047 -0.9657 -0.0656
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart failure ; disease ; therapeutics
H-1073	-0.6005999445915222	▁Heart ▁failure ▁; ▁disease
D-1073	-0.6005999445915222	Heart failure ; disease
P-1073	-0.4467 -0.1076 -1.1969 -0.9691 -0.7548 -0.1284
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary outcomes ; hemostasis
H-1116	-0.4324475824832916	▁hemos tas is
D-1116	-0.4324475824832916	hemostasis
P-1116	-1.5075 -0.1429 -0.2209 -0.1451 -0.1459
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective matched cohort study
H-1619	-0.5317614078521729	
D-1619	-0.5317614078521729	
P-1619	-0.9375 -0.1260
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 ; gene expression ; heart failure
H-169	-0.49248719215393066	▁Cas pas e -3 ▁gene ▁expression ▁; ▁heart ▁failure
D-169	-0.49248719215393066	Caspase-3 gene expression ; heart failure
P-169	-0.2763 -0.0038 -0.1839 -0.6348 -2.0951 -0.3820 -0.2913 -0.5320 -0.4947 -0.2635 -0.2598
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic ; heart failure ; outcomes
H-1198	-0.5504804253578186	▁di ure tic ▁; ▁heart ▁failure
D-1198	-0.5504804253578186	diuretic ; heart failure
P-1198	-0.8554 -0.3375 -0.4943 -0.8441 -1.1214 -0.2614 -0.3718 -0.1180
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute right heart failure ; pulmonary hypertension
H-1090	-0.2992295026779175	▁right ▁heart ▁failure ▁; ▁pulmonar y ▁hyper tension
D-1090	-0.2992295026779175	right heart failure ; pulmonary hypertension
P-1090	-1.6996 -0.7101 -0.0599 -0.1354 -0.0012 -0.0398 -0.0762 -0.0316 -0.1341 -0.1042
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart failure ; patients ; bisphosphonates
H-1534	-0.31735140085220337	▁Heart ▁failure ▁; ▁bis phos phon ates
D-1534	-0.31735140085220337	Heart failure ; bisphosphonates
P-1534	-0.4997 -0.0808 -0.3364 -0.5236 -0.0328 -0.1908 -0.5300 -0.4748 -0.1873
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients ; functional capacity ; symptoms
H-550	-0.6449123024940491	▁functional ▁capacity
D-550	-0.6449123024940491	functional capacity
P-550	-1.1583 -0.8914 -0.4133 -0.1167
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology ; diagnosed
H-352	-0.15695804357528687	▁MR ▁; ▁MS
D-352	-0.15695804357528687	MR ; MS
P-352	-0.3199 -0.2375 -0.0271 -0.1372 -0.0631
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients ; hypertension
H-1889	-0.8540511131286621	▁hyper tension
D-1889	-0.8540511131286621	hypertension
P-1889	-3.0302 -0.0885 -0.1198 -0.1777
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american ; hf
H-1843	-0.8593828678131104	▁American ▁; ▁Canadian ▁; ▁ HF
D-1843	-0.8593828678131104	American ; Canadian ; HF
P-1843	-2.8365 -0.1522 -0.0730 -0.1266 -1.9439 -0.7413 -0.9133 -0.0883
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart rate ; arterial pressure
H-424	-0.284408837556839	▁Heart ▁rate ▁; ▁arterial ▁pressure
D-424	-0.284408837556839	Heart rate ; arterial pressure
P-424	-0.3955 -0.1900 -0.4838 -0.0745 -0.5142 -0.2237 -0.1091
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up ; patients
H-1009	-0.35867440700531006	
D-1009	-0.35867440700531006	
P-1009	-0.6230 -0.0944
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic hf ; death
H-1796	-0.1688285619020462	▁Chro nic ▁ HF
D-1796	-0.1688285619020462	Chronic HF
P-1796	-0.0353 -0.0286 -0.1455 -0.0258 -0.6733 -0.1044
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac amyloidosis
H-997	-0.17459948360919952	▁Card iac ▁a my lo idos is
D-997	-0.17459948360919952	Cardiac amyloidosis
P-997	-0.3242 -0.0094 -0.0785 -0.1958 -0.0163 -0.1143 -0.4622 -0.3058 -0.0648
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training ; heart failure ; patients
H-1911	-0.6042933464050293	▁Robot - assist ed ▁training ▁; ▁heart ▁failure ▁patients
D-1911	-0.6042933464050293	Robot-assisted training ; heart failure patients
P-1911	-1.3567 -0.3074 -0.0071 -0.1542 -1.5789 -0.6488 -0.9102 -0.2565 -0.9758 -0.2588 -0.1928
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.5053017139434814	
D-1616	-0.5053017139434814	
P-1616	-0.9176 -0.0930
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.4248897135257721	▁Interna l ▁reli ability ▁; ▁Cro n bach
D-786	-0.4248897135257721	Internal reliability ; Cronbach
P-786	-0.4715 -0.2015 -1.1927 -0.1726 -0.2818 -0.2159 -0.0242 -0.0165 -1.5559 -0.1162
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients ; hfpef
H-787	-0.28326669335365295	▁ HF p EF
D-787	-0.28326669335365295	HFpEF
P-787	-0.9715 -0.1762 -0.0549 -0.2147 -0.1454 -0.1368
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection fraction ; bnp
H-194	-0.23875181376934052	▁e je ction ▁ fraction ▁; ▁sex ▁; ▁b NP
D-194	-0.23875181376934052	ejection fraction ; sex ; bNP
P-194	-0.7015 -0.0719 -0.0067 -0.3051 -0.0053 -0.0791 -0.0992 -0.6630 -0.4264 -0.2437 -0.1303 -0.1329
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic ; medication ; death
H-507	-0.28202593326568604	▁Pig s ▁; ▁anti ar rhythm ic ▁medication
D-507	-0.28202593326568604	Pigs ; antiarrhythmic medication
P-507	-0.6061 -0.0779 -0.5773 -0.0458 -0.0790 -0.0362 -0.2375 -0.1072 -0.8960 -0.1573
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients ; therapy ; beta blockade
H-1736	-0.8478535413742065	▁beta ▁block ade
D-1736	-0.8478535413742065	beta blockade
P-1736	-3.7440 -0.1998 -0.0358 -0.1484 -0.1112
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf ; patients ; intubated
H-219	-0.3336217701435089	▁CHF ▁patients ▁; ▁in tuba ted
D-219	-0.3336217701435089	CHF patients ; intubated
P-219	-0.0194 -0.8337 -1.0748 -0.0177 -0.0293 -0.4387 -0.1711 -0.0842
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical ; hypothermic circulatory arrest
H-598	-0.481234073638916	▁Sur g ical ▁tac tics ▁; ▁circula tory ▁arrest
D-598	-0.481234073638916	Surgical tactics ; circulatory arrest
P-598	-2.8977 -0.4162 -0.3435 -0.1067 -0.2878 -0.1798 -0.6616 -0.1031 -0.0670 -0.1285 -0.1016
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary outcomes ; functional capacity ; quality of life
H-616	-0.5922266840934753	▁functional ▁capacity ▁; ▁quality
D-616	-0.5922266840934753	functional capacity ; quality
P-616	-0.2714 -0.8859 -1.0195 -0.1786 -1.0618 -0.1363
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end point
H-266	-0.24182669818401337	
D-266	-0.24182669818401337	
P-266	-0.4123 -0.0713
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected ; patients ; systolic dysfunction
H-1069	-0.1909429132938385	▁sy sto lic ▁dys function
D-1069	-0.1909429132938385	systolic dysfunction
P-1069	-0.4120 -0.1882 -0.1786 -0.0654 -0.1397 -0.2412 -0.1115
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.4008488953113556	
D-32	-0.4008488953113556	
P-32	-0.6731 -0.1286
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.34322431683540344	
D-804	-0.34322431683540344	
P-804	-0.5712 -0.1152
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise ; quality of life ; heart failure
H-612	-2.005125045776367	▁heart ▁failure
D-612	-2.005125045776367	heart failure
P-612	-7.2847 -0.3325 -0.2601 -0.1432
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.2872033417224884	▁implant ed ▁monitoring ▁devices
D-156	-0.2872033417224884	implanted monitoring devices
P-156	-0.6561 -0.2216 -0.0115 -0.5787 -0.1530 -0.1023
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.6718085408210754	
D-1469	-0.6718085408210754	
P-1469	-1.2680 -0.0756
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient ; conditions
H-0	-0.8144164085388184	▁patient ▁safety
D-0	-0.8144164085388184	patient safety
P-0	-1.6233 -1.0012 -0.3912 -0.2420
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea ; afterload
H-518	-1.0263391733169556	▁Ea ▁; ▁after load ▁burde n
D-518	-1.0263391733169556	Ea ; afterload burden
P-518	-4.9977 -0.3527 -1.8781 -0.0197 -0.4639 -0.1231 -0.1894 -0.1861
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths ; strokes
H-778	-0.5288904309272766	▁per i pro ced ural ▁; ▁stroke s
D-778	-0.5288904309272766	periprocedural ; strokes
P-778	-0.7925 -0.0816 -0.0567 -0.0120 -0.0075 -2.2517 -1.7772 -0.1569 -0.0787 -0.0741
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.4553025960922241	▁media n ▁age
D-677	-0.4553025960922241	median age
P-677	-0.9055 -0.0691 -0.6968 -0.5200 -0.0851
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras ; atherosclerosis
H-1594	-0.7691745162010193	▁ RAS ▁; ▁at hero sc ler osis
D-1594	-0.7691745162010193	RAS ; atherosclerosis
P-1594	-3.0199 -0.0081 -0.2107 -0.9308 -0.1770 -0.0332 -2.9700 -0.0343 -0.1672 -0.1405
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty ; heart failure
H-1000	-0.3028998076915741	▁fra il ty ▁; ▁heart ▁failure
D-1000	-0.3028998076915741	frailty ; heart failure
P-1000	-0.1769 -0.2993 -0.1024 -0.5398 -0.5955 -0.1029 -0.4445 -0.1618
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas ; heart failure ; disease
H-1479	-0.259199321269989	▁micro RNA s ▁; ▁heart ▁failure ▁; ▁disease ▁management
D-1479	-0.259199321269989	microRNAs ; heart failure ; disease management
P-1479	-0.1829 -0.0179 -0.1059 -0.8289 -0.3448 -0.1839 -0.6408 -0.2067 -0.1004 -0.1507 -0.0883
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard ratios ; cox regression analysis
H-1770	-0.5659675002098083	▁co x ▁re gression ▁analysis
D-1770	-0.5659675002098083	cox regression analysis
P-1770	-2.7798 -0.1890 -0.1421 -0.0340 -0.3260 -0.2780 -0.2129
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss ; exercise ; training ; outcomes
H-1932	-0.6614924073219299	▁PS SS
D-1932	-0.6614924073219299	PSSS
P-1932	-0.7255 -0.3011 -1.5096 -0.1096
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart failure with preserved ejection fraction
H-1885	-0.1980334371328354	▁management ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1885	-0.1980334371328354	management ; heart failure ; preserved ejection fraction
P-1885	-0.5629 -0.5981 -0.2808 -0.0341 -0.2935 -0.0864 -0.0259 -0.2322 -0.0182 -0.0578 -0.0175 -0.4991 -0.0039 -0.1498 -0.1105
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology ; bromodomain ; halts ; heart failure
H-1033	-0.4845215082168579	▁Card i ology ▁; ▁bro modo main ▁inhibi tion ▁halt s ▁heart ▁failure
D-1033	-0.4845215082168579	Cardiology ; bromodomain inhibition halts heart failure
P-1033	-0.5743 -0.1724 -0.1270 -0.1537 -0.8014 -0.0020 -0.1206 -0.0807 -0.1928 -1.9800 -0.3609 -1.9755 -0.3556 -0.2839 -0.0871
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.28707751631736755	▁AT
D-1759	-0.28707751631736755	AT
P-1759	-0.4613 -0.2329 -0.1670
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin ; congestive heart failure
H-633	-0.2880430221557617	▁vaso press in ▁; ▁con ges tive ▁heart ▁failure
D-633	-0.2880430221557617	vasopressin ; congestive heart failure
P-633	-0.0742 -0.1622 -0.3458 -0.1946 -0.0183 -0.0760 -1.4468 -0.4340 -0.1771 -0.1516 -0.0879
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral stenosis ; medical treatment ; heart failure
H-332	-0.5654860138893127	▁Mit ral ▁sten osis ▁rever sed ▁; ▁medical ▁treatment ▁; ▁heart ▁failure
D-332	-0.5654860138893127	Mitral stenosis reversed ; medical treatment ; heart failure
P-332	-1.3005 -0.0182 -0.0447 -0.0234 -1.6557 -1.4892 -0.4036 -0.4174 -0.8792 -0.6524 -0.1711 -0.3616 -0.3302 -0.1696
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart failure ; hospitalization ; cardiovascular death
H-410	-0.5818676948547363	▁heart ▁failure ▁hospital ization ▁; ▁cardiovascular ▁death
D-410	-0.5818676948547363	heart failure hospitalization ; cardiovascular death
P-410	-1.6231 -0.2629 -1.4840 -0.4694 -0.4199 -0.0173 -0.6526 -0.1675 -0.1400
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity ; patients ; breast cancer
H-669	-0.525593101978302	▁Tras tuz um ab - related ▁cardio toxic ity ▁; ▁breast ▁cancer
D-669	-0.525593101978302	Trastuzumab-related cardiotoxicity ; breast cancer
P-669	-0.4726 -0.0481 -0.0300 -0.8241 -0.1925 -0.3180 -0.1926 -0.5280 -1.8787 -0.5765 -1.5759 -0.2652 -0.2932 -0.1629
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart failure ; hf ; therapy
H-1067	-0.698327898979187	▁Device s ▁; ▁heart ▁failure ▁; HF
D-1067	-0.698327898979187	Devices ; heart failure ;HF
P-1067	-1.3301 -0.0508 -0.3750 -2.3375 -0.0956 -0.2330 -0.0294 -1.6928 -0.1407
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality ; sts
H-159	-1.011252999305725	▁voordeel ▁; ▁mortal ity ▁; ▁s ts ▁ HM
D-159	-1.011252999305725	voordeel ; mortality ; sts HM
P-159	-4.6128 -0.9600 -0.3081 -1.1828 -0.9128 -0.4259 -1.3717 -0.8552 -0.1535 -0.1938 -0.1473
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 ; hf
H-1211	-0.19960424304008484	▁p de 2 ▁; ▁ HF
D-1211	-0.19960424304008484	pde2 ; HF
P-1211	-0.5347 -0.2763 -0.0288 -0.1423 -0.3084 -0.1586 -0.0652 -0.0825
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital ; coprimary outcome
H-1651	-0.48640385270118713	▁Night s ▁spent ▁in ▁hospital
D-1651	-0.48640385270118713	Nights spent in hospital
P-1651	-1.0422 -0.1008 -0.5244 -1.1379 -0.1643 -0.2989 -0.1363
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart failure ; public ; health
H-1606	-0.8840367197990417	▁Heart ▁failure ▁; ▁public ▁health
D-1606	-0.8840367197990417	Heart failure ; public health
P-1606	-1.7762 -0.7287 -0.6511 -0.1066 -0.7695 -1.8995 -0.2566
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative ; albumin
H-539	-0.7257780432701111	▁album in ▁level
D-539	-0.7257780432701111	albumin level
P-539	-2.6346 -0.2874 -0.1417 -0.4801 -0.0850
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet ; aortic pressure
H-581	-0.517572820186615	▁l VET ▁; ▁a or tic ▁pressure ▁cur ve
D-581	-0.517572820186615	lVET ; aortic pressure curve
P-581	-2.4678 -0.1450 -0.2451 -0.1255 -0.1052 -0.6085 -0.8574 -0.7031 -0.1385 -0.1647 -0.1325
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician ; outcomes ; discharge
H-1414	-0.7007700204849243	▁physician ▁continu ity
D-1414	-0.7007700204849243	physician continuity
P-1414	-0.3502 -0.1010 -0.2908 -2.6122 -0.1497
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication ; sst2
H-403	-0.6208124160766602	▁Medica tion ▁regime n ▁; ▁s ST 2
D-403	-0.6208124160766602	Medication regimen ; sST2
P-403	-0.4866 -0.5004 -0.2961 -0.2777 -0.4084 -0.0008 -2.5607 -0.1457 -1.3782 -0.1536
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-0.7074201703071594	▁system a tic ▁review ▁; ▁network ▁meta - analys is
D-150	-0.7074201703071594	systematic review ; network meta-analysis
P-150	-3.9883 -0.2221 -0.8588 -0.0128 -0.2336 -1.0669 -0.2638 -0.2918 -0.7895 -0.4184 -0.1647 -0.1783
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac ; symptoms ; congenital ; lesions
H-983	-0.31643131375312805	▁Card iac ▁symptoms ▁; ▁children ▁; ▁con geni tal ▁les ions
D-983	-0.31643131375312805	Cardiac symptoms ; children ; congenital lesions
P-983	-0.5230 -0.0210 -0.3192 -0.2437 -1.4303 -0.8977 -0.0591 -0.0087 -0.0403 -0.1272 -0.2264 -0.1154 -0.1017
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone ; systolic heart failure
H-437	-0.12252391874790192	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-437	-0.12252391874790192	spironolactone ; systolic heart failure
P-437	-0.1606 -0.0097 -0.0244 -0.0202 -0.1781 -0.0113 -0.0371 -0.0339 -0.4160 -0.2104 -0.2249 -0.1438
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular scaffolds ; heart ; pathology
H-989	-0.5879076719284058	▁e RK 1/2 ▁molecular ▁sc af fold s ▁; ▁heart ▁path ology
D-989	-0.5879076719284058	eRK1/2 molecular scaffolds ; heart pathology
P-989	-1.9896 -0.0173 -0.0903 -0.1544 -1.5004 -1.6256 -0.3547 -0.1086 -0.3669 -0.2546 -0.6608 -0.7133 -0.1798 -0.2145
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional ms ; reported ; patients ; degenerative mr
H-339	-0.09261893481016159	▁Fun ction al ▁MS ▁; ▁de genera tive ▁MR
D-339	-0.09261893481016159	Functional MS ; degenerative MR
P-339	-0.0989 -0.0058 -0.0026 -0.0380 -0.2734 -0.1427 -0.0081 -0.1981 -0.0163 -0.1541 -0.0807
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology ; chronic heart failure ; bisoprolol
H-645	-0.6434370875358582	▁chronic ▁heart ▁failure ▁; ▁bis o pro lol
D-645	-0.6434370875358582	chronic heart failure ; bisoprolol
P-645	-4.0634 -1.3803 -0.1175 -0.0673 -0.1101 -0.1956 -0.0262 -0.0548 -0.2818 -0.1374
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart failure ; hf ; leading ; mortality ; society
H-1034	-0.4129526615142822	▁Heart ▁failure ▁; HF ▁; ▁mortal ity
D-1034	-0.4129526615142822	Heart failure ;HF ; mortality
P-1034	-0.4067 -0.0305 -0.1125 -0.0298 -0.5941 -0.7943 -0.8420 -0.7679 -0.1387
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate adjustment ; cox proportional hazards models
H-785	-0.7972466349601746	▁co x ▁proportion al ▁hazard s ▁models
D-785	-0.7972466349601746	cox proportional hazards models
P-785	-0.0849 -3.6149 -0.0708 -0.0147 -0.2296 -1.0665 -1.6915 -0.2223 -0.1799
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician ; hospital ; physician
H-1726	-0.672454833984375	▁physician ▁volume ▁; ▁hospital ▁volume
D-1726	-0.672454833984375	physician volume ; hospital volume
P-1726	-0.6002 -0.1562 -0.4588 -0.2861 -0.2823 -2.6860 -0.2377
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan ; vasopressin type 2 receptor antagonist
H-1195	-0.33453020453453064	▁Tol va p tan ▁; ▁vaso press in ▁; ▁receptor
D-1195	-0.33453020453453064	Tolvaptan ; vasopressin ; receptor
P-1195	-0.0459 -0.0353 -0.2150 -0.0171 -0.1375 -0.0451 -0.0912 -0.7417 -0.7786 -0.0055 -1.7507 -0.1506
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs ; expenditures
H-1238	-0.6818520426750183	▁ar rhythm ia - related ▁costs
D-1238	-0.6818520426750183	arrhythmia-related costs
P-1238	-1.0614 -0.1433 -0.7537 -0.1014 -0.0869 -2.2343 -0.9397 -0.1341
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.6281459331512451	▁ metric ▁choice ▁; ▁read mission ▁metri cs
D-134	-0.6281459331512451	metric choice ; readmission metrics
P-134	-0.4928 -0.1408 -0.8946 -0.1185 -0.5856 -2.6737 -0.2634 -0.7019 -0.2669 -0.1432
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.881866455078125	▁read mission ▁ metric
D-145	-0.881866455078125	readmission metric
P-145	-0.5398 -2.0595 -1.1037 -0.0448 -1.4402 -0.1032
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.5026170611381531	
D-1998	-0.5026170611381531	
P-1998	-0.8793 -0.1259
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-1.0102428197860718	▁media n ▁follow up
D-1758	-1.0102428197860718	median followup
P-1758	-0.9806 -0.1879 -0.1729 -4.4868 -0.1522 -0.0811
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.41422778367996216	
D-1261	-0.41422778367996216	
P-1261	-0.6628 -0.1656
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-0.8342203497886658	
D-958	-0.8342203497886658	
P-958	-1.5852 -0.0833
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-0.49923402070999146	▁black ▁patients
D-1634	-0.49923402070999146	black patients
P-1634	-0.4021 -1.1991 -0.2205 -0.1752
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-0.9016275405883789	▁mechanism ▁; ▁ET ▁; ▁CHF
D-261	-0.9016275405883789	mechanism ; ET ; CHF
P-261	-1.7724 -0.3083 -2.1147 -0.5847 -1.0703 -0.2939 -0.1671
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable hf
H-481	-0.5855610370635986	▁ HF
D-481	-0.5855610370635986	HF
P-481	-1.9015 -0.1997 -0.1655 -0.0755
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.5918897986412048	▁Res idu al ▁con found ing
D-1839	-0.5918897986412048	Residual confounding
P-1839	-3.0531 -0.0964 -0.0256 -0.0095 -0.1581 -0.0307 -1.2674 -0.0944
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality of life
H-1919	-1.157494068145752	
D-1919	-1.157494068145752	
P-1919	-2.1997 -0.1153
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.3941326439380646	▁pro pens ity
D-1837	-0.3941326439380646	propensity
P-1837	-0.2516 -0.0235 -0.9145 -0.6858 -0.0952
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb ; correlated ; baseline ; hrqol
H-840	-0.376098096370697	▁h gb ▁level ▁; ▁HR Qo L
D-840	-0.376098096370697	hgb level ; HRQoL
P-840	-0.3633 -0.0179 -0.1632 -0.1217 -1.6545 -0.0056 -0.7615 -0.1610 -0.1361
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved ejection fraction ; outcomes
H-1464	-0.5481048822402954	▁pres er ved ▁e je ction ▁ fraction
D-1464	-0.5481048822402954	preserved ejection fraction
P-1464	-1.4652 -0.0658 -0.2802 -0.1026 -0.0824 -0.0172 -0.5783 -0.0078 -2.7045 -0.1771
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic ; biomarkers ; chronic heart failure
H-1471	-0.2038065493106842	▁bio mark ers ▁; ▁chronic ▁heart ▁failure
D-1471	-0.2038065493106842	biomarkers ; chronic heart failure
P-1471	-0.1194 -0.1322 -0.0852 -0.2674 -0.1171 -0.6610 -0.1785 -0.1488 -0.1246
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated hf ; cardiovascular ; hospitalization
H-1797	-0.4700459837913513	▁ HF ▁; ▁cardiovascular ▁hospital ization
D-1797	-0.4700459837913513	HF ; cardiovascular hospitalization
P-1797	-1.8184 -0.2511 -0.3337 -0.0708 -0.5523 -0.4773 -0.1165 -0.1402
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients ; cardiac ; inflammatory ; biomarkers
H-1914	-0.19308310747146606	▁cardiac ▁; ▁infla mma tory ▁bio mark ers
D-1914	-0.19308310747146606	cardiac ; inflammatory biomarkers
P-1914	-0.0635 -0.6770 -0.0350 -0.3343 -0.1352 -0.0210 -0.1112 -0.1588 -0.1785 -0.2164
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed ; mortality ; random-effects models
H-64	-0.7648675441741943	▁mortal ity
D-64	-0.7648675441741943	mortality
P-64	-0.2969 -1.1945 -1.3649 -0.2031
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes ; patients ; heart failure ; emergency department
H-461	-1.1370915174484253	▁heart ▁failure ▁; ▁emergency ▁department
D-461	-1.1370915174484253	heart failure ; emergency department
P-461	-3.4710 -0.3621 -1.4434 -0.2855 -0.0842 -2.1699 -0.1435
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological ; acute heart failure
H-1465	-0.537759006023407	▁Pharma c ological ▁treatment ▁; ▁a cute ▁heart ▁failure
D-1465	-0.537759006023407	Pharmacological treatment ; acute heart failure
P-1465	-2.1714 -0.0282 -0.2393 -1.5111 -0.3185 -0.0337 -0.0144 -0.7925 -0.1254 -0.5866 -0.0942
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping ; baseline ; heart failure
H-1059	-1.519205093383789	▁heart ▁failure
D-1059	-1.519205093383789	heart failure
P-1059	-3.6903 -0.5231 -1.6774 -0.1860
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal ; heartmate ii
H-772	-0.33248618245124817	▁off - pump ▁; ▁ster nal ▁spar ing ▁approach ▁; ▁Heart Mate ▁II ▁exchange
D-772	-0.33248618245124817	off-pump ; sternal sparing approach ; HeartMate II exchange
P-772	-0.0074 -0.0607 -0.0806 -0.7597 -0.8235 -0.3029 -0.1880 -0.0243 -1.3918 -0.2083 -0.2153 -0.1020 -0.8518 -0.0334 -0.1675 -0.1026
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis ; patients ; implantation
H-913	-0.6410561203956604	▁di al ysis ▁patients ▁; ▁device ▁implant ation
D-913	-0.6410561203956604	dialysis patients ; device implantation
P-913	-0.1643 -0.0357 -0.0154 -0.8395 -0.4562 -3.8441 -0.1619 -0.4980 -0.2468 -0.1487
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary angiography ; lesions
H-349	-0.4222815930843353	▁Corona ry ▁ang i ography
D-349	-0.4222815930843353	Coronary angiography
P-349	-0.0283 -1.2120 -0.4451 -0.6519 -0.1383 -0.3874 -0.0930
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic phenotype ; fontan
H-223	-0.35636916756629944	▁Hem o dynamic ▁ph eno type ▁; ▁fail ing ▁Font an
D-223	-0.35636916756629944	Hemodynamic phenotype ; failing Fontan
P-223	-0.5931 -0.1748 -0.0019 -1.4293 -0.0640 -0.0033 -0.0795 -0.8087 -0.0437 -0.2141 -0.2027 -0.9553 -0.0625
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient ; surgery ; echocardiography
H-358	-0.17789381742477417	▁MS ▁; ▁e cho card i ography
D-358	-0.17789381742477417	MS ; echocardiography
P-358	-0.0845 -0.4379 -0.2390 -0.0283 -0.1494 -0.3760 -0.0980 -0.1281 -0.0598
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise ; life expectancy
H-1902	-0.47141560912132263	
D-1902	-0.47141560912132263	
P-1902	-0.7985 -0.1444
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate analyses
H-826	-1.0356736183166504	
D-826	-1.0356736183166504	
P-826	-1.9618 -0.1096
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart failure ; cox proportional hazard analyses
H-1537	-0.450860857963562	▁heart ▁failure ▁; ▁co x ▁proportion al ▁hazard ▁analyse s
D-1537	-0.450860857963562	heart failure ; cox proportional hazard analyses
P-1537	-3.3336 -0.2466 -0.5135 -0.0396 -0.0304 -0.0436 -0.0082 -0.1695 -0.4644 -0.3069 -0.1432 -0.1108
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized ; walking ; patients ; severe heart failure
H-567	-1.5162583589553833	▁Nordic ▁walking ▁; ▁severe ▁heart ▁failure
D-567	-1.5162583589553833	Nordic walking ; severe heart failure
P-567	-1.1421 -2.3943 -0.4706 -5.7376 -1.6903 -0.2675 -0.2369 -0.1908
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric ; self-care of heart failure index version 6.2
H-1503	-0.4782400131225586	▁psycho metric ▁testing ▁; ▁Self - car e ▁; ▁Heart ▁Fail ure ▁index
D-1503	-0.4782400131225586	psychometric testing ; Self-care ; Heart Failure index
P-1503	-0.9711 -0.0072 -0.2413 -0.1514 -0.2375 -0.0316 -1.2453 -0.1787 -1.3248 -0.3115 -0.1918 -0.9675 -1.0282 -0.1686 -0.1171
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient ; postoperatively ; multiorgan failure ; sepsis
H-551	-0.16160966455936432	▁multi organ ▁failure ▁; ▁se psis
D-551	-0.16160966455936432	multiorgan failure ; sepsis
P-551	-0.6500 -0.0119 -0.1172 -0.2786 -0.0152 -0.0051 -0.0986 -0.1164
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients ; acute kidney injury ; postoperatively
H-975	-0.3732014000415802	▁a cute ▁ki dne y ▁injury
D-975	-0.3732014000415802	acute kidney injury
P-975	-0.7191 -0.0083 -0.0588 -0.7270 -0.0389 -0.5105 -0.7667 -0.1562
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max ; significance
H-1255	-0.40483471751213074	▁VO 2 max
D-1255	-0.40483471751213074	VO2max
P-1255	-1.1391 -0.1833 -0.0384 -0.5281 -0.1352
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive statistics ; cox proportional hazards models
H-675	-0.5112462043762207	▁co x ▁proportion al ▁hazard s ▁models
D-675	-0.5112462043762207	cox proportional hazards models
P-675	-0.3267 -0.1474 -0.0736 -0.0122 -0.3977 -1.0988 -2.0708 -0.2525 -0.2215
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle heart failure model
H-2011	-0.9359340667724609	▁Seattle ▁Heart ▁Fail ure ▁model
D-2011	-0.9359340667724609	Seattle Heart Failure model
P-2011	-3.1936 -1.1118 -0.2804 -0.3985 -1.3477 -0.1172 -0.1023
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-1.339061975479126	▁health care ▁programme s
D-603	-1.339061975479126	healthcare programmes
P-603	-6.6268 -0.4300 -0.2117 -0.3237 -0.2662 -0.1759
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart failure
H-1204	-1.0711779594421387	▁heart ▁failure
D-1204	-1.0711779594421387	heart failure
P-1204	-3.4854 -0.5138 -0.1846 -0.1009
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.29101070761680603	
D-1854	-0.29101070761680603	
P-1854	-0.4477 -0.1343
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.2568257749080658	
D-1923	-0.2568257749080658	
P-1923	-0.4130 -0.1007
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.45994308590888977	
D-800	-0.45994308590888977	
P-800	-0.8505 -0.0694
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.787026584148407	▁ab normal ▁cardiac ▁T 2
D-746	-0.787026584148407	abnormal cardiac T2
P-746	-0.4298 -0.0035 -0.0178 -2.6422 -0.0263 -2.2764 -0.1132
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.4346523880958557	
D-1028	-0.4346523880958557	
P-1028	-0.8022 -0.0671
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.8419379591941833	
D-1206	-0.8419379591941833	
P-1206	-1.5910 -0.0928
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated ; hf
H-608	-0.3710423707962036	▁HR ▁; ▁ HF
D-608	-0.3710423707962036	HR ; HF
P-608	-0.1540 -0.4458 -1.3382 -0.0589 -0.1237 -0.1055
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.6570454239845276	
D-591	-0.6570454239845276	
P-591	-1.1461 -0.1680
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug ; japan
H-1197	-0.8680219650268555	▁drug ▁; ▁Japan
D-1197	-0.8680219650268555	drug ; Japan
P-1197	-2.1455 -1.1213 -0.8636 -0.1171 -0.0926
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.1852359175682068	▁bio mark ers
D-70	-0.1852359175682068	biomarkers
P-70	-0.4284 -0.1099 -0.0586 -0.1895 -0.1397
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome ; tug test
H-799	-0.8617375493049622	▁m AIN ▁o UTC OME ▁me as URE
D-799	-0.8617375493049622	mAIN oUTCOME measURE
P-799	-2.4486 -0.1305 -0.3984 -0.0038 -0.0739 -2.8741 -0.1132 -0.1944 -2.3310 -0.0494
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients ; esrd
H-394	-1.0300981998443604	▁ES RD
D-394	-1.0300981998443604	ESRD
P-394	-3.3753 -0.3102 -0.1669 -0.2680
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart failure with preserved left ventricular ejection fraction
H-1299	-0.2453954666852951	▁Heart ▁failure ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1299	-0.2453954666852951	Heart failure ; preserved left ventricular ejection fraction
P-1299	-0.1526 -0.0559 -0.1727 -0.9385 -0.0183 -0.1479 -0.1792 -0.0493 -0.4637 -0.1804 -0.0914 -0.1286 -0.0660 -1.1662 -0.0068 -0.2585 -0.0957
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome ; all-cause readmissions
H-1580	-0.9577963948249817	▁m AIN ▁o UTC OME
D-1580	-0.9577963948249817	mAIN oUTCOME
P-1580	-3.4818 -0.4683 -0.9252 -0.0086 -0.3186 -1.4212 -0.0808
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence ; systolic hf
H-1798	-0.12954096496105194	▁sy sto lic ▁ HF
D-1798	-0.12954096496105194	systolic HF
P-1798	-0.0831 -0.1005 -0.0108 -0.3941 -0.0801 -0.1491 -0.0891
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary outcome ; patient ; post
H-617	-0.8259164094924927	
D-617	-0.8259164094924927	
P-617	-1.4958 -0.1560
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients ; lvad ; implantation
H-545	-0.44826897978782654	▁l VAD ▁implant ation
D-545	-0.44826897978782654	lVAD implantation
P-545	-1.1413 -0.0825 -0.6451 -0.4071 -0.2742 -0.1393
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation ; postsystolic function
H-331	-0.8105664253234863	▁post y sto lic ▁function
D-331	-0.8105664253234863	postystolic function
P-331	-4.4344 -0.2696 -0.1173 -0.0298 -0.5320 -0.1876 -0.1033
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication ; resting hemodynamics
H-828	-0.30127763748168945	▁medication ▁; ▁rest ing ▁hem o dynamic s
D-828	-0.30127763748168945	medication ; resting hemodynamics
P-828	-0.8180 -0.1900 -0.1719 -0.0933 -0.5028 -0.6464 -0.0061 -0.2101 -0.2790 -0.0953
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis ; pathophysiological
H-1276	-0.8235485553741455	▁prognos is
D-1276	-0.8235485553741455	prognosis
P-1276	-1.2117 -0.0964 -1.9051 -0.0810
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac ; cardiac hypertrophy
H-1782	-0.32557442784309387	▁a ac ▁; ▁cardiac ▁hyper trop hy
D-1782	-0.32557442784309387	aac ; cardiac hypertrophy
P-1782	-0.3461 -0.2733 -0.1614 -0.4036 -0.6577 -0.0283 -0.7269 -0.1788 -0.1541
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha ; esc
H-1908	-1.005436658859253	AHA ▁; ▁ESC
D-1908	-1.005436658859253	AHA ; ESC
P-1908	-0.3998 -0.1103 -2.7496 -1.6048 -0.1627
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician ; outcomes ; patients ; heart failure
H-1720	-1.6825158596038818	▁patients ▁; ▁heart ▁failure
D-1720	-1.6825158596038818	patients ; heart failure
P-1720	-6.5645 -1.9206 -0.8810 -0.2883 -0.1844 -0.2564
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal muscle ; exercise capacity ; fontan circulation
H-1491	-0.36637550592422485	▁s kelet al ▁muscle ▁ab normal ities ▁; ▁exercise ▁capacity ▁; ▁adults ▁; ▁Font an ▁circulation
D-1491	-0.36637550592422485	skeletal muscle abnormalities ; exercise capacity ; adults ; Fontan circulation
P-1491	-2.3333 -0.0098 -0.0314 -0.1697 -0.0683 -0.0263 -0.5283 -0.1490 -0.2633 -0.3619 -0.2107 -1.6337 -0.3805 -0.0662 -0.0652 -0.0454 -0.1590 -0.0929
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission ; hospital ; heart failure ; discharge
H-147	-0.9684194326400757	▁Read mission ▁to ▁hospital ▁; ▁heart ▁failure
D-147	-0.9684194326400757	Readmission to hospital ; heart failure
P-147	-4.8589 -0.5333 -1.1516 -0.1999 -0.7195 -0.6819 -0.1028 -0.3643 -0.1036
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease ; lead ; hypertension ; kidney failure
H-1598	-0.28615158796310425	▁progressive ▁disease ▁; ▁hyper tension ▁; ▁ki dne y ▁failure
D-1598	-0.28615158796310425	progressive disease ; hypertension ; kidney failure
P-1598	-0.6578 -0.7368 -0.0798 -1.2656 -0.0166 -0.0691 -0.1352 -0.1452 -0.0222 -0.0728 -0.1410 -0.0917
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients ; chronic kidney disease ; ckd
H-898	-0.4933203458786011	▁chronic ▁ki dne y ▁disease ▁; CK d
D-898	-0.4933203458786011	chronic kidney disease ;CKd
P-898	-1.4087 -0.1869 -0.6552 -0.1571 -0.3327 -0.3242 -0.1705 -1.2448 -0.2716 -0.1815
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income ; expenditure ; health
H-1792	-0.6545569896697998	▁gross ▁income ▁; ▁ex pendi ture ▁; ▁health ▁per ▁capita
D-1792	-0.6545569896697998	gross income ; expenditure ; health per capita
P-1792	-3.2710 -0.2990 -0.0758 -1.9556 -0.0248 -0.5756 -0.5385 -0.4945 -0.2182 -0.0051 -0.2575 -0.1391
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations ; hospital ; longitudinal ; change
H-143	-0.8018640279769897	
D-143	-0.8018640279769897	
P-143	-1.4618 -0.1419
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr variability ; cardiac death
H-1589	-0.40686458349227905	▁ab normal ▁HR ▁variabil ity ▁; ▁sud den ▁; ▁non - sud den ▁cardiac ▁death
D-1589	-0.40686458349227905	abnormal HR variability ; sudden ; non-sudden cardiac death
P-1589	-0.5512 -0.0029 -1.1007 -0.2015 -0.4654 -0.1996 -0.5934 -0.0063 -1.4159 -1.2089 -0.0498 -0.0054 -0.0052 -0.0310 -0.6889 -0.2021 -0.1887
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient ; circulation
H-1824	-0.8443619608879089	
D-1824	-0.8443619608879089	
P-1824	-1.5593 -0.1294
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic blood pressure
H-1048	-0.6555206179618835	▁ toxic ity ▁; ▁system ic ▁blood ▁pressure
D-1048	-0.6555206179618835	toxicity ; systemic blood pressure
P-1048	-0.2466 -0.2012 -1.2066 -0.1664 -2.1340 -0.3833 -1.2181 -0.6997 -0.1758 -0.1235
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.3753443956375122	
D-1881	-0.3753443956375122	
P-1881	-0.6091 -0.1416
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.3049730658531189	
D-1576	-0.3049730658531189	
P-1576	-0.4969 -0.1131
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.4871211051940918	▁ therapy
D-1965	-0.4871211051940918	therapy
P-1965	-1.7078 -0.0790 -0.0658 -0.0959
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north america
H-75	-0.6430889368057251	▁North ▁America
D-75	-0.6430889368057251	North America
P-75	-2.1676 -0.2533 -0.0725 -0.0790
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.8197635412216187	▁c PG s
D-1848	-0.8197635412216187	cPGs
P-1848	-3.0640 -0.5422 -0.0993 -0.2246 -0.1687
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.38257113099098206	▁MS
D-372	-0.38257113099098206	MS
P-372	-0.3362 -0.7405 -0.0709
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity ; outcomes
H-709	-0.8537542819976807	
D-709	-0.8537542819976807	
P-709	-1.5827 -0.1248
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute heart failure
H-1014	-0.285207599401474	▁a cute ▁heart ▁failure ▁trial s
D-1014	-0.285207599401474	acute heart failure trials
P-1014	-0.6448 -0.0083 -0.3672 -0.1022 -0.7325 -0.1418 -0.1673 -0.1175
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients ; heart failure
H-1821	-1.0676850080490112	▁patients ▁; ▁heart ▁failure
D-1821	-1.0676850080490112	patients ; heart failure
P-1821	-2.8388 -2.3047 -0.7608 -0.1240 -0.2477 -0.1303
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic ; hf
H-1072	-0.6458226442337036	▁stand - a lone ▁diagnostic ▁devices ▁; HF
D-1072	-0.6458226442337036	stand-alone diagnostic devices ;HF
P-1072	-0.8310 -0.0649 -0.2036 -0.0075 -1.0718 -0.1768 -0.3497 -3.5630 -0.0969 -0.0930
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end stage heart failure
H-1669	-1.3566815853118896	▁end ▁stage ▁heart ▁failure
D-1669	-1.3566815853118896	end stage heart failure
P-1669	-6.7771 -0.1701 -0.8882 -0.1141 -0.1226 -0.0680
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician ; hf
H-1732	-0.7768412232398987	▁ HF
D-1732	-0.7768412232398987	HF
P-1732	-1.6167 -0.3606 -1.0135 -0.1166
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial function ; flow-mediated dilatation
H-253	-0.4713747203350067	▁en dot heli al ▁function ▁; ▁di la tation
D-253	-0.4713747203350067	endothelial function ; dilatation
P-253	-1.0106 -0.1540 -0.0479 -0.0072 -0.0720 -0.7121 -2.7194 -0.2533 -0.0153 -0.1107 -0.0826
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone ; severe heart failure
H-1701	-0.3279280364513397	▁Race ▁; ▁spi rono lac tone ▁; ▁severe ▁heart ▁failure
D-1701	-0.3279280364513397	Race ; spironolactone ; severe heart failure
P-1701	-0.6749 -0.2251 -0.5832 -0.0129 -0.0527 -0.0656 -0.3264 -1.3067 -0.1288 -0.1628 -0.1882 -0.2077
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients ; heart failure ; cardiac rehabilitation
H-568	-0.6825294494628906	▁heart ▁failure ▁; ▁cardiac ▁rehabilita tion
D-568	-0.6825294494628906	heart failure ; cardiac rehabilitation
P-568	-3.3363 -0.4642 -0.6604 -0.0866 -0.1244 -0.4749 -0.1877 -0.1257
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control ; outcomes
H-1232	-0.45168960094451904	▁ Rhythm - ▁and ▁rate - control ▁strategie s
D-1232	-0.45168960094451904	Rhythm- and rate-control strategies
P-1232	-0.1997 -0.0458 -0.0757 -2.4918 -0.0781 -0.3122 -0.0268 -0.8711 -0.2637 -0.4588 -0.1448
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise ; training ; outcomes
H-1640	-0.5793450474739075	▁race ▁; ▁exercise ▁training
D-1640	-0.5793450474739075	race ; exercise training
P-1640	-1.1271 -0.6327 -0.0732 -1.3582 -0.1731 -0.1118
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia ; patients ; heart disease
H-39	-0.9907294511795044	▁voordelen ▁; ▁an emia ▁treatment ▁; ▁patients ▁; ▁heart ▁disease
D-39	-0.9907294511795044	voordelen ; anemia treatment ; patients ; heart disease
P-39	-2.5004 -0.6241 -0.3855 -0.3894 -2.0728 -0.3761 -1.7592 -2.4997 -0.5093 -0.4672 -0.1496 -0.1555
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians ; patients ; hf
H-1724	-1.0675773620605469	▁physician s ▁; ▁ HF
D-1724	-1.0675773620605469	physicians ; HF
P-1724	-1.7362 -0.0932 -0.4217 -4.4588 -0.4543 -0.2067 -0.1020
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial infarction
H-1137	-0.30276617407798767	▁My o card ial ▁in far ction ▁; ▁Wi star ▁rat s
D-1137	-0.30276617407798767	Myocardial infarction ; Wistar rats
P-1137	-0.2354 -0.1475 -0.2289 -0.3160 -0.0348 -0.2812 -0.0905 -0.4024 -1.6687 -0.1377 -0.0406 -0.1842 -0.3073 -0.1634
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad ai
H-543	-0.4165992736816406	▁algorithm s ▁; ▁post - ▁l VAD ▁AI
D-543	-0.4165992736816406	algorithms ; post- lVAD AI
P-543	-1.4997 -0.1654 -0.4361 -0.1101 -0.0090 -1.5206 -0.0214 -0.0820 -0.1984 -0.1232
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients ; surgical
H-547	-0.7953256964683533	▁AI
D-547	-0.7953256964683533	AI
P-547	-0.9291 -1.3206 -0.1362
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus rhythm ; adverse outcomes
H-1644	-0.295312762260437	▁sinus ▁ rhythm ▁; ▁AF
D-1644	-0.295312762260437	sinus rhythm ; AF
P-1644	-0.4659 -0.2247 -0.0696 -0.5024 -0.6450 -0.0896 -0.0701
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public reporting ; patients ; hospitals
H-1689	-1.1500003337860107	▁public ▁report ing ▁; ▁quality ▁; ▁patients
D-1689	-1.1500003337860107	public reporting ; quality ; patients
P-1689	-2.4945 -0.0783 -0.0559 -0.9499 -2.1414 -0.8325 -2.0363 -1.6333 -0.1279
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative ; operative ; outcomes
H-299	-0.28089162707328796	
D-299	-0.28089162707328796	
P-299	-0.4879 -0.0739
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth ; longitudinal ; medicare
H-1617	-0.7515584230422974	▁care ▁management ▁; ▁tele health ▁; ▁medica re ▁data
D-1617	-0.7515584230422974	care management ; telehealth ; medicare data
P-1617	-5.0959 -0.0713 -0.1285 -0.1494 -0.3616 -0.4518 -0.0378 -0.0361 -1.6159 -0.1679 -0.1508
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal ; diagnostic ; filling pressures
H-490	-0.7382808327674866	▁diagnosti ▁performance ▁; ▁fill ing ▁pressure s
D-490	-0.7382808327674866	diagnosti performance ; filling pressures
P-490	-2.5839 -1.6709 -0.1294 -0.9512 -0.1215 -0.3623 -0.4336 -0.3072 -0.0846
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity pathway analysis
H-875	-0.6458235383033752	▁ingen u ity ▁path way ▁analysis
D-875	-0.6458235383033752	ingenuity pathway analysis
P-875	-0.3376 -0.3284 -0.7751 -1.2532 -0.2440 -1.9364 -0.1041 -0.1877
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf ; chromatin hyperacetylation
H-1036	-0.25693511962890625	▁molecular ▁level ▁; ▁ HF ▁; ▁chr omat in ▁hyper ace ty lation
D-1036	-0.25693511962890625	molecular level ; HF ; chromatin hyperacetylation
P-1036	-1.0267 -0.1188 -0.0864 -0.6651 -0.0450 -0.1907 -0.0926 -0.0260 -0.8853 -0.1583 -0.0909 -0.1446 -0.0649 -0.1835 -0.0753
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing ; nursing
H-1397	-0.9451936483383179	▁nur sing ▁terminologi es
D-1397	-0.9451936483383179	nursing terminologies
P-1397	-2.9192 -0.2157 -0.8578 -0.0606 -1.4872 -0.1307
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute heart failure
H-468	-0.3614078164100647	▁a cute ▁heart ▁failure
D-468	-0.3614078164100647	acute heart failure
P-468	-0.6861 -0.0109 -1.0564 -0.0656 -0.2071 -0.1423
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse events
H-1263	-0.37482133507728577	
D-1263	-0.37482133507728577	
P-1263	-0.6717 -0.0779
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.5205987691879272	▁MS
D-370	-0.5205987691879272	MS
P-370	-1.0876 -0.3967 -0.0775
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-0.5651537775993347	▁g LS ▁; ▁CV ▁events ▁; ▁AF
D-810	-0.5651537775993347	gLS ; CV events ; AF
P-810	-0.4733 -0.4152 -0.2228 -1.6715 -0.3855 -1.6467 -0.0427 -0.1392 -0.0894
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit index
H-1006	-0.36427056789398193	▁deficit ▁index ▁; ▁deficit s
D-1006	-0.36427056789398193	deficit index ; deficits
P-1006	-0.1966 -0.0332 -1.0964 -0.1661 -0.7444 -0.2083 -0.1049
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.16261282563209534	
D-1855	-0.16261282563209534	
P-1855	-0.2399 -0.0853
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.9640188813209534	
D-1165	-0.9640188813209534	
P-1165	-1.8698 -0.0583
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-1.1533328294754028	▁mortal ity
D-1696	-1.1533328294754028	mortality
P-1696	-3.2438 -1.0989 -0.1290 -0.1416
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients ; hospitals
H-3	-0.7548500895500183	
D-3	-0.7548500895500183	
P-3	-1.3869 -0.1228
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs duration
H-888	-0.7908290028572083	▁QR s
D-888	-0.7908290028572083	QRs
P-888	-0.6519 -1.5872 -0.8082 -0.1159
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort study
H-1829	-0.4112657308578491	
D-1829	-0.4112657308578491	
P-1829	-0.7463 -0.0762
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf ; unilateral renal dnx ; cardiac ; autonomic balance
H-1372	-0.5760468244552612	▁CHF ▁; ▁unilateral ▁renal ▁DN x ▁; ▁cardiac ▁autonomi c
D-1372	-0.5760468244552612	CHF ; unilateral renal DNx ; cardiac autonomic
P-1372	-0.0020 -0.1056 -0.0032 -0.0132 -0.4998 -0.0416 -0.3390 -0.0348 -0.0157 -0.2145 -5.5628 -0.0803
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral regurgitation ; hf ; symptoms ; surgery
H-362	-0.34338274598121643	▁mit ral ▁re gur gi tation ▁; ▁ HF
D-362	-0.34338274598121643	mitral regurgitation ; HF
P-362	-1.6603 -0.0887 -0.1267 -0.3243 -0.1493 -0.1916 -0.2526 -0.3419 -0.1920 -0.3249 -0.1249
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone system inhibitors ; heart failure
H-1486	-0.18157923221588135	▁re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁; ▁heart ▁failure
D-1486	-0.18157923221588135	renin-angiotensin-aldosterone system inhibitors ; heart failure
P-1486	-0.1913 -0.1653 -0.0315 -0.0005 -0.1645 -0.5504 -0.1051 -0.0243 -0.1754 -0.0378 -0.3642 -0.1309 -0.0829 -0.1801 -0.4347 -0.1070 -0.3782 -0.1753 -0.1507
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic ; anaerobic threshold ; heart failure
H-1752	-0.3105830252170563	▁ana ero bic ▁thre s hold ▁; ▁heart ▁failure
D-1752	-0.3105830252170563	anaerobic threshold ; heart failure
P-1752	-0.9707 -0.6380 -0.5047 -0.1796 -0.0769 -0.1383 -0.2349 -0.1449 -0.2646 -0.1441 -0.1197
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical ; patients ; functional ms
H-373	-0.33488893508911133	▁functional ▁MS
D-373	-0.33488893508911133	functional MS
P-373	-1.0325 -0.0775 -0.1465 -0.0831
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients ; patients ; echocardiographic
H-813	-0.46513235569000244	▁af ▁patients ▁; ▁e cho car dio graphic ▁examina tion
D-813	-0.46513235569000244	af patients ; echocardiographic examination
P-813	-1.1543 -1.0125 -0.4837 -0.0445 -0.0408 -0.0282 -0.4124 -0.8293 -0.4332 -0.7738 -0.2319 -0.1371
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses ; patients ; disease
H-2020	-1.3200589418411255	▁patients
D-2020	-1.3200589418411255	patients
P-2020	-2.9262 -0.8822 -0.1518
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic ; accounting ; cost
H-1582	-0.44830453395843506	▁net ▁economic ▁sav ings
D-1582	-0.44830453395843506	net economic savings
P-1582	-0.2526 -0.3246 -0.3030 -0.0478 -1.6672 -0.0946
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf ; pb
H-1349	-0.44400501251220703	▁PV F ▁; ▁recovery ▁; ▁ PB
D-1349	-0.44400501251220703	PVF ; recovery ; PB
P-1349	-0.1100 -1.0952 -0.0945 -0.5192 -0.1742 -1.2948 -0.1729 -0.4661 -0.0691
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life ; patients
H-161	-0.7387761473655701	
D-161	-0.7387761473655701	
P-161	-1.3176 -0.1600
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital ; heart ; lesions
H-985	-0.3518371284008026	▁con geni tal ▁heart ▁les ions
D-985	-0.3518371284008026	congenital heart lesions
P-985	-0.6820 -0.0127 -0.0366 -0.8950 -0.6757 -0.2763 -0.1584 -0.0780
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf ; surgical
H-353	-0.16559629142284393	▁MS ▁; HF ▁; ▁sur g ical ▁indica tion ▁; ▁MS
D-353	-0.16559629142284393	MS ;HF ; surgical indication ; MS
P-353	-0.0254 -0.1793 -0.4705 -0.1525 -0.2525 -0.0942 -0.0757 -0.0531 -0.1633 -0.4779 -0.0267 -0.1098 -0.0720
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu ; mortality
H-582	-0.3330456018447876	▁ ICU ▁mortal ity
D-582	-0.3330456018447876	ICU mortality
P-582	-0.1894 -0.0418 -0.3408 -0.5118 -0.8209 -0.0934
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray ; genes ; heart failure
H-1605	-0.6977556347846985	▁bio informati c ▁analysis ▁; ▁micro arra y ▁data ▁; ▁heart ▁failure
D-1605	-0.6977556347846985	bioinformatic analysis ; microarray data ; heart failure
P-1605	-0.1593 -0.0364 -0.0964 -0.5781 -0.2677 -0.0146 -0.0130 -0.0412 -1.6268 -0.5807 -5.4213 -0.5511 -0.2390 -0.1430
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up ; cardiovascular events ; deaths
H-974	-0.4700830578804016	▁cardiovascular ▁events
D-974	-0.4700830578804016	cardiovascular events
P-974	-0.5632 -0.3420 -0.8979 -0.0772
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic ; outcomes ; hf
H-1202	-0.7649304270744324	▁di ure tic ▁; ▁ HF
D-1202	-0.7649304270744324	diuretic ; HF
P-1202	-0.6849 -0.4360 -0.6147 -0.9977 -3.0741 -0.1071 -0.1174 -0.0875
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad ; systolic hf ; prognostic
H-1183	-0.12749210000038147	▁CAD ▁; ▁sy sto lic ▁ HF
D-1183	-0.12749210000038147	CAD ; systolic HF
P-1183	-0.0747 -0.1679 -0.0282 -0.0505 -0.0063 -0.3189 -0.0485 -0.3824 -0.0701
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin ; inflammation ; metabolism ; heart disease
H-940	-0.5878127217292786	▁ inflammation ▁; ▁metabolism ▁; ▁heart ▁disease
D-940	-0.5878127217292786	inflammation ; metabolism ; heart disease
P-940	-3.1053 -0.0785 -0.2185 -0.0149 -0.3538 -0.5414 -0.6337 -0.1738 -0.1704
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 ; therapy
H-401	-0.5667740702629089	▁s st 2 ▁concentration s ▁; ▁benefit ▁; ▁BB ▁ therapy
D-401	-0.5667740702629089	sst2 concentrations ; benefit ; BB therapy
P-401	-0.0722 -2.6139 -0.0902 -0.8515 -0.1716 -0.2323 -1.4325 -0.4752 -0.5169 -0.5116 -0.0233 -0.2129 -0.1640
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart block ; pulmonary artery ; bivp
H-322	-0.16093741357326508	▁Heart ▁block ▁; ▁pulmonar y ▁arter y ▁snar ed ▁; ▁Bi VP
D-322	-0.16093741357326508	Heart block ; pulmonary artery snared ; BiVP
P-322	-0.6270 -0.0811 -0.1319 -0.0131 -0.0418 -0.0101 -0.1739 -0.2535 -0.1009 -0.2188 -0.3345 -0.0375 -0.1497 -0.0792
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance ; attrition
H-1319	-0.4561195969581604	
D-1319	-0.4561195969581604	
P-1319	-0.8579 -0.0543
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt ; patients
H-905	-0.5085033178329468	▁c RT ▁; ▁di al ysis - dependent ▁patients
D-905	-0.5085033178329468	cRT ; dialysis-dependent patients
P-905	-0.5980 -2.9933 -0.5484 -0.2064 -0.0497 -0.0253 -0.1633 -0.0737 -0.5475 -0.2358 -0.1522
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.2901124060153961	▁beta - block ers
D-865	-0.2901124060153961	beta-blockers
P-865	-0.5097 -0.0721 -0.2243 -0.0736 -0.7653 -0.0957
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf ; patients
H-217	-0.5125753879547119	▁CHF ▁patients
D-217	-0.5125753879547119	CHF patients
P-217	-0.1422 -1.1379 -0.7007 -0.0695
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-1.504368543624878	
D-163	-1.504368543624878	
P-163	-2.9000 -0.1087
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.7921892404556274	▁ HF
D-556	-0.7921892404556274	HF
P-556	-2.7497 -0.1419 -0.1928 -0.0844
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac function ; catheter
H-1143	-0.26664119958877563	▁Card iac ▁function ▁; ▁pressure - volu me ▁conduct ance ▁; ▁cat heter ▁system
D-1143	-0.26664119958877563	Cardiac function ; pressure-volume conductance ; catheter system
P-1143	-0.2838 -0.0387 -0.0734 -0.2950 -0.4165 -0.0444 -0.0034 -0.1310 -0.0182 -0.3639 -1.6531 -0.4299 -0.0068 -0.2242 -0.2104 -0.0736
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence ; idiopathic dilated cardiomyopathy
H-1741	-0.22330306470394135	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1741	-0.22330306470394135	idiopathic dilated cardiomyopathy
P-1741	-0.7265 -0.0120 -0.0078 -0.0617 -0.1742 -0.1275 -0.1686 -0.7409 -0.2576 -0.0150 -0.2935 -0.0944
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded protein response ; cardiac sodium ; systolic ; heart failure
H-1079	-0.4017391800880432	▁un fold ed ▁protein ▁response ▁; ▁cardiac ▁so dium ▁current ▁; ▁sy sto lic ▁human ▁heart ▁failure
D-1079	-0.4017391800880432	unfolded protein response ; cardiac sodium current ; systolic human heart failure
P-1079	-2.0033 -0.0003 -0.0315 -0.7298 -0.1909 -0.8868 -0.5216 -0.0125 -0.0062 -0.0366 -0.1610 -0.0326 -0.0204 -0.0076 -1.8567 -0.4437 -0.3140 -0.2203 -0.1570
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia ; prognostic ; patients ; heart failure
H-529	-0.544478714466095	▁hypo album in emia ▁; ▁heart ▁failure
D-529	-0.544478714466095	hypoalbuminemia ; heart failure
P-529	-1.1772 -0.0381 -0.1264 -0.0369 -0.3837 -2.4650 -0.4043 -0.1185 -0.1502
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient ; diagnosed ; hypertensive lv dysfunction
H-350	-0.15067514777183533	▁hyper tensi ve ▁LV ▁dys function ▁; ▁MR ▁; ▁MS
D-350	-0.15067514777183533	hypertensive LV dysfunction ; MR ; MS
P-350	-0.1929 -0.0490 -0.0123 -0.0126 -0.0224 -0.0243 -0.1713 -0.1392 -0.1876 -0.8561 -0.0720 -0.0684
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis ; hf ; etiologies
H-1795	-0.6027309894561768	▁prognos is ▁; ▁c ▁d ▁ HF
D-1795	-0.6027309894561768	prognosis ; c d HF
P-1795	-1.3842 -0.0488 -0.1514 -0.3994 -2.1073 -0.3801 -0.1166 -0.7679 -0.0690
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin receptor neprilysin inhibitor ; heart failure
H-1461	-0.4939236044883728	▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁; ▁heart ▁failure
D-1461	-0.4939236044883728	angiotensin receptor neprilysin inhibitor ; heart failure
P-1461	-1.7202 -0.7289 -0.0365 -0.6800 -0.0681 -1.6515 -0.2775 -0.6541 -0.0756 -0.0456 -0.7028 -0.1132 -0.3101 -0.2149 -0.1300
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western blot ; immunohistochemistry ; electron microscopy
H-1252	-0.23092858493328094	▁Western ▁blot ▁analysis ▁; ▁immun oh isto che mist ry ▁; ▁electro n ▁micro s copy
D-1252	-0.23092858493328094	Western blot analysis ; immunohistochemistry ; electron microscopy
P-1252	-0.1566 -0.0463 -0.2544 -0.1261 -0.0037 -0.0389 -0.5404 -0.2291 -0.3199 -0.9080 -0.1585 -0.0019 -0.0151 -0.0150 -0.4368 -0.4917 -0.2691 -0.1455
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic dysfunction ; patients ; peripheral artery disease
H-1566	-0.1894063800573349	▁dia sto lic ▁dys function ▁; ▁per i pher al ▁arter y ▁disease
D-1566	-0.1894063800573349	diastolic dysfunction ; peripheral artery disease
P-1566	-0.0098 -0.0752 -0.0719 -0.0789 -0.0658 -0.1848 -0.5770 -0.0726 -0.0159 -0.0903 -0.0666 -0.6239 -0.4873 -0.2741 -0.1472
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic cardiomyopathy ; mortality
H-67	-0.37654930353164673	▁i sche mic ▁cardio my o pathy ▁; ▁male ▁sex ▁; ▁mortal ity
D-67	-0.37654930353164673	ischemic cardiomyopathy ; male sex ; mortality
P-67	-1.1742 -0.0010 -0.0428 -0.0843 -0.5554 -0.2769 -0.0137 -0.1056 -0.3702 -0.4017 -0.4822 -0.9012 -0.9709 -0.1156 -0.1527
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical ; hfpef
H-943	-0.8448246121406555	▁AF ▁; ▁clinic al ▁deteriora tion ▁; ▁h FP EF
D-943	-0.8448246121406555	AF ; clinical deterioration ; hFPEF
P-943	-0.6702 -0.2924 -4.8829 -0.0242 -0.1214 -0.8202 -0.5956 -1.2065 -0.8224 -0.4300 -0.1483 -0.1237
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients ; heart transplant ; ecct
H-714	-0.7831591963768005	▁heart ▁transplant ▁; ▁ec CT
D-714	-0.7831591963768005	heart transplant ; ecCT
P-714	-3.3384 -0.0858 -0.6816 -0.9474 -0.2365 -0.0961 -0.0962
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome ; hdl
H-254	-0.4179708957672119	▁prote ome ▁; ▁HD L ▁parti cles ▁; ▁shot gun ▁; LC - MS
D-254	-0.4179708957672119	proteome ; HDL particles ; shotgun ;LC-MS
P-254	-0.7038 -0.0562 -0.1990 -0.2092 -1.8797 -0.1928 -0.0268 -0.3502 -0.3492 -0.0212 -0.5095 -0.8211 -0.0429 -0.0759 -1.1426 -0.1073
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty ; hf
H-632	-0.4120856523513794	▁fra il ty ▁; ▁risk ▁; ▁ HF
D-632	-0.4120856523513794	frailty ; risk ; HF
P-632	-0.7612 -0.3303 -0.0608 -0.0960 -0.8399 -0.3000 -0.8343 -0.0654 -0.7436 -0.0893
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota ; hf
H-1003	-0.3578307032585144	▁South e a stern ▁Minnesota ▁residents ▁; ▁ HF
D-1003	-0.3578307032585144	Southeastern Minnesota residents ; HF
P-1003	-2.3595 -0.0290 -0.0301 -0.0067 -0.0490 -0.4083 -0.4712 -0.2271 -0.1602 -0.1152 -0.0799
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left bundle branch block
H-1153	-0.7264930605888367	▁bund le ▁bran ch ▁block ▁; ▁electric al ▁activa tion ▁se que nce
D-1153	-0.7264930605888367	bundle branch block ; electrical activation sequence
P-1153	-1.2789 -0.9473 -0.9312 -0.1150 -0.6879 -0.5653 -0.6599 -0.0383 -0.0077 -0.4175 -0.5787 -3.1142 -1.2293 -0.2155 -0.1107
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4 inhibitors ; drugs
H-1834	-0.26251131296157837	▁h HF ▁; ▁d PP -4 ▁inhibi tors ▁; ▁drugs
D-1834	-0.26251131296157837	hHF ; dPP-4 inhibitors ; drugs
P-1834	-0.0477 -0.2697 -0.1794 -0.3756 -0.1933 -0.0726 -0.0241 -0.0915 -1.1800 -0.4798 -0.1464 -0.0900
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins ; tac
H-872	-0.7036581635475159	▁protein s ▁; TAC
D-872	-0.7036581635475159	proteins ;TAC
P-872	-1.4938 -0.1096 -0.5782 -1.6974 -0.2457 -0.0972
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac cachexia
H-9	-0.3610423505306244	▁Card iac ▁cache xia ▁; cc
D-9	-0.3610423505306244	Cardiac cachexia ;cc
P-9	-0.8754 -0.0092 -0.0173 -0.0837 -0.2284 -0.3535 -1.2294 -0.0914
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling pathways ; cardiac remodelling
H-992	-0.5656139254570007	▁signal ling ▁path ways ▁activa ting ▁; ▁mal adapt ive ▁cardiac ▁remodel ling
D-992	-0.5656139254570007	signalling pathways activating ; maladaptive cardiac remodelling
P-992	-1.9835 -0.4836 -0.8989 -0.2265 -0.8964 -0.5334 -0.6657 -1.7870 -0.0103 -0.0911 -0.2323 -0.1087 -0.1252 -0.3017 -0.1400
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications ; dialysis ; patients
H-908	-0.509376585483551	▁di al ysis ▁patients
D-908	-0.509376585483551	dialysis patients
P-908	-1.4350 -0.0504 -0.0425 -1.2422 -0.1523 -0.1338
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end point ; neurological ; cardiovascular events
H-1872	-0.9500097632408142	▁neurologi cal ▁; ▁cardiovascular
D-1872	-0.9500097632408142	neurological ; cardiovascular
P-1872	-2.3942 -0.7079 -0.8638 -0.0058 -1.5815 -0.1469
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary disease ; leading ; heart failure
H-981	-0.42248573899269104	▁corona ry ▁disease ▁; ▁heart ▁failure
D-981	-0.42248573899269104	coronary disease ; heart failure
P-981	-0.2181 -1.0340 -0.2448 -0.0886 -1.4372 -0.0981 -0.1754 -0.0837
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ; ffm ; stable
H-20	-0.562605619430542	▁f FM ▁; ▁FM ▁; ▁body ▁weight ▁; ▁CC
D-20	-0.562605619430542	fFM ; FM ; body weight ; CC
P-20	-0.3447 -1.0165 -0.2437 -1.1309 -0.3310 -1.9874 -0.1153 -0.7036 -0.1187 -0.0984 -0.0985
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart failure ; nurse
H-84	-1.0406572818756104	▁heart ▁failure ▁guidelines ▁; ▁nurse ▁leaders
D-84	-1.0406572818756104	heart failure guidelines ; nurse leaders
P-84	-4.7621 -0.1037 -1.7969 -1.0754 -0.2024 -0.0754 -0.1751 -0.1344
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise ; training ; endothelial function
H-248	-0.2816166281700134	▁ Protect ive ▁effects ▁; ▁exercise ▁training ▁; ET ▁; ▁en dot heli al ▁function
D-248	-0.2816166281700134	Protective effects ; exercise training ;ET ; endothelial function
P-248	-1.7330 -0.1780 -0.0401 -0.3045 -0.4290 -0.2945 -0.3179 -0.1641 -0.3573 -0.4107 -0.0202 -0.1909 -0.0345 -0.0115 -0.0502 -0.1602 -0.0908
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery ; mva
H-361	-0.4071462154388428	▁MS
D-361	-0.4071462154388428	MS
P-361	-0.4280 -0.7182 -0.0752
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise ; exercise
H-1931	-1.4302245378494263	▁social ▁support ▁; ▁barrier s ▁to ▁exercise
D-1931	-1.4302245378494263	social support ; barriers to exercise
P-1931	-4.3227 -0.8187 -0.1829 -3.8836 -0.0720 -0.8019 -0.3689 -2.3101 -0.1114
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart rate
H-1446	-1.2009105682373047	▁heart ▁rate ▁variation
D-1446	-1.2009105682373047	heart rate variation
P-1446	-3.8993 -0.6509 -1.0765 -0.2128 -0.1650
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.3389127552509308	▁c RF
D-1769	-0.3389127552509308	cRF
P-1769	-0.8506 -0.2051 -0.2333 -0.0667
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.500159502029419	▁Mediterrane an ▁; ▁DAS h ▁die t ▁score s
D-688	-0.500159502029419	Mediterranean ; DASh diet scores
P-688	-0.7159 -0.0134 -0.1700 -0.0105 -0.1275 -2.1605 -0.1222 -0.3413 -0.1677 -1.5548 -0.1180
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.8220154047012329	▁re hospital ization
D-1711	-0.8220154047012329	rehospitalization
P-1711	-3.4548 -0.0266 -0.3706 -0.1375 -0.1204
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl ; hno ; acute ; heart failure
H-412	-0.4217803478240967	▁ni tro x yl ▁; ▁h no ▁; ▁a cute ▁treatment ▁; ▁heart ▁failure
D-412	-0.4217803478240967	nitroxyl ; hno ; acute treatment ; heart failure
P-412	-0.2815 -0.0084 -0.1774 -0.0700 -0.0635 -1.4415 -0.6812 -0.2009 -1.1251 -0.0319 -1.1264 -0.8463 -0.2613 -0.1630 -0.1570 -0.1131
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization therapy ; heart failure ; narrow qrs complex
H-844	-0.41256222128868103	▁Card iac - re syn chron ization ▁ therapy ▁; ▁heart ▁failure
D-844	-0.41256222128868103	Cardiac-resynchronization therapy ; heart failure
P-844	-0.6478 -0.0758 -0.0499 -0.2220 -0.1600 -0.0131 -0.7863 -1.9932 -0.0303 -0.3530 -0.3778 -0.2658 -0.7073 -0.0935
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate models ; odds ratios ; accounting ; hospital
H-191	-0.20545358955860138	▁odds ▁ratio s ▁; ▁account ing ▁; ▁hospital ▁cluster ing
D-191	-0.20545358955860138	odds ratios ; accounting ; hospital clustering
P-191	-0.5021 -0.0322 -0.2044 -0.3254 -0.0287 -0.0221 -0.8393 -0.1139 -0.0048 -0.0744 -0.1743 -0.1437
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change ; lvet ; admission ; follow-up ; outcome
H-588	-0.3840295076370239	▁l VET ▁; ▁follow - up ▁measure ment
D-588	-0.3840295076370239	lVET ; follow-up measurement
P-588	-1.4496 -0.1461 -0.4872 -0.5585 -0.0982 -0.0224 -0.5328 -0.1983 -0.2090 -0.1382
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute walk distance ; peak vo2 ; baseline
H-1636	-0.6142297387123108	▁black s ▁; ▁VO 2
D-1636	-0.6142297387123108	blacks ; VO2
P-1636	-0.7267 -0.0567 -0.9691 -2.0425 -0.1133 -0.2115 -0.1798
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician ; death ; readmission ; discharge ; patients ; heart failure
H-1412	-0.7284360527992249	▁physician ▁continu ity ▁; ▁death ▁; ▁urgent ▁read mission ▁; ▁dis charge ▁; ▁heart ▁failure
D-1412	-0.7284360527992249	physician continuity ; death ; urgent readmission ; discharge ; heart failure
P-1412	-0.5243 -0.1602 -0.2086 -0.3129 -3.3857 -0.1065 -0.1093 -1.1218 -0.6246 -0.7624 -0.3217 -0.0810 -1.0154 -3.1694 -0.1524 -0.1916 -0.1356
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref ; hfpef ; patients ; regression line
H-497	-0.581913411617279	▁h Fr EF ▁; ▁ HF p EF
D-497	-0.581913411617279	hFrEF ; HFpEF
P-497	-2.0211 -0.4431 -0.5904 -0.0446 -0.0828 -0.2400 -0.0576 -0.3751 -1.8245 -0.1400
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home ; hospital ; readmission ; congestive heart failure
H-1573	-0.6586059331893921	▁hospital - to - Home ▁; ▁read mission ▁re duction ▁program ▁; ▁con ges tive ▁heart ▁failure
D-1573	-0.6586059331893921	hospital-to-Home ; readmission reduction program ; congestive heart failure
P-1573	-0.9268 -0.2068 -0.0375 -0.0295 -0.1819 -0.4583 -3.6391 -2.2237 -0.0589 -0.0491 -1.6041 -0.4099 -0.0241 -0.1336 -1.4192 -0.5191 -0.2821 -0.1946 -0.1151
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk stratification ; death ; all-cause hospitalization ; heart failure ; clinic ; outpatients
H-377	-0.94051593542099	▁risk ▁strat ification ▁; ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure ▁clinic
D-377	-0.94051593542099	risk stratification ; death ; hospitalization ; heart failure clinic
P-377	-3.3572 -2.5508 -0.5274 -0.3038 -1.8200 -0.2159 -1.5057 -0.4248 -0.3576 -0.1094 -0.1252 -0.2444 -1.4593 -0.1657
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients ; diabetes ; eo-cfus ; functional capacity
H-132	-0.40474236011505127	▁diabetes ▁; ▁ EO - c FU s
D-132	-0.40474236011505127	diabetes ; EO-cFUs
P-132	-0.1054 -0.2662 -1.6231 -0.0123 -0.0214 -0.9231 -0.0818 -0.3187 -0.5924 -0.1029
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-0.976665198802948	▁patient ▁safety
D-1	-0.976665198802948	patient safety
P-1	-3.1569 -0.4834 -0.1155 -0.1509
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients ; transplants
H-2000	-0.5435027480125427	▁transplant s
D-2000	-0.5435027480125427	transplants
P-2000	-1.5491 -0.1430 -0.4144 -0.0675
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy ; engage ; exercise
H-1903	-1.255605697631836	▁health y ▁; ▁aero bic
D-1903	-1.255605697631836	healthy ; aerobic
P-1903	-3.9895 -0.3369 -1.6918 -0.4924 -0.0792 -2.0855 -0.1139
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals ; outcome
H-1690	-1.2789281606674194	
D-1690	-1.2789281606674194	
P-1690	-2.4115 -0.1463
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf ; patients
H-671	-0.6353256106376648	▁tras tuz um ab - related ▁CHF
D-671	-0.6353256106376648	trastuzumab-related CHF
P-671	-1.8851 -0.0291 -0.0229 -1.3142 -0.3069 -0.6728 -0.5533 -0.7481 -0.1854
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.479570597410202	▁hospital s
D-1694	-0.479570597410202	hospitals
P-1694	-1.0769 -0.3550 -0.4211 -0.0653
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak vo2
H-1498	-0.2767818570137024	▁Peak ▁VO 2
D-1498	-0.2767818570137024	Peak VO2
P-1498	-0.4866 -0.1600 -0.2086 -0.3992 -0.1294
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.4331614375114441	▁ pharma ce ut ically ▁assist ed
D-948	-0.4331614375114441	pharmaceutically assisted
P-948	-0.2245 -0.2492 -1.2896 -0.0632 -0.2229 -1.0468 -0.1603 -0.5660 -0.0760
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.1974389553070068	
D-1955	-1.1974389553070068	
P-1955	-2.2823 -0.1126
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary artery disease ; cad ; systolic heart failure ; hf
H-1182	-0.13722705841064453	▁Corona ry ▁arter y ▁disease ▁; CAD ▁; ▁sy sto lic ▁heart ▁failure ▁; HF
D-1182	-0.13722705841064453	Coronary artery disease ;CAD ; systolic heart failure ;HF
P-1182	-0.0477 -0.8313 -0.0409 -0.0750 -0.2833 -0.0703 -0.0435 -0.0736 -0.0072 -0.0089 -0.0366 -0.2275 -0.1369 -0.2411 -0.0124 -0.1332 -0.0635
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative ; hypoalbuminemia ; prognosis ; lvad ; surgery
H-538	-0.5994164943695068	▁hypo album in emia ▁; ▁l VAD
D-538	-0.5994164943695068	hypoalbuminemia ; lVAD
P-538	-1.0695 -0.0662 -0.1066 -0.0891 -0.3823 -0.2807 -0.0125 -3.2728 -0.1152
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis ; atherosclerosis ; cardiovascular events ; rotterdam study
H-1554	-0.3585396409034729	▁p sori asis ▁; ▁at hero sc ler osis ▁; ▁incident ▁cardiovascular ▁events ▁; ▁Rotterdam ▁Study
D-1554	-0.3585396409034729	psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam Study
P-1554	-1.0240 -0.0447 -0.0281 -0.0873 -0.5998 -0.1068 -0.0217 -2.1549 -0.0139 -0.1173 -0.1744 -0.0319 -0.1300 -0.6133 -0.0800 -0.9109 -0.2205 -0.0941
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality ; hf ; hospital ; admissions ; transplant ; ventricular assist device
H-125	-0.2977987825870514	▁mortal ity ▁; HF ▁hospital ▁ad missions ▁; ▁transplant ▁; ▁vent ri cular ▁assist ▁device
D-125	-0.2977987825870514	mortality ;HF hospital admissions ; transplant ; ventricular assist device
P-125	-0.2971 -0.6223 -0.1339 -1.2228 -0.5382 -0.1477 -0.0797 -0.0794 -0.0110 -0.2437 -0.0171 -0.6449 -0.1700 -0.4325 -0.1673 -0.1698 -0.0851
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart failure ; patients ; rheumatoid arthritis ; tnf antagonist
H-600	-0.4069332182407379	▁Heart ▁failure ▁; ▁rhe um ato id ▁ar thri tis ▁; ▁t NF ▁anta gon ist
D-600	-0.4069332182407379	Heart failure ; rheumatoid arthritis ; tNF antagonist
P-600	-0.3246 -0.2643 -1.1727 -1.6205 -0.0217 -0.1710 -0.1470 -0.0275 -0.1974 -0.3923 -0.8912 -1.0147 -0.0403 -0.4888 -0.0023 -0.1419 -0.2732 -0.1333
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade ; holosystolic murmur ; third heart sound ; apex
H-342	-0.4577399492263794	▁holo sy sto lic ▁mur mur ▁; ▁heart ▁sound
D-342	-0.4577399492263794	holosystolic murmur ; heart sound
P-342	-0.0278 -0.1681 -0.1465 -0.0192 -0.1328 -0.0194 -0.2199 -3.5799 -0.5239 -0.1235 -0.0742
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death ; stroke ; hospitalisation ; heart failure
H-815	-0.3405521810054779	▁CV ▁; ▁non - fa tal ▁stroke ▁; ▁hospital isation ▁; ▁heart ▁failure
D-815	-0.3405521810054779	CV ; non-fatal stroke ; hospitalisation ; heart failure
P-815	-0.1103 -0.6966 -2.3211 -0.0262 -0.0248 -0.0268 -0.2594 -0.1609 -0.3276 -0.0393 -0.5810 -0.1264 -0.0750 -0.1675 -0.1654
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling ; hf ; haemodynamic ; neuronal stressors
H-1039	-0.291744589805603	▁ha emo dynamic ▁; ▁neuron al ▁stress ors
D-1039	-0.291744589805603	haemodynamic ; neuronal stressors
P-1039	-1.6455 -0.1252 -0.0018 -0.1208 -0.0620 -0.0232 -0.2531 -0.3417 -0.2511 -0.0930
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit index ; biological phenotype ; mortality
H-1012	-0.6020212173461914	▁deficit ▁index ▁; ▁bi ological ▁ph eno type
D-1012	-0.6020212173461914	deficit index ; biological phenotype
P-1012	-1.1266 -0.0507 -0.0998 -0.5478 -0.1765 -0.8559 -0.2647 -0.0014 -2.7398 -0.1568
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right ventricular function ; prognosis ; heart failure
H-1157	-0.6807419657707214	▁right ▁vent ri cular ▁function ▁; ▁body ▁composition ▁; ▁heart ▁failure
D-1157	-0.6807419657707214	right ventricular function ; body composition ; heart failure
P-1157	-1.3422 -0.1317 -1.0123 -0.3078 -0.3352 -0.2389 -0.5187 -0.0990 -0.1380 -4.0543 -0.4388 -0.1157 -0.1170
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia ; right ventricle ; heart failure
H-1457	-0.2736782133579254	▁Fat ▁; ▁cache xia ▁; ▁right ▁vent ric le ▁; ▁heart ▁failure
D-1457	-0.2736782133579254	Fat ; cachexia ; right ventricle ; heart failure
P-1457	-0.1744 -0.3517 -0.0092 -0.0247 -0.0790 -0.9973 -0.0302 -0.9545 -0.1967 -0.3947 -0.1119 -0.1088 -0.2880 -0.1104
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial fibrillation ; patients ; heart failure
H-1231	-0.344744473695755	▁At rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure
D-1231	-0.344744473695755	Atrial fibrillation ;AF ; heart failure
P-1231	-1.7880 -0.0094 -0.3713 -0.0143 -0.0739 -0.2428 -0.2129 -0.3166 -0.6799 -0.1472 -0.1748 -0.1056
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct ; heart failure ; therapy ; patients
H-718	-0.408103346824646	▁ec CT ▁; ▁advanced ▁heart ▁failure ▁ therapy
D-718	-0.408103346824646	ecCT ; advanced heart failure therapy
P-718	-0.3791 -1.2318 -0.2171 -0.4900 -0.7419 -0.1350 -0.3439 -0.0202 -0.3784 -0.1437
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart transplantation ; left ventricular assist device
H-306	-0.6173267960548401	▁e ligi bility ▁; ▁heart ▁transplant ation ▁; ▁left ▁vent ri cular ▁assist ▁device
D-306	-0.6173267960548401	eligibility ; heart transplantation ; left ventricular assist device
P-306	-2.1966 -0.0055 -0.4030 -0.1553 -0.7729 -0.3111 -0.4716 -0.2391 -0.6154 -0.0442 -1.3893 -0.1768 -1.1673 -0.4758 -1.3582 -0.0952
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise intolerance ; chronic heart failure ; prognosis
H-1273	-0.35065826773643494	▁Exerci se ▁in tolerance ▁; ▁chronic ▁heart ▁failure
D-1273	-0.35065826773643494	Exercise intolerance ; chronic heart failure
P-1273	-1.2215 -0.0486 -0.0127 -0.0260 -0.1663 -0.5312 -0.8233 -0.2079 -0.3663 -0.1029
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd ; vvd ; free wall rs
H-328	-0.3664528429508209	▁AV d ▁; ▁VVD ▁; ▁co ▁; ▁free ▁wall ▁RS
D-328	-0.3664528429508209	AVd ; VVD ; co ; free wall RS
P-328	-0.1541 -0.6800 -0.0548 -0.2280 -0.3325 -1.9327 -0.1722 -0.0484 -0.1507 -0.4430 -0.1215 -0.0794
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical ; connected ; elevated ; resistin ; heart failure
H-929	-1.2205898761749268	▁resist in ▁; ▁heart ▁failure
D-929	-1.2205898761749268	resistin ; heart failure
P-929	-3.8452 -0.6228 -2.7980 -0.7839 -0.2675 -0.1410 -0.0857
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ; ecgs ; electrocardiographers
H-884	-0.273146390914917	▁e CG s ▁; ▁electro car dio graph ers
D-884	-0.273146390914917	eCGs ; electrocardiographers
P-884	-0.6004 -0.2047 -0.2268 -0.3879 -0.0355 -0.0209 -0.4982 -0.5260 -0.1147 -0.2708 -0.1187
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left ventricular assist device ; right ventricular support
H-293	-0.425740510225296	▁left ▁vent ri cular ▁assist ▁device ▁; ▁right ▁vent ri cular ▁support
D-293	-0.425740510225296	left ventricular assist device ; right ventricular support
P-293	-0.6363 -0.0247 -0.4140 -0.1081 -1.1328 -0.3217 -0.2113 -0.6906 -0.0342 -0.5748 -0.1476 -1.2937 -0.2791 -0.0915
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence ; esrd ; outpatients ; hf
H-388	-0.39629054069519043	▁incide nce ▁; ▁predict ors ▁; ▁ES RD ▁; ▁out patient s ▁; HF
D-388	-0.39629054069519043	incidence ; predictors ; ESRD ; outpatients ;HF
P-388	-1.5372 -0.8721 -0.0539 -0.3167 -0.1254 -0.1589 -0.1788 -0.2184 -0.2270 -0.3128 -0.0048 -0.0610 -0.6404 -1.3646 -0.1678 -0.1009
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon matched-pairs signed-rank tests
H-923	-0.3872928321361542	▁Wil co xon
D-923	-0.3872928321361542	Wilcoxon
P-923	-0.2720 -0.0100 -0.1402 -1.3787 -0.1355
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical ; atherosclerosis ; linear models
H-1557	-0.8890612721443176	▁sub clin ical ▁at hero sc ler osis ▁; ▁linear ▁models
D-1557	-0.8890612721443176	subclinical atherosclerosis ; linear models
P-1557	-2.8631 -0.0886 -0.2426 -1.8910 -0.4530 -0.0382 -3.6541 -0.0299 -1.2916 -0.0322 -0.6382 -0.1613 -0.1741
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal artery stenosis ; ras ; peripheral arterial disease
H-1593	-0.10720369964838028	▁Ren al ▁arter y ▁sten osis ▁; RAS ▁; ▁per i pher al ▁arterial ▁disease
D-1593	-0.10720369964838028	Renal artery stenosis ;RAS ; peripheral arterial disease
P-1593	-0.1409 -0.0182 -0.0322 -0.1565 -0.0055 -0.0192 -0.1537 -0.0061 -0.2865 -0.0460 -0.0364 -0.0083 -0.0329 -0.0460 -0.5553 -0.1513 -0.1275
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline ; outcomes ; ecct ; cardiac transplant
H-711	-0.3540647029876709	▁ec CT ▁; ▁cardiac ▁transplant ▁recipient s
D-711	-0.3540647029876709	ecCT ; cardiac transplant recipients
P-711	-0.4668 -1.3353 -0.1977 -0.1326 -0.1502 -0.0643 -0.3975 -0.2467 -0.1956
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone ; primary composite endpoint
H-1227	-0.2558611333370209	▁e pler en one
D-1227	-0.2558611333370209	eplerenone
P-1227	-0.1645 -0.0012 -0.0542 -0.2601 -0.9274 -0.1276
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient ; asymptomatic ; follow-up
H-599	-0.6567966341972351	
D-599	-0.6567966341972351	
P-599	-1.2375 -0.0761
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients ; extubated ; blood ; transfusion
H-777	-1.0839673280715942	▁ex tuba ted ▁; ▁blood ▁loss
D-777	-1.0839673280715942	extubated ; blood loss
P-777	-1.7628 -0.0275 -0.2576 -0.4604 -0.7510 -0.2391 -5.0884 -0.0849
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate ii ; lvads ; patients
H-776	-0.45842358469963074	▁techniek ▁; ▁mal function ing ▁Heart Mate ▁II ▁l VAD s
D-776	-0.45842358469963074	techniek ; malfunctioning HeartMate II lVADs
P-776	-0.9188 -0.3080 -1.4102 -0.0570 -0.0346 -0.8720 -0.0443 -1.0535 -0.4197 -0.0166 -0.2807 -0.3789 -0.1654
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart failure ; hf ; cardiovascular ; hospitalization
H-1074	-0.302123099565506	▁Heart ▁failure ▁; HF ▁; ▁cardiovascular ▁hospital ization
D-1074	-0.302123099565506	Heart failure ;HF ; cardiovascular hospitalization
P-1074	-0.4806 -0.0318 -0.1201 -0.0177 -0.2835 -0.1400 -0.6298 -0.3841 -0.8201 -0.1135
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf inhibition ; cardiac function ; remodeling
H-458	-0.4321306645870209	▁VE GF ▁inhibi tion ▁; ▁b ▁; ▁cardiac ▁function ▁; ▁remodel ing
D-458	-0.4321306645870209	VEGF inhibition ; b ; cardiac function ; remodeling
P-458	-0.5190 -0.0804 -0.0452 -0.1176 -0.2450 -2.1578 -1.1589 -0.0400 -0.0701 -1.3566 -0.0139 -0.0319 -0.1433 -0.0700
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing ; β-blocker ; sst2
H-400	-0.5768340826034546	▁β - block er ▁; bb ▁; ▁s ST 2
D-400	-0.5768340826034546	β-blocker ;bb ; sST2
P-400	-0.4979 -0.0628 -0.1823 -0.0907 -0.3502 -0.7739 -0.8212 -0.0116 -1.9808 -0.1337 -1.8472 -0.1696
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas ; cardiac ; pathogenesis
H-1484	-0.7336107492446899	▁mi RNA s ▁; ▁cardiac ▁path ogen es
D-1484	-0.7336107492446899	miRNAs ; cardiac pathogenes
P-1484	-1.1135 -0.0247 -0.1030 -0.2425 -0.1297 -1.0256 -0.1443 -0.1009 -4.3525 -0.0994
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet ; exercise rehabilitation ; patients ; chf
H-1884	-0.3991084396839142	▁c PET ▁gu iding ▁exercise ▁rehabilita tion ▁; ▁CHF
D-1884	-0.3991084396839142	cPET guiding exercise rehabilitation ; CHF
P-1884	-0.3036 -1.7040 -0.4324 -0.0079 -0.6967 -0.1500 -0.2092 -0.4134 -0.2628 -0.1313 -0.0789
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient ; heart failure with reduced ejection fraction
H-1203	-0.4804384410381317	▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-1203	-0.4804384410381317	heart failure ; reduced ejection fraction
P-1203	-3.0818 -0.0818 -0.5349 -0.8784 -0.0092 -0.0165 -0.1076 -0.0327 -0.3955 -0.0062 -0.5131 -0.1078
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients ; heart failure ; diagnostic ; medication ; follow-up
H-732	-0.9279072880744934	▁heart ▁failure
D-732	-0.9279072880744934	heart failure
P-732	-2.3450 -0.3404 -0.8654 -0.1609
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart failure ; hf ; morbidity ; mortality
H-199	-0.42786845564842224	▁Pediatri c ▁heart ▁failure ▁; HF
D-199	-0.42786845564842224	Pediatric heart failure ;HF
P-199	-0.5305 -0.0159 -0.7569 -0.0651 -0.1317 -0.0404 -1.7809 -0.1016
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression ; type i regulatory subunit ; ri ; hf
H-1429	-0.45643436908721924	▁regulator y ▁sub un it ▁; RI ▁; ▁ HF
D-1429	-0.45643436908721924	regulatory subunit ;RI ; HF
P-1429	-2.5857 -0.0515 -0.0350 -0.2670 -0.0573 -0.1412 -0.4369 -0.2584 -1.2080 -0.2538 -0.0875 -0.0950
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients ; discharge ; follow-up ; medication
H-730	-1.0937449932098389	▁dis charge ▁; ▁follow - up
D-730	-1.0937449932098389	discharge ; follow-up
P-730	-2.7206 -0.0785 -0.5480 -0.0164 -0.1128 -0.0115 -5.1234 -0.1389
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain proteins
H-1042	-0.5334246158599854	bro modo main ▁protein s
D-1042	-0.5334246158599854	bromodomain proteins
P-1042	-3.1077 -0.0282 -0.0279 -0.1814 -0.0603 -0.2387 -0.0897
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative ; clinical ; mortality
H-532	-0.9796565175056458	
D-532	-0.9796565175056458	
P-532	-1.8586 -0.1007
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart failure ; readmission ; outcome
H-1030	-1.1691184043884277	▁heart ▁failure
D-1030	-1.1691184043884277	heart failure
P-1030	-0.9083 -0.0837 -3.5645 -0.1199
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt ; dt ; implantation
H-315	-0.3967071771621704	▁b t ▁; ▁ DT
D-315	-0.3967071771621704	bt ; DT
P-315	-0.8048 -0.7182 -0.2387 -0.1585 -0.1214 -0.6419 -0.0935
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes ; hospitalization
H-566	-1.230760097503662	▁Fa tal ▁; ▁non fa tal
D-566	-1.230760097503662	Fatal ; nonfatal
P-566	-4.4361 -0.0377 -1.1907 -0.0929 -0.1187 -0.1289 -3.6894 -0.1517
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse event ; hypotension
H-1970	-0.4902999699115753	▁hypo tension
D-1970	-0.4902999699115753	hypotension
P-1970	-1.3745 -0.0879 -0.4075 -0.0913
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers ; hf
H-1475	-0.2846626043319702	▁bio mark ers ▁; ▁treatment ▁; ▁ HF
D-1475	-0.2846626043319702	biomarkers ; treatment ; HF
P-1475	-0.0167 -0.0808 -0.0698 -0.1767 -0.9427 -0.7319 -0.5608 -0.0780 -0.0766 -0.1127
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up ; hf
H-288	-0.7591596245765686	▁ HF
D-288	-0.7591596245765686	HF
P-288	-2.3615 -0.4836 -0.1158 -0.0757
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 ; patients ; plasma
H-699	-0.5317566394805908	▁ST 2 ▁; ▁plasma ▁sample s
D-699	-0.5317566394805908	ST2 ; plasma samples
P-699	-0.7228 -0.2038 -1.2068 -1.3057 -0.3139 -0.2249 -0.1647 -0.1114
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients ; condition ; economic
H-1575	-1.328524112701416	▁economische
D-1575	-1.328524112701416	economische
P-1575	-3.3176 -0.5186 -0.1493
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing ; medications ; heart failure
H-1121	-1.637001395225525	▁medication s ▁; ▁heart ▁failure
D-1121	-1.637001395225525	medications ; heart failure
P-1121	-5.7463 -0.2184 -0.8046 -4.1275 -0.1363 -0.2695 -0.1566
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient ; mortality ; therapeutic
H-1667	-1.0523895025253296	▁mortal ity
D-1667	-1.0523895025253296	mortality
P-1667	-2.0424 -0.8145 -1.2562 -0.0964
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary heart disease ; stroke ; heart failure
H-1564	-0.2525571286678314	▁corona ry ▁heart ▁disease ▁; ▁stroke ▁; ▁heart ▁failure
D-1564	-0.2525571286678314	coronary heart disease ; stroke ; heart failure
P-1564	-0.0479 -0.7466 -0.4129 -0.4793 -0.1078 -0.0362 -0.1476 -0.3827 -0.2040 -0.1209 -0.0921
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality of life ; mlhf questionnaire
H-1991	-0.7742519378662109	▁ ML HF ▁Question naire
D-1991	-0.7742519378662109	MLHF Questionnaire
P-1991	-2.0546 -0.5155 -0.7918 -1.8190 -0.0076 -0.1058 -0.1254
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions ; septal ; surgical
H-984	-0.3404291570186615	▁sept al ▁defect s
D-984	-0.3404291570186615	septal defects
P-984	-0.4285 -0.0255 -0.0161 -0.0829 -1.4179 -0.0716
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis ; mortality ; patients
H-61	-0.7758005857467651	▁i CD - HF ▁patients
D-61	-0.7758005857467651	iCD-HF patients
P-61	-2.7711 -0.5985 -0.0376 -0.0898 -1.2891 -0.2959 -0.3486
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral renal denervation ; autonomic balance ; chronic heart failure
H-1369	-0.4044135510921478	▁renal ▁den er va tion ▁; ▁autonomi c ▁balance ▁; ▁rabbi ts ▁; ▁chronic ▁heart ▁failure
D-1369	-0.4044135510921478	renal denervation ; autonomic balance ; rabbits ; chronic heart failure
P-1369	-1.1411 -0.7613 -0.1929 -0.2423 -0.3341 -0.1342 -0.0058 -0.3602 -0.2151 -0.2174 -0.8703 -0.0639 -0.3226 -0.8418 -0.8112 -0.4334 -0.2019 -0.1300
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient ; clinical ; symptoms
H-1468	-0.9663776159286499	
D-1468	-0.9663776159286499	
P-1468	-1.8362 -0.0966
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients ; trastuzumab
H-676	-0.22375182807445526	▁tras tuz um ab
D-676	-0.22375182807445526	trastuzumab
P-676	-0.5642 -0.0428 -0.0103 -0.4425 -0.1855 -0.0972
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna ; genotyped
H-1454	-0.5443841218948364	▁germ line ▁DNA ▁; ▁geno type d
D-1454	-0.5443841218948364	germline DNA ; genotyped
P-1454	-2.4431 -0.0421 -0.3513 -1.3253 -0.0160 -0.0028 -0.3789 -0.2457 -0.0941
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart failure ; disease ; medical
H-2008	-0.801388680934906	▁Heart ▁failure ▁disease ▁management ▁; ▁medical ▁resource
D-2008	-0.801388680934906	Heart failure disease management ; medical resource
P-2008	-0.8095 -0.3265 -0.5590 -0.4024 -1.5388 -1.3607 -0.6159 -1.4712 -0.1285
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal dnx ; plasma
H-1381	-0.28303855657577515	▁Ren al ▁DN x ▁; ▁circula ting ▁plasma ▁NE ▁; ▁CHF - IN v ▁rabbi ts
D-1381	-0.28303855657577515	Renal DNx ; circulating plasma NE ; CHF-INv rabbits
P-1381	-0.0525 -0.0062 -0.1145 -0.0474 -0.1442 -0.0007 -0.2008 -0.0298 -1.8803 -0.5176 -0.3021 -0.0273 -0.9704 -0.4007 -0.0248 -0.0999 -0.1547 -0.1207
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow up ; hf
H-627	-0.5949639081954956	▁ HF
D-627	-0.5949639081954956	HF
P-627	-1.8589 -0.3276 -0.1122 -0.0811
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients ; blood ; medication
H-729	-0.9407721161842346	▁blood ▁work ▁draw n ▁; ▁medication
D-729	-0.9407721161842346	blood work drawn ; medication
P-729	-3.0595 -1.0241 -0.6477 -0.1317 -0.8427 -0.2970 -1.3755 -0.1480
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses ; patients
H-1021	-0.2688991129398346	▁ NP ▁assessment ▁; ▁ED ▁patients
D-1021	-0.2688991129398346	NP assessment ; ED patients
P-1021	-0.8130 -0.0562 -0.0650 -0.3380 -0.0513 -0.5957 -0.0969 -0.1351
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac hypertrophy ; energy metabolism
H-1778	-0.35315078496932983	▁Card iac ▁hyper trop hy ▁; ▁energy ▁metabolism
D-1778	-0.35315078496932983	Cardiac hypertrophy ; energy metabolism
P-1778	-1.3522 -0.0351 -0.1502 -0.0173 -0.6715 -0.2042 -0.6778 -0.0454 -0.2490 -0.1287
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients ; lvad ; implantation
H-531	-0.30465930700302124	▁l VAD ▁implant ation
D-531	-0.30465930700302124	lVAD implantation
P-531	-0.6894 -0.0397 -0.2927 -0.1802 -0.5168 -0.1091
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.39245882630348206	▁HD L - bound ▁malo ndi alde hy de ▁; ▁HD L - indu ced ▁; ▁ec
D-252	-0.39245882630348206	HDL-bound malondialdehyde ; HDL-induced ; ec
P-252	-1.3088 -0.5933 -0.0131 -0.0320 -0.1998 -0.2327 -0.0243 -0.7911 -0.1585 -0.1428 -0.5949 -0.6877 -0.0262 -0.0169 -0.0313 -1.4790 -0.6997 -0.3119 -0.1124
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal dysfunction ; morbidity
H-719	-0.3083440959453583	▁renal ▁dys function ▁; ▁post - trans plant ▁morbi d ity
D-719	-0.3083440959453583	renal dysfunction ; post-transplant morbidity
P-719	-0.3396 -0.1819 -0.1371 -0.4602 -0.5134 -0.0207 -0.0266 -0.0341 -0.2745 -0.1456 -1.6402 -0.1118 -0.1227
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients ; cad ; cad
H-1189	-0.5660727024078369	▁deriva tion ▁co hor t ▁; ▁CAD
D-1189	-0.5660727024078369	derivation cohort ; CAD
P-1189	-1.8218 -0.1336 -0.0085 -0.1254 -0.0461 -0.1622 -0.0763 -2.6458 -0.0750
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.39327672123908997	
D-154	-0.39327672123908997	
P-154	-0.7053 -0.0812
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients ; randomized
H-1874	-0.5466107130050659	
D-1874	-0.5466107130050659	
P-1874	-0.9926 -0.1006
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital ; discharge
H-302	-0.7703580260276794	▁Sur vi val ▁to ▁hospital ▁dis charge
D-302	-0.7703580260276794	Survival to hospital discharge
P-302	-3.8412 -0.1916 -0.0205 -0.6809 -1.1217 -0.6021 -0.1471 -0.2480 -0.0801
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.7581672072410583	
D-1713	-0.7581672072410583	
P-1713	-1.4276 -0.0888
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia ; heart disease
H-40	-0.6845623850822449	▁an emia ▁; ▁adults ▁; ▁heart ▁disease
D-40	-0.6845623850822449	anemia ; adults ; heart disease
P-40	-2.7294 -0.2656 -0.3128 -0.6810 -1.3693 -0.3333 -0.2085 -0.1384 -0.1227
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right atrial myxoma ; pulmonary embolism ; right heart failure
H-592	-0.29402950406074524	▁Right ▁at rial ▁my xo ma ▁; ▁pulmonar y ▁e mbol ism ▁; ▁right ▁heart ▁failure
D-592	-0.29402950406074524	Right atrial myxoma ; pulmonary embolism ; right heart failure
P-592	-0.3556 -0.2794 -0.0519 -1.4733 -0.0214 -0.2708 -0.3114 -0.0118 -0.0446 -0.0567 -0.0078 -0.7588 -0.3036 -0.2031 -0.3969 -0.4737 -0.1902 -0.0815
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
H-638	-0.35092559456825256	▁n fat ▁; ▁mi r -25 ▁; ▁tran scription ▁factor ▁; ▁hand 2 ▁in ▁heart ▁failure
D-638	-0.35092559456825256	nfat ; mir-25 ; transcription factor ; hand2 in heart failure
P-638	-3.0018 -0.0254 -0.0498 -0.1103 -0.3372 -0.0210 -0.2264 -0.0261 -0.0422 -0.0367 -0.4686 -0.3929 -0.1384 -0.8475 -0.0800 -0.1225 -0.1905 -0.1991
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation ; resistin ; correlated ; ejection fraction
H-938	-0.2532794177532196	▁resist in ▁; ▁e je ction ▁ fraction
D-938	-0.2532794177532196	resistin ; ejection fraction
P-938	-0.1474 -0.3376 -0.4276 -0.2079 -0.0429 -0.0280 -0.3063 -0.0057 -0.8662 -0.1632
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic heart transplantation ; oht ; end-stage heart failure
H-1280	-0.5849682092666626	▁Ort ho topic ▁heart ▁transplant ation ▁; ▁o HT ▁; ▁heart ▁failure
D-1280	-0.5849682092666626	Orthotopic heart transplantation ; oHT ; heart failure
P-1280	-0.5768 -0.0701 -0.1032 -1.0612 -0.1194 -0.1370 -0.2553 -0.0100 -0.8958 -0.3542 -4.1923 -0.2105 -0.1200 -0.0837
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas ; right atrium ; embolize ; pulmonary arterial vasculature
H-594	-0.2092474400997162	▁My xo mas ▁; ▁right ▁at rium ▁; ▁pulmonar y ▁arterial ▁vas cula ture
D-594	-0.2092474400997162	Myxomas ; right atrium ; pulmonary arterial vasculature
P-594	-0.2283 -0.0074 -0.2954 -0.2808 -0.1203 -0.4004 -0.0031 -0.2883 -0.0037 -0.0782 -0.0204 -0.2520 -0.2122 -0.8651 -0.1675 -0.1248
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change ; readmissions ; follow-up ; heart failure ; readmission
H-720	-0.6398398280143738	▁read missions ▁; ▁follow - up ▁visit s ▁; ▁heart ▁failure
D-720	-0.6398398280143738	readmissions ; follow-up visits ; heart failure
P-720	-2.1893 -0.0940 -0.1838 -0.0121 -0.0849 -0.0093 -0.3138 -0.0758 -0.2594 -0.2310 -0.0924 -4.6283 -0.1439
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas ; bridge to transplantation ; destination therapy
H-1999	-0.333315372467041	▁l VAS ▁; ▁ bridge ▁to ▁transplant ation
D-1999	-0.333315372467041	lVAS ; bridge to transplantation
P-1999	-0.2596 -0.2033 -0.8583 -0.4630 -0.0045 -0.0508 -0.0158 -0.1516 -1.2538 -0.0726
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac overexpression ; mammalian enabled ; mena ; heart failure
H-1809	-0.30588290095329285	▁Card iac ▁over expression ▁; ▁Mamma lian ▁enabled ▁; ▁men a ▁; ▁heart ▁failure
D-1809	-0.30588290095329285	Cardiac overexpression ; Mammalian enabled ; mena ; heart failure
P-1809	-0.2167 -0.0119 -0.3479 -0.0394 -0.1590 -0.0846 -0.0523 -0.6716 -0.0910 -0.9378 -0.0634 -0.2086 -0.8719 -0.1360 -0.8820 -0.1199
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs ; functional capacity ; peak vo2
H-123	-0.4895365834236145	▁c PC s ▁; ▁functional ▁capacity ▁; ▁VO 2
D-123	-0.4895365834236145	cPCs ; functional capacity ; VO2
P-123	-0.1925 -1.1478 -0.0710 -0.3246 -0.0146 -0.2964 -0.5844 -1.2757 -1.2181 -0.1100 -0.1499
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction ; pump ; driveline ; pump ; curative
H-774	-0.2302447408437729	▁dys function ▁; ▁pump ▁failure ▁; ▁drive line ▁injury ▁; ▁isola ted ▁pump ▁replace ment
D-774	-0.2302447408437729	dysfunction ; pump failure ; driveline injury ; isolated pump replacement
P-774	-1.4493 -0.0100 -0.1417 -0.2957 -0.1183 -0.0593 -0.0547 -0.0130 -0.0271 -0.2547 -0.0162 -0.0325 -0.8291 -0.1588 -0.1943 -0.1872 -0.0722
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis ; chronic heart failure ; tachycardia
H-164	-0.8787305355072021	▁figuur ▁; ▁chronic ▁heart ▁failure ▁; ▁ta chy car dia
D-164	-0.8787305355072021	figuur ; chronic heart failure ; tachycardia
P-164	-7.0926 -0.3190 -0.5643 -0.7322 -0.2020 -1.0835 -0.1124 -0.1288 -0.0166 -0.0083 -0.1510 -0.1341
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil ; orally ; doxorubicin
H-959	-0.45309895277023315	▁Nico rand il ▁; ▁do xor ubi cin
D-959	-0.45309895277023315	Nicorandil ; doxorubicin
P-959	-0.0023 -0.0102 -0.0532 -0.1498 -2.4635 -0.0137 -0.0142 -0.2821 -1.4841 -0.0578
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical ; outcomes ; hfpef
H-1525	-0.29806214570999146	▁EH ▁; ▁ HF p EF
D-1525	-0.29806214570999146	EH ; HFpEF
P-1525	-0.2658 -0.4776 -0.8752 -0.2211 -0.0394 -0.2494 -0.1260 -0.1299
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east ; rhythm control therapy ; cardiovascular ; complications
H-1648	-0.31290701031684875	▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁cardiovascular ▁complica tions
D-1648	-0.31290701031684875	east ; rhythm control therapy ; cardiovascular complications
P-1648	-0.5213 -0.1956 -0.1166 -0.5585 -0.2417 -0.1679 -0.2712 -0.0135 -0.5149 -0.1204 -0.0163 -0.1049 -1.3896 -0.1484
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients ; clinical ; radiological ; hf ; hospitalization
H-560	-0.6840767860412598	▁ HF
D-560	-0.6840767860412598	HF
P-560	-2.2170 -0.0927 -0.2942 -0.1324
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics ; symptoms ; patients ; heart failure ; hf
H-1199	-0.32548078894615173	▁di ure tics ▁; ▁con ges tive ▁symptoms ▁; ▁heart ▁failure ▁; HF
D-1199	-0.32548078894615173	diuretics ; congestive symptoms ; heart failure ;HF
P-1199	-0.4662 -0.2905 -0.1777 -0.3551 -0.6432 -0.1054 -0.8974 -0.2948 -0.1961 -0.6085 -0.0741 -0.5292 -0.0235 -0.1314 -0.0891
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based ; therapies ; patients ; fes
H-1333	-1.1517168283462524	▁ therapie s
D-1333	-1.1517168283462524	therapies
P-1333	-2.9882 -0.8427 -0.1249 -1.6976 -0.1053
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 ; prognosis ; heart failure
H-399	-1.105745553970337	▁solu ble ▁; ▁sp 2 ▁; ▁heart ▁failure
D-399	-1.105745553970337	soluble ; sp2 ; heart failure
P-399	-2.9155 -0.2275 -0.1904 -4.7976 -0.0683 -0.6753 -1.4644 -0.4613 -0.1487 -0.1085
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham heart study ; hf ; ef
H-1103	-0.31681784987449646	▁Fram ing ham ▁Heart ▁Study ▁criteri a ▁; ▁ HF ▁; ▁EF
D-1103	-0.31681784987449646	Framingham Heart Study criteria ; HF ; EF
P-1103	-0.0521 -0.0383 -0.0181 -0.2197 -0.0619 -0.4950 -0.0430 -0.1323 -0.6456 -0.1200 -0.1551 -2.3215 -0.0912 -0.0418
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up ; hf ; deaths
H-1771	-0.39769095182418823	▁ HF
D-1771	-0.39769095182418823	HF
P-1771	-0.5785 -0.1944 -0.6899 -0.1280
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations ; acr ; cms
H-140	-0.3229552209377289	▁a cr ▁; ▁CMS ▁metri cs
D-140	-0.3229552209377289	acr ; CMS metrics
P-140	-0.2721 -0.1827 -0.1499 -0.0675 -1.2529 -0.5005 -0.0884 -0.0697
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase ; myocardium
H-171	-0.45899632573127747	▁Cas pas e ▁; ▁pace d ▁my o car dium
D-171	-0.45899632573127747	Caspase ; paced myocardium
P-171	-3.3798 -0.0151 -0.2906 -0.2105 -0.3816 -0.0182 -0.8386 -0.0466 -0.0056 -0.0473 -0.1818 -0.0921
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty ; heart failure ; health
H-621	-0.39133182168006897	▁fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; ▁older ▁adults
D-621	-0.39133182168006897	frailty ; risk ; heart failure ; older adults
P-621	-0.8897 -0.0671 -0.0812 -0.0945 -0.5400 -0.2325 -0.9134 -0.2478 -0.2932 -0.2175 -0.1573 -1.2732 -0.0798
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin ; sitagliptin
H-1828	-0.26086923480033875	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin
D-1828	-0.26086923480033875	hHF ; saxagliptin ; sitagliptin
P-1828	-0.0133 -0.8530 -0.1159 -0.2286 -0.0070 -0.1873 -0.8271 -0.1061 -0.2827 -0.0770 -0.0283 -0.6003 -0.2431 -0.0826
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart ; heart failure ; arrhythmias
H-747	-0.7519747018814087	▁Heart ▁t 2 ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-747	-0.7519747018814087	Heart t2 ; heart failure ; arrhythmias
P-747	-0.5493 -3.1043 -0.0122 -0.4619 -3.4727 -0.2343 -0.3707 -0.0224 -0.0972 -0.4580 -0.1580 -0.0827
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic ; inflammatory ; abdominal
H-1285	-0.7874725461006165	▁ ische mic ▁; ▁in flam ma tory ▁abdominal ▁; ▁MT
D-1285	-0.7874725461006165	ischemic ; inflammatory abdominal ; MT
P-1285	-0.4116 -0.0761 -0.3265 -1.6558 -0.5329 -0.1250 -1.8859 -0.3703 -0.5773 -3.2194 -0.3129 -0.5827 -0.1606
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations ; congestive heart failure
H-208	-0.2780316174030304	▁ED ▁visit s ▁; ▁in tuba tions ▁; ▁con ges tive ▁heart ▁failure
D-208	-0.2780316174030304	ED visits ; intubations ; congestive heart failure
P-208	-0.4671 -0.7718 -0.0493 -0.0986 -0.0030 -0.0620 -0.0807 -0.5423 -0.0242 -0.0853 -1.3467 -0.3140 -0.1170 -0.1092 -0.0994
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline ; embase ; cinahl
H-62	-0.4218873381614685	▁med Line ▁; ▁ EMBA se ▁; ▁c INA HL
D-62	-0.4218873381614685	medLine ; EMBAse ; cINAHL
P-62	-0.4692 -1.3202 -0.1211 -0.3032 -0.0526 -1.3198 -0.1658 -0.2018 -0.4243 -0.4007 -0.1845 -0.0995
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence ; acp ; clinical practice guidelines
H-35	-0.6984816789627075	▁a CP ▁; ▁clinic al ▁practice ▁guidelines
D-35	-0.6984816789627075	aCP ; clinical practice guidelines
P-35	-1.0122 -0.2579 -1.5296 -0.3334 -0.0141 -0.1198 -2.1085 -0.7739 -0.1369
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise ; adverse events ; coronary artery disease ; cad
H-1899	-0.4510135352611542	▁corona ry ▁arter y ▁disease ▁; CAD
D-1899	-0.4510135352611542	coronary artery disease ;CAD
P-1899	-2.4033 -0.5477 -0.0288 -0.1540 -0.2193 -0.4610 -0.0360 -0.1031 -0.1059
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.5579814314842224	
D-1852	-0.5579814314842224	
P-1852	-1.0469 -0.0691
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical ; change
H-792	-0.4843672513961792	▁responsive heid ▁to ▁clinic al ▁change
D-792	-0.4843672513961792	responsiveheid to clinical change
P-792	-0.5799 -1.8281 -0.9461 -0.0897 -0.0168 -0.2973 -0.0676 -0.0495
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-0.8702202439308167	▁ED ▁; ▁CHF
D-216	-0.8702202439308167	ED ; CHF
P-216	-1.7201 -2.3936 -0.0604 -0.0859 -0.0911
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-0.9277477860450745	▁QR s
D-892	-0.9277477860450745	QRs
P-892	-1.9566 -1.3872 -0.2966 -0.0707
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare ; policy
H-1716	-0.44799208641052246	▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1716	-0.44799208641052246	Medicare ; post-acute care transfer policy
P-1716	-0.3370 -0.0499 -0.7916 -0.0589 -0.0213 -0.0450 -0.0078 -1.2701 -0.4229 -1.5275 -0.6898 -0.1540
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-0.43288952112197876	▁Diet ▁score ▁; ▁vegetables ▁; ▁nu ts ▁; ▁whole ▁grain ▁in take ▁; ▁mortal ity
D-692	-0.43288952112197876	Diet score ; vegetables ; nuts ; whole grain intake ; mortality
P-692	-3.9382 -0.2923 -0.4290 -0.2183 -0.1663 -0.0171 -0.0301 -0.1845 -0.0383 -0.0874 -0.0743 -0.2498 -0.5728 -0.1524 -0.7186 -0.0796 -0.1100
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.7448663115501404	
D-1508	-0.7448663115501404	
P-1508	-1.3839 -0.1058
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs ; osprey
H-1611	-0.4286908209323883	▁de g s ▁; ▁o spre y
D-1611	-0.4286908209323883	degs ; osprey
P-1611	-0.2334 -2.8204 -0.0811 -0.3668 -0.0199 -0.0062 -0.0321 -0.2506 -0.0477
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis ; therapy
H-1467	-0.42138686776161194	▁ therapy
D-1467	-0.42138686776161194	therapy
P-1467	-1.3366 -0.1556 -0.0680 -0.1253
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world health organization ; hf
H-1791	-0.6411218643188477	▁electronic ▁database s ▁; ▁world ▁health ▁Organization ▁; ▁ HF ▁; ▁LA
D-1791	-0.6411218643188477	electronic databases ; world health Organization ; HF ; LA
P-1791	-1.8663 -0.0704 -0.0614 -0.0581 -0.7778 -1.0068 -0.3119 -0.7124 -1.0065 -0.2881 -1.3969 -1.0004 -0.3462 -0.0724
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit index
H-1008	-0.3962245583534241	▁deficit ▁index
D-1008	-0.3962245583534241	deficit index
P-1008	-0.2725 -0.0439 -1.1508 -0.1177
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients ; implantation ; crt
H-848	-0.5773230791091919	▁device ▁implant ation ▁; ▁c RT ▁cap ability
D-848	-0.5773230791091919	device implantation ; cRT capability
P-848	-0.5166 -0.1886 -0.2940 -0.3298 -0.4203 -2.1141 -1.0612 -0.1108 -0.6503 -0.0875
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-0.9325688481330872	
D-619	-0.9325688481330872	
P-619	-1.7854 -0.0798
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.7619709968566895	▁ir on
D-49	-0.7619709968566895	iron
P-49	-0.3354 -0.1367 -2.4775 -0.0982
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote monitoring ; hospital ; discharge ; patients ; heart failure ; meta-analysis
H-146	-0.7023658156394958	▁remote ▁monitoring ▁; ▁hospital ▁dis charge ▁; ▁patients ▁with ▁heart ▁failure
D-146	-0.7023658156394958	remote monitoring ; hospital discharge ; patients with heart failure
P-146	-1.0026 -0.0942 -0.6973 -2.3172 -0.3028 -0.0745 -0.8096 -0.6581 -2.1671 -0.4081 -0.1629 -0.3371 -0.0993
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv filling pressure ; stable ; severe systolic hf
H-489	-0.3336608409881592	▁LV ▁fill ing ▁pressure ▁; ▁severe ▁sy sto lic ▁ HF
D-489	-0.3336608409881592	LV filling pressure ; severe systolic HF
P-489	-0.8999 -1.1564 -0.0622 -0.1644 -0.1202 -1.3768 -0.0064 -0.0451 -0.0080 -0.2450 -0.0504 -0.1236 -0.0793
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ; ambulatory ; patients ; heart failure ; functional capacity ; outcomes
H-695	-0.3592328131198883	▁Solu ble ▁ST 2 ▁; ▁ambula tory ▁patients ▁; ▁heart ▁failure
D-695	-0.3592328131198883	Soluble ST2 ; ambulatory patients ; heart failure
P-695	-0.1003 -0.0978 -0.3092 -0.1343 -0.7743 -0.2720 -0.1103 -0.4213 -1.5618 -0.3992 -0.1285 -0.2678 -0.0932
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline ; echocardiograms ; evidence ; reverse remodeling
H-907	-0.35587719082832336	▁e cho card i ogram s
D-907	-0.35587719082832336	echocardiograms
P-907	-0.2410 -0.0359 -0.1800 -0.3906 -0.0044 -0.4976 -1.4034 -0.0942
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin hypophosphorylation ; myocardial dd
H-771	-0.31106775999069214	▁Tit in ▁hypo phos phor y lation ▁; ▁my o card ial ▁ DD
D-771	-0.31106775999069214	Titin hypophosphorylation ; myocardial DD
P-771	-0.0497 -0.5069 -0.2584 -0.0520 -0.6699 -0.6625 -0.1103 -0.1342 -0.7664 -0.0821 -0.1551 -0.2318 -0.9560 -0.0387 -0.1573 -0.1457
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic ; right ventricular contractile reserve ; patients ; pulmonary hypertension
H-821	-0.25605446100234985	▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension
D-821	-0.25605446100234985	ventricular contractile reserve ; pulmonary hypertension
P-821	-1.3753 -0.5507 -0.1428 -0.0195 -0.0652 -0.0119 -0.2025 -0.4392 -0.1013 -0.1587 -0.0341 -0.1423 -0.0850
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck stent ; chronic myocardial ischemia ; heart failure
H-502	-0.19910715520381927	▁bottle ne ck ▁sten t ▁model ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure ▁; ▁pig s
D-502	-0.19910715520381927	bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
P-502	-0.2244 -0.0245 -0.0065 -0.0268 -0.0696 -0.5261 -0.1648 -0.0763 -0.6821 -0.1366 -0.2622 -0.1369 -0.1084 -0.0250 -0.4600 -0.1141 -0.2178 -0.0643 -0.9136 -0.0087 -0.0598 -0.1844 -0.0864
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt intervals ; sd of all qt intervals ; sdqt
H-1439	-0.8132885098457336	▁ QT ▁interval s ▁; ▁SD
D-1439	-0.8132885098457336	QT intervals ; SD
P-1439	-0.2857 -0.1322 -0.0058 -0.0893 -0.1651 -0.0225 -5.6386 -0.1672
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal bleeding ; patients ; ventricular assist devices ; cardiac ; nurse
H-1656	-0.39261820912361145	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse
D-1656	-0.39261820912361145	Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
P-1656	-0.2078 -0.3789 -1.1430 -0.0973 -0.1026 -0.5466 -0.2189 -0.3754 -0.5351 -0.5113 -0.1980 -1.0360 -0.2565 -1.0137 -0.0192 -0.1281 -0.1907 -0.1080
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker ; uptitration ; hfpef
H-183	-0.43217283487319946	▁benefit ▁; ▁ RAS - ▁; ▁β - block er ▁up tit ration ▁; ▁ HF p EF
D-183	-0.43217283487319946	benefit ; RAS- ; β-blocker uptitration ; HFpEF
P-183	-0.8877 -0.1285 -1.2201 -0.0123 -0.0386 -1.0513 -0.1342 -0.0615 -0.1636 -0.0793 -2.3160 -0.2364 -0.5296 -0.4195 -0.5475 -0.2311 -0.0321 -0.3613 -0.0971 -0.0958
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition ; compliance ; exercise ; injections ; patients
H-1321	-0.8897665739059448	
D-1321	-0.8897665739059448	
P-1321	-1.7061 -0.0734
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump ; pump ; pump thrombosis ; hemolysis
H-2004	-0.35516199469566345	▁pump ▁exchange s ▁; ▁pump ▁mal function s ▁; ▁pump ▁ thro mbo sis ▁; ▁hem ol ysis ▁events
D-2004	-0.35516199469566345	pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
P-2004	-0.1026 -0.1743 -0.1056 -0.2020 -0.2741 -1.2040 -0.0224 -0.1633 -0.1796 -0.3677 -1.1477 -0.3107 -0.4392 -0.4610 -0.2582 -0.0889 -0.1467 -0.0806 -1.4711 -0.1758 -0.0831
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac resynchronization therapy ; patients ; heart failure
H-903	-0.33020275831222534	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure
D-903	-0.33020275831222534	cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
P-903	-0.3072 -0.0474 -0.1766 -0.0460 -0.7861 -1.5755 -0.0200 -0.2798 -0.1351 -0.0203 -0.0196 -0.1572 -0.0484 -0.5950 -1.2132 -0.2537 -0.1754 -0.2252 -0.1922
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc ; outcomes ; outcome ; admission ; discharge
H-1401	-0.7824453115463257	▁no c ▁outcome s ▁; ▁outcome ▁; ▁ad mission ▁to ▁dis charge
D-1401	-0.7824453115463257	noc outcomes ; outcome ; admission to discharge
P-1401	-0.4877 -1.0180 -2.7905 -0.2410 -0.5072 -0.4789 -2.3583 -1.0563 -0.9504 -0.5609 -0.1255 -0.0613 -0.1608 -0.1574
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol ; exercise ; training ; baseline ; hgb
H-843	-0.5976776480674744	▁HR Qo L ▁; ▁exercise ▁training ▁; ▁h gb
D-843	-0.5976776480674744	HRQoL ; exercise training ; hgb
P-843	-1.2851 -0.0077 -0.5834 -0.3051 -0.3747 -0.5125 -0.7948 -2.4672 -0.0537 -0.1051 -0.0852
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient ; patients ; discharged ; hf
H-1400	-0.35964295268058777	▁in patient ▁records ▁; ▁patients ▁dis charge d ▁; ▁ HF
D-1400	-0.35964295268058777	inpatient records ; patients discharged ; HF
P-1400	-0.0785 -0.0383 -0.3347 -0.2405 -1.0213 -0.5012 -0.0398 -0.0407 -1.5672 -0.5272 -0.0999 -0.0929 -0.0934
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal muscle ; correlated ; vo2 max
H-1500	-0.5680326819419861	▁skelet al ▁muscle ▁mass ▁cor related ▁; ▁VO 2
D-1500	-0.5680326819419861	skeletal muscle mass correlated ; VO2
P-1500	-1.1935 -0.0225 -0.3456 -0.2041 -0.9869 -0.3288 -0.5331 -2.2014 -0.1001 -0.2650 -0.0673
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac catheterization ; patient ; extubated ; transferred
H-1297	-0.553629457950592	▁emergency ▁cardiac ▁cat heter ization
D-1297	-0.553629457950592	emergency cardiac catheterization
P-1297	-0.8223 -0.0113 -0.5424 -0.0243 -0.5137 -1.9050 -0.0565
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial ; exercise ; training ; heart failure ; hf ; patients
H-1925	-0.49686720967292786	▁psycho social ▁factors ▁; ▁exercise ▁training ▁; ▁heart ▁failure ▁; HF
D-1925	-0.49686720967292786	psychosocial factors ; exercise training ; heart failure ;HF
P-1925	-0.8696 -0.1958 -0.5821 -0.3728 -1.2625 -0.8348 -0.4572 -0.3130 -0.0878 -0.4102 -0.0345 -0.8716 -0.1673
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis ; medical ; heart failure ; canadian cardiovascular society
H-198	-0.5882434248924255	▁medical ▁management ▁; ▁heart ▁failure ▁; ▁children ▁; ▁Canadian ▁Card io vas cular ▁Society ▁guidelines
D-198	-0.5882434248924255	medical management ; heart failure ; children ; Canadian Cardiovascular Society guidelines
P-198	-3.4584 -0.4181 -0.2085 -0.4116 -0.0869 -0.2406 -1.6998 -0.1571 -0.1253 -0.7571 -0.4845 -0.0719 -0.2150 -0.3149 -1.1344 -0.1133 -0.1027
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized ; double-blind ; active ; placebo
H-77	-1.6237237453460693	
D-77	-1.6237237453460693	
P-77	-3.1189 -0.1285
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report ; aric ; hf
H-290	-0.5166051983833313	▁a RIC ▁ HF
D-290	-0.5166051983833313	aRIC HF
P-290	-0.7892 -0.7208 -0.2263 -0.4293 -0.8336 -0.1004
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients ; atrial fibrillation ; pacemaker
H-883	-0.45866474509239197	▁at rial ▁fi bril lation ▁; ▁pace maker
D-883	-0.45866474509239197	atrial fibrillation ; pacemaker
P-883	-3.2463 -0.0201 -0.3484 -0.0178 -0.0978 -0.2208 -0.3230 -0.0528 -0.1816 -0.0780
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis ; mortality ; patients
H-68	-0.9056678414344788	▁i CD - HF ▁patients
D-68	-0.9056678414344788	iCD-HF patients
P-68	-2.5092 -0.9896 -0.0284 -0.1327 -2.1763 -0.2694 -0.2340
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients ; therapy ; hospitalized ; cardiovascular
H-1223	-0.9067478179931641	▁cardiovascular ▁reason
D-1223	-0.9067478179931641	cardiovascular reason
P-1223	-1.8285 -1.5300 -0.1087 -0.1597
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter ablation ; sinus rhythm
H-945	-0.4349495470523834	▁AF - free ▁probabil ity ▁; ▁cat heter ▁ab lation ▁; ▁sinus ▁ rhythm
D-945	-0.4349495470523834	AF-free probability ; catheter ablation ; sinus rhythm
P-945	-0.7452 -0.0360 -0.0526 -2.0772 -0.5017 -0.4141 -0.5433 -0.0135 -0.0142 -0.0574 -0.1267 -1.6691 -0.2014 -0.2206 -0.1657 -0.1204
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body mass index ; crf ; exercise
H-1768	-0.26781004667282104	▁body ▁mass ▁index ▁; ▁c RF ▁; ▁tre ad m ill ▁exercise ▁testing
D-1768	-0.26781004667282104	body mass index ; cRF ; treadmill exercise testing
P-1768	-0.3633 -0.1630 -0.0073 -0.0822 -0.0977 -0.1290 -0.3228 -0.2339 -0.0064 -0.2734 -0.0723 -1.4977 -0.4184 -0.2186 -0.1313
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial tissue ; pka
H-1426	-0.3247683644294739	▁human ▁my o card ial ▁tissu e ▁; ▁p ka ▁sub un its
D-1426	-0.3247683644294739	human myocardial tissue ; pka subunits
P-1426	-0.7747 -1.2771 -0.1025 -0.2134 -0.1066 -0.0368 -0.1602 -0.3776 -0.1713 -0.7730 -0.6170 -0.0622 -0.0071 -0.1146 -0.0776
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease ; accounting ; cardiac transplants
H-982	-0.20358014106750488	▁pa e dia tric ▁cardiac ▁transplant s
D-982	-0.20358014106750488	paediatric cardiac transplants
P-982	-0.1940 -0.0838 -0.0154 -0.0272 -0.0093 -0.0578 -0.1532 -1.1772 -0.1144
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ; ventricular-arterial coupling
H-526	-0.17015743255615234	▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁SV
D-526	-0.17015743255615234	ees ; ventricular-arterial coupling ; SV
P-526	-0.4800 -0.0317 -0.0908 -0.0633 -0.4430 -0.0776 -0.0721 -0.0113 -0.0218 -0.1128 -0.3205 -0.5802 -0.0539 -0.0850 -0.1084
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic failure ; cardiomyopathic
H-986	-0.13217319548130035	▁dia sto lic ▁failure ▁; ▁cardio my o pathi c ▁restriction ▁to ▁flow
D-986	-0.13217319548130035	diastolic failure ; cardiomyopathic restriction to flow
P-986	-0.0962 -0.0308 -0.0331 -0.0390 -0.2340 -0.0356 -0.4631 -0.1575 -0.0052 -0.0401 -0.1495 -0.4483 -0.0153 -0.1556 -0.0792
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic nervous system ; activity ; qtv
H-1436	-0.30368849635124207	▁autonomi c ▁ner vous ▁system ▁; ▁Q TV
D-1436	-0.30368849635124207	autonomic nervous system ; QTV
P-1436	-0.0444 -0.1567 -0.4072 -0.3940 -0.1001 -1.1365 -0.2860 -0.3394 -0.0895 -0.0830
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients ; pneumonia ; surgical ; conditions
H-5	-0.4962778687477112	▁pneu monia ▁; ▁sur g ical ▁conditions
D-5	-0.4962778687477112	pneumonia ; surgical conditions
P-5	-1.0964 -0.5090 -0.3951 -0.3219 -0.3115 -0.3574 -1.2767 -0.1003 -0.0982
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1 mapping ; clinically ; myocardial fibrosis
H-1065	-0.8308342695236206	▁t 1 ▁ma pping ▁; ▁my o card ial ▁fibro sis
D-1065	-0.8308342695236206	t1 mapping ; myocardial fibrosis
P-1065	-4.3758 -0.7701 -0.3952 -0.1141 -0.2936 -2.6095 -0.2653 -0.7164 -0.5855 -0.0122 -0.4200 -0.1492 -0.0940
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.47274619340896606	
D-1862	-0.47274619340896606	
P-1862	-0.8573 -0.0881
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients ; prognosis
H-1315	-0.8357059955596924	
D-1315	-0.8357059955596924	
P-1315	-1.5910 -0.0804
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-1.2372496128082275	
D-1983	-1.2372496128082275	
P-1983	-2.3550 -0.1195
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-1.0038729906082153	▁white
D-626	-1.0038729906082153	white
P-626	-2.8061 -0.0715 -0.1340
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics rounds
H-1681	-0.27906689047813416	▁e thi cs ▁Round s
D-1681	-0.27906689047813416	ethics Rounds
P-1681	-0.8999 -0.0645 -0.2991 -0.1066 -0.1048 -0.3920 -0.0865
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.8414422869682312	
D-2013	-0.8414422869682312	
P-2013	-1.6107 -0.0722
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
H-13	-0.0846199318766594	▁bio mark ers ▁; ▁neuro hormon al ▁stimul ation ▁; ▁ inflammation ▁; ▁en dot heli al ▁dys function
D-13	-0.0846199318766594	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
P-13	-0.1328 -0.0780 -0.0279 -0.2363 -0.0176 -0.0215 -0.0522 -0.0440 -0.1881 -0.1494 -0.0515 -0.0231 -0.1476 -0.0126 -0.2399 -0.0363 -0.0060 -0.0191 -0.0972 -0.1124 -0.0836
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart failure ; pathophysiology ; diagnosis ; medical treatment ; nursing
H-2018	-0.3374868631362915	▁Heart ▁Fail ure ▁; ▁Path o phy si ology ▁; ▁Medical ▁Treatment ▁Guide lines ▁; ▁Nur sing ▁Management
D-2018	-0.3374868631362915	Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing Management
P-2018	-0.2622 -0.1450 -0.3274 -0.2762 -0.0616 -0.6817 -0.0331 -0.8603 -0.1664 -0.1621 -0.8668 -0.2507 -0.4721 -0.2483 -0.7752 -0.1427 -0.0614 -0.7944 -0.0767 -0.0853
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia ; patients ; heart disease ; clinical practice guideline ; american college of physicians
H-29	-0.9032920002937317	▁an emia ▁; ▁patients ▁; ▁heart ▁disease
D-29	-0.9032920002937317	anemia ; patients ; heart disease
P-29	-0.6343 -0.0873 -0.3825 -2.0164 -2.3467 -0.4411 -0.2745 -1.8608 -0.0859
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart rate reduction ; ivabradine ; left ventricle ; heart failure ; patients
H-515	-0.5559394359588623	▁i va bra dine ▁un load s ▁; ▁left ▁vent ric le ▁; ▁heart ▁failure ▁patients
D-515	-0.5559394359588623	ivabradine unloads ; left ventricle ; heart failure patients
P-515	-3.4760 -0.0365 -0.2262 -0.0519 -0.3777 -0.0118 -0.1877 -0.7557 -0.0583 -0.0878 -1.0678 -0.3336 -0.4080 -0.3531 -0.4670 -1.5029 -0.3753 -0.2298
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence ; end-stage renal disease ; outpatients ; systolic heart failure
H-386	-0.3397635817527771	▁end - s tage ▁renal ▁disease ▁; ▁out patient s ▁; ▁sy sto lic ▁heart ▁failure
D-386	-0.3397635817527771	end-stage renal disease ; outpatients ; systolic heart failure
P-386	-2.0449 -0.0710 -0.1096 -0.0025 -0.0081 -0.1480 -0.1362 -1.7040 -0.0028 -0.0489 -0.8073 -0.0109 -0.0288 -0.1187 -0.4408 -0.1072 -0.1912 -0.1347
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo ; bivp ; correlated ; rs synchrony
H-327	-0.36442703008651733	▁ RV PO ▁; ▁Bi VP ▁; ▁co ▁; ▁RS ▁synchron y ▁; ▁CS
D-327	-0.36442703008651733	RVPO ; BiVP ; co ; RS synchrony ; CS
P-327	-0.8620 -1.2340 -0.3494 -0.1834 -0.3361 -0.0877 -0.1124 -1.1950 -0.2412 -0.6265 -0.0023 -0.0921 -0.2982 -0.0051 -0.0974 -0.1081
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal dnx ; cardiac ; autonomic balance ; chf ; sympathetic tone
H-1382	-0.1807475984096527	▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance ▁; ▁CHF ▁; ▁sympa the tic ▁tone
D-1382	-0.1807475984096527	renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
P-1382	-0.0201 -0.1525 -0.0460 -0.2051 -0.0254 -0.0109 -0.2124 -0.1800 -0.2229 -0.0038 -0.6645 -0.0084 -0.4046 -0.5997 -0.0492 -0.1905 -0.0766
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin ; acute ; anthracycline-induced cardiotoxicity
H-931	-0.33353954553604126	▁resist in ▁; ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic iteit
D-931	-0.33353954553604126	resistin ; acute anthracycline-induced cardiotoxiciteit
P-931	-0.2240 -0.2448 -0.1362 -0.6481 -0.0180 -0.1401 -0.1045 -0.0977 -0.7563 -0.2580 -0.0150 -0.1354 -0.0446 -0.4502 -1.9533 -0.2824 -0.1616
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute ; autonomic nervous system ; qtv ; hf ; patients
H-1447	-0.33210718631744385	▁a cute ▁autonomi c ▁ner vous ▁system ▁modul ation ▁; ▁Q TV ▁; ▁ HF ▁patients
D-1447	-0.33210718631744385	acute autonomic nervous system modulation ; QTV ; HF patients
P-1447	-0.4251 -0.0045 -0.0777 -0.2082 -0.4389 -0.5705 -0.0796 -0.5252 -0.1434 -0.1977 -0.2705 -0.3209 -0.2001 -0.9485 -0.1265 -1.2222 -0.1252 -0.0932
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart rate ; aortic ; blood flow ; doxorubicin
H-960	-0.2364625483751297	▁Heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁do xor ubi cin
D-960	-0.2364625483751297	Heart rate ; aortic blood flow ; doxorubicin
P-960	-0.5889 -0.1560 -0.2485 -0.0091 -0.0306 -0.5868 -0.3149 -0.1234 -0.7927 -0.2314 -0.0081 -0.0182 -0.2428 -0.1317 -0.0638
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical ; outcomes ; hospitalisations ; readmissions ; mortality
H-1850	-1.0009055137634277	
D-1850	-1.0009055137634277	
P-1850	-1.8767 -0.1251
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial ; pde2 ; expression ; activity ; hf
H-1213	-0.6846960783004761	▁My o card ial ▁p de 2 ▁expression ▁; ▁ HF
D-1213	-0.6846960783004761	Myocardial pde2 expression ; HF
P-1213	-0.7205 -0.0778 -0.1273 -0.1320 -1.6582 -0.7549 -0.0505 -0.7528 -0.3077 -3.2820 -0.7441 -0.1610 -0.1323
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat ; sympathetic outflow ; parasympathetic activity
H-1869	-0.3731735050678253	▁BAT ▁; ▁sympa the tic ▁out flow ▁; ▁para sy mpa the tic ▁activity
D-1869	-0.3731735050678253	BAT ; sympathetic outflow ; parasympathetic activity
P-1869	-0.0229 -0.6254 -0.1431 -0.4331 -0.3900 -1.0517 -0.1232 -0.2170 -0.0395 -0.2064 -0.1496 -0.8791 -0.7669 -0.5877 -0.2163 -0.1189
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
H-426	-0.21721793711185455	▁e cho car dio graphic ▁; ▁rever se ▁remodel ing ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-426	-0.21721793711185455	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
P-426	-0.3871 -0.0136 -0.0249 -0.2615 -0.1807 -1.0102 -0.0357 -0.0123 -0.0158 -0.0378 -0.3244 -0.0160 -0.0361 -0.0287 -0.0115 -0.4980 -1.1154 -0.0177 -0.2119 -0.1049
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular death ; hf ; hospitalization ; exercise ; training ; patients ; btes
H-1933	-0.4322727620601654	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁exercise ▁training
D-1933	-0.4322727620601654	cardiovascular death ; HF hospitalization ; exercise training
P-1933	-0.1100 -0.2661 -0.0382 -0.6453 -0.0114 -0.2131 -0.2501 -0.1222 -0.0819 -0.3309 -3.0475 -0.0706
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise ; training ; patients ; chronic heart failure ; high-density lipoprotein
H-245	-1.014117956161499	▁chronic ▁heart ▁failure ▁; ▁lipo prote in ▁functional ▁properties
D-245	-1.014117956161499	chronic heart failure ; lipoprotein functional properties
P-245	-4.5501 -0.9722 -0.1371 -0.3426 -1.6336 -0.0721 -0.4865 -1.3300 -1.3047 -0.2257 -0.1008
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal ; pathophysiology ; congestive heart failure ; chf
H-634	-0.3502034842967987	▁Neuro hormon al ▁ab normal ities ▁; ▁pat ho phy si ology ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-634	-0.3502034842967987	Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
P-634	-0.7063 -0.0163 -0.0108 -0.0512 -0.0229 -0.9035 -0.0831 -0.8602 -0.0498 -0.0843 -0.5461 -0.3350 -0.1037 -0.0082 -0.0774 -1.2748 -0.6553 -0.0988 -0.3498 -0.3670 -1.2619 -0.1142 -0.0741
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic neurotransmission ; acetylcholinesterase inhibition
H-1135	-0.3275790214538574	▁para sy mpa the tic ▁neuro trans mission ▁; ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.3275790214538574	parasympathetic neurotransmission ; acetylcholinesterase inhibition
P-1135	-0.0081 -0.1438 -0.1801 -0.8924 -0.5933 -0.0856 -0.0091 -0.8624 -0.1670 -0.0605 -0.2632 -0.0982 -0.1369 -0.1493 -0.1723 -1.2075 -0.0739 -1.0078 -0.3229 -0.1173
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential effect ; lvef ; mortality
H-118	-0.42189133167266846	▁LV EF ▁; ▁long - term ▁mortal ity
D-118	-0.42189133167266846	LVEF ; long-term mortality
P-118	-1.2994 -0.2135 -0.6187 -0.3289 -0.1250 -0.1806 -0.2113 -0.7998 -0.2944 -0.1474
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash ; mortality ; heart failure ; health
H-684	-0.5233488082885742	▁Mediterrane an ▁; ▁DAS h ▁die t ▁score s ▁; ▁mortal ity ▁; ▁women ▁; ▁heart ▁failure ▁; ▁Women s ▁Health ▁Initiative
D-684	-0.5233488082885742	Mediterranean ; DASh diet scores ; mortality ; women ; heart failure ; Womens Health Initiative
P-684	-0.8666 -0.0126 -0.2377 -0.0027 -0.1434 -1.1497 -0.0592 -0.0430 -0.0715 -0.0865 -0.0202 -0.5307 -0.1169 -1.5334 -1.5040 -0.2220 -0.1809 -0.3960 -0.8501 -2.6654 -1.4642 -0.1611 -0.1190 -0.1237
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness ; sickle cell disease ; anemia
H-1682	-0.4733697772026062	▁Jehovah ' s ▁Wit ness ▁; ▁sick le ▁cell ▁disease ▁; ▁an emia
D-1682	-0.4733697772026062	Jehovah's Witness ; sickle cell disease ; anemia
P-1682	-0.0574 -3.1233 -0.1335 -0.1242 -0.8155 -0.7443 -0.0345 -0.1024 -0.2542 -0.1211 -0.6115 -0.5183 -0.1848 -0.1163 -0.1593
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas ; therapeutic ; heart failure
H-1485	-0.386370986700058	▁mi RNA s ▁; ▁ therapeut ic ▁target s ▁; ▁heart ▁failure
D-1485	-0.386370986700058	miRNAs ; therapeutic targets ; heart failure
P-1485	-1.5173 -0.0158 -0.0883 -0.3693 -1.3222 -0.0667 -0.2167 -0.2453 -0.1244 -1.0152 -0.1425 -0.0690 -0.1116 -0.1049
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine ; furosemide ; outcome
H-586	-0.2496708631515503	▁do bu tamine ▁; ▁fur os em ide ▁dose ▁; ▁oxygen ▁flow
D-586	-0.2496708631515503	dobutamine ; furosemide dose ; oxygen flow
P-586	-0.4838 -0.0249 -0.0732 -0.8096 -0.8090 -0.1584 -0.0196 -0.0223 -0.1525 -0.0836 -0.4836 -0.1158 -0.1972 -0.0621
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health buddy program ; hospital ; hospitalized
H-1626	-0.45231977105140686	▁Health ▁Budd y ▁Program ▁; ▁ED
D-1626	-0.45231977105140686	Health Buddy Program ; ED
P-1626	-1.2003 -0.0219 -0.0588 -0.4014 -0.1292 -0.0215 -1.6895 -0.0960
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad variant ; congestive heart failure
H-1670	-0.6024312973022461	▁l - type ▁ca 2 + ▁current s ▁; ▁Rad ▁variant ▁; ▁con ges tive ▁heart ▁failure
D-1670	-0.6024312973022461	l-type ca2+ currents ; Rad variant ; congestive heart failure
P-1670	-4.0849 -0.0444 -0.0022 -0.5526 -0.0696 -0.7571 -0.0464 -0.1490 -0.1760 -1.6927 -0.5796 -0.8496 -0.0275 -0.0911 -1.2022 -0.4725 -0.2996 -0.2106 -0.1386
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs ; outcomes ; patients ; diabetes
H-130	-0.5929539799690247	▁c PC s ▁; ▁outcome s ▁; ▁diabetes
D-130	-0.5929539799690247	cPCs ; outcomes ; diabetes
P-130	-0.5921 -1.2969 -0.1688 -0.4127 -1.0854 -0.1328 -0.5940 -1.3731 -0.0979 -0.1757
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin ; breast cancer ; patients ; cardiotoxicity
H-936	-0.3429063856601715	▁resist in ▁levels ▁; ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁patients ▁; ▁cardio toxic ity
D-936	-0.3429063856601715	resistin levels ; anthracycline-treated breast cancer patients ; cardiotoxicity
P-936	-0.4233 -0.4655 -0.3566 -0.1520 -0.0331 -0.0439 -0.3202 -0.7147 -0.2033 -0.0087 -0.4523 -0.0431 -0.1342 -0.5931 -0.4244 -0.1021 -0.1962 -1.7873 -0.2696 -0.1345
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left pulmonary artery ; right pulmonary artery
H-597	-0.37968510389328003	▁left ▁pulmonar y ▁arter y ▁; ▁pulmonar y ▁arter y
D-597	-0.37968510389328003	left pulmonary artery ; pulmonary artery
P-597	-0.4101 -0.0195 -0.0558 -0.0202 -0.2424 -0.5367 -2.4553 -0.0597 -0.0289 -0.2356 -0.3934 -0.0986
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri scanner ; baseline ; heart failure
H-1057	-0.7105821371078491	▁m RI ▁scanner ▁; ▁heart ▁failure
D-1057	-0.7105821371078491	mRI scanner ; heart failure
P-1057	-2.2947 -0.7236 -0.0421 -0.5891 -1.3801 -0.3420 -0.1576 -0.1554
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical ; therapeutic
H-1368	-0.6249077916145325	
D-1368	-0.6249077916145325	
P-1368	-1.1710 -0.0788
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive heart failure ; chf
H-209	-0.47161349654197693	▁con ges tive ▁heart ▁failure ▁; CH f
D-209	-0.47161349654197693	congestive heart failure ;CHf
P-209	-1.1618 -0.0866 -0.7132 -0.4381 -0.0885 -0.3425 -0.4134 -1.2917 -0.0967 -0.0836
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome ; heart failure ; fontan
H-1493	-0.1903446614742279	▁muscle - was ting ▁syndrome ▁; ▁acquire d ▁heart ▁failure ▁; ▁Font an
D-1493	-0.1903446614742279	muscle-wasting syndrome ; acquired heart failure ; Fontan
P-1493	-0.5189 -0.0932 -0.0740 -0.0182 -0.0198 -0.0867 -0.0260 -0.0046 -0.4710 -0.0948 -1.1672 -0.0414 -0.0309 -0.1422 -0.0662
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty ; health ; outcomes
H-623	-0.5085586309432983	▁fra il ty ▁; ▁el der ly
D-623	-0.5085586309432983	frailty ; elderly
P-623	-0.5951 -0.4035 -0.1803 -0.2291 -0.7905 -0.0272 -0.5128 -1.7465 -0.0921
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf ; intubation
H-221	-0.24292349815368652	▁ED ▁visit s ▁; ▁CHF ▁; ▁in tub ation ▁rates
D-221	-0.24292349815368652	ED visits ; CHF ; intubation rates
P-221	-1.1962 -0.4134 -0.0331 -0.2022 -0.0131 -0.2214 -0.0014 -0.0665 -0.1537 -0.2817 -0.2467 -0.0857
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol ; mortality
H-650	-0.48080897331237793	▁bis o pro lol ▁; ▁ reducing ▁mortal ity
D-650	-0.48080897331237793	bisoprolol ; reducing mortality
P-650	-0.3822 -0.2027 -0.0370 -0.4127 -0.7372 -1.3557 -0.5190 -0.3728 -1.0127 -0.1416 -0.1154
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health buddy program ; telehealth
H-1622	-0.4412378966808319	▁Health ▁Budd y ▁Program ▁; ▁content - driv en ▁tele health ▁system ▁; ▁care ▁management
D-1622	-0.4412378966808319	Health Buddy Program ; content-driven telehealth system ; care management
P-1622	-2.1108 -0.0448 -0.0452 -0.6902 -0.2362 -2.3720 -0.0215 -0.0037 -0.0281 -0.5068 -0.2092 -0.1133 -0.6118 -0.1483 -0.0810 -0.1530 -0.1251
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare ; hospitalizations
H-1714	-0.4065825939178467	▁Medica re ▁fee - for - service
D-1714	-0.4065825939178467	Medicare fee-for-service
P-1714	-0.3726 -0.0862 -0.9114 -0.0781 -0.0624 -0.0443 -0.0856 -1.8673 -0.1514
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician ; conditions ; hospital ; discharge
H-1422	-0.5683109164237976	▁physician ▁continu ity
D-1422	-0.5683109164237976	physician continuity
P-1422	-0.2470 -0.1219 -0.2756 -2.0938 -0.1033
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic ; patients ; heart failure
H-1740	-1.0415058135986328	▁ therapeut ic ▁; ▁survival ▁; ▁patients ▁; ▁heart ▁failure
D-1740	-1.0415058135986328	therapeutic ; survival ; patients ; heart failure
P-1740	-2.4863 -0.2509 -0.2873 -1.7729 -3.0673 -0.4711 -1.1221 -2.1442 -0.5159 -0.1379 -0.1342 -0.1081
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss ; btes ; exercise
H-1928	-0.6627579927444458	▁PS SS ▁; ▁social ▁support ▁; ▁b tes
D-1928	-0.6627579927444458	PSSS ; social support ; btes
P-1928	-1.1810 -0.5460 -0.2302 -0.6483 -0.6411 -0.7056 -0.9364 -0.4702 -1.1600 -0.1088
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac stress ; β-ar ; drive
H-1219	-0.5110117197036743	▁cardiac ▁stress ▁; ▁anta gon izing ▁excessive ▁β - AR ▁drive
D-1219	-0.5110117197036743	cardiac stress ; antagonizing excessive β-AR drive
P-1219	-1.8323 -0.3677 -0.3079 -2.4809 -0.0004 -0.0057 -0.7709 -0.1389 -0.0366 -0.2186 -0.1259 -0.2443 -0.1130
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin subproteome ; diseased ; heart
H-99	-0.3460661470890045	▁chr omat in ▁sub prote ome ▁; ▁mouse ▁heart
D-99	-0.3460661470890045	chromatin subproteome ; mouse heart
P-99	-0.8542 -0.0175 -0.9427 -0.0719 -0.0331 -0.0246 -0.1035 -1.3432 -0.2367 -0.1012 -0.0781
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated ; septal ; wall ; avd ; free wall cs ; vvd
H-329	-0.44270434975624084	▁sept al ▁wall ▁CS ▁; ▁AV d ▁variation ▁; ▁free ▁wall ▁CS ▁; ▁VVD
D-329	-0.44270434975624084	septal wall CS ; AVd variation ; free wall CS ; VVD
P-329	-1.5659 -0.0215 -0.0428 -1.1352 -0.1530 -1.2581 -0.7305 -0.8822 -0.0317 -0.0310 -0.0984 -0.3193 -0.1906 -0.1743 -0.3397 -0.1093
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv strain ; strain ; echocardiography ; baseline ; ablation
H-946	-0.7790965437889099	▁e cho card i ography
D-946	-0.7790965437889099	echocardiography
P-946	-3.9876 -0.0213 -0.3220 -0.3281 -0.1310 -0.5852 -0.0783
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed up ; adverse events ; death ; transplantation ; circulatory assist device
H-1162	-0.5255222916603088	▁death ▁; ▁transplant ation ▁; ▁circula tory ▁assist ▁device
D-1162	-0.5255222916603088	death ; transplantation ; circulatory assist device
P-1162	-4.4184 -0.3376 -0.0138 -0.0805 -0.2684 -0.0001 -0.0549 -0.1642 -0.1938 -0.1706 -0.0784
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular pacing ; left heart twist ; strain ; right heart failure
H-318	-0.41967537999153137	▁bi ven tri cular ▁pa cing ▁; ▁left ▁heart ▁twist ▁; ▁strain ▁; ▁por cine ▁model ▁; ▁right ▁heart ▁failure
D-318	-0.41967537999153137	biventricular pacing ; left heart twist ; strain ; porcine model ; right heart failure
P-318	-1.5955 -0.0457 -0.8799 -0.2455 -0.0331 -0.0203 -0.4075 -0.4549 -0.8458 -1.6278 -0.2692 -0.0428 -0.1546 -1.3987 -0.0173 -0.0971 -0.3955 -0.0740 -0.1599 -0.1487 -0.1832 -0.1359
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic ; acute rv failure ; left ventricular dysfunction
H-1092	-0.33438485860824585	▁et i ologic ▁causes ▁; ▁a cute ▁ RV ▁failure ▁; ▁left ▁vent ri cular ▁dys function
D-1092	-0.33438485860824585	etiologic causes ; acute RV failure ; left ventricular dysfunction
P-1092	-1.3877 -0.0551 -0.0408 -1.1502 -0.1897 -0.3582 -0.0058 -0.1772 -0.2475 -0.1169 -0.1744 -0.1618 -0.0504 -1.4861 -0.1734 -0.0716 -0.1672 -0.2133 -0.1260
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs ; functional capacity ; outcomes ; heart failure ; hf
H-121	-0.27471089363098145	▁c PC s ▁; ▁functional ▁capacity ▁; ▁heart ▁failure ▁; HF
D-121	-0.27471089363098145	cPCs ; functional capacity ; heart failure ;HF
P-121	-1.0371 -0.7985 -0.1284 -0.1194 -0.0185 -0.2574 -0.1030 -0.4136 -0.0647 -0.3598 -0.0348 -0.1253 -0.1107
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein kinase a ; guanylate cyclase ; contractile response
H-418	-0.41308826208114624	▁inhibi tion ▁; ▁protein ▁kina se ▁; ▁solu ble ▁gua ny late ▁cy cla se ▁; ▁contract ile ▁response
D-418	-0.41308826208114624	inhibition ; protein kinase ; soluble guanylate cyclase ; contractile response
P-418	-0.2414 -0.2679 -1.2606 -0.0819 -0.0119 -0.0511 -0.9546 -0.5376 -0.5760 -0.0373 -0.8796 -0.6890 -0.1752 -0.0428 -0.5625 -1.0886 -0.0034 -0.0764 -0.6537 -0.2935 -0.1897
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating progenitor cells ; outcome ; heart failure ; patients ; longitudinal
H-119	-0.4475530683994293	▁circula ting ▁pro gen itor ▁cell s ▁; ▁heart ▁failure ▁patients
D-119	-0.4475530683994293	circulating progenitor cells ; heart failure patients
P-119	-0.0104 -0.3281 -0.2119 -0.2780 -0.1110 -0.9952 -0.1335 -0.4183 -2.0776 -0.1356 -0.6760 -0.3044 -0.1384
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress doppler echocardiography ; prognostic ; pulmonary hypertension ; patients
H-832	-0.4444054365158081	▁do pp ler ▁e cho card i ography ▁; ▁pulmonar y ▁hyper tension
D-832	-0.4444054365158081	doppler echocardiography ; pulmonary hypertension
P-832	-2.8399 -0.0119 -0.4857 -0.0671 -0.1977 -0.2809 -0.4732 -0.2177 -0.2629 -0.0657 -0.0652 -0.1269 -0.1194 -1.3279 -0.1241
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic ; diastolic mitral leaflet motions ; organic ; lesion
H-351	-0.3357315957546234	▁sy sto lic ▁; ▁dia sto lic ▁mit ral ▁le a flet ▁motion s
D-351	-0.3357315957546234	systolic ; diastolic mitral leaflet motions
P-351	-0.0139 -0.0454 -0.0101 -0.2613 -0.0046 -0.0451 -0.0119 -0.4680 -0.0403 -1.5698 -0.0966 -0.0090 -1.0375 -0.1789 -1.4619 -0.1173
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity ; mortality ; quality of life ; patients ; hf
H-2023	-0.5071032643318176	▁morbi d ity ▁; ▁mortal ity ▁; ▁ HF
D-2023	-0.5071032643318176	morbidity ; mortality ; HF
P-2023	-0.1729 -0.0618 -0.8017 -0.2420 -0.0113 -0.5526 -0.2678 -3.0956 -0.1631 -0.0993 -0.1100
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt ; nt-probnp ; hf
H-291	-0.36237096786499023	▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF ▁risk ▁predict ion
D-291	-0.36237096786499023	ctnt ; NT-probNP ; HF risk prediction
P-291	-0.0132 -0.1544 -0.0346 -0.1604 -0.0401 -0.1361 -0.0371 -0.0104 -0.6538 -0.1569 -0.2225 -0.6642 -0.3305 -2.7594 -0.7105 -0.0425 -0.2369 -0.1593
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student t test ; confidence intervals ; cis ; regression analyses
H-215	-0.3728535771369934	▁Student ▁t ▁test ▁; ▁confidence ▁interval s ▁; CI s
D-215	-0.3728535771369934	Student t test ; confidence intervals ;CIs
P-215	-2.0494 -0.0268 -0.1848 -0.2733 -0.4992 -0.0047 -0.0721 -0.1780 -0.1632 -0.0651 -0.8733 -0.0844
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical ; radiological ; hf ; quality of life
H-565	-0.8638107776641846	▁ HF
D-565	-0.8638107776641846	HF
P-565	-2.5569 -0.2015 -0.5888 -0.1081
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital ; mortality ; patients ; bnp ; mortality
H-195	-0.5235246419906616	▁in hospital ▁mortal ity ▁; ▁b NP ▁level ▁; ▁mortal ity
D-195	-0.5235246419906616	inhospital mortality ; bNP level ; mortality
P-195	-0.1860 -0.0104 -0.0703 -0.4772 -0.4111 -1.6453 -0.5866 -0.2585 -1.1779 -0.5848 -1.1400 -0.1740 -0.0835
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality ; deaths ; acs ; consultation ; operation
H-1287	-0.6855381727218628	▁Mor t ality
D-1287	-0.6855381727218628	Mortality
P-1287	-0.7817 -0.2025 -0.0151 -2.3383 -0.0902
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right ventricle ; rv ; cardiac function ; medical
H-1091	-0.3456386625766754	▁right ▁vent ric le ▁; RV ▁; ▁cardiac ▁function
D-1091	-0.3456386625766754	right ventricle ;RV ; cardiac function
P-1091	-0.5564 -0.0444 -0.4691 -0.2254 -0.2259 -0.5732 -0.5129 -0.1395 -0.1570 -0.8120 -0.0862
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes ; costs ; patients ; heart failure ; hf
H-1721	-1.3420943021774292	▁heart ▁failure ▁; HF
D-1721	-1.3420943021774292	heart failure ;HF
P-1721	-6.9638 -0.1422 -0.5301 -0.0969 -0.2082 -0.1115
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv dysfunction ; correlated ; lean body mass
H-1164	-0.6080787777900696	▁ RV ▁dys function ▁; ▁weight ▁loss ▁; ▁fat ▁; lean ▁body ▁mass ▁ratio
D-1164	-0.6080787777900696	RV dysfunction ; weight loss ; fat ;lean body mass ratio
P-1164	-0.8825 -0.8381 -0.1991 -0.0545 -0.1788 -1.2655 -0.7153 -0.3842 -0.4608 -2.5485 -0.2291 -1.1846 -0.3313 -0.0951 -0.2020 -0.1599
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr reduction ; beta blockers ; exercise capacity ; hfref
H-1937	-0.23817726969718933	▁HR ▁re duction ▁; ▁beta ▁block ers ▁; ▁exercise ▁capacity ▁; ▁h Fr EF
D-1937	-0.23817726969718933	HR reduction ; beta blockers ; exercise capacity ; hFrEF
P-1937	-0.4731 -0.1659 -0.0092 -0.1860 -0.0288 -0.0898 -0.0112 -0.4980 -0.0458 -0.1616 -0.4764 -0.9829 -0.2106 -0.3139 -0.0925 -0.0654
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary ; exercise ; prognostically ; heart failure
H-1274	-0.844581663608551	▁cardio pul mon ary ▁exercise ▁; ▁heart ▁failure
D-1274	-0.844581663608551	cardiopulmonary exercise ; heart failure
P-1274	-0.5659 -0.3416 -1.5510 -0.2303 -1.8111 -0.5659 -2.9492 -0.1795 -0.1543 -0.0970
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle cohort study ; canada
H-1951	-1.178383469581604	
D-1951	-1.178383469581604	
P-1951	-2.2594 -0.0974
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary outcome ; sympathetic activity ; myocardial washout
H-1115	-0.7191169857978821	▁sympa the tic ▁activity ▁; ▁i - mi BG ▁my o card ial ▁was hout
D-1115	-0.7191169857978821	sympathetic activity ; i-miBG myocardial washout
P-1115	-0.7926 -0.5228 -0.2394 -0.8090 -0.1516 -1.2031 -0.3137 -0.6976 -2.1173 -1.9755 -0.2275 -0.4813 -0.1362 -1.6328 -0.4644 -0.2474 -0.2128
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial diastolic dysfunction ; dd ; collagen deposition ; titin
H-761	-0.14860640466213226	▁my o card ial ▁dia sto lic ▁dys function ▁; DD ▁; ▁collage n ▁de position ▁; ▁titi n ▁modification
D-761	-0.14860640466213226	myocardial diastolic dysfunction ;DD ; collagen deposition ; titin modification
P-761	-0.3288 -0.0900 -0.1542 -0.1036 -0.0424 -0.0399 -0.0400 -0.0152 -0.0635 -0.2617 -0.1120 -0.8719 -0.0062 -0.0402 -0.0349 -0.1317 -0.3361 -0.0037 -0.0514 -0.2789 -0.1726 -0.0903
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome ; death ; hospitalization ; heart failure
H-849	-1.289272427558899	▁sterf ▁; ▁worse ning ▁heart ▁failure
D-849	-1.289272427558899	sterf ; worsening heart failure
P-849	-4.9707 -0.7145 -3.4855 -0.1947 -0.5160 -0.2301 -0.0972 -0.1054
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline ; st2 ; interquartile range
H-701	-0.6521269679069519	▁ST 2 ▁level ▁; inter quart ile ▁range
D-701	-0.6521269679069519	ST2 level ;interquartile range
P-701	-3.5504 -0.1162 -0.2721 -1.3714 -0.5424 -0.0211 -0.0037 -0.3022 -0.2145 -0.1273
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up ; outcomes ; mortality
H-1637	-0.28475916385650635	▁black ▁race ▁; ▁mortal ity
D-1637	-0.28475916385650635	black race ; mortality
P-1637	-0.0073 -0.1017 -0.5563 -0.5533 -0.5856 -0.0827 -0.1064
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome ; change ; hospitalized ; heart failure
H-1395	-0.6105313301086426	▁Nur sing - sensitiv e ▁outcome ▁change ▁score s ▁; ▁hospital ized ▁older ▁adults ▁; ▁heart ▁failure
D-1395	-0.6105313301086426	Nursing-sensitive outcome change scores ; hospitalized older adults ; heart failure
P-1395	-3.1921 -0.0804 -0.0477 -0.0020 -0.0584 -0.4232 -2.2447 -0.3629 -0.0759 -0.3687 -1.3170 -0.0745 -0.4170 -0.1905 -1.6378 -0.5532 -0.2780 -0.1386 -0.1372
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic ; diagnostic ; fluid overload
H-1071	-0.4994383752346039	▁ therapeut ic ▁function s ▁; ▁devices ▁; ▁fluid ▁over load
D-1071	-0.4994383752346039	therapeutic functions ; devices ; fluid overload
P-1071	-0.7950 -0.0282 -0.2019 -0.2242 -0.1069 -0.3953 -1.0008 -0.5453 -2.5051 -0.0385 -0.4186 -0.1420 -0.0908
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin ; heart failure ; breast cancer
H-927	-0.3296012878417969	▁Human ▁resist in ▁; ▁che mo therapy - indu ced ▁heart ▁failure ▁; ▁human ized ▁male ▁mi ce ▁; ▁breast ▁cancer
D-927	-0.3296012878417969	Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
P-927	-1.7622 -0.3089 -0.1222 -1.0649 -0.0365 -0.1553 -0.0120 -0.2090 -0.0079 -0.0362 -0.4281 -0.0489 -0.2865 -0.3250 -0.0704 -0.0810 -0.1789 -0.1033 -0.1498 -1.6471 -0.2086 -0.2076 -0.1307
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise ; clinical ; outcomes
H-1926	-0.7429407238960266	▁social ▁support ▁; ▁barrier s ▁; ▁exercise ▁ad her ence
D-1926	-0.7429407238960266	social support ; barriers ; exercise adherence
P-1926	-3.1514 -0.4744 -0.2757 -1.0443 -0.1384 -0.7768 -1.1385 -0.0872 -0.5840 -0.3980 -0.7201 -0.1263
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure ulcers ; surgical ; patients
H-6	-0.3621040880680084	▁pressure ▁ul cer s ▁; ▁sur g ical ▁patients
D-6	-0.3621040880680084	pressure ulcers ; surgical patients
P-6	-1.2902 -0.2019 -0.0302 -0.1398 -0.2725 -0.8313 -0.0900 -0.1484 -0.3669 -0.4949 -0.1170
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf ; valve plasty ; mva
H-369	-0.25018149614334106	▁ HF ▁; ▁val ve ▁plast y ▁; ▁MS
D-369	-0.25018149614334106	HF ; valve plasty ; MS
P-369	-0.8567 -0.0485 -0.0802 -0.2588 -0.0168 -0.0210 -0.2033 -0.1871 -0.0528 -0.9597 -0.0671
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd ; congestive heart failure ; chf
H-902	-0.27349865436553955	▁PD ▁; ▁re frac tory ▁; ▁end - s tage ▁con ges tive ▁heart ▁failure ▁; CH f
D-902	-0.27349865436553955	PD ; refractory ; end-stage congestive heart failure ;CHf
P-902	-0.5764 -0.1521 -0.1178 -0.0129 -0.0469 -0.1169 -0.7546 -0.0270 -0.0626 -0.0015 -0.0099 -0.1545 -0.7437 -0.5760 -0.0680 -0.2950 -0.3767 -1.1787 -0.1248 -0.0740
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression models ; comorbidities
H-662	-0.7922917008399963	▁insurance ▁status ▁; ▁como rbi di ties
D-662	-0.7922917008399963	insurance status ; comorbidities
P-662	-5.7976 -0.1196 -0.7397 -0.0593 -0.0019 -0.0923 -0.0502 -0.1072 -0.1628
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta blockers ; mortality ; patients ; heart failure
H-649	-0.7438607215881348	▁beta ▁block ers ▁; ▁mortal ity ▁; ▁heart ▁failure
D-649	-0.7438607215881348	beta blockers ; mortality ; heart failure
P-649	-1.1098 -0.4131 -0.0652 -0.7172 -2.3480 -1.0180 -0.2663 -1.8386 -0.2290 -0.0993 -0.0779
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter ; invasive ; surgery
H-553	-0.4678746163845062	▁trans cat heter ▁; ▁surgery
D-553	-0.4678746163845062	transcatheter ; surgery
P-553	-0.0348 -0.1677 -0.0209 -1.2190 -1.6069 -0.1162 -0.1096
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-0.5664010047912598	▁fut ility ▁; ▁data ▁monitoring ▁board
D-850	-0.5664010047912598	futility ; data monitoring board
P-850	-0.6280 -0.0704 -0.3894 -0.9320 -2.0234 -0.2328 -0.1693 -0.0859
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic ; complication
H-1661	-0.7661492228507996	▁complica tion
D-1661	-0.7661492228507996	complication
P-1661	-1.6026 -1.2848 -0.0908 -0.0864
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation ; heart iron
H-748	-0.3785424530506134	▁che lation ▁regime ns ▁; ▁remove ▁heart ▁ir on
D-748	-0.3785424530506134	chelation regimens ; remove heart iron
P-748	-0.2876 -0.0189 -0.1205 -0.1670 -0.2993 -1.9269 -0.3295 -0.1459 -0.0551 -0.7411 -0.0721
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients ; consultation ; abdominal
H-1284	-0.7164590358734131	▁MT ▁; ▁abdominal ▁problems
D-1284	-0.7164590358734131	MT ; abdominal problems
P-1284	-1.7529 -0.8418 -0.1550 -1.2110 -0.2193 -0.1188
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients ; chronic organ failure
H-793	-0.6587451696395874	▁Time d ▁Up ▁& ▁Go ▁test ▁; ▁advanced ▁chronic ▁organ ▁failure
D-793	-0.6587451696395874	Timed Up & Go test ; advanced chronic organ failure
P-793	-1.0633 -0.0926 -0.4722 -1.5288 -0.4088 -0.1157 -0.3084 -3.5666 -0.4933 -0.0409 -0.1598 -0.1417 -0.1716
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms ; patients ; nyha
H-1893	-0.6775003671646118	▁NY HA ▁functional ▁assessment
D-1893	-0.6775003671646118	NYHA functional assessment
P-1893	-3.0171 -0.6867 -0.1939 -0.0164 -0.0670 -0.0839
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.6168114542961121	▁follow - up
D-727	-0.6168114542961121	follow-up
P-727	-1.4557 -0.1943 -0.0271 -1.3340 -0.0730
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-1.0377230644226074	▁mortal ity
D-2001	-1.0377230644226074	mortality
P-2001	-2.6202 -0.7162 -0.7352 -0.0793
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
H-576	-0.18909941613674164	▁vent ri cular ▁e je ction ▁; ▁a cute ▁heart ▁failure ▁; ▁pre cap illa ry ▁pulmonar y ▁hyper tension
D-576	-0.18909941613674164	ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
P-576	-0.1017 -0.6585 -0.1095 -0.0880 -0.0351 -0.0107 -1.4268 -0.0955 -0.0081 -0.2951 -0.0910 -0.2975 -0.1566 -0.0794 -0.0267 -0.0772 -0.0086 -0.0488 -0.1315 -0.0320 -0.2294 -0.1528
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical ; aortic valve insufficiency ; left ventricular assist device ; implantation
H-541	-0.28623348474502563	▁a or tic ▁val ve ▁insu ffi cie ncy ▁; ▁left ▁vent ri cular ▁assist ▁device ▁implant ation
D-541	-0.28623348474502563	aortic valve insufficiency ; left ventricular assist device implantation
P-541	-0.3556 -0.0399 -0.6148 -0.0700 -0.0567 -0.1866 -0.1372 -0.4625 -0.0255 -0.2127 -0.1353 -0.0322 -0.4734 -0.0809 -1.2389 -0.5222 -0.4616 -0.3216 -0.2207 -0.0763
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection fraction ; clinical ; cardiac resynchronization therapy ; mild heart failure
H-750	-0.16063810884952545	▁e je ction ▁ fraction ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁mild ▁heart ▁failure
D-750	-0.16063810884952545	ejection fraction ; cardiac resynchronization therapy ; mild heart failure
P-750	-0.1674 -0.0176 -0.0082 -0.2560 -0.0013 -0.1265 -0.1023 -0.0267 -0.0814 -0.0193 -0.3376 -0.7713 -0.0119 -0.4331 -0.1167 -0.1959 -0.1288 -0.1422 -0.1080
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary outcome ; functional capacity ; 6-minute walk test ; 6mwt
H-571	-0.8094127774238586	▁functional ▁capacity
D-571	-0.8094127774238586	functional capacity
P-571	-0.3120 -1.1639 -1.6537 -0.1080
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef ; sodium ; ventricular ; vascular stiffness
H-917	-0.47184109687805176	▁H FP EF ▁; ▁so dium ▁restriction ▁; ▁vent ri cular ▁; ▁vas cular ▁sti ff ness
D-917	-0.47184109687805176	HFPEF ; sodium restriction ; ventricular ; vascular stiffness
P-917	-2.3846 -0.1765 -0.4586 -0.5710 -1.2274 -0.0631 -0.1144 -0.0934 -0.0122 -0.5146 -0.0882 -0.2724 -0.1903 -0.2575 -0.2351 -0.2393 -1.4466 -0.5380 -0.0818
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully magnetically levitated left ventricular assist system ; hf
H-1992	-0.3835369050502777	▁magnet ically ▁Lev itate d ▁le ft ▁vent ri cular ▁Assist ▁system ▁; ▁Tre ating ▁Advanced ▁ HF
D-1992	-0.3835369050502777	magnetically Levitated left ventricular Assist system ; Treating Advanced HF
P-1992	-0.5651 -0.0671 -0.1532 -0.3268 -0.0148 -0.6152 -0.0071 -1.3140 -1.4590 -0.1878 -0.0424 -1.0873 -0.6108 -0.7527 -0.0103 -0.1146 -0.0559 -0.0793 -0.1531 -0.0544
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf ; atrial explants ; cells ; explants
H-1341	-0.27454981207847595	▁CHF ▁at rial ▁ex plant s ▁; ▁c - K it + ▁cell s ▁; ▁sham ▁ex plant s
D-1341	-0.27454981207847595	CHF atrial explants ; c-Kit+ cells ; sham explants
P-1341	-0.0106 -2.0456 -0.0314 -0.0648 -0.0116 -0.2296 -0.3857 -0.0624 -0.0794 -0.3743 -0.0073 -0.9266 -0.1443 -0.1601 -0.2805 -0.1337 -0.2674 -0.0192 -0.1993 -0.2454 -0.0862
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic heart failure ; chf ; sympathetic tone ; autonomic imbalance
H-1370	-0.29434993863105774	▁chronic ▁heart ▁failure ▁; CH f ▁; ▁sympa the tic ▁tone ▁; ▁autonomi c ▁im balance
D-1370	-0.29434993863105774	chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
P-1370	-0.1188 -0.8111 -0.0666 -0.1248 -0.5638 -1.0737 -0.2922 -0.0382 -0.2927 -0.4319 -0.0733 -0.1802 -0.0024 -0.2875 -0.6202 -0.0261 -0.1731 -0.1217
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart failure ; leading ; mortality ; western ; society ; cardiovascular diseases
H-1480	-0.4603792428970337	▁Heart ▁failure ▁; ▁mortal ity ▁; ▁Western ▁society ▁; ▁cardiovascular ▁disease s
D-1480	-0.4603792428970337	Heart failure ; mortality ; Western society ; cardiovascular diseases
P-1480	-1.0256 -0.1257 -0.1762 -2.4927 -0.9057 -0.1987 -0.4256 -0.0437 -0.1919 -0.1194 -0.3429 -0.1617 -0.1288 -0.1068
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal membrane oxygenation ; refractory right heart failure
H-1290	-0.21098339557647705	▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ bridge ▁to ▁recovery ▁; ▁in far ction - related ▁re frac tory ▁right ▁heart ▁failure
D-1290	-0.21098339557647705	extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
P-1290	-0.3463 -0.0032 -0.0784 -0.0075 -0.0067 -0.0486 -0.3885 -0.0853 -0.2880 -0.5514 -0.0019 -0.4596 -0.0404 -1.2311 -0.0232 -0.0451 -0.0286 -0.1073 -0.0413 -0.0231 -0.0044 -0.1321 -0.8847 -0.2983 -0.2939 -0.1993 -0.0784
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical ; echocardiographic ; invasive ; hemodynamic ; outcome
H-1527	-0.1409287452697754	▁e cho car dio graphic ▁; ▁invasi ve ▁hem o dynamic
D-1527	-0.1409287452697754	echocardiographic ; invasive hemodynamic
P-1527	-0.2258 -0.0158 -0.0215 -0.2359 -0.1859 -0.1563 -0.0033 -0.0427 -0.1757 -0.2686 -0.0019 -0.4095 -0.0891
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac catheterization ; thrombotic obstruction ; right coronary artery
H-1292	-0.4156900942325592	▁cardiac ▁cat heter ization ▁; ▁ thro mbo tic ▁ob struct ion ▁; ▁right ▁corona ry ▁arter y
D-1292	-0.4156900942325592	cardiac catheterization ; thrombotic obstruction ; right coronary artery
P-1292	-0.8725 -0.7757 -0.0222 -0.4573 -0.1854 -0.2121 -0.2423 -0.8182 -2.0640 -0.3688 -0.0207 -0.0152 -0.3643 -0.2338 -0.0765 -0.6874 -0.0123 -0.5958 -0.1683 -0.1210
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california office of statewide health planning and development patient discharge data nonpublic file
H-136	-0.8634116053581238	▁California ▁office ▁of ▁State wide ▁health plan ning ▁and ▁Development ▁Patient ▁Dis charge
D-136	-0.8634116053581238	California office of Statewide healthplanning and Development Patient Discharge
P-136	-1.4249 -0.9582 -1.2792 -2.0095 -0.0634 -1.0876 -0.8305 -0.0122 -1.4483 -0.6411 -0.6002 -1.1584 -0.0355 -1.3243 -0.0779
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan failure ; systolic ventricular function ; liver disease
H-224	-0.1834079772233963	▁Font an ▁failure ▁; ▁sy sto lic ▁vent ri cular ▁function ▁; ▁ liver ▁disease
D-224	-0.1834079772233963	Fontan failure ; systolic ventricular function ; liver disease
P-224	-0.1559 -0.1641 -0.2561 -0.1277 -0.0173 -0.0172 -0.0400 -0.0230 -0.4014 -0.0939 -0.3392 -0.1607 -0.1842 -0.2114 -0.7446 -0.1027 -0.0784
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing ; outcomes ; hospitalized ; hf
H-1402	-0.9494543075561523	▁nur sing ▁; ▁hospital ized ▁older ▁adults ▁; ▁ HF
D-1402	-0.9494543075561523	nursing ; hospitalized older adults ; HF
P-1402	-6.1005 -0.0888 -0.4100 -2.2572 -0.0912 -0.2690 -0.0750 -0.6780 -1.1336 -0.0461 -0.1167 -0.1273
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis ; pacing-induced dilated cardiomyopathy
H-165	-0.3317158818244934	▁pa cing - indu ced ▁dil ated ▁cardio my o pathy
D-165	-0.3317158818244934	pacing-induced dilated cardiomyopathy
P-165	-0.7438 -0.8118 -0.0426 -0.0070 -0.0556 -0.4603 -0.4663 -0.0887 -0.9412 -0.3782 -0.0357 -0.1308 -0.1505
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical delay ; dyssynchronous heart failure
H-1146	-0.327648788690567	▁me chan istic ▁insight ▁; ▁prolong ed ▁electro me chan ical ▁de lay ▁; ▁dys syn chron ous ▁heart ▁failure
D-1146	-0.327648788690567	mechanistic insight ; prolonged electromechanical delay ; dyssynchronous heart failure
P-1146	-2.2516 -0.0064 -0.0732 -0.3011 -0.2534 -0.5042 -0.0504 -0.0335 -0.0305 -0.0167 -0.1377 -0.0237 -0.0638 -0.5912 -0.0240 -0.0245 -0.0070 -0.5500 -0.9990 -0.2339 -0.8968 -0.1357
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients ; trastuzumab ; cardiac ; comorbidities
H-682	-0.4739697277545929	▁tras tuz um ab ▁; ▁cardiac ▁como rbi di ties
D-682	-0.4739697277545929	trastuzumab ; cardiac comorbidities
P-682	-0.6405 -0.0180 -0.0037 -0.5049 -0.3568 -0.0254 -2.8709 -0.0028 -0.2408 -0.1357 -0.7397 -0.1483
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype ; perioperative ; deaths
H-279	-0.5322945713996887	
D-279	-0.5322945713996887	
P-279	-0.9857 -0.0789
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic ; patients ; heart failure ; québec ; canada
H-1233	-0.6474714279174805	▁economic ▁impact ▁; ▁af ▁; ▁heart ▁failure ▁; ▁Québec ▁; ▁Canada
D-1233	-0.6474714279174805	economic impact ; af ; heart failure ; Québec ; Canada
P-1233	-1.2753 -0.4223 -0.1846 -2.2573 -0.3703 -0.6209 -0.1078 -0.7816 -0.6380 -0.5907 -0.9782 -0.1165 -0.0736
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac ; mena deletion ; cardiac dysfunction ; hypertrophy
H-1811	-0.23306086659431458	▁cardiac ▁Men a ▁dele tion ▁; ▁cardiac ▁dys function ▁; ▁con duction ▁ab normal ities ▁; ▁hyper trop hy
D-1811	-0.23306086659431458	cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
P-1811	-0.1209 -0.7376 -0.0983 -0.0098 -0.1956 -0.1995 -0.0472 -0.1418 -0.0635 -0.4101 -0.1086 -0.0112 -0.0309 -0.0147 -0.4574 -0.4694 -0.0552 -0.0092 -1.5024 -0.1059 -0.1049
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left bundle-branch block ; lbbb
H-886	-0.25688883662223816	▁bund le - bran ch ▁block ▁; LB bb ▁; ▁non - LB bb
D-886	-0.25688883662223816	bundle-branch block ;LBbb ; non-LBbb
P-886	-0.0384 -0.1001 -0.0327 -0.0064 -0.1150 -0.2136 -0.2082 -0.2142 -1.1214 -0.5061 -0.4428 -0.0164 -0.1013 -0.7964 -0.1138 -0.0835
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein ; genes ; western blot ; dna fragmentation ; tunel
H-167	-0.4457772672176361	▁protein ▁levels ▁; ▁Western ▁blot ▁; ▁DNA ▁fragment ation ▁; ▁tu nel ▁; ▁auto psy ▁sample s
D-167	-0.4457772672176361	protein levels ; Western blot ; DNA fragmentation ; tunel ; autopsy samples
P-167	-0.6548 -0.3931 -0.2792 -1.6058 -0.0554 -0.1637 -0.3710 -0.0735 -0.1134 -0.3588 -1.0889 -0.1990 -2.2204 -0.0382 -0.0283 -0.3814 -0.1486 -0.1985 -0.0976
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine ; dilated cardiomyopathy ; patients ; heart failure
H-1257	-0.2888396680355072	▁Chinese ▁herbal ▁medicine ▁; ▁ad ju nc tive ▁treatment ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure
D-1257	-0.2888396680355072	Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
P-1257	-1.0263 -0.1048 -0.1337 -0.1377 -0.4845 -0.0187 -0.0009 -0.0843 -0.3179 -0.3389 -0.0129 -0.1011 -0.0680 -0.9474 -0.2909 -0.0224 -0.3372 -0.9762 -0.1905 -0.2825 -0.1889
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient ; implantable cardioverter-defibrillator
H-1856	-0.2530384361743927	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1856	-0.2530384361743927	implantable cardioverter-defibrillator deactivation
P-1856	-1.0488 -0.0683 -0.4412 -0.0130 -0.1553 -0.0337 -0.0763 -0.0545 -0.3811 -0.0873 -0.0526 -0.1405 -0.0630 -0.3950 -0.8791 -0.1589
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated ; cardiac filling pressures ; adverse outcomes
H-1532	-0.3608630299568176	▁EH ▁; ▁CH ▁; ▁cardiac ▁fill ing ▁pressure s
D-1532	-0.3608630299568176	EH ; CH ; cardiac filling pressures
P-1532	-0.1937 -0.0750 -0.9658 -0.4192 -0.3095 -0.4623 -0.1119 -0.5254 -0.2733 -0.5283 -0.1052
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right atrium ; prolapse ; tricuspid valve ; stenotic physiology
H-596	-0.3354607820510864	▁right ▁at rium ▁mass ▁; ▁pro lapse ▁; ▁tri cus pid ▁val ve
D-596	-0.3354607820510864	right atrium mass ; prolapse ; tricuspid valve
P-596	-0.3319 -0.5784 -0.0053 -0.1306 -0.1362 -0.0771 -0.0474 -0.3307 -0.0135 -0.0626 -0.0104 -0.1231 -0.1121 -3.0123 -0.0602
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp ; sensitivity
H-271	-0.25898459553718567	▁cut off ▁level ▁; ▁NT - pro b NP
D-271	-0.25898459553718567	cutoff level ; NT-probNP
P-271	-0.3373 -0.1123 -0.1815 -0.1369 -0.1660 -0.0207 -0.0138 -0.4902 -0.1652 -1.1182 -0.1068
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart failure ; protein kinase a ; expression
H-1423	-0.6523332595825195	▁heart ▁failure ▁; ▁alter ed ▁protein ▁kina se
D-1423	-0.6523332595825195	heart failure ; altered protein kinase
P-1423	-2.8693 -0.2069 -0.3637 -1.9805 -0.0134 -0.0756 -0.0044 -0.0513 -0.8210 -0.1373
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up ; patients ; hf
H-1106	-0.4492509365081787	▁ HF
D-1106	-0.4492509365081787	HF
P-1106	-1.2611 -0.1128 -0.3330 -0.0902
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality of life ; seattle heart failure model
H-2012	-0.9273552894592285	▁resource ▁use ▁; ▁quality ▁of ▁life
D-2012	-0.9273552894592285	resource use ; quality of life
P-2012	-1.7066 -1.6543 -0.1599 -0.2275 -0.3474 -0.4573 -2.7727 -0.0931
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized ; dopamine ; nesiritide
H-76	-0.29049205780029297	▁dop amine ▁; ▁nesi riti de ▁strategy
D-76	-0.29049205780029297	dopamine ; nesiritide strategy
P-76	-0.5087 -0.1006 -0.1284 -0.0165 -0.0054 -0.0697 -1.5375 -0.1441 -0.1036
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical ; nitrite ; vascular
H-414	-0.37013009190559387	▁chemical ▁in st ability ▁; ▁co genera tion ▁; ▁nit rite ▁; ▁vas cular ▁effects
D-414	-0.37013009190559387	chemical instability ; cogeneration ; nitrite ; vascular effects
P-414	-2.1153 -0.0305 -0.0765 -0.0822 -0.0889 -0.0204 -0.0109 -0.2537 -0.5794 -0.0213 -0.5292 -0.6627 -0.0642 -0.1198 -1.3229 -0.2016 -0.1126
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological ; cardiovascular ; bound
H-1875	-0.422796368598938	▁neurologi cal ▁; ▁cardiovascular
D-1875	-0.422796368598938	neurological ; cardiovascular
P-1875	-0.2142 -0.2599 -0.3088 -0.0619 -1.6013 -0.0907
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox regression ; cardiovascular events ; psoriasis
H-1558	-0.12731420993804932	▁co x ▁re gression ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1558	-0.12731420993804932	cox regression ; cardiovascular events ; psoriasis
P-1558	-0.0718 -0.1241 -0.0240 -0.0132 -0.1106 -0.2767 -0.1735 -0.3520 -0.0033 -0.1558 -0.0954
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective studies ; cpg ; hf
H-1845	-0.6773661971092224	▁c PG ▁recommendations ▁; ▁ HF
D-1845	-0.6773661971092224	cPG recommendations ; HF
P-1845	-1.4295 -0.7112 -1.2227 -0.4569 -1.0072 -0.3171 -0.1321 -0.1423
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation ; flow-mediated dilatation
H-259	-0.31726792454719543	▁HD L - indu ced ▁NO ▁production ▁; ▁flow - media ted ▁di la tation ▁; ▁ET
D-259	-0.31726792454719543	HDL-induced NO production ; flow-mediated dilatation ; ET
P-259	-1.4471 -0.8885 -0.0299 -0.0031 -0.0160 -0.6571 -0.3194 -0.1077 -0.1197 -0.0348 -0.0979 -0.2889 -0.1312 -0.2049 -0.0162 -1.0234 -0.4606 -0.1014 -0.0804
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ; ahf ; risk stratification
H-58	-0.6903653740882874	▁patients ▁; ▁a HF
D-58	-0.6903653740882874	patients ; aHF
P-58	-1.1311 -1.1888 -0.3120 -0.2075 -1.1625 -0.1402
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients ; systolic function ; therapeutic
H-1070	-0.4860244691371918	▁pres er ved ▁sy sto lic ▁function ▁; ▁ therapeut ic
D-1070	-0.4860244691371918	preserved systolic function ; therapeutic
P-1070	-2.9806 -0.0458 -0.1782 -0.0944 -0.0738 -0.0489 -0.0768 -1.1104 -0.1808 -0.0753 -0.4186 -0.9402 -0.0946
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets ; tac ; hf
H-1050	-0.26168498396873474	▁ BET s ▁; ▁mouse ▁ TAC ▁model ▁; ▁human ▁ HF
D-1050	-0.26168498396873474	BETs ; mouse TAC model ; human HF
P-1050	-1.0292 -0.1393 -0.1775 -0.1260 -0.2191 -0.4286 -0.0079 -0.1425 -0.2011 -0.3458 -0.5161 -0.1556 -0.0849 -0.0900
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-0.8847431540489197	▁cost - effect ive ▁; ▁participa tory
D-614	-0.8847431540489197	cost-effective ; participatory
P-614	-2.8380 -0.0274 -0.0033 -0.0385 -0.3775 -0.5115 -0.0231 -4.0368 -0.1067
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac ; nurses
H-1662	-0.16514316201210022	▁cardiac ▁nurse s
D-1662	-0.16514316201210022	cardiac nurses
P-1662	-0.0743 -0.0646 -0.0607 -0.5361 -0.0900
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations ; patients ; patients
H-1282	-0.5078927278518677	
D-1282	-0.5078927278518677	
P-1282	-0.9425 -0.0733
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion ; mortality
H-50	-0.5638424754142761	▁trans fusion ▁thre s hold s ▁; ▁mortal ity
D-50	-0.5638424754142761	transfusion thresholds ; mortality
P-50	-0.3022 -0.3172 -0.4877 -0.1535 -0.3010 -0.2388 -0.4266 -0.3426 -0.9671 -2.5076 -0.1580
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech republic
H-1972	-0.4271543323993683	▁Czech ▁Republic
D-1972	-0.4271543323993683	Czech Republic
P-1972	-0.3376 -0.0703 -1.1624 -0.1383
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients ; madit-crt
H-858	-0.8356490135192871	▁MAD it - c RT ▁; ▁device
D-858	-0.8356490135192871	MADit-cRT ; device
P-858	-0.2803 -1.3292 -0.0142 -0.7846 -2.8995 -1.7128 -0.2616 -0.1342 -0.1045
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients ; randomization
H-851	-0.5808369517326355	
D-851	-0.5808369517326355	
P-851	-1.0872 -0.0744
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c statistics
H-383	-0.7865835428237915	▁concorda nce ▁c ▁statistic s ▁; ▁UM / VA / VA - RT
D-383	-0.7865835428237915	concordance c statistics ; UM/VA/VA-RT
P-383	-2.1714 -0.3266 -0.1187 -0.5419 -0.0583 -0.2311 -0.1402 -1.6104 -0.6879 -1.8034 -1.3953 -0.0911 -2.0170 -0.5028 -0.1027
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart failure
H-1539	-0.8448233008384705	▁absolute ▁risk ▁; ▁heart ▁failure
D-1539	-0.8448233008384705	absolute risk ; heart failure
P-1539	-3.7553 -0.5911 -0.6156 -0.2554 -0.1042 -0.5207 -0.0714
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hf
H-1431	-0.3993075489997864	▁Western ▁blot s ▁; ▁mono clo nal ▁anti bo dies ▁; ▁Ser 83 ▁ phos phor y lation ▁; HF
D-1431	-0.3993075489997864	Western blots ; monoclonal antibodies ; Ser83 phosphorylation ;HF
P-1431	-0.0722 -0.0072 -0.0566 -0.5121 -0.0037 -0.0665 -1.2446 -0.0175 -0.0748 -1.1853 -0.1858 -0.3698 -0.4712 -0.1489 -0.0201 -1.2955 -0.9565 -0.0935 -0.5050 -1.1731 -0.2077 -0.1171
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative ; serum albumin ; patients ; left ventricular assist device ; implantation
H-528	-0.5198630094528198	▁se rum ▁album in ▁; ▁survival ▁; ▁left ▁vent ri cular ▁assist ▁device ▁implant ation
D-528	-0.5198630094528198	serum albumin ; survival ; left ventricular assist device implantation
P-528	-1.6911 -0.1097 -0.4807 -0.0871 -0.6241 -1.9973 -0.1462 -0.3873 -0.0504 -1.0491 -0.1017 -0.9691 -0.3546 -0.2306 -0.2483 -0.2086 -0.1019
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new york heart association classification ; 6-min walk test ; quality-of-life
H-2005	-0.7344415783882141	▁New ▁York ▁Heart ▁Association ▁; ▁quality - of - life ▁score s
D-2005	-0.7344415783882141	New York Heart Association ; quality-of-life scores
P-2005	-1.6080 -0.5417 -1.1176 -0.8907 -1.1298 -3.4629 -0.0485 -0.0145 -0.0501 -0.1799 -0.6907 -0.3090 -0.1364 -0.1024
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional ms ; ring annuloplasty ; ischemic mr ; lv dilatation
H-366	-0.09917178750038147	▁functional ▁MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁MR ▁; ▁LV ▁di la tation
D-366	-0.09917178750038147	functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
P-366	-0.0943 -0.1263 -0.0804 -0.0069 -0.2618 -0.0548 -0.0197 -0.1296 -0.1206 -0.1445 -0.0157 -0.0402 -0.0206 -0.3618 -0.0176 -0.1313 -0.0435 -0.0048 -0.2434 -0.0658
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change ; paco2 ; cerebral ; blood flow ; perfusion ; carotid
H-1350	-0.1975405365228653	▁Paco 2 ▁; ▁cerebral ▁blood ▁flow ▁; ▁per fusion ▁; ▁caro tid ▁bo dies
D-1350	-0.1975405365228653	Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
P-1350	-0.0460 -0.0552 -1.2180 -0.0146 -0.5378 -0.1397 -0.1196 -0.0666 -0.0056 -0.3429 -0.1934 -0.0397 -0.0091 -0.1505 -0.1337 -0.0881
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin receptor antagonist ; tolvaptan ; heart failure ; patients
H-1194	-0.23038330674171448	▁vaso press in ▁receptor ▁anta gon ist ▁; ▁to lv ap tan ▁; ▁Japanese ▁heart ▁failure ▁patients
D-1194	-0.23038330674171448	vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure patients
P-1194	-0.0129 -0.0455 -0.3114 -0.0088 -0.1967 -0.0034 -0.3261 -0.0939 -0.0062 -0.0993 -0.2331 -0.0135 -0.1640 -0.9218 -0.5234 -0.0764 -1.0849 -0.1648 -0.0913
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology ; hf ; diagnosis ; medical ; nursing
H-2021	-0.6819546818733215	▁pat ho phy si ology ▁; HF ▁; ▁medical ▁management
D-2021	-0.6819546818733215	pathophysiology ;HF ; medical management
P-2021	-0.8281 -0.4826 -0.3712 -1.0894 -0.3181 -0.1103 -2.5317 -0.5444 -0.6359 -0.1063 -1.0846 -0.0808
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients ; physicians ; hospitals ; new jersey ; new york
H-212	-0.3521558940410614	▁ED ▁physician s ▁; ▁subur ban ▁hospital s ▁; ▁New ▁Jersey ▁; ▁New ▁York
D-212	-0.3521558940410614	ED physicians ; suburban hospitals ; New Jersey ; New York
P-212	-1.5702 -0.2167 -0.0854 -0.4494 -0.2766 -0.0453 -0.1401 -0.1780 -0.5347 -0.7073 -0.0532 -0.4869 -0.5446 -0.0925 -0.1725 -0.0812
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis ; patients ; diastolic blood pressure ; body mass index
H-1560	-0.26917725801467896	▁p sori asis ▁patients ▁; ▁smo ked ▁; ▁dia sto lic ▁blood ▁pressure ▁; ▁body ▁mass ▁index
D-1560	-0.26917725801467896	psoriasis patients ; smoked ; diastolic blood pressure ; body mass index
P-1560	-0.9265 -0.0123 -0.0757 -0.7552 -0.2196 -0.4302 -0.1127 -0.3449 -0.0201 -0.0344 -0.0382 -0.2757 -0.5765 -0.1930 -0.1305 -0.2448 -0.0087 -0.6010 -0.1143
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise intolerance ; heart failure ; exercise ; diagnosis ; prognosis ; therapeutic
H-1272	-0.5930655002593994	▁Exerci se ▁in tolerance ▁; ▁heart ▁failure
D-1272	-0.5930655002593994	Exercise intolerance ; heart failure
P-1272	-2.4601 -0.2173 -0.0092 -0.0072 -1.0579 -0.4843 -0.1215 -0.8969 -0.0831
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients ; clinical ; echocardiography ; baseline ; shunt ; implantation
H-1954	-0.24210092425346375	▁e cho card i ography ▁; ▁shu nt ▁implant ation
D-1954	-0.24210092425346375	echocardiography ; shunt implantation
P-1954	-0.1341 -0.0189 -0.2621 -0.4328 -0.1983 -1.0678 -0.1543 -0.0230 -0.0974 -0.2874 -0.1220 -0.1071
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
H-1383	-0.21200984716415405	▁vent ri cular ▁assist ▁device ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁renal ▁function ▁; ▁pediatr ic ▁heart ▁failure
D-1383	-0.21200984716415405	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
P-1383	-0.0145 -0.5159 -0.1163 -0.7202 -0.2512 -0.1057 -0.0068 -0.0126 -0.1400 -0.0156 -0.0227 -0.0539 -0.3519 -0.2090 -0.3590 -0.0297 -0.1345 -0.3203 -0.3804 -0.1388 -0.5090 -0.3503 -0.2016 -0.1284
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations ; cox models ; st2 ; functional capacity ; outcomes
H-700	-0.42780375480651855	▁co x ▁models ▁; ▁ST 2
D-700	-0.42780375480651855	cox models ; ST2
P-700	-0.3752 -0.0754 -0.5695 -0.4357 -0.7994 -0.0764 -1.0003 -0.0906
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause hospitalisations ; sts
H-160	-0.8316628336906433	▁TM ▁intervention s ▁; ▁s TS
D-160	-0.8316628336906433	TM interventions ; sTS
P-160	-1.0667 -1.3857 -0.1402 -0.5727 -0.2172 -1.5007 -1.6163 -0.1539
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol ; linear mixed models ; intention-to-treat
H-838	-0.8844852447509766	▁treatment ▁group ▁effects ▁; ▁HR Qo L
D-838	-0.8844852447509766	treatment group effects ; HRQoL
P-838	-2.8157 -2.1273 -0.2076 -0.6438 -0.4463 -0.0049 -0.6050 -1.0516 -0.0581
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp ; circulation ; hf ; patients
H-1513	-0.3079933524131775	▁NT - pro b NP ▁; ▁circulation ▁; ▁ HF ▁patients
D-1513	-0.3079933524131775	NT-probNP ; circulation ; HF patients
P-1513	-0.6554 -0.0242 -0.0064 -0.6194 -0.1195 -0.2208 -0.3580 -0.5972 -0.3717 -0.1396 -0.4787 -0.2256 -0.1875
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy metabolism ; heart failure ; hypertrophied ; heart
H-1779	-0.3454728424549103	▁energy ▁metabolism ▁; ▁heart ▁failure ▁; ▁hyper trop hi ed ▁heart
D-1779	-0.3454728424549103	energy metabolism ; heart failure ; hypertrophied heart
P-1779	-1.1570 -0.0594 -0.1032 -1.6898 -0.3271 -0.1429 -0.0967 -0.0144 -0.0100 -0.1532 -0.5583 -0.0798 -0.0995
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional ms ; lv dilatation ; functional ms
H-368	-0.21178720891475677	▁functional ▁MS ▁; ▁LV ▁di la tation ▁; ▁functional ▁MS
D-368	-0.21178720891475677	functional MS ; LV dilatation ; functional MS
P-368	-0.1856 -0.1667 -0.2126 -0.4957 -0.3803 -0.1308 -0.0038 -0.3945 -0.1502 -0.1813 -0.1473 -0.0926
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients ; pad ; ankle-brachial index
H-1568	-0.38519537448883057	▁ PAD ▁; ▁an kle - bra chi al ▁index
D-1568	-0.38519537448883057	PAD ; ankle-brachial index
P-1568	-2.5171 -0.0406 -0.4555 -0.2293 -0.2077 -0.1477 -0.2504 -0.3323 -0.0381 -0.0106 -0.2646 -0.1286
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr reduction ; ivabradine ; tac ; ea
H-525	-0.6698585152626038	▁HR ▁re duction ▁; ▁i va bra dine ▁; ▁ TAC
D-525	-0.6698585152626038	HR reduction ; ivabradine ; TAC
P-525	-3.8232 -0.6359 -0.0226 -0.1382 -0.0044 -0.0328 -0.1188 -0.0425 -0.0771 -1.2461 -0.0372 -2.3951 -0.1343
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline ; mechanical cardiac support ; renal function
H-1388	-0.3144420385360718	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function
D-1388	-0.3144420385360718	mechanical cardiac support ; renal function
P-1388	-0.9892 -0.0116 -0.1400 -0.7490 -0.1883 -0.0130 -0.4248 -0.1933 -0.1208
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ; ecmo ; patients ; vad ; ecmo ; vad
H-1390	-0.8298395872116089	▁patients ▁; ▁ec mo ▁group ▁; ▁ VAD ▁; ▁ec mo + VAD ▁groups
D-1390	-0.8298395872116089	patients ; ecmo group ; VAD ; ecmo+VAD groups
P-1390	-1.9590 -0.1349 -0.5174 -1.2187 -2.1619 -0.1921 -1.0738 -0.0460 -0.2302 -0.7977 -1.8897 -1.2888 -0.1710 -1.1134 -0.2927 -0.1901
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality ; morbidity ; health-care ; budget
H-1075	-0.35392969846725464	▁mortal ity ▁; ▁morbi d ity ▁; ▁cancer s ▁; ▁budget
D-1075	-0.35392969846725464	mortality ; morbidity ; cancers ; budget
P-1075	-0.6758 -0.6287 -0.1272 -0.0081 -0.0386 -0.8939 -0.1696 -0.1610 -0.1216 -0.2627 -1.2508 -0.1540 -0.1090
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation ; therapy ; heart disease ; rate control
H-1652	-0.22172938287258148	▁antico ag ulation ▁; ▁ therapy ▁; ▁under ly ing ▁heart ▁disease ▁; ▁rate ▁control
D-1652	-0.22172938287258148	anticoagulation ; therapy ; underlying heart disease ; rate control
P-1652	-0.2605 -0.0788 -0.0545 -0.0877 -0.7026 -0.0087 -0.3750 -0.5723 -0.1231 -0.0330 -0.2562 -0.2719 -0.3726 -0.0234 -0.2808 -0.1673 -0.1011
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic effect ; beta blockers ; heart failure
H-648	-0.2843911051750183	▁in o tropi c ▁effect ▁; ▁beta ▁block ers ▁; ▁heart ▁failure
D-648	-0.2843911051750183	inotropic effect ; beta blockers ; heart failure
P-648	-0.1172 -0.3641 -0.0118 -0.0541 -0.0570 -0.1470 -0.1164 -0.2629 -0.0452 -0.4482 -2.0283 -0.1334 -0.1114 -0.0844
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin receptor ; st2 ; beta-blocker ; therapy ; chronic heart failure
H-398	-0.38737010955810547	▁inter le u kin ▁receptor ▁family ▁member ▁; ▁ST 2 ▁; ▁beta - block er ▁ therapy ▁; ▁chronic ▁heart ▁failure
D-398	-0.38737010955810547	interleukin receptor family member ; ST2 ; beta-blocker therapy ; chronic heart failure
P-398	-0.0525 -0.1512 -0.0383 -4.1817 -0.0052 -0.5343 -0.5583 -1.0316 -0.1189 -0.0554 -0.1149 -0.0957 -0.0434 -0.0786 -0.0357 -0.3527 -0.0087 -0.4664 -0.0797 -0.4191 -0.2412 -0.1502 -0.0959
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients ; heart failure ; systolic heart failure
H-725	-0.6528877019882202	▁heart ▁failure ▁; ▁sy sto lic ▁heart ▁failure
D-725	-0.6528877019882202	heart failure ; systolic heart failure
P-725	-4.7299 -0.1509 -0.3142 -0.0279 -0.0291 -0.0739 -0.8729 -0.0881 -0.1383 -0.1035
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline ; rhythm-control ; rate-control
H-1237	-0.31179386377334595	▁ rhythm - control ▁; ▁rate - control
D-1237	-0.31179386377334595	rhythm-control ; rate-control
P-1237	-0.3319 -0.7133 -0.2905 -0.0195 -0.3207 -0.4159 -0.3414 -0.0293 -0.4997 -0.1557
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin ; health ; outcomes
H-43	-0.7871814370155334	▁hem o glob in ▁levels
D-43	-0.7871814370155334	hemoglobin levels
P-43	-1.2639 -0.1883 -0.1679 -0.7660 -1.5127 -1.5161 -0.0954
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional ms ; medical treatment ; surgical
H-376	-0.5612073540687561	▁Fun ction al ▁MS
D-376	-0.5612073540687561	Functional MS
P-376	-0.2686 -0.0084 -0.0034 -0.0830 -2.9191 -0.0847
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf ; epidemiology ; health ; hf
H-1790	-0.48410648107528687	▁ HF ▁epidemi ology ▁; ▁health ▁service ▁provision ▁; ▁ HF ▁; ▁LA
D-1790	-0.48410648107528687	HF epidemiology ; health service provision ; HF ; LA
P-1790	-0.5584 -0.0902 -0.6873 -0.2333 -0.0688 -1.2626 -0.6871 -0.6030 -0.3069 -0.3343 -0.1229 -1.0096 -0.9645 -0.2262 -0.1065
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart failure ; hf ; chronic ; disease
H-2019	-0.18890967965126038	▁Heart ▁failure ▁; HF ▁; ▁de bilitat ing ▁chronic ▁disease
D-2019	-0.18890967965126038	Heart failure ;HF ; debilitating chronic disease
P-2019	-0.4010 -0.0359 -0.1575 -0.0471 -0.7752 -0.1107 -0.0015 -0.0312 -0.0572 -0.1674 -0.3944 -0.0877
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes ; heart failure ; hf
H-555	-0.8656046390533447	▁heart ▁failure ▁; HF
D-555	-0.8656046390533447	heart failure ;HF
P-555	-4.2665 -0.1361 -0.4765 -0.0549 -0.1258 -0.1337
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up ; lvad ; patients ; heart failure
H-548	-0.3904169797897339	▁CF ▁l VAD ▁patients ▁; ▁AI ▁; ▁heart ▁failure
D-548	-0.3904169797897339	CF lVAD patients ; AI ; heart failure
P-548	-0.1399 -0.6584 -0.0278 -0.9280 -0.3865 -0.6679 -0.2830 -0.8183 -0.1713 -0.1178 -0.0955
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade ; evidence ; anemia ; patients ; heart disease
H-38	-0.7705501317977905	▁an emia ▁; ▁patients ▁with ▁heart ▁disease
D-38	-0.7705501317977905	anemia ; patients with heart disease
P-38	-2.2434 -0.1884 -0.3231 -1.2140 -2.1356 -0.2221 -0.2425 -0.2279 -0.1380
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients ; left ventricular dilatation ; dysfunction
H-1746	-1.0185052156448364	▁vent ri cular ▁di la tation
D-1746	-1.0185052156448364	ventricular dilatation
P-1746	-4.5339 -0.8758 -0.2065 -0.6184 -0.3268 -0.0372 -1.4423 -0.1072
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular assist devices ; therapies
H-203	-0.3420701324939728	▁vent ri cular ▁assist ▁devices ▁; ▁device ▁ therapie s
D-203	-0.3420701324939728	ventricular assist devices ; device therapies
P-203	-1.0289 -0.5277 -0.0658 -0.8546 -0.1691 -0.6832 -0.1470 -0.0901 -0.0662 -0.1086 -0.2591 -0.1046
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted ; patients ; adverse events ; follow-up
H-1956	-0.8542649149894714	▁device
D-1956	-0.8542649149894714	device
P-1956	-1.7096 -0.7730 -0.0802
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal dysfunction ; mechanical cardiac support
H-1394	-0.5391159653663635	▁renal ▁dys function ▁; ▁mechanic al ▁cardiac
D-1394	-0.5391159653663635	renal dysfunction ; mechanical cardiac
P-1394	-0.2663 -0.2751 -0.0710 -0.2031 -0.3647 -0.0098 -0.0476 -3.5439 -0.0705
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.4206005930900574	▁ HF ▁co hor t
D-1002	-0.4206005930900574	HF cohort
P-1002	-1.6197 -0.3352 -0.3491 -0.3284 -0.0967 -0.1111 -0.1041
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions ; hospital
H-144	-1.0697633028030396	▁computing ▁read missions ▁; ▁hospital ▁ranking s
D-144	-1.0697633028030396	computing readmissions ; hospital rankings
P-144	-0.5784 -2.5326 -0.2672 -0.2773 -1.5040 -0.3390 -0.1207 -3.8848 -0.1239
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory factor analysis ; cfa
H-1506	-0.5418017506599426	▁explora tory ▁factor ▁analysis ▁; ▁c fa
D-1506	-0.5418017506599426	exploratory factor analysis ; cfa
P-1506	-1.8739 -0.0165 -0.0314 -0.3477 -0.5356 -0.2300 -1.5288 -0.1809 -0.1314
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb ; patients ; hf
H-1351	-0.7627238035202026	▁p ▁; ▁patients ▁; ▁ HF
D-1351	-0.7627238035202026	p ; patients ; HF
P-1351	-0.4626 -1.0743 -0.7006 -0.7240 -0.4299 -0.2768 -2.3280 -0.1056
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic ; clinicians ; patients
H-1124	-0.585116982460022	▁non tre at ment
D-1124	-0.585116982460022	nontreatment
P-1124	-2.3917 -0.0674 -0.0219 -0.2347 -0.7065 -0.0885
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates ; coagulability
H-1113	-0.8020147085189819	▁se rum ▁factors ▁; ▁marker s
D-1113	-0.8020147085189819	serum factors ; markers
P-1113	-1.1824 -0.0831 -0.1528 -0.5781 -0.7088 -0.0904 -3.4961 -0.1245
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd ; patients
H-65	-0.8335826396942139	▁i CD ▁patients
D-65	-0.8335826396942139	iCD patients
P-65	-0.4347 -1.6572 -1.5589 -0.3039 -0.2132
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients ; patients
H-267	-0.6018258333206177	
D-267	-0.6018258333206177	
P-267	-1.0883 -0.1153
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp ; nt-probnp ; diagnostic ; prognostic ; biomarkers ; patients ; heart failure
H-1365	-0.3523766100406647	▁b NP ▁; ▁NT - pro b NP ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1365	-0.3523766100406647	bNP ; NT-probNP ; biomarkers ; heart failure
P-1365	-0.4559 -0.3678 -0.1103 -0.3362 -0.0459 -0.0052 -0.3578 -0.2526 -0.4709 -0.8543 -0.1121 -0.1152 -0.5156 -1.4662 -0.2332 -0.1602 -0.1309
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory fitness ; body mass index ; heart failure ; mortality ; cooper center longitudinal study
H-1765	-0.346087783575058	▁Card i ore spira tory ▁fitness ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁mortal ity ▁; ▁Cooper ▁Center ▁Long itud in al ▁Study
D-1765	-0.346087783575058	Cardiorespiratory fitness ; body mass index ; heart failure mortality ; Cooper Center Longitudinal Study
P-1765	-0.8024 -0.3829 -0.4644 -0.0428 -0.0760 -0.9456 -0.1118 -0.0832 -0.2027 -0.0060 -0.1221 -0.9486 -0.4771 -0.2213 -0.3739 -0.4722 -0.2172 -0.9852 -0.8263 -0.0445 -0.0906 -0.0303 -0.4376 -0.1868 -0.1008
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse correlation ; pro-adrenomedullin ; mr-proadm ; ffm
H-15	-0.19940471649169922	▁pro - ad re nom edu llin ▁; MR - pro AD m ▁; ▁f FM
D-15	-0.19940471649169922	pro-adrenomedullin ;MR-proADm ; fFM
P-15	-0.2391 -0.0146 -0.0153 -0.0868 -0.0875 -0.1553 -0.3590 -0.1515 -0.0189 -0.0042 -0.0065 -0.7865 -0.2376 -0.2603 -0.2163 -0.7517 -0.1093 -0.0890
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-0.8500471115112305	▁die t ▁; ▁exercise ▁; ▁attention ▁control
D-1979	-0.8500471115112305	diet ; exercise ; attention control
P-1979	-1.8847 -0.0496 -0.1937 -0.2253 -0.3091 -1.1971 -0.4261 -3.2471 -0.1178
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart failure ; hf ; elevated ; sympathetic activity ; parasympathetic control ; heart
H-1133	-0.3837343454360962	▁Heart ▁failure ▁; HF ▁; ▁sympa the tic ▁activity ▁; ▁para sy mpa the tic ▁control ▁; ▁heart
D-1133	-0.3837343454360962	Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
P-1133	-0.3932 -0.0419 -0.1279 -0.0298 -0.2997 -0.0982 -0.3399 -0.7246 -0.9877 -0.0595 -0.0977 -0.1179 -0.0464 -0.9710 -0.6155 -0.3918 -0.3227 -1.7657 -0.1456 -0.0982
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality ; patients ; implantable cardiac defibrillator ; meta-analysis
H-59	-0.563636302947998	▁mortal ity ▁; ▁implant able ▁cardiac ▁de fi br illa tor
D-59	-0.563636302947998	mortality ; implantable cardiac defibrillator
P-59	-4.5408 -1.4236 -0.2181 -0.3016 -0.0436 -0.0158 -0.0607 -0.0798 -0.1111 -0.0796 -0.0921 -0.2560 -0.1045
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp ; xo-mediated ros ; mitochondrial respiration ; contractile function
H-471	-0.23140110075473785	▁ATP ▁demand ▁; XO - media ted ▁ ROS ▁; ▁mito cho ndri al ▁respira tion ▁; ▁contract ile ▁function
D-471	-0.23140110075473785	ATP demand ;XO-mediated ROS ; mitochondrial respiration ; contractile function
P-471	-0.0730 -0.0428 -0.0529 -2.9344 -0.0076 -0.0184 -0.0245 -0.0949 -0.0946 -0.3982 -0.0285 -0.1293 -0.2952 -0.0148 -0.0520 -0.1812 -0.2933 -0.0016 -0.0153 -0.0984 -0.1678 -0.0718
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical ; activity ; cardiovascular ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
H-1898	-0.49972933530807495	▁cardiovascular ▁; ▁diabetes ▁mell itus ▁; ▁hyper tension ▁; ▁hyper li pida emia
D-1898	-0.49972933530807495	cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
P-1898	-3.0964 -1.4336 -0.7463 -0.0102 -0.0503 -0.2807 -0.0449 -0.0788 -0.2413 -0.1330 -0.5080 -0.2115 -0.2362 -0.2661 -0.1586
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients ; systolic hf ; etiology ; coronary angiography
H-1184	-0.15961682796478271	▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology ▁; ▁corona ry ▁ang i ography
D-1184	-0.15961682796478271	systolic HF ; unclear etiology ; coronary angiography
P-1184	-0.0407 -0.0256 -0.0064 -0.2488 -0.0206 -0.1622 -0.0131 -0.0114 -0.0044 -0.0374 -0.0637 -0.1262 -0.0830 -0.6385 -0.6614 -0.4567 -0.0996 -0.2471 -0.0860
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
H-1230	-0.4143407642841339	▁At rial ▁fi bril lation ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ rhythm - control ▁; ▁rate - control ▁strategie s
D-1230	-0.4143407642841339	Atrial fibrillation ; congestive heart failure ; rhythm-control ; rate-control strategies
P-1230	-2.4484 -0.0048 -0.4273 -0.0109 -0.0343 -0.1221 -0.0069 -0.1472 -0.9117 -0.3799 -0.1203 -0.6538 -2.0007 -0.9176 -0.0958 -0.0139 -0.4278 -0.1223 -0.2501 -0.0146 -0.3765 -0.1076 -0.2508 -0.0989
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection fraction ; ef ; infarct ; collateral growth ; myocardial perfusion
H-506	-0.19610582292079926	▁e je ction ▁ fraction ▁; EF ▁; ▁in far ct ▁size ▁; ▁col lateral ▁growth ▁; ▁my o card ial ▁per fusion
D-506	-0.19610582292079926	ejection fraction ;EF ; infarct size ; collateral growth ; myocardial perfusion
P-506	-0.2412 -0.0312 -0.0072 -0.1970 -0.0015 -0.1811 -0.2179 -0.0876 -0.0023 -0.0667 -0.1527 -1.2443 -0.1042 -0.0025 -0.0005 -0.2334 -0.1700 -0.4089 -0.2121 -0.1800 -0.5366 -0.3468 -0.0317 -0.1363 -0.1089
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure ; patients
H-1510	-0.3729647994041443	▁circula ting ▁fragment s ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti des ▁; ▁plasma ▁; ▁heart ▁failure ▁patients
D-1510	-0.3729647994041443	circulating fragments ; n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure patients
P-1510	-0.1262 -0.0249 -0.1709 -0.1594 -0.2783 -1.8190 -0.0135 -0.0137 -0.0062 -0.1602 -0.0171 -1.0200 -0.0209 -0.0021 -0.0147 -0.1467 -0.2431 -2.1062 -0.6308 -0.4005 -0.3442 -0.3483 -0.0573 -0.6479 -0.2302 -0.0927 -1.2587 -0.2691 -0.1932
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients ; heart failure ; hf ; preserved left ventricular ejection fraction ; hfpef
H-1300	-0.31113842129707336	▁heart ▁failure ▁; HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; HF p EF
D-1300	-0.31113842129707336	heart failure ;HF ; left ventricular ejection fraction ;HFpEF
P-1300	-2.0121 -0.0631 -0.0789 -0.0510 -0.1102 -1.5430 -0.0464 -0.5547 -0.2720 -0.0868 -0.0883 -0.0781 -0.4158 -0.0047 -0.2202 -0.1832 -0.0480 -0.1133 -0.1788 -0.0744
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients ; end-stage heart failure ; implantation ; ventricular assist device
H-1657	-0.5585060119628906	▁end - s tage ▁heart ▁failure ▁; ▁implant ation ▁; ▁long - term ▁vent ri cular ▁assist ▁device
D-1657	-0.5585060119628906	end-stage heart failure ; implantation ; long-term ventricular assist device
P-1657	-3.5027 -0.0783 -0.2248 -0.0038 -1.1684 -0.2050 -0.5263 -1.2056 -0.0984 -0.4028 -0.7679 -0.0792 -0.0728 -0.0998 -1.3028 -0.2224 -0.4405 -0.2623 -0.3519 -0.1544
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf ; symptom ; cardiac murmurs ; blood pressure
H-356	-0.42206740379333496	▁ HF ▁; ▁cardiac ▁mur mur s ▁; ▁blood ▁pressure
D-356	-0.42206740379333496	HF ; cardiac murmurs ; blood pressure
P-356	-0.6113 -0.0489 -0.9708 -0.4622 -0.1326 -0.0355 -0.2359 -0.3973 -1.0027 -0.4396 -0.5948 -0.1334
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors ; adenylyl cyclase ; g-protein coupling
H-1406	-0.2833554744720459	▁a den yl yl ▁cy cla se ▁; ▁g - prote in ▁coup ling
D-1406	-0.2833554744720459	adenylyl cyclase ; g-protein coupling
P-1406	-0.6492 -0.0571 -0.0204 -0.4998 -0.0407 -0.0086 -0.2651 -0.3654 -1.2144 -0.0707 -0.0496 -0.3421 -0.0619 -0.4597 -0.2835 -0.1453
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients ; hf ; spontaneous vt ; qt intervals
H-1445	-0.20495817065238953	▁ HF ▁; ▁spontane ous ▁ VT ▁; ▁beat - to - beat ▁ QT ▁interval s
D-1445	-0.20495817065238953	HF ; spontaneous VT ; beat-to-beat QT intervals
P-1445	-1.5447 -0.0354 -0.0491 -0.0213 -0.0474 -0.2465 -0.0187 -0.3857 -0.0079 -0.0506 -0.0826 -0.0627 -0.2271 -0.5658 -0.0660 -0.0203 -0.0977 -0.2481 -0.1168
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular dysfunction ; outcome ; patients ; heartmate ii
H-305	-0.5875113606452942	▁bi ven tri cular ▁dys function ▁; ▁isola ted ▁Heart Mate ▁II
D-305	-0.5875113606452942	biventricular dysfunction ; isolated HeartMate II
P-305	-0.5108 -0.1891 -2.5185 -1.1873 -0.2783 -0.3379 -0.1983 -0.7725 -0.1173 -0.7979 -0.0945 -0.7935 -0.2880 -0.1412
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug test ; patients ; copd ; chf ; crf
H-806	-0.5371300578117371	▁tu g ▁test ▁; ▁advanced ▁COP d ▁; ▁CHF ▁; ▁c RF
D-806	-0.5371300578117371	tug test ; advanced COPd ; CHF ; cRF
P-806	-0.9988 -2.1269 -0.1022 -0.1065 -1.6760 -0.1266 -1.6663 -0.0711 -0.0020 -0.1154 -0.1599 -0.1863 -0.1028 -0.0791
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling pathways ; pressure-overload-induced heart failure
H-877	-0.7270828485488892	▁pressure - over load - indu ced ▁heart ▁failure
D-877	-0.7270828485488892	pressure-overload-induced heart failure
P-877	-5.6321 -0.0740 -0.0271 -0.1268 -0.1541 -0.0329 -0.2286 -0.9395 -0.3939 -0.1889 -0.2000
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing ; mandate ; accountable ; outcomes ; nursing
H-1396	-1.023689866065979	▁Nur sing ▁; ▁social ▁mandat e
D-1396	-1.023689866065979	Nursing ; social mandate
P-1396	-3.3385 -0.0440 -0.3728 -1.9577 -0.1631 -0.0649 -2.1253 -0.1233
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical ; patient ; hemodynamically ; cpr
H-1294	-0.6070176959037781	▁hem o dynamic ally ▁uns table ▁; ▁c PR
D-1294	-0.6070176959037781	hemodynamically unstable ; cPR
P-1294	-3.3908 -0.0895 -0.0024 -0.1593 -0.7578 -0.4432 -0.2531 -0.3065 -1.0866 -0.1188 -0.0693
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol ; cxl-1020 ; myocytes ; hearts
H-419	-0.4377986788749695	▁iso prot eren ol ▁; ▁c XL -10 20 ▁; ▁my o cy tes ▁; ▁heart s
D-419	-0.4377986788749695	isoproterenol ; cXL-1020 ; myocytes ; hearts
P-419	-0.0064 -0.0521 -0.0521 -0.1707 -0.2305 -0.3699 -0.1742 -0.0786 -0.0471 -1.0609 -0.6045 -0.0997 -0.0589 -0.0469 -0.9061 -3.4901 -0.3294 -0.3685 -0.1717
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
H-454	-0.3609151840209961	▁b ▁treatment ▁; ▁cardiac ▁ang io gene sis ▁; ▁in ▁vivo ▁corona ry ▁per fusion ▁; ▁cardiac ▁fibro sis
D-454	-0.3609151840209961	b treatment ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
P-454	-1.5578 -2.3093 -0.1791 -0.0871 -0.9801 -0.4941 -0.1191 -0.2434 -0.1459 -0.0760 -0.0005 -0.0752 -0.3099 -0.1988 -0.0080 -0.2010 -0.1780 -0.0124 -0.1204 -0.2082 -0.0750
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization ; patients ; heart failure ; ventricular tachycardia
H-1434	-0.40095874667167664	▁auto no mic ▁modul ation ▁; ▁repo lar ization ▁in st ability ▁; ▁heart ▁failure ▁pro ne ▁to ▁vent ri cular ▁ta chy car dia
D-1434	-0.40095874667167664	autonomic modulation ; repolarization instability ; heart failure prone to ventricular tachycardia
P-1434	-4.1793 -0.0535 -0.2159 -0.1364 -0.1553 -0.4607 -0.0113 -0.3886 -0.2017 -0.0898 -0.1433 -0.2487 -0.2872 -1.3617 -0.1125 -0.6764 -0.0844 -0.3150 -0.0128 -0.5850 -0.1303 -0.2262 -0.1765 -0.0282 -0.0171 -0.4148 -0.1133
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine ; myocyte ; collagen ; left ventricle
H-1141	-0.1319265067577362	▁Pyr ido stig mine ▁; ▁my o cy te ▁diameter ▁; ▁collage n ▁den s ity ▁; ▁left ▁vent ric le
D-1141	-0.1319265067577362	Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
P-1141	-0.0099 -0.0061 -0.0010 -0.0560 -0.0671 -0.2771 -0.0363 -0.0213 -0.0295 -0.0271 -0.0341 -0.0013 -0.0377 -0.0406 -0.2494 -0.4205 -0.1112 -0.5611 -0.0296 -0.4384 -0.3250 -0.1761 -0.0781
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise intolerance ; symptom ; chronic hfpef ; quality of life ; qol
H-1975	-0.6217553019523621	▁Exerci se ▁in tolerance ▁; ▁chronic ▁H FP EF ▁; Q OL
D-1975	-0.6217553019523621	Exercise intolerance ; chronic HFPEF ;QOL
P-1975	-1.0106 -0.0639 -0.0098 -0.0097 -0.1272 -0.5141 -1.5596 -0.4240 -0.1579 -0.2583 -4.2550 -0.1400 -0.0818 -0.0925
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy substrate metabolism ; hearts ; aac
H-1781	-0.6826620101928711	▁energy ▁substrat e ▁metabolism
D-1781	-0.6826620101928711	energy substrate metabolism
P-1781	-1.1964 -0.0100 -0.0728 -0.0837 -2.6684 -0.0645
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence ; schfi v.6.2 ; clinical
H-1509	-0.9828089475631714	▁ SCH fi
D-1509	-0.9828089475631714	SCHfi
P-1509	-1.0565 -0.9453 -1.7772 -1.0620 -0.0730
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule ; patients ; cad ; patients ; cad
H-1191	-0.9800609946250916	▁CAD ▁; ▁severe ▁CAD
D-1191	-0.9800609946250916	CAD ; severe CAD
P-1191	-2.5994 -0.9570 -1.9444 -0.1575 -0.1201 -0.1019
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes mellitus ; cardiovascular disease ; baseline
H-630	-0.21426281332969666	▁diabetes ▁mell itus ▁; ▁cardiovascular ▁disease
D-630	-0.21426281332969666	diabetes mellitus ; cardiovascular disease
P-630	-0.6578 -0.0020 -0.0374 -0.2575 -0.0035 -0.5211 -0.0971 -0.1376
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd ; psoriasis ; hazard ratio ; confidence interval
H-1563	-0.6690974235534668	▁CV d ▁; ▁psoriasis
D-1563	-0.6690974235534668	CVd ; psoriasis
P-1563	-2.1536 -0.7348 -0.1162 -0.0263 -0.8346 -0.1492
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise ; haemodynamic ; pulmonary
H-1277	-0.5822056531906128	▁ha emo dynamic ▁; ▁pulmonar y
D-1277	-0.5822056531906128	haemodynamic ; pulmonary
P-1277	-0.2180 -0.0443 -0.0011 -0.0977 -0.0038 -0.0738 -4.0361 -0.1829
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic ; rule ; prospectively
H-1188	-0.2613426446914673	▁diagnostic ▁performance ▁; ▁predict ion ▁rule
D-1188	-0.2613426446914673	diagnostic performance ; prediction rule
P-1188	-0.9844 -0.3085 -0.2568 -0.0915 -0.0164 -0.1526 -0.2078 -0.0728
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam study ; psoriasis ; cardiovascular ; outcomes
H-1556	-0.7505212426185608	▁Rotterdam ▁; ▁psoriasis ▁; ▁cardiovascular ▁outcome s
D-1556	-0.7505212426185608	Rotterdam ; psoriasis ; cardiovascular outcomes
P-1556	-2.5951 -3.2064 -0.2120 -0.2722 -0.0057 -0.2132 -0.0839 -0.1038 -0.0623
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf antagonists ; nbdmard
H-607	-0.24991333484649658	▁HR ▁; ▁t NF ▁anta gon ists ▁; ▁n b DM ARD
D-607	-0.24991333484649658	HR ; tNF antagonists ; nbDMARD
P-607	-0.0416 -0.1069 -0.8188 -0.2928 -0.6339 -0.0015 -0.1240 -0.1959 -0.0268 -0.0071 -0.3933 -0.4911 -0.2901 -0.0750
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications ; acs ; patients ; patients ; vad
H-1286	-0.6319249272346497	▁a CS ▁procedure s ▁; ▁MT ▁; ▁patients ▁under go ing ▁ VAD
D-1286	-0.6319249272346497	aCS procedures ; MT ; patients undergoing VAD
P-1286	-0.2776 -2.4497 -0.2629 -0.0977 -0.1418 -1.2852 -0.1642 -1.4655 -2.6770 -0.0898 -0.0635 -0.1876 -0.0231 -0.1450 -0.1483
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital ; cardiac ; hospital ; south dakota
H-1577	-0.8927582502365112	▁hospital ▁; ▁cardiac ▁special ty ▁hospital ▁; ▁rural ▁South ▁da kota
D-1577	-0.8927582502365112	hospital ; cardiac specialty hospital ; rural South dakota
P-1577	-4.4795 -0.1071 -0.0222 -0.1500 -0.0170 -0.6402 -0.7940 -3.2832 -1.4640 -0.3878 -0.0101 -0.1328 -0.1179
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.7095131874084473	▁medical ▁records
D-1131	-0.7095131874084473	medical records
P-1131	-1.6853 -0.3380 -0.7228 -0.0919
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo ; egfr ; egfr
H-1392	-0.5432119965553284	▁ec mo ▁group ▁; ▁e g FR ▁; ▁e g FR
D-1392	-0.5432119965553284	ecmo group ; egFR ; egFR
P-1392	-0.4887 -1.3437 -1.1117 -0.0921 -0.0437 -1.1822 -0.1202 -0.5423 -0.1165 -1.4397 -0.1814 -0.3077 -0.0917
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration ; chf
H-683	-0.6023170948028564	▁administratie ▁; ▁tras tuz um ab - related ▁CHF
D-683	-0.6023170948028564	administratie ; trastuzumab-related CHF
P-683	-4.4946 -0.1348 -0.4027 -0.0169 -0.0112 -0.6995 -0.3617 -0.1022 -0.1088 -0.2039 -0.0892
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute hf
H-1018	-0.44851991534233093	▁a cute ▁ HF
D-1018	-0.44851991534233093	acute HF
P-1018	-0.4938 -0.0019 -0.1593 -0.0763 -1.8602 -0.0996
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.3980950713157654	▁bio mark er - guide d ▁clinic al ▁trial
D-1476	-0.3980950713157654	biomarker-guided clinical trial
P-1476	-0.0930 -0.0829 -0.0372 -0.0711 -0.0012 -0.0283 -0.1770 -0.0470 -0.0802 -3.6295 -0.1316
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.449282705783844	▁hospital s
D-142	-0.449282705783844	hospitals
P-142	-0.7432 -0.2422 -0.6729 -0.1389
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.2341519296169281	▁long - term ▁survival
D-272	-0.2341519296169281	long-term survival
P-272	-0.8074 -0.0681 -0.0543 -0.0932 -0.3170 -0.0648
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac death
H-1905	-0.552589476108551	▁cardiac ▁death ▁; ▁ath letes
D-1905	-0.552589476108551	cardiac death ; athletes
P-1905	-1.6618 -0.5683 -1.0327 -0.1153 -0.0381 -0.3602 -0.0916
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia ; rv function
H-1159	-0.3402344882488251	▁ HF - related ▁cache xia ▁; ▁ RV ▁function ▁; ▁body ▁composition
D-1159	-0.3402344882488251	HF-related cachexia ; RV function ; body composition
P-1159	-0.8820 -0.1206 -0.0380 -0.1440 -0.2132 -0.1883 -0.3059 -0.6901 -0.3077 -0.1306 -1.2701 -0.2491 -0.1043 -0.3408 -0.1190
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital ; mortality
H-1692	-0.920087456703186	▁hospital ▁mortal ity
D-1692	-0.920087456703186	hospital mortality
P-1692	-3.2740 -0.1332 -0.9326 -0.1091 -0.1515
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital ; rehospitalization
H-1719	-0.4025910794734955	▁re hospital ization
D-1719	-0.4025910794734955	rehospitalization
P-1719	-1.1459 -0.2091 -0.4366 -0.1352 -0.0862
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality ; readmission
H-207	-0.3309043347835541	▁cognitive ▁im pair ment ▁; ▁mortal ity ▁; ▁read mission
D-207	-0.3309043347835541	cognitive impairment ; mortality ; readmission
P-207	-0.1368 -0.2134 -0.0283 -0.3286 -0.3867 -0.4879 -0.9123 -0.7794 -0.0490 -0.4858 -0.0763 -0.0864
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic ; histological ; gastrointestinal
H-1359	-0.8648179173469543	▁sono graphic ▁; ▁his t ological ▁; ▁functional ▁ab normal ities
D-1359	-0.8648179173469543	sonographic ; histological ; functional abnormalities
P-1359	-4.4779 -0.8030 -0.2660 -0.4356 -0.1563 -0.2564 -0.2030 -0.0682 -0.2916 -0.0382 -1.1798 -2.9163 -0.1504
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic peptide ; biomarkers ; point of care ; poc
H-1023	-0.4112512171268463	▁na tri ure tic ▁pe pti de ▁; ▁bio mark ers
D-1023	-0.4112512171268463	natriuretic peptide ; biomarkers
P-1023	-0.1869 -0.1062 -0.3356 -1.1862 -0.6437 -0.0847 -0.0974 -1.3841 -0.0092 -0.0618 -0.0514 -1.1365 -0.0626
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
H-1352	-0.3018604815006256	▁antico a gul ants ▁; ▁anti plate let ▁drugs ▁; ▁heart ▁failure ▁; ▁at rial ▁fi bril lation
D-1352	-0.3018604815006256	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
P-1352	-0.3373 -0.1079 -0.1127 -0.0281 -0.0914 -0.0048 -0.0394 -0.0933 -0.1494 -0.2289 -3.0440 -0.1541 -0.1692 -0.9030 -0.0382 -0.1894 -0.0135 -0.0892 -0.1580 -0.0853
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone ; hyperkalemia ; acute kidney injury
H-445	-0.2035478949546814	▁Spir ono lac tone ▁; ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury
D-445	-0.2035478949546814	Spironolactone ; hyperkalemia ; acute kidney injury
P-445	-0.1338 -0.0439 -0.0220 -0.0249 -0.1219 -0.7769 -0.2250 -0.1520 -0.1877 -0.6617 -0.0150 -0.0361 -0.6474 -0.0479 -0.0997 -0.1637 -0.1005
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence ; bnp ; patients ; pad ; bnp ; hf
H-1572	-0.8970133662223816	▁b NP ▁levels ▁; ▁patients ▁; PAD ▁; ▁b NP ▁measure ments ▁; ▁ HF
D-1572	-0.8970133662223816	bNP levels ; patients ;PAD ; bNP measurements ; HF
P-1572	-2.6104 -0.1305 -2.1649 -0.0888 -2.7099 -0.4330 -0.4389 -0.0706 -1.6467 -0.1186 -2.3812 -0.1805 -0.2022 -1.5066 -0.3652 -0.1239 -0.0772
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic ; parasympathetic activity ; hf ; symptoms ; disease
H-1868	-0.522935152053833	▁sympa the tic ▁; ▁para sy mpa the tic ▁activity ▁; ▁ HF
D-1868	-0.522935152053833	sympathetic ; parasympathetic activity ; HF
P-1868	-0.1484 -0.4806 -0.4591 -0.0524 -0.2248 -0.2792 -0.0949 -1.1382 -0.8613 -1.6906 -0.1806 -0.2421 -0.1558 -1.7294 -0.1065
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients ; systolic blood pressure ; renal impairment ; hypertension
H-1529	-0.3072449266910553	▁EH ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁renal ▁im pair ment ▁; ▁hyper tension
D-1529	-0.3072449266910553	EH ; systolic blood pressure ; renal impairment ; hypertension
P-1529	-1.3674 -0.1119 -0.7755 -0.0447 -0.1121 -0.3165 -0.6540 -0.0857 -0.0124 -0.1081 -0.0022 -0.2786 -0.2616 -0.7945 -0.0662 -0.1199 -0.1119
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes ; exercise ; training ; patients ; ambulatory ; hf
H-1631	-0.2256930023431778	▁race ▁; ▁outcome s ▁; ▁exercise ▁training ▁; ▁ambula tory ▁ HF
D-1631	-0.2256930023431778	race ; outcomes ; exercise training ; ambulatory HF
P-1631	-0.4818 -0.1603 -0.1737 -0.0742 -0.3401 -0.2905 -0.1698 -0.3799 -0.5618 -0.0535 -0.1853 -0.0602 -0.1015 -0.1272
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf ; transition ; compensated lv hypertrophy ; hf ; hhd
H-283	-0.3436812460422516	▁mouse ▁ HF ▁model ▁; ▁compensa ted ▁LV ▁hyper trop hy ▁; ▁ HF ▁; ▁h HD
D-283	-0.3436812460422516	mouse HF model ; compensated LV hypertrophy ; HF ; hHD
P-283	-0.5831 -1.1446 -0.1054 -0.8451 -0.1408 -0.0900 -0.1086 -0.1146 -0.1898 -0.0121 -0.4299 -0.3005 -0.4905 -0.0815 -0.1839 -0.8575 -0.5362 -0.2341 -0.0819
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global left ventricular longitudinal systolic strain ; cardiovascular events ; patients ; atrial fibrillation
H-808	-0.25437361001968384	▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation
D-808	-0.25437361001968384	left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
P-808	-0.3609 -0.0879 -0.5149 -0.1581 -0.0242 -0.1165 -0.0120 -0.0311 -0.0638 -0.0200 -0.2889 -0.2222 -0.1189 -0.5853 -0.2452 -1.8078 -0.0598 -0.4048 -0.0272 -0.1437 -0.2005 -0.1025
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up ; deaths ; heart transplantations ; lv assist device implantations ; heart failure ; admissions
H-434	-0.4673579931259155	▁heart ▁transplant ations ▁; LV ▁assist ▁device ▁implant ations ▁; ▁heart ▁failure ▁ad missions
D-434	-0.4673579931259155	heart transplantations ;LV assist device implantations ; heart failure admissions
P-434	-3.7852 -0.1488 -0.0436 -0.2374 -0.2400 -0.5509 -0.1208 -0.1454 -0.0212 -0.3585 -0.5838 -0.2367 -0.6503 -0.0650 -0.1762 -0.1139
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic myocardial ischemia ; heart failure ; therapeutic
H-503	-0.7879619002342224	▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure
D-503	-0.7879619002342224	chronic myocardial ischemia ; heart failure
P-503	-4.3862 -2.8970 -0.1413 -0.4108 -0.2879 -0.1951 -0.0343 -0.6078 -0.2023 -0.2439 -0.0642 -0.6595 -0.1131
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients ; hfpef ; adverse outcomes
H-237	-0.5129662156105042	▁ HF p EF
D-237	-0.5129662156105042	HFpEF
P-237	-1.4593 -0.0779 -0.0277 -0.0750 -1.3135 -0.1244
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical cardiac support ; renal function ; end-stage heart failure
H-1384	-0.58030104637146	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function ▁; ▁end - s tage ▁heart ▁failure
D-1384	-0.58030104637146	mechanical cardiac support ; renal function ; end-stage heart failure
P-1384	-0.4216 -0.0126 -0.2000 -1.2132 -0.5714 -0.0269 -0.1029 -0.2902 -4.7164 -0.1036 -0.1323 -0.0037 -0.6710 -0.4686 -0.2066 -0.1437
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical ; revascularization ; revascularization
H-1603	-0.41189688444137573	▁Sur g ical ▁re vas cular ization ▁; ▁cat heter - based ▁re vas cular ization
D-1603	-0.41189688444137573	Surgical revascularization ; catheter-based revascularization
P-1603	-1.4552 -0.8501 -1.2125 -0.0958 -0.2712 -0.3393 -0.3726 -0.8806 -0.3743 -0.0024 -0.0493 -0.0184 -0.1191 -0.2316 -0.3008 -0.4543 -0.2489 -0.1379
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline ; hgb ; exercise ; training ; kccq
H-841	-0.6895497441291809	▁base line ▁h gb ▁; ▁exercise ▁training ▁; ▁k cc q
D-841	-0.6895497441291809	baseline hgb ; exercise training ; kccq
P-841	-1.8266 -0.4260 -1.3006 -0.0085 -0.1847 -1.5921 -0.5840 -0.3827 -0.5738 -0.0924 -1.6201 -0.2469 -0.1258
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based ; nucleolin ; protein expression
H-96	-0.46703436970710754	▁Mor pho lino - based ▁knock down ▁; ▁nucleo lin ▁; ▁protein ▁expression
D-96	-0.46703436970710754	Morpholino-based knockdown ; nucleolin ; protein expression
P-96	-1.2403 -0.0566 -0.1686 -0.0681 -0.0391 -0.0526 -0.1661 -0.3926 -0.5773 -2.2496 -0.6435 -0.3756 -0.1387 -0.7357 -0.1010
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical ; rule ; cad ; systolic hf
H-1185	-0.19345785677433014	▁clinic al ▁predict ion ▁rule ▁; ▁CAD ▁; ▁sy sto lic ▁ HF
D-1185	-0.19345785677433014	clinical prediction rule ; CAD ; systolic HF
P-1185	-1.1890 -0.0059 -0.1212 -0.0107 -0.4408 -0.1512 -0.0068 -0.3294 -0.0313 -0.0590 -0.0110 -0.2704 -0.0430 -0.1515 -0.0807
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo sternotomy ; cardiopulmonary bypass
H-775	-0.882914125919342	▁techniek ▁; ▁redo ▁ster no to my ▁; ▁cardio pul mon ary ▁by pass
D-775	-0.882914125919342	techniek ; redo sternotomy ; cardiopulmonary bypass
P-775	-4.0172 -0.1855 -3.9124 -0.2240 -0.0427 -0.0508 -0.7887 -0.1768 -0.0399 -0.3528 -0.8496 -0.2372 -2.7648 -0.0398 -0.2929 -0.1516
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical treatment ; hf ; functional ms ; medical treatment
H-354	-0.556770384311676	▁MS ▁; ▁ HF ▁; ▁functional ▁MS ▁; ▁medical ▁treatment
D-354	-0.556770384311676	MS ; HF ; functional MS ; medical treatment
P-354	-0.0912 -0.2082 -3.5198 -0.0953 -0.4016 -0.1266 -0.1347 -0.6620 -0.7465 -0.3172 -0.3254 -0.0527
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence ; parasympathetic ; therapeutic ; hf
H-1134	-0.4880477488040924	▁para sy mpa the tic ▁function ▁; ▁ therapeut ic ▁; ▁slow ▁ HF
D-1134	-0.4880477488040924	parasympathetic function ; therapeutic ; slow HF
P-1134	-0.4217 -0.3757 -0.2182 -0.8772 -0.6633 -0.1629 -0.1660 -0.1690 -0.2524 -0.4088 -0.7967 -0.1716 -0.0786 -0.1597 -2.8028 -0.0842
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical treatment ; hf ; hf ; symptom ; mva
H-371	-0.4270296096801758	▁aggressiv e ▁medical ▁treatment ▁; ▁ HF ▁; ▁ HF ▁symptom ▁; ▁MS
D-371	-0.4270296096801758	aggressive medical treatment ; HF ; HF symptom ; MS
P-371	-0.3010 -0.0334 -0.2512 -0.5209 -0.1142 -1.1899 -0.1351 -0.1346 -0.4560 -0.2120 -1.8667 -0.2513 -0.2417 -0.5992 -0.0983
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular venous pressure ; peripheral oedema ; patient
H-1895	-0.15095584094524384	▁jugu lar ▁ve nous ▁pressure ▁; ▁per i pher al ▁oed ema
D-1895	-0.15095584094524384	jugular venous pressure ; peripheral oedema
P-1895	-0.0008 -0.0908 -0.2664 -0.0842 -0.1415 -0.0539 -0.0586 -0.0227 -0.0027 -0.0185 -0.0973 -0.0596 -1.1486 -0.0677
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart failure ; hf ; condition ; morbidity ; mortality
H-1487	-0.4983084499835968	▁Heart ▁failure ▁; HF
D-1487	-0.4983084499835968	Heart failure ;HF
P-1487	-0.7122 -0.0453 -0.1559 -0.0502 -1.9429 -0.0833
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported ; functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-333	-0.1093912273645401	▁functional ▁mit ral ▁sten osis ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation
D-333	-0.1093912273645401	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
P-333	-0.0672 -0.4096 -0.0254 -0.0055 -0.0058 -0.1421 -0.0214 -0.1720 -0.0393 -0.0302 -0.1054 -0.2203 -0.3160 -0.0143 -0.0593 -0.2184 -0.1105 -0.0154 -0.0510 -0.0583 -0.0648 -0.2875 -0.0763
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients ; fontan circulation ; svr ; cardiac index
H-232	-0.3015868663787842	▁Font an ▁circulation ▁; ▁s VR ▁index ▁; ▁cardiac ▁index
D-232	-0.3015868663787842	Fontan circulation ; sVR index ; cardiac index
P-232	-1.8156 -0.1222 -0.0630 -0.1183 -0.3238 -0.0556 -0.0116 -0.0534 -0.0104 -0.0147 -0.9591 -0.0713
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients ; lvad ; patients ; biventricular support
H-297	-0.5745061635971069	▁isola ted ▁l VAD ▁; ▁patients ▁; ▁bi ven tri cular ▁support
D-297	-0.5745061635971069	isolated lVAD ; patients ; biventricular support
P-297	-1.1047 -0.0829 -0.4852 -0.0141 -0.2054 -0.5470 -2.6325 -0.7613 -0.0525 -0.7088 -0.1635 -0.9801 -0.1787 -0.1264
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid receptor antagonists
H-1709	-0.4471714496612549	▁mineral o cor tico id ▁receptor ▁anta gon ists
D-1709	-0.4471714496612549	mineralocorticoid receptor antagonists
P-1709	-2.2985 -0.1076 -0.5785 -0.4980 -0.1758 -0.0105 -0.1425 -0.0097 -0.3214 -0.6609 -0.1154
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary ; congenital ; heart ; death
H-1906	-0.44753697514533997	▁her edit ary ▁; ▁con geni tal ▁ab normal ities ▁; ▁heart ▁; ▁non trau matic ▁death
D-1906	-0.44753697514533997	hereditary ; congenital abnormalities ; heart ; nontraumatic death
P-1906	-1.8196 -0.0262 -0.1171 -0.4939 -0.0088 -0.0301 -0.0357 -0.0542 -0.0718 -1.3759 -0.2340 -0.8388 -0.4594 -0.1474 -0.0459 -0.4224 -0.7666 -1.3711 -0.1842
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan circulation ; skeletal muscle ; metabolic
H-1494	-0.21851083636283875	▁Font an ▁circulation ▁; ▁skelet al ▁muscle ▁mass ▁; ▁metabol ic ▁ab normal ities
D-1494	-0.21851083636283875	Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
P-1494	-0.4622 -0.0905 -0.0525 -0.2663 -0.3632 -0.0293 -0.3172 -0.1980 -0.4482 -0.0101 -0.1508 -0.0657 -0.0387 -0.8008 -0.1374 -0.0652
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients ; heartmate ii ; lvad
H-303	-0.34199586510658264	▁isola ted ▁Heart Mate ▁II ▁l VAD
D-303	-0.34199586510658264	isolated HeartMate II lVAD
P-303	-0.9275 -0.1003 -0.6460 -0.0710 -0.6624 -0.2765 -0.0253 -0.2565 -0.1126
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based ; patient ; outcomes
H-85	-1.0717124938964844	
D-85	-1.0717124938964844	
P-85	-2.0517 -0.0917
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health ; health ; u.s. ; drug ; administration
H-1830	-0.8059474229812622	▁health ▁insurance ▁; ▁health ▁system ▁data ▁partners ▁; ▁u . s . ▁Food ▁and ▁Drug ▁Administration
D-1830	-0.8059474229812622	health insurance ; health system data partners ; u.s. Food and Drug Administration
P-1830	-1.4818 -0.3561 -0.2508 -0.3654 -0.1174 -2.3761 -0.9472 -0.1424 -2.8271 -0.1821 -0.3013 -0.2787 -0.8992 -1.7673 -0.4295 -0.0681 -1.4983 -0.2184
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp ; patients ; acute heart failure
H-262	-0.40168052911758423	▁cut off ▁value ▁; ▁NT - pro b NP ▁testing ▁; ▁ED ▁patients ▁; ▁a cute ▁heart ▁failure
D-262	-0.40168052911758423	cutoff value ; NT-probNP testing ; ED patients ; acute heart failure
P-262	-0.9790 -0.0708 -0.9933 -0.1188 -0.0892 -0.0250 -0.0074 -0.4888 -0.0999 -1.0957 -0.2236 -0.9639 -0.7351 -1.1061 -0.0243 -0.0233 -0.4620 -0.1963 -0.1825 -0.1486
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension ; diabetes ; ischemic ; etiology
H-1635	-0.11752589046955109	▁black s ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁ ische mic ▁et i ology ▁; ▁socio economic ▁status ▁; ▁white s
D-1635	-0.11752589046955109	blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
P-1635	-0.2975 -0.0764 -0.1058 -0.0659 -0.0171 -0.0675 -0.0241 -0.1026 -0.0251 -0.0116 -0.0551 -0.0050 -0.1280 -0.2230 -0.1833 -0.1173 -0.0869 -0.0492 -0.5317 -0.1853 -0.0803 -0.1683 -0.0962
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin ; lvad ; postoperative
H-536	-0.6809151768684387	▁l VAD ▁; ▁post operativ e ▁survival
D-536	-0.6809151768684387	lVAD ; postoperative survival
P-536	-2.9508 -0.0602 -1.8218 -0.8417 -0.0155 -0.0532 -0.1333 -0.0950 -0.1569
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape ; functional enrichment analysis ; david
H-1612	-0.2239697128534317	▁Cy to scape ▁; ▁functional ▁en rich ment ▁analysis ▁; ▁DA VID
D-1612	-0.2239697128534317	Cytoscape ; functional enrichment analysis ; DAVID
P-1612	-0.7227 -0.0367 -0.0372 -0.1950 -0.0352 -0.0273 -0.0520 -0.3089 -0.3124 -0.3758 -0.3486 -0.0054 -0.5971 -0.0814
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular ; conditions ; patients ; hf
H-694	-1.044531226158142	▁cardiovascular ▁conditions ▁; ▁ HF
D-694	-1.044531226158142	cardiovascular conditions ; HF
P-694	-2.7945 -1.7482 -0.2439 -2.1896 -0.0948 -0.1274 -0.1133
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-0.7483499646186829	▁patient ▁safety ▁initiative s
D-7	-0.7483499646186829	patient safety initiatives
P-7	-1.0277 -0.7908 -2.1193 -0.0775 -0.3607 -0.1140
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling ; emd
H-1151	-0.2848246097564697	▁ HF - indu ced ▁remodel ing ▁; ▁EM d ▁prolong ation
D-1151	-0.2848246097564697	HF-induced remodeling ; EMd prolongation
P-1151	-0.9545 -0.1396 -0.0316 -0.0040 -0.0507 -0.0245 -0.0286 -1.2567 -0.3226 -0.6514 -0.0787 -0.2190 -0.1343 -0.0915
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right heart circulation ; right heart failure
H-1459	-0.9711341857910156	▁right ▁heart ▁circulation ▁; ▁right ▁heart ▁failure
D-1459	-0.9711341857910156	right heart circulation ; right heart failure
P-1459	-3.4109 -0.5961 -0.2129 -0.2506 -2.9622 -0.4040 -0.6133 -0.1782 -0.1118
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling pathway ; remodelling
H-994	-0.396889865398407	▁Raf - MEK 1/2 - ER k 1/2 ▁signal ling ▁; ▁remodel ling
D-994	-0.396889865398407	Raf-MEK1/2-ERk1/2 signalling ; remodelling
P-994	-0.0096 -0.0442 -0.0050 -0.0972 -0.0388 -0.8935 -0.2006 -0.3092 -0.3916 -0.1274 -1.5446 -1.9497 -0.1140 -0.1357 -0.0922
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi ; mi ; hf
H-1104	-0.7048949599266052	▁MI ▁; ▁ HF
D-1104	-0.7048949599266052	MI ; HF
P-1104	-0.9439 -0.4472 -1.9791 -0.6059 -0.1114 -0.1419
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate ; heart failure
H-1544	-0.8715826869010925	▁bis phos phon ate ▁users ▁; ▁heart ▁failure
D-1544	-0.8715826869010925	bisphosphonate users ; heart failure
P-1544	-1.2249 -0.0223 -0.2043 -1.8096 -2.4496 -0.3050 -1.9524 -0.3541 -0.3055 -0.0881
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs ; outcomes
H-2009	-0.8372541069984436	▁kosten ▁; ▁survival
D-2009	-0.8372541069984436	kosten ; survival
P-2009	-2.7698 -0.7576 -0.2045 -0.3662 -0.0881
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary outcomes
H-620	-0.6339649558067322	▁sustain ability
D-620	-0.6339649558067322	sustainability
P-620	-0.1746 -0.1477 -2.1325 -0.0811
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.566389262676239	▁mal adapt ive ▁molecular ▁process es
D-1473	-0.566389262676239	maladaptive molecular processes
P-1473	-1.7873 -0.0165 -0.0290 -0.2346 -2.1753 -0.0847 -0.1324 -0.0712
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine oxidase inhibition ; left ventricular ; systolic ; diastolic function ; cardiac volume overload
H-469	-0.3082858622074127	▁Xan thi ne ▁oxid ase ▁inhibi tion ▁; ▁left ▁vent ri cular ▁sy sto lic ▁; ▁dia sto lic ▁function ▁; ▁cardiac ▁volume ▁over load
D-469	-0.3082858622074127	Xanthine oxidase inhibition ; left ventricular systolic ; diastolic function ; cardiac volume overload
P-469	-0.0011 -0.3511 -0.3766 -0.0411 -1.8931 -0.1220 -0.6075 -0.1589 -1.5907 -0.0225 -1.0134 -0.2027 -0.0401 -0.1756 -0.0269 -0.1346 -0.0081 -0.0589 -0.0239 -0.2410 -0.2912 -0.0103 -0.1043 -0.1400 -0.0747 -0.4878 -0.1256
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis ; heart failure with preserved ejection fraction ; clinical ; doppler echocardiography
H-21	-0.30371564626693726	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁clinic al ▁do pp ler ▁e cho card i ography
D-21	-0.30371564626693726	heart failure ; preserved ejection fraction ; clinical doppler echocardiography
P-21	-1.8118 -0.0963 -0.4121 -0.0273 -0.0293 -0.2177 -0.0161 -0.0543 -0.0165 -0.4716 -0.0018 -0.2491 -1.0346 -0.0068 -0.8507 -0.0035 -0.6466 -0.0610 -0.1106 -0.1606 -0.5915 -0.1788 -0.1642 -0.0762
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients ; heart failure ; hf ; heart failure adherence and retention trial ; hart
H-238	-0.33678320050239563	▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁Heart ▁Fail ure ▁Ad her ence ▁; ▁re tention ▁tri al ▁; HAR t
D-238	-0.33678320050239563	patients ; heart failure ;HF ; Heart Failure Adherence ; retention trial ;HARt
P-238	-1.8517 -0.6427 -0.3106 -0.0696 -0.1923 -0.0238 -0.1199 -0.8065 -0.2133 -0.5143 -0.6618 -0.3893 -0.2676 -0.2344 -0.2664 -0.0272 -0.2481 -0.0197 -0.1581 -0.0125 -0.4948 -0.1430 -0.0785
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf with preserved ejection fraction ; hfpef ; hypertension
H-1076	-0.2790173590183258	HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁hyper tension
D-1076	-0.2790173590183258	HF ; preserved ejection fraction ;HFpEF ; hypertension
P-1076	-0.2585 -1.1300 -0.1261 -0.0563 -0.4224 -0.0509 -0.0685 -0.0324 -0.4281 -0.0049 -0.1558 -0.1013 -0.0685 -0.1552 -0.2541 -1.7248 -0.0350 -0.1319 -0.0966
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end points ; nyha functional class ; quality-of-life ; 6-minute hall walk
H-1873	-0.40723294019699097	▁NY ha ▁functional ▁class ▁; ▁quality - of - life ▁score
D-1873	-0.40723294019699097	NYha functional class ; quality-of-life score
P-1873	-1.9413 -0.9476 -0.2891 -0.1873 -0.2009 -0.0687 -0.0393 -0.0141 -0.0669 -0.1982 -0.1418 -1.0124 -0.1865
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial infarction ; left anterior descending coronary artery occlusion
H-1338	-0.36356121301651	▁My o card ial ▁in far ction ▁; ▁left ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.36356121301651	Myocardial infarction ; left anterior descending coronary artery occlusion
P-1338	-0.9250 -0.2407 -0.3396 -0.2765 -0.0593 -0.6342 -0.0778 -0.5345 -0.9179 -0.6137 -0.0340 -0.0216 -0.7185 -0.6983 -0.0124 -0.6623 -0.0199 -0.0065 -0.2804 -0.4062 -0.1553
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical ; symptoms ; hfpef ; symptoms ; breathlessness ; fluid retention
H-1891	-0.851476788520813	▁ HF p EF
D-1891	-0.851476788520813	HFpEF
P-1891	-1.1618 -0.3609 -0.0816 -0.4297 -2.9412 -0.1337
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection ; nt-probnp ; antibodies ; terminal
H-1521	-0.20171761512756348	▁immun o det ection ▁; ▁NT - pro b NP ▁; ▁anti bo dies
D-1521	-0.20171761512756348	immunodetection ; NT-probNP ; antibodies
P-1521	-0.1835 -0.0851 -0.0545 -0.1174 -0.2587 -0.1325 -0.0259 -0.0079 -0.5804 -0.1037 -0.6758 -0.0177 -0.0195 -0.5915 -0.2859 -0.0873
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; heart failure
H-574	-0.6665078401565552	▁Nordic ▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-574	-0.6665078401565552	Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
P-574	-0.2335 -1.6188 -0.2084 -0.2053 -0.0836 -0.2345 -0.6606 -1.7364 -1.3463 -0.2526 -2.2301 -0.2066 -0.2006 -0.1139
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
H-1132	-0.254596084356308	▁para sy mpa the tic ▁tone ▁; ▁py rido stig mine ▁; ▁vent ri cular ▁dys function ▁; ▁heart ▁failure
D-1132	-0.254596084356308	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
P-1132	-0.0576 -0.5789 -0.0774 -1.1289 -0.5189 -0.0472 -0.0772 -0.0237 -0.0060 -0.0016 -0.0737 -0.1214 -0.0129 -0.9704 -0.3359 -0.0779 -0.0745 -0.3057 -0.5634 -0.3098 -0.1412 -0.0970
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade ; cardiac angiogenesis ; heart failure ; vegf signaling pathway
H-459	-0.38203030824661255	▁β - Block ade ▁; ▁cardiac ▁ang io gene sis ▁; ▁heart ▁failure ▁; ▁VE GF ▁signal ing ▁path way
D-459	-0.38203030824661255	β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
P-459	-0.5619 -0.0861 -0.2137 -0.4543 -0.6193 -0.0801 -0.7942 -1.0065 -0.3266 -0.5535 -0.4731 -0.2243 -0.1878 -0.4557 -0.7166 -0.0198 -0.2139 -0.2827 -0.2242 -0.4077 -0.3287 -0.1740
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes ; myocardial ischemic events ; patients ; cardiac resynchronization therapy
H-101	-0.4019814133644104	▁my o card ial ▁ ische mic ▁events ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.4019814133644104	myocardial ischemic events ; cardiac resynchronization therapy
P-101	-2.8015 -0.1714 -0.2543 -0.3087 -0.1516 -0.0302 -0.6521 -0.5225 -0.2714 -0.1417 -0.0566 -0.0357 -0.0159 -0.5916 -0.8464 -0.0142 -0.2014 -0.1684
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report ; patients ; aortic valve ; surgery ; post-lvad ai
H-544	-0.33296000957489014	▁a or tic ▁val ve ▁surgery ▁; ▁post - ▁l VAD ▁AI
D-544	-0.33296000957489014	aortic valve surgery ; post- lVAD AI
P-544	-0.1882 -0.0157 -0.4477 -0.0640 -0.0215 -0.0629 -0.2548 -1.4923 -0.0071 -0.8464 -0.0157 -1.0804 -0.0821 -0.0824
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart ; hr reduction ; patients ; systolic heart failure
H-527	-0.3458949029445648	▁un load ing ▁; ▁heart ▁; ▁isola ted ▁HR ▁re duction ▁; ▁sy sto lic ▁heart ▁failure
D-527	-0.3458949029445648	unloading ; heart ; isolated HR reduction ; systolic heart failure
P-527	-0.0463 -0.0228 -0.0252 -0.5733 -3.7412 -0.2038 -0.1001 -0.0252 -0.5222 -0.0989 -0.0094 -0.2292 -0.0656 -0.0407 -0.0646 -0.4848 -0.0833 -0.1537 -0.0819
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone ; diagnosed ; systolic heart failure ; clinical
H-439	-0.2222822904586792	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-439	-0.2222822904586792	spironolactone ; systolic heart failure
P-439	-0.1331 -0.0091 -0.0324 -0.0304 -0.1682 -1.2244 -0.0535 -0.0601 -0.4693 -0.1195 -0.2800 -0.0875
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart failure ; clinical ; medicine ; prevalence ; coronary disease
H-980	-0.39902937412261963	▁Heart ▁failure ▁; ▁clinic al ▁burde n ▁; ▁adult ▁medicine ▁; ▁a ther omat ous ▁corona ry ▁disease
D-980	-0.39902937412261963	Heart failure ; clinical burden ; adult medicine ; atheromatous coronary disease
P-980	-0.8178 -0.0772 -0.2194 -2.9885 -0.0123 -0.0774 -0.0975 -0.1667 -0.1934 -0.1633 -0.1158 -0.0318 -0.2136 -0.0185 -0.7178 -0.1982 -1.3489 -0.2695 -0.1507 -0.1022
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart failure ; hf ; latin america ; health ; hf
H-1789	-0.3894781470298767	▁Heart ▁failure ▁; HF ▁; ▁Latin ▁America ▁; LA ▁; ▁health ▁service ▁planning ▁; ▁ HF
D-1789	-0.3894781470298767	Heart failure ;HF ; Latin America ;LA ; health service planning ; HF
P-1789	-0.9202 -0.0380 -0.1725 -0.1195 -0.2713 -0.5544 -0.1291 -0.1223 -0.7352 -0.3213 -1.1964 -0.6301 -0.1242 -0.1147 -1.1397 -0.1692 -0.1659 -0.0868
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization ; medicare ; discharged ; nursing
H-1710	-0.4098151624202728	▁re hospital ization ▁; ▁medica re ▁fee - for - service ▁beneficiar ies ▁; ▁skille d ▁nur sing ▁facilities
D-1710	-0.4098151624202728	rehospitalization ; medicare fee-for-service beneficiaries ; skilled nursing facilities
P-1710	-2.1626 -0.0185 -0.1213 -0.2883 -0.0323 -0.0262 -0.3886 -0.0412 -0.0472 -0.0229 -0.0309 -1.1821 -0.0327 -1.1907 -1.9736 -0.0085 -0.3708 -0.2350 -0.1805 -0.1480 -0.1041
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death ; hf ; hospitalization ; crt ; hazard ratio
H-755	-0.609721302986145	▁ HF ▁hospital ization ▁; ▁c RT ▁; haz ard ▁ratio
D-755	-0.609721302986145	HF hospitalization ; cRT ;hazard ratio
P-755	-1.3232 -0.2510 -1.5645 -0.4478 -0.2367 -0.1571 -2.4109 -1.1701 -0.0296 -0.0051 -0.0191 -0.2017 -0.1097
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative care ; patients ; terminal ; disease ; therapeutic
H-1820	-0.9336277842521667	▁palli ative ▁; ▁patients ▁; ▁advanced ▁disease
D-1820	-0.9336277842521667	palliative ; patients ; advanced disease
P-1820	-0.0394 -0.0597 -1.8557 -1.7769 -0.6596 -3.1333 -0.3300 -0.4800 -0.0681
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic ; hfpef ; medical history ; physical examination
H-1892	-0.6148138642311096	▁diagnostic ▁test ▁; ▁ HF p EF
D-1892	-0.6148138642311096	diagnostic test ; HFpEF
P-1892	-1.8242 -0.6136 -0.1130 -0.5233 -0.0942 -0.0312 -0.1975 -2.0395 -0.0969
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative stress ; gtpase ; rac1 ; activity ; hearts
H-281	-0.4565852880477905	▁o xi da tive ▁stress ▁; ▁GT Pas e ▁Rac 1 ▁; ▁heart s ▁; ▁ ANS ▁mi ce
D-281	-0.4565852880477905	oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
P-281	-0.2809 -0.1293 -0.0201 -0.2829 -0.1938 -0.1075 -1.4678 -0.4900 -0.0133 -0.1880 -1.1749 -0.9489 -0.7440 -0.0593 -0.4670 -1.1843 -0.1039 -1.0082 -0.5131 -0.1230 -0.0880
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin ; insulin resistance ; monocytes ; inflammatory
H-928	-0.22940950095653534	▁Res istin ▁; ▁circula ting ▁media tor ▁; ▁insulin ▁resist ance ▁; ▁mono cy tes ▁; ▁infla mma tory ▁stimul i
D-928	-0.22940950095653534	Resistin ; circulating mediator ; insulin resistance ; monocytes ; inflammatory stimuli
P-928	-0.7311 -0.0086 -0.1648 -0.0006 -0.0403 -0.0060 -0.0512 -0.4152 -0.0136 -0.0545 -0.0419 -0.2155 -0.0046 -0.0177 -0.0119 -0.2398 -2.1455 -0.2217 -0.0955 -0.0416 -0.4296 -0.1777 -0.1475
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end point ; cardiovascular death ; cardiac transplant ; secondary end point ; death
H-1757	-0.33358803391456604	▁cardiovascular ▁death ▁; ▁urgent ▁cardiac ▁transplant
D-1757	-0.33358803391456604	cardiovascular death ; urgent cardiac transplant
P-1757	-0.5678 -0.7585 -0.0977 -0.0193 -0.0192 -0.0857 -0.9978 -0.1227
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications ; outpatients ; heart failure ; ncdr pinnacle
H-658	-0.9493387341499329	▁medication s ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁NC DR ▁PIN NA CLE
D-658	-0.9493387341499329	medications ; outpatients ; heart failure ; NCDR PINNACLE
P-658	-3.6020 -0.1395 -0.9156 -3.5556 -0.0036 -0.1394 -2.4211 -0.3375 -0.0548 -0.8040 -0.8988 -0.4512 -0.3278 -0.3425 -0.8940 -1.1153 -0.1361
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; patients ; heart failure
H-1110	-0.46087121963500977	▁non sel ective ▁; ▁select ive ▁beta - block ers ▁; ▁cardiac ▁sympa the tic ▁activity ▁; ▁hemos tas is ▁; ▁heart ▁failure
D-1110	-0.46087121963500977	nonselective ; selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
P-1110	-0.8541 -0.0167 -0.0159 -0.5964 -0.0629 -0.0262 -1.4326 -0.0971 -0.2387 -0.0926 -0.6276 -0.0196 -0.1160 -0.8259 -2.5386 -0.6322 -0.2821 -0.1049 -0.0439 -0.4872 -0.5708 -1.3368 -0.1561 -0.2157 -0.1311
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission ; patients
H-1581	-0.878373920917511	
D-1581	-0.878373920917511	
P-1581	-1.5987 -0.1580
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.39792367815971375	
D-86	-0.39792367815971375	
P-86	-0.7122 -0.0836
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous ; symptoms ; patients ; heart failure
H-51	-0.38879477977752686	▁Intra ven ous ▁ir on ▁; ▁heart ▁failure ▁; ▁ir on ▁de fici en cy
D-51	-0.38879477977752686	Intravenous iron ; heart failure ; iron deficiency
P-51	-0.1908 -0.0061 -1.1413 -0.2484 -0.1571 -0.4810 -3.3944 -0.1303 -0.2167 -0.0644 -0.1204 -0.0993 -0.0131 -0.0810 -0.0402 -0.1191 -0.1059
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart failure ; emergency department ; patient ; outcomes
H-462	-0.35627007484436035	▁he art ▁failure ▁; ▁Emer gen cy ▁Department ▁; ED ▁; ▁ED ▁volume
D-462	-0.35627007484436035	heart failure ; Emergency Department ;ED ; ED volume
P-462	-0.3775 -0.2473 -0.0929 -0.2131 -0.1716 -0.1479 -0.0143 -0.1605 -0.2573 -0.1454 -0.6516 -0.1421 -0.3621 -2.2051 -0.1553
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions ; remodelling ; leading ; heart failure
H-991	-0.56022709608078	▁stress ▁conditions ▁; ▁mal adapt ive ▁remodel ling ▁; ▁heart ▁failure
D-991	-0.56022709608078	stress conditions ; maladaptive remodelling ; heart failure
P-991	-4.0973 -0.5940 -0.6051 -0.2673 -0.0124 -0.0325 -0.0357 -0.0617 -0.3830 -0.7398 -0.2478 -0.1034 -0.1029
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ; ischemic heart failure
H-1613	-0.3470708429813385	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure
D-1613	-0.3470708429813385	non-ischemic ; ischemic heart failure
P-1613	-0.9260 -0.0371 -0.0377 -0.1665 -0.5957 -0.0959 -0.0410 -0.3063 -1.4151 -0.2239 -0.2112 -0.1087
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis ; systemic ; followed up
H-1559	-0.462817907333374	▁psoriasis ▁; ▁system ic / UV ▁treatment
D-1559	-0.462817907333374	psoriasis ; systemic/UV treatment
P-1559	-0.0284 -0.4503 -0.0378 -0.1265 -2.4264 -0.0181 -0.6786 -0.3287 -0.0705
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv dysfunction ; prognosis ; hf
H-1160	-0.4334070086479187	▁ RV ▁dys function ▁; ▁weight ▁loss ▁; ▁ab normal ▁body ▁composition ▁; ▁ HF
D-1160	-0.4334070086479187	RV dysfunction ; weight loss ; abnormal body composition ; HF
P-1160	-1.4492 -0.6049 -0.1789 -0.0491 -0.1047 -0.4927 -0.3779 -0.2579 -0.1644 -0.0074 -0.3224 -0.0357 -0.2244 -2.7333 -0.1697 -0.0566 -0.1387
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-0.8618098497390747	
D-609	-0.8618098497390747	
P-609	-1.6347 -0.0889
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.33097368478775024	
D-158	-0.33097368478775024	
P-158	-0.5794 -0.0825
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis ; clinical ; prognostic ; diastolic dysfunction ; leading ; hfpef
H-26	-0.346197247505188	▁dia sto lic ▁dys function ▁; ▁H FP EF
D-26	-0.346197247505188	diastolic dysfunction ; HFPEF
P-26	-1.3211 -0.0650 -0.0764 -0.0336 -0.0433 -0.2852 -1.4514 -0.1668 -0.1455 -0.1056 -0.1141
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic receptor blockade ; mortality ; all-cause hospitalizations ; patients ; heart failure ; hf
H-1424	-0.5768659710884094	▁β - Ad r energi c ▁receptor ▁block ade ▁; ▁hospital ization s ▁; ▁heart ▁failure ▁; HF
D-1424	-0.5768659710884094	β-Adrenergic receptor blockade ; hospitalizations ; heart failure ;HF
P-1424	-0.1243 -0.0324 -0.7212 -0.2648 -0.4580 -0.0335 -0.0169 -0.4989 -0.1640 -0.2738 -4.8558 -0.9358 -0.3099 -0.3648 -1.3106 -0.2266 -0.6627 -0.0326 -0.1505 -0.1002
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right ventricle ; leads ; stroke volume ; shortens ; left ventricular ejection time ; lvet
H-578	-0.3273727595806122	▁right ▁vent ric le ▁over load ▁; ▁stroke ▁volume ▁; ▁left ▁vent ri cular ▁e je ction ▁time ▁; ▁l VET
D-578	-0.3273727595806122	right ventricle overload ; stroke volume ; left ventricular ejection time ; lVET
P-578	-1.5274 -0.1770 -0.8142 -0.2138 -0.1145 -0.0324 -0.1625 -0.8536 -0.0340 -0.1165 -0.3668 -0.0637 -0.6378 -0.0861 -0.0792 -0.1384 -0.0349 -0.9974 -0.7280 -0.0420 -0.0398 -0.1872 -0.0824
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp ; hf ; patient ; plasma ; immunoprecipitation ; mass spectrometric analysis
H-1515	-0.35918524861335754	▁NT - pro b NP ▁; ▁ HF ▁patient ▁plasma ▁; ▁immun o preci pit ation ▁; ▁mass ▁spec tro metric ▁analysis
D-1515	-0.35918524861335754	NT-probNP ; HF patient plasma ; immunoprecipitation ; mass spectrometric analysis
P-1515	-0.4240 -0.0360 -0.0073 -0.4424 -0.1957 -0.2984 -2.5067 -0.2251 -0.8124 -0.1798 -0.1724 -0.0225 -0.2621 -0.2068 -0.1525 -0.3983 -0.6934 -0.0309 -0.4254 -0.1187 -0.1796 -0.3377 -0.3369 -0.1555
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated proteins ; chromatin structure ; changing ; dna ; gene expression profile
H-90	-0.485287606716156	▁Chro mat in - as soci ated ▁protein s ▁; ▁chr omat in ▁structure ▁; ▁DNA
D-90	-0.485287606716156	Chromatin-associated proteins ; chromatin structure ; DNA
P-90	-1.8443 -0.0371 -1.1738 -0.0881 -0.0265 -0.0006 -0.3329 -0.9389 -0.1334 -0.4495 -0.0646 -0.0305 -0.9401 -0.7059 -0.1415 -0.5718 -1.1399 -0.1160
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd ; clinical ; hospitalizations ; complications ; therapy ; end-stage hf
H-895	-0.548061728477478	▁PD ▁; ▁ therapy ▁; ▁severe ▁end - s tage ▁ HF
D-895	-0.548061728477478	PD ; therapy ; severe end-stage HF
P-895	-0.2019 -0.3659 -3.9173 -0.0885 -0.3917 -1.6483 -0.3530 -0.0801 -0.1488 -0.0050 -0.2242 -0.0613 -0.0692 -0.1177
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive ; patients ; pulmonary hypertension ; heart failure
H-577	-0.45679253339767456	▁pulmonar y ▁hyper tension ▁; PH ▁; ▁heart ▁failure
D-577	-0.45679253339767456	pulmonary hypertension ;PH ; heart failure
P-577	-2.7821 -0.0469 -0.0671 -0.0328 -0.1804 -0.0544 -0.2890 -1.1621 -0.0921 -0.1886 -0.1293
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait ; therapy ; lokomat ; heart failure ; patients
H-1912	-0.316817969083786	▁robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁system ▁; ▁heart ▁failure ▁patients
D-1912	-0.316817969083786	robot-assisted gait therapy ; Lokomat® system ; heart failure patients
P-1912	-1.4301 -0.0884 -0.0046 -0.0507 -0.0697 -0.1397 -0.2150 -0.0106 -0.2133 -0.0486 -0.0110 -1.4925 -0.0671 -0.9125 -0.0994 -0.0570 -0.8339 -0.1614 -0.1139
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
H-1647	-0.1989021748304367	▁cat heter ▁ab lation ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁ rhythm ▁control ▁ therapy
D-1647	-0.1989021748304367	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
P-1647	-0.9202 -0.0109 -0.0085 -0.0472 -0.0408 -0.0425 -0.1184 -0.1421 -0.2026 -0.0377 -0.3354 -0.3756 -0.3888 -0.3028 -0.2475 -0.0116 -0.2121 -0.1354
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy ; hdl ; chf-nyha-iiib ; hdl
H-258	-0.573698103427887	▁et ▁; ▁HD L ▁function ▁; ▁ET ▁; ▁CHF - NY ha - III b ▁; ▁HD L ▁function
D-258	-0.573698103427887	et ; HDL function ; ET ; CHF-NYha-IIIb ; HDL function
P-258	-1.4895 -0.2653 -2.0020 -1.2983 -0.0509 -0.2771 -1.8689 -0.1584 -0.2089 -0.0724 -0.0458 -0.5232 -0.0678 -0.1678 -0.0314 -0.5259 -0.8547 -1.8248 -0.0827 -0.1581 -0.0739
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac failure ; death ; patients ; type 2 diabetes ; diabetes ; heart failure
H-652	-0.6064607501029968	▁Card iac ▁failure ▁; ▁diabetes ▁; ▁molecular ▁mechanism ▁; ▁diabetes ▁; ▁heart ▁failure
D-652	-0.6064607501029968	Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
P-652	-2.2172 -0.0666 -0.0417 -0.1202 -1.2946 -0.1595 -2.7174 -0.0043 -0.1537 -1.0931 -0.3668 -0.5339 -0.1362 -0.0944 -0.0973
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient ; symptomatic ; therapeutic ; exercise ; hemodynamic
H-1179	-0.4336101710796356	▁ex er tion ▁; ▁ therapeut ic ▁treatment s ▁; ▁ab normal ▁exercise ▁; ▁hem o dynamic ▁status
D-1179	-0.4336101710796356	exertion ; therapeutic treatments ; abnormal exercise ; hemodynamic status
P-1179	-1.7091 -0.0337 -0.1663 -0.2072 -0.6471 -0.0266 -0.2732 -0.9342 -0.2749 -0.8485 -0.1845 -0.0063 -1.2522 -1.3987 -0.2201 -0.1994 -0.0026 -0.0364 -0.1575 -0.0936
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet ; sensitivity ; specificity ; death ; icu
H-584	-0.955077588558197	▁l VET ▁; ▁ sensitiv ity ▁; ▁death
D-584	-0.955077588558197	lVET ; sensitivity ; death
P-584	-1.1658 -0.2978 -0.4267 -1.7601 -0.1456 -0.5227 -0.2106 -1.9906 -2.9430 -0.0877
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients ; diagnosis ; congestive heart failure
H-1578	-0.44201579689979553	▁con ges tive ▁heart ▁failure
D-1578	-0.44201579689979553	congestive heart failure
P-1578	-0.7247 -0.1197 -1.3750 -0.5276 -0.1576 -0.1063 -0.0831
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient ; implantable cardioverter-defibrillator
H-1859	-0.2894454002380371	▁a IM ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1859	-0.2894454002380371	aIM ; implantable cardioverter-defibrillator deactivation
P-1859	-0.2391 -0.2437 -0.3601 -1.9790 -0.0324 -0.4870 -0.0240 -0.1980 -0.0416 -0.1029 -0.1096 -0.3762 -0.1003 -0.0469 -0.2584 -0.0338 -0.2623 -0.4858 -0.1183
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial structure ; sarcomeric microstructure
H-1250	-0.3075755834579468	▁mito cho ndri al ▁structure ▁; ▁sar come ric ▁micro structure
D-1250	-0.3075755834579468	mitochondrial structure ; sarcomeric microstructure
P-1250	-0.0760 -0.2635 -0.1969 -0.0206 -0.5564 -0.2671 -0.5368 -0.5963 -1.0343 -0.0201 -0.1959 -0.1195 -0.1150
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients ; heart failure and reduced ejection fraction
H-668	-0.6448785066604614	▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-668	-0.6448785066604614	heart failure ; reduced ejection fraction
P-668	-5.1051 -0.0764 -0.2490 -1.4514 -0.0153 -0.0219 -0.1574 -0.0261 -0.2383 -0.0072 -0.2168 -0.1737
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut ; inflammation ; heart failure ; patients ; heart failure
H-1363	-0.5736717581748962	▁gut ▁; ▁ inflammation ▁; ▁dieta ry ▁intervention s ▁; ▁heart ▁failure ▁patients
D-1363	-0.5736717581748962	gut ; inflammation ; dietary interventions ; heart failure patients
P-1363	-0.7311 -0.0989 -0.3392 -0.0339 -0.1128 -1.0730 -1.1069 -0.5312 -0.1701 -0.3662 -0.1662 -0.0740 -1.6335 -2.0436 -0.1246
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr ; acr ; cms ; correlated
H-141	-0.36178600788116455	▁p PR ▁; ▁a cr ▁; ▁CMS
D-141	-0.36178600788116455	pPR ; acr ; CMS
P-141	-0.2655 -1.1158 -0.0598 -0.0630 -0.1020 -0.1237 -0.0728 -1.3687 -0.0848
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality ; lcx ; lad ; disease
H-513	-0.39581358432769775	▁mortal ity ▁; LC X ▁; ▁ LAD ▁; ▁two - ves sel ▁disease ▁model
D-513	-0.39581358432769775	mortality ;LCX ; LAD ; two-vessel disease model
P-513	-0.3304 -0.5843 -0.1354 -0.7885 -1.1348 -0.1594 -0.0613 -0.0601 -1.1536 -1.3660 -0.1005 -0.1277 -0.0081 -0.1875 -0.3259 -0.1269 -0.0784
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf ; patients ; emergency department ; intubated
H-210	-0.17846928536891937	▁CHF ▁patients ▁; ▁emergency ▁department ▁; ED ▁; ▁in tuba ted
D-210	-0.17846928536891937	CHF patients ; emergency department ;ED ; intubated
P-210	-0.0186 -0.6757 -0.1974 -0.3087 -0.0307 -0.1223 -0.1174 -0.3318 -0.0213 -0.0339 -0.2179 -0.1468 -0.0975
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis ; patients ; chf ; therapeutic ; neurohormonal systems
H-635	-0.2571644186973572	▁CHF ▁; ▁ therapeut ic ▁interrupt ion ▁; ▁activa ted ▁neuro hormon al ▁systems
D-635	-0.2571644186973572	CHF ; therapeutic interruption ; activated neurohormonal systems
P-635	-0.7281 -1.0009 -0.9161 -0.0439 -0.2637 -0.0101 -0.0120 -0.4740 -0.0019 -0.0798 -0.0649 -0.0645 -0.0211 -0.0878 -0.2609 -0.0850
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese ; zsf1 ; heart failure with preserved ejection fraction
H-770	-0.2783006727695465	▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-770	-0.2783006727695465	zSF1 rats ; heart failure ; preserved ejection fraction
P-770	-0.3853 -0.4369 -1.3437 -0.1114 -0.0703 -0.8795 -0.4088 -0.1033 -0.3814 -0.0531 -0.0278 -0.2777 -0.0348 -0.0714 -0.0335 -0.3662 -0.0097 -0.1640 -0.1290
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician ; follow-up ; discharge ; death ; readmission ; patients ; heart failure
H-1413	-0.7276979088783264	▁physician ▁follow - up ▁; ▁dis charge ▁; ▁death ▁; ▁read mission ▁; ▁heart ▁failure
D-1413	-0.7276979088783264	physician follow-up ; discharge ; death ; readmission ; heart failure
P-1413	-1.6296 -0.3512 -0.0744 -0.0096 -1.4015 -0.4990 -0.0882 -0.3185 -2.7349 -0.2833 -0.8290 -0.8491 -0.4854 -2.3869 -0.2046 -0.1328 -0.0930
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart magnetic resonance imaging ; chelation ; compliance ; heart disease ; patients ; thalassaemia major
H-744	-0.5324262976646423	▁impact ▁; ▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁heart ▁disease ▁; ▁tha lassa emia
D-744	-0.5324262976646423	impact ; heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
P-744	-1.8957 -0.9074 -0.2959 -0.0837 -0.6844 -0.3143 -0.6700 -0.5542 -0.1757 -0.3087 -0.0169 -0.0166 -0.1841 -0.0837 -0.1722 -3.8270 -0.3249 -0.2071 -0.0388 -0.1370 -0.4287 -0.8269 -0.0918
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial tonometry ; lvet ; prognostic ; patients ; precapillary ph ; heart failure
H-579	-0.30701807141304016	▁arterial ▁ton ometr y ▁; ▁l VET ▁car ries ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-579	-0.30701807141304016	arterial tonometry ; lVET carries ; precapillary PH ; heart failure
P-579	-0.3217 -0.1481 -0.0322 -0.0909 -0.5200 -1.3096 -0.0889 -0.5197 -0.0360 -0.4666 -0.7891 -0.1126 -0.0495 -0.1488 -0.1374 -0.3827 -0.5419 -0.1565 -0.1570 -0.1314
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk ; heart ; adipose tissue ; cachectic heart failure ; patients ; prospective study
H-8	-0.4801424443721771	▁Cross - talk ▁between ▁the ▁heart ▁; ▁adi pose ▁tissu e ▁; ▁cache ctic ▁heart ▁failure ▁patients ▁; ▁body ▁composition
D-8	-0.4801424443721771	Cross-talk between the heart ; adipose tissue ; cachectic heart failure patients ; body composition
P-8	-0.9284 -0.1707 -0.0314 -1.4755 -1.1680 -0.7095 -0.6154 -0.0106 -0.0950 -0.0310 -0.0643 -0.3660 -0.0228 -0.1737 -0.4599 -0.0468 -1.0378 -0.8700 -1.9465 -0.1122 -0.1421 -0.0857
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 ; healthy ; heart muscle ; cells ; phenotype ; pathological ; hypertrophy
H-641	-0.45393362641334534	▁mu tant ▁mi ce ▁over express ing ▁hand 2 ▁; ▁healthy ▁heart ▁muscle ▁cell s ▁; ▁path ological ▁hyper trop hy
D-641	-0.45393362641334534	mutant mice overexpressing hand2 ; healthy heart muscle cells ; pathological hypertrophy
P-641	-1.1417 -0.2506 -0.2041 -0.2245 -0.1121 -0.0609 -0.0146 -0.9506 -0.2641 -0.2727 -3.2355 -0.2681 -0.1679 -0.2200 -0.1592 -1.2728 -0.1437 -0.3641 -0.1864 -0.0038 -0.6585 -0.1563 -0.1081
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal echocardiography ; shunts ; thrombosis
H-1957	-0.3291083872318268	▁trans o es op hage al ▁e cho card i ography ▁; ▁patent ▁; ▁ thro mbo sis
D-1957	-0.3291083872318268	transoesophageal echocardiography ; patent ; thrombosis
P-1957	-0.0929 -0.2495 -0.1465 -0.0346 -0.3979 -0.0405 -0.0665 -0.0384 -0.1667 -0.3198 -0.1724 -0.2371 -0.7702 -0.1806 -0.2383 -0.3581 -0.2431 -0.7696 -1.9689 -0.0906
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients ; uptitration ; heart rate ; renal function ; spironolactone
H-180	-0.666485071182251	▁up tit ration ▁; ▁heart ▁rate ▁; ▁renal ▁function ▁; ▁spi rono lac tone
D-180	-0.666485071182251	uptitration ; heart rate ; renal function ; spironolactone
P-180	-6.1463 -0.1966 -0.2091 -0.2998 -2.3293 -0.1955 -0.0814 -0.0447 -0.1585 -0.5106 -0.1259 -0.0126 -0.0364 -0.0461 -0.1312 -0.1396
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis ; patients ; adverse events ; echocardiographic ; outcomes
H-914	-0.512402355670929	▁di al ysis ▁patients ▁; ▁e cho car dio graphic
D-914	-0.512402355670929	dialysis patients ; echocardiographic
P-914	-0.1776 -0.0374 -0.0263 -0.5528 -0.6032 -0.9719 -0.0887 -0.0321 -0.2084 -1.2426 -2.0644 -0.1435
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence ; micrornas ; mirnas ; pathogenesis ; heart failure
H-1481	-0.29805904626846313	▁micro RNA s ▁; mi RNA s ▁; ▁heart ▁failure
D-1481	-0.29805904626846313	microRNAs ;miRNAs ; heart failure
P-1481	-0.0751 -0.0264 -0.0807 -0.1933 -0.1315 -0.0120 -0.0431 -0.3120 -2.1389 -0.2680 -0.1908 -0.1050
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf ; shift ; chronic heart failure ; chronic heart failure ; cardiology
H-1964	-0.7121740579605103	▁para DIG m - HF ▁; ▁paradigm ▁shift ▁; ▁chronic ▁heart ▁failure ▁; ▁Chro nic ▁heart ▁failure ▁; ▁card i ology
D-1964	-0.7121740579605103	paraDIGm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
P-1964	-3.4483 -0.7562 -0.6176 -0.0361 -0.0470 -0.1222 -2.2794 -0.0451 -0.1889 -1.8977 -0.5945 -0.1098 -0.4403 -3.7441 -0.1054 -0.3784 -0.0646 -0.4670 -0.4431 -0.1676 -0.1691 -0.1385 -0.1189
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory ; hf ; patients ; left ventricular ejection fraction
H-122	-0.3269839584827423	▁consenti ng ▁ambula tory ▁ HF ▁patients ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction
D-122	-0.3269839584827423	consenting ambulatory HF patients ; left ventricular ejection fraction
P-122	-1.0136 -0.0135 -0.0553 -0.1320 -0.3123 -0.0991 -0.4394 -0.2209 -0.6382 -0.0187 -0.0326 -1.1267 -0.3299 -0.1118 -0.1141 -0.1271 -1.1043 -0.0078 -0.5163 -0.1262
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new zealand ; renal dnx ; pacing-induced chf
H-1373	-0.24198560416698456	▁ conscious ▁; ▁chronic ally ▁instrument ed ▁New ▁Zealand ▁White ▁rabbi ts ▁; ▁renal ▁DN x ▁; ▁pa cing - indu ced ▁CHF
D-1373	-0.24198560416698456	conscious ; chronically instrumented New Zealand White rabbits ; renal DNx ; pacing-induced CHF
P-1373	-1.7135 -0.0195 -0.3451 -0.5742 -0.0190 -0.0220 -0.0840 -0.9073 -0.0083 -1.2052 -0.0193 -0.0349 -0.2880 -0.0473 -0.0613 -0.0314 -0.2808 -0.0376 -0.0497 -0.0413 -0.0018 -0.0195 -0.0198 -0.1404 -0.0784
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt variability ; qtv ; repolarization ; qtv ; cardiac death
H-1435	-0.4337623417377472	▁ QT ▁variabil ity ▁; Q TV ▁; ▁repo lar ization ▁la bility ▁; ▁Q TV ▁; ▁risk ▁predict or ▁; ▁sud den ▁cardiac ▁death
D-1435	-0.4337623417377472	QT variability ;QTV ; repolarization lability ; QTV ; risk predictor ; sudden cardiac death
P-1435	-1.9314 -0.0555 -0.0753 -0.5937 -0.1670 -1.0701 -1.9019 -0.3165 -0.0473 -0.3146 -0.1142 -0.0605 -0.0162 -0.1770 -0.4195 -1.3575 -0.2086 -1.0479 -0.4026 -0.0954 -0.4849 -0.0877 -0.0144 -0.0065 -0.4636 -0.1516 -0.1302
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker ; patients ; resting hr ; bpm ; p value
H-1941	-0.6449899077415466	▁Beta - block er ▁dose ▁; ▁rest ing ▁HR
D-1941	-0.6449899077415466	Beta-blocker dose ; resting HR
P-1941	-0.3183 -0.0569 -0.0659 -0.1155 -0.1123 -0.4604 -2.3169 -0.1039 -1.5412 -1.9432 -0.0603
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping ; mri ; tidal respiration ; myocardial t1 ; heart failure
H-1054	-0.34717729687690735	▁m RI ▁; ▁tid al ▁respira tion ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁; ▁heart ▁failure
D-1054	-0.34717729687690735	mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
P-1054	-0.8688 -1.6576 -0.3533 -0.0797 -0.0111 -0.0751 -0.0922 -0.1481 -0.5644 -0.1104 -0.0932 -0.0267 -1.5055 -0.3720 -0.2705 -0.0334 -0.0103 -0.1512 -0.7730 -0.3209 -0.1214 -0.2091 -0.1371
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular disease ; baseline
H-1767	-1.0308139324188232	▁cardiovascular ▁disease
D-1767	-1.0308139324188232	cardiovascular disease
P-1767	-2.9124 -0.8207 -0.2199 -0.1703
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage ; poc
H-1029	-1.047179937362671	▁PO c ▁technology
D-1029	-1.047179937362671	POc technology
P-1029	-3.7967 -0.8734 -0.3446 -0.1027 -0.1185
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis ; cardiovascular disease ; cvd
H-1555	-0.3205806612968445	▁p sori asis ▁; ▁cardiovascular ▁disease ▁; CV d
D-1555	-0.3205806612968445	psoriasis ; cardiovascular disease ;CVd
P-1555	-1.3125 -0.0512 -0.0395 -0.1439 -0.3344 -0.6757 -0.1770 -0.0256 -0.4637 -0.2153 -0.0877
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital compare ; ami ; mortality
H-1697	-0.4699317514896393	▁ AMI ▁mortal ity ▁rates
D-1697	-0.4699317514896393	AMI mortality rates
P-1697	-0.5450 -0.6542 -0.3045 -0.4755 -1.0280 -0.1493 -0.1330
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause readmissions
H-726	-0.8713981509208679	▁read missions
D-726	-0.8713981509208679	readmissions
P-726	-2.2350 -0.2833 -0.9022 -0.0651
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins ; subproteome
H-94	-1.326007604598999	▁protein s ▁; ▁strong ▁acid
D-94	-1.326007604598999	proteins ; strong acid
P-94	-2.5638 -0.1538 -0.3501 -5.8961 -0.1620 -0.0896 -0.0666
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm control therapy
H-1645	-0.3477705419063568	▁ Rhythm ▁control ▁ therapy
D-1645	-0.3477705419063568	Rhythm control therapy
P-1645	-0.1197 -0.0684 -0.1892 -0.3928 -0.0201 -1.5645 -0.0797
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal ; likelihood ratio
H-487	-0.9542025327682495	▁cut off ▁; ▁negative ▁predict ive ▁value ▁; ▁e - sept al
D-487	-0.9542025327682495	cutoff ; negative predictive value ; e-septal
P-487	-3.0269 -0.1080 -0.1347 -1.2517 -1.0293 -0.0156 -0.7314 -0.1019 -0.1124 -4.3848 -0.7493 -0.0105 -1.6056 -0.0966
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs ; clinical
H-2015	-1.0705065727233887	▁interne ▁; ▁external ▁valid ity ▁; ▁kosten
D-2015	-1.0705065727233887	interne ; external validity ; kosten
P-2015	-2.8978 -0.4636 -0.6898 -0.9334 -0.6804 -0.3922 -2.2428 -1.2559 -0.0786
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
H-1546	-0.14956891536712646	▁cardiac ▁dys function ▁; ▁sub cel lular ▁altera tions ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1546	-0.14956891536712646	cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
P-1546	-0.1107 -0.0654 -0.0446 -0.1237 -0.0059 -0.0126 -0.0107 -0.0699 -0.0658 -0.3515 -0.0097 -0.0940 -0.0094 -0.1046 -0.3939 -0.2132 -0.0593 -0.3011 -0.5454 -0.1221 -0.2867 -0.2272 -0.0343 -0.1359 -0.1857 -0.2973 -0.1580
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv diastolic dysfunction ; filling pressures ; non-invasively ; doppler echocardiography
H-28	-0.21837079524993896	▁dia sto lic ▁dys function ▁; ▁fill ing ▁pressure s ▁; ▁do pp ler ▁e cho card i ography
D-28	-0.21837079524993896	diastolic dysfunction ; filling pressures ; doppler echocardiography
P-28	-0.1621 -0.0992 -0.0283 -0.0239 -0.0280 -0.0963 -0.0428 -0.0623 -0.3448 -0.1803 -0.5678 -0.8188 -0.0079 -0.8177 -0.0632 -0.0643 -0.1648 -0.4854 -0.1831 -0.2177 -0.1270
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac magnetic resonance postcontrast t1 time ; outcome ; patients ; heart failure ; preserved ejection fraction
H-733	-0.2727404534816742	▁Card iac ▁magnetic ▁res on ance ▁post contra st ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-733	-0.2727404534816742	Cardiac magnetic resonance postcontrast ; heart failure ; preserved ejection fraction
P-733	-0.3442 -0.0307 -0.0429 -0.2021 -0.1621 -0.2839 -0.2349 -0.0174 -0.0288 -0.2636 -3.1583 -0.1103 -0.2413 -0.0196 -0.0247 -0.3054 -0.0218 -0.0908 -0.0445 -0.3676 -0.0112 -0.1837 -0.0833
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial collagen ; collagen cross-linking ; titin ; isoforms ; phosphorylation
H-764	-0.16458234190940857	▁My o card ial ▁collage n ▁; ▁collage n ▁cross - link ing ▁; ▁titi n ▁iso form s ▁; ▁ phos phor y lation
D-764	-0.16458234190940857	Myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
P-764	-0.5089 -0.0567 -0.1613 -0.2025 -0.0409 -0.2193 -0.2360 -0.0280 -0.0634 -0.5023 -0.0171 -0.0057 -0.0349 -0.2277 -0.0117 -0.0396 -0.0059 -0.0605 -0.1269 -0.4187 -0.0631 -0.0189 -0.6305 -0.4430 -0.1059 -0.1218 -0.0927
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker ; uptitration ; clinical ; outcome ; patients ; hfref ; hfpef
H-185	-0.44355323910713196	RAS - block er ▁up tit ration ▁; ▁clinic al ▁outcome ▁; ▁h Fr EF ▁; ▁ HF p EF
D-185	-0.44355323910713196	RAS-blocker uptitration ; clinical outcome ; hFrEF ; HFpEF
P-185	-0.3883 -0.0524 -0.1735 -0.1365 -2.0212 -0.1294 -0.1639 -0.3733 -1.2218 -0.0208 -0.1351 -0.2061 -2.1282 -0.2343 -0.2837 -0.2278 -0.8866 -0.3796 -0.1207 -0.2156 -0.1655 -0.0939
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin ; exercise ; training ; health ; patients ; chronic heart failure ; hf-action ; randomized
H-833	-0.5201738476753235	▁Hem o glob in ▁; ▁exercise ▁training ▁; ▁health ▁status ▁; ▁chronic ▁heart ▁failure ▁; ▁ HF - ac TION
D-833	-0.5201738476753235	Hemoglobin ; exercise training ; health status ; chronic heart failure ; HF-acTION
P-833	-0.3836 -0.1273 -0.0510 -0.5775 -0.2142 -1.1269 -0.7633 -0.1514 -1.4299 -0.0459 -0.2062 -1.9911 -0.4024 -0.3382 -0.9203 -0.3318 -0.1018 -0.0257 -0.6379 -1.0368 -0.4730 -0.1077
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
H-88	-0.4924357533454895	▁systems ▁prote o mics ▁; ▁cardiac ▁chr omat in ▁; ▁nucleo lin ▁; ▁cel lular ▁plastic ity ▁; ▁cardio my o cy tes
D-88	-0.4924357533454895	systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
P-88	-1.8407 -0.7201 -0.6286 -0.0018 -0.2552 -0.0390 -0.0507 -0.0165 -0.7254 -0.1591 -0.2281 -1.3778 -0.1963 -4.2110 -0.0195 -0.0302 -0.4501 -0.3292 -0.0128 -0.3081 -0.2756 -0.0209 -0.1019 -0.2047 -0.1077
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma ; collected ; hf ; patients
H-1514	-0.4050105810165405	▁Plas ma ▁sample s ▁; ▁ HF ▁patients
D-1514	-0.4050105810165405	Plasma samples ; HF patients
P-1514	-0.2010 -1.1020 -0.2334 -0.0895 -0.3720 -0.3834 -0.1128 -0.5504 -0.9355 -0.0700
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes ; hypertrophic
H-1217	-0.3556840121746063	▁p de 2- over express ing ▁cardio my o cy tes ▁; ▁no re pine ph rine - indu ced ▁hyper trop hic
D-1217	-0.3556840121746063	pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic
P-1217	-1.3596 -0.2563 -0.0139 -0.0287 -0.0407 -0.0217 -0.5892 -0.4124 -0.2856 -0.0847 -0.1143 -0.4943 -0.0170 -0.1000 -0.0242 -0.7382 -0.0526 -0.0986 -0.0144 -0.1255 -0.0669 -0.0059 -0.2123 -3.5601 -0.1752
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported ; heart failure ; clcnka ; snp
H-1804	-0.9738396406173706	▁heart ▁failure ▁; ▁CL cn ka ▁s NP
D-1804	-0.9738396406173706	heart failure ; CLcnka sNP
P-1804	-5.9124 -0.3016 -0.1948 -0.1257 -1.2923 -1.0576 -0.3703 -0.0850 -0.3011 -0.0976
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt ; gdmt ; bat
H-1871	-0.37863945960998535	▁GD MT ▁; control ▁group ▁; ▁GD MT ▁; ▁BAT ▁; tre at ment ▁group
D-1871	-0.37863945960998535	GDMT ;control group ; GDMT ; BAT ;treatment group
P-1871	-0.3064 -0.3501 -0.6594 -0.6771 -0.3759 -0.2181 -0.4355 -0.5532 -0.3153 -0.0757 -1.2431 -0.0063 -0.0109 -0.0668 -0.9236 -0.1561 -0.0633
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline ; patients ; resting hr ; bpm
H-1940	-1.0269219875335693	
D-1940	-1.0269219875335693	
P-1940	-1.9894 -0.0644
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction pathways ; engage ; signalling proteins
H-993	-0.7322649955749512	▁trans duction ▁; ▁signal ling ▁protein s
D-993	-0.7322649955749512	transduction ; signalling proteins
P-993	-0.1411 -0.5322 -3.1342 -1.7602 -0.1563 -0.5604 -0.0866 -0.1422 -0.0773
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate ; alendronate ; heart failure
H-1545	-0.8192399740219116	▁ale ndr onate ▁; ▁risk ▁; ▁ale ndr onate ▁; ▁heart ▁failure
D-1545	-0.8192399740219116	alendronate ; risk ; alendronate ; heart failure
P-1545	-0.5643 -0.0447 -0.2103 -0.1812 -4.5724 -0.3019 -1.3200 -0.0650 -0.3781 -0.3277 -2.8169 -0.4691 -0.1253 -0.0924
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients ; cardiovascular disease ; drs
H-1838	-0.34612077474594116	▁cardiovascular ▁disease ▁; ▁d RS ▁deci les
D-1838	-0.34612077474594116	cardiovascular disease ; dRS deciles
P-1838	-0.8020 -0.2401 -0.9812 -0.1792 -0.1403 -0.3592 -0.2400 -0.0886 -0.0843
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician ; patient ; admission ; admission
H-1417	-0.7953231930732727	▁index ▁ad mission
D-1417	-0.7953231930732727	index admission
P-1417	-2.0676 -0.0400 -0.6059 -1.0705 -0.1925
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy ; patients ; follow-up
H-861	-0.14204712212085724	▁in appropria te ▁ therapy
D-861	-0.14204712212085724	inappropriate therapy
P-861	-0.3338 -0.0234 -0.0665 -0.1343 -0.0345 -0.3041 -0.0978
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients ; beta-blocker ; therapy
H-1939	-0.6319165825843811	▁beta - block er ▁ therapy
D-1939	-0.6319165825843811	beta-blocker therapy
P-1939	-3.8703 -0.0287 -0.1306 -0.0491 -0.5316 -0.0301 -0.1593 -0.2554
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart failure ; patients ; bisphosphonates
H-1535	-0.7137913703918457	▁heart ▁failure ▁; ▁bis phos phon ates
D-1535	-0.7137913703918457	heart failure ; bisphosphonates
P-1535	-4.5693 -0.1508 -0.2226 -0.4603 -0.0307 -0.1802 -0.3837 -0.2712 -0.1552
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty ; heart failure ; hf
H-622	-0.23252756893634796	▁fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; HF
D-622	-0.23252756893634796	frailty ; risk ; heart failure ;HF
P-622	-0.1030 -0.2098 -0.1345 -0.0611 -0.2425 -0.4921 -0.4560 -0.0864 -0.2341 -0.1007 -0.5742 -0.0959
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas ; cardiac remodeling ; heart failure
H-1483	-0.23471835255622864	▁mi RNA s ▁; ▁cardiac ▁remodel ing ▁; ▁heart ▁failure
D-1483	-0.23471835255622864	miRNAs ; cardiac remodeling ; heart failure
P-1483	-0.9028 -0.0057 -0.0636 -0.1132 -0.1295 -0.0238 -0.0278 -0.1342 -0.3482 -0.2367 -0.7518 -0.0793
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis ; medical ; hf
H-200	-0.653399646282196	▁ diagnos is ▁; ▁early ▁medical ▁management ▁; ▁ HF
D-200	-0.653399646282196	diagnosis ; early medical management ; HF
P-200	-2.9688 -1.0186 -0.0448 -0.0805 -0.1677 -0.1295 -0.0878 -0.1785 -1.4298 -0.0664 -1.5692 -0.0992
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical ; diastolic dysfunction ; mortality
H-25	-0.3960072100162506	▁dia sto lic ▁dys function ▁; ▁cause ▁mortal ity
D-25	-0.3960072100162506	diastolic dysfunction ; cause mortality
P-25	-1.0096 -0.0607 -0.1125 -0.0662 -0.0677 -0.7903 -1.4277 -0.0213 -0.6590 -0.0656 -0.0755
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa ; immunoassays ; nt-probnp
H-1516	-0.49643298983573914	▁Alpha LIS a ▁; ▁immun o assa ys ▁; ▁NT - pro b NP
D-1516	-0.49643298983573914	AlphaLISa ; immunoassays ; NT-probNP
P-1516	-3.2212 -0.1802 -0.5394 -1.1727 -0.0052 -0.1103 -0.0361 -0.4887 -1.0963 -0.1586 -0.0134 -0.0079 -0.6572 -0.0580 -0.1164 -0.0814
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic adult fontan ; saf ; patients ; catheterization
H-226	-0.5889270901679993	▁symptom a tic ▁adult ▁Font an ▁; SAF
D-226	-0.5889270901679993	symptomatic adult Fontan ;SAF
P-226	-2.5516 -0.1090 -0.2441 -0.4399 -0.1647 -0.1823 -0.4512 -0.0341 -1.6117 -0.1007
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death ; c-statistics ; biological phenotype ; deficit index
H-1011	-0.441603422164917	▁c - stat istic s ▁; ▁bi ological ▁ph eno type ▁; ▁deficit ▁index
D-1011	-0.441603422164917	c-statistics ; biological phenotype ; deficit index
P-1011	-4.8322 -0.1474 -0.0016 -0.0207 -0.0340 -0.4287 -0.3156 -0.1821 -0.3640 -0.0818 -0.0026 -0.1928 -0.0614 -0.0290 -0.2103 -0.1615
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients ; sinus rhythm ; antiplatelet agents ; anticoagulants
H-1354	-0.12852104008197784	▁sinus ▁ rhythm ▁; ▁anti plate let ▁agents ▁; ▁antico a gul ants
D-1354	-0.12852104008197784	sinus rhythm ; antiplatelet agents ; anticoagulants
P-1354	-0.1667 -0.1566 -0.0664 -0.2942 -0.0291 -0.0482 -0.1681 -0.1729 -0.1348 -0.0147 -0.1186 -0.1679 -0.0748 -0.2191 -0.0956
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported ; patient ; implantable cardioverter-defibrillator
H-1858	-0.311794638633728	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1858	-0.311794638633728	implantable cardioverter-defibrillator deactivation
P-1858	-2.8418 -0.0298 -0.3326 -0.0180 -0.1043 -0.0315 -0.0931 -0.0662 -0.2443 -0.0558 -0.0493 -0.1689 -0.0445 -0.4298 -0.3759 -0.1028
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients ; heart failure ; left ventricular ; ejection fraction
H-22	-0.4351919889450073	▁heart ▁failure ▁; ▁pres er ved ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-22	-0.4351919889450073	heart failure ; preserved left ventricular ;LV ; ejection fraction
P-22	-4.9361 -0.1248 -0.1315 -0.5122 -0.0250 -0.2740 -0.1834 -0.0683 -0.5581 -0.0621 -0.1556 -0.0656 -0.9050 -0.0107 -0.0333 -0.0176 -0.2762 -0.0029 -0.2181 -0.1432
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity ; doxorubicin ; anti-neoplastic agent
H-955	-0.22071799635887146	▁cardio toxic ity ▁; ▁do xor ubi cin ▁; ▁anti - neo plast ic ▁agent ▁; ▁cancer s
D-955	-0.22071799635887146	cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
P-955	-0.0767 -0.2610 -1.5334 -0.1392 -0.0487 -0.0039 -0.0116 -0.1914 -0.2363 -0.0276 -0.0693 -0.0192 -0.1070 -0.1013 -0.1015 -0.5027 -0.2610 -0.4476 -0.1841 -0.0910
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs ; patients ; oht ; transplant ; vad
H-1288	-0.39251890778541565	▁a CS ▁; ▁o HT ▁ bridge d ▁to ▁transplant ▁; ▁MT ▁; ▁ VAD
D-1288	-0.39251890778541565	aCS ; oHT bridged to transplant ; MT ; VAD
P-1288	-0.2408 -2.3710 -0.7357 -0.2565 -0.4248 -0.8808 -0.0001 -0.0159 -0.0528 -0.0032 -0.8337 -0.1919 -0.3011 -0.1828 -0.0060 -0.0913 -0.0845
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic peptides ; point of care ; ambulatory
H-1019	-0.48659709095954895	▁na tri ure tic ▁pe pti des ▁; ▁emergency ▁; ▁ambula tory
D-1019	-0.48659709095954895	natriuretic peptides ; emergency ; ambulatory
P-1019	-0.0203 -0.1963 -0.4178 -1.2606 -0.7315 -0.0781 -0.1265 -0.5984 -1.9221 -0.4905 -0.0040 -0.0353 -0.8483 -0.0827
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients ; β-blocker ; patients ; uptitration
H-179	-0.6117122769355774	▁ RAS - ▁; ▁β - block er ▁dose
D-179	-0.6117122769355774	RAS- ; β-blocker dose
P-179	-0.5859 -0.0042 -0.0414 -2.4621 -0.0987 -0.0794 -0.1535 -0.0795 -0.2070 -2.8881 -0.1292
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac angiogenesis ; therapy ; cardiac function ; remodeling
H-460	-0.3380577266216278	▁β - Block er - indu ced ▁enhance ment ▁; ▁cardiac ▁ang io gene sis ▁; ▁cardiac ▁function ▁; ▁remodel ing
D-460	-0.3380577266216278	β-Blocker-induced enhancement ; cardiac angiogenesis ; cardiac function ; remodeling
P-460	-0.1069 -0.0329 -0.2053 -0.0441 -0.0405 -0.0084 -0.2618 -0.2072 -0.1160 -0.5186 -0.0150 -0.7028 -0.4999 -0.2056 -0.2095 -0.3863 -2.0962 -0.2651 -1.5507 -0.0090 -0.0359 -0.1742 -0.0835
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf ; patients ; rheumatoid arthritis ; ra
H-602	-0.4534894824028015	▁ HF ▁; ▁rhe um ato id ▁ar thri tis ▁; RA
D-602	-0.4534894824028015	HF ; rheumatoid arthritis ;RA
P-602	-1.8568 -0.2090 -0.2504 -2.7128 -0.0153 -0.1053 -0.1030 -0.0060 -0.0505 -0.1161 -0.4420 -0.0963 -0.2755 -0.1099
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression ; bax ; bcl-2 ; proteins ; pacing
H-170	-0.32616105675697327	▁Bax ▁; ▁b cl -2 ▁protein s
D-170	-0.32616105675697327	Bax ; bcl-2 proteins
P-170	-0.0670 -0.1002 -0.2767 -0.0607 -0.2079 -0.1177 -0.0940 -1.9124 -0.0988
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal ; hospital ; hf ; patients ; cms ; conditions
H-139	-0.6695381999015808	▁hospital ▁rates ▁; ▁ HF ▁patients ▁; ▁CMS
D-139	-0.6695381999015808	hospital rates ; HF patients ; CMS
P-139	-3.8504 -0.1937 -0.1631 -0.4041 -0.0271 -0.2997 -0.1165 -0.0054 -1.5044 -0.1309
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation ; anti-inflammatory ; chf
H-1362	-0.39705875515937805	▁regula tion ▁; ▁feed ing ▁; ▁nutrition al ▁strategie s ▁; ▁anti - in flam ma tory ▁effects ▁; ▁CHF
D-1362	-0.39705875515937805	regulation ; feeding ; nutritional strategies ; anti-inflammatory effects ; CHF
P-1362	-0.9202 -0.1888 -1.3984 -0.0681 -0.0711 -0.1597 -0.3118 -0.0286 -0.3135 -0.0729 -0.2532 -0.0348 -0.0836 -0.4892 -0.0225 -2.6206 -0.3646 -0.6675 -0.2070 -0.2406 -0.1430 -0.0755
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs ; hf with reduced ejection fraction ; hfref
H-1077	-0.5526166558265686	▁drugs ▁; HF ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF
D-1077	-0.5526166558265686	drugs ;HF ; reduced ejection fraction ;HFrEF
P-1077	-3.8349 -0.1411 -1.4414 -0.4252 -2.2419 -0.0146 -0.0075 -0.0489 -0.0099 -0.1973 -0.0026 -0.1457 -0.4127 -0.0348 -0.1319 -0.2352 -0.0689
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia ; acute kidney injury ; spironolactone ; clinical
H-444	-0.38941025733947754	▁Cru de ▁rates ▁; ▁severe ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury ▁; ▁spi rono lac tone
D-444	-0.38941025733947754	Crude rates ; severe hyperkalemia ; acute kidney injury ; spironolactone
P-444	-3.8600 -0.0326 -0.1803 -0.4907 -0.9205 -0.2230 -0.0878 -0.0158 -0.0990 -0.0918 -0.0066 -0.0284 -0.6521 -0.0317 -0.1042 -0.3229 -0.0034 -0.0094 -0.0273 -0.0174 -1.2707 -0.0914
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal denervation ; dnx ; chf ; patients ; symptomatic
H-1371	-0.3423490822315216	▁Ren al ▁den er va tion ▁; DN x ▁; ▁CHF ▁patients
D-1371	-0.3423490822315216	Renal denervation ;DNx ; CHF patients
P-1371	-0.5628 -0.0561 -0.2295 -0.5769 -0.3225 -0.4582 -0.1889 -0.3404 -0.2935 -0.1533 -0.0203 -0.8795 -0.6248 -0.0861
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence ; vad ; acs ; consultations ; operations ; mortality ; morbidity
H-1289	-0.48967984318733215	▁MT ▁; ▁ VAD ▁groups ▁; ▁a CS
D-1289	-0.48967984318733215	MT ; VAD groups ; aCS
P-1289	-0.0976 -0.1449 -0.0649 -0.0161 -0.1766 -0.2162 -0.3009 -1.9013 -1.8757 -0.1027
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
H-893	-0.26781758666038513	▁re frac tory ▁con ges tive ▁heart ▁failure ▁; ▁per ito ne al ▁di al ysis
D-893	-0.26781758666038513	refractory congestive heart failure ; peritoneal dialysis
P-893	-0.6856 -0.0132 -0.3884 -0.0534 -0.2763 -1.0800 -0.8266 -0.0766 -0.5360 -0.0482 -0.2478 -0.1127 -0.0213 -0.2064 -0.0317 -0.0229 -0.0999 -0.0938
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ; hf
H-1810	-0.26872971653938293	▁Mamma lian ▁enabled ▁; ▁men a ▁; ▁cy tos kelet al ▁act in ▁dynamic s ▁; ▁heart ▁failure ▁; HF
D-1810	-0.26872971653938293	Mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ;HF
P-1810	-0.2222 -0.0453 -0.0287 -0.1219 -1.0184 -0.0369 -0.1623 -2.0857 -0.2509 -0.2683 -0.0151 -0.0641 -0.5587 -0.0425 -0.0484 -0.1198 -0.1965 -0.1439 -0.2690 -0.0304 -0.1111 -0.0719
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients ; heart failure ; elevated ; left atrial pressure ; symptoms ; hospital ; admission
H-1949	-0.9197996854782104	▁heart ▁failure ▁; ▁eleva ted ▁left ▁at rial ▁pressure
D-1949	-0.9197996854782104	heart failure ; elevated left atrial pressure
P-1949	-1.8519 -0.1090 -0.2492 -3.8044 -0.0814 -0.2686 -1.5115 -0.3613 -0.2219 -1.5709 -0.0876
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart failure with preserved ejection fraction ; hfpef ; cardiovascular reserve
H-916	-0.3008559048175812	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF ▁; ▁cardiovascular ▁reserve
D-916	-0.3008559048175812	Heart failure ; preserved ejection fraction ; hFPEF ; cardiovascular reserve
P-916	-0.8127 -0.0985 -0.5502 -0.0160 -0.0392 -0.2438 -0.0206 -0.0933 -0.0170 -0.3121 -0.0027 -0.1425 -0.6184 -1.0053 -0.4927 -0.2167 -1.1346 -0.0082 -0.1183 -0.0743
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv diastolic dysfunction ; combination ; figure ; hfpef
H-24	-0.4976680278778076	▁dia sto lic ▁dys function ▁; ▁H FP EF
D-24	-0.4976680278778076	diastolic dysfunction ; HFPEF
P-24	-0.3527 -0.0489 -0.0391 -0.0191 -0.0519 -0.2238 -3.6894 -0.4600 -0.4046 -0.0950 -0.0898
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician ; follow-up ; discharge ; physician ; outcomes ; patients ; heart failure
H-1421	-0.4762757122516632	▁physician ▁follow - up ▁; ▁dis charge ▁; ▁physician ▁continu ity ▁; ▁heart ▁failure
D-1421	-0.4762757122516632	physician follow-up ; discharge ; physician continuity ; heart failure
P-1421	-0.8670 -0.2121 -0.0863 -0.0089 -1.2684 -0.5327 -0.0698 -0.2130 -0.0114 -0.0730 -0.1765 -0.5754 -3.0577 -0.2342 -0.1271 -0.1070
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory ; icd ; patients ; mortality ; multivariable regression
H-63	-0.2890961468219757	▁ambula tory ▁i CD ▁patients ▁; ▁predict or ▁; ▁mortal ity ▁; ▁multi vari able ▁re gression
D-63	-0.2890961468219757	ambulatory iCD patients ; predictor ; mortality ; multivariable regression
P-63	-0.2394 -0.0694 -0.5679 -0.6207 -0.2438 -0.2861 -0.4248 -0.0300 -0.4724 -0.0148 -0.5371 -1.5256 -0.0103 -0.0342 -0.1570 -0.0112 -0.0033 -0.1003 -0.1445
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni inhibitors ; angiotensin-receptor neprilysin inhibitors
H-1966	-0.31802302598953247	▁AR NI ▁inhibi tors ▁; angi oten sin - recept or ▁nepri ly sin ▁inhibi tors
D-1966	-0.31802302598953247	ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
P-1966	-1.4522 -0.5647 -0.0477 -0.0780 -0.1809 -0.0049 -0.1320 -1.1743 -0.2231 -0.0077 -0.0257 -0.3912 -0.4467 -0.2648 -0.0932 -0.1643 -0.3481 -0.1252
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal bleeding ; reported ; patients ; ventricular assist devices
H-1659	-0.3331931531429291	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices
D-1659	-0.3331931531429291	Gastrointestinal bleeding ; ventricular assist devices
P-1659	-0.3892 -0.5869 -0.8454 -0.0580 -0.1390 -0.6562 -0.2394 -0.2775 -0.1365 -0.5063 -0.1075 -0.6199 -0.1662 -0.1763 -0.0936
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil ; cytotoxic ; doxorubicin ; ehrlich carcinoma
H-966	-0.19281300902366638	▁nic oran dil ▁; ▁cy to toxic ▁effect ▁; ▁do xor ubi cin ▁; ▁eh r lich ▁car cino ma
D-966	-0.19281300902366638	nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
P-966	-0.0385 -0.0218 -0.0988 -0.1381 -0.3899 -0.0363 -0.0207 -0.0333 -0.1895 -0.0618 -0.0058 -0.0063 -0.1735 -1.1188 -0.8622 -0.0130 -0.0154 -0.0064 -0.0427 -0.6075 -0.2625 -0.0991
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas ; cardiac ; benign tumors ; left atrium ; right atrium
H-593	-0.3450683653354645	▁My xo mas ▁; ▁cardiac ▁benign ▁tumor s ▁; ▁left ▁at rium
D-593	-0.3450683653354645	Myxomas ; cardiac benign tumors ; left atrium
P-593	-1.2392 -0.0058 -0.1271 -0.1890 -0.1076 -0.0160 -0.0318 -0.1343 -0.9401 -0.1500 -0.5574 -0.0009 -1.2329 -0.0990
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes ; patients ; preserved ejection fraction ; hfpef
H-1328	-0.26097655296325684	▁f es ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1328	-0.26097655296325684	fes ; preserved ejection fraction ;HFpEF
P-1328	-1.1204 -0.6843 -0.1564 -0.8685 -0.0495 -0.2615 -0.0326 -0.0960 -0.0406 -0.2236 -0.0062 -0.2689 -0.1837 -0.0273 -0.1402 -0.1848 -0.0920
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic ; bnp ; nt-probnp ; patients ; coronary artery disease ; cad
H-1366	-0.32740020751953125	▁b NP ▁; ▁NT - pro b NP ▁; ▁corona ry ▁arter y ▁disease ▁; CAD
D-1366	-0.32740020751953125	bNP ; NT-probNP ; coronary artery disease ;CAD
P-1366	-1.5139 -0.7550 -0.0672 -0.1048 -0.0219 -0.0047 -0.6092 -0.1992 -0.1423 -0.1614 -1.1433 -0.0486 -0.3547 -0.2676 -0.2225 -0.0325 -0.1451 -0.0995
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant ; exercise
H-1883	-0.5975023508071899	▁control ▁group ▁; ▁exercise ▁group
D-1883	-0.5975023508071899	control group ; exercise group
P-1883	-2.0392 -0.4935 -0.6813 -0.1596 -0.5780 -0.1525 -0.0784
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.2519797682762146	▁circula ting ▁form s ▁; ▁NT - pro b NP
D-1512	-0.2519797682762146	circulating forms ; NT-probNP
P-1512	-0.0487 -0.0687 -0.2427 -0.0638 -0.2940 -0.1035 -0.0246 -0.0108 -0.6788 -0.1356 -1.2493 -0.1032
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ; ecct
H-713	-0.907792329788208	▁ec CT
D-713	-0.907792329788208	ecCT
P-713	-2.4961 -0.8561 -0.1597 -0.1192
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.22659464180469513	▁aero bic ▁capacity ▁; ▁left - hand ▁grip ▁; ▁body ▁weight ▁; ▁wa ist ▁circum ferenc e ▁; ▁anxiety
D-573	-0.22659464180469513	aerobic capacity ; left-hand grip ; body weight ; waist circumference ; anxiety
P-573	-0.1741 -0.0781 -0.1984 -0.1217 -0.0578 -0.0385 -0.0278 -0.2651 -1.8854 -0.6486 -0.1531 -0.1689 -0.0024 -0.0719 -0.0024 -0.0093 -0.0458 -0.3593 -0.2747 -0.0813 -0.0939
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-1.4765541553497314	▁Process ▁re design
D-1851	-1.4765541553497314	Process redesign
P-1851	-1.6002 -1.7165 -0.2474 -3.7388 -0.0798
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial ; irs1 ; irs2 ; heart failure ; p38alpha ; mapk ; insulin resistance
H-651	-0.26801037788391113	▁My o card ial ▁loss ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁failure ▁; ▁p 38 al pha ▁MA PK ▁; ▁insulin ▁resist ance
D-651	-0.26801037788391113	Myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
P-651	-0.9051 -0.0885 -0.3322 -0.1608 -0.1144 -0.2043 -0.7776 -0.0990 -1.3903 -0.1390 -0.3820 -0.2547 -0.1351 -0.2695 -0.5013 -0.1000 -0.1743 -0.3717 -0.2233 -0.0188 -0.0004 -0.2172 -0.0292 -0.3641 -0.0085 -0.0940 -0.0238 -0.2267 -0.1664
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart failure ; hypertensive heart disease ; angiotensin ii ; infusion ; nephrectomy ; salt loading
H-273	-0.33040571212768555	▁heart ▁failure ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁ang io ten sin ▁II ▁in fusion ▁; ▁nep hr ecto my ▁; ▁salt ▁load ing
D-273	-0.33040571212768555	heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
P-273	-1.1235 -0.0577 -1.8999 -0.5297 -0.1167 -0.0322 -1.2545 -0.4388 -0.1259 -0.0838 -0.1201 -0.0220 -0.2667 -0.5764 -0.0032 -0.0042 -0.1533 -0.0062 -0.4356 -0.1013 -0.6684 -0.3893 -0.0021 -0.0159 -0.0251 -0.3284 -0.1403
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-337	-0.15179143846035004	▁Fun ction al ▁mit ral ▁sten osis ▁; MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation ▁; MR
D-337	-0.15179143846035004	Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
P-337	-0.2980 -0.0239 -0.0092 -0.7855 -0.0367 -0.0132 -0.0317 -0.1761 -0.4878 -0.1952 -0.0457 -0.1480 -0.0421 -0.0245 -0.0729 -0.1961 -0.0970 -0.0203 -0.0858 -0.2568 -0.1009 -0.0123 -0.0997 -0.0677 -0.0318 -0.7581 -0.0101 -0.2009 -0.0738
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened ; lvet ; icu ; admission ; prognostic ; patients ; precapillary ph ; heart failure
H-590	-0.4088614881038666	▁Short en ed ▁l VET ▁; ▁ ICU ▁ad mission ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-590	-0.4088614881038666	Shortened lVET ; ICU admission ; precapillary PH ; heart failure
P-590	-2.7309 -0.0283 -0.0912 -0.8578 -0.0496 -0.1202 -0.8138 -0.0103 -0.0746 -0.2493 -0.1501 -1.3684 -0.1202 -0.0508 -0.1993 -0.1333 -0.4354 -0.7068 -0.1071 -0.1606 -0.1283
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart ; hospitalization ; death ; patients ; preserved left ventricular ejection fraction
H-235	-0.6407749056816101	▁heart ▁failure - related ▁hospital ization ▁; ▁death ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-235	-0.6407749056816101	heart failure-related hospitalization ; death ; left ventricular ejection fraction
P-235	-4.3606 -0.4806 -0.2552 -0.0723 -0.2758 -0.4570 -0.3039 -0.6192 -0.3611 -2.0070 -0.1280 -0.9677 -0.3871 -0.1573 -0.2051 -0.1102 -1.1159 -0.0167 -0.2919 -0.2429
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart failure with preserved ejection fraction ; hfpef ; cardiovascular morbidity ; mortality
H-236	-0.2516036629676819	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁cardiovascular ▁morbi d ity ▁; ▁mortal ity
D-236	-0.2516036629676819	Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity ; mortality
P-236	-0.4567 -0.0525 -1.0315 -0.0272 -0.0604 -0.4208 -0.0300 -0.1276 -0.0195 -0.3542 -0.0047 -0.1574 -0.0716 -0.0237 -0.2733 -0.4167 -0.0488 -0.0565 -0.0414 -0.7227 -1.1082 -0.0053 -0.6341 -0.0679 -0.0774
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue doppler ; left ventricular filling pressure ; patients ; stable ; severe systolic heart failure
H-479	-0.4532047212123871	▁tissu e ▁; ▁do pp ler ▁imagin g ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁; ▁sy sto lic ▁heart ▁failure
D-479	-0.4532047212123871	tissue ; doppler imaging ; left ventricular filling pressure ; systolic heart failure
P-479	-0.3683 -0.0664 -1.1582 -0.6258 -0.0090 -1.2931 -0.1534 -0.0577 -0.1659 -0.6043 -0.0685 -0.9881 -0.2031 -1.4287 -0.1059 -1.2988 -0.2748 -0.7116 -0.0488 -0.0621 -0.6038 -0.1939 -0.2713 -0.1152
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 ; hypertensive ; obese ; zsf1 ; hypertensive ; diabetic
H-766	-0.36793503165245056	▁lean ▁; ▁z SF 1 ▁group ▁; ▁hyper tensi ve ▁; ▁obes e ▁; ▁z SF 1 ▁groups ▁; ▁hyper tensi ve ▁; ▁diabet ic
D-766	-0.36793503165245056	lean ; zSF1 group ; hypertensive ; obese ; zSF1 groups ; hypertensive ; diabetic
P-766	-0.0682 -1.5437 -0.3260 -0.1933 -1.1704 -1.2814 -0.1710 -0.0708 -0.0316 -0.0310 -0.1755 -0.1464 -0.0395 -1.3257 -0.6576 -0.1296 -0.8286 -0.6871 -0.4340 -0.0696 -0.0804 -0.0406 -0.1746 -0.0238 -0.0863 -0.0875 -0.0600
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence ; heart failure with preserved ejection fraction ; hfpef ; prognosis
H-23	-0.30374521017074585	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF
D-23	-0.30374521017074585	heart failure ; preserved ejection fraction ; hFPEF
P-23	-1.0489 -0.0619 -0.5087 -0.0245 -0.0378 -0.3014 -0.0301 -0.0849 -0.0184 -0.2727 -0.0055 -0.1656 -0.7115 -1.0503 -0.3514 -0.4175 -0.0725
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas city cardiomyopathy questionnaire ; patients ; heart failure ; reduced ejection fraction
H-779	-0.28565436601638794	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁heart ▁failure ▁; ▁pres er ved ▁; ▁e je ction ▁ fraction
D-779	-0.28565436601638794	Kansas City Cardiomyopathy Questionnaire ; heart failure ; preserved ; ejection fraction
P-779	-0.3664 -0.4243 -0.7976 -0.0284 -0.0307 -1.2228 -0.0829 -0.2828 -0.0027 -0.1621 -1.2647 -0.0276 -0.4282 -0.3748 -0.0238 -0.1103 -0.4038 -0.1212 -0.0551 -0.0193 -0.3479 -0.0062 -0.1415 -0.1308
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial ; pde2 ; intracellular ; antiadrenergic ; therapeutic ; hf
H-1220	-0.40124523639678955	▁activa ting ▁my o card ial ▁p de 2 ▁; ▁intra cel lular ▁anti ad r energi c ▁ therapeut ic ▁strategy ▁; ▁ HF
D-1220	-0.40124523639678955	activating myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ; HF
P-1220	-0.8006 -0.0947 -0.7772 -0.1059 -0.0992 -0.1387 -1.8719 -0.5849 -0.0810 -0.1695 -0.4449 -0.0206 -0.0084 -0.0257 -0.1377 -0.1368 -0.1747 -0.1004 -0.7338 -0.2852 -0.6329 -1.0047 -0.4283 -1.4123 -0.2896 -0.1306 -0.1434
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone ; clinical ; medications
H-447	-0.6087305545806885	▁voordelen ▁; ▁spi rono lac tone
D-447	-0.6087305545806885	voordelen ; spironolactone
P-447	-1.8291 -0.3244 -0.0443 -0.0186 -0.0480 -0.0412 -2.4528 -0.1114
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up ; hf ; hospitalization
H-690	-0.6789535880088806	▁ HF ▁hospital ization
D-690	-0.6789535880088806	HF hospitalization
P-690	-1.0280 -0.1437 -1.7230 -0.5214 -0.5610 -0.0967
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart failure ; hf ; death ; crt-d
H-105	-0.6621962189674377	▁IE ▁; ▁heart ▁failure ▁; HF ▁; ▁c RT - d ▁recipient s
D-105	-0.6621962189674377	IE ; heart failure ;HF ; cRT-d recipients
P-105	-3.4634 -0.2016 -1.0615 -0.0480 -0.1522 -0.0881 -0.2051 -2.0522 -0.8131 -0.0357 -0.5265 -0.8603 -0.0912 -0.1853 -0.1488
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic ; clinical ; pharmacologic
H-1470	-0.5963578224182129	▁ pharma c ologic ▁treatment ▁; ▁ pharma c ologic
D-1470	-0.5963578224182129	pharmacologic treatment ; pharmacologic
P-1470	-0.1685 -0.4626 -0.0761 -0.0461 -1.1101 -0.5617 -1.9745 -0.3148 -0.0918 -0.0798 -2.1517 -0.1185
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients ; narrow qrs complex ; crt ; patients
H-846	-0.3859637677669525	▁Mechanic al ▁dys syn chron y ▁; ▁QR s ▁complex ▁; ▁c RT
D-846	-0.3859637677669525	Mechanical dyssynchrony ; QRs complex ; cRT
P-846	-0.2083 -0.0039 -0.0515 -0.0168 -0.0027 -0.2350 -0.1767 -0.9046 -1.9243 -0.0684 -0.1982 -0.3241 -1.3310 -0.2439 -0.1001
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary occlusion ; collateral growth ; stent
H-510	-0.17134995758533478	▁corona ry ▁oc clusi on ▁; ▁col lateral ▁growth ▁; ▁sten t ▁oc clusi on
D-510	-0.17134995758533478	coronary occlusion ; collateral growth ; stent occlusion
P-510	-0.1288 -0.6487 -0.0030 -0.0289 -0.0980 -0.2645 -0.0168 -0.0012 -0.3792 -0.5245 -0.2665 -0.1416 -0.0102 -0.0203 -0.1617 -0.1488 -0.0702
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid intima-media thickness ; psoriasis
H-1561	-0.3687819242477417	▁caro tid ▁intim a - media ▁; ▁psoriasis
D-1561	-0.3687819242477417	carotid intima-media ; psoriasis
P-1561	-0.4119 -0.1045 -0.2812 -0.0356 -0.0714 -0.0560 -2.3597 -0.1171 -0.1518 -0.0986
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions ; patients ; heart disease
H-48	-0.456633061170578	▁trans fusion s ▁; ▁heart ▁disease
D-48	-0.456633061170578	transfusions ; heart disease
P-48	-0.1597 -0.0565 -0.1707 -0.6199 -1.8586 -0.2979 -0.3656 -0.1240
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination ; exercise ; peak vo2 ; joint
H-1985	-1.4278831481933594	▁exercise ▁; ▁die t
D-1985	-1.4278831481933594	exercise ; diet
P-1985	-3.0998 -0.1640 -0.6117 -0.0534 -4.5505 -0.0878
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf ; pb ; bp
H-1348	-0.5988547801971436	▁PV f ▁; ▁ PB ▁cycle ▁; ▁low ▁BP
D-1348	-0.5988547801971436	PVf ; PB cycle ; low BP
P-1348	-0.1365 -1.3378 -0.1056 -1.2366 -0.2792 -0.6604 -0.2395 -2.3143 -0.1058 -0.0889 -0.0828
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence ; chronic heart failure ; hungary
H-646	-0.8978198766708374	▁chronic ▁heart ▁failure ▁; ▁Hungary
D-646	-0.8978198766708374	chronic heart failure ; Hungary
P-646	-2.5044 -1.7666 -0.2010 -0.4179 -0.3392 -0.9238 -0.1319
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv dysfunction ; cardiac cachexia
H-1168	-0.3442986309528351	▁ rv ▁dys function ▁; ▁cardiac ▁cache xia
D-1168	-0.3442986309528351	rv dysfunction ; cardiac cachexia
P-1168	-1.4265 -0.9878 -0.0271 -0.0220 -0.0499 -0.0094 -0.0771 -0.1385 -0.5852 -0.1196
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote monitoring ; rm ; heart failure
H-148	-0.8125009536743164	▁remote ▁monitoring ▁; RM ▁; ▁heart ▁failure
D-148	-0.8125009536743164	remote monitoring ;RM ; heart failure
P-148	-0.5689 -0.0045 -0.1547 -0.0271 -0.4755 -4.2813 -0.0692 -1.6606 -0.0707
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg ; crt ; clinical
H-881	-0.5042997598648071	▁e CG ▁parameter s ▁; ▁effect ▁; ▁c RT
D-881	-0.5042997598648071	eCG parameters ; effect ; cRT
P-881	-0.9760 -0.1479 -0.5156 -0.0625 -0.0841 -0.9306 -0.5448 -0.3620 -1.5775 -0.2684 -0.0781
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients ; sst2 ; cardiovascular event
H-407	-0.6118177771568298	▁s st 2 ▁; ▁low - dos e ▁BB ▁; ▁cardiovascular ▁event ▁rate
D-407	-0.6118177771568298	sst2 ; low-dose BB ; cardiovascular event rate
P-407	-0.0482 -1.5409 -0.1302 -0.5453 -1.7638 -0.0110 -0.3203 -0.0526 -0.7370 -0.5120 -0.0399 -0.7464 -1.5260 -1.1040 -0.0998
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast cancer ; patients ; chf ; reported ; clinical
H-681	-0.32274213433265686	▁breast ▁cancer ▁patients ▁; ▁tras tuz um b - related ▁CHF
D-681	-0.32274213433265686	breast cancer patients ; trastuzumb-related CHF
P-681	-1.8722 -0.1189 -0.3349 -0.1921 -0.6224 -0.0079 -0.0086 -0.1234 -0.2145 -0.0764 -0.1468 -0.3872 -0.0903
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf ; remodeling ; emd ; dyssynchronous failing heart
H-1150	-0.3164498805999756	▁ HF ▁remodel ing ▁; ▁EM d ▁; ▁dys syn chron ous ▁fail ing ▁heart
D-1150	-0.3164498805999756	HF remodeling ; EMd ; dyssynchronous failing heart
P-1150	-0.3404 -0.1323 -0.0958 -0.0114 -1.3238 -0.9374 -0.7644 -0.1918 -0.0459 -0.0199 -0.0176 -0.4761 -0.0219 -0.0330 -0.6821 -0.1768 -0.1090
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute heart failure ; ahf ; symptoms ; heart failure ; hf
H-1466	-0.41139349341392517	▁a cute ▁heart ▁failure ▁; ▁a HF ▁; ▁heart ▁failure ▁; HF
D-1466	-0.41139349341392517	acute heart failure ; aHF ; heart failure ;HF
P-1466	-0.2964 -0.0045 -0.2767 -0.0330 -0.1043 -0.4460 -0.6556 -0.2098 -2.7815 -0.0880 -0.2575 -0.4323 -0.0862 -0.0876
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis ; post-myocardial infarction ; heart ; heart failure
H-449	-0.5255676507949829	▁ang io gene sis ▁; ▁post - my o card ial ▁in far ction ▁heart ▁; ▁progression ▁to ▁heart ▁failure
D-449	-0.5255676507949829	angiogenesis ; post-myocardial infarction heart ; progression to heart failure
P-449	-3.0017 -1.5507 -0.1520 -0.7175 -0.1592 -0.0733 -0.0273 -0.3110 -0.3038 -0.4842 -0.2250 -0.0475 -0.1725 -0.1845 -1.2212 -0.2406 -1.1652 -0.7658 -0.2436 -0.1336 -0.2644 -0.1178
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical ; clinical ; outcomes ; aldosterone antagonist ; heart failure
H-1734	-0.2612832486629486	▁al do ster one ▁anta gon ist ▁; ▁heart ▁failure
D-1734	-0.2612832486629486	aldosterone antagonist ; heart failure
P-1734	-1.0457 -0.0477 -0.0220 -0.1907 -0.2139 -0.0034 -0.2713 -0.3762 -0.5516 -0.1796 -0.1538 -0.0794
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery ; medical treatment ; hf ; hypertension ; vasodilators ; diuretics
H-355	-0.2822675406932831	▁surgery ▁; ▁aggressiv e ▁medical ▁treatment ▁; HF ▁; ▁hyper tension ▁; ▁vaso dila tors ▁; ▁di ure tics
D-355	-0.2822675406932831	surgery ; aggressive medical treatment ;HF ; hypertension ; vasodilators ; diuretics
P-355	-1.0001 -0.1416 -1.3093 -0.0189 -0.1560 -0.4167 -0.1463 -0.8293 -0.1420 -0.0505 -0.0134 -0.3172 -0.0042 -0.0016 -0.0718 -0.3123 -0.0603 -0.3220 -0.2858 -0.2528 -0.0755
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic ; congestive heart failure ; haematopoietic cell transplantation
H-1448	-0.33901405334472656	▁Gene tic ▁sus cept i bility ▁; ▁an thra cycli ne - related ▁con ges tive ▁heart ▁failure ▁; ▁ha e mato po ie tic ▁cell ▁transplant ation
D-1448	-0.33901405334472656	Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
P-1448	-1.4247 -0.2060 -0.6681 -0.0038 -0.1405 -0.2083 -0.3186 -0.0324 -0.1264 -0.5131 -0.4243 -0.2309 -0.1206 -0.0262 -0.1542 -1.3887 -0.8676 -0.1563 -0.2502 -0.0239 -0.1324 -0.0133 -0.0911 -0.2072 -1.4137 -0.3500 -0.0232 -0.2411 -0.2848 -0.1289
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration ; patients ; hr reduction ; beta-blocker ; therapy
H-1947	-0.43541330099105835	▁aggressiv e ▁dose ▁up tit ration ▁; ▁HR ▁re duction ▁; ▁beta - block er ▁ therapy
D-1947	-0.43541330099105835	aggressive dose uptitration ; HR reduction ; beta-blocker therapy
P-1947	-2.8442 -0.0190 -0.0463 -1.5196 -0.0746 -0.1511 -0.2577 -1.9522 -0.1062 -0.0101 -0.3435 -0.0752 -0.0524 -0.0917 -0.0510 -0.3788 -0.0233 -0.1536 -0.1223
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 ; hearts ; acute ; β-ar
H-1218	-0.3350946009159088	▁p de 2 ▁; ▁fail ing ▁heart s ▁; ▁desen siti zes ▁; ▁a cute ▁β - AR ▁stimul ation
D-1218	-0.3350946009159088	pde2 ; failing hearts ; desensitizes ; acute β-AR stimulation
P-1218	-0.5386 -0.2828 -0.0698 -0.5788 -0.1710 -0.0739 -0.5086 -0.0780 -0.3842 -0.8119 -0.0157 -0.3986 -1.5429 -0.4623 -0.0045 -0.1260 -0.0176 -0.3337 -0.0957 -0.4346 -0.2450 -0.1978
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis ; patients ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
H-1565	-0.6113153100013733	▁psoriasis ▁patients ▁; ▁mild ▁disease ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1565	-0.6113153100013733	psoriasis patients ; mild disease ; atherosclerosis ; cardiovascular events ; psoriasis
P-1565	-0.5595 -2.1359 -0.2540 -3.2862 -0.2566 -0.1207 -1.7916 -0.0417 -0.0174 -0.9759 -0.0280 -0.1500 -0.0072 -0.5067 -0.4122 -0.1375 -0.1611 -0.1615
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians ; patient ; anemic ; patients ; heart disease
H-34	-0.5523532629013062	▁a ne mic ▁; ▁ir on - d eficient ▁adult ▁patients ▁; ▁heart ▁disease
D-34	-0.5523532629013062	anemic ; iron-deficient adult patients ; heart disease
P-34	-3.9951 -0.1028 -0.0981 -0.3462 -0.1636 -0.0322 -0.0871 -0.0492 -0.1968 -0.7181 -0.7137 -1.0561 -0.6421 -0.3767 -0.1130 -0.1468
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence ; prevalence ; heart failure ; leading ; death ; hospitalisation
H-1664	-0.7518675327301025	▁heart ▁failure ▁; ▁hospital isation
D-1664	-0.7518675327301025	heart failure ; hospitalisation
P-1664	-0.8297 -0.1771 -0.6255 -2.0952 -0.0602 -1.3457 -0.1298
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr ; diuretics ; hypertension ; patients ; esrd
H-397	-0.3535001277923584	▁e G FR ▁; ▁di ure tics ▁; ▁un control led ▁hyper tension ▁; ▁ES RD
D-397	-0.3535001277923584	eGFR ; diuretics ; uncontrolled hypertension ; ESRD
P-397	-0.0825 -1.5888 -0.0081 -0.0687 -1.4784 -0.1911 -0.2543 -0.1288 -0.0102 -0.0065 -0.4233 -0.1007 -0.0433 -0.1392 -1.4374 -0.1529 -0.1312 -0.1177
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab ; chf ; nontrastuzumab users
H-678	-0.41171348094940186	▁tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab ▁users
D-678	-0.41171348094940186	trastuzumab ; CHF ; nontrastuzumab users
P-678	-0.2949 -0.0157 -0.0084 -0.4752 -0.6205 -0.0976 -0.1463 -0.4157 -0.0844 -0.0189 -0.0219 -1.2248 -1.9448 -0.7194 -0.0873
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus ; mortality ; hazard ratio ; confidence interval
H-129	-0.5224452614784241	▁ EO - c FU s ▁; ▁reduce d ▁mortal ity ▁; haz ard ▁ratio
D-129	-0.5224452614784241	EO-cFUs ; reduced mortality ;hazard ratio
P-129	-2.1660 -0.1125 -0.0228 -0.9140 -0.9928 -0.3156 -0.3936 -1.6022 -0.0129 -0.0621 -0.5716 -0.7643 -0.0163 -0.0039 -0.0255 -0.7993 -0.1060
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care ; outpatient ; acute heart failure
H-1026	-0.35842111706733704	▁Point - of - care ▁systems ▁; ▁ NP ▁levels ▁; ▁ED ▁; ▁community ▁out patient ▁setting s ▁; ▁a cute ▁heart ▁failure
D-1026	-0.35842111706733704	Point-of-care systems ; NP levels ; ED ; community outpatient settings ; acute heart failure
P-1026	-0.7230 -0.1202 -0.0363 -0.0876 -0.1120 -0.1811 -0.3218 -2.2226 -0.0433 -0.5951 -0.0953 -0.2075 -0.1167 -1.0594 -0.8923 -0.0058 -0.6565 -0.0249 -0.3723 -0.3729 -0.0150 -0.2584 -0.0743 -0.2290 -0.1374
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart failure ; preserved ejection fraction ; myocardial infarction
H-1098	-0.3266177475452423	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁my o card ial ▁in far ction
D-1098	-0.3266177475452423	heart failure ; preserved ejection fraction ; myocardial infarction
P-1098	-1.5731 -0.0802 -0.2246 -1.8191 -0.0192 -0.1120 -0.0347 -0.0360 -0.0149 -0.3477 -0.0023 -0.6873 -0.4741 -0.1604 -0.3301 -0.3098 -0.0177 -0.1221 -0.0963 -0.3005 -0.0969
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective ; lvas
H-1995	-0.7299385666847229	▁l VAS
D-1995	-0.7299385666847229	lVAS
P-1995	-2.3371 -0.4036 -0.0911 -0.0879
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf ; hospitalization ; cardiovascular mortality
H-1639	-0.30507978796958923	▁black ▁race ▁; ▁ HF ▁hospital ization ▁; ▁cardiovascular ▁mortal ity
D-1639	-0.30507978796958923	black race ; HF hospitalization ; cardiovascular mortality
P-1639	-0.0216 -0.0845 -0.1546 -0.6948 -0.0433 -0.4560 -0.2513 -0.1791 -1.1166 -0.0216 -0.7035 -0.1136 -0.1255
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise ; health ; cardiac disease ; heart failure
H-1904	-1.1463942527770996	▁cardiovascular ▁disease ▁; ▁heart ▁failure
D-1904	-1.1463942527770996	cardiovascular disease ; heart failure
P-1904	-6.3238 -0.5558 -0.1821 -0.4337 -0.2594 -0.1578 -0.1122
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients ; hfpef ; prospective
H-736	-1.0099260807037354	▁H FP EF
D-736	-1.0099260807037354	HFPEF
P-736	-3.7129 -0.4751 -0.4801 -0.3015 -0.0799
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician ; hf ; cpgs
H-1853	-0.37209776043891907	▁physician ▁ad her ence ▁; ▁ HF ▁c PG s
D-1853	-0.37209776043891907	physician adherence ; HF cPGs
P-1853	-0.8975 -0.0312 -0.5385 -0.4932 -0.4231 -0.4702 -0.0714 -0.9060 -0.1070 -0.1173 -0.2058 -0.2039
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf ; hf ; mortality
H-1774	-0.35626646876335144	▁ HF ▁risk ▁factors ▁; ▁fit ▁men ▁; ▁ HF ▁mortal ity ▁; ▁un fit ▁men
D-1774	-0.35626646876335144	HF risk factors ; fit men ; HF mortality ; unfit men
P-1774	-0.6402 -0.0699 -2.2808 -0.1184 -0.1047 -0.0794 -0.2821 -0.1449 -0.2593 -0.1467 -0.3216 -0.7223 -0.3980 -0.0152 -0.0115 -0.3968 -0.3122 -0.1086
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl ; chf ; vascular
H-260	-0.4084395170211792	▁HD L ▁function ▁; ▁CHF ▁; ▁ET ▁; ▁HD L - media ted ▁vas cular ▁effects
D-260	-0.4084395170211792	HDL function ; CHF ; ET ; HDL-mediated vascular effects
P-260	-0.9964 -1.3202 -0.0776 -0.1114 -0.0248 -0.0600 -1.1939 -0.2326 -0.8700 -1.4729 -0.0414 -0.0370 -0.0488 -0.1838 -0.0706 -0.3936 -0.1445 -0.0726
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical ; coronary artery disease ; patients ; systolic heart failure ; etiology
H-1181	-0.21973544359207153	▁corona ry ▁arter y ▁disease ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁un clear ▁et i ology
D-1181	-0.21973544359207153	coronary artery disease ; systolic heart failure ; unclear etiology
P-1181	-0.3119 -0.7315 -0.0496 -0.1600 -0.4557 -0.1006 -0.0188 -0.0214 -0.0758 -0.3171 -0.0800 -1.2191 -0.0325 -0.0142 -0.0125 -0.1529 -0.2103 -0.1195 -0.0915
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt ; implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
H-1953	-0.25535163283348083	▁Shu nt ▁implant s ▁; ▁trans sept al ▁cat heter isation ▁; ▁trans o es op hage al ▁e cho car dio graphic ▁guidance ▁; ▁ana es the sia
D-1953	-0.25535163283348083	Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic guidance ; anaesthesia
P-1953	-0.0874 -0.0191 -0.2050 -0.0775 -0.3899 -0.0061 -0.0330 -0.1526 -0.1866 -0.0076 -0.0735 -0.3598 -0.0015 -0.6544 -0.1874 -0.0149 -0.3587 -0.0706 -0.0955 -0.0629 -0.0329 -0.2614 -0.7528 -1.2887 -1.2555 -0.0704 -0.0473 -0.1120 -0.7374 -0.2134 -0.1003
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea ; total arterial compliance ; tac ; end-systolic elastance ; ees ; baseline
H-520	-0.29986900091171265	▁Ea ▁; ▁total ▁arterial ▁compliance ▁; TAC ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es
D-520	-0.29986900091171265	Ea ; total arterial compliance ;TAC ; end-systolic elastance ; ees
P-520	-2.1761 -0.1780 -0.2431 -0.0016 -0.0361 -0.0753 -0.0231 -0.0405 -1.5408 -0.0285 -0.2961 -0.0459 -0.0164 -0.0245 -0.4569 -0.1657 -0.2468 -0.0136 -0.3331 -0.0553
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular support ; heartmate ii ; lvad ; centrimag ; rvad ; mortality ; hospital ; discharge
H-304	-0.5730264782905579	▁Bi ven tri cular ▁support ▁; ▁Heart Mate ▁II ▁l VAD ▁; ▁Centri Mag ▁r VAD
D-304	-0.5730264782905579	Biventricular support ; HeartMate II lVAD ; CentriMag rVAD
P-304	-1.2031 -0.0517 -1.7637 -0.3992 -0.5664 -0.2325 -1.5954 -0.0306 -0.7649 -0.2127 -0.0142 -0.0723 -0.1275 -0.3257 -1.3338 -0.0912 -1.3650 -0.1646
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal dysfunction ; mortality ; myocardial infarction ; coronary artery bypass grafting ; cabg
H-969	-0.29859715700149536	▁Ren al ▁dys function ▁; ▁long - term ▁mortal ity ▁; ▁my o card ial ▁in far ction ▁; ▁corona ry ▁arter y ▁by pass ▁graf ting ▁; CA BG
D-969	-0.29859715700149536	Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ;CABG
P-969	-0.2365 -0.0416 -0.0514 -0.0394 -0.1578 -1.1264 -0.0333 -0.0477 -0.0680 -0.8652 -0.1200 -0.3439 -0.1073 -0.1378 -0.0845 -0.0166 -0.1051 -0.0468 -0.5792 -0.0162 -0.4892 -0.0197 -0.3898 -1.9361 -0.1752 -0.0364 -0.4156 -0.6266 -0.6296 -0.3444 -0.1643 -0.1033
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpef
H-1890	-0.28912800550460815	▁cardiovascular ▁; ▁diabetes ▁mell itus ▁; ▁at rial ▁fi bril lation ▁; ▁corona ry ▁arter y ▁disease ▁; ▁ HF p EF
D-1890	-0.28912800550460815	cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
P-1890	-0.0821 -1.4904 -0.2309 -0.0052 -0.0243 -0.0681 -0.2400 -0.0099 -0.2345 -0.0103 -0.0342 -0.0856 -0.0123 -0.7809 -0.0314 -0.4099 -0.8617 -0.7484 -0.6970 -0.0771 -0.0298 -0.2016 -0.4488 -0.1247
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline ; isoprenaline ; infusion ; sdqt ; hf ; patients
H-1443	-0.3413218855857849	▁iso pren a line ▁in fusion ▁; ▁SD QT ▁; ▁h Nor m ▁; ▁ HF
D-1443	-0.3413218855857849	isoprenaline infusion ; SDQT ; hNorm ; HF
P-1443	-0.0273 -0.2131 -0.2192 -0.0377 -0.0321 -0.0188 -0.1228 -0.0209 -0.2168 -0.1790 -1.3424 -1.2313 -0.0669 -0.3642 -0.6256 -0.2576 -1.0042 -0.1637
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal dysfunction ; all-cause mortality ; cardiovascular events ; postoperative ; cabg
H-978	-0.5059292912483215	▁Ren al ▁dys function ▁; ▁all - ca use ▁mortal ity ▁; ▁cardiovascular ▁events
D-978	-0.5059292912483215	Renal dysfunction ; all-cause mortality ; cardiovascular events
P-978	-0.3527 -0.0407 -0.0369 -0.0594 -0.1517 -3.5168 -0.0244 -0.0089 -0.1336 -0.0107 -1.2664 -0.1864 -0.0069 -0.2295 -1.9869 -0.0830
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
H-1142	-0.3033613860607147	▁Pyr ido stig mine ▁; ▁vas cular ▁en dot heli al ▁growth ▁factor ▁protein ▁; ▁left ▁vent ric le ▁; ▁my o card ial ▁ang io gene sis
D-1142	-0.3033613860607147	Pyridostigmine ; vascular endothelial growth factor protein ; left ventricle ; myocardial angiogenesis
P-1142	-0.0246 -0.0052 -0.0007 -0.0816 -0.1369 -0.1130 -0.0899 -0.0092 -0.3892 -0.0189 -0.0088 -0.2386 -0.1464 -2.6816 -0.2428 -0.1577 -0.0413 -0.8360 -0.2326 -0.2478 -0.4980 -0.0780 -0.2974 -0.2290 -1.0592 -0.4836 -0.1324 -0.2581 -0.2305 -0.1322
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr ; vad ; ecmo ; vad ; ecmo
H-1393	-0.7302252650260925	▁e g FR ▁; ▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁ec mo ▁group
D-1393	-0.7302252650260925	egFR ; VAD group ; ecmo+VAD group ; ecmo group
P-1393	-0.0451 -1.0474 -0.3002 -0.0623 -0.4331 -0.0227 -1.2006 -0.0734 -0.8552 -1.4640 -1.5632 -0.0682 -1.2040 -0.2745 -1.2255 -1.1375 -2.5443 -0.2492 -0.1038
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients ; chf ; international classification of diseases
H-213	-0.38658738136291504	▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision
D-213	-0.38658738136291504	CHF ; international Classification of Diseases ; Ninth revision
P-213	-0.4800 -0.5391 -0.6008 -0.0131 -0.0562 -0.3153 -0.0310 -0.0140 -0.9924 -0.0279 -0.0135 -1.4626 -0.0300 -1.0846 -0.1383
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv dysfunction ; body mass index ; fat mass ; cachexia
H-1163	-0.2309984266757965	▁ RV ▁dys function ▁; ▁lower ▁body ▁mass ▁index ▁; ▁fat ▁mass ▁index ▁; ▁cache xia
D-1163	-0.2309984266757965	RV dysfunction ; lower body mass index ; fat mass index ; cachexia
P-1163	-0.6209 -0.5854 -0.1125 -0.0475 -0.1463 -0.8441 -0.2421 -0.0678 -0.0052 -0.1751 -0.3868 -0.0716 -0.0047 -0.3263 -0.1573 -0.0987 -0.1476 -0.1180
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline ; crf ; hf ; mortality ; hf
H-1775	-0.44143834710121155	▁c RF ▁; ▁ HF ▁mortal ity ▁risk ▁; ▁men ▁; ▁ HF ▁risk ▁factors
D-1775	-0.44143834710121155	cRF ; HF mortality risk ; men ; HF risk factors
P-1775	-1.1883 -0.5395 -0.0889 -0.4636 -0.1909 -0.0766 -0.2646 -1.2277 -0.1857 -0.6435 -0.2011 -0.1351 -0.1863 -1.5756 -0.2150 -0.1961 -0.1260
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait ; therapy ; lokomat ; heart failure ; patients
H-1921	-0.28459563851356506	▁Robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁system ▁; ▁heart ▁failure ▁patients
D-1921	-0.28459563851356506	Robot-assisted gait therapy ; Lokomat® system ; heart failure patients
P-1921	-0.4892 -0.0905 -0.0053 -0.0631 -0.0598 -0.1366 -0.1677 -0.0124 -0.2458 -0.0451 -0.0194 -1.3447 -0.6662 -0.4175 -0.2968 -0.0636 -0.9144 -0.2813 -0.0877
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests ; cardiac growth ; disease ; chromatin ; remodeling
H-92	-0.30567431449890137	▁cardiac ▁growth ▁; ▁plastic ity ▁; ▁disease ▁recap it ulat es ▁; ▁chr omat in ▁remodel ing
D-92	-0.30567431449890137	cardiac growth ; plasticity ; disease recapitulates ; chromatin remodeling
P-92	-0.0851 -0.6466 -0.3864 -0.0470 -0.8519 -0.1865 -0.3488 -0.0024 -0.0238 -0.0014 -0.4420 -0.1804 -0.4330 -0.0154 -0.4394 -0.0144 -0.0344 -1.5811 -0.0879
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis ; idiopathic dilated cardiomyopathy
H-1742	-0.29973846673965454	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁co hor t
D-1742	-0.29973846673965454	idiopathic dilated cardiomyopathy cohort
P-1742	-0.9399 -0.0884 -0.0349 -0.1774 -0.1369 -0.1186 -0.1335 -1.2737 -0.3222 -0.0454 -0.4002 -0.4041 -0.1074 -0.1927 -0.1206
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine ; nesiritide ; placebo
H-78	-0.46940428018569946	▁dop amine ▁; ▁nesi riti de
D-78	-0.46940428018569946	dopamine ; nesiritide
P-78	-0.0004 -0.0149 -0.0293 -0.0617 -0.0036 -0.0522 -3.5297 -0.0634
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline ; embase ; cochrane ; clinical
H-41	-0.2979293763637543	▁med line ▁; ▁ EMBA se ▁; ▁co ch rane ▁database s ▁; ▁clinic al ▁trial ▁registri es
D-41	-0.2979293763637543	medline ; EMBAse ; cochrane databases ; clinical trial registries
P-41	-0.7806 -0.4294 -0.1145 -0.1446 -0.0154 -0.4301 -0.1300 -0.0304 -0.0506 -0.0104 -0.0745 -0.1128 -0.0604 -0.0493 -0.0187 -0.3254 -0.0316 -0.0391 -2.9517 -0.1588
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician ; nonprescribing ; patient
H-1127	-0.39673319458961487	▁non pre scribi ng ▁; ▁chart ▁review
D-1127	-0.39673319458961487	nonprescribing ; chart review
P-1127	-2.2150 -0.0680 -0.0268 -0.0181 -0.7208 -0.1747 -0.0145 -0.2095 -0.1234
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients ; severe hf ; prognostic ; hf
H-1764	-0.8410845994949341	▁ HF ▁; ▁ HF
D-1764	-0.8410845994949341	HF ; HF
P-1764	-1.5824 -0.2962 -0.8767 -2.0143 -0.1935 -0.7473 -0.1771
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ; ea ; tac ; ees ; patients
H-522	-0.4054630696773529	▁Ea ▁; ▁ TAC ▁; ▁HR ▁; ▁e es ▁; ▁i va bra dine -
D-522	-0.4054630696773529	Ea ; TAC ; HR ; ees ; ivabradine-
P-522	-0.1369 -0.2241 -0.6857 -0.0157 -0.1216 -0.0736 -0.2299 -0.4166 -0.0311 -0.5732 -0.0149 -0.0224 -0.1864 -0.0514 -0.4825 -3.4880 -0.1390
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth ; health ; outcomes ; medicare
H-1628	-0.5034107565879822	▁Care ▁management ▁; ▁content - driv en ▁tele health ▁technology ▁; ▁health ▁outcome s ▁; ▁Medica re ▁beneficiar ies
D-1628	-0.5034107565879822	Care management ; content-driven telehealth technology ; health outcomes ; Medicare beneficiaries
P-1628	-1.6879 -0.0861 -0.1070 -0.7903 -0.0246 -0.0091 -0.0279 -2.0776 -0.2254 -0.2853 -0.2869 -1.6751 -0.3189 -0.1071 -0.2466 -1.4482 -0.0175 -0.8616 -0.0454 -0.1462 -0.0970
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant ; erc ; epicatechin ; muscle
H-1256	-0.44443050026893616	▁ ERC ▁; ▁pure ▁epi cate chin
D-1256	-0.44443050026893616	ERC ; pure epicatechin
P-1256	-0.9537 -0.0276 -0.0828 -0.0194 -0.0583 -0.0054 -0.2279 -2.5177 -0.1070
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical ; nonprescribing ; patients
H-1128	-0.21535129845142365	▁bio medic al ▁reasons ▁; ▁non pre scribi ng
D-1128	-0.21535129845142365	biomedical reasons ; nonprescribing
P-1128	-0.0165 -0.0227 -0.0017 -0.2707 -0.9524 -0.1601 -0.1020 -0.0773 -0.0833 -0.5794 -0.1028
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium ; expression ; pka ; downstream signaling
H-1433	-0.36947742104530334	▁my o car dium ▁display s ▁; ▁post - trans la tional ▁modification ▁; ▁p ka ▁sub un its ▁; ▁down stream ▁signal ing
D-1433	-0.36947742104530334	myocardium displays ; post-translational modification ; pka subunits ; downstream signaling
P-1433	-0.4543 -0.0375 -0.0164 -0.0281 -0.8914 -0.1032 -0.3089 -2.7828 -0.0031 -0.0083 -0.0888 -0.0027 -0.7161 -0.1193 -0.5802 -0.8825 -0.7422 -0.1159 -0.0090 -0.3711 -0.4627 -0.0091 -0.2989 -0.2429 -0.2196 -0.1115
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-867	-0.3753587603569031	▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-867	-0.3753587603569031	therapy ; atrial fibrillation ; carvedilol ; metoprolol
P-867	-3.7990 -0.0664 -0.6135 -0.4526 -0.0268 -0.3299 -0.0189 -0.0652 -0.2578 -0.1125 -0.0150 -0.0294 -0.4780 -0.1062 -0.2633 -0.0123 -0.0796 -0.2862 -0.1192
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect ; heart failure ; patients ; implantable cardioverter-defibrillator
H-1860	-0.4462239444255829	▁heart ▁failure ▁patients ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
D-1860	-0.4462239444255829	heart failure patients ; implantable cardioverter-defibrillator
P-1860	-5.2436 -0.0514 -0.6762 -0.3128 -0.1039 -0.0353 -0.1624 -0.0152 -0.0970 -0.0826 -0.1195 -0.0185 -0.0782 -0.0776 -0.0671 -0.3215 -0.1231
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-367	-0.15479697287082672	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-367	-0.15479697287082672	functional MS ; valve plasty ; degenerative MR ; LV
P-367	-0.0521 -0.0383 -0.0741 -0.6107 -0.0068 -0.0255 -0.1360 -0.2489 -0.0052 -0.0022 -0.0909 -0.0596 -0.2420 -0.0258 -0.8006 -0.0581
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients ; heartmate ii ; biventricular support ; heartmate ii ; implantation
H-300	-0.5160068273544312	▁Heart Mate ▁II ▁ insertion ▁; ▁bi ven tri cular ▁support ▁; ▁Heart Mate ▁II ▁implant ation
D-300	-0.5160068273544312	HeartMate II insertion ; biventricular support ; HeartMate II implantation
P-300	-1.6432 -0.0847 -0.4428 -0.6129 -0.0149 -0.1147 -1.0675 -0.0529 -1.2714 -0.2082 -0.9222 -0.2778 -1.2250 -0.1202 -0.6136 -0.4536 -0.2976 -0.2390 -0.1420
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end stage heart failure ; heart failure ; public ; health ; patient ; europe ; north america
H-1663	-0.9578117728233337	▁management ▁; ▁end ▁stage ▁heart ▁failure ▁Heart ▁failure ▁; ▁public ▁health ▁problem ▁; ▁europa ▁; ▁North ▁America
D-1663	-0.9578117728233337	management ; end stage heart failure Heart failure ; public health problem ; europa ; North America
P-1663	-1.9641 -0.5734 -0.9164 -0.0397 -1.5752 -0.0808 -4.0621 -0.0790 -0.3648 -0.1204 -0.4653 -2.6161 -0.6650 -2.5581 -0.5873 -1.1542 -0.1515 -0.1150 -0.1099
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient ; st-segment-elevation mis ; killip class ; comorbid ; conditions
H-1105	-0.6948701739311218	▁m s ▁; ▁Kill ip ▁class
D-1105	-0.6948701739311218	ms ; Killip class
P-1105	-3.2635 -1.0787 -0.2434 -0.4154 -0.0949 -0.0844 -0.2698 -0.1090
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart failure ; cardiology-cardiovascular surgery consensus report ; heart failure ; disease
H-1818	-0.4292122423648834	▁heart ▁failure ▁; ▁mechanic al ▁support ▁devices ▁; ▁Card i ology - car dio vas cular ▁Sur ger y ▁Cons en sus ▁Report ▁Heart ▁failure
D-1818	-0.4292122423648834	heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus Report Heart failure
P-1818	-2.7420 -0.0758 -0.0856 -0.0571 -0.0038 -0.2740 -0.2007 -0.1445 -1.5019 -0.0483 -0.2217 -0.0243 -0.4282 -0.4006 -0.1143 -0.1765 -0.9457 -0.2058 -0.0570 -0.1253 -0.0123 -0.0225 -0.7153 -1.7636 -0.1539 -0.9895 -0.0983
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 ; n2bus ; s12884 ; pevk
H-769	-0.6065260767936707	▁elastic ▁N 2 ▁bu s ▁segment ▁; ▁PE v k ▁segment
D-769	-0.6065260767936707	elastic N2 bus segment ; PEvk segment
P-769	-0.5079 -2.3659 -0.0610 -0.8710 -0.1281 -0.1582 -0.1847 -0.7611 -0.7895 -1.0428 -0.7381 -0.1574 -0.1190
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care of heart failure index version 6.2 ; schfi v.6.2 ; psychometric
H-1504	-0.47320616245269775	▁Self - car e ▁of ▁Heart ▁Fail ure ▁index ▁; ▁sch fi ▁; ▁psycho metric ▁profile
D-1504	-0.47320616245269775	Self-care of Heart Failure index ; schfi ; psychometric profile
P-1504	-0.0881 -0.0320 -1.3017 -0.1145 -0.3116 -0.3151 -0.2750 -0.5977 -0.6081 -0.2974 -1.2900 -1.8392 -1.1648 -0.0126 -0.0194 -0.0903 -0.1039 -0.0563
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics ; chromatin-associated proteins ; disease
H-93	-0.3312602639198303	▁quantitat ive ▁prote o mics ▁; ▁chr omat in - as soci ated ▁protein s ▁; ▁detergent
D-93	-0.3312602639198303	quantitative proteomics ; chromatin-associated proteins ; detergent
P-93	-0.3995 -0.0393 -0.1363 -0.4580 -0.0043 -0.2406 -0.1366 -0.0120 -0.4503 -0.0439 -0.0422 -0.0003 -0.2580 -0.3011 -0.0801 -1.7616 -0.2189 -1.6341 -0.0768
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate ; left ventricular assist system ; lvas ; patients ; heart failure
H-1993	-0.5139574408531189	▁Heart Mate ▁; ▁left ▁vent ri cular ▁assist ▁system ▁; ▁l VAS ▁; ▁patients ▁; ▁advanced ▁heart ▁failure
D-1993	-0.5139574408531189	HeartMate ; left ventricular assist system ; lVAS ; patients ; advanced heart failure
P-1993	-0.3366 -0.1289 -0.4486 -0.1806 -0.0692 -1.1907 -0.3768 -0.9314 -0.1370 -0.2892 -0.0306 -0.2238 -0.6430 -2.6072 -1.4131 -0.3962 -0.3803 -0.2501 -0.1529 -0.0929
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil ; mitochondrial dysfunction ; heart failure ; cardioprotection
H-954	-0.2417343556880951	▁Nico rand il ▁a meli orat es ▁mito cho ndri al ▁dys function ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s
D-954	-0.2417343556880951	Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats
P-954	-0.0015 -0.0344 -0.0394 -0.5398 -0.0012 -0.0040 -0.0875 -0.0195 -0.7717 -0.4474 -0.0216 -0.0213 -0.0564 -0.2311 -0.0980 -0.0022 -0.0057 -0.4910 -0.0654 -0.0196 -0.1387 -0.4961 -0.1553 -0.3493 -0.0644 -0.0300 -2.4578 -0.1182
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic ; acute hf ; adverse event ; chronic hf
H-1016	-0.3990239202976227	▁ pharma c ologic ▁; ▁a cute ▁ HF ▁; ▁advers e ▁event ▁rates ▁; ▁chronic ▁ HF
D-1016	-0.3990239202976227	pharmacologic ; acute HF ; adverse event rates ; chronic HF
P-1016	-0.4399 -0.1275 -0.0417 -0.0448 -3.9148 -0.0313 -0.0040 -0.1776 -0.0537 -0.3376 -0.8672 -0.0307 -0.5604 -0.2893 -0.3606 -0.1534 -0.2400 -0.0775 -0.1460 -0.0825
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
H-517	-0.3749702572822571	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁pulsa tile ▁after load ▁; ▁heart ▁; ▁pressure ▁volume ▁relation
D-517	-0.3749702572822571	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
P-517	-0.3841 -0.3055 -0.8173 -0.1125 -0.3940 -0.0103 -0.2864 -0.2998 -0.0047 -1.5289 -0.0224 -0.1918 -0.7619 -0.4272 -0.1181 -0.0648 -0.9722 -0.3416 -0.0808
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 ; hno ; cxl-1051 ; t1
H-416	-0.4005068242549896	▁c XL -10 20 ▁convert s ▁; ▁h no ▁; ▁in active ▁c XL -10 51
D-416	-0.4005068242549896	cXL-1020 converts ; hno ; inactive cXL-1051
P-416	-0.8662 -0.3632 -0.1032 -0.1385 -0.3097 -0.1711 -0.5139 -1.6652 -0.5650 -0.0844 -0.0080 -0.0392 -1.2467 -0.4577 -0.1777 -0.1546 -0.2113 -0.1336
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf antagonists ; hf ; hospital ; admissions ; nbdmards ; ra
H-611	-0.22875435650348663	▁t NF ▁anta gon ists ▁; ▁ HF ▁hospital ▁ad missions ▁; ▁n b DM ARD s ▁; ▁RA
D-611	-0.22875435650348663	tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
P-611	-0.7859 -0.0902 -0.1148 -0.0064 -0.1913 -0.1156 -1.0241 -0.0892 -0.5522 -0.0227 -0.1342 -0.2129 -0.0084 -0.0049 -0.0752 -0.1244 -0.0963 -0.5976 -0.0553 -0.3883 -0.1138
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ; ejection fraction
H-1236	-0.43474268913269043	▁e je ction ▁ fraction
D-1236	-0.43474268913269043	ejection fraction
P-1236	-1.7458 -0.1240 -0.0555 -0.5770 -0.0072 -0.3860 -0.1477
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate analysis ; gls
H-817	-1.0509148836135864	▁g LS ▁; HR ▁; ▁ci
D-817	-1.0509148836135864	gLS ;HR ; ci
P-817	-1.8221 -0.8115 -0.1268 -0.8188 -0.4144 -2.1969 -2.0701 -0.1469
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized ; exercise ; exercise
H-1981	-0.8509212732315063	▁exercise ▁; ▁die t
D-1981	-0.8509212732315063	exercise ; diet
P-1981	-3.9054 -0.1790 -0.1015 -0.0646 -0.7555 -0.0995
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality ; hospitals
H-1695	-0.5407789945602417	▁odds ▁; ▁risk - ad just ed ▁mortal ity
D-1695	-0.5407789945602417	odds ; risk-adjusted mortality
P-1695	-1.4441 -0.6469 -1.2074 -0.0366 -0.0191 -0.0087 -0.0385 -0.0646 -0.6558 -1.7131 -0.1137
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses ; magnet
H-87	-1.583842396736145	▁magnet ( ®
D-87	-1.583842396736145	magnet(®
P-87	-2.8236 -2.0542 -1.0493 -1.9054 -0.0867
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician ; evidence
H-1842	-0.5205506682395935	▁physician ▁ad her ence ▁; ▁class ▁I ▁recommendations
D-1842	-0.5205506682395935	physician adherence ; class I recommendations
P-1842	-0.5020 -0.0393 -0.6638 -0.5320 -0.8350 -1.5878 -0.3059 -0.0828 -0.5492 -0.1076
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed ; patients ; hf ; drug treatment ; paf ; biosynthetic enzymes ; lyso-paf-at
H-1271	-0.4080367386341095	▁ HF ▁; ▁drug ▁treatment ▁; ▁PA F ▁bio syn the tic ▁enzym es ▁; ▁lys o - pa f - AT
D-1271	-0.4080367386341095	HF ; drug treatment ; PAF biosynthetic enzymes ; lyso-paf-AT
P-1271	-1.2401 -0.0661 -0.2472 -1.6582 -0.2032 -0.1565 -0.4892 -1.2265 -0.0085 -0.0147 -0.5888 -0.7553 -0.0705 -0.0892 -0.3128 -0.0195 -0.0468 -0.0162 -0.8494 -0.8352 -0.0511 -0.3294 -0.3791 -0.1393
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology ; myocardial infarction ; mi ; outcomes ; heart failure ; hf
H-1099	-0.3412039875984192	▁epidemi ology ▁; ▁my o card ial ▁in far ction ▁; MI ▁; ▁heart ▁failure ▁; HF
D-1099	-0.3412039875984192	epidemiology ; myocardial infarction ;MI ; heart failure ;HF
P-1099	-1.5959 -0.4291 -0.1577 -0.2982 -0.1440 -0.3915 -0.2339 -0.0353 -0.1681 -0.0856 -0.1967 -1.1438 -0.1261 -0.8132 -0.0946 -0.2484 -0.0168 -0.1904 -0.1134
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic ; tests ; cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments ; baseline
H-737	-0.251714825630188	▁cardiac ▁magnetic ▁res on ance ▁imagin g ▁; ▁t 1 ▁ma pping ▁; ▁invasi ve ▁hem o dynamic ▁assessment s
D-737	-0.251714825630188	cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
P-737	-0.0642 -0.1526 -0.4550 -0.1669 -0.5244 -0.5127 -0.1809 -0.1528 -1.2034 -0.2975 -0.0100 -0.0204 -0.1843 -0.0268 -0.0785 -0.1725 -0.4447 -0.0033 -0.0555 -0.4814 -0.2480 -0.1021
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart rate reduction ; exercise ; heart failure with reduced ejection fraction ; beta-blocker
H-1935	-0.40628939867019653	▁Heart ▁rate ▁re duction ▁; ▁exercise ▁performance ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁beta - block er
D-1935	-0.40628939867019653	Heart rate reduction ; exercise performance ; heart failure ; ejection fraction ; beta-blocker
P-1935	-0.6978 -0.3829 -0.1269 -0.0944 -0.2257 -0.0600 -0.0732 -0.1537 -1.9507 -0.0652 -0.3869 -0.2164 -0.0260 -0.0086 -0.2467 -0.0015 -0.6751 -0.6495 -0.0248 -0.0767 -0.0235 -3.0810 -0.0973
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ; ras ; asymptomatic ; clinically ; hypertension ; nephropathy ; congestive heart failure
H-1597	-0.2526981830596924	RAS ▁; ▁hyper tension ▁; ▁nep hro pathy ▁; ▁con ges tive ▁heart ▁failure
D-1597	-0.2526981830596924	RAS ; hypertension ; nephropathy ; congestive heart failure
P-1597	-1.0419 -0.4831 -0.6053 -0.0258 -0.1016 -0.0072 -0.0085 -0.0474 -0.0757 -0.0178 -0.0822 -1.0110 -0.2151 -0.0845 -0.1285 -0.1076
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic ; admission ; brain natriuretic peptide ; bnp ; creatinine ; natremia
H-585	-0.5065812468528748	▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁creati nine ▁; ▁na trem ia
D-585	-0.5065812468528748	natriuretic peptide ; bNP ; creatinine ; natremia
P-585	-4.4419 -0.2928 -0.0846 -1.0987 -0.3069 -0.1058 -0.2002 -0.2013 -0.4931 -0.5219 -0.2558 -0.0087 -0.0546 -0.2377 -0.0821 -0.0366 -0.8486 -0.1904 -0.1633
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-868	-0.3519255220890045	▁m ADI t - c RT ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-868	-0.3519255220890045	mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
P-868	-0.6594 -0.0307 -0.1007 -0.0057 -0.6642 -1.2106 -0.1718 -0.8457 -0.0109 -0.3478 -0.0311 -0.4334 -0.0169 -0.2054 -0.0458 -0.1382 -0.1713 -0.9002 -0.2420 -0.0539 -0.9839 -0.0554 -0.0123 -0.4619 -0.2058 -1.3939 -0.1031
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated ; baseline ; nt-probnp ; mr-proanp ; mr-proadm
H-17	-0.22873224318027496	▁NT - pro b NP ▁; ▁MR - pro AN p ▁; ▁MR - pro ad m
D-17	-0.22873224318027496	NT-probNP ; MR-proANp ; MR-proadm
P-17	-0.6882 -0.0183 -0.0062 -0.7383 -0.1928 -0.0850 -0.0358 -0.0170 -0.0069 -0.6166 -0.4658 -0.1395 -0.0505 -0.0234 -0.0216 -0.8360 -0.1522 -0.1255 -0.1264
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric focusing ; riα ; ser77 ; ser83 ; in vivo ; phosphorylation
H-1430	-0.44029316306114197	▁iso electric ▁focus ing ▁; ▁RI α ▁; ▁ser 77 ▁; ▁ser 83 ▁; ▁vivo ▁ phos phor y lation ▁sites
D-1430	-0.44029316306114197	isoelectric focusing ; RIα ; ser77 ; ser83 ; vivo phosphorylation sites
P-1430	-0.8426 -0.3859 -0.2294 -0.0538 -0.1811 -0.2329 -0.0679 -0.2127 -1.0720 -0.2377 -0.2111 -1.0326 -1.3864 -0.7244 -0.2165 -0.1853 -0.0530 -1.0336 -0.8438 -0.1163 -0.5416 -0.1799 -0.0861
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt ; sd of rr intervals ; sdrr ; qtv ; heart rate variability
H-1440	-0.34940391778945923	▁SD QT ▁; ▁SD ▁; ▁ RR ▁interval s ▁; SD RR ▁; ▁index ▁; ▁Q TV ▁; ▁heart ▁rate ▁variabil ity
D-1440	-0.34940391778945923	SDQT ; SD ; RR intervals ;SDRR ; index ; QTV ; heart rate variability
P-1440	-0.5722 -0.1050 -0.1905 -0.0159 -0.8001 -0.9011 -0.3381 -0.0064 -0.0209 -0.1252 -0.4071 -1.0239 -0.2751 -0.3101 -0.2713 -0.3374 -0.4846 -0.1803 -0.6632 -0.4118 -0.0695 -0.4512 -0.2559 -0.1690
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs ; septal ; qrs ; resynchronization
H-486	-0.7216421961784363	▁e / e sept al ▁; ▁e / eme an ▁; ▁s ' sept al ▁; ▁QR s ▁ width
D-486	-0.7216421961784363	e/eseptal ; e/emean ; s'septal ; QRs width
P-486	-1.2142 -4.5971 -0.1058 -0.0170 -0.0111 -0.0875 -0.1806 -2.3954 -0.0027 -0.0141 -0.2677 -0.5498 -2.3077 -0.0148 -0.0104 -0.2238 -0.0167 -1.3497 -0.8932 -0.0257 -1.4588 -0.1325
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic regression ; primary outcome ; secondary outcome ; death
H-973	-0.5467112064361572	▁Log istic ▁re gression ▁models ▁; ▁risk ▁; ▁seconda ry ▁outcome ▁; ▁death
D-973	-0.5467112064361572	Logistic regression models ; risk ; secondary outcome ; death
P-973	-0.4265 -0.0195 -0.0399 -0.0051 -0.5141 -0.4350 -2.7932 -0.2492 -1.4548 -0.2627 -0.0800 -0.6964 -0.3269 -0.8286 -0.0688
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc occlusion ; correlated ; rs ; rs synchrony
H-326	-0.21133247017860413	▁IV c ▁oc clusi on ▁; ▁CO ▁cor related ▁; ▁twist ▁; ▁ap ical ▁ro tation ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS
D-326	-0.21133247017860413	IVc occlusion ; CO correlated ; twist ; apical rotation ; RS ; RS synchrony ; CS
P-326	-0.2425 -0.8176 -0.0012 -0.0038 -0.2040 -0.1226 -1.1889 -0.0594 -0.1647 -0.5916 -0.0302 -0.1750 -0.0297 -0.0616 -0.0027 -0.0046 -0.0920 -0.0165 -0.3174 -0.4830 -0.0020 -0.0789 -0.6253 -0.0059 -0.0751 -0.0986
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission ; hospital ; congestive heart failure ; united states
H-1574	-0.5995426774024963	▁con ges tive ▁heart ▁failure
D-1574	-0.5995426774024963	congestive heart failure
P-1574	-2.2388 -0.0598 -0.5200 -0.2989 -0.1070 -0.8661 -0.1062
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective ; diuretics ; morbidity ; mortality
H-1200	-0.5139463543891907	▁di ure tics ▁; ▁morbi d ity ▁; ▁mortal ity
D-1200	-0.5139463543891907	diuretics ; morbidity ; mortality
P-1200	-0.2040 -0.2039 -0.2360 -0.4918 -2.0507 -0.0451 -1.2779 -0.9513 -0.0085 -0.5602 -0.0761 -0.0620
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital ; readmission ; patients ; heart failure ; follow-up
H-731	-1.2033183574676514	▁read mission ▁rate ▁; ▁patients ▁; ▁heart ▁failure
D-731	-1.2033183574676514	readmission rate ; patients ; heart failure
P-731	-6.6388 -1.0580 -0.4426 -0.1284 -0.7746 -1.9457 -0.3371 -0.0836 -0.5199 -0.1044
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health care ; clinically ; gastrointestinal bleeding
H-1658	-0.6618411540985107	▁devices ▁; ▁gastro inte stin al ▁ble ed ing
D-1658	-0.6618411540985107	devices ; gastrointestinal bleeding
P-1658	-3.1235 -0.3126 -1.5393 -0.3842 -0.5132 -0.0573 -0.0805 -0.5619 -0.2457 -0.3752 -0.0867
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients ; t1 times ; cardiac events
H-740	-0.42331984639167786	▁cardiac ▁events
D-740	-0.42331984639167786	cardiac events
P-740	-0.9498 -0.4747 -0.1929 -0.0759
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr ; vad ; ecmo ; vad ; renal function
H-1391	-0.4936303198337555	▁e g FR ▁; ▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁renal ▁function
D-1391	-0.4936303198337555	egFR ; VAD group ; ecmo+VAD group ; renal function
P-1391	-0.0324 -1.0653 -0.1476 -0.0724 -0.9433 -0.0095 -1.0165 -0.1230 -0.4349 -1.7731 -0.6469 -0.0419 -1.6328 -0.4126 -0.0281 -0.2298 -0.1782 -0.0970
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 ; sst2 ; outcomes
H-406	-0.47347360849380493	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB
D-406	-0.47347360849380493	sst2/low-dose BB ; sst2/high-dose BB
P-406	-0.1853 -1.5915 -0.0803 -0.1569 -0.0205 -0.3825 -0.0705 -0.7327 -0.3598 -0.2690 -2.2439 -0.1041 -0.8738 -0.0360 -0.7251 -0.0532 -0.7408 -0.2454 -0.1248
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf ; chf ; patients ; intubated
H-214	-0.7015529274940491	▁CHF ▁; ▁ED ▁visit s ▁; ▁CHF ▁patients ▁in tuba ted
D-214	-0.7015529274940491	CHF ; ED visits ; CHF patients intubated
P-214	-0.1921 -2.4888 -3.0564 -0.6883 -0.1518 -0.2782 -0.7134 -1.1120 -0.1089 -0.0140 -0.0432 -0.1956 -0.0775
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician ; mortality ; hf ; physicians
H-1731	-0.30907556414604187	▁Physic ian ▁volume ▁; ▁lower ▁mortal ity ▁; ▁ HF ▁; ▁non car dio logist ▁physician s
D-1731	-0.30907556414604187	Physician volume ; lower mortality ; HF ; noncardiologist physicians
P-1731	-1.1519 -0.4382 -0.0272 -0.1105 -0.6221 -0.1028 -0.5627 -0.1302 -1.0667 -0.0453 -0.3918 -0.3753 -0.0251 -0.1944 -0.0581 -0.2359 -0.0717 -0.1815 -0.0810
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin ; genomic reprogramming ; disease
H-100	-0.29818713665008545	▁zebra fish ▁; ▁nu cle olin ▁; ▁genom ic ▁re programm ing ▁events
D-100	-0.29818713665008545	zebrafish ; nucleolin ; genomic reprogramming events
P-100	-0.2158 -0.0202 -0.1396 -0.2215 -0.0009 -0.0101 -0.8491 -0.1434 -0.2595 -0.0251 -0.1122 -0.0167 -1.5231 -0.8539 -0.0817
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv ejection fraction ; pcwp
H-483	-0.6253758668899536	▁LV ▁e je ction ▁ fraction
D-483	-0.6253758668899536	LV ejection fraction
P-483	-0.2510 -0.5222 -0.0507 -0.0309 -0.6960 -0.0081 -3.3608 -0.0834
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence ; hf ; ami ; mortality
H-1314	-0.40084972977638245	▁ HF ▁complicat ing ▁ AMI ▁; ▁high ▁mortal ity
D-1314	-0.40084972977638245	HF complicating AMI ; high mortality
P-1314	-1.1503 -0.0731 -1.1663 -0.0234 -0.1472 -0.0759 -0.3772 -1.0882 -0.0517 -0.4890 -0.0831 -0.0850
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency department ; acute heart failure ; clinical ; patient ; collins
H-56	-0.4730437397956848	▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁clinic al ▁trial s
D-56	-0.4730437397956848	emergency department ; acute heart failure clinical trials
P-56	-1.7041 -0.0701 -0.1028 -0.0180 -0.0058 -0.5169 -0.1271 -0.5864 -0.0191 -0.1337 -0.1574 -2.6167 -0.0916
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary exercise test ; quality of life ; muscular ; peak quadriceps force
H-1915	-0.603762686252594	▁cardio pul mon ary ▁exercise ▁; ▁quality ▁of ▁life ▁score ▁; ▁muscular ▁strength ▁; ▁quadri cep s ▁force
D-1915	-0.603762686252594	cardiopulmonary exercise ; quality of life score ; muscular strength ; quadriceps force
P-1915	-0.0538 -0.3304 -1.0831 -0.3758 -2.2771 -1.6167 -3.5761 -0.1365 -0.1231 -0.2887 -0.0687 -0.1599 -0.5021 -0.1371 -0.5014 -0.0980 -0.0400 -0.3691 -0.2041 -0.1339
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians ; public ; health ; air ; cardiovascular ; health ; lead ; hospitalisation ; death
H-1808	-0.781087338924408	▁public ▁health ▁; ▁air ▁pollution ▁; ▁industrial ▁areas ▁; ▁cardiovascular ▁health
D-1808	-0.781087338924408	public health ; air pollution ; industrial areas ; cardiovascular health
P-1808	-1.5110 -0.7327 -0.3247 -0.1533 -0.1747 -0.3354 -1.6749 -1.0702 -0.8377 -0.9921 -0.7805 -1.4089 -0.1581
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg ; congenital ; accessory ; ion channelopathies ; cardiomyopathy
H-1909	-0.19857482612133026	▁e CG ▁; ▁con geni tal ▁accesso ry ▁path ways ▁; ▁ion ▁channel o pathi es ▁; ▁cardio my o pathy
D-1909	-0.19857482612133026	eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
P-1909	-0.6399 -0.2598 -0.2786 -0.4303 -0.0136 -0.0378 -0.0226 -0.3827 -0.4354 -0.0481 -0.1350 -0.0117 -0.1142 -0.3384 -0.0153 -0.0817 -0.1687 -0.1796 -0.5848 -0.1107 -0.0398 -0.1490 -0.0893
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients ; idiopathic dilated cardiomyopathy ; tuscany ; evidence-based
H-1739	-0.29836854338645935	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁tu sca ny
D-1739	-0.29836854338645935	idiopathic dilated cardiomyopathy ; tuscany
P-1739	-0.9542 -0.0461 -0.0415 -0.1294 -0.1640 -0.2370 -0.2428 -1.2681 -0.2775 -0.0331 -0.3965 -0.0508 -0.0007 -0.2536 -0.5929 -0.0858
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf ; pyridostigmine ; basal heart rate ; sympathetic control of heart rate
H-1140	-0.2104717493057251	▁ conscious ▁ HF ▁rat s ▁; ▁py rido stig mine ▁; ▁bas al ▁heart ▁rate ▁; ▁va gal ▁; ▁sympa the tic ▁control ▁; ▁heart ▁rate
D-1140	-0.2104717493057251	conscious HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
P-1140	-0.3205 -0.5369 -0.6677 -0.1399 -0.0598 -0.0426 -0.1127 -0.0016 -0.0034 -0.0020 -0.1286 -0.1065 -0.2084 -0.0296 -0.5397 -0.2759 -0.1941 -0.0016 -0.0127 -0.2617 -0.0258 -0.2910 -0.2933 -0.2416 -0.4809 -0.4596 -0.3441 -0.1989 -0.1224
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity ; mortality ; hfpef ; patients ; hf ; reduced ef
H-1301	-0.452050119638443	▁Morbi d ity ▁; ▁mortal ity ▁; ▁ HF p EF ▁; ▁patients ▁; ▁ HF ▁; ▁reduce d ▁EF
D-1301	-0.452050119638443	Morbidity ; mortality ; HFpEF ; patients ; HF ; reduced EF
P-1301	-0.0446 -0.0726 -0.8384 -0.3913 -0.0064 -0.4868 -0.1040 -1.5170 -0.0366 -0.0321 -0.0606 -0.2220 -2.4343 -0.7350 -0.5825 -0.0546 -0.1414 -0.8882 -0.0028 -0.0683 -1.1656 -0.0600
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf ; heart failure ; t2d ; type 2 diabetes ; skm ; skeletal muscle
H-1244	-0.2658320367336273	HF ▁; heart ▁failure ▁; ▁t 2 d ▁; ▁type ▁2 ▁diabetes ▁; ▁Sk m ▁; s kelet al ▁muscle
D-1244	-0.2658320367336273	HF ;heart failure ; t2d ; type 2 diabetes ; Skm ;skeletal muscle
P-1244	-0.2231 -0.3655 -0.0974 -0.0108 -0.0760 -1.0220 -0.0168 -0.3681 -0.0619 -1.0273 -0.2621 -0.0144 -0.3483 -0.0738 -0.3344 -0.2850 -0.7781 -0.0142 -0.0126 -0.0607 -0.3163 -0.0795
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart failure ; hf ; risk stratification ; inpatient ; outpatient
H-378	-0.45499148964881897	▁heart ▁failure ▁; HF ▁; ▁risk ▁strat ification ▁; ▁in patient ▁; ▁out patient ▁models
D-378	-0.45499148964881897	heart failure ;HF ; risk stratification ; inpatient ; outpatient models
P-378	-0.4066 -0.1113 -0.2639 -0.0249 -0.4247 -0.7691 -0.3091 -0.2226 -2.2563 -0.0139 -0.0037 -0.8419 -0.5772 -0.0068 -1.1286 -0.2652 -0.1088
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence ; biomarkers ; pathophysiology ; chronic hf ; therapeutic
H-1474	-0.2770897448062897	▁molecular ▁bio mark ers ▁; ▁pat ho phy si ology ▁; ▁chronic ▁ HF
D-1474	-0.2770897448062897	molecular biomarkers ; pathophysiology ; chronic HF
P-1474	-0.3538 -0.0379 -0.1767 -0.0624 -0.1663 -0.9416 -0.1587 -0.1253 -0.8012 -0.2748 -0.1343 -0.0520 -0.1648 -0.1061 -0.7426 -0.1350
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol ; metoprolol ; therapy ; heart failure ; patients
H-857	-0.26580584049224854	▁car vedi lol ▁; ▁met o pro lol ▁; ▁in appropria te ▁ therapy ▁; ▁heart ▁failure ▁patients ▁; ▁devices
D-857	-0.26580584049224854	carvedilol ; metoprolol ; inappropriate therapy ; heart failure patients ; devices
P-857	-0.0238 -0.0138 -0.0376 -0.2536 -0.0096 -0.1746 -0.0165 -0.1010 -0.5934 -0.7514 -0.0095 -0.0493 -0.2448 -0.0183 -0.7124 -0.1553 -0.0645 -0.6865 -1.6183 -0.0551 -0.1132 -0.1452
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating agents ; patients ; anemia ; heart disease
H-52	-0.5778027176856995	▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁heart ▁disease
D-52	-0.5778027176856995	erythropoiesis-stimulating agents ; anemia ; heart disease
P-52	-1.6769 -0.3902 -0.5970 -0.6325 -1.3994 -0.2154 -0.2854 -0.0324 -0.6235 -1.4410 -0.3564 -1.2169 -0.1278 -0.1688 -0.3751 -0.4430 -0.2936 -0.1252
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence ; intravenous ; exercise tolerance ; quality of life ; patients ; heart failure
H-46	-0.6671480536460876	▁intra ven ous ▁ir on ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure
D-46	-0.6671480536460876	intravenous iron ; exercise tolerance ; heart failure
P-46	-2.1316 -0.0077 -0.8443 -0.1908 -0.0453 -0.3498 -1.8046 -0.0854 -0.0019 -0.1681 -3.2832 -0.1663 -0.1721 -0.0891
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report ; mitral valve plasty ; degenerative mitral regurgitation
H-335	-0.12904880940914154	▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁mit ral ▁re gur gi tation
D-335	-0.12904880940914154	mitral valve plasty ; degenerative mitral regurgitation
P-335	-0.3435 -0.0147 -0.0470 -0.0307 -0.1587 -0.1832 -0.2127 -0.0389 -0.0024 -0.2882 -0.2219 -0.1542 -0.0303 -0.1552 -0.0856 -0.1130 -0.1665 -0.0761
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs ; québec health insurance board ; costs ; ontario case costing initiative
H-1235	-0.3507440388202667	▁in - t rial ▁resource ▁utiliza tion ▁; ▁unit ▁costs ▁; ▁Québec ▁Health ▁Insurance ▁Board ▁database s ▁; ▁disease - specific ▁costs ▁; ▁Ontario ▁Case ▁Cost ing ▁Initiative
D-1235	-0.3507440388202667	in-trial resource utilization ; unit costs ; Québec Health Insurance Board databases ; disease-specific costs ; Ontario Case Costing Initiative
P-1235	-0.1278 -0.3050 -0.2555 -0.0355 -0.0732 -0.2067 -0.1857 -0.1585 -0.0080 -0.1806 -0.2523 -0.0910 -1.0999 -0.3257 -0.1501 -0.9134 -0.2042 -0.4036 -2.2881 -0.0192 -0.0141 -0.8295 -0.2132 -0.6228 -0.2534 -0.7948 -0.1118 -0.1405 -0.1822 -0.0760
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet ; bromodomain-containing protein 4 ; brd4 ; cardiac
H-1045	-0.3790282905101776	▁knock down ▁; ▁ BET ▁bro modo main - conta ining ▁protein ▁4 ▁; br d 4) ▁; ▁cardiac ▁tissu es
D-1045	-0.3790282905101776	knockdown ; BET bromodomain-containing protein 4 ;brd4) ; cardiac tissues
P-1045	-1.1577 -0.0793 -0.2155 -1.4374 -0.0628 -0.1525 -0.0065 -0.0453 -0.0349 -0.0158 -0.0828 -0.0450 -1.1799 -0.5240 -0.8435 -0.1181 -0.9998 -1.2977 -0.0122 -0.0533 -0.1006 -0.1575 -0.0951
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras ; neprilysin inhibition ; change ; stable ; chronic heart failure ; systolic dysfunction
H-1971	-0.42876163125038147	▁ RAS ▁; ▁nepri ly sin ▁inhibi tion ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁treatment
D-1971	-0.42876163125038147	RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction treatment
P-1971	-2.3081 -0.0073 -0.3344 -0.1084 -0.3412 -0.4949 -0.0481 -0.2771 -0.4438 -0.9041 -0.5102 -0.1250 -0.3953 -0.0065 -0.0421 -0.1421 -0.0350 -0.0296 -1.7394 -0.5503 -0.1609
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change ; readmission ; follow-up ; follow-up
H-724	-0.7752074003219604	▁read mission ▁; ▁follow - up ▁visit s
D-724	-0.7752074003219604	readmission ; follow-up visits
P-724	-2.0250 -1.4343 -3.5388 -0.0443 -0.0707 -0.0113 -0.2211 -0.1073 -0.2178 -0.0816
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage heart failure ; mechanical cardiac support
H-1386	-1.167242407798767	▁wind ▁failure ▁; ▁pediatr ic ▁mechanic al ▁cardiac ▁support
D-1386	-1.167242407798767	wind failure ; pediatric mechanical cardiac support
P-1386	-7.3933 -0.9603 -0.5011 -1.1636 -0.3926 -0.3642 -0.0088 -0.0414 -1.5544 -0.3368 -0.1232
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence ; economic ; lvad ; outcomes
H-317	-0.4988759160041809	▁economic ▁models ▁; ▁Canadian ▁; ▁mandato ry ▁; ▁systematic ▁monitoring ▁; ▁l VAD
D-317	-0.4988759160041809	economic models ; Canadian ; mandatory ; systematic monitoring ; lVAD
P-317	-0.8695 -0.3017 -0.1172 -1.5036 -0.4429 -1.7231 -0.1150 -0.4658 -0.0758 -0.0093 -0.5005 -0.1979 -0.0200 -1.0229 -0.1180
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic ; crt
H-428	-0.5627148151397705	▁e cho car dio graphic ▁score ▁; ▁c RT ▁response
D-428	-0.5627148151397705	echocardiographic score ; cRT response
P-428	-1.5467 -0.0575 -0.0231 -0.1163 -0.1939 -0.3025 -0.1131 -0.4236 -2.3041 -1.4345 -0.0978 -0.1396
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection fraction ; patients
H-909	-0.4588381350040436	▁het e rogen ous ▁improvement ▁; ▁e je ction ▁ fraction
D-909	-0.4588381350040436	heterogenous improvement ; ejection fraction
P-909	-2.2306 -0.0909 -0.0165 -0.3722 -0.8532 -0.4760 -0.0221 -0.0987 -0.0780 -0.2850 -0.0058 -1.3489 -0.0869
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized ; af ablation
H-953	-0.7403156757354736	▁af ▁ab lation
D-953	-0.7403156757354736	af ablation
P-953	-3.0675 -0.0717 -0.0471 -0.4062 -0.1091
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel inhibition ; hemodynamic ; exercise tolerance ; heart failure with preserved ejection fraction ; randomized
H-1170	-0.23398357629776	▁If - chan nel ▁inhibi tion ▁; ▁hem o dynamic ▁status ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1170	-0.23398357629776	If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
P-1170	-2.1335 -0.0626 -0.0102 -0.0316 -0.1063 -0.6589 -0.6240 -0.0852 -0.2253 -0.0017 -0.0151 -0.1159 -0.0748 -0.0577 -0.0016 -0.2872 -0.0714 -0.0512 -0.5730 -0.0083 -0.0385 -0.5497 -0.0268 -0.0835 -0.0437 -0.4748 -0.0085 -0.2608 -0.1039
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping ; tidal respiration ; administration ; gadolinium-chelate contrast agent
H-1058	-0.3018287420272827	▁tid al ▁respira tion ▁; ▁ gado lini um - che late ▁contrast ▁agent
D-1058	-0.3018287420272827	tidal respiration ; gadolinium-chelate contrast agent
P-1058	-1.7478 -0.0252 -0.1296 -0.2142 -0.3108 -0.7189 -0.0168 -0.0909 -0.0192 -0.0536 -0.0066 -0.6372 -0.4871 -0.0381 -0.2205 -0.1126
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
H-1777	-0.19405294954776764	▁Card iac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁energy ▁production ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁pressure - over load ▁hyper trop hy
D-1777	-0.19405294954776764	Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
P-1777	-0.9100 -0.0079 -0.1284 -0.0370 -0.0635 -0.2371 -0.0036 -0.0428 -0.0458 -0.3421 -0.1712 -0.0192 -0.4441 -0.9979 -0.1137 -0.0121 -0.0161 -0.0302 -0.4038 -0.1932 -0.3149 -0.0288 -0.1140 -0.0235 -0.0424 -0.1745 -0.0024 -0.6223 -0.1742 -0.1048
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare ; inpatient ; hf ; admissions ; acute ; hospitals ; united states
H-1723	-0.33064892888069153	▁Medica re ▁in patient ▁data ▁; ▁ HF ▁ad missions ▁to ▁a cute ▁care ▁hospital s ▁; ▁United ▁States
D-1723	-0.33064892888069153	Medicare inpatient data ; HF admissions to acute care hospitals ; United States
P-1723	-0.0222 -0.0163 -0.0226 -0.0083 -1.0321 -0.1436 -0.7614 -0.2547 -0.0979 -0.1253 -0.5724 -0.0188 -0.0093 -1.2668 -0.1947 -0.1096 -1.4486 -0.3395 -0.2226 -0.1574 -0.1192
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes ; catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction
H-941	-0.28922349214553833	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-941	-0.28922349214553833	catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
P-941	-2.1939 -0.1087 -0.0201 -0.0475 -0.4104 -0.3465 -0.0847 -0.3799 -0.0218 -0.0304 -0.2046 -1.0998 -0.0522 -0.4762 -0.0146 -0.0377 -0.4658 -0.0347 -0.1034 -0.0436 -0.3768 -0.0041 -0.2446 -0.1394
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose ; acute heart failure ; randomized
H-71	-0.25215932726860046	▁dop amine ▁; ▁nesi riti de ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁a cute ▁heart ▁failure
D-71	-0.25215932726860046	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; acute heart failure
P-71	-0.1086 -0.0426 -0.0409 -1.4668 -0.0051 -0.0862 -0.3200 -0.0163 -0.0055 -0.2951 -0.0502 -0.4781 -0.0080 -0.0468 -0.0478 -0.4150 -0.7127 -0.0424 -0.6394 -0.0969 -0.5315 -0.0916
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report ; dapc ; dystrophin-associated protein complex ; sarcomeric microstructure ; baseline
H-1253	-0.24165119230747223	▁DAP c ▁; dys trop hin - as soci ated ▁protein ▁complex ▁; ▁sar come ric ▁micro structure
D-1253	-0.24165119230747223	DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
P-1253	-0.1006 -0.9461 -0.2322 -0.0377 -0.0355 -0.6200 -0.0563 -0.0550 -0.0001 -0.4853 -0.0726 -0.0529 -0.5068 -0.0721 -0.3753 -0.7461 -0.0283 -0.1771 -0.1305 -0.1025
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf ; hhd ; salt loading ; uninephrectomy ; ang ii infusion
H-275	-0.3080214560031891	▁mouse ▁ HF ▁model ▁; ▁h h ▁; ▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion
D-275	-0.3080214560031891	mouse HF model ; hh ; salt loading ; uninephrectomy ; ANG II infusion
P-275	-0.1010 -1.0576 -0.0334 -0.1918 -0.1487 -0.9452 -1.1814 -0.1000 -0.0978 -0.0125 -0.0302 -0.1143 -0.0095 -0.4963 -1.3900 -0.0691 -0.0180 -0.9258 -0.1873 -0.0366 -0.2024 -0.0035 -0.0040 -0.2463 -0.0978
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf with preserved ejection fraction ; pef ; uptitration ; hospitalization
H-176	-0.3505769670009613	▁ HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁p EF ▁; ▁up tit ration ▁; ▁hospital ization
D-176	-0.3505769670009613	HF ; preserved ejection fraction ; pEF ; uptitration ; hospitalization
P-176	-2.3230 -0.2605 -0.3528 -0.2966 -0.0382 -0.3401 -0.0361 -0.1163 -0.0495 -0.3081 -0.0069 -0.2644 -0.1483 -0.1463 -0.5072 -0.1787 -0.0554 -0.1323 -1.3821 -0.1220 -0.7695 -0.1344 -0.0945
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial ; titin hypophosphorylation ; heart failure with preserved ejection fraction ; metabolic
H-759	-0.32091429829597473	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁rat ▁metabol ic ▁risk
D-759	-0.32091429829597473	Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
P-759	-0.8016 -0.0424 -0.0820 -0.0928 -0.4409 -0.0945 -0.2588 -0.0696 -0.8033 -0.6459 -0.0665 -0.1567 -0.4253 -0.0566 -0.3038 -0.9115 -0.0261 -0.0144 -0.2912 -0.0046 -0.3342 -0.3175 -0.0260 -0.0406 -0.5296 -1.6891 -0.1393
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic ; cardiac resynchronization therapy ; crt
H-427	-0.28973013162612915	▁e cho car dio graphic ▁predict ors ▁; ▁response ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-427	-0.28973013162612915	echocardiographic predictors ; response ; cardiac resynchronization therapy ; cRT
P-427	-0.0214 -0.0187 -0.0322 -0.2996 -0.1344 -1.0454 -0.1262 -0.2349 -0.0601 -1.0588 -0.0246 -0.0334 -0.0477 -0.0165 -0.4712 -0.4364 -0.0120 -0.2398 -0.5069 -1.3263 -0.1450 -0.0826
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients ; baseline ; serum creatinine ; serum potassium
H-441	-0.3336069881916046	▁se rum ▁creati nine ▁level ▁; ▁se rum ▁po tas s ium ▁level
D-441	-0.3336069881916046	serum creatinine level ; serum potassium level
P-441	-0.7117 -0.0751 -0.5057 -0.1206 -0.1363 -0.1689 -0.5707 -0.0631 -0.7452 -0.2756 -0.2489 -0.1789 -0.1393 -0.9528 -0.1111
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin subproteomes ; heart failure ; proteins ; chromatin structure
H-91	-0.5945114493370056	▁chr omat in ▁sub prote om es ▁; ▁heart ▁failure ▁; ▁chr omat in ▁structure
D-91	-0.5945114493370056	chromatin subproteomes ; heart failure ; chromatin structure
P-91	-1.6366 -0.0205 -0.6467 -0.1812 -0.0622 -0.1735 -0.4277 -0.2683 -0.5527 -0.1904 -0.4484 -4.0465 -0.0611 -0.6648 -0.4260 -0.1828 -0.1173
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac mrna ; inflammatory ; cell adhesion genes ; retn
H-934	-0.4474874436855316	▁Hum - ▁re t n ▁mi ce ▁; ▁cardiac ▁m RNA ▁levels ▁; ▁infla mma tory ▁; ▁cell ▁a dhe sion ▁gene s ▁; ▁Ret n ▁; ▁mi ce
D-934	-0.4474874436855316	Hum- retn mice ; cardiac mRNA levels ; inflammatory ; cell adhesion genes ; Retn ; mice
P-934	-0.1336 -0.0330 -1.8311 -0.0712 -0.0181 -0.7418 -0.2397 -0.2240 -0.0397 -0.0082 -0.0125 -0.8157 -0.1835 -0.1000 -0.1606 -0.0665 -0.3169 -0.1954 -0.0835 -0.0235 -0.2773 -0.6691 -0.1011 -0.5059 -0.0166 -0.0339 -1.8381 -4.5647 -0.3085 -0.1465 -0.1118
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia ; patients ; chronic heart failure ; hf ; prevalence ; outcomes
H-834	-0.3484356999397278	▁an emia ▁; ▁chronic ▁heart ▁failure ▁; HF
D-834	-0.3484356999397278	anemia ; chronic heart failure ;HF
P-834	-0.8116 -0.0112 -0.1730 -0.2991 -0.7265 -0.0840 -0.1978 -0.0172 -1.0607 -0.1033
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university of connecticut heart failure center ; heart failure ; nurse practitioner
H-728	-0.2212504893541336	▁University ▁of ▁Connect i cut ▁Heart ▁Fail ure ▁Center ▁; ▁cardio logist ▁; ▁heart ▁failure ▁nurse ▁prac ti tioner
D-728	-0.2212504893541336	University of Connecticut Heart Failure Center ; cardiologist ; heart failure nurse practitioner
P-728	-0.9760 -0.0244 -0.2071 -0.0075 -0.0451 -0.4808 -0.2376 -0.4876 -0.4071 -0.2418 -0.0258 -0.0226 -0.0629 -0.1117 -0.0515 -0.5749 -0.2913 -0.0672 -0.1173 -0.1234 -0.0825
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp ; antibodies ; nonterminal epitopes
H-1519	-0.2528371214866638	▁circula ting ▁NT - pro b NP ▁concentration ▁; ▁anti bo dies ▁target ing ▁non gly cos yla ted ▁; ▁non termin al ▁e pito pes
D-1519	-0.2528371214866638	circulating NT-probNP concentration ; antibodies targeting nonglycosylated ; nonterminal epitopes
P-1519	-0.3035 -0.0457 -0.7524 -0.0208 -0.0088 -0.6677 -0.1539 -1.2054 -0.1722 -0.0060 -0.0233 -0.7316 -0.2128 -0.0755 -0.0378 -0.2551 -0.2358 -0.3222 -0.1758 -0.7009 -0.0164 -0.3913 -0.0046 -0.0692 -0.0364 -0.1816 -0.1709 -0.1018
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv failure ; diagnostic ; left ventricular dysfunction
H-1093	-0.414623498916626	▁ RV ▁failure ▁; ▁diagnosti ▁procedure s ▁; ▁management ▁strategie s ▁; ▁intr in sic ▁left ▁vent ri cular ▁dys function
D-1093	-0.414623498916626	RV failure ; diagnosti procedures ; management strategies ; intrinsic left ventricular dysfunction
P-1093	-0.7306 -0.9022 -0.2380 -0.2012 -3.1978 -0.6424 -0.0335 -0.1730 -0.0633 -0.4952 -0.0734 -0.2292 -0.8280 -0.0538 -0.0057 -0.1086 -0.0489 -0.9999 -0.1246 -0.0343 -0.1025 -0.1438 -0.1063
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd ; diuretic ; peripheral edema ; functional class
H-899	-0.33916378021240234	▁PD ▁; ▁weight ▁loss ▁; ▁di ure tic ▁response ▁; ▁per i pher al ▁ed ema ▁; ▁functional
D-899	-0.33916378021240234	PD ; weight loss ; diuretic response ; peripheral edema ; functional
P-899	-0.1798 -0.6319 -0.6236 -0.7937 -0.3619 -0.0745 -0.1386 -0.4038 -0.2863 -0.1711 -0.0083 -0.0321 -0.0086 -0.0137 -0.2470 -0.0122 -0.6974 -0.0022 -2.0267 -0.0699
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic heart failure ; yield ; atrial ; cells
H-1334	-0.36249229311943054	▁Chro nic ▁heart ▁failure ▁; ▁transform ing ▁growth ▁factor ▁beta - dependent ▁yi eld ▁; ▁functional ▁decline ▁; ▁at rial ▁ex plant - der i ved ▁c - K it + ▁cell s
D-1334	-0.36249229311943054	Chronic heart failure ; transforming growth factor beta-dependent yield ; functional decline ; atrial explant-derived c-Kit+ cells
P-1334	-0.2140 -0.0456 -0.6378 -0.0837 -0.1828 -0.6481 -0.0115 -0.3114 -0.0470 -4.3876 -0.0097 -0.0293 -0.0536 -0.0006 -0.1386 -0.6376 -1.2475 -0.3605 -0.3750 -0.0260 -0.6738 -0.0022 -0.0453 -0.0253 -0.1033 -0.0845 -0.0460 -0.0397 -0.7966 -0.0070 -0.8496 -0.1767 -0.1597 -0.1438 -0.0859
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients ; hfpef ; kccq ; health ; prognostic
H-791	-0.5747950673103333	▁ HF p EF ▁; ▁k cc q
D-791	-0.5747950673103333	HFpEF ; kccq
P-791	-1.1976 -0.0579 -0.0348 -0.1955 -0.0787 -1.0433 -0.0401 -1.2129 -1.7886 -0.0985
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients ; heartmate ii ; lvad ; centrimag ; rvad
H-298	-0.32836034893989563	▁Heart Mate ▁II ▁l VAD ▁; ▁Centri Mag ▁r VAD
D-298	-0.32836034893989563	HeartMate II lVAD ; CentriMag rVAD
P-298	-0.4271 -0.0428 -0.5857 -0.2555 -0.0121 -0.3357 -0.2392 -0.3563 -1.4144 -0.0250 -0.1614 -0.0852
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods study ; exercise ; patients ; heart failure
H-615	-1.2263332605361938	▁voordelen ▁; ▁structure d ▁exercise ▁programme ▁; ▁heart ▁failure
D-615	-1.2263332605361938	voordelen ; structured exercise programme ; heart failure
P-615	-4.1307 -0.3365 -3.0813 -0.0094 -1.0117 -0.1062 -0.5297 -3.8254 -0.1364 -0.1897 -0.1326
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf ; mi ; reduced ejection fraction ; ef
H-1100	-0.27698051929473877	▁ HF ▁; ▁MI ▁; ▁pres er ved ▁; ▁reduce d ▁e je ction ▁ fraction ▁; EF
D-1100	-0.27698051929473877	HF ; MI ; preserved ; reduced ejection fraction ;EF
P-1100	-2.0506 -0.0596 -0.2488 -0.3393 -0.2282 -0.4246 -0.0273 -0.0835 -0.2613 -0.2837 -0.0133 -0.0310 -0.0543 -0.0213 -0.3785 -0.0045 -0.5686 -0.1219 -0.2054 -0.1338
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality ; inpatient ; admissions ; hospital ; emergency department
H-1623	-0.154524564743042	▁Mor t ality ▁; ▁in patient ▁ad missions ▁; ▁hospital ▁days ▁; ▁emergency ▁department ▁; ED
D-1623	-0.154524564743042	Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
P-1623	-0.3767 -0.0734 -0.0338 -0.1989 -0.0039 -0.0451 -0.0916 -0.1038 -0.2309 -0.0786 -0.2688 -0.1941 -0.0467 -0.0306 -0.4725 -0.2433 -0.1979 -0.0908
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard ; tnf antagonist ; baseline ; covariates
H-606	-0.3667132258415222	▁n b DM ARD ▁; ▁t NF ▁anta gon ist
D-606	-0.3667132258415222	nbDMARD ; tNF antagonist
P-606	-0.0344 -0.0090 -0.1191 -0.5230 -0.1081 -2.8425 -0.2284 -0.0721 -0.0035 -0.0837 -0.2646 -0.1122
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab ; adjuvant ; outcomes ; cardiotoxicity ; congestive heart failure ; chf
H-670	-0.39569273591041565	▁tras tuz um ab ▁; ▁cardio toxic iteit ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-670	-0.39569273591041565	trastuzumab ; cardiotoxiciteit ; congestive heart failure ;CHf
P-670	-0.1146 -0.0112 -0.0032 -0.6363 -0.0925 -0.5929 -0.2926 -1.5059 -0.1010 -0.0109 -0.0401 -1.1659 -0.2932 -0.0929 -0.5630 -0.4922 -1.3009 -0.1209 -0.0881
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac ; sympathovagal balance
H-1138	-0.24236682057380676	▁py rido stig mine ▁; ▁met hy la tropi ne ▁; ▁propra no lol ▁; ▁cardiac ▁sympa t hova gal ▁balance
D-1138	-0.24236682057380676	pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
P-1138	-0.0119 -0.0073 -0.0014 -0.0839 -1.2998 -0.4134 -0.0654 -0.1334 -0.0021 -1.1966 -0.0977 -0.0087 -0.0060 -0.0545 -0.5385 -0.0312 -0.2090 -0.1796 -0.0378 -0.2234 -0.6155 -0.2544 -0.1030
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr ; protein kinase r-like er kinase ; perk ; calreticulin ; chop ; hf
H-1084	-0.3000675439834595	▁u PR ▁effect ors ▁; ▁protein ▁kina se ▁; ▁r - like ▁ER ▁kina se ▁; per k ▁; ▁cal ret icul in ▁; ▁CHO p ▁; ▁ HF ▁tissu es
D-1084	-0.3000675439834595	uPR effectors ; protein kinase ; r-like ER kinase ;perk ; calreticulin ; CHOp ; HF tissues
P-1084	-2.2715 -0.0866 -0.1353 -0.0810 -0.1762 -0.0308 -0.0103 -0.0477 -1.1442 -0.5936 -0.0330 -0.1056 -0.8775 -0.0053 -0.0226 -0.2035 -0.5114 -0.2555 -0.0541 -0.0011 -0.0751 -0.0007 -0.3344 -0.2100 -0.0580 -0.3311 -0.3623 -1.2320 -0.2918 -0.0814 -0.0363 -0.1575 -0.0850
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin ; protein-c ; phosphorylation ; troponin i ; phosphorylation ; hf
H-1427	-0.5991618633270264	▁total ▁my os in ▁ binding ▁protein - c ▁ phos phor y lation ▁; ▁Ser 23 /24 ▁trop onin ▁I ▁ phos phor y lation ▁; ▁ HF
D-1427	-0.5991618633270264	total myosin binding protein-c phosphorylation ; Ser23/24 troponin I phosphorylation ; HF
P-1427	-2.5276 -0.6379 -0.0532 -0.8440 -0.2478 -0.0008 -0.9445 -0.0845 -1.4084 -0.4893 -0.0631 -1.5590 -1.1348 -0.0886 -0.1393 -0.9306 -0.1605 -0.0073 -0.0234 -0.0806 -1.6120 -0.1524 -0.0408 -1.9526 -1.4744 -0.1532 -0.4906 -0.9307 -0.1214 -0.1026 -0.1179
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory
H-1324	-0.32713091373443604	▁e cho car dio graphic ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s
D-1324	-0.32713091373443604	echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory markers
P-1324	-0.7035 -0.3280 -0.1915 -0.1670 -0.1820 -0.6078 -2.6799 -0.0096 -0.0203 -0.0026 -0.0645 -0.0198 -0.0519 -0.0752 -0.0464 -0.1297 -0.1505 -1.4324 -0.7011 -0.1329 -0.1943 -0.2359 -0.0236 -0.2430 -0.4311 -0.2152 -0.1864 -0.1197 -0.1410
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
H-1207	-0.29103735089302063	▁Pho s pho dies tera se -2 ▁; ▁fail ing ▁heart s ▁; ▁blu nts ▁beta - ad r energi c ▁response s ▁; ▁cardio my o cy tes
D-1207	-0.29103735089302063	Phosphodiesterase-2 ; failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
P-1207	-0.3029 -0.0670 -0.0967 -1.8022 -0.0181 -0.0530 -0.2919 -0.4122 -1.5463 -0.0334 -0.5674 -0.0645 -0.2062 -0.1079 -0.0654 -0.9026 -0.0179 -0.0899 -0.2041 -0.4616 -0.1017 -0.1342 -0.1320 -0.3466 -0.0149 -0.3267 -0.0981 -0.0289 -0.1414 -0.2039 -0.1828
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol ; thromboembolic events ; patients ; heart failure ; β2-receptor haplotype
H-1120	-0.2696649432182312	▁car vedi lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure ▁; ▁β 2- recept or ▁ha plo type ▁status
D-1120	-0.2696649432182312	carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype status
P-1120	-0.0037 -0.0046 -0.0741 -0.3135 -0.4540 -0.2904 -1.2375 -0.2750 -0.0571 -0.6563 -0.8647 -0.2131 -0.8791 -0.0960 -0.4035 -0.0349 -0.0416 -0.0152 -0.0113 -0.0185 -0.0352 -0.0204 -0.3882 -0.2695 -0.0843
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref ; exercise ; resting hr ; bpm ; beta-blocker ; therapy
H-1946	-0.3084183633327484	▁h Fr EF ▁; ▁exercise ▁performance ▁; ▁rest ing ▁HR ▁; ▁beta - block er ▁ therapy
D-1946	-0.3084183633327484	hFrEF ; exercise performance ; resting HR ; beta-blocker therapy
P-1946	-2.0348 -0.4138 -0.6934 -0.1205 -0.2108 -0.0208 -0.1172 -0.5442 -0.0362 -0.3182 -0.3456 -0.2189 -0.0410 -0.0669 -0.0290 -0.3558 -0.0093 -0.1851 -0.0985
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline ; follow-up ; paf ; activity ; metabolic ; enzymes ; patients ; heart failure ; healthy
H-1266	-0.5285258293151855	▁pa f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure
D-1266	-0.5285258293151855	paf ; metabolic enzymes ; heart failure
P-1266	-1.6917 -1.2767 -0.1496 -0.0608 -0.0847 -0.0503 -0.0857 -0.3369 -0.8899 -0.0898 -1.4821 -0.1440
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo inhibition ; cardiomyocyte bioenergetics ; lv function ; chronic acf
H-472	-0.243735209107399	▁ XO ▁inhibi tion ▁; ▁cardio my o cy te ▁bio ener ge tics ▁; ▁LV ▁function ▁; ▁chronic ▁a CF ▁; ▁rat
D-472	-0.243735209107399	XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic aCF ; rat
P-472	-1.0337 -0.0097 -0.0331 -0.2820 -0.0507 -0.0088 -0.2667 -0.1281 -0.0665 -0.0871 -0.0047 -0.2665 -0.4443 -0.3407 -0.0661 -0.0601 -0.1269 -0.1029 -0.0061 -1.0009 -0.5435 -0.9279 -0.0116 -0.1406 -0.0840
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled trials ; rcts ; observational cohort studies ; contemporaneous control group
H-152	-0.3837876319885254	▁random ised - control led ▁trial s ▁; RC t s ▁; ▁observation al ▁co hor t ▁studies
D-152	-0.3837876319885254	randomised-controlled trials ;RCts ; observational cohort studies
P-152	-1.2047 -0.9101 -0.0757 -0.0096 -0.5732 -0.1292 -0.0861 -0.3757 -0.0862 -0.3487 -0.1135 -1.3210 -0.0412 -0.0090 -0.0482 -0.5443 -0.1588 -0.2329 -1.2620 -0.1459
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox hazard models ; esrd ; death ; composite end point ; esrd ; death ; esrd
H-391	-0.48257768154144287	▁co x ▁hazard ▁models ▁; ▁time ▁to ▁ES RD ▁; ▁to ▁death ▁; ▁ES RD ▁; ▁death ▁; ▁predict ors ▁; ▁ES RD
D-391	-0.48257768154144287	cox hazard models ; time to ESRD ; to death ; ESRD ; death ; predictors ; ESRD
P-391	-0.1664 -0.0052 -0.2539 -0.2467 -0.0767 -1.2913 -0.8420 -0.6491 -0.3365 -0.0996 -1.4326 -0.1921 -0.1677 -1.4862 -0.2842 -0.1210 -0.7552 -0.4371 -1.3057 -0.1777 -0.3766 -0.7959 -0.3836 -0.0868 -0.0948
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative ; renal dysfunction ; stroke ; myocardial infarction ; heart failure ; cabg
H-970	-0.27498921751976013	▁renal ▁dys function ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁CA BG
D-970	-0.27498921751976013	renal dysfunction ; stroke ; myocardial infarction ; heart failure ; CABG
P-970	-0.7126 -0.0352 -0.0234 -0.0386 -1.4888 -0.0678 -0.3373 -0.2461 -0.2322 -0.2233 -0.0219 -0.1195 -0.1025 -0.0918 -0.2783 -0.0419 -0.6508 -0.7953 -0.0883 -0.0830 -0.0961
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients ; heart failure ; hf ; cardiopulmonary exercise test ; anaerobic threshold
H-1753	-0.3449902832508087	▁heart ▁failure ▁; HF ▁; ▁cardio pul mon ary ▁exercise ▁test ▁; ▁ana ero bic ▁thre s hold ▁; AT
D-1753	-0.3449902832508087	heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
P-1753	-1.4039 -0.1252 -0.1730 -0.0160 -0.1234 -0.9276 -0.1292 -0.5490 -0.2458 -1.0851 -0.6631 -0.1730 -0.0053 -0.0886 -0.3237 -0.0551 -0.0605 -0.3732 -0.6515 -0.1235 -0.1967 -0.0973
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients ; heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortality
H-1896	-0.4718351662158966	▁heart ▁failure ▁; ▁heart ▁failure ▁nurse s ▁; ▁follow - up ▁; ▁card i ology ▁services
D-1896	-0.4718351662158966	heart failure ; heart failure nurses ; follow-up ; cardiology services
P-1896	-1.3084 -0.0767 -0.3703 -1.9560 -0.0410 -0.2026 -0.0281 -0.1812 -0.9126 -0.0359 -0.0058 -0.4974 -0.3315 -0.1507 -0.1624 -0.8090 -1.3131 -0.1103
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
H-1144	-0.2191450446844101	▁ HF ▁rat s ▁; ▁py rido stig mine ▁; ▁stroke ▁volume ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁output ▁; ▁contract ility ▁; ▁left ▁vent ric le
D-1144	-0.2191450446844101	HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
P-1144	-1.7295 -0.0256 -0.5071 -0.0554 -0.8664 -0.0522 -0.0034 -0.0024 -0.2424 -0.0775 -0.4216 -0.0925 -0.0556 -0.0113 -0.0448 -0.0146 -0.1639 -0.0020 -0.0633 -0.0051 -0.0014 -0.0813 -0.0422 -0.1160 -0.3073 -0.1010 -0.0904 -0.7359 -0.6275 -0.1769 -0.0771
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac deaths ; atherosclerotic cad
H-1907	-0.6802921295166016	▁middle - a ged ▁recrea tional ▁ath letes ▁; ▁sud den ▁cardiac ▁death s
D-1907	-0.6802921295166016	middle-aged recreational athletes ; sudden cardiac deaths
P-1907	-3.8258 -0.0578 -0.0946 -0.0663 -0.0695 -0.1152 -0.7272 -0.0089 -0.4548 -0.0843 -0.0088 -0.0103 -0.3880 -0.2038 -4.5888 -0.1805
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery ; rheumatic ; surgery ; mva
H-359	-0.731451153755188	▁rhe u matic ▁; ▁MS
D-359	-0.731451153755188	rheumatic ; MS
P-359	-2.4874 -0.0216 -0.0264 -0.0524 -1.8059 -0.6547 -0.0716
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health ; followed up ; hf ; hospitalization ; death ; contact
H-687	-0.7830227017402649	▁women s ▁Health ▁Initiative ▁; ▁ HF ▁hospital ization
D-687	-0.7830227017402649	womens Health Initiative ; HF hospitalization
P-687	-1.4941 -2.3711 -1.1900 -0.2625 -0.5204 -0.3762 -0.1674 -0.8117 -0.1663 -1.1302 -0.1233
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted ; left ventricle end-diastolic pressure
H-1340	-0.3615574538707733	▁CHF - develop ed ▁in far cted ▁animals ▁; ▁left ▁vent ric le ▁end - dia sto lic ▁pressure
D-1340	-0.3615574538707733	CHF-developed infarcted animals ; left ventricle end-diastolic pressure
P-1340	-0.0521 -0.1464 -0.0182 -0.0159 -0.0052 -0.0253 -1.3575 -0.3374 -0.3468 -0.1570 -0.0330 -0.5891 -0.2331 -1.3666 -0.0667 -0.0153 -0.1060 -0.0831 -0.5370 -2.0316 -0.0694
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv ; pathophysiologic ; rv dysfunction
H-1094	-0.40283066034317017	▁ rv ▁; ▁pat ho phy si ologic ▁mechanism s ▁; ▁ RV ▁dys function
D-1094	-0.40283066034317017	rv ; pathophysiologic mechanisms ; RV dysfunction
P-1094	-1.0812 -0.9777 -0.3282 -0.9101 -0.2337 -0.6031 -0.7430 -0.0567 -0.0372 -0.1746 -0.3542 -0.4875 -0.3182 -0.2014 -0.0773 -0.1227 -0.1412
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients ; hf ; crt ; implantation ; complications
H-912	-0.30694815516471863	▁di al ysis - dependent ▁patients ▁; ▁ HF ▁; ▁c RT ▁implant ation
D-912	-0.30694815516471863	dialysis-dependent patients ; HF ; cRT implantation
P-912	-0.3129 -0.0122 -0.0107 -0.0626 -0.0402 -0.4519 -0.6867 -0.5499 -0.0561 -0.2163 -0.5102 -1.2587 -0.2424 -0.2610 -0.1837 -0.0558
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak oxygen consumption ; pulse ; patients
H-1918	-0.3426133394241333	▁Peak ▁oxygen ▁consum p tion ▁; ▁oxygen ▁puls e
D-1918	-0.3426133394241333	Peak oxygen consumption ; oxygen pulse
P-1918	-0.0891 -1.5691 -0.1529 -0.0513 -0.6266 -0.1566 -0.5302 -0.0167 -0.1541 -0.3544 -0.0677
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic ; nhs ; chronic ; disease ; exercise ; acute ; hospital
H-613	-0.33222469687461853	▁economic ▁climate ▁; ▁NH s ▁; ▁behaviour al - change ▁; ▁chronic ▁disease ▁; ▁exercise ▁programme s ▁; ▁a cute ▁hospital ▁facilities
D-613	-0.33222469687461853	economic climate ; NHs ; behavioural-change ; chronic disease ; exercise programmes ; acute hospital facilities
P-613	-0.5984 -0.8229 -0.0966 -0.7025 -0.7308 -0.1792 -0.2473 -0.0322 -0.0918 -0.0387 -0.9108 -0.4046 -0.1329 -0.3881 -0.0766 -0.1952 -0.1027 -1.0305 -0.4133 -0.0017 -0.1461 -0.3361 -0.1362 -0.1581
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf ; patients ; hct ; city of hope
H-1452	-0.5708920955657959	▁post - h CT ▁CHF ▁; ▁h CT ▁; ▁City ▁of ▁Hope
D-1452	-0.5708920955657959	post-hCT CHF ; hCT ; City of Hope
P-1452	-1.8033 -0.0070 -0.5847 -0.4002 -0.0813 -0.3834 -2.4398 -0.2815 -0.2716 -0.9550 -0.1116 -0.4377 -0.1653 -0.0700
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.5434659719467163	
D-557	-0.5434659719467163	
P-557	-0.9988 -0.0882
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior vena cava ; ivc
H-321	-0.6432713270187378	▁pig s ▁; ▁inferior ▁ve na ▁ca va ▁; IV c ▁; ▁snar ed ▁to ▁decrease ▁CO
D-321	-0.6432713270187378	pigs ; inferior vena cava ;IVc ; snared to decrease CO
P-321	-1.8677 -0.0390 -0.2118 -0.4371 -0.3244 -0.5642 -0.0089 -0.0419 -0.1538 -0.6265 -0.5693 -0.2279 -3.2213 -0.1150 -2.2668 -0.0770 -0.5666 -0.8208 -0.0822
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin ; resistin
H-932	-0.46070733666419983	▁do xor ubi cin ▁; ▁i p ▁; ▁se rum ▁resist in ▁; ▁Hum - re t n ▁mi ce
D-932	-0.46070733666419983	doxorubicin ; ip ; serum resistin ; Hum-retn mice
P-932	-0.0122 -0.0133 -0.0123 -0.1544 -0.1461 -1.0508 -0.0158 -0.3558 -0.2225 -0.1028 -0.1082 -0.2576 -2.0562 -0.1232 -0.0625 -2.9930 -0.2036 -0.0351 -1.1793 -0.6460 -0.2477 -0.1369
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs ; physicians ; hospital
H-1729	-0.5201109051704407	▁kosten ▁; ▁high - volu me ▁physician s
D-1729	-0.5201109051704407	kosten ; high-volume physicians
P-1729	-1.4446 -0.4070 -0.6577 -0.0344 -0.0132 -0.0284 -0.1963 -0.0544 -2.2859 -0.0794
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf ; proteins
H-1361	-0.6069148182868958	▁CHF ▁; ▁fat ▁; ▁car bo hydrat es ▁; ▁protein s ▁; ▁water
D-1361	-0.6069148182868958	CHF ; fat ; carbohydrates ; proteins ; water
P-1361	-2.2840 -0.4211 -2.6654 -0.2310 -0.0045 -0.0330 -0.1494 -0.0987 -0.2152 -0.0773 -0.0468 -0.3858 -0.1034 -2.2992 -0.0890
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.2234787493944168	▁de activa tion
D-1864	-0.2234787493944168	deactivation
P-1864	-0.1315 -0.0555 -0.1991 -0.6637 -0.0677
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone receptor antagonists ; randomized ; morbidity ; mortality ; symptomatic systolic heart failure
H-438	-0.2353857010602951	▁al do ster one ▁receptor ▁anta gon ists ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁sy sto lic ▁heart ▁failure
D-438	-0.2353857010602951	aldosterone receptor antagonists ; morbidity ; mortality ; systolic heart failure
P-438	-0.3121 -0.0416 -0.0493 -0.2631 -0.0069 -0.0911 -0.0071 -0.5023 -0.2700 -0.1821 -0.0234 -1.0466 -0.2643 -0.0170 -0.4728 -0.1774 -0.5201 -0.0449 -0.0813 -0.5998 -0.2089 -0.1566 -0.0753
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a ; upr ; downregulation ; cardiac ; genes ; hf
H-1089	-0.5431564450263977	▁s cn 5 a ▁tran script ▁; ▁u PR ▁; ▁down regul ation ▁; ▁cardiac ▁gene s ▁; ▁ HF
D-1089	-0.5431564450263977	scn5a transcript ; uPR ; downregulation ; cardiac genes ; HF
P-1089	-0.9710 -0.1400 -0.1475 -0.3029 -0.0242 -0.0169 -0.0742 -1.4779 -0.6452 -0.2581 -3.5198 -0.0806 -0.0931 -0.6801 -1.5003 -0.7238 -0.0612 -0.3467 -0.4280 -0.2228 -0.1282 -0.1068
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east ; rhythm control therapy ; diagnosis ; cardiovascular ; complications
H-1655	-0.2629286050796509	▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1655	-0.2629286050796509	east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
P-1655	-0.7831 -0.2478 -0.1133 -0.0457 -0.1037 -0.1365 -0.1810 -0.0101 -0.1959 -0.5195 -0.4112 -0.0375 -0.0064 -0.0913 -1.4085 -0.2345 -0.0956 -0.1111
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin ; inflammation ; hepatic ; prognosis ; patients ; lvad ; implantation
H-540	-0.24254754185676575	▁album in ▁levels ▁; ▁nutrition ▁; ▁ inflammation ▁; ▁he pati c ▁function ▁; ▁l VAD ▁implant ation
D-540	-0.24254754185676575	albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD implantation
P-540	-0.2191 -0.2546 -0.5345 -0.1294 -1.2484 -0.0875 -0.0244 -0.0093 -0.1615 -0.0097 -0.0838 -0.0923 -0.0460 -0.3255 -0.8681 -0.0257 -0.2942 -0.1684 -0.1615 -0.1072
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right ventricular ; rv ; left ventricular assist device ; lvad ; outcomes
H-294	-0.398598849773407	▁Right ▁vent ri cular ▁; RV ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-294	-0.398598849773407	Right ventricular ;RV ; left ventricular assist device ; lVAD
P-294	-0.6967 -0.0420 -0.7080 -0.1102 -0.3327 -0.3972 -0.3352 -1.5066 -0.0333 -0.8816 -0.1444 -0.9608 -0.3879 -0.2424 -0.0392 -0.0119 -0.2631 -0.0816
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse ; pasp ; downward ; regression line ; shift ; pasp ; tapse
H-496	-0.9609437584877014	▁t AP se ▁; ▁PAS p ▁; ▁non sur viv ors ▁; ▁PAS p ▁; ▁t AP se
D-496	-0.9609437584877014	tAPse ; PASp ; nonsurvivors ; PASp ; tAPse
P-496	-3.7572 -0.5166 -1.9473 -0.6515 -0.6106 -1.3597 -0.3899 -1.9025 -0.0522 -0.0108 -0.2915 -0.5834 -1.0018 -0.9108 -0.4378 -2.7070 -0.4070 -1.4901 -0.0857 -0.1053
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox proportional hazards models ; health ; health ; hazard ratios ; confidence intervals
H-689	-0.4629845917224884	▁co x ▁proportion al ▁hazard s ▁models ▁; ▁health ▁behavior s ▁; ▁health ▁status
D-689	-0.4629845917224884	cox proportional hazards models ; health behaviors ; health status
P-689	-0.0293 -0.0315 -0.0611 -0.0067 -0.2341 -0.2544 -1.2998 -0.3312 -1.4197 -0.4673 -0.0702 -0.2506 -0.6756 -0.0790 -2.1290 -0.0684
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis ; expenditure ; b natriuretic peptides ; nps
H-10	-0.3756917417049408	▁li poly sis ▁; ▁energie ▁ex pendi ture ▁; ▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁CC
D-10	-0.3756917417049408	lipolysis ; energie expenditure ; natriuretic peptides ;NPs ; CC
P-10	-0.7666 -0.0121 -0.1230 -0.0945 -1.9723 -0.1378 -0.0696 -1.0498 -0.3059 -0.2521 -0.1798 -0.1692 -1.5513 -0.2726 -0.0985 -0.1410 -0.2413 -0.0186 -0.0453 -0.6281 -0.3397 -0.0714 -0.1004
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths ; stroke ; hospitalisations ; heart failure ; follow-up
H-816	-0.2769602835178375	▁CV ▁death s ▁; ▁non - fa tal ▁stroke ▁; ▁hospital isation s ▁; ▁heart ▁failure
D-816	-0.2769602835178375	CV deaths ; non-fatal stroke ; hospitalisations ; heart failure
P-816	-0.6206 -1.2045 -0.0824 -0.1338 -0.0874 -0.0440 -0.0365 -0.0600 -0.2136 -0.1518 -0.5923 -0.0479 -0.0709 -1.0278 -0.3258 -0.0998 -0.0973 -0.0889
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts ; mena ; cardiac injury ; mena ; hf ; pathophysiology
H-1817	-0.4237634539604187	▁heart s ▁; ▁men a ▁; ▁cardiac ▁injury ▁; ▁men a ▁; ▁ HF ▁pat ho phy si ology
D-1817	-0.4237634539604187	hearts ; mena ; cardiac injury ; mena ; HF pathophysiology
P-1817	-1.2232 -0.0791 -0.3627 -1.1233 -0.1623 -0.5522 -0.8517 -0.1512 -0.1350 -0.9062 -0.1874 -0.2302 -0.4381 -0.1785 -0.6653 -0.1708 -0.2071 -0.6030 -0.3450 -0.2386 -0.0881
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic ; biomarkers ; molecular dysfunction ; chronic hf
H-1477	-0.13655196130275726	▁bio mark ers ▁; ▁molecular ▁dys function ▁; ▁chronic ▁ HF
D-1477	-0.13655196130275726	biomarkers ; molecular dysfunction ; chronic HF
P-1477	-0.4867 -0.1285 -0.0587 -0.2634 -0.0567 -0.0098 -0.0341 -0.1730 -0.0200 -0.2131 -0.1161 -0.1147 -0.1004
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 ; c statistic ; net reclassification improvement ; integrated discrimination improvement
H-705	-0.3925973176956177	▁ST 2 ▁; ▁re class ification ▁; ▁risk ▁; ▁c ▁statistic ▁; ▁net ▁re class ification ▁; ▁integrat ed ▁discrimina tion
D-705	-0.3925973176956177	ST2 ; reclassification ; risk ; c statistic ; net reclassification ; integrated discrimination
P-705	-1.9828 -0.0664 -0.2554 -0.5111 -0.0882 -0.1686 -0.8357 -0.2405 -0.1149 -0.6732 -0.0676 -0.1170 -0.0347 -0.0368 -0.2296 -0.1372 -0.6087 -0.3853 -0.0599 -0.0907 -0.6549 -1.5500 -0.1207
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome ; gls ; beat ; cox proportional hazards analyses
H-814	-0.43187883496284485	▁g ls ▁; ▁index ▁beat ▁method ▁; ▁CV ▁; ▁co x ▁proportion al ▁hazard s ▁analyse s
D-814	-0.43187883496284485	gls ; index beat method ; CV ; cox proportional hazards analyses
P-814	-1.4450 -1.4178 -0.0699 -0.0125 -0.0048 -0.3833 -0.1418 -0.2020 -2.9243 -0.1432 -0.0317 -0.0286 -0.0050 -0.0461 -0.2466 -0.6103 -0.2357 -0.1690 -0.0880
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ; ischemic heart failure ; biomarkers ; heart failure
H-1615	-0.4328927993774414	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1615	-0.4328927993774414	non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
P-1615	-1.4768 -0.0338 -0.0432 -0.1022 -0.5325 -0.1096 -0.0300 -0.1765 -2.3174 -0.1022 -0.3796 -0.0409 -0.0554 -0.0499 -0.3713 -1.9835 -0.1033 -0.1849 -0.1319
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients ; vad ; patients ; ecmo ; vad ; patients ; ecmo
H-1389	-0.9046043753623962	▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁ec mo ▁group
D-1389	-0.9046043753623962	VAD group ; ecmo+VAD group ; ecmo group
P-1389	-0.8148 -0.0191 -1.7504 -0.0850 -1.5913 -1.3074 -1.0239 -0.0341 -1.0912 -0.2392 -1.6906 -1.3746 -2.1863 -0.2309 -0.1302
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air ; cardiovascular ; health ; acute myocardial infarction
H-1806	-0.45306888222694397	▁Ambient ▁air ▁pollution ▁; ▁cardiovascular ▁health ▁; ▁a cute ▁my o card ial ▁in far ction
D-1806	-0.45306888222694397	Ambient air pollution ; cardiovascular health ; acute myocardial infarction
P-1806	-0.0517 -0.3638 -0.1523 -0.1255 -0.8033 -1.0206 -0.3805 -1.0809 -0.0094 -2.0576 -0.3898 -0.4365 -0.2652 -0.0406 -0.2388 -0.4236 -0.1899 -0.1253
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq ; kaplan-meier curves ; death ; all-cause hospitalization
H-784	-0.6221388578414917	▁k cc q ▁; ▁ka plan - me ier ▁cur ves ▁; ▁death ▁; ▁hospital ization
D-784	-0.6221388578414917	kccq ; kaplan-meier curves ; death ; hospitalization
P-784	-1.8979 -0.0521 -1.0674 -0.4714 -0.8850 -0.0143 -0.0093 -0.6501 -0.0423 -0.2249 -1.4098 -0.7118 -0.9906 -0.7225 -1.1539 -0.6678 -0.0957 -0.1318
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ; ras ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
H-1599	-0.25687310099601746	▁ RAS ▁; ▁do pp ler ▁ultra son ography ▁; ▁com put ed ▁to mo graphic ▁ang i ography ▁; ▁magnetic ▁res on ance ▁ang i ography
D-1599	-0.25687310099601746	RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
P-1599	-1.9932 -0.0023 -0.3145 -0.3838 -0.0169 -1.0251 -0.0562 -0.0261 -0.2368 -0.1200 -0.0330 -0.0031 -0.0578 -0.0099 -0.0984 -0.1273 -0.4851 -0.1521 -0.1151 -0.2088 -0.0299 -0.0903 -0.0702 -0.2832 -0.8063 -0.2102 -0.0925 -0.2790 -0.1223
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone ; double-blind ; randomized
H-1316	-0.627800703048706	▁test o ster one ▁ therapy ▁; ▁exercise ▁rehabilita tion ▁; ▁chronic ▁heart ▁failure ▁; ▁low ▁testosteron e ▁status
D-1316	-0.627800703048706	testosterone therapy ; exercise rehabilitation ; chronic heart failure ; low testosterone status
P-1316	-1.6648 -0.5032 -0.0346 -0.3953 -1.2386 -0.0208 -0.7227 -0.9098 -0.0368 -0.3283 -0.3934 -3.9082 -0.5918 -0.0922 -0.4571 -1.4474 -0.0228 -0.0388 -0.0422 -0.2463 -0.0887
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic ; renal underperfusion ; renin- angiotensin-aldosterone pathway
H-1596	-0.43515703082084656	▁pat ho phy si ologic ▁mechanism ▁; ▁renal ▁under per fusion ▁; ▁re nin - ▁ang io ten sin - al do ster one ▁path way
D-1596	-0.43515703082084656	pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
P-1596	-2.3269 -0.4214 -0.8658 -0.9095 -0.0665 -0.0750 -1.5431 -0.0743 -1.3342 -0.1003 -0.0452 -0.2082 -0.1472 -0.1046 -0.0165 -0.6911 -0.3913 -0.0175 -0.4684 -0.1542 -0.0309 -0.1382 -0.0143 -0.3783 -0.7975 -0.4250 -0.2394 -0.1994
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ; ami ; complications ; heart failure ; kidney infection ; uti ; complications ; rehospitalization
H-1718	-0.4019101560115814	▁ AMI ▁; ▁heart ▁failure ▁; ▁ki dne y ▁infection ▁; ▁ UTI
D-1718	-0.4019101560115814	AMI ; heart failure ; kidney infection ; UTI
P-1718	-2.4948 -0.0341 -0.3139 -1.4190 -0.0416 -0.1706 -0.0426 -0.1023 -0.0232 -0.1218 -0.0947 -0.6552 -0.0086 -0.3958 -0.1104
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
H-869	-0.2171797752380371	▁prote o mics ▁; ▁path way ▁analysis ▁; ▁pressure - over load - indu ced ▁heart ▁failure ▁; ▁mito cho ndri al - tar get ed ▁pe pti des
D-869	-0.2171797752380371	proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
P-869	-0.8690 -0.4562 -0.0023 -0.0830 -1.2613 -0.0540 -0.1165 -0.4433 -0.0265 -0.0530 -0.0209 -0.0527 -0.1144 -0.0381 -0.1034 -0.9278 -0.1400 -0.3399 -0.1252 -0.1920 -0.2831 -0.0166 -0.0651 -0.0476 -0.0174 -0.0291 -0.2822 -0.0750 -0.2283 -0.1500 -0.1189
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil ; cardioprotection ; apoptotic signaling pathway ; dna fragmentation ; mitochondrial
H-965	-0.215157151222229	▁nic oran dil ▁; ▁cardio protec tion ▁; ▁apo pto tic ▁signal ing ▁path way ▁; ▁DNA ▁fragment ation ▁; ▁mito cho ndri al ▁ultra struct ural
D-965	-0.215157151222229	nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural
P-965	-0.1107 -0.0185 -0.1574 -0.1530 -0.0472 -0.0949 -0.2545 -0.2239 -0.7565 -0.0488 -0.6826 -0.0308 -0.1714 -0.2965 -0.4520 -0.3077 -0.0908 -0.0671 -0.1138 -0.2140 -0.0021 -0.2117 -0.0769 -0.0157 -0.1633 -0.0767 -0.0188 -1.2583 -0.1239
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ; ic ; multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy
H-103	-0.28558626770973206	▁IC ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁tri al - Card iac ▁re syn chron ization ▁Therapy
D-103	-0.28558626770973206	IC ; multicenter Automatic Defibrillator Implantation trial-Cardiac resynchronization Therapy
P-103	-1.3473 -0.2589 -0.6562 -0.0188 -0.4107 -0.0300 -0.7105 -0.0326 -0.2722 -0.0349 -0.1171 -0.1417 -0.6625 -0.0346 -0.0178 -0.3842 -0.1412 -0.7600 -0.0194 -0.0054 -0.3803 -0.1575 -0.1647 -0.0953
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted county ; minnesota ; mi ; diagnosed ; hf ; followed-up
H-1102	-0.20454543828964233	▁Ol m sted ▁County ▁; ▁Minnesota ▁; ▁MI ▁diagnose d ▁; ▁ HF
D-1102	-0.20454543828964233	Olmsted County ; Minnesota ; MI diagnosed ; HF
P-1102	-1.1377 -0.0418 -0.0305 -0.0238 -0.1966 -0.0109 -0.0991 -0.5379 -0.1167 -0.0086 -0.2066 -0.3442 -0.1878 -0.0648 -0.0611
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health buddy program ; admissions ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
H-1627	-0.32106560468673706	▁Health ▁Budd y ▁Program ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁mortal ity ▁; ▁con ges tive ▁heart ▁failure
D-1627	-0.32106560468673706	Health Buddy Program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
P-1627	-1.2136 -0.0534 -0.0249 -0.5628 -0.2003 -0.6709 -0.4838 -0.1356 -0.1509 -0.0087 -0.0931 -0.5224 -0.1208 -0.0573 -0.5436 -0.1232 -0.0888 -0.0601 -1.1003 -0.6555 -0.2558 -0.1671 -0.0915
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected ; clinical ; death ; medical ; hospitalization ; hf ; clinic ; outpatients
H-379	-1.3205572366714478	▁ HF
D-379	-1.3205572366714478	HF
P-379	-3.3739 -0.4136 -1.3423 -0.1526
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence ; adjusted odds ratio ; hazard ratio ; death ; hf ; ami ; admission ; discharge
H-1308	-0.5335683226585388	▁odds ▁ratio ▁; haz ard ▁ratio ▁; ▁death ▁; ▁ HF ▁concurrent ▁; ▁ AMI ▁ad mission
D-1308	-0.5335683226585388	odds ratio ;hazard ratio ; death ; HF concurrent ; AMI admission
P-1308	-0.4370 -0.0153 -1.4108 -0.0093 -0.0028 -0.0037 -0.2519 -0.4689 -0.3691 -1.7704 -0.0918 -0.9933 -1.3168 -0.3392 -0.0993 -0.6171 -0.6755 -1.1378 -0.1278
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration ; neurohumoral blockers ; hf ; hospitalization ; patients ; co-morbidity
H-184	-0.45358842611312866	▁neuro hu moral ▁block ers ▁; ▁ HF ▁; ▁co - mor bid ity ▁burde n
D-184	-0.45358842611312866	neurohumoral blockers ; HF ; co-morbidity burden
P-184	-0.2012 -0.0043 -0.6978 -0.5407 -0.0800 -0.2943 -0.3847 -0.0296 -3.0021 -1.7005 -0.0331 -0.0758 -0.3299 -0.3017 -0.1166 -0.1198 -0.1612 -0.0913
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left ventricular ejection fraction ; mortality ; patients ; heart failure ; heart failure survey ; israel
H-110	-0.5792233943939209	▁age - dependent ▁effect ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁long - term ▁mortal ity ▁; ▁patients ▁with ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁IS ra el
D-110	-0.5792233943939209	age-dependent effect ; left ventricular ejection fraction ; long-term mortality ; patients with heart failure ; Heart Failure Survey ; ISrael
P-110	-4.6584 -0.0671 -0.0382 -0.0276 -0.5403 -0.0499 -0.0717 -1.1730 -0.5411 -0.1165 -0.0778 -0.0740 -1.0902 -0.0149 -0.2736 -2.7176 -0.0906 -0.1293 -0.0444 -0.4763 -0.2142 -1.5472 -1.8360 -0.2514 -0.0931 -0.2847 -0.7845 -0.2521 -0.8572 -0.1883 -1.0763 -0.8772 -0.0258 -0.0073 -0.1643 -0.1198
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular endothelial growth factor ; vegf ; transition ; compensatory hypertrophy ; cardiac failure
H-450	-0.3526609241962433	▁inhibi tion ▁; ▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ve GF ▁; ▁compensa tory ▁hyper trop hy ▁; ▁cardiac ▁failure
D-450	-0.3526609241962433	inhibition ; vascular endothelial growth factor ;veGF ; compensatory hypertrophy ; cardiac failure
P-450	-0.4496 -0.1449 -1.6868 -0.0512 -0.1831 -0.0104 -0.7410 -0.0279 -0.0071 -0.2688 -0.0935 -0.5520 -1.0066 -0.2700 -1.0070 -0.4080 -0.0680 -0.1050 -0.0051 -0.5483 -0.6610 -0.0026 -0.3114 -0.1391 -0.0681
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective ; patients ; rule ; sensitivity ; specificity ; cad ; sensitivity ; cad
H-1192	-0.6559110879898071	▁ sensitiv ity ▁; ▁CAD ▁; ▁severe ▁CAD
D-1192	-0.6559110879898071	sensitivity ; CAD ; severe CAD
P-1192	-2.1188 -0.0163 -0.3830 -0.0964 -0.0538 -0.4502 -3.1559 -0.1110 -0.0918 -0.0819
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia ; postoperative ; mortality ; patients ; left ventricular assist device ; lvad ; implantation
H-530	-0.20450656116008759	▁hypo album in emia ▁; ▁post operativ e ▁mortal ity ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-530	-0.20450656116008759	hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
P-530	-0.0336 -0.0382 -0.1412 -0.0816 -0.1728 -0.0114 -0.0607 -0.0773 -0.0231 -0.4808 -0.2057 -0.1209 -0.0296 -1.1864 -0.1285 -0.5081 -0.2505 -0.3207 -0.0427 -0.0054 -0.4718 -0.1081
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis ; pathogenesis ; heart failure
H-173	-0.3608417510986328	▁apo pto sis ▁; ▁path ogen es is ▁; ▁heart ▁failure
D-173	-0.3608417510986328	apoptosis ; pathogenesis ; heart failure
P-173	-0.8503 -0.1895 -0.3353 -0.1746 -0.6895 -0.0904 -0.0519 -0.2025 -0.7646 -0.3087 -0.0538 -0.8833 -0.0964
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients ; terminal ; diagnostic ; follow-up
H-1819	-0.7802291512489319	▁diagnosti ▁procedure ▁; ▁alternatieve ▁treatment s
D-1819	-0.7802291512489319	diagnosti procedure ; alternatieve treatments
P-1819	-2.1461 -1.0825 -0.4212 -0.8419 -0.9326 -0.2364 -0.4915 -0.0897
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic ; neurohormonal ; symptoms ; fluid overload
H-1201	-0.2793882191181183	▁di ure tic ▁ef fica cy ▁; ▁neuro hormon al ▁activa tion ▁; ▁fluid ▁over load
D-1201	-0.2793882191181183	diuretic efficacy ; neurohormonal activation ; fluid overload
P-1201	-0.4300 -0.1915 -0.9954 -0.3200 -0.0558 -0.0726 -0.2590 -0.0906 -0.0230 -0.0344 -0.0084 -0.2818 -0.3177 -1.5671 -0.0353 -0.1308 -0.1330 -0.0826
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr ; mrna splice ; cardiac ; hf
H-1088	-0.413346529006958	▁u PR ▁; ▁na + ▁channel ▁m RNA ▁sp lice ▁; ▁cardiac ▁; ▁na + ▁current ▁; ▁human ▁ HF
D-1088	-0.413346529006958	uPR ; na+ channel mRNA splice ; cardiac ; na+ current ; human HF
P-1088	-1.6834 -1.1296 -0.1390 -0.2112 -0.4380 -0.0102 -0.0188 -0.0975 -0.0092 -0.1120 -0.5930 -0.6381 -1.5764 -0.2820 -0.4612 -0.0338 -0.2056 -0.7431 -0.3374 -0.1876 -0.0973 -0.0893
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients ; preserved lvef ; lvef
H-114	-0.4886184334754944	▁LV EF ▁; ▁LV EF
D-114	-0.4886184334754944	LVEF ; LVEF
P-114	-1.3886 -0.1464 -0.6958 -0.7791 -0.1463 -0.1913 -0.0728
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence ; lvad ; transplantation ; patients ; budget
H-316	-0.31653672456741333	▁l VAD ▁; ▁transplant ation ▁e ligi bility ▁status
D-316	-0.31653672456741333	lVAD ; transplantation eligibility status
P-316	-0.4760 -0.0538 -0.6453 -0.1880 -0.2186 -0.2243 -0.0126 -0.5694 -0.0522 -0.9719 -0.0699
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets ; transcriptional pause release ; pathological
H-1052	-0.3031756579875946	▁ BET s ▁; ▁tran scription al ▁pause ▁release ▁; ▁tran scription ▁; ▁path ological ▁stress
D-1052	-0.3031756579875946	BETs ; transcriptional pause release ; transcription ; pathological stress
P-1052	-0.8553 -0.1118 -0.2867 -0.3605 -0.2163 -0.0874 -0.0389 -0.1000 -0.1053 -0.1522 -0.6324 -0.0438 -1.5033 -0.1638 -0.3158 -0.2206 -0.1565 -0.1067
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg ; atherosclerotic cad ; cardiac death
H-1910	-0.2962515950202942	▁screen ing ▁; ▁e CG ▁; ▁older ▁ath letes ▁; ▁a ther os cle ro tic ▁CAD ▁; ▁sud den ▁cardiac ▁death
D-1910	-0.2962515950202942	screening ; eCG ; older athletes ; atherosclerotic CAD ; sudden cardiac death
P-1910	-1.8076 -0.1274 -0.3802 -0.7239 -0.1743 -0.1815 -1.4299 -0.0921 -0.0057 -0.1493 -0.1229 -0.1312 -0.1010 -0.0926 -0.0341 -0.2430 -0.0672 -0.5443 -0.0542 -0.0124 -0.0038 -0.3396 -0.1779 -0.1140
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ; ami ; hazard ratio ; mortality
H-1313	-0.7664883136749268	▁ HF ▁; ▁index ▁ AMI ▁; ▁hazard ▁ratio
D-1313	-0.7664883136749268	HF ; index AMI ; hazard ratio
P-1313	-1.6764 -0.3305 -0.1276 -0.0171 -0.9718 -0.0436 -0.4246 -1.7688 -0.0157 -2.9304 -0.1249
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d ; therapy
H-107	-0.43499279022216797	▁c RT - d ▁; ▁IE ▁; ▁de fi br illa tor - on ly ▁ therapy
D-107	-0.43499279022216797	cRT-d ; IE ; defibrillator-only therapy
P-107	-0.3709 -2.0386 -0.0455 -0.6885 -0.2434 -1.1824 -1.1101 -0.1265 -0.0239 -0.0837 -0.1506 -0.0217 -0.0887 -0.1139 -0.7700 -0.2165 -0.0569 -0.7779 -0.1553
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr variability ; risk stratification
H-1587	-0.7018991112709045	▁HR ▁dynamic s ▁; ▁non - line ar ▁; ▁HR ▁variabil ity ▁; ▁risk ▁strat ification
D-1587	-0.7018991112709045	HR dynamics ; non-linear ; HR variability ; risk stratification
P-1587	-0.7615 -0.0470 -0.0594 -0.1638 -5.8875 -0.0082 -0.0077 -0.0231 -0.7193 -1.6792 -0.0904 -1.0330 -0.5895 -0.3411 -0.4249 -0.4077 -0.2082 -0.1828
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary exercise testing ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
H-1174	-0.28894713521003723	▁Card io pul mon ary ▁exercise ▁; ▁e cho car dio graphic ▁assessment ▁; ▁my o card ial ▁function ▁; ▁left ▁vent ri cular ▁fill ing
D-1174	-0.28894713521003723	Cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling
P-1174	-0.6595 -1.2943 -0.0879 -0.8594 -0.2003 -0.6926 -0.5961 -0.0120 -0.0073 -0.0151 -0.0562 -0.1610 -0.1888 -0.1986 -0.2297 -0.0515 -0.3181 -0.1710 -0.5437 -0.1056 -0.0809 -0.0247 -0.5569 -0.1590 -0.3743 -0.0378 -0.3394 -0.0688
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle tracking echocardiography ; ste ; bivp ; acute ; right ventricular pressure overload ; rvpo
H-320	-0.2898653447628021	▁spec kle ▁track ing ▁e cho card i ography ▁; STE ▁; ▁Bi VP ▁; ▁right ▁vent ri cular ▁pressure ▁over load ▁; RV PO
D-320	-0.2898653447628021	speckle tracking echocardiography ;STE ; BiVP ; right ventricular pressure overload ;RVPO
P-320	-0.0322 -0.4244 -0.0161 -0.0352 -0.0879 -0.0176 -0.0961 -0.3715 -0.0921 -0.2570 -1.2591 -0.1661 -0.6929 -0.0439 -0.3140 -1.6028 -0.0279 -0.5085 -0.2964 -0.1062 -0.0473 -0.0289 -0.4258 -0.2782 -0.3348 -0.1775 -0.0859
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary endpoints ; therapy ; atrial fibrillation ; atrial tachyarrhythmias ; atp ; shock therapy
H-860	-0.4008098244667053	▁at rial ▁fi bril lation ▁; ▁at rial ▁ta chy ar rhythm ias ▁; ▁ATP ▁; ▁shock ▁ therapy
D-860	-0.4008098244667053	atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
P-860	-4.6248 -0.0126 -0.1737 -0.0055 -0.0347 -0.1491 -0.1951 -0.0243 -0.3418 -0.3809 -0.0237 -0.0363 -1.0158 -0.3694 -0.0619 -0.1941 -0.0072 -0.4002 -0.0103 -0.2334 -0.1221
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous ; coronary revascularization ; hemodynamically ; stable ; patient ; intensive care unit ; icu
H-1293	-0.2799437642097473	▁per cuta ne ous ▁corona ry ▁re vas cular ization ▁; ▁hem o dynamic ally
D-1293	-0.2799437642097473	percutaneous coronary revascularization ; hemodynamically
P-1293	-0.0949 -0.0016 -0.1791 -0.4410 -0.0842 -0.9292 -0.0335 -0.1506 -0.2958 -0.4312 -0.3648 -0.0704 -0.0618 -0.0021 -0.2293 -1.3268 -0.0626
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity ; diabetes mellitus ; metabolic ; comorbidities ; heart failure with preserved ejection fraction
H-760	-0.3528512418270111	▁obes ity ▁; ▁diabetes ▁mell itus ▁; ▁metabol ic ▁risk ▁factors ▁; ▁como rbi di ties ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-760	-0.3528512418270111	obesity ; diabetes mellitus ; metabolic risk factors ; comorbidities ; heart failure ; preserved ejection fraction
P-760	-2.0994 -2.2080 -0.0959 -0.0431 -0.0044 -0.0291 -0.3594 -0.0893 -0.0582 -0.4527 -0.6000 -0.1491 -1.8132 -0.0010 -0.1051 -0.0340 -0.4129 -0.0642 -0.0634 -0.4042 -0.0112 -0.0370 -0.3256 -0.0285 -0.0787 -0.0452 -0.5229 -0.0186 -0.2436 -0.1878
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef ; bnp ; hf ; patients ; prognostic ; significance ; bnp ; ef
H-188	-0.6231318116188049	▁sex ▁; ▁EF ▁; ▁b NP ▁; ▁ HF ▁patients ▁; ▁b NP ▁; ▁sex ▁; ▁EF
D-188	-0.6231318116188049	sex ; EF ; bNP ; HF patients ; bNP ; sex ; EF
P-188	-1.2983 -0.0695 -0.1677 -0.0577 -0.5427 -0.5374 -0.0912 -1.0526 -0.0732 -0.8427 -0.0853 -2.3222 -0.3081 -0.0865 -2.6967 -0.1601 -0.9314 -0.3870 -0.1292
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk ; scn5a ; kv4.3 ; mrna ; mrna splice
H-1087	-0.43075940012931824	▁per k ▁inhibi tion ▁; ▁s cn 5 a ▁; ▁Kv 4.3 ▁m RNA ▁levels ▁; ▁na + ▁channel ▁m RNA ▁sp lice ▁variant s
D-1087	-0.43075940012931824	perk inhibition ; scn5a ; Kv4.3 mRNA levels ; na+ channel mRNA splice variants
P-1087	-1.7629 -0.5298 -0.0413 -0.1900 -0.1639 -1.9731 -0.3759 -0.4105 -0.3413 -0.1477 -1.0892 -0.1050 -0.0032 -0.0480 -0.6656 -0.2455 -0.3126 -0.7297 -0.0118 -0.0107 -0.1465 -0.0594 -0.1915 -1.0371 -0.5057 -0.4254 -0.1072
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential effect ; lvef ; mortality ; hospitalization ; acute ; decompensated hf
H-112	-0.24458178877830505	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁hospital ization ▁; ▁a cute ▁de com pensa ted ▁ HF
D-112	-0.24458178877830505	LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
P-112	-0.5904 -0.2198 -0.4781 -0.7689 -0.0584 -0.0779 -0.0558 -0.6503 -0.6025 -0.2543 -0.2594 -0.4721 -0.0426 -0.0183 -0.0078 -0.0561 -0.0195 -0.1754 -0.2403 -0.0886 -0.1383 -0.1060
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated ; mena expression ; correlates ; hf ; mena ; cardiac ; pathophysiology
H-1812	-0.4977610409259796	▁Men a ▁expression ▁; ▁ HF ▁; ▁men a ▁; ▁cardiac ▁pat ho phy si ology
D-1812	-0.4977610409259796	Mena expression ; HF ; mena ; cardiac pathophysiology
P-1812	-1.0555 -0.0555 -0.0745 -0.1187 -0.5006 -0.1587 -0.1117 -3.4334 -0.1309 -0.3529 -0.0738 -0.6718 -0.5192 -0.2969 -0.9120 -0.2417 -0.1417 -0.1102
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt loading ; uninephrectomy ; ang ii infusion ; cardiac function ; hf
H-282	-0.3684113025665283	▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion ▁mouse ▁; ▁cardiac ▁function ▁; ▁mi ce ▁; ▁ HF
D-282	-0.3684113025665283	salt loading ; uninephrectomy ; ANG II infusion mouse ; cardiac function ; mice ; HF
P-282	-0.0222 -0.0139 -0.0179 -0.0751 -0.0023 -0.5434 -1.0202 -0.0649 -0.0186 -1.3459 -0.0796 -0.2026 -0.1803 -0.0021 -0.0039 -0.6786 -2.1338 -0.0119 -0.1152 -0.3242 -1.2045 -0.1245 -0.7027 -0.8822 -0.0647 -0.0580 -0.0537
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination ; echocardiographic ; lv reverse remodeling ; sensitivity ; specificity
H-433	-0.1196298599243164	▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing
D-433	-0.1196298599243164	echocardiographic score ; LV reverse remodeling
P-433	-0.0538 -0.0199 -0.0401 -0.1584 -0.3440 -0.1664 -0.0981 -0.0788 -0.1587 -0.0313 -0.0251 -0.0644 -0.3191 -0.1168
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients ; atrial fibrillation ; heart failure ; hf ; stroke ; anticoagulation ; patients
H-1353	-0.30274155735969543	▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; HF ▁; ▁stroke ▁; ▁antico ag ulation
D-1353	-0.30274155735969543	atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
P-1353	-1.3621 -0.0204 -0.4095 -0.0077 -0.0684 -0.2397 -0.2304 -0.1054 -0.3518 -0.1057 -0.1448 -0.0284 -0.2138 -1.1892 -0.2601 -0.3911 -0.0588 -0.0506 -0.7313 -0.0856
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration ; hr reduction ; bpm ; p value
H-1942	-0.5786100625991821	▁dose ▁up tit ration ▁; ▁HR ▁re duction
D-1942	-0.5786100625991821	dose uptitration ; HR reduction
P-1942	-0.4320 -1.6557 -0.1288 -0.2266 -0.2002 -1.5475 -0.4390 -0.0710 -0.9828 -0.1024
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck stent ; myocardial infarction ; antiplatelet medication
H-508	-0.1983480602502823	▁bottle ne ck ▁sten t ▁; ▁my o card ial ▁in far ction ▁; ▁anti plate let ▁medication
D-508	-0.1983480602502823	bottleneck stent ; myocardial infarction ; antiplatelet medication
P-508	-0.2678 -0.0594 -0.0094 -0.0118 -0.1061 -0.0933 -1.5958 -0.1531 -0.2862 -0.1854 -0.0212 -0.1149 -0.0445 -0.4127 -0.0112 -0.0315 -0.0699 -0.1338 -0.2378 -0.1209
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv fractional shortening ; lung ; incidence
H-278	-0.43228718638420105	▁ ANS ▁mi ce ▁; ▁LV ▁ fraction al ▁short en ing ▁; ▁lung ▁weight
D-278	-0.43228718638420105	ANS mice ; LV fractional shortening ; lung weight
P-278	-2.4612 -0.0774 -1.5592 -0.4638 -0.2525 -0.1360 -1.1192 -0.0049 -0.0101 -0.1508 -0.0652 -0.1543 -0.1383 -0.1113 -0.2430 -0.3060 -0.0955
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan failure ; circulatory ; hemodynamic ; portal hypertension ; cardiac output
H-234	-0.17183594405651093	▁Font an ▁failure ▁; ▁circula tory ▁de rang ement ▁; ▁hem o dynamic ▁; ▁portal ▁hyper tension ▁; ▁cardiac ▁output
D-234	-0.17183594405651093	Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
P-234	-0.1061 -0.0496 -0.0361 -0.1022 -0.0008 -0.0388 -0.0199 -0.0060 -0.4043 -0.2593 -0.0357 -0.1132 -0.0007 -0.5795 -0.0070 -0.0720 -0.0115 -0.1704 -1.5963 -0.0037 -0.1142 -0.0532
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab ; chf ; nontrastuzumab users ; hazard ratio
H-679	-0.40219733119010925	▁Tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab ▁users ▁; haz ard ▁ratio ▁; HR
D-679	-0.40219733119010925	Trastuzumab ; CHF ; nontrastuzumab users ;hazard ratio ;HR
P-679	-1.3236 -0.0371 -0.0089 -0.4411 -0.8686 -0.0657 -0.1374 -0.3443 -0.0357 -0.0156 -0.0197 -1.7987 -1.5260 -0.5070 -0.1541 -0.0023 -0.0044 -0.2233 -0.0711 -0.7433 -0.1182
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic heart failure ; spironolactone ; hospitalization ; death
H-446	-0.18073424696922302	▁sy sto lic ▁heart ▁failure ▁; ▁spi rono lac tone
D-446	-0.18073424696922302	systolic heart failure ; spironolactone
P-446	-0.3329 -0.0407 -0.0572 -0.4616 -0.0654 -0.2493 -0.0510 -0.0042 -0.0196 -0.0336 -0.7293 -0.1240
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction ; rad variant ; q66p ; congestive heart failure
H-1673	-0.48832666873931885	▁Rad ▁variant ▁; Q 66 p ▁; ▁con ges tive ▁heart ▁failure ▁; ▁humans
D-1673	-0.48832666873931885	Rad variant ;Q66p ; congestive heart failure ; humans
P-1673	-1.8878 -0.0518 -0.1314 -2.1178 -0.2002 -0.3282 -0.1227 -0.0213 -0.0936 -0.8688 -0.3357 -0.0830 -1.2233 -0.1634 -0.1048 -0.0794
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional enrichment analysis ; regulation ; cell death ; degs
H-1614	-0.28690528869628906	▁functional ▁en rich ment ▁analysis ▁; ▁programme d ▁cell ▁death
D-1614	-0.28690528869628906	functional enrichment analysis ; programmed cell death
P-1614	-0.1831 -0.0410 -0.0460 -0.3454 -0.3692 -0.2266 -0.2906 -0.0283 -0.3416 -0.2266 -1.2440 -0.1005
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes ; patients ; atrial fibrillation ; early treatment of atrial fibrillation for stroke prevention trial
H-1642	-0.5027173757553101	▁patients ▁; ▁at rial ▁fi bril lation ▁; ▁e ar ly ▁treatment ▁; ▁At rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁tri al
D-1642	-0.5027173757553101	patients ; atrial fibrillation ; early treatment ; Atrial fibrillation ; Stroke prevention trial
P-1642	-3.4778 -0.9665 -0.7872 -0.0630 -0.3356 -0.0338 -0.0973 -0.1976 -4.9789 -0.1055 -0.1043 -0.1482 -0.2764 -0.4601 -0.0331 -0.2354 -0.0294 -0.0642 -0.2353 -0.1019 -0.0754 -0.0784 -0.0055 -0.4211 -0.0507 -0.1237 -0.0872
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology ; comorbidities ; patients ; outcomes
H-564	-0.34005439281463623	▁et i ology ▁; ▁como rbi di ties
D-564	-0.34005439281463623	etiology ; comorbidities
P-564	-1.0034 -0.1059 -0.1336 -0.0896 -0.1957 -0.0138 -0.2853 -0.0300 -1.4337 -0.1097
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence ; intestinal ; patients ; chf
H-1358	-0.5492380261421204	▁REC ENT ▁FIN ding s ▁; ▁perturba tions ▁; ▁intestinal ▁ morph ology ▁; ▁per me ability ▁; ▁ab sor p tion ▁function ▁; ▁CHF
D-1358	-0.5492380261421204	RECENT FINdings ; perturbations ; intestinal morphology ; permeability ; absorption function ; CHF
P-1358	-1.8963 -0.6525 -0.0746 -2.9740 -0.3325 -0.5224 -4.1727 -0.0648 -0.2058 -0.1328 -0.0709 -0.0245 -0.6141 -0.0917 -0.0794 -0.0492 -0.1604 -0.1812 -0.0076 -0.1337 -0.5786 -0.4396 -0.0985 -0.3190 -0.7186 -0.1429 -0.0913
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients ; exercise ; anaerobic metabolism ; peak respiratory quotient
H-1756	-1.1263612508773804	▁ana ero bic ▁metabolism ▁; ▁respirator y
D-1756	-1.1263612508773804	anaerobic metabolism ; respiratory
P-1756	-6.0545 -0.2323 -0.0992 -0.0951 -0.3922 -1.1575 -0.1154 -1.8735 -0.1176
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni ; cardiovascular mortality ; hospitalization ; heart failure ; quality of life
H-1969	-0.5045393705368042	▁AR NI ▁; ▁cardiovascular ▁mortal ity ▁; ▁hospital ization ▁; ▁heart ▁failure
D-1969	-0.5045393705368042	ARNI ; cardiovascular mortality ; hospitalization ; heart failure
P-1969	-2.0141 -0.4922 -0.2532 -0.4528 -0.0449 -0.4777 -0.1641 -0.2824 -0.2550 -1.0209 -0.2428 -0.1598 -1.0577 -0.1459
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial dd ; muscle ; titin hypophosphorylation
H-768	-0.3306380808353424	▁my o card ial ▁ DD ▁; ▁muscle ▁strip ▁sti ff ness ▁; ▁titi n ▁hypo phos phor y lation
D-768	-0.3306380808353424	myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
P-768	-0.8423 -0.0521 -0.0661 -0.0502 -0.6191 -0.0430 -0.2105 -1.8484 -0.1556 -0.1295 -0.0463 -1.3121 -0.2050 -0.1102 -0.0293 -0.0463 -0.0496 -0.6715 -0.4762 -0.0878 -0.1355 -0.0873
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined training ; peak work rate ; peak quadriceps force
H-1917	-0.6756125688552856	▁pe ak ▁work ▁rate ▁; ▁pe ak ▁quadri cep s ▁force
D-1917	-0.6756125688552856	peak work rate ; peak quadriceps force
P-1917	-5.3261 -0.0102 -1.0947 -0.2244 -0.1694 -0.9428 -0.0165 -0.1596 -0.0958 -0.0528 -0.2205 -0.3379 -0.1323
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins ; expression ; cardiac hypertrophy ; proteins ; nucleolin
H-95	-0.5059590935707092	▁protein s ▁; ▁cardiac ▁hyper trop hy ▁; ▁nu cle olin
D-95	-0.5059590935707092	proteins ; cardiac hypertrophy ; nucleolin
P-95	-1.5244 -0.0921 -0.3436 -0.2785 -0.1701 -0.0153 -0.4357 -0.3267 -3.0102 -0.0042 -0.0286 -0.2128 -0.1354
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based ; prognosis ; idiopathic dilated cardiomyopathy
H-1750	-0.4117686450481415	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1750	-0.4117686450481415	idiopathic dilated cardiomyopathy
P-1750	-1.3283 -1.2514 -0.0549 -0.1155 -0.1713 -0.2077 -0.2278 -1.0126 -0.3068 -0.0371 -0.1502 -0.0775
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients ; physicians ; readmission ; hospital
H-1728	-0.6460113525390625	▁high - volu me ▁physician s ▁; ▁read mission ▁rates
D-1728	-0.6460113525390625	high-volume physicians ; readmission rates
P-1728	-2.1599 -0.0271 -0.0112 -0.0360 -0.1944 -0.0634 -0.5470 -0.8019 -1.6908 -0.2193 -1.9171 -0.0841
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc ; nps ; clinical
H-1024	-0.5431576371192932	▁ NP ▁measure ment ▁; ▁PO c ▁measure ment ▁; ▁ NP s
D-1024	-0.5431576371192932	NP measurement ; POc measurement ; NPs
P-1024	-0.8749 -0.0444 -0.9665 -0.0644 -0.1029 -0.3223 -1.7110 -1.0686 -0.0490 -0.1401 -0.6319 -0.0313 -0.2276 -1.8128 -0.0996
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized ; follow-up
H-1751	-0.4618653655052185	▁voordelen ▁; ▁control led ▁random ized ▁trial s ▁; ▁follow - up
D-1751	-0.4618653655052185	voordelen ; controlled randomized trials ; follow-up
P-1751	-0.8688 -0.4588 -0.8384 -0.2930 -0.0849 -0.1823 -0.1902 -0.0772 -1.0387 -1.4933 -0.0572 -0.0127 -0.7940 -0.0764
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas city cardiomyopathy questionnaire ; kccq ; hf with reduced ef ; patients ; hfpef
H-781	-0.41046831011772156	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁k cc q ▁; ▁ HF ▁; ▁reduce d ▁EF ▁; ▁patients ▁; ▁ HF p EF
D-781	-0.41046831011772156	Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; reduced EF ; patients ; HFpEF
P-781	-0.0150 -0.3400 -1.2880 -0.0500 -0.0316 -1.2193 -0.0684 -0.1141 -0.0041 -0.1281 -0.6043 -0.0434 -0.8407 -0.0461 -0.4515 -0.2020 -0.3076 -3.2489 -0.0020 -0.0505 -0.1179 -0.5942 -0.9071 -0.5491 -0.2269 -0.0662 -0.1721 -0.1159 -0.0986
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; right ventricular contractile function ; prognosis
H-491	-0.2379388064146042	▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; ▁heart ▁failure ▁; ▁index ▁; ▁right ▁vent ri cular ▁contract ile
D-491	-0.2379388064146042	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index ; right ventricular contractile
P-491	-0.0393 -0.0162 -0.0093 -0.1331 -0.0025 -0.0322 -0.0357 -0.0951 -0.0571 -0.2487 -0.0086 -0.1028 -0.0012 -0.0162 -0.0141 -0.0151 -0.0311 -0.0551 -1.2963 -0.3575 -0.9144 -0.1968 -0.2806 -0.5955 -0.9305 -0.2990 -0.0594 -0.5108 -0.1708 -0.0096 -0.0146 -1.2074 -0.0955
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients ; biventricular support ; heartmate ii ; lvad ; centrimag ; right ventricular assist device ; rvad
H-296	-0.314820796251297	▁bi ven tri cular ▁support ▁; ▁hybrid ▁system ▁; ▁Heart Mate ▁II ▁l VAD ▁; ▁Centri Mag ▁right ▁vent ri cular ▁assist ▁device ▁; ▁r VAD
D-296	-0.314820796251297	biventricular support ; hybrid system ; HeartMate II lVAD ; CentriMag right ventricular assist device ; rVAD
P-296	-1.2021 -0.0692 -1.1134 -0.4751 -1.2405 -0.2349 -0.1250 -0.1138 -0.0896 -0.7260 -0.0268 -0.5016 -0.2469 -0.0069 -0.0459 -0.1085 -0.1569 -0.2983 -0.0144 -0.4801 -0.1286 -0.2823 -0.1996 -0.1743 -0.5037 -0.0221 -0.1387 -0.0895
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
H-521	-0.135928213596344	▁Blood ▁pressure ▁; ▁arm ▁cu ff ▁; ▁stroke ▁volume ▁; SV ▁; ▁e je ction ▁ fraction ▁; ▁end - dia sto lic ▁volume ▁; ▁e cho card i ography
D-521	-0.135928213596344	Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
P-521	-0.0973 -0.0481 -0.1029 -0.7924 -0.0651 -0.0351 -0.0194 -0.0310 -0.0379 -0.1291 -0.4769 -0.1059 -0.0369 -0.0243 -0.0068 -0.1056 -0.0010 -0.2297 -0.7320 -0.0316 -0.0102 -0.0603 -0.0368 -0.0611 -0.2664 -0.0459 -0.0279 -0.1124 -0.1899 -0.1971 -0.1529 -0.0801
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis ; heart failure ; myocardial tissue ; left ventricular ; trichrome blue histologic analysis
H-1060	-0.29354506731033325	▁fibro sis ▁; ▁heart ▁failure ▁; ▁my o card ial ▁tissu e ▁; ▁left ▁vent ri cular ▁tissu e ▁; ▁tri ch rom e ▁blue ▁his t ologic ▁analysis
D-1060	-0.29354506731033325	fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic analysis
P-1060	-0.0011 -0.1087 -0.6318 -0.4850 -0.0570 -0.4159 -1.2918 -0.1921 -0.4460 -0.2709 -0.1449 -0.2230 -0.2657 -0.1453 -0.0371 -0.8441 -0.2792 -0.0871 -0.1310 -0.4941 -0.0226 -0.0145 -0.0013 -0.0204 -0.1604 -1.1309 -0.1684 -0.0933 -0.5884 -0.2426 -0.1052
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped ; snp ; rs10927887 ; ka renal chloride channel gene ; clcnka
H-1802	-0.4007488489151001	▁Cau ca sian ▁; ▁s NP ▁rs 109 27 887 ▁; ▁ka ▁renal ▁chlor ide ▁channel ▁gene ▁; CL cn ka
D-1802	-0.4007488489151001	Caucasian ; sNP rs10927887 ; ka renal chloride channel gene ;CLcnka
P-1802	-1.3597 -0.0093 -0.0935 -0.1248 -1.7188 -0.1280 -0.2962 -0.0217 -0.8788 -0.0576 -0.1884 -0.3388 -0.0019 -0.1066 -0.0797 -0.0234 -1.2085 -0.1794 -0.1234 -1.2129 -0.7466 -0.2007 -0.1183
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise ; training ; outcomes ; hf ; patients ; exercise ; training ; therapy ; clinical
H-1934	-0.8723481297492981	▁exercise ▁training ▁; ▁ HF ▁patients
D-1934	-0.8723481297492981	exercise training ; HF patients
P-1934	-1.5183 -0.6315 -0.2289 -1.5632 -0.0587 -0.6627 -2.2118 -0.1037
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile function ; lv dilatation ; lv end-diastolic pressure ; wall stress ; lung
H-476	-0.3169616758823395	▁contract ile ▁function ▁; ▁LV ▁di la tation ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight
D-476	-0.3169616758823395	contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
P-476	-0.0056 -0.0200 -0.0998 -0.0984 -0.6476 -0.2268 -0.1171 -0.0068 -0.1169 -1.0302 -1.1458 -2.3772 -0.0141 -0.0120 -0.0577 -0.0220 -0.1082 -0.5608 -0.5802 -0.1675 -0.1042 -0.0326 -0.1330 -0.1479 -0.0915
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp ; plasma ; patients ; dyspnea ; left ventricular dysfunction ; admission
H-265	-0.3661106526851654	▁NT - pro b NP ▁; ▁plasma ▁; ▁dys pne a ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ad mission ▁; ▁ED
D-265	-0.3661106526851654	NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; admission ; ED
P-265	-0.9437 -0.0227 -0.0062 -0.5678 -0.3387 -1.4169 -0.1232 -0.2364 -0.2590 -0.0119 -0.1345 -0.1418 -0.0334 -0.0501 -0.9691 -0.3336 -0.0670 -0.1125 -0.4830 -0.5080 -0.1444 -1.8711 -0.1441 -0.1342 -0.0995
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological ; remodelling ; heart ; cardiac hypertrophy ; hf ; death ; fibrosis ; inflammation
H-1035	-0.28454121947288513	▁path ological ▁remodel ling ▁; ▁heart ▁; ▁cardiac ▁hyper trop hy ▁; ▁ HF ▁; ▁fibro sis ▁; ▁ inflammation
D-1035	-0.28454121947288513	pathological remodelling ; heart ; cardiac hypertrophy ; HF ; fibrosis ; inflammation
P-1035	-1.6263 -0.4373 -0.0131 -0.1828 -0.2716 -1.4400 -0.1577 -0.0577 -0.1192 -0.0054 -0.4405 -0.0692 -0.3179 -0.0379 -0.1730 -0.2833 -0.0672 -0.2555 -0.0396 -0.0094 -0.1624 -0.0927
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action ; correlation ; baseline ; hgb ; baseline ; hrqol ; kccq
H-842	-0.3022828996181488	▁ HF - ac TION ▁co hor t ▁; ▁h gb ▁; ▁base line ▁HR Qo L ▁; ▁k cc q
D-842	-0.3022828996181488	HF-acTION cohort ; hgb ; baseline HRQoL ; kccq
P-842	-0.5410 -0.1277 -0.0092 -0.5390 -0.8583 -0.0260 -0.1694 -0.0339 -0.0805 -1.3542 -0.0253 -0.0376 -0.2460 -0.0029 -0.4995 -0.0040 -0.4265 -0.1040 -0.4701 -0.0845 -1.1132 -0.1143 -0.0853
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating progenitor cells ; cpcs ; endothelial ; prognostic ; cardiovascular diseases
H-120	-0.3112300634384155	▁circula ting ▁pro gen itor ▁cell s ▁; ▁c PC s ▁; ▁en dot heli al ▁repair ▁; ▁cardiovascular
D-120	-0.3112300634384155	circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular
P-120	-0.1010 -0.1022 -0.0649 -0.1204 -0.0373 -0.4471 -0.0647 -0.2114 -0.1590 -0.9899 -0.0663 -0.2524 -0.0367 -0.1658 -0.0412 -0.0059 -0.0892 -0.2223 -0.0365 -3.2266 -0.0951
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right ventricular ; rv ; prognosis ; patients ; heart failure ; hf
H-1158	-0.5503782033920288	▁right ▁vent ri cular ▁; RV ▁; ▁body ▁composition ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1158	-0.5503782033920288	right ventricular ;RV ; body composition ; advanced heart failure ;HF
P-1158	-1.6061 -0.0311 -0.4760 -0.0927 -0.2777 -0.3544 -0.3885 -1.8667 -0.0973 -0.1100 -3.0818 -0.2888 -0.1037 -0.3317 -0.0173 -0.1181 -0.1145
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular assist device ; vad ; extracorporeal membrane oxygenation ; ecmo ; renal function
H-1385	-0.23239116370677948	▁vent ri cular ▁assist ▁device ▁; VAD ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁renal ▁function
D-1385	-0.23239116370677948	ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
P-1385	-0.0178 -0.5375 -0.0705 -0.6027 -0.2693 -0.1650 -0.0044 -0.0999 -0.0047 -0.0242 -0.2798 -0.0365 -0.0106 -0.0557 -0.1270 -0.1249 -0.3090 -0.4044 -1.0531 -0.3773 -0.0050 -0.1978 -0.6923 -0.1079
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american college of cardiology ; american heart association ; patients ; ras ; patients ; ras
H-1604	-0.7465122938156128	▁American ▁college ▁of ▁Card i ology ▁; American ▁Heart ▁association ▁; ▁evaluat ▁; ▁management ▁; ▁patients ▁; RAS
D-1604	-0.7465122938156128	American college of Cardiology ;American Heart association ; evaluat ; management ; patients ;RAS
P-1604	-2.1127 -0.8445 -0.2696 -1.6788 -0.0775 -0.0802 -0.2544 -0.1454 -0.7852 -0.7864 -0.7573 -1.6539 -1.8865 -0.0604 -0.3079 -0.3763 -1.5200 -0.4593 -0.8093 -0.0649
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-375	-0.16860994696617126	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-375	-0.16860994696617126	functional MS ; valve plasty ; degenerative MR ; LV
P-375	-0.0283 -0.0467 -0.0849 -0.6580 -0.0079 -0.0263 -0.1359 -0.3239 -0.0047 -0.0032 -0.0837 -0.0440 -0.2503 -0.0178 -0.9280 -0.0539
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus ; cells ; functional capacity ; mortality ; nondiabetic ; patients
H-131	-0.6022210121154785	▁ EO - c FU s ▁; ▁lower ▁CD 34 + ve g FR 2 ▁; ▁cell s ▁; ▁functional ▁capacity ▁; ▁non dia be tic ▁patients
D-131	-0.6022210121154785	EO-cFUs ; lower CD34+vegFR2 ; cells ; functional capacity ; nondiabetic patients
P-131	-1.4088 -0.0438 -0.0323 -1.1763 -0.1812 -0.2203 -0.0900 -0.6140 -0.6357 -0.1386 -1.5948 -0.2197 -1.0225 -0.6652 -0.4573 -2.2333 -0.2242 -0.0975 -0.5160 -1.3866 -0.4984 -0.1923 -1.5729 -0.0076 -0.0864 -0.8339 -0.9974 -0.2001 -0.1174
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable cardioverter-defibrillator ; physicians ; heart failure ; patients
H-1857	-0.46263986825942993	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁physician s ▁; ▁heart ▁failure
D-1857	-0.46263986825942993	implantable cardioverter-defibrillator deactivation ; physicians ; heart failure
P-1857	-1.5301 -0.0331 -0.3040 -0.0167 -0.1428 -0.0515 -0.0826 -0.1098 -0.4914 -0.0966 -0.0649 -0.1217 -0.0541 -0.5333 -0.6692 -1.6345 -0.0632 -0.5139 -0.1784 -0.1173 -3.1660 -0.2029
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional ms ; patients ; valve plasty ; degenerative mr ; dilated ; disease
H-340	-0.13261650502681732	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁ann ular ▁size ▁re duction ▁; ▁de genera tive ▁MR ▁; ▁LV
D-340	-0.13261650502681732	functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
P-340	-0.0209 -0.0166 -0.1086 -1.0893 -0.0071 -0.0197 -0.1092 -0.0688 -0.0021 -0.0010 -0.1746 -0.0573 -0.0106 -0.1505 -0.0047 -0.0025 -0.0870 -0.0374 -0.1650 -0.0181 -0.7199 -0.0468
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty ; prognostic ; heart failure ; hf ; biological phenotype
H-1001	-0.608343243598938	▁fra il ty ▁; ▁heart ▁failure ▁; HF ▁; ▁bi ological ▁ph eno type
D-1001	-0.608343243598938	frailty ; heart failure ;HF ; biological phenotype
P-1001	-0.4727 -0.2921 -0.0702 -0.1067 -2.6611 -0.1232 -0.1742 -0.0920 -0.7971 -1.9519 -0.2179 -0.5725 -0.0813 -0.0012 -2.0040 -0.1155
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv remodeling ; diastolic ; xo inhibition ; symptoms ; hospitalizations ; patients ; severe heart failure
H-478	-0.32160472869873047	▁LV ▁remodel ing ▁; ▁dia sto lic ▁properties ▁; ▁ XO ▁inhibi tion
D-478	-0.32160472869873047	LV remodeling ; diastolic properties ; XO inhibition
P-478	-0.0367 -0.0440 -0.0170 -0.1588 -0.0058 -0.0874 -0.0156 -0.1422 -0.2924 -0.3496 -0.0429 -0.0146 -0.1649 -3.3602 -0.0920
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt ; atrial pacing
H-1442	-0.49339014291763306	▁SD QT ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁h Nor m ▁group ▁; ▁fixed - rate ▁at rial ▁pa cing
D-1442	-0.49339014291763306	SDQT ; HFVT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
P-1442	-0.0054 -0.1013 -0.0782 -0.4882 -0.1810 -0.1596 -0.2641 -0.1456 -0.2251 -0.3397 -0.3225 -2.0120 -0.8040 -0.7000 -0.2775 -1.2799 -2.6498 -0.0256 -1.4549 -0.5144 -0.0314 -0.1088 -0.0572 -1.1766 -0.1416 -0.0167 -0.3279 -0.3055 -0.1138
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ; ef
H-192	-1.0286768674850464	▁border line ▁; ▁female ▁; ▁pres er ved ▁; ▁female
D-192	-1.0286768674850464	borderline ; female ; preserved ; female
P-192	-7.5221 -0.0365 -0.2180 -1.8228 -0.3331 -0.1661 -0.0370 -0.3903 -0.4032 -0.5812 -0.7341 -0.0995
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping ; myocardial ; heart failure
H-1063	-0.47203364968299866	▁diffuse ▁my o card ial ▁changes ▁; ▁heart ▁failure ▁; ▁contrast ▁agent ▁; ▁breath - hold ing
D-1063	-0.47203364968299866	diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
P-1063	-1.4324 -0.8101 -0.1258 -0.4884 -0.2402 -2.9401 -0.3836 -0.5637 -0.2294 -0.3188 -0.1477 -0.0107 -0.4281 -0.0993 -0.1215 -0.1657 -0.0613 -0.2403 -0.1614
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical ; bnp ; inhospital ; mortality
H-196	-0.45978304743766785	▁b NP ▁; ▁in hospital ▁mortal ity
D-196	-0.45978304743766785	bNP ; inhospital mortality
P-196	-0.8233 -1.3751 -0.4645 -0.0358 -0.0313 -0.1234 -0.5789 -0.6287 -0.0771
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies ; crt-d ; heart failure ; death
H-108	-0.6237640976905823	▁i s ▁; ▁c RT - d ▁recipient s ▁; ▁heart ▁failure ▁; ▁death
D-108	-0.6237640976905823	is ; cRT-d recipients ; heart failure ; death
P-108	-1.9606 -0.3011 -0.2031 -0.1378 -0.9682 -0.0381 -0.5503 -0.3350 -0.0737 -0.2407 -3.1439 -0.2617 -1.0206 -0.5394 -0.1049 -0.1011
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure ; health ; income ; hf
H-1800	-0.6808775663375854	▁ex pendi ture ▁; ▁health ▁per ▁capita ▁; ▁gross ▁national ▁income ▁per ▁capita ▁; ▁ HF ▁; ▁la
D-1800	-0.6808775663375854	expenditure ; health per capita ; gross national income per capita ; HF ; la
P-1800	-5.5335 -0.0531 -0.5123 -0.3837 -1.0509 -0.2865 -0.0060 -0.0497 -0.2666 -0.5632 -0.1098 -0.4154 -0.0079 -0.2052 -1.1308 -0.2472 -1.2569 -0.7261 -0.7449 -0.0679
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt ; dt ; btt ; patients
H-314	-0.8195024132728577	▁b t ▁; ▁ DT ▁; ▁cost - effect ive ness
D-314	-0.8195024132728577	bt ; DT ; cost-effectiveness
P-314	-0.6578 -0.9714 -0.1356 -0.2081 -0.0630 -0.5387 -2.1190 -0.1041 -0.0177 -0.5287 -1.4348 -3.7408 -0.1337
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals ; patients ; hfpef
H-952	-0.4601077735424042	▁AF ▁; ▁ pharma ce u tical s ▁; ▁h FP EF
D-952	-0.4601077735424042	AF ; pharmaceuticals ; hFPEF
P-952	-0.4068 -0.4633 -0.6996 -0.1592 -0.5607 -0.0577 -0.0216 -0.0989 -0.3534 -2.3392 -0.5910 -0.4532 -0.1095 -0.1275
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood pressure ; therapy ; patients ; ras
H-1600	-0.24876683950424194	▁blood ▁pressure ▁control ▁; ▁goal - direct ed ▁lipid - lo wering ▁ therapy ▁; ▁smoking ▁ces s ation ▁; ▁ RAS
D-1600	-0.24876683950424194	blood pressure control ; goal-directed lipid-lowering therapy ; smoking cessation ; RAS
P-1600	-0.3539 -0.1441 -0.4099 -0.0493 -0.5339 -0.0051 -0.0015 -0.0138 -0.0451 -0.0383 -0.0282 -0.0171 -0.3907 -0.0303 -0.0746 -0.0086 -0.1706 -0.0401 -0.2393 -0.5589 -2.6385 -0.0301 -0.0524 -0.0961
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-0.7387198209762573	▁simula tions ▁; ▁virtual ▁co hor ts
D-2014	-0.7387198209762573	simulations ; virtual cohorts
P-2014	-2.2699 -0.0538 -0.2966 -0.7262 -0.0190 -0.2217 -0.1311 -2.8560 -0.0739
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac magnetic resonance ; amyloidotic ; diagnosis ; multiple myeloma ; osteomedullary biopsy
H-999	-0.18099133670330048	▁cardiac ▁magnetic ▁res on ance ▁; ▁a my lo ido tic ▁pattern ▁; ▁multiple ▁mye loma ▁; ▁osteo me dulla ry ▁bio psy
D-999	-0.18099133670330048	cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
P-999	-0.0050 -0.0202 -0.1192 -0.0877 -0.1883 -0.1278 -0.0134 -0.2402 -0.0151 -0.0229 -1.3140 -0.3164 -0.0930 -0.1874 -0.0467 -0.1980 -0.3797 -0.0234 -0.0377 -0.0257 -0.8007 -0.0016 -0.0265 -0.1712 -0.0630
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable cardioverter-defibrillators ; icds ; mortality ; cardiac resynchronization therapy ; crt ; symptoms ; mortality
H-1068	-0.390800803899765	▁Implant able ▁cardio ver ter - de fi br illa tors ▁; IC d s ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-1068	-0.390800803899765	Implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cRT
P-1068	-1.1064 -0.0194 -0.1798 -0.0139 -0.3786 -0.0550 -0.0607 -0.0958 -0.5595 -0.1480 -0.2703 -0.3452 -0.9279 -0.5728 -0.1321 -0.3302 -1.2947 -0.0755 -0.0488 -0.0157 -0.6284 -0.6755 -0.0119 -0.3018 -0.5960 -1.3354 -0.6543 -0.1088
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular endothelial growth factor blockade ; beta-blocker ; therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
H-448	-0.2868737578392029	▁Vas cular ▁en dot heli al ▁growth ▁factor ▁block ade ▁; ▁beta - block er ▁ therapy ▁; ▁cardiac ▁function ▁; ▁ang io gene sis ▁; ▁remodel ing ▁; ▁heart ▁failure
D-448	-0.2868737578392029	Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
P-448	-0.6954 -0.0514 -0.0189 -0.4799 -0.0314 -0.0047 -0.3306 -0.2056 -1.9552 -0.3185 -0.1942 -0.4676 -0.0141 -0.0939 -0.0612 -0.4232 -0.0135 -0.3815 -0.0101 -0.0550 -0.3354 -0.2122 -0.5661 -0.1301 -0.3560 -0.2824 -0.1787 -0.0124 -0.9882 -0.1311 -0.2062 -0.1646 -0.0976
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure with preserved ejection fraction
H-915	-0.21954116225242615	▁DAS h ▁; ▁dia sto lic ▁function ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-915	-0.21954116225242615	DASh ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; preserved ejection fraction
P-915	-1.8168 -0.1667 -1.2481 -0.0650 -0.0216 -0.0181 -0.1611 -0.0677 -0.0039 -0.4642 -0.0632 -0.0936 -0.0612 -0.0419 -0.0239 -0.2074 -0.2496 -0.1275 -0.0622 -0.0359 -0.4418 -0.1063 -0.4254 -0.0092 -0.0449 -0.2272 -0.0167 -0.0648 -0.0386 -0.5345 -0.0066 -0.2391 -0.0900
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis ; hfpef ; clinical ; echo-doppler cardiography ; invasive haemodynamic assessment
H-1303	-0.28954583406448364	▁ HF p EF ▁; ▁e cho - D opp ler ▁card i ography ▁; ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.28954583406448364	HFpEF ; echo-Doppler cardiography ; invasive haemodynamic assessment
P-1303	-1.2517 -0.3200 -0.0278 -0.2532 -0.1517 -0.2583 -0.0137 -0.0144 -2.2381 -0.0165 -0.6093 -0.2153 -0.1637 -0.1963 -0.1871 -0.0272 -0.0580 -0.0086 -0.3716 -0.0028 -0.0404 -0.1643 -0.0696
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker ; uptitrations ; patients ; hfref ; hfpef ; hospital ; admission
H-177	-0.587626039981842	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁patients ▁; ▁h Fr EF ▁; ▁ HF p EF
D-177	-0.587626039981842	RAS- ; β-blocker uptitrations ; patients ; hFrEF ; HFpEF
P-177	-1.1238 -0.0087 -0.0425 -2.8581 -0.1041 -0.0693 -0.3997 -0.0610 -2.8344 -0.1908 -1.4647 -0.3359 -0.3095 -0.9671 -0.6812 -1.0842 -0.1194 -0.6185 -0.2724 -0.2522 -0.1864 -0.0612 -0.3059 -0.2047 -0.1350
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients ; exercise-induced pasp ; pasp ; patients ; pasp
H-827	-0.8529643416404724	▁exercise - indu ced ▁PAS p ▁; ▁pas p
D-827	-0.8529643416404724	exercise-induced PASp ; pasp
P-827	-2.7130 -0.0411 -0.0075 -0.0295 -0.5646 -1.1031 -0.4881 -3.1055 -0.3769 -0.8834 -0.0698
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal muscle ; sarcomere ; patients ; heart failure ; type 2 diabetes
H-1243	-0.2617281377315521	▁skelet al ▁muscle ▁sar com ere ▁structure ▁; ▁heart ▁failure ▁; ▁type ▁2 ▁diabetes ▁; ▁e pica tech in - rich ▁coco a
D-1243	-0.2617281377315521	skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
P-1243	-0.7569 -0.0440 -0.3056 -0.5313 -0.1502 -0.1721 -1.1955 -0.1461 -0.9670 -0.0674 -0.1167 -0.2463 -0.1791 -0.0100 -0.4527 -0.3449 -0.0034 -0.0403 -0.0418 -0.1023 -0.0053 -0.3258 -0.0369 -0.1669 -0.1347
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician ; outcomes ; patients ; outcomes ; medically ; diseases ; hf
H-1722	-0.5089613795280457	▁Physic ian ▁volume ▁; ▁outcome s ▁; ▁med ically ▁managed ▁disease s ▁; HF
D-1722	-0.5089613795280457	Physician volume ; outcomes ; medically managed diseases ;HF
P-1722	-0.1529 -0.3372 -0.0274 -0.1822 -2.8172 -0.0561 -0.1929 -1.0857 -0.2570 -0.0370 -0.2863 -0.0415 -0.2767 -2.1916 -0.1165 -0.0851
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal flow pump ; hemocompatibility ; blood-flow ; pulse
H-1994	-0.2418728768825531	▁centri fu gal ▁flow ▁pump ▁; ▁hem o com pati bility ▁; ▁magnet ically ▁le vita ted ▁ro tor ▁; ▁blood - flow ▁path s ▁; ▁artificial ▁puls e
D-1994	-0.2418728768825531	centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
P-1994	-0.0285 -0.7068 -0.1013 -0.3913 -0.9199 -0.1757 -0.2994 -0.1566 -0.0865 -0.0332 -0.2769 -0.1350 -0.0234 -0.1615 -0.0096 -0.0111 -0.1288 -0.0140 -0.0152 -0.4197 -2.1619 -0.0410 -0.0435 -0.2535 -0.0416 -0.1917 -0.1867 -0.0693 -0.2273 -0.1099 -0.0773
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone ; patients ; hf-ref ; hyperkalemia ; patients
H-1224	-0.4064166247844696	▁e pler en one ▁; ▁ HF - RE F ▁; ▁hyper kal emia ▁; ▁w RF
D-1224	-0.4064166247844696	eplerenone ; HF-REF ; hyperkalemia ; wRF
P-1224	-0.0705 -0.0287 -0.1696 -0.5334 -0.2433 -0.9874 -0.0922 -0.0109 -1.2550 -1.0447 -0.2852 -1.9361 -0.0784 -0.1632 -0.1520 -0.0864 -0.2020 -0.2493 -0.1337
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial complex v activity ; phosphocreatine ; atp
H-1786	-0.48991239070892334	▁mito cho ndri al ▁complex ▁v ▁activity ▁; ▁a ac ▁; ▁ phos pho creati ne ▁; ▁ATP
D-1786	-0.48991239070892334	mitochondrial complex v activity ; aac ; phosphocreatine ; ATP
P-1786	-0.1253 -0.5153 -0.3660 -0.0158 -0.0636 -2.1522 -1.4809 -0.2845 -0.5519 -0.1161 -0.2503 -1.0616 -0.0156 -0.1253 -0.3571 -0.9478 -1.0937 -0.0635 -0.1232 -0.0885
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients ; sst2 ; sst2 ; odds ratios ; cardiovascular events
H-409	-0.4040316641330719	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB ▁; ▁cardiovascular ▁events
D-409	-0.4040316641330719	sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
P-409	-0.2150 -1.2231 -0.0916 -0.1270 -0.0246 -0.2890 -0.0782 -0.8046 -0.1177 -0.1518 -1.6452 -0.0870 -0.6374 -0.0302 -0.4640 -0.0510 -0.7132 -0.4427 -0.4461 -0.9956 -0.1205 -0.1331
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients ; frail ; frail ; biological phenotype
H-1007	-0.31306058168411255	▁fra il ▁; ▁intermedi ate ▁fra il
D-1007	-0.31306058168411255	frail ; intermediate frail
P-1007	-0.1653 -0.0661 -0.4116 -0.0674 -1.0568 -0.0339 -0.1086 -0.8337 -0.0742
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs morphology ; cardiac resynchronization therapy ; crt
H-880	-0.33809056878089905	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-880	-0.33809056878089905	QRs morphology ; cardiac resynchronization therapy ; cRT
P-880	-0.2647 -0.6872 -0.1655 -0.0141 -0.3684 -0.0622 -0.8111 -0.0395 -0.1373 -0.0283 -0.6250 -0.6990 -0.0171 -0.2513 -0.5174 -1.1690 -0.1287 -0.0996
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients ; hfpef ; longitudinal ; cardiac event
H-738	-0.5391261577606201	▁h FP EF ▁; ▁longitud in al ▁outcome - monitor ing ▁phase ▁; ▁cardiac ▁event
D-738	-0.5391261577606201	hFPEF ; longitudinal outcome-monitoring phase ; cardiac event
P-738	-1.6091 -1.5975 -0.3609 -0.5019 -0.4405 -0.1254 -0.0379 -0.6478 -0.1552 -0.1561 -0.0359 -1.3798 -0.3913 -0.1164 -1.3938 -0.1278 -0.0878
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm ; outcomes ; discharged ; admission ; heart failure
H-149	-1.228974461555481	▁RM ▁strategie s
D-149	-1.228974461555481	RM strategies
P-149	-0.6120 -0.3747 -0.0237 -5.0606 -0.0738
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient ; emergency department ; acute heart failure ; ahf ; clinical
H-57	-0.3885312080383301	▁a cute ▁heart ▁failure ▁; ▁a HF
D-57	-0.3885312080383301	acute heart failure ; aHF
P-57	-1.2525 -0.0083 -0.4946 -0.0949 -0.2446 -0.2690 -0.4974 -0.5229 -0.1126
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene ; pathological ; heart disease ; transcription factors ; driving ; gene
H-639	-0.7741848230361938	▁aber rant ▁re activa tion ▁; ▁em bry o nic ▁gene ▁programs ▁; ▁path ological ▁heart ▁disease ▁; ▁tran scription ▁factors
D-639	-0.7741848230361938	aberrant reactivation ; embryonic gene programs ; pathological heart disease ; transcription factors
P-639	-4.9099 -0.9846 -0.0284 -0.0298 -0.2376 -0.7342 -0.1544 -0.1583 -0.1536 -1.5845 -1.7448 -0.2987 -0.2407 -0.1100 -0.3055 -0.8310 -0.3912 -0.6250 -0.0463 -0.0275 -0.3486 -3.7017 -0.1601
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard error of measurement ; mdc ; clinical ; change
H-807	-0.7990819215774536	▁m DC
D-807	-0.7990819215774536	mDC
P-807	-1.8486 -0.5364 -0.6737 -0.1377
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients ; lbbb ; implantable ; primary outcome ; primary outcome
H-887	-0.4023209512233734	▁l b ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - c RT
D-887	-0.4023209512233734	lb ; implantable cardioverter defibrillator-cRT
P-887	-2.3331 -1.0947 -0.3229 -0.3043 -0.0192 -0.1658 -0.0122 -0.0381 -0.0986 -0.0299 -0.0991 -0.0625 -0.0153 -0.1001 -0.9267 -0.9899 -0.5447 -0.0846
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart rate ; ivabradine ; afterload ; patients ; systolic heart failure
H-516	-0.3079553246498108	▁isola ted ▁heart ▁rate ▁; HR ▁; ▁i va bra dine ▁; ▁sy sto lic ▁heart ▁failure
D-516	-0.3079553246498108	isolated heart rate ;HR ; ivabradine ; systolic heart failure
P-516	-0.0252 -0.0571 -0.4110 -0.1220 -0.2502 -0.0628 -0.2483 -0.0497 -0.0210 -0.1174 -0.0521 -0.1358 -3.2583 -0.0526 -0.0448 -0.4714 -0.1433 -0.2231 -0.1050
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients ; followed up ; composite primary outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
H-1650	-0.2770005166530609	▁cardiovascular ▁death ▁; ▁stroke ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1650	-0.2770005166530609	cardiovascular death ; stroke ; heart failure ; myocardial infarction
P-1650	-0.7988 -0.7107 -0.0770 -0.2660 -0.0769 -0.8485 -0.0602 -0.1672 -0.5247 -0.1191 -0.1710 -0.2805 -0.0340 -0.0651 -0.2052 -0.1563 -0.1478
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical treatment ; heart failure
H-336	-0.31010013818740845	▁heart ▁failure ▁; ▁severe ▁hyper tension ▁; ▁mit ral ▁re gur gi tation ▁; ▁mit ral ▁sten osis ▁; ▁aggressiv e ▁medical ▁treatment ▁; ▁heart ▁failure
D-336	-0.31010013818740845	heart failure ; severe hypertension ; mitral regurgitation ; mitral stenosis ; aggressive medical treatment ; heart failure
P-336	-1.3778 -0.0686 -0.1324 -0.8140 -0.1252 -0.0157 -0.0987 -0.0864 -0.0177 -0.0127 -0.0834 -0.0332 -0.0336 -0.2447 -0.0916 -0.0166 -0.0209 -0.0072 -0.2222 -3.2620 -0.0092 -0.2225 -0.3941 -0.7894 -0.1762 -0.1170 -0.1277 -0.0820
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization therapy ; crt ; morbidity ; mortality ; chronic systolic heart failure ; wide qrs complex
H-845	-0.3868589699268341	▁Card iac - re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁chronic ▁sy sto lic ▁heart ▁failure ▁; ▁QR s
D-845	-0.3868589699268341	Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure ; QRs
P-845	-1.1585 -0.1143 -0.0232 -0.1879 -0.1199 -0.0193 -0.9682 -0.9408 -0.0444 -0.1659 -0.6016 -1.7233 -0.2113 -0.2847 -0.0158 -0.7961 -0.2255 -0.0416 -0.4691 -0.1431 -0.0571 -0.0122 -0.0418 -0.0864 -0.5366 -0.2280 -1.1805 -0.0018 -0.9358 -0.5548 -0.1033
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk ; scn5a ; kv4.3 ; mrnas ; transient receptor potential cation channel m7 ; trpm7 ; mrna
H-1086	-0.32791951298713684	▁per k ▁activa tion ▁destabiliz ed ▁s cn 5 a ▁; ▁Kv 4.3 ▁channel ▁m RNA s ▁; ▁trans ient ▁receptor ▁potential ▁ cation ▁channel ▁m 7 ▁; TR PM 7) ▁channel ▁m RNA
D-1086	-0.32791951298713684	perk activation destabilized scn5a ; Kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7) channel mRNA
P-1086	-1.9250 -0.6819 -0.0248 -0.1892 -0.5707 -0.1644 -0.9844 -0.3172 -0.4607 -0.3195 -0.0992 -1.0356 -0.0343 -0.0446 -0.0179 -0.0277 -0.2195 -0.2027 -0.0062 -0.0263 -0.0219 -0.7697 -0.0850 -0.0099 -0.1311 -0.6158 -0.0899 -0.1903 -0.2321 -0.5445 -1.2413 -0.0940 -0.0114 -0.0685 -0.2569 -0.0912
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients ; implantable cardioverter-defibrillator ; heart function clinic ; university health network ; toronto ; canada
H-1861	-0.4295366108417511	▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁Heart ▁Fun ction ▁Clinic ▁; ▁University ▁Health ▁Network ▁; Tor onto
D-1861	-0.4295366108417511	implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto
P-1861	-0.3925 -0.0279 -0.2009 -0.0167 -0.1719 -0.0289 -0.1024 -0.0671 -0.3167 -0.1010 -0.0404 -0.3753 -1.3462 -0.1597 -0.0022 -0.4490 -0.4348 -2.0666 -1.0861 -0.6136 -0.5911 -0.4504 -0.0005 -1.6103 -0.0862
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced pasp ; clinical ; prognostic ; pulmonary hypertension ; patients ; right ventricular contractile reserve
H-831	-0.35285162925720215	▁Exerci se - indu ced ▁PAS p ▁; ▁pulmonar y ▁hyper tension ▁patients ▁; ▁vent ri cular ▁contract ile ▁reserve
D-831	-0.35285162925720215	Exercise-induced PASp ; pulmonary hypertension patients ; ventricular contractile reserve
P-831	-2.7082 -0.1132 -0.0307 -0.0160 -0.0313 -0.5208 -1.1347 -0.4997 -0.0198 -0.0895 -0.0929 -0.0273 -0.7607 -0.1866 -0.3837 -0.5812 -0.2093 -0.0209 -0.0384 -0.0203 -0.1877 -0.0896
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi ; metoprolol ; elevated ; plasma norepinephrine ; dopamine ; elevated ; epinephrine
H-1550	-0.36646777391433716	▁MI ▁animals ▁; ▁met o pro lol ▁; ▁plasma ▁no re pine ph rine ▁; ▁dop amine ▁; ▁e pine ph rine
D-1550	-0.36646777391433716	MI animals ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
P-1550	-2.8443 -1.4712 -0.6201 -0.0053 -0.1257 -0.0258 -0.1561 -0.1362 -0.5999 -0.1390 -0.2566 -0.0513 -0.8632 -0.0854 -0.1449 -0.0014 -0.0552 -0.1584 -0.0406 -0.0103 -0.6160 -0.1359 -0.1475 -0.1050
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis ; biomedical ; biomedical ; patients ; dcm ; heart failure
H-1264	-0.3646673560142517	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1264	-0.3646673560142517	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
P-1264	-0.0175 -0.1224 -0.0057 -0.8947 -0.3365 -1.3801 -0.4691 -0.2505 -0.0158 -0.0382 -0.0081 -0.4823 -0.8055 -1.0879 -0.0703 -0.2135 -0.4603 -0.2088 -0.2701 -0.1560
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ; hf
H-696	-0.23097097873687744	▁ST 2 ▁; ▁cardio protec tive ▁signal ing ▁; ▁my o car dium ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; HF
D-696	-0.23097097873687744	ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
P-696	-1.2001 -0.0969 -0.1932 -0.0688 -0.1526 -0.6444 -0.4277 -0.3348 -0.2349 -0.2274 -0.0285 -0.0147 -0.0298 -0.1017 -0.0131 -0.0475 -0.1197 -0.5442 -0.1851 -0.1044 -0.4464 -0.0608 -0.1693 -0.0974
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular outcomes in renal atherosclerotic lesions ; coral ; stenting ; ras
H-1602	-0.22942028939723969	▁Card io vas cular ▁Out com es ▁; ▁Ren al ▁Ath eros cle ro tic ▁Les ions ▁; co RAL ▁; ▁sten ting ▁; ▁ RAS
D-1602	-0.22942028939723969	Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;coRAL ; stenting ; RAS
P-1602	-0.2626 -0.4384 -0.0353 -0.2141 -0.2684 -0.0277 -0.0977 -0.6469 -0.0430 -0.0353 -0.0372 -0.0597 -0.0288 -0.4608 -0.7549 -0.4185 -0.1887 -0.1400 -0.5325 -0.0585 -0.1609 -0.1666 -0.0925 -0.3526 -0.6819 -0.0147 -0.1370 -0.0687
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality ; heart failure ; hf ; implantable cardioverter defibrillators ; icds
H-60	-0.39354008436203003	▁mortal ity ▁; ▁heart ▁failure ▁; HF ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; IC d s
D-60	-0.39354008436203003	mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
P-60	-3.8357 -1.5498 -0.2672 -0.6530 -0.1403 -0.1311 -0.0394 -0.1770 -0.1876 -0.0286 -0.2109 -0.0099 -0.0790 -0.1677 -0.0422 -0.2060 -0.0737 -0.1735 -0.3105 -0.3854 -0.3771 -0.0819 -0.2317 -0.0860
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic ; interatrial shunting ; patients ; heart failure with reduced ejection fraction
H-1950	-0.33031153678894043	▁ therapeut ic ▁left - to - right ▁inter at rial ▁sh unting ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1950	-0.33031153678894043	therapeutic left-to-right interatrial shunting ; heart failure ; ejection fraction
P-1950	-2.4847 -0.0755 -0.1913 -0.8152 -0.0356 -0.0713 -0.0541 -0.0434 -0.0231 -0.0156 -0.0670 -0.2373 -0.4484 -0.3974 -1.1122 -0.0382 -0.6869 -0.3926 -0.0529 -0.0252 -0.4079 -0.0038 -0.1567 -0.0911
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary approaches to stop hypertension ; dash ; mortality ; postmenopausal ; hf
H-686	-0.33247774839401245	▁Mediterrane an ▁; ▁Diet ary ▁App ro ach es ▁to ▁Stop ▁Hyper tension ▁; DAS h ▁; ▁die t ▁score s ▁; ▁mortal ity ▁; ▁post meno paus al ▁women ▁; HF
D-686	-0.33247774839401245	Mediterranean ; Dietary Approaches to Stop Hypertension ;DASh ; diet scores ; mortality ; postmenopausal women ;HF
P-686	-0.4345 -0.0101 -1.0495 -0.0659 -0.0811 -0.1108 -0.1019 -1.9125 -0.0453 -0.1198 -0.1339 -0.1940 -0.0160 -0.2724 -0.0091 -0.0696 -0.1173 -1.6280 -0.0248 -0.0117 -0.0298 -0.3135 -0.0250 -0.8121 -0.2576 -0.0154 -0.0252 -0.0051 -0.0159 -1.1762 -0.4389 -1.5904 -0.0916 -0.0993
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic ; patients ; reverse remodeling ; crt ; clinical ; outcomes
H-436	-0.2250194102525711	▁multi para metric ▁e cho car dio graphic ▁score ▁; ▁rever se ▁remodel ing ▁; ▁c RT
D-436	-0.2250194102525711	multiparametric echocardiographic score ; reverse remodeling ; cRT
P-436	-0.1817 -0.0348 -0.0535 -0.0575 -0.0651 -0.0271 -0.2581 -0.4764 -0.2025 -0.1610 -0.2376 -0.0154 -0.0159 -0.0149 -0.4874 -0.4298 -1.1752 -0.2996 -0.0818
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire ; implanted ; pacemakers ; ventricularly ; beats ; heart failure
H-1056	-0.2783915102481842	▁York shire ▁s win e ▁; ▁pace makers ▁; ▁vent ri cular ly ▁pace d ▁; ▁induc e ▁heart ▁failure
D-1056	-0.2783915102481842	Yorkshire swine ; pacemakers ; ventricularly paced ; induce heart failure
P-1056	-0.4728 -0.0053 -0.0169 -0.0970 -0.1705 -0.1960 -0.5782 -0.0579 -0.2355 -0.0219 -0.3095 -0.0397 -0.0924 -0.0592 -0.0790 -0.2929 -2.8157 -0.0304 -0.2211 -0.0791 -0.1629 -0.0908
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; clinical ; outcomes ; chf
H-636	-0.21354760229587555	▁anta gon ists ▁; ▁inhibi tors ▁; ▁re nin - angi oten sin - al do ster one ▁; ▁sympa the tic ▁ner vous ▁systems ▁; ▁CHF
D-636	-0.21354760229587555	antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
P-636	-0.3747 -0.0103 -0.2956 -0.1927 -0.0010 -0.0535 -0.2404 -0.0145 -0.1855 -0.0249 -0.0016 -0.0269 -0.4462 -0.1109 -0.0244 -0.0575 -0.0133 -0.3946 -0.1683 -0.0020 -0.4709 -1.0220 -0.3851 -0.7697 -0.0880 -0.6734 -0.0097 -0.0584 -0.0770
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf ; hf ; epidemiology ; rheumatic fever
H-1799	-0.5039227604866028	▁ HF ▁; ▁ HF ▁; ▁epidemi ology ▁; ▁SH ▁; ▁c ' d ▁; ▁rhe u matic ▁fe ver
D-1799	-0.5039227604866028	HF ; HF ; epidemiology ; SH ; c'd ; rheumatic fever
P-1799	-1.2957 -0.1001 -0.3957 -0.6862 -0.1423 -0.4501 -1.8655 -0.3374 -0.1019 -1.8018 -0.1015 -0.2692 -2.8838 -0.0545 -0.0779 -0.0264 -0.0234 -0.1359 -0.0294 -0.0163 -0.1736 -0.1176
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality ; readmissions ; costs ; patient ; physician ; hospital
H-1725	-0.3791593909263611	▁risk - ad just ed ▁mortal ity ▁; ▁read missions ▁; ▁costs
D-1725	-0.3791593909263611	risk-adjusted mortality ; readmissions ; costs
P-1725	-1.9812 -0.0171 -0.0084 -0.0213 -0.0374 -0.0492 -0.3814 -0.2228 -0.0528 -0.1297 -0.4453 -0.6826 -1.1932 -0.0858
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise ; training ; exercise ; exercise capacity ; qol ; obese ; patients ; hfpef
H-1976	-0.3300709128379822	▁calor ic ▁restriction ▁; diet ▁; ▁aero bic ▁exercise ▁training ▁; exe rci se ▁; ▁exercise ▁capacity ▁; ▁Q OL ▁; ▁obes e ▁older ▁patients ▁; ▁h FP EF
D-1976	-0.3300709128379822	caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese older patients ; hFPEF
P-1976	-0.2320 -0.3070 -0.0735 -0.0618 -0.0220 -0.0423 -0.0024 -0.0577 -0.2525 -0.5394 -0.1041 -0.0975 -0.0077 -0.0428 -0.0736 -2.6586 -0.2772 -0.0583 -0.9234 -0.0673 -0.1159 -0.4028 -0.0444 -0.2448 -0.5773 -0.5166 -1.2845 -0.6183 -0.3292 -0.0925 -0.1049
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic heart failure ; hf ; hemodynamic ; syndrome ; dysfunction ; molecular pathways
H-1472	-0.33649173378944397	▁chronic ▁heart ▁failure ▁; HF ▁; ▁hem o dynamic ▁disorder ▁; ▁syndrome ▁; ▁dys function ▁; ▁molecular ▁path ways
D-1472	-0.33649173378944397	chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction ; molecular pathways
P-1472	-0.2923 -1.0038 -0.0815 -0.1612 -0.0687 -0.2680 -0.2301 -0.1086 -0.0014 -0.1372 -0.3318 -0.0153 -0.7892 -0.3826 -0.0348 -1.0889 -1.6902 -0.1248 -0.0593 -0.1097 -0.0870
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications ; patients ; heart failure and reduced ejection fraction ; outpatient
H-667	-0.4895726144313812	▁guide line - re com mend ed ▁medication s ▁; ▁patients ▁with ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-667	-0.4895726144313812	guideline-recommended medications ; patients with heart failure ; reduced ejection fraction
P-667	-5.0478 -0.0100 -0.0484 -0.0101 -0.0185 -0.0070 -0.0466 -0.0400 -0.1051 -0.4598 -0.8103 -1.9687 -0.1953 -0.0224 -0.1925 -0.4555 -0.0105 -0.0137 -0.1268 -0.0185 -0.4004 -0.0060 -1.5628 -0.1731
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms ; hfpef ; diastolic filling time ; heart rate ; symptoms
H-1172	-0.395270437002182	▁ HF p EF ▁; ▁dia sto lic ▁fill ing ▁time ▁; ▁control ling ▁heart ▁rate
D-1172	-0.395270437002182	HFpEF ; diastolic filling time ; controlling heart rate
P-1172	-0.9335 -0.1822 -0.0755 -0.3588 -0.1871 -0.4854 -0.0515 -0.0358 -0.3548 -0.0241 -1.1981 -0.1332 -2.2004 -0.0268 -0.3827 -0.1272 -0.2657 -0.0922
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac ; myocyte-specific mena overexpression ; cardiac ; pathology
H-1813	-0.3082764446735382	▁mi ce ▁; ▁cardiac ▁my o cy te - specific ▁Men a ▁over expression ▁; TTA ▁; ▁t g t et Men a ▁; ▁cardiac ▁path ology
D-1813	-0.3082764446735382	mice ; cardiac myocyte-specific Mena overexpression ;TTA ; tgtetMena ; cardiac pathology
P-1813	-0.9013 -0.2745 -0.6588 -0.0076 -0.7800 -0.0856 -0.0188 -0.0437 -0.3961 -0.0212 -0.9100 -0.0305 -0.0166 -0.0267 -0.1097 -0.1595 -0.9039 -1.7036 -0.0458 -0.0964 -0.0184 -0.3947 -0.0170 -0.4217 -0.0065 -0.2047 -0.4650 -0.1296 -0.0919
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk stratification ; antiplatelet agents ; combination ; anticoagulants ; vascular diseases
H-1355	-0.3307223618030548	▁anti plate let ▁agents ▁; ▁antico a gul ants ▁; ▁vas cular ▁disease s
D-1355	-0.3307223618030548	antiplatelet agents ; anticoagulants ; vascular diseases
P-1355	-1.6457 -0.0749 -0.2109 -0.3139 -0.3048 -0.1587 -0.1479 -0.2962 -0.0567 -0.5449 -0.8058 -0.0562 -0.3141 -0.0752 -0.1860 -0.0995
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international right heart foundation working group ; step ; syndrome ; right heart failure
H-1458	-0.87506103515625	▁international ▁Right ▁Heart ▁Foundation ▁Work ing ▁Group ▁; ▁defect s ▁; ▁right ▁heart ▁failure
D-1458	-0.87506103515625	international Right Heart Foundation Working Group ; defects ; right heart failure
P-1458	-2.7159 -0.6800 -0.4690 -1.2499 -1.8083 -0.0130 -0.8812 -0.4060 -2.9291 -0.0735 -0.1783 -1.7903 -0.2621 -0.3330 -0.1146 -0.0967
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc ; diagnostic
H-1025	-0.48561373353004456	▁PO c ▁systems ▁; ▁me as uring ▁ NP ▁levels
D-1025	-0.48561373353004456	POc systems ; measuring NP levels
P-1025	-0.6801 -1.9967 -0.3178 -0.7316 -0.2693 -0.0692 -0.0117 -0.1765 -0.0231 -0.6155 -0.8540 -0.0817
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients ; lbbb ; qrs ; implantable
H-890	-0.4315996468067169	▁l b ▁; ▁QR s ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - c RT
D-890	-0.4315996468067169	lb ; QRs ; implantable cardioverter defibrillator-cRT
P-890	-1.5760 -0.8956 -0.1789 -1.0503 -1.1215 -0.0520 -1.2079 -0.0223 -0.1379 -0.0070 -0.0395 -0.4374 -0.0238 -0.0602 -0.0518 -0.0112 -0.0908 -0.9251 -0.9095 -0.1963 -0.0687
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography ; cardiac ; cardiac function
H-453	-0.2055157572031021	▁e cho card i ography ▁; ▁cardiac ▁diameter s ▁; ▁cardiac ▁function ▁; ▁vehicle - tre ated ▁rat s
D-453	-0.2055157572031021	echocardiography ; cardiac diameters ; cardiac function ; vehicle-treated rats
P-453	-0.0385 -0.0182 -0.1331 -0.4565 -0.2228 -0.2027 -0.0913 -0.0425 -0.1992 -0.1443 -0.2592 -0.2409 -0.5708 -1.0190 -0.0388 -0.0085 -0.1183 -0.1559 -0.1106 -0.1867 -0.0578
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline ; embase ; psycinfo
H-151	-0.2769536077976227	▁electronic ▁database s ▁; ▁med line ▁; ▁ EMBA se ▁; ▁Psy c INFO
D-151	-0.2769536077976227	electronic databases ; medline ; EMBAse ; PsycINFO
P-151	-1.2159 -0.0697 -0.0912 -0.0760 -0.8386 -0.3718 -0.1214 -0.2258 -0.0123 -0.4141 -0.0678 -0.3259 -0.0840 -0.0022 -0.4581 -0.0564
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality of life ; functional capacity
H-618	-1.0515868663787842	▁quality ▁; ▁functional ▁capacity
D-618	-1.0515868663787842	quality ; functional capacity
P-618	-3.0464 -1.9764 -0.0948 -0.7226 -0.3477 -0.1216
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized ; medical
H-1977	-1.689739465713501	▁urban ▁academic ▁medical ▁center
D-1977	-1.689739465713501	urban academic medical center
P-1977	-7.5529 -0.7533 -1.0352 -0.5557 -0.1343 -0.1069
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients ; systolic hf ; cxl-1020 ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
H-423	-0.4159127473831177	▁sy sto lic ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁; ▁right ▁heart ▁fill ing ▁pressure s ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁cardiac ▁; ▁stroke
D-423	-0.4159127473831177	systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
P-423	-0.0426 -0.0306 -0.0049 -0.5237 -0.0763 -0.0632 -0.4746 -0.0575 -0.0769 -0.0421 -0.7289 -0.4126 -0.9323 -0.9410 -1.9937 -0.6678 -0.0501 -0.7711 -0.2511 -0.1738 -0.0398 -0.4301 -0.0769 -0.2109 -0.1550 -0.0699 -0.2682 -0.0306 -0.6481 -0.1975 -2.7447 -0.1227
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic ; patients ; severe heart failure ; financial
H-1242	-0.5382190346717834	▁ therapeut ic ▁strategy ▁; ▁AF ▁; ▁severe ▁heart ▁failure ▁; ▁financial ▁burde n
D-1242	-0.5382190346717834	therapeutic strategy ; AF ; severe heart failure ; financial burden
P-1242	-1.9543 -0.0323 -0.1897 -0.7927 -0.2654 -0.7890 -0.3652 -1.6685 -0.2627 -0.0657 -0.3870 -1.1306 -0.3818 -0.0908 -0.1529 -0.0829
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow up ; ffm ; patients
H-16	-0.8281176090240479	▁follow ▁up ▁body ▁weight ▁; ▁FM ▁; ▁f FM ▁; cc
D-16	-0.8281176090240479	follow up body weight ; FM ; fFM ;cc
P-16	-1.8666 -1.2861 -0.8201 -0.2796 -0.2996 -0.6547 -0.3007 -0.3330 -1.1060 -0.7360 -2.1887 -0.8010 -0.0936
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential analysis ; cluster analysis
H-1610	-0.3113362193107605	▁r . ▁Clu ster ▁analysis
D-1610	-0.3113362193107605	r. Cluster analysis
P-1610	-0.5012 -0.6582 -0.4491 -0.0075 -0.2320 -0.2682 -0.0632
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1260	-0.3959704339504242	▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1260	-0.3959704339504242	ventricular ejection fraction ; left ventricular diastolic end diameter
P-1260	-3.8473 -0.6365 -0.1548 -0.1897 -0.1173 -0.0440 -0.4843 -0.0045 -0.1153 -0.0201 -0.0261 -0.6720 -0.1226 -0.1350 -0.0546 -0.0195 -0.7664 -0.0588 -0.3396 -0.1111
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence ; clinical ; outcomes ; concentric left ventricular hypertrophy ; heart failure with preserved ejection fraction
H-1523	-0.25208601355552673	▁ecce n tric ▁versus ▁concentr ic ▁left ▁vent ri cular ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1523	-0.25208601355552673	eccentric versus concentric left ventricular hypertrophy ; heart failure ; preserved ejection fraction
P-1523	-0.3879 -0.0157 -0.0445 -0.8779 -0.0136 -0.1024 -0.6521 -0.0922 -0.9536 -0.5662 -0.3053 -0.0140 -0.5422 -0.3327 -0.2276 -0.0624 -0.4426 -0.0227 -0.0445 -0.3210 -0.0286 -0.0860 -0.0417 -0.3690 -0.0041 -0.1555 -0.1003
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients ; left ventricular ejection fraction ; heart failure with preserved ejection fraction ; hfpef
H-1887	-0.21889910101890564	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1887	-0.21889910101890564	left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
P-1887	-0.9225 -0.0539 -0.4843 -0.1892 -0.2108 -0.0888 -0.0474 -0.4208 -0.0040 -0.1192 -0.8919 -0.0726 -0.6363 -0.0591 -0.0460 -0.2306 -0.0299 -0.1093 -0.0322 -0.2517 -0.0046 -0.2736 -0.2717 -0.0279 -0.1518 -0.1673 -0.1128
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
H-451	-0.2061987668275833	▁β - ad r energi c ▁receptor ▁block er ▁ therapy ▁; ▁my o card ial ▁per fusion ▁; ▁neo angi ogen es is ▁; ▁fail ing ▁heart
D-451	-0.2061987668275833	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
P-451	-0.0165 -0.0261 -0.0512 -0.1348 -0.4275 -0.0186 -0.0108 -0.2768 -0.0836 -1.0897 -0.0174 -0.2010 -1.5096 -0.0927 -0.3488 -0.3027 -0.2450 -0.0107 -0.1376 -0.0710 -0.0120 -0.0400 -0.0504 -0.1347 -0.2480 -0.0635 -0.0275 -0.3093 -0.1278 -0.1004
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
H-1780	-0.3333526849746704	▁cardiac ▁hyper trop hy ▁; ▁pressure - over load ▁; ▁abdominal ▁a or tic ▁con stri ction ▁; ▁a ac
D-1780	-0.3333526849746704	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
P-1780	-2.1498 -0.1460 -0.0099 -0.2766 -0.4842 -0.1381 -0.0957 -0.0215 -0.0431 -0.3089 -0.0423 -0.0600 -0.2044 -0.7503 -0.0159 -0.4202 -0.0619 -1.4223 -0.2801 -0.1584 -0.1125 -0.1315
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline ; hgb ; correlated ; baseline ; kccq ; hgb ; exercise ; training ; hrqol
H-839	-0.5633145570755005	▁h gb ▁; ▁k cc q ▁scale s ▁; ▁h gb ▁; ▁exercise ▁training ▁; ▁HR Qo L
D-839	-0.5633145570755005	hgb ; kccq scales ; hgb ; exercise training ; HRQoL
P-839	-1.7352 -0.0488 -0.0473 -1.7306 -0.0461 -0.8934 -0.7109 -0.0426 -0.0742 -0.7301 -0.0673 -0.0702 -2.2789 -0.5684 -0.4842 -0.5584 -0.0043 -0.8784 -0.1631 -0.1342
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient ; patients ; heart failure ; hospital ; discharge ; readmissions ; patient ; follow-up
H-722	-0.8711405992507935	▁in patient ▁assessment s ▁; ▁heart ▁failure ▁; ▁hospital ▁dis charge ▁; ▁read missions
D-722	-0.8711405992507935	inpatient assessments ; heart failure ; hospital discharge ; readmissions
P-722	-4.6709 -0.0508 -0.1506 -0.0982 -0.2750 -4.1109 -0.1170 -0.3156 -1.5465 -0.6430 -0.0451 -0.4797 -0.4355 -0.2069 -0.6783 -0.1142
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; svr ; cardiac index
H-225	-0.23708102107048035	▁Font an ▁failure ▁; ▁hem o dynamic ally ▁; ▁heart ▁failure ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁s VR ▁; ▁pres er ved ▁cardiac ▁index
D-225	-0.23708102107048035	Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; preserved cardiac index
P-225	-0.1347 -0.1130 -0.0896 -0.0844 -0.1242 -0.0738 -0.0012 -0.0762 -0.2316 -2.5674 -0.0516 -0.0995 -0.3566 -0.3149 -0.1202 -0.5258 -0.0964 -0.0520 -0.1440 -0.3020 -0.2008 -0.2475 -0.4192 -0.0228 -0.1520 -0.0284 -0.0082 -0.1589 -0.0784
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous hf
H-1156	-0.2890090346336365	▁my o fi ber ▁dynamic s ▁; ▁my o fi ber ▁short en ing ▁; ▁EM d ▁; ▁dys syn chron ous ▁ HF
D-1156	-0.2890090346336365	myofiber dynamics ; myofiber shortening ; EMd ; dyssynchronous HF
P-1156	-1.2264 -0.1426 -0.0449 -0.1784 -0.0574 -0.0579 -0.1574 -0.3861 -0.0653 -0.0290 -0.0874 -0.9190 -0.0436 -0.1839 -0.1554 -1.4751 -1.0314 -0.1242 -0.0283 -0.0105 -0.0026 -0.3241 -0.3008 -0.1581 -0.2065 -0.1182
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial index ; pulse-wave ; coronary artery calcium scores
H-1562	-0.10075950622558594	▁cru de ▁; ▁adjust ed ▁an kle - bra chi al ▁index ▁; ▁puls e - wa ve ▁veloci ty ▁; ▁corona ry ▁arter y ▁calci um ▁score s
D-1562	-0.10075950622558594	crude ; adjusted ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
P-1562	-0.0167 -0.0390 -0.0683 -0.1320 -0.0284 -0.0830 -0.1679 -0.0502 -0.1766 -0.2273 -0.0529 -0.0241 -0.1210 -0.0056 -0.1188 -0.0398 -0.0616 -0.0271 -0.1081 -0.0564 -0.1741 -0.0229 -0.4110 -0.0257 -0.2173 -0.1147 -0.0112 -0.0735 -0.2112 -0.1903 -0.0671
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate ; unfolded protein response ; upr ; scn5a ; remodeling ; hf
H-1081	-0.2605724632740021	▁tru nca ted ▁na + ▁channel s ▁activa te ▁; ▁un fold ed ▁protein ▁response ▁; ▁u PR ▁; ▁electric ▁remodel ing ▁; ▁ HF
D-1081	-0.2605724632740021	truncated na+ channels activate ; unfolded protein response ; uPR ; electric remodeling ; HF
P-1081	-0.2808 -0.0350 -0.0254 -0.1240 -0.3986 -0.0252 -0.0800 -0.4374 -0.2357 -1.2917 -0.0014 -0.0005 -0.0187 -0.0527 -0.0376 -0.1042 -0.5270 -0.1273 -0.0432 -1.4404 -0.0236 -0.0130 -0.2461 -0.6737 -0.5564 -0.1698 -0.0659
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary endpoint ; intermacs ; interagency registry for mechanically assisted circulatory support
H-1996	-0.5482509732246399	▁inter age ncy ▁Registr y ▁for ▁Mechanic ally ▁Assist ed ▁circula tory ▁Support
D-1996	-0.5482509732246399	interagency Registry for Mechanically Assisted circulatory Support
P-1996	-1.3708 -3.3329 -0.0125 -0.4126 -0.0669 -0.9959 -0.0446 -0.2749 -0.0837 -0.0840 -0.4795 -0.1176 -0.4262 -0.3876 -0.1340
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol ; lv contractile function ; xo-mediated ros ; myofilament ; sensitivity
H-477	-0.2312374711036682	▁allo puri nol ▁; ▁contract ile ▁function ▁; ▁efficiency ▁; ▁ XO - media ted ▁ ROS ▁effects ▁; ▁my o fila ment
D-477	-0.2312374711036682	allopurinol ; contractile function ; efficiency ; XO-mediated ROS effects ; myofilament
P-477	-0.0242 -0.0057 -0.1024 -0.0501 -0.2534 -0.0132 -0.2137 -0.1438 -0.0973 -0.0717 -0.3247 -0.0175 -0.0039 -0.0319 -0.0343 -0.0467 -0.1053 -0.5914 -0.4820 -0.4408 -0.0405 -0.0019 -0.2555 -2.3355 -0.0935
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic function ; hfpef ; patients ; long axis function ; exercise
H-1888	-0.4839445650577545	▁sy sto lic ▁function ▁; ▁ HF p EF ▁patients ▁; ▁long ▁a xis ▁function ▁; ▁exercise
D-1888	-0.4839445650577545	systolic function ; HFpEF patients ; long axis function ; exercise
P-1888	-2.8655 -0.1007 -0.0947 -0.0875 -0.0997 -0.9045 -0.0511 -0.0360 -0.0887 -1.0099 -0.2066 -1.6178 -0.0439 -0.0176 -0.0253 -0.3083 -1.3965 -0.1272 -0.1136
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians ; patients ; heart failure ; equitable ; therapeutic
H-1823	-0.9758082032203674	▁physician s ▁; ▁patients ▁; ▁advanced ▁heart ▁failure
D-1823	-0.9758082032203674	physicians ; patients ; advanced heart failure
P-1823	-2.2470 -0.0400 -0.4419 -2.8966 -1.7051 -0.1957 -0.3138 -0.0642 -1.7314 -0.1225
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf ; multivariate-adjusted odds ratio ; mortality ; hazard ratio ; mortality
H-1312	-0.660777747631073	▁con current ▁ HF ▁; ▁odds ▁ratio ▁; ▁28- day ▁mortal ity ▁; ▁hazard ▁ratio
D-1312	-0.660777747631073	concurrent HF ; odds ratio ; 28-day mortality ; hazard ratio
P-1312	-2.0392 -0.0082 -0.2872 -0.0987 -0.3042 -3.1537 -0.0164 -0.2171 -0.2157 -0.2590 -0.0183 -0.6460 -0.2697 -0.1095 -0.0113 -3.4527 -0.1263
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas ; hf ; hyperkalemia ; hypokalemia ; spironolactone ; clinical
H-1708	-0.2872995436191559	▁AA s ▁; ▁ HF ▁; ▁hyper kal emia ▁; ▁hypo kal emia ▁; ▁spi rono lac tone
D-1708	-0.2872995436191559	AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
P-1708	-0.6345 -0.4622 -0.7653 -0.7409 -0.1435 -0.1795 -0.2253 -0.1063 -0.0701 -0.0921 -0.0185 -0.1788 -0.1021 -0.1547 -0.0129 -0.0066 -0.0190 -0.0397 -1.7103 -0.0836
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors ; g-protein-coupled receptor ; kinase-2 ; downregulation
H-1407	-0.49706995487213135	▁g - prote in - co up led ▁receptor ▁kina se -2
D-1407	-0.49706995487213135	g-protein-coupled receptor kinase-2
P-1407	-4.4357 -0.0651 -0.0187 -0.1803 -0.0267 -0.0049 -0.0173 -0.3113 -0.0130 -0.2040 -0.0317 -0.1065 -1.4102 -0.1336
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp ; nonterminal epitopes ; central glycosylated region
H-1522	-0.33891725540161133	▁NT - pro b NP ▁as say ▁; ▁non termin al ▁e pito pes ▁; ▁gly cos yla ted
D-1522	-0.33891725540161133	NT-probNP assay ; nonterminal epitopes ; glycosylated
P-1522	-0.1107 -0.0173 -0.0055 -0.4154 -0.2672 -0.1232 -0.0495 -1.0912 -0.2021 -0.4197 -0.0041 -0.0602 -0.0782 -0.5362 -0.5016 -0.4230 -0.2414 -0.3155 -0.1098 -2.0274 -0.1181
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a ; angii ; hypoxia ; expression ; upr ; downregulation
H-1085	-0.4950796663761139	▁s cn 5 a ▁; ▁Ang II ▁; ▁hypo xia ▁; ▁u PR ▁; ▁down regul ation ▁; ▁na + ▁current
D-1085	-0.4950796663761139	scn5a ; AngII ; hypoxia ; uPR ; downregulation ; na+ current
P-1085	-0.8605 -0.1331 -0.3972 -0.3691 -1.4679 -0.5745 -0.2901 -0.0643 -0.0198 -0.0177 -0.0783 -2.2702 -0.8118 -0.4586 -0.8155 -0.0763 -0.0941 -0.8518 -0.0934 -0.8708 -0.4941 -0.1403 -0.1376
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients ; heart transplant ; prospectively ; ecct
H-710	-0.6178808212280273	▁isola ted ▁heart ▁transplant ▁; ▁ec CT
D-710	-0.6178808212280273	isolated heart transplant ; ecCT
P-710	-0.6365 -0.2784 -1.5563 -0.0590 -1.4421 -0.5979 -0.7951 -0.0737 -0.1220
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate logistic regression analysis ; bnp ; patients ; diastolic dysfunction
H-1571	-0.2840179204940796	▁b NP ▁; ▁dia sto lic ▁dys function
D-1571	-0.2840179204940796	bNP ; diastolic dysfunction
P-1571	-0.7864 -0.9654 -0.1532 -0.1777 -0.0376 -0.2456 -0.0515 -0.2036 -0.1332 -0.0860
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate ratio ; therapy ; patient ; comorbidities
H-663	-0.8420762419700623	▁ therapy ▁; ▁como rbi di ties
D-663	-0.8420762419700623	therapy ; comorbidities
P-663	-2.7466 -0.2791 -0.4511 -3.4578 -0.0110 -0.2720 -0.0555 -0.2005 -0.1052
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization ; medicare ; hospital ; medicare ; policy
H-1715	-0.3160613775253296	▁re hospital ization ▁; ▁Medica re ▁hospital ▁claims ▁; ▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1715	-0.3160613775253296	rehospitalization ; Medicare hospital claims ; Medicare ; post-acute care transfer policy
P-1715	-1.1533 -0.0426 -0.2311 -0.2782 -0.0170 -0.0089 -1.6117 -0.2312 -0.1153 -0.0816 -0.0122 -0.4959 -0.0212 -0.0129 -0.0552 -0.0090 -1.1744 -0.2052 -0.5374 -0.2092 -0.1340
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart failure ; compliance ; etidronate ; alendronate
H-1543	-0.21923509240150452	▁risk ▁; ▁heart ▁failure ▁; ▁re fill ▁compliance ▁; ▁et id rona te ▁; ▁ale ndr onate
D-1543	-0.21923509240150452	risk ; heart failure ; refill compliance ; etidronate ; alendronate
P-1543	-1.3633 -0.7389 -0.1892 -0.1190 -0.1260 -0.0747 -0.0204 -0.2449 -0.0514 -0.0057 -0.0217 -0.0095 -0.0128 -0.0609 -0.6360 -0.0059 -0.0500 -0.3752 -0.0600
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis ; metabolic exercise ; cardiac ; kidney
H-1762	-0.28367841243743896	▁AT ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score
D-1762	-0.28367841243743896	AT ; metabolic exercise ; cardiac ; kidney index score
P-1762	-0.7831 -0.5792 -0.0222 -0.0471 -0.1113 -0.0889 -0.0068 -1.2290 -0.0269 -0.2757 -0.0322 -0.0156 -0.0214 -0.9098 -0.1061
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical ; activity ; crf ; hf ; mortality
H-1776	-0.4393996596336365	▁physical ▁activity ▁; ▁c RF ▁; ▁ HF ▁mortal ity
D-1776	-0.4393996596336365	physical activity ; cRF ; HF mortality
P-1776	-2.3017 -0.4299 -0.0997 -0.2080 -0.1376 -0.1545 -1.0500 -0.2027 -0.1006 -0.3948 -0.1095 -0.0839
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular pathways ; patients ; chronic heart failure ; chf
H-249	-0.49376988410949707	▁et ▁; ▁HD L - media ted ▁protect ive ▁effects ▁; ▁molecular ▁path ways ▁; ▁chronic ▁heart ▁failure ▁; CH f
D-249	-0.49376988410949707	et ; HDL-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
P-249	-1.0086 -0.5158 -3.6601 -0.8769 -0.0287 -0.0476 -0.0527 -0.6380 -0.0577 -0.4630 -0.1481 -0.6275 -0.0829 -0.0510 -0.2960 -0.1650 -0.3310 -0.1384 -0.3562 -0.3324 -1.2600 -0.1295 -0.0896
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo ; dopamine ; nesiritide ; secondary end points ; renal function ; clinical ; outcomes
H-82	-0.23112070560455322	▁dop amine ▁; ▁nesi riti de ▁; ▁de con gestion ▁; ▁renal ▁function
D-82	-0.23112070560455322	dopamine ; nesiritide ; decongestion ; renal function
P-82	-1.5415 -0.1468 -0.0502 -0.0143 -0.0057 -0.1145 -0.3590 -0.0590 -0.0076 -0.0158 -0.3440 -0.0004 -0.1761 -0.5505 -0.0812
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia ; medline ; cochrane library
H-31	-0.35870760679244995	▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁med line ▁; ▁co ch rane ▁Library
D-31	-0.35870760679244995	anemia ; iron deficiency ; medline ; cochrane Library
P-31	-3.5181 -0.0896 -0.4850 -0.0185 -0.0674 -0.0381 -0.0081 -0.1119 -0.0553 -0.5097 -1.0194 -0.3660 -0.1309 -0.0221 -0.0239 -0.0127 -0.0792 -0.1331 -0.1264
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq ; patients ; hfpef
H-790	-0.5257535576820374	▁k cc q ▁domain s ▁; ▁internal ▁consiste ncy ▁; ▁patients ▁; ▁ HF p EF ▁; ▁c ron bach
D-790	-0.5257535576820374	kccq domains ; internal consistency ; patients ; HFpEF ; cronbach
P-790	-1.3068 -0.0491 -0.9560 -1.3758 -0.0929 -0.2165 -1.0791 -0.1865 -0.0214 -0.2117 -1.3122 -0.6966 -0.3338 -0.0828 -0.0348 -0.1371 -0.2049 -1.8055 -0.0263 -0.0142 -1.3517 -0.0707
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable ; patients ; qrs duration
H-891	-0.358934223651886	▁implant able ▁cardio ver ter ▁de fi br illa tor - c RT ▁; ▁non - LB bb ▁; ▁QR s ▁du ration
D-891	-0.358934223651886	implantable cardioverter defibrillator-cRT ; non-LBbb ; QRs duration
P-891	-0.4020 -0.0289 -0.1039 -0.0120 -0.0361 -0.1643 -0.0102 -0.0962 -0.0320 -0.0160 -0.0824 -1.6632 -1.0639 -0.2447 -1.1948 -0.0240 -0.0189 -0.9636 -1.1700 -0.0183 -0.8145 -0.4461 -0.0437 -0.2406 -0.0830
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal ; diagnostic ; clinical
H-1304	-0.603698194026947	▁mechanism s ▁; ▁diagnostic ▁approach es ▁; ▁clinic al ▁trial s
D-1304	-0.603698194026947	mechanisms ; diagnostic approaches ; clinical trials
P-1304	-4.4903 -0.0982 -0.2118 -0.3138 -0.3591 -0.0521 -0.1725 -0.1379 -0.0362 -0.1368 -0.0889 -1.6875 -0.0629
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up ; patients
H-1538	-0.3232559561729431	▁ale ndr onate - ▁; ▁et id rona te - ▁; ▁ra lo xi fen e - tre ated
D-1538	-0.3232559561729431	alendronate- ; etidronate- ; raloxifene-treated
P-1538	-1.5186 -0.0091 -0.0222 -0.3544 -1.1999 -0.0025 -0.0125 -0.0070 -0.0085 -0.1717 -0.9133 -0.0848 -0.0098 -0.0879 -0.0615 -0.0780 -0.1368 -0.0053 -0.5104 -1.4760 -0.1181
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy ; trastuzumab ; comorbidities ; chf ; international classification of diseases ; healthcare common procedure coding system codes
H-674	-0.2711375653743744	▁che mo therapy ▁; ▁tras tuz um ab ▁; ▁como rbi di ties ▁; ▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁health care ▁Common ▁Procedur e ▁co ding ▁system ▁code s
D-674	-0.2711375653743744	chemotherapy ; trastuzumab ; comorbidities ; CHF ; international Classification of Diseases ; healthcare Common Procedure coding system codes
P-674	-0.7618 -0.1524 -0.0092 -0.0771 -0.0203 -0.0171 -0.0059 -0.4598 -0.5506 -0.4413 -0.0011 -0.1098 -0.0234 -0.1268 -0.0178 -0.2573 -0.2948 -0.0264 -0.0301 -0.1147 -0.0428 -0.0106 -0.1714 -1.5155 -0.0398 -0.9794 -0.9301 -0.0192 -1.1958 -0.0186 -0.6629 -0.0505 -0.0953 -0.1717 -0.0882
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart failure ; hf ; therapies ; outcomes ; patients ; hf ; preserved left ventricular ejection fraction ; lvef
H-111	-0.3018764853477478	▁con tempor ary ▁heart ▁failure ▁; HF ▁; ▁ therapie s ▁; ▁ HF ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF
D-111	-0.3018764853477478	contemporary heart failure ;HF ; therapies ; HF ; preserved left ventricular ejection fraction ;LVEF
P-111	-0.3209 -0.0005 -0.0502 -0.4288 -0.0556 -0.2327 -0.0721 -0.2106 -0.8341 -0.1822 -0.0559 -0.2121 -2.1620 -0.2989 -0.0647 -1.3575 -0.0310 -0.2005 -0.1213 -0.0360 -0.7445 -0.2360 -0.0999 -0.1656 -0.0796 -0.6595 -0.0092 -0.3927 -0.0795 -0.0515 -0.1268 -0.0876
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart ; patients ; hfpef ; hf with reduced ejection fraction ; hfref
H-240	-0.3107144236564636	▁h ART ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF
D-240	-0.3107144236564636	hART ; HFpEF ; HF ; reduced ejection fraction ;HFrEF
P-240	-1.1719 -0.0158 -0.0822 -0.9537 -0.1000 -0.1833 -0.2161 -0.0424 -0.8065 -0.1047 -0.8885 -1.6836 -0.0197 -0.0223 -0.0804 -0.0237 -0.1701 -0.0061 -0.1527 -0.2532 -0.0847 -0.1139 -0.1941 -0.0875
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced hf ; cxl-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
H-421	-0.3658956289291382	▁ conscious ▁dog s ▁; ▁ta chy pac ing - indu ced ▁ HF ▁; ▁contract ility ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁ve no arte rial ▁di lation
D-421	-0.3658956289291382	conscious dogs ; tachypacing-induced HF ; contractility ; end-systolic elastance ; venoarterial dilation
P-421	-0.5453 -0.0317 -0.6031 -0.0382 -0.4374 -0.1614 -0.7537 -0.0143 -0.0667 -0.0569 -0.0044 -0.0317 -0.2800 -0.2726 -0.0725 -0.6413 -0.0265 -0.2411 -5.6785 -0.0172 -0.4851 -0.0520 -0.0165 -0.0158 -0.7273 -0.3809 -0.2070 -0.0241 -0.0187 -0.0274 -0.1573 -0.0561 -0.1884 -0.1091
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone morphogenetic protein 4 ; expression ; rrna transcription ; shift ; heterochromatic chromatin
H-98	-0.40049663186073303	▁bone ▁mor pho gene tic ▁protein ▁; ▁r RNA ▁tran scription ▁; ▁hetero ch ro matic ▁chr omat in
D-98	-0.40049663186073303	bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
P-98	-2.8586 -0.4134 -0.2515 -0.9929 -1.4571 -0.1926 -0.4115 -0.0451 -0.0172 -0.0066 -0.0068 -0.4464 -0.3061 -0.0756 -0.0303 -0.1300 -0.0133 -0.0166 -0.4074 -0.2022 -0.1295
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ; gluconeogenesis ; citrate cycle
H-873	-0.15734758973121643	▁act in ▁cy tos kelet on ▁; ▁mito cho ndri al ▁function ▁; ▁intermedi ate ▁metabolism ▁; ▁gly col ysis ▁; glu cone ogen es is ▁; ▁cit rate ▁cycle
D-873	-0.15734758973121643	actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
P-873	-0.0084 -0.3538 -0.2727 -0.2623 -0.0679 -0.1102 -0.1649 -0.0050 -0.3336 -0.2564 -0.0197 -0.0931 -0.1119 -0.0175 -0.2475 -0.0667 -0.0835 -0.0103 -0.0310 -0.0637 -0.7135 -0.0553 -0.0355 -0.3683 -0.0430 -0.1957 -0.2284 -0.0268 -0.0562 -0.5041 -0.1240 -0.1041
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated ; resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
H-939	-0.1658787727355957	▁eleva ted ▁resist in ▁; ▁bio mark er ▁; ▁an thra cycli ne - indu ced ▁cardio toxic ity ▁; ▁heart ▁failure ▁; ▁macro pha ges
D-939	-0.1658787727355957	elevated resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
P-939	-0.0868 -0.0726 -0.0670 -0.1245 -0.1464 -0.1435 -0.0165 -0.0399 -0.1910 -0.0153 -0.0076 -0.0627 -0.4033 -0.1578 -0.0101 -0.0485 -0.0238 -0.1457 -1.1194 -0.1332 -0.5013 -0.0636 -0.4423 -0.1704 -0.0133 -0.2169 -0.1397 -0.0815
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular matrix ; left ventricular ; biopsies ; tissuefaxs ; correlated ; t1 time
H-741	-0.29588747024536133	▁extra cel lular ▁matri x ▁; ▁left ▁vent ri cular ▁bio psi es ▁; ▁t issue FAX s ▁technology
D-741	-0.29588747024536133	extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
P-741	-0.3400 -0.0448 -0.0663 -0.0180 -0.1218 -0.3495 -0.0143 -0.0526 -0.8665 -0.3582 -0.0403 -0.2696 -0.1631 -0.1822 -1.0337 -0.0029 -0.0509 -1.0173 -0.2774 -0.8768 -0.0675
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients ; systolic hf ; the danish heart failure database ; esrd ; danish registry on dialysis
H-389	-0.33610978722572327	▁sy sto lic ▁ HF ▁; ▁Danish ▁Heart ▁Fail ure ▁database ▁; ▁ES RD ▁; ▁Danish ▁Registr y ▁on ▁Dia lys is
D-389	-0.33610978722572327	systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
P-389	-0.0617 -0.0363 -0.0119 -0.1480 -0.0688 -0.1454 -1.5379 -0.3804 -0.1513 -0.3523 -0.0315 -0.0388 -1.0749 -0.4001 -0.1129 -0.9678 -0.9787 -0.0667 -0.1385 -0.7219 -0.1172 -0.2442 -0.1907 -0.0886
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left ventricular assist devices ; lvads ; patients ; heart failure ; incidence ; pump dysfunction ; pump
H-773	-0.413308709859848	▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁patients ▁; ▁advanced ▁heart ▁failure ▁; ▁pump ▁dys function ▁; ▁pump ▁replace ment
D-773	-0.413308709859848	left ventricular assist devices ; lVADs ; patients ; advanced heart failure ; pump dysfunction ; pump replacement
P-773	-0.0672 -0.0372 -0.6570 -0.0933 -0.6396 -0.2557 -0.2171 -0.0606 -0.0118 -0.0474 -0.2993 -3.4501 -0.9498 -0.1707 -0.2952 -0.1111 -0.2286 -0.3249 -1.5275 -0.0145 -0.3034 -0.3941 -0.1718 -0.1917 -0.1324 -0.0941
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable models ; st2 ; outcomes ; clinical ; amino-terminal pro-b-type natriuretic peptide
H-704	-0.5812727212905884	▁ST 2 ▁; ▁amino - termin al ▁; ▁na tri ure tic ▁pe pti de
D-704	-0.5812727212905884	ST2 ; amino-terminal ; natriuretic peptide
P-704	-0.5076 -0.1145 -0.8148 -0.9509 -0.0411 -0.0297 -0.0044 -2.9571 -0.2026 -0.2141 -0.5970 -1.7803 -0.8898 -0.1317 -0.4430 -0.1125 -0.0906
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular pacing ; bivp ; cardiac output ; cardiac ; surgery ; patients
H-319	-0.478167325258255	▁Bi ven tri cular ▁pa cing ▁; Bi VP ▁; ▁cardiac ▁output ▁; co ▁; ▁cardiac ▁surgery ▁patients
D-319	-0.478167325258255	Biventricular pacing ;BiVP ; cardiac output ;co ; cardiac surgery patients
P-319	-1.0711 -0.0679 -2.5352 -0.4703 -0.0453 -0.3209 -0.2064 -1.4438 -0.0778 -0.1523 -0.0432 -0.0180 -0.1921 -0.8414 -0.4631 -0.0429 -0.0243 -0.9643 -0.4649 -0.1180
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully magnetically levitated lvas ; mortality ; seattle ; heart failure
H-2002	-0.37181100249290466	▁fully ▁magnet ically ▁le vita ted ▁l VAS ▁; ▁mortal ity ▁; ▁Seattle ▁Heart ▁Fail ure ▁model - pred i cted ▁survival
D-2002	-0.37181100249290466	fully magnetically levitated lVAS ; mortality ; Seattle Heart Failure model-predicted survival
P-2002	-1.7986 -0.0427 -0.0578 -0.0130 -0.0163 -0.0941 -0.2187 -0.1894 -0.3285 -0.4375 -0.5582 -1.9155 -0.0780 -0.3703 -0.1444 -0.4840 -1.4530 -0.1978 -0.0137 -0.1754 -0.0544 -0.0488 -0.1530 -0.0803
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients ; new york heart association ; nyha ; chronic heart failure ; reduced ejection fraction
H-1952	-0.44994276762008667	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁chronic ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction ▁; ▁Canadian ▁special ▁access ▁programme
D-1952	-0.44994276762008667	New York Heart association ;NYha ; chronic heart failure ; reduced ejection fraction ; Canadian special access programme
P-1952	-1.5428 -0.4063 -1.2821 -0.8245 -0.1209 -0.1423 -1.0029 -0.3363 -0.4849 -0.3672 -0.1324 -0.7648 -0.4494 -0.0118 -0.0174 -0.0698 -0.0203 -0.1975 -0.0067 -1.2081 -0.9358 -0.8410 -0.1017 -0.2039 -0.1406 -0.0870
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa ; immunoassays ; antibodies ; c termini ; nt-probnp
H-1518	-0.37576669454574585	▁Alpha LIS a ▁immun o assa ys ▁; ▁anti bo dies ▁target ing ▁the ▁extreme ▁n ▁; ▁c ▁termini ▁; ▁circula ting ▁NT - pro b NP
D-1518	-0.37576669454574585	AlphaLISa immunoassays ; antibodies targeting the extreme n ; c termini ; circulating NT-probNP
P-1518	-0.0267 -0.1827 -0.7462 -0.0265 -0.1317 -0.0497 -0.5608 -0.1263 -0.0169 -0.0136 -0.5029 -0.5972 -0.0423 -2.6278 -0.7227 -1.2464 -1.7027 -0.1606 -0.0342 -0.1176 -0.0084 -0.0239 -0.3849 -0.0247 -0.0142 -0.5406 -0.0857 -0.1055 -0.0739
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine ; bnp ; furosemide ; dobutamine ; norepinephrine ; outcome
H-587	-0.20983225107192993	▁creati nine ▁; ▁b NP ▁; ▁fur os em ide ▁dose ▁; ▁oxygen ▁flow ▁; ▁dobu tamine ▁; ▁no re pine ph rine
D-587	-0.20983225107192993	creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
P-587	-0.4093 -0.0768 -0.0808 -0.8348 -0.6756 -0.0555 -0.0661 -0.0867 -0.0168 -0.0407 -0.0509 -0.0475 -0.0673 -0.0488 -0.1026 -0.0148 -0.0174 -0.0625 -0.0044 -0.0441 -0.0077 -0.8284 -0.0285 -1.5053 -0.0726
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule ; expression ; regulation ; rad ; q66p ; rgk protein ; in vivo
H-1678	-0.4812925457954407	▁expression ▁; ▁mis tar ge ting ▁; ▁alter ed ▁regula tion ▁; ▁Rad ▁Q 66 p ▁; ▁r GK ▁protein
D-1678	-0.4812925457954407	expression ; mistargeting ; altered regulation ; Rad Q66p ; rGK protein
P-1678	-4.9275 -0.0648 -0.0035 -0.0682 -0.0461 -0.0303 -0.0662 -0.4667 -0.0323 -0.1276 -0.0789 -0.0962 -1.1732 -0.3954 -0.1843 -0.3528 -0.0921 -0.2590 -0.1169 -0.1094 -1.8359 -0.0610
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte hypertrophy ; heart failure ; global gene expression ; dna ; genomic
H-89	-0.47012919187545776	▁My o cy te ▁hyper trop hy ▁antecede nt ▁to ▁heart ▁failure ▁; ▁gene ▁expression
D-89	-0.47012919187545776	Myocyte hypertrophy antecedent to heart failure ; gene expression
P-89	-0.6658 -0.0300 -0.0485 -0.0423 -0.1358 -0.0085 -0.3681 -0.5671 -0.0099 -0.2365 -0.5996 -0.2027 -0.4989 -2.2434 -0.2818 -1.9423 -0.1110
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change ; correlation ; hospitals ; longitudinal
H-138	-1.2097198963165283	▁performance ▁; ▁hospital s
D-138	-1.2097198963165283	performance ; hospitals
P-138	-4.3558 -0.3165 -0.7607 -0.1312 -1.5975 -0.0966
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical ; biomedical ; patients ; dcm ; heart failure ; pubmed
H-1259	-0.36054062843322754	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1259	-0.36054062843322754	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
P-1259	-0.0612 -0.0753 -0.0027 -0.7151 -0.2142 -0.6126 -0.5843 -0.3976 -0.0035 -0.0194 -0.0042 -0.3156 -0.8477 -1.5333 -0.0681 -0.1010 -0.6689 -0.1234 -0.7795 -0.0832
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 ; sst2 ; odds ratio ; cardiovascular event
H-408	-0.7017104625701904	▁s st 2/ high - dos e ▁BB ▁; ▁s st 2 ▁; ▁low - dos e ▁BB ▁; ▁cardiovascular ▁event
D-408	-0.7017104625701904	sst2/high-dose BB ; sst2 ; low-dose BB ; cardiovascular event
P-408	-0.1343 -1.3365 -0.3101 -0.3204 -0.0315 -0.4718 -0.0675 -1.3743 -0.5082 -0.1440 -1.9151 -0.1014 -0.6599 -4.8442 -0.0262 -0.5455 -0.0460 -0.7571 -0.7872 -0.2566 -1.2927 -0.0905 -0.1183
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones ; adipokines ; fat free mass ; ffm ; fat mass
H-11	-0.2830277681350708	▁neuro hormon es ▁; ▁adi pok ines ▁; ▁body ▁composition ▁; ▁CC ▁; ▁fat ▁free ▁mass ▁; FF m ▁; ▁fat ▁mass ▁; FM
D-11	-0.2830277681350708	neurohormones ; adipokines ; body composition ; CC ; fat free mass ;FFm ; fat mass ;FM
P-11	-0.0379 -0.0186 -0.1269 -0.1071 -0.0042 -0.0307 -0.0713 -0.1741 -1.7202 -0.0954 -0.0603 -0.1441 -0.0610 -1.7384 -0.1466 -0.0923 -0.1808 -0.8910 -0.3211 -0.1683 -0.1047 -0.1214 -0.6215 -0.0049 -0.2234 -0.0924
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac plasma membrane ; s1pr1 ; β1ar ; heart failure
H-1411	-0.5918790698051453	▁resto ration ▁; ▁cardiac ▁plasma ▁membran e ▁; ▁s 1 PR 1 ▁; ▁over stimul ation ▁; ▁heart ▁failure
D-1411	-0.5918790698051453	restoration ; cardiac plasma membrane ; s1PR1 ; overstimulation ; heart failure
P-1411	-2.7509 -0.0586 -1.0067 -0.0142 -0.0862 -0.0042 -0.0636 -1.4047 -0.4706 -0.4160 -0.2373 -2.1836 -0.4570 -1.8157 -0.0920 -0.2338 -0.4527 -0.2457 -0.1634 -0.1758 -0.0969
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley ; randomized ; acf ; allopurinol
H-473	-0.24787263572216034	▁Spr a gue - ▁da w ley ▁rat s ▁; ▁sham ▁; ▁a CF ▁; ▁allo puri nol
D-473	-0.24787263572216034	Sprague- dawley rats ; sham ; aCF ; allopurinol
P-473	-0.1896 -0.1437 -0.1066 -0.0150 -0.5998 -0.0047 -0.1362 -0.1402 -0.0546 -0.3277 -0.0198 -0.1125 -0.7116 -0.4975 -0.1859 -0.0178 -0.0079 -0.2062 -1.3685 -0.1115
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 ; myocardial collagen ; myocardial
H-1064	-0.3382856845855713	▁my o card ial ▁collage n ▁; ▁my o card ial ▁de lay ed ▁enhance ment ▁imagin g
D-1064	-0.3382856845855713	myocardial collagen ; myocardial delayed enhancement imaging
P-1064	-1.9748 -0.0760 -0.2361 -0.2062 -0.0635 -0.1728 -0.1963 -2.1789 -0.1115 -0.4615 -0.4138 -0.0213 -0.0213 -0.0227 -0.1608 -0.0858 -0.0671 -0.0480 -0.1843 -0.0629
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin ; sitagliptin ; follow-up
H-1833	-0.7557867169380188	▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁follow - up
D-1833	-0.7557867169380188	saxagliptin ; sitagliptin ; follow-up
P-1833	-0.0319 -0.0201 -0.3006 -2.5829 -0.7196 -1.7950 -0.1979 -0.1088 -1.9474 -1.5773 -0.2769 -0.1097 -0.0121 -1.5671 -0.0897
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter ablation ; patients ; compensated hfpef ; left ventricular ; ejection fraction
H-944	-0.2759931683540344	▁Cat heter ▁ab lation ▁; ▁AF ▁; ▁compensa ted ▁H FP EF ▁; ▁le ft ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-944	-0.2759931683540344	Catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV ; ejection fraction
P-944	-1.1710 -0.0377 -0.0144 -0.1046 -0.8067 -0.0863 -0.2238 -0.0075 -0.0459 -1.0698 -0.2161 -0.2351 -0.1045 -0.5360 -0.0067 -0.0163 -0.6667 -0.0606 -0.1610 -0.1820 -0.8843 -0.0232 -0.0573 -0.0186 -0.6682 -0.0041 -0.2238 -0.0955
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy ; sst2 ; patients ; chronic heart failure
H-411	-0.5805646181106567	▁BB ▁ therapy ▁; ▁s st 2 ▁measure ment ▁; ▁chronic ▁heart ▁failure
D-411	-0.5805646181106567	BB therapy ; sst2 measurement ; chronic heart failure
P-411	-0.5003 -0.5709 -0.0256 -0.3220 -2.0224 -0.8284 -0.0252 -0.9328 -0.1465 -0.3057 -0.3442 -0.4550 -0.1405 -1.9621 -0.1268
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths ; crt ; hazard ratio
H-853	-0.7384389042854309	▁c r ▁group ▁; ▁control ▁group ▁; ▁hazard ▁ratio
D-853	-0.7384389042854309	cr group ; control group ; hazard ratio
P-853	-0.4466 -3.0700 -1.5729 -0.0975 -0.4908 -0.4844 -0.2197 -0.0513 -0.0036 -1.5779 -0.1083
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd ; outpatients ; systolic hf ; patients ; egfr
H-396	-0.4583057165145874	▁ES RD ▁; ▁sy sto lic ▁ HF ▁; ▁e G FR
D-396	-0.4583057165145874	ESRD ; systolic HF ; eGFR
P-396	-1.7087 -0.2445 -0.1082 -1.6129 -0.0297 -0.0200 -0.3257 -0.0969 -0.2656 -0.0893 -1.3110 -0.0775 -0.3710 -0.1554
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse ; pasp ; step ; rv function ; lv dysfunction
H-501	-0.5149679183959961	▁t AP se ▁; ▁PAS p ▁; ▁length - force ▁relationship ▁; ▁ RV ▁function ▁evaluation ▁; ▁LV ▁dys function
D-501	-0.5149679183959961	tAPse ; PASp ; length-force relationship ; RV function evaluation ; LV dysfunction
P-501	-4.3276 -0.1260 -0.7028 -1.1598 -0.9090 -0.4154 -0.8263 -0.0757 -0.0414 -0.0347 -0.3734 -0.1316 -0.3021 -0.2877 -0.1093 -0.4911 -0.1272 -0.1290 -0.5527 -0.0237 -0.0885 -0.0942
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel ; apoptotic cells ; tunel-positive cells
H-172	-0.39343491196632385	▁tu nel ▁as say ▁; ▁apo pto tic ▁cell s ▁; ▁tu nel - posi tive ▁cell s
D-172	-0.39343491196632385	tunel assay ; apoptotic cells ; tunel-positive cells
P-172	-1.3837 -0.5697 -0.1857 -0.0559 -0.1360 -0.6945 -0.2057 -0.4643 -0.3216 -0.0595 -0.3453 -0.9308 -0.5405 -0.0553 -0.0013 -0.2357 -0.3459 -0.0438 -1.2176 -0.0760
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno donor ; myocardial function ; evidence ; hf
H-425	-0.47213274240493774	▁functional ▁ef fica cy ▁; ▁pure ▁H no ▁donor ▁; ▁my o card ial ▁function ▁; ▁ HF
D-425	-0.47213274240493774	functional efficacy ; pure Hno donor ; myocardial function ; HF
P-425	-1.8025 -0.2561 -0.0877 -0.0890 -0.0937 -0.6737 -0.5722 -0.8527 -0.0611 -0.3945 -2.0347 -0.1171 -0.2158 -0.3295 -0.1510 -0.1288 -1.2107 -0.1895 -0.0907 -0.0918
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular support ; rvads ; explanted
H-301	-0.5327181220054626	▁bi ven tri cular ▁support ▁; ▁r VAD s
D-301	-0.5327181220054626	biventricular support ; rVADs
P-301	-1.2181 -0.0547 -0.8033 -0.2038 -1.1340 -0.3735 -0.8991 -0.2592 -0.2521 -0.5634 -0.0986
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions ; readmission ; patients ; congestive heart failure ; south dakota
H-1583	-0.4548000693321228	▁con ges tive ▁heart ▁failure ▁; ▁Mid we stern ▁state ▁; ▁South ▁da kota
D-1583	-0.4548000693321228	congestive heart failure ; Midwestern state ; South dakota
P-1583	-1.2424 -0.1717 -0.6742 -0.4056 -0.1412 -0.4913 -2.1230 -0.0705 -0.0460 -0.6889 -0.2144 -0.2622 -0.3820 -0.0045 -0.1948 -0.1641
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes ; myocardium ; conditions
H-990	-0.2618647813796997	▁cardio my o cy tes ▁; ▁mechanic al ▁; ▁humor al ▁stimul i ▁; ▁my o car dium
D-990	-0.2618647813796997	cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
P-990	-0.0843 -0.1831 -0.0788 -0.0468 -0.0564 -0.3895 -0.8178 -0.0029 -0.3745 -0.0241 -0.0352 -0.0874 -0.1838 -0.2720 -0.4704 -0.0228 -0.0114 -0.0861 -1.9113 -0.0988
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation ; consultation ; consultation ; operation
H-1283	-1.0662727355957031	▁transplant ation ▁; ▁consultation
D-1283	-1.0662727355957031	transplantation ; consultation
P-1283	-2.5651 -0.1891 -0.9877 -0.4835 -2.1142 -0.0580
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox proportional hazards models ; death ; transplantation ; lv assist device implantation ; heart failure ; hospitalization ; follow-up
H-431	-0.31799283623695374	▁co x ▁proportion al ▁hazard s ▁models ▁; ▁death ▁; ▁transplant ation ▁; ▁LV ▁assist ▁device ▁implant ation ▁; ▁heart ▁failure ▁hospital ization
D-431	-0.31799283623695374	cox proportional hazards models ; death ; transplantation ; LV assist device implantation ; heart failure hospitalization
P-431	-0.0498 -0.0140 -0.0402 -0.0040 -0.0362 -0.2366 -1.4431 -0.2906 -2.8232 -0.1339 -0.0634 -0.1268 -0.0556 -0.0423 -0.1724 -0.1280 -0.2166 -0.2013 -0.1726 -0.1745 -0.1667 -0.8182 -0.3602 -0.0991 -0.0804
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity
H-964	-0.3254557251930237	▁Nico rand il ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se
D-964	-0.3254557251930237	Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase
P-964	-0.0010 -0.0432 -0.0310 -0.2060 -0.2779 -0.0290 -0.1139 -0.2312 -0.9730 -0.2636 -0.0056 -0.0057 -1.0739 -0.0237 -0.0801 -0.0755 -0.7735 -0.0376 -0.1754 -0.1033 -0.0169 -0.0241 -0.0679 -0.2826 -0.0271 -2.0304 -0.9631 -0.0653 -1.8147 -0.2872 -0.0042 -0.1845 -0.0018 -0.0307 -1.2900 -0.1015
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass correlation coefficient ; icc ; kappa coefficient ; standard error of measurement ; minimal detectable change ; mdc
H-801	-0.3900034725666046	▁intra class ▁corre lation ▁co e ffi cient ▁; ▁i cc ▁; ▁ka ppa ▁co e ffi cient ▁; ▁standard ▁error ▁; ▁detect able ▁change ▁; ▁m DC
D-801	-0.3900034725666046	intraclass correlation coefficient ; icc ; kappa coefficient ; standard error ; detectable change ; mDC
P-801	-0.9469 -0.0698 -0.0583 -0.2368 -0.0262 -0.2473 -0.1027 -0.0593 -0.1757 -1.1944 -0.9902 -0.1395 -0.0020 -0.0643 -0.0093 -0.0882 -0.0338 -0.0158 -0.2939 -3.9443 -0.2491 -0.5160 -0.7253 -0.0410 -0.2460 -0.2586 -0.0369 -0.6725 -0.1507 -0.1051
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized ; heart failure ; saxagliptin ; sitagliptin ; antihyperglycemic drugs ; retrospective cohort study
H-1826	-0.4331633746623993	▁Risk ▁; ▁Hospital ized ▁Heart ▁Fail ure ▁; ▁Sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁Drug s
D-1826	-0.4331633746623993	Risk ; Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
P-1826	-1.6844 -0.7678 -0.3770 -0.0840 -0.2100 -0.0550 -0.3443 -0.1973 -0.0311 -0.0179 -0.2319 -2.2369 -0.0984 -1.2972 -0.0876 -0.0432 -1.7715 -0.1379 -0.1492 -0.1765 -0.0610 -0.4267 -0.4532 -0.3661 -0.4116 -0.0409 -0.2914 -0.0786
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise ; training ; outcomes ; chronic heart failure ; heart failure - a controlled trial investigating outcomes in exercise training ; hf-action
H-1629	-0.39505258202552795	▁race ▁; ▁exercise ▁training ▁; ▁chronic ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁tri al ▁Investiga ting ▁Out com es ▁in ▁Exerci se ▁Tra i N ing ▁; HF - ac TION
D-1629	-0.39505258202552795	race ; exercise training ; chronic heart failure ; Heart Failure ; controlled trial Investigating Outcomes in Exercise TraiNing ;HF-acTION
P-1629	-1.2499 -0.1573 -0.2326 -0.2021 -0.0981 -1.1671 -0.1807 -0.0645 -0.2583 -1.7089 -0.2358 -0.5770 -0.0794 -1.7206 -0.1517 -0.2634 -0.0343 -0.0922 -0.0248 -0.1620 -0.0323 -0.0300 -0.8946 -0.2218 -0.0366 -0.2654 -0.2338 -1.7517 -0.0738 -0.2933 -0.2446 -0.0213 -0.5831 -0.6374 -0.1492 -0.0921
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient ; primary end point ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cabg
H-972	-0.21382653713226318	▁Swedish ▁national ▁in patient ▁Registr y ▁; ▁re hospital ization ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca BG
D-972	-0.21382653713226318	Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
P-972	-0.2452 -0.9804 -0.0867 -0.1032 -0.4716 -0.0426 -0.1302 -0.0573 -0.0056 -0.1732 -0.3168 -0.1303 -0.0885 -0.1763 -0.2105 -0.1403 -0.1506 -0.0106 -0.0772 -0.0747 -0.0882 -0.1884 -0.0458 -0.9825 -0.5846 -0.2646 -0.0863 -0.0748
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients ; heart failure with preserved ejection fraction ; hfpef ; heart failure ; obese
H-1974	-0.31313300132751465	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF ▁; ▁heart ▁failure ▁; ▁over weight ▁; ▁obes e
D-1974	-0.31313300132751465	heart failure ; preserved ejection fraction ; hFPEF ; heart failure ; overweight ; obese
P-1974	-1.9783 -0.0818 -0.5144 -0.0210 -0.0505 -0.3912 -0.0279 -0.0914 -0.0255 -0.2720 -0.0072 -0.1680 -0.8418 -1.0777 -0.3819 -0.1278 -0.6323 -0.1025 -0.3189 -0.0929 -0.0749 -0.6071 -0.0061 -0.0482 -0.1041 -0.0961
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal dialysis ; pd ; diuretic ; volume overload ; heart failure ; hf
H-894	-0.16587099432945251	▁Peri tone al ▁di al ysis ▁; PD ▁; ▁di ure tic ▁resist ant ▁volume ▁over load ▁; ▁heart ▁failure ▁; HF
D-894	-0.16587099432945251	Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
P-894	-0.1238 -0.0922 -0.0236 -0.1151 -0.0285 -0.0461 -0.1786 -0.0477 -0.1343 -0.2972 -0.1543 -0.8059 -0.1800 -0.0240 -0.0824 -0.0256 -0.0632 -0.5442 -0.2006 -0.0892 -0.3164 -0.0893 -0.2421 -0.0767
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal dysfunction ; prognostic ; heart failure ; hf ; dysfunction ; end-stage renal disease ; esrd
H-387	-0.4680640995502472	▁Ren al ▁dys function ▁; ▁heart ▁failure ▁; HF ▁; ▁renal ▁disease ▁; ES RD
D-387	-0.4680640995502472	Renal dysfunction ; heart failure ;HF ; renal disease ;ESRD
P-387	-2.0772 -0.1117 -0.0801 -0.0832 -0.0858 -2.3772 -0.1041 -0.1664 -0.0327 -0.0870 -0.5546 -0.2522 -0.1665 -1.3088 -0.2220 -0.1465 -0.1012
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression analysis ; echocardiographic ; lv reverse remodeling ; lv end-systolic volume
H-430	-0.21314434707164764	▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing ▁; ▁LV ▁end - sy sto lic ▁volume
D-430	-0.21314434707164764	echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
P-430	-0.5491 -0.0453 -0.0326 -0.1590 -0.1926 -0.1569 -0.0593 -0.3672 -0.0771 -0.0210 -0.0259 -0.0363 -0.1566 -0.7793 -1.2928 -0.0284 -0.3412 -0.0589 -0.0121 -0.0941 -0.1294 -0.0740
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral artery disease ; pad ; heart failure ; hf ; prevalence ; hf ; patients ; pad
H-1567	-0.32760345935821533	▁Peri pher al ▁arter y ▁disease ▁; PAD ▁; ▁heart ▁failure ▁; HF ▁; ▁ HF ▁; ▁patients ▁; PAD
D-1567	-0.32760345935821533	Peripheral artery disease ;PAD ; heart failure ;HF ; HF ; patients ;PAD
P-1567	-0.1021 -0.0306 -0.1040 -0.1027 -0.4959 -0.4628 -0.0887 -0.0247 -0.0471 -0.4127 -0.1462 -0.1736 -0.0578 -0.1891 -0.7462 -0.1299 -0.1563 -1.9284 -0.7229 -0.8057 -0.1584 -0.1212
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission ; disease ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia
H-137	-0.6417538523674011	▁ STU DY ▁DESIGN ▁; ▁read mission ▁rates ▁; ▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia
D-137	-0.6417538523674011	STUDY DESIGN ; readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
P-137	-4.6198 -0.3995 -0.1434 -0.0866 -0.2526 -5.5317 -1.5179 -0.2508 -0.3296 -2.6878 -0.1544 -0.1697 -0.0608 -0.0503 -0.0151 -0.0024 -0.8505 -0.3006 -0.2350 -0.2402 -0.0087 -0.0945 -0.0961 -0.2200 -0.2270 -0.1904 -0.0148 -0.2792 -0.1233 -0.1000
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; fontan circulation
H-1492	-0.16101370751857758	▁per i pher al ▁muscle ▁pump ▁; ▁cardiac ▁fill ing ▁; ▁sub pul mon ary ▁vent ric le ▁; ▁Font an ▁circulation
D-1492	-0.16101370751857758	peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
P-1492	-0.0862 -0.0206 -0.0100 -0.0177 -0.2070 -0.4401 -0.1409 -0.5085 -0.1458 -0.0270 -0.5180 -0.1476 -0.1088 -0.4676 -0.0498 -0.0148 -0.3654 -0.1065 -0.1637 -0.0207 -0.0244 -0.0349 -0.1535 -0.0850
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological phenotype ; clinically ; deficit index ; medical ; frailty
H-1013	-0.62136310338974	▁bi ological ▁ph eno type ▁; ▁deficit ▁index ▁; ▁medical ▁records
D-1013	-0.62136310338974	biological phenotype ; deficit index ; medical records
P-1013	-0.9028 -0.2136 -0.8571 -0.1785 -0.0018 -0.1830 -2.9279 -0.0355 -0.3489 -0.4602 -0.1786 -1.7261 -0.0638
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt ; elevated ; acute ; β-adrenoceptor blockade ; esmolol
H-1444	-0.361050009727478	▁SD QT ▁; ▁ HF VT ▁; ▁h Nor m ▁group ▁; ▁β - ad re no cept or ▁block ade ▁; ▁es mol ol
D-1444	-0.361050009727478	SDQT ; HFVT ; hNorm group ; β-adrenoceptor blockade ; esmolol
P-1444	-0.0056 -0.0967 -0.0441 -0.8745 -0.1487 -0.3219 -0.1145 -1.4708 -1.8218 -0.0189 -1.1628 -0.1629 -0.5726 -0.0273 -0.0527 -0.2019 -0.0785 -0.2446 -0.2217 -0.3040 -0.4568 -0.4874 -0.4709 -0.0023 -0.1073 -0.2046 -0.0723
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology ; national cardiovascular disease registry practice innovation and clinical excellence registry
H-660	-0.5458330512046814	▁Card i ology ▁practice s ▁; ▁national ▁Card io vas cular ▁Disease ▁Registr y ▁; ▁practice ▁Innovation ▁; ▁Clinic al ▁Excellence ▁registr y
D-660	-0.5458330512046814	Cardiology practices ; national Cardiovascular Disease Registry ; practice Innovation ; Clinical Excellence registry
P-660	-1.3803 -0.4069 -0.2724 -0.3353 -0.0298 -0.3867 -2.1110 -0.8387 -0.7268 -0.0602 -0.3674 -0.2684 -0.4804 -0.0151 -0.9881 -1.7591 -1.1041 -0.5111 -0.4640 -0.0053 -0.1033 -0.7482 -0.0610 -0.1221 -0.1002
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts ; hh ; medical ; all-cause mortality ; discharged ; patients ; heart failure
H-162	-0.945516049861908	▁s ts ▁ HH ▁; ▁TM ▁; ▁medical ▁support ▁; ▁all - ca use ▁mortal ity ▁; ▁dis charge d ▁patients ▁; ▁heart ▁failure
D-162	-0.945516049861908	sts HH ; TM ; medical support ; all-cause mortality ; discharged patients ; heart failure
P-162	-0.9801 -2.1404 -1.1843 -0.0344 -0.1160 -0.5424 -0.8693 -2.8874 -1.7670 -0.5070 -6.3224 -0.0272 -0.0092 -0.0772 -0.0181 -0.5939 -0.1743 -2.7259 -0.0558 -0.0184 -0.6125 -1.7078 -0.8008 -0.1586 -0.1333 -0.1196
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically ; myocardial infarction ; heart failure ; randomized ; bisoprolol
H-452	-0.28783905506134033	▁sur g ically ▁induc ed ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁rat s ▁; ▁bis o pro lol ▁; ▁vehicle
D-452	-0.28783905506134033	surgically induced myocardial infarction ; heart failure rats ; bisoprolol ; vehicle
P-452	-3.1031 -0.1278 -0.0944 -0.0190 -0.0756 -0.3734 -0.1345 -0.2694 -0.3720 -0.0156 -0.1440 -0.0735 -0.1987 -0.1233 -0.0403 -0.2283 -0.0244 -0.3377 -0.2402 -0.0859 -0.0177 -0.1077 -0.5969 -0.4460 -0.1350 -0.0995
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions ; training ; patients ; out-patient ; follow-up ; patient ; health care
H-1579	-1.1821143627166748	▁in - patient ▁follow - up
D-1579	-1.1821143627166748	in-patient follow-up
P-1579	-5.1856 -0.3674 -0.1168 -0.3263 -0.1296 -0.0123 -3.1773 -0.1417
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf ; phenotype ; cardiac ; explant ; progenitors ; regulation
H-1337	-0.3142183721065521	▁CHF ▁; ▁cardiac ▁ex plant ▁c - K it + ▁pro geni tors ▁; ▁mechanism s
D-1337	-0.3142183721065521	CHF ; cardiac explant c-Kit+ progenitors ; mechanisms
P-1337	-0.3643 -0.2762 -0.4591 -0.0399 -0.0052 -0.2486 -0.0397 -0.8695 -0.0110 -1.2133 -0.0855 -0.0239 -0.0988 -0.8196 -0.1497 -0.1034 -0.7850 -0.0633
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia ; intravenous ; atropine ; cardiac ; vagal tone
H-1380	-0.28597694635391235	▁ta chy car dia ▁; ▁intra ven ous ▁a tropi ne ▁; ▁cardiac ▁va gal ▁tone ▁; ▁CHF - DN x ▁; ▁CHF - IN v
D-1380	-0.28597694635391235	tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-INv
P-1380	-0.0933 -0.6186 -0.0438 -0.0095 -0.3822 -0.1963 -0.0072 -1.2241 -0.0188 -0.0370 -1.2377 -0.1324 -0.0812 -0.0246 -0.0918 -0.0127 -0.5565 -0.0452 -0.0213 -0.1728 -0.1521 -0.5333 -0.0537 -0.0302 -0.8754 -0.4470 -0.8270 -0.0816
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report ; stable ; hno donor ; cxl-1020 ; myoctyes ; hearts ; patients ; heart failure ; hf
H-415	-0.5564156174659729	▁h no ▁donor ▁; ▁c XL -10 20) ▁isola ted ▁my oc ty es ▁; ▁intact ▁heart s ▁; ▁heart ▁failure ▁; HF
D-415	-0.5564156174659729	hno donor ; cXL-1020) isolated myoctyes ; intact hearts ; heart failure ;HF
P-415	-4.3582 -0.5453 -0.0990 -0.0569 -1.2821 -0.1072 -0.0943 -0.7810 -2.1639 -0.0350 -0.3714 -0.0543 -0.0162 -0.2085 -0.2625 -0.0077 -0.2243 -0.0342 -0.1614 -2.4046 -0.0300 -0.3116 -0.0552 -0.1510 -0.0945
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.6100767850875854	▁drug - free
D-947	-0.6100767850875854	drug-free
P-947	-1.9954 -0.2017 -0.0746 -0.7062 -0.0724
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet ; patient ; subvalvular ; annular ms
H-374	-0.3267277777194977	▁MS ▁; ▁sub val vu lar ▁; ▁dynamic ▁; ▁ann ular ▁MS ▁; ▁fixed ▁ring ▁size
D-374	-0.3267277777194977	MS ; subvalvular ; dynamic ; annular MS ; fixed ring size
P-374	-1.5146 -0.3253 -0.6031 -0.0738 -0.0017 -0.0489 -0.0896 -0.7514 -0.1671 -0.4212 -0.0019 -0.0950 -0.5011 -0.4631 -0.0126 -0.6190 -0.1178 -0.0737
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes ; chronic heart failure ; hf ; exercise ; training
H-1630	-0.8944920897483826	▁race ▁; ▁chronic ▁heart ▁failure ▁; HF ▁; ▁exercise ▁training
D-1630	-0.8944920897483826	race ; chronic heart failure ;HF ; exercise training
P-1630	-1.8598 -0.1400 -2.6535 -0.5521 -0.0916 -0.3298 -0.0628 -1.2288 -0.7918 -0.6522 -2.2781 -0.0933
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological ; capillary ; coronary perfusion
H-457	-0.6016570329666138	▁cap illa ry ▁; ▁corona ry ▁per fusion ▁; ▁ad - f lk ▁rat s ▁; ▁b - tre ated ▁; ▁ad - c ▁rat s
D-457	-0.6016570329666138	capillary ; coronary perfusion ; ad-flk rats ; b-treated ; ad-c rats
P-457	-3.2920 -0.0447 -0.7607 -0.4670 -0.1000 -0.6829 -0.4203 -0.0145 -0.3156 -0.5274 -0.0687 -1.2187 -0.0486 -0.2254 -0.0626 -0.6852 -3.3450 -0.0385 -0.0019 -0.2051 -0.5540 -0.6935 -0.0765 -1.8624 -0.6665 -0.0915 -0.2394 -0.1377
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician ; mortality ; internists ; cardiologists
H-1730	-0.30130332708358765	▁physician ▁volume ▁; ▁mortal ity ▁; ▁intern ists ▁; ▁cardio logist s
D-1730	-0.30130332708358765	physician volume ; mortality ; internists ; cardiologists
P-1730	-0.2577 -0.0674 -0.4164 -0.0333 -0.9443 -0.2742 -0.0122 -1.0137 -0.2089 -0.3426 -0.1272 -0.1724 -0.2682 -0.0799
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle walk test ; hand ; baseline
H-1322	-0.4333057701587677	▁shu ttle ▁walk ▁test ▁; ▁body ▁mass ▁; ▁hand ▁grip ▁strength
D-1322	-0.4333057701587677	shuttle walk test ; body mass ; hand grip strength
P-1322	-0.3423 -0.0006 -0.3352 -0.3266 -0.1491 -0.2550 -0.2136 -0.1628 -0.9546 -0.6263 -0.6309 -1.4920 -0.1442
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc ; frame ; patient ; consultation ; patients
H-1027	-0.5297360420227051	▁protocol - driv en ▁PO c ▁testing ▁; ▁ NP ▁; ▁patient ▁consultation ▁; ▁ED
D-1027	-0.5297360420227051	protocol-driven POc testing ; NP ; patient consultation ; ED
P-1027	-1.5144 -0.0296 -0.0010 -0.0169 -0.1253 -2.0756 -0.3506 -0.3832 -0.6857 -0.0275 -0.2636 -1.0093 -0.0507 -0.2133 -0.6339 -1.4938 -0.1313
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical ; outcomes ; heart failure ; charm ; candesartan in heart failure assessment of reduction in mortality and morbidity
H-554	-0.4472615122795105	▁heart ▁failure ▁; ▁CHA RM ▁programme ▁; Can des ar tan ▁in ▁Heart ▁Fail ure ▁Assessment ▁; ▁Mor t ality ▁; ▁Morbi d ity
D-554	-0.4472615122795105	heart failure ; CHARM programme ;Candesartan in Heart Failure Assessment ; Mortality ; Morbidity
P-554	-4.6535 -0.0896 -0.2315 -0.2771 -1.1776 -0.0718 -0.0948 -0.0736 -0.0215 -0.0210 -0.0026 -0.0624 -0.4831 -0.1633 -0.7225 -0.9009 -0.6739 -0.5742 -0.0770 -0.0049 -0.4647 -0.0014 -0.0302 -0.5254 -0.1315 -0.0988
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk in communities
H-284	-0.543149471282959	▁Tro ponin ▁T ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁bio mark er ▁; ▁heart ▁failure ▁risk ▁; ▁at hero sc ler osis
D-284	-0.543149471282959	Troponin T ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure risk ; atherosclerosis
P-284	-0.8389 -0.0034 -1.3669 -0.1752 -1.4927 -0.0167 -0.0125 -0.0017 -0.0473 -0.0128 -1.1789 -0.0231 -0.0048 -0.0169 -0.2163 -0.2428 -1.6307 -1.2493 -0.2088 -0.2125 -0.2888 -0.1914 -0.0490 -0.0605 -1.1344 -1.8938 -0.0490 -1.0038 -0.2788 -1.9149 -0.1067 -0.0457 -1.9129 -0.0390 -1.5112 -0.1214
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial shunting ; patients ; heart failure with reduced ejection fraction ; proof-of-principle cohort study
H-1948	-0.5539796948432922	▁left - to - right ▁inter at rial ▁sh unting ▁; ▁patients ▁with ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-1948	-0.5539796948432922	left-to-right interatrial shunting ; patients with heart failure ; reduced ejection fraction
P-1948	-3.0587 -0.0400 -0.0752 -0.0614 -0.0262 -0.0412 -0.0094 -0.0596 -0.5462 -0.4508 -0.4733 -1.5074 -2.4999 -0.5433 -0.0517 -0.9348 -2.1759 -0.0104 -0.0158 -0.0928 -0.0509 -0.3254 -0.0082 -0.6884 -0.1024
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical examination ; patient ; bmi ; heart rate ; rhythm ; blood pressure ; auscultation ; rule ; valvular disease ; pulmonary congestion
H-1894	-0.2238987237215042	▁b mi ▁; ▁weight ▁; ▁heart ▁rate ▁; ▁ rhythm ▁; ▁ly ing ▁; ▁standing ▁blood ▁pressure ▁; ▁aus cul tation ▁; ▁val vu lar ▁disease ▁; ▁pulmonar y ▁con gestion
D-1894	-0.2238987237215042	bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
P-1894	-0.8033 -1.1996 -0.0690 -0.8003 -0.0835 -0.6667 -0.1614 -0.1525 -0.0844 -0.0637 -0.0951 -0.0108 -0.0199 -0.1575 -0.0491 -0.4617 -0.1561 -0.0912 -0.5843 -0.0067 -0.0084 -0.1917 -0.0796 -0.0315 -0.1404 -0.4654 -0.1394 -0.0014 -0.1439 -0.0229 -0.0560 -0.2531 -0.1383
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial extracellular matrix ; cardiac magnetic resonance ; t1 mapping ; pathobiology ; pathophysiology ; prognosis
H-735	-0.3463200330734253	▁my o card ial ▁extra cel lular ▁matri x ▁; ▁cardiac ▁magnetic ▁res on ance ▁T 1 ▁ma pping ▁; ▁path obi ology
D-735	-0.3463200330734253	myocardial extracellular matrix ; cardiac magnetic resonance T1 mapping ; pathobiology
P-735	-0.8260 -0.0822 -0.1747 -0.0673 -0.1067 -0.0450 -0.0179 -0.0407 -0.4850 -0.2031 -0.0018 -0.0309 -0.3100 -0.0826 -0.1278 -1.7948 -0.2759 -0.1259 -0.0533 -0.3785 -0.1261 -0.0193 -0.3943 -2.7917 -0.0963
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone antagonist ; therapy ; chronic advanced heart failure ; patients ; post-myocardial infarction ; heart failure ; patients
H-1738	-0.3295028805732727	▁al do ster one ▁anta gon ist ▁ therapy ▁; ▁chronic ▁advanced ▁heart ▁failure ▁patients ▁; ▁post - my o card ial ▁in far ction ▁heart ▁failure ▁patients ▁; ▁reduce d ▁e je ction
D-1738	-0.3295028805732727	aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction heart failure patients ; reduced ejection
P-1738	-0.2038 -0.0317 -0.0306 -0.2399 -0.0904 -0.0043 -0.2513 -0.9462 -0.0161 -0.1593 -1.2849 -0.8715 -0.7280 -0.0643 -0.5460 -0.2416 -0.0403 -0.0246 -0.1893 -0.3937 -0.3180 -0.2061 -0.0213 -0.1139 -0.0558 -1.8174 -0.0486 -0.5787 -1.1399 -0.6537 -0.0089 -0.0193 -0.1022 -0.1338 -0.1568 -0.1301
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil ; heart rate ; aortic ; blood flow ; mitochondrial ; oxidative stress ; doxorubicin ; cardiotoxicity
H-963	-0.2325795590877533	▁Nico rand il ▁; ▁de cre ment ▁; ▁heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁mito cho ndri al ▁oxid ative ▁stress ▁; ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.2325795590877533	Nicorandil ; decrement ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxicity
P-963	-0.0021 -0.0202 -0.0172 -0.1682 -1.6783 -0.0122 -0.1879 -1.2409 -0.3381 -0.2631 -0.1055 -0.0040 -0.0115 -0.2116 -0.1742 -0.0973 -0.0909 -0.0053 -0.1701 -0.1246 -0.0090 -0.0106 -0.0171 -0.2196 -0.5651 -0.0479 -0.0012 -0.0062 -0.3130 -0.2504 -0.2251 -1.0812 -0.1611 -0.0771
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed ; heart failure ; left ventricular ejection fraction ; spironolactone ; kaiser permanente ; northern california
H-440	-0.27498751878738403	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁; ▁spi rono lac tone ▁; ▁Kaiser ▁Permanent e ▁Northern ▁California
D-440	-0.27498751878738403	heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
P-440	-2.3359 -0.0641 -0.1224 -0.0343 -0.0255 -0.6666 -0.2030 -0.0453 -0.0685 -0.0290 -1.1297 -0.0460 -0.0037 -0.0131 -0.0096 -0.8259 -0.1744 -0.0556 -0.0512 -0.1545 -0.0269 -0.1577 -0.0820
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative ; renal dysfunction ; cardiovascular events ; stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
H-968	-0.3315298855304718	▁renal ▁dys function ▁; ▁cardiovascular ▁events ▁; stro ke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁corona ry ▁arter y ▁by pass ▁graf ting
D-968	-0.3315298855304718	renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; coronary artery bypass grafting
P-968	-0.3271 -0.0219 -0.0224 -0.0749 -0.0244 -0.1839 -0.1059 -0.0885 -0.0369 -0.3855 -0.1950 -0.2009 -0.1963 -0.1020 -0.0169 -0.0869 -0.0419 -0.0971 -0.1571 -0.0398 -0.2783 -4.1494 -0.3841 -0.0155 -0.2073 -2.0250 -0.0976 -0.0358 -0.4088 -0.1810 -0.0893
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum ; systolic ; lv posterior wall ; lv internal diameter ; metoprolol
H-1549	-0.5997992753982544	▁sept um ▁; sy sto lic ▁; ▁thi ck ness ▁; ▁LV ▁posterior ▁wall ▁thi ck ness ▁; ▁LV ▁internal ▁diameter ▁; ▁met o pro lol
D-1549	-0.5997992753982544	septum ;systolic ; thickness ; LV posterior wall thickness ; LV internal diameter ; metoprolol
P-1549	-0.6783 -0.0062 -0.7536 -0.4205 -0.1667 -0.0349 -0.5990 -3.6432 -0.0161 -1.3353 -0.0758 -1.8326 -0.7417 -1.2258 -1.9806 -0.0198 -0.8397 -0.1085 -0.3092 -0.7804 -0.0076 -0.6459 -0.0059 -0.0830 -0.0190 -0.2235 -0.1353 -0.1064
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american college of physicians ; acp ; evidence ; clinical ; anemia ; patients ; heart disease
H-30	-0.47140929102897644	▁American ▁college ▁of ▁Physic ians ▁; ▁a CP ▁; ▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁heart ▁disease
D-30	-0.47140929102897644	American college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
P-30	-2.7157 -1.1228 -0.1261 -0.1375 -0.0377 -0.1950 -0.2559 -0.1542 -0.3032 -2.6918 -0.0812 -0.1167 -0.0409 -0.0532 -0.0366 -0.0257 -0.1394 -0.0394 -0.2425 -1.7369 -0.3630 -0.1174 -0.1094
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese ; patients ; clinically ; stable ; hfpef ; exercise ; training ; peak vo2
H-1990	-0.35942602157592773	▁obes e ▁older ▁patients ▁; ▁h FP EF ▁; ▁calor ic ▁restriction ▁; ▁aero bic ▁exercise ▁training ▁; ▁VO 2
D-1990	-0.35942602157592773	obese older patients ; hFPEF ; caloric restriction ; aerobic exercise training ; VO2
P-1990	-0.6719 -0.0414 -0.5123 -0.5092 -0.1928 -1.1132 -0.6385 -0.2808 -0.0963 -0.0171 -0.2963 -0.0687 -0.0372 -0.0052 -0.0622 -0.1558 -0.7818 -0.6571 -1.4442 -0.0428 -0.1766 -0.1058
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2007	-0.6518555283546448	▁economic ▁analysis ▁; ▁Patient ▁Management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁; ▁cost - effect ive ness ▁; ▁disease ▁management ▁programs ▁in ▁heart ▁failure
D-2007	-0.6518555283546448	economic analysis ; Patient Management Interventions in Heart Failure ; cost-effectiveness ; disease management programs in heart failure
P-2007	-1.7621 -0.7628 -0.7037 -0.6067 -0.9621 -0.2920 -0.0492 -0.8487 -0.4662 -0.2300 -0.5798 -0.7569 -3.1497 -0.0357 -1.3964 -0.1382 -0.8421 -0.4315 -0.9140 -0.0641 -0.4276 -0.7841 -0.4030 -0.0712 -0.1542 -0.1167
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective ; hf ; patients ; hf with reduced ef ; ef ; hfpef ; ef
H-782	-0.5444901585578918	▁ HF ▁registr y ▁; ▁dicho tom ized ▁patients ▁; ▁ HF ▁; EF ▁; ▁ HF p EF ▁; EF
D-782	-0.5444901585578918	HF registry ; dichotomized patients ; HF ;EF ; HFpEF ;EF
P-782	-0.3940 -0.5676 -0.1615 -0.1012 -0.1781 -2.8244 -0.0007 -0.0791 -0.4178 -0.2693 -0.2028 -0.2935 -0.2784 -2.0524 -0.4246 -0.9785 -0.3267 -0.4709 -0.2708 -0.6704 -0.2044 -1.2436 -0.1126
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat ; n-terminal pro-brain natriuretic peptide ; hospitalized ; hf
H-1877	-0.40601229667663574	▁BAT ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁ HF
D-1877	-0.40601229667663574	BAT ; n-terminal pro-brain natriuretic peptide ; HF
P-1877	-0.0302 -0.6711 -2.2691 -0.0197 -0.0306 -0.0048 -0.0378 -0.0380 -0.0652 -0.0729 -0.0566 -0.1982 -0.3784 -1.0102 -0.8445 -0.0805 -0.1451 -0.3278 -2.0455 -0.4393 -0.0932 -0.0735
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients ; hr variability ; mortality ; ami ; diagnosis ; chf ; lv dysfunction
H-1586	-0.48784637451171875	▁HR ▁variabil ity ▁; ▁mortal ity ▁; ▁ AMI ▁; ▁CHF ▁; LV ▁dys function
D-1586	-0.48784637451171875	HR variability ; mortality ; AMI ; CHF ;LV dysfunction
P-1586	-2.3525 -0.0543 -0.4967 -0.2190 -0.3042 -0.6279 -0.2357 -0.5139 -0.0385 -0.0954 -0.4787 -2.0598 -0.2106 -0.2955 -0.0783 -0.1454 -0.0869
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence ; exercise ; cell senescence ; active ; osteoporosis
H-1901	-0.4688264727592468	▁exercise ▁; ▁cell ▁se nesc ence ▁; ▁active ▁; ▁malign a ncies ▁; ▁cancer ▁; ▁prostat e ▁; ▁colon ▁; ▁osteo por osis ▁; ▁depression ▁; ▁dem entia
D-1901	-0.4688264727592468	exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
P-1901	-3.6647 -0.3038 -0.6918 -0.0582 -0.0580 -0.1679 -0.1785 -2.1844 -1.3459 -0.4458 -0.4773 -0.0754 -0.1078 -0.1319 -0.4818 -0.0191 -0.0522 -0.0862 -1.5792 -0.3372 -0.0185 -0.2003 -0.0297 -0.1875 -0.1229 -0.6941 -0.1920 -0.0167 -0.0752 -0.0807
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended criteria cardiac transplant ; ecct ; transplant ; donors ; transplant ; comorbidity
H-708	-0.5041394233703613	▁cardiac ▁transplant ▁; ▁ec CT ▁; ▁transplant ▁pool ▁; ▁donor s ▁; ▁recipient s
D-708	-0.5041394233703613	cardiac transplant ; ecCT ; transplant pool ; donors ; recipients
P-708	-0.1652 -0.1131 -0.2981 -0.2772 -1.4425 -0.4912 -0.1855 -0.4359 -0.5533 -0.4501 -0.1383 -0.5290 -0.3825 -0.1101 -2.4052 -0.0890
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic ; pediatric fontan ; patients ; catheterization
H-227	-0.34748148918151855	▁as ym pto matic ▁pediatr ic ▁Font an ▁; PF ▁; ▁cat heter ization
D-227	-0.34748148918151855	asymptomatic pediatric Fontan ;PF ; catheterization
P-227	-0.2970 -0.0568 -0.0282 -0.1334 -0.0491 -0.0981 -0.1368 -0.1691 -0.4380 -0.0835 -0.9859 -1.4189 -0.0171 -0.8317 -0.7323 -0.0838
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ; ventricular assist devices ; cardiac ; nurses ; gastrointestinal bleeding
H-1660	-0.2890477776527405	▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse s ▁; ▁management ▁; ▁gastro inte stin al ▁ble ed ing
D-1660	-0.2890477776527405	ventricular assist devices ; cardiac nurses ; management ; gastrointestinal bleeding
P-1660	-0.0200 -0.8323 -0.1038 -0.6438 -0.2254 -0.2905 -0.8293 -0.0251 -0.0364 -0.2543 -0.5642 -0.7119 -0.0901 -0.1439 -0.2371 -0.0430 -0.0510 -0.4796 -0.2074 -0.1762 -0.1047
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the lancet ; anoop shah ; air ; heart failure ; morbidity ; mortality
H-1807	-0.24937647581100464	▁Lance t ▁; ▁Ano op ▁Shah ▁; ▁air ▁pollution ▁; ▁heart ▁failure ▁; ▁morbi d ity ▁; ▁mortal ity
D-1807	-0.24937647581100464	Lancet ; Anoop Shah ; air pollution ; heart failure ; morbidity ; mortality
P-1807	-0.0469 -0.0161 -0.0549 -0.5890 -0.0171 -0.0311 -0.1412 -0.3988 -0.1100 -0.3330 -0.6889 -0.1012 -0.3363 -0.3499 -0.0215 -0.5579 -0.2186 -0.0125 -0.3907 -0.7198 -0.1014
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia ; hf ; health-related quality of life ; hrqol ; hf
H-835	-0.4364509582519531	▁an emia ▁; ▁ HF ▁; ▁health - related ▁quality ▁of ▁life ▁; HR Qo L ▁; ▁ HF
D-835	-0.4364509582519531	anemia ; HF ; health-related quality of life ;HRQoL ; HF
P-835	-0.6105 -0.0323 -0.3933 -0.8247 -0.1550 -0.2712 -2.2828 -0.0900 -0.0405 -0.2172 -0.5155 -0.4432 -0.1794 -0.4252 -0.0074 -0.3691 -0.4047 -1.1495 -0.4021 -0.2585 -0.0932
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell therapy ; chronic heart failure ; chf ; disease ; progenitor cells
H-1336	-0.294389009475708	▁cell ▁ therapy ▁; ▁chronic ▁heart ▁failure ▁; CH F ▁; ▁ex plant - der i ved ▁pro gen itor ▁cell s
D-1336	-0.294389009475708	cell therapy ; chronic heart failure ;CHF ; explant-derived progenitor cells
P-1336	-0.8426 -0.2412 -0.0122 -0.1761 -0.0616 -0.3034 -0.0686 -0.1464 -0.6461 -1.4922 -0.2455 -1.0384 -0.0016 -0.0197 -0.0213 -0.0474 -0.1441 -0.2288 -0.0454 -0.0250 -0.9200 -0.0636 -0.1897 -0.0848
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous nonfailing ; hf ; combinations ; remodeling
H-1152	-0.2683635652065277	▁m RI - based ▁models ▁; ▁dys syn chron ous ▁non fail ing ▁; ▁ HF ▁can ine ▁electro me chan ics
D-1152	-0.2683635652065277	mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
P-1152	-0.4156 -0.6961 -0.0525 -0.0157 -0.5822 -0.3401 -0.0017 -0.0161 -0.0141 -0.2690 -0.0497 -0.0552 -0.0421 -0.0925 -0.2309 -0.1564 -1.3003 -0.3198 -0.0374 -0.0373 -0.0230 -0.7130 -0.8798 -0.1003
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients ; acute rv failure ; chronic pulmonary arterial hypertension ; pah ; acute ; pulmonary embolism
H-1095	-0.2682381868362427	▁a cute ▁ RV ▁failure ▁; ▁chronic ▁pulmonar y ▁arterial ▁hyper tension ▁; PA h ▁; ▁a cute ▁pulmonar y ▁e mbol ism
D-1095	-0.2682381868362427	acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
P-1095	-1.1326 -0.0184 -0.1281 -0.2586 -0.0503 -0.2156 -0.2747 -0.0068 -0.0344 -0.0077 -0.1982 -0.0147 -0.2544 -0.9436 -0.2336 -0.2439 -0.5651 -0.0081 -0.0139 -0.0669 -0.1714 -0.0181 -1.4687 -0.2628 -0.1154
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute rv failure ; pulmonary embolism ; mortality ; diagnostic
H-1097	-0.32321417331695557	▁a cute ▁ RV ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁mortal ity
D-1097	-0.32321417331695557	acute RV failure ; pulmonary embolism ; mortality
P-1097	-0.5578 -0.0222 -0.1061 -0.3228 -0.0446 -0.0848 -0.0421 -0.0475 -0.1431 -0.0310 -0.9865 -0.6048 -0.5968 -1.1660 -0.3331 -0.0823
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin ; chemotherapy ; elevated ; cardiotoxicity
H-937	-0.4049704968929291	▁se rum ▁resist in ▁; ▁women ▁; ▁an thra cycli ne - conta ining ▁che mo therapy ▁; ▁cardio toxic ity
D-937	-0.4049704968929291	serum resistin ; women ; anthracycline-containing chemotherapy ; cardiotoxicity
P-937	-0.1063 -0.1233 -0.1753 -0.3418 -1.8140 -1.0090 -0.4269 -0.1828 -0.0635 -0.2851 -0.9389 -0.1473 -0.0296 -0.4367 -0.1295 -0.2561 -0.0460 -0.5276 -0.1016 -0.2250 -1.7339 -0.1099 -0.1043
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients ; sst2 ; titrated ; cardiovascular event
H-405	-0.5179586410522461	▁s st 2 ▁ti tra ted ▁to ▁high - dos e ▁BB ▁; ▁cardiovascular ▁event ▁rate
D-405	-0.5179586410522461	sst2 titrated to high-dose BB ; cardiovascular event rate
P-405	-0.1792 -1.2372 -0.0765 -1.3485 -0.1156 -0.1265 -1.4380 -0.6566 -0.0087 -0.2517 -0.0480 -0.5183 -0.3560 -0.0270 -0.5880 -0.6919 -1.5855 -0.0702
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad ; q66p ; cardiomyopathy
H-1677	-0.5275012850761414	▁Rad ▁Q 66 p ▁; ▁cardio my o pathy ▁; ▁mechanism
D-1677	-0.5275012850761414	Rad Q66p ; cardiomyopathy ; mechanism
P-1677	-0.5503 -1.1186 -0.1489 -0.3764 -0.3116 -0.1416 -0.6472 -0.1570 -0.0274 -0.6503 -0.0796 -2.5729 -0.0756
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular ; wall stiffness
H-1148	-0.562317430973053	▁vent ri cular ▁structure ▁; ▁bo th ▁ge ometr y ▁; ▁fiber ▁; she et ▁ orientation ▁; ▁handling ▁; ▁slow ed ▁con duction ▁; ▁wall ▁sti ff ness
D-1148	-0.562317430973053	ventricular structure ; both geometry ; fiber ;sheet orientation ; handling ; slowed conduction ; wall stiffness
P-1148	-0.2164 -0.8349 -0.1700 -0.6511 -0.0836 -2.2077 -0.1776 -0.0138 -0.0076 -0.0930 -0.0717 -0.0077 -1.9702 -0.0770 -0.0149 -0.3341 -0.0074 -0.1933 -2.4897 -0.1713 -0.1670 -0.3647 -0.0170 -0.0465 -0.3249 -3.7668 -0.0456 -0.1237 -2.3607 -0.2871 -0.1349
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.537310779094696	▁SD QT - to - SD RR ▁ratio ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁h Nor m
D-1441	-0.537310779094696	SDQT-to-SDRR ratio ; HFVT ; HFVT ; hNorm
P-1441	-0.3505 -0.1816 -0.0786 -0.0660 -0.0196 -0.1273 -0.9394 -0.1853 -0.0863 -0.5178 -0.1628 -0.2256 -0.4489 -1.3616 -0.6803 -0.7593 -0.3483 -1.4518 -2.2968 -0.0393 -1.3851 -0.1084
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration ; renin-angiotensin system blocker ; beta-blocker ; therapy ; patients ; hospitalized ; heart failure ; preserved left ventricular ejection fractions
H-174	-0.321084201335907	▁re nin - angi oten sin ▁system ▁block er ▁; ▁beta - block er ▁ therapy ▁; ▁heart ▁failure ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction
D-174	-0.321084201335907	renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; preserved left ventricular ejection
P-174	-0.0223 -0.4099 -0.0309 -0.0112 -0.2697 -0.3574 -0.0531 -0.3200 -0.1155 -0.2209 -0.0574 -0.0327 -0.0831 -0.0608 -0.7277 -0.0095 -0.3173 -1.1569 -0.0923 -0.3483 -1.8451 -0.0123 -0.1158 -0.2657 -0.0718 -0.7878 -0.3100 -0.1667 -0.1549 -0.0838 -1.6054 -0.1583
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestion
H-1180	-0.4380932152271271	▁Exerci se ▁; ▁Medical ▁Therapie s ▁; ▁Card iac ▁Fun ction ▁; ▁Short ness ▁; ▁Breath ▁Du e ▁to ▁Lung ▁con gestion
D-1180	-0.4380932152271271	Exercise ; Medical Therapies ; Cardiac Function ; Shortness ; Breath Due to Lung congestion
P-1180	-0.7623 -0.0403 -0.4513 -0.2755 -0.1600 -0.0505 -0.6290 -1.0997 -0.0622 -0.0386 -0.0045 -0.3476 -1.9691 -1.4834 -0.9212 -0.2024 -0.3302 -0.0092 -0.0183 -0.1228 -0.6435 -0.0324 -0.7857 -0.0747
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional electrical stimulation ; peripheral muscles ; endothelial function ; clinical ; heart failure ; patients ; preserved left ventricular ejection fraction
H-1326	-0.340122789144516	▁Fun ction al ▁electric al ▁stimul ation ▁; ▁per i pher al ▁muscle s ▁; ▁en dot heli al ▁function ▁; ▁heart ▁failure ▁patients ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1326	-0.340122789144516	Functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure patients ; preserved left ventricular ejection fraction
P-1326	-1.3982 -0.0158 -0.0123 -0.3936 -0.0113 -0.0767 -0.2749 -0.4859 -0.0684 -0.0796 -0.0641 -0.1067 -0.4865 -0.1072 -0.3100 -0.0659 -0.3454 -0.0220 -0.0039 -0.2332 -0.1197 -3.0129 -0.0796 -1.1152 -0.3550 -0.3555 -0.0185 -0.1657 -0.1502 -0.1197 -0.6985 -0.2250 -0.1759 -0.1520 -0.2041 -1.3200 -0.0104 -0.3062 -0.1189
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
H-1139	-0.25323978066444397	▁ta chy car dic ▁response ▁; ▁met hy la tropi ne ▁; ▁va gal ▁tone ▁; ▁bra dy car dic ▁response ▁; ▁propra no lol ▁; ▁sympa the tic ▁tone
D-1139	-0.25323978066444397	tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol ; sympathetic tone
P-1139	-0.1485 -0.9001 -0.0672 -0.1158 -0.4218 -0.2818 -0.0064 -0.0884 -0.2922 -0.0033 -1.2456 -0.1389 -0.0471 -0.0177 -0.0443 -0.1308 -0.0861 -0.3368 -0.0557 -0.1369 -1.0314 -0.1798 -0.0714 -0.0067 -0.0482 -0.6720 -0.0236 -0.3405 -0.7947 -0.2250 -0.0760 -0.0687
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac resynchronization therapy ; crt ; mild heart failure ; hf ; patients ; qrs prolongation ; ejection fraction ; ef
H-751	-0.28420794010162354	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁mild ▁heart ▁failure ▁; HF ▁; ▁QR s ▁prolong ation ▁; ▁e je ction ▁ fraction ▁; EF
D-751	-0.28420794010162354	cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction ;EF
P-751	-0.6350 -0.0350 -0.1022 -0.0264 -0.6010 -1.3759 -0.0381 -0.1768 -0.4885 -1.5516 -0.1626 -0.0301 -0.1485 -0.0894 -0.1431 -0.0618 -0.2427 -0.3128 -0.7798 -0.0415 -0.2300 -0.1860 -0.0030 -0.0518 -0.0318 -0.4180 -0.0024 -0.4526 -0.0495 -0.2043 -0.1383
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ; lad
H-509	-0.2698335349559784	▁Fra ction al ▁flow ▁reserve ▁; ▁posi tron ▁e mission ▁tom ography ▁imagin g ▁; ▁ ische mia ▁; ▁bottle ne ck ▁sten ting ▁; ▁left ▁vent ric le ▁; ▁proxima l ▁ LAD
D-509	-0.2698335349559784	Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD
P-509	-1.1264 -0.0013 -0.0248 -0.0588 -0.0153 -0.2447 -0.0451 -0.0460 -0.0426 -0.3884 -0.8449 -0.3142 -1.5272 -0.1060 -0.1840 -0.5004 -0.0175 -0.2838 -0.2133 -0.0263 -0.0580 -0.0136 -0.0187 -0.1211 -1.0450 -0.0357 -0.0385 -0.8303 -0.3841 -0.3636 -0.1578 -0.0102 -0.0675 -0.0347 -0.4620 -0.0623
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity ; oxidative stress ; dna fragmentation
H-962	-0.29132863879203796	▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se ▁activity ▁; ▁oxid ative ▁stress ▁marker s ▁; ▁DNA ▁fragment ation
D-962	-0.29132863879203796	mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
P-962	-0.0019 -0.2583 -0.1286 -0.0149 -0.0799 -0.0493 -0.2259 -0.0327 -1.5929 -1.1701 -0.0558 -0.6369 -0.1275 -0.0044 -0.0967 -0.0008 -0.0423 -0.7687 -0.1165 -0.0062 -0.0397 -0.2030 -0.0797 -0.0816 -0.5945 -0.1428 -0.1295 -0.1725 -1.8014 -0.0849
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox regression ; covariates ; spironolactone ; death ; hospitalization ; hyperkalemia ; acute kidney injury
H-442	-0.3156965970993042	▁co x ▁re gression ▁; ▁spi rono lac tone ▁; ▁death ▁; ▁hospital ization ▁; ▁severe ▁hyper kal emia ▁; ▁ki dne y ▁injury
D-442	-0.3156965970993042	cox regression ; spironolactone ; death ; hospitalization ; severe hyperkalemia ; kidney injury
P-442	-0.0559 -0.0526 -0.0136 -0.0067 -0.2572 -0.1894 -0.0103 -0.0483 -0.0395 -1.0150 -2.1473 -0.1545 -0.8153 -0.3694 -0.1297 -0.2549 -0.1240 -0.0909 -0.0585 -0.2247 -1.4752 -0.2591 -0.0378 -0.0859 -0.1601 -0.1323
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes ; mortality ; hospitalization ; mortality ; cardiovascular mortality ; hf ; hospitalization ; cox models ; exercise ; training
H-1633	-0.5233721137046814	mortal ity ▁; hospital ization ▁; ▁mortal ity ▁; ▁cardiovascular ▁mortal ity ▁; HF ▁hospital ization ▁; ▁co x ▁; ▁exercise ▁training
D-1633	-0.5233721137046814	mortality ;hospitalization ; mortality ; cardiovascular mortality ;HF hospitalization ; cox ; exercise training
P-1633	-2.3912 -0.6002 -0.6779 -0.6941 -0.3222 -0.1761 -0.0978 -0.5434 -0.1096 -0.0112 -0.0426 -0.6416 -0.1668 -0.7638 -0.3679 -0.2323 -0.6898 -0.5617 -0.0513 -2.3892 -0.2044 -0.5954 -0.1081 -0.1226
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin inhibitors ; natriuretic peptide ; atrial natriuretic peptide ; b-type natriuretic peptide
H-1462	-0.6495420336723328	▁ne pri ly sin ▁inhibi tors ▁; ▁na tri ure tic ▁pe pti de ▁system ▁; ▁at rial ▁na tri ure tic ▁pe pti de ▁; ▁na tri ure tic ▁pe pti de
D-1462	-0.6495420336723328	neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; natriuretic peptide
P-1462	-1.0619 -0.1197 -0.8482 -0.6423 -0.0378 -0.1110 -0.1940 -0.0359 -0.3696 -0.5647 -2.2457 -0.9061 -0.1627 -0.3186 -0.4163 -0.2186 -4.3877 -0.0160 -0.0729 -0.5712 -0.5725 -1.9852 -0.8948 -0.0858 -0.2363 -0.3454 -0.2481 -0.4647 -0.4775 -2.1269 -1.1862 -0.1165 -0.2977 -0.2556 -0.1398
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse ; pasp ; downward ; hfref ; hfpef ; prognostic ; resolution
H-500	-0.5389221906661987	▁T AP se ▁; ▁PAS p ▁; ▁non sur viv ors ▁; ▁h Fr EF ▁; ▁ HF p EF
D-500	-0.5389221906661987	TAPse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
P-500	-2.8916 -0.1252 -0.8748 -1.8963 -0.6825 -0.5367 -0.6908 -0.0651 -0.0404 -0.0071 -0.1218 -0.0742 -1.1976 -0.2369 -0.5033 -0.0768 -0.1404 -0.1688 -0.0406 -0.2472 -1.1645 -0.0734
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action ; randomized ; patients ; hf ; ejection fraction ; exercise ; training
H-1632	-0.6282638907432556	▁ HF - ac TION ▁; ▁patients ▁; ▁ HF ▁; ▁e je ction ▁ fraction
D-1632	-0.6282638907432556	HF-acTION ; patients ; HF ; ejection fraction
P-1632	-0.5272 -0.4124 -0.0410 -0.6374 -1.1824 -0.3082 -2.6545 -0.7389 -0.3997 -0.1280 -0.4700 -0.2612 -0.1668 -0.0294 -0.4347 -0.0048 -2.7838 -0.1285
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic ; proteins ; histone acetyltransferases ; epigenetic ; histone deacetylases ; cardiac ; disease
H-1041	-0.2766781151294708	▁epi gene tic ▁; writer ▁; ▁protein s ▁; hi stone ▁a ce tyl transfer as es ▁; ▁epi gene tic ▁; eras ers ▁; hi stone ▁de ace ty las es ▁; ▁cardiac ▁development
D-1041	-0.2766781151294708	epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development
P-1041	-1.0294 -0.1332 -0.3360 -0.6364 -0.6454 -0.6737 -0.1587 -0.0577 -0.1184 -0.0214 -0.0214 -0.0157 -0.6431 -0.2365 -0.0153 -0.0609 -0.1592 -0.2794 -0.0637 -0.0635 -0.5517 -0.5085 -0.0216 -0.0184 -0.2709 -0.0439 -0.1404 -0.0302 -0.0648 -0.0471 -0.0095 -0.0613 -0.5426 -0.0043 -0.9086 -1.5295 -0.1147
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated ; nt-probnp ; admission ; all-cause mortality ; patients ; acute hf ; admission
H-270	-0.3327181041240692	▁NT - pro b NP ▁; ▁mortal ity ▁; ▁a cute ▁ HF
D-270	-0.3327181041240692	NT-probNP ; mortality ; acute HF
P-270	-0.1049 -0.0118 -0.0071 -0.3693 -0.1256 -0.7113 -1.3660 -1.0603 -0.3046 -0.3899 -0.0161 -0.1778 -0.1187 -0.0729 -0.1544
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic cell transplantation ; hct ; congestive heart failure ; chf ; anthracyclines
H-1449	-0.6165576577186584	▁ha e mato po ie tic ▁cell ▁transplant ation ▁; ▁h CT ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁pre - h CT ▁exposure ▁to ▁an thra cycli nes
D-1449	-0.6165576577186584	haematopoietic cell transplantation ; hCT ; congestive heart failure ;CHf ; pre-hCT exposure to anthracyclines
P-1449	-0.0660 -0.7321 -0.0861 -0.1779 -0.3367 -1.6630 -0.6071 -0.0453 -0.1694 -0.3043 -1.2372 -0.7860 -0.1881 -1.6894 -0.5254 -1.2991 -0.5727 -0.1196 -0.2448 -0.5126 -1.1389 -0.1333 -1.4705 -0.0054 -1.4451 -0.5138 -0.7487 -1.1558 -0.0904 -0.0335 -0.0907 -2.3680 -0.2887 -0.1174
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; administration ; doxorubicin
H-956	-0.14826728403568268	▁cardio protec tive ▁effect ▁; ▁nic oran dil ▁; ▁hem o dynamic ▁altera tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁cum ul ative ▁administration ▁; ▁do xor ubi cin
D-956	-0.14826728403568268	cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; cumulative administration ; doxorubicin
P-956	-0.0666 -0.2059 -0.3358 -0.1406 -0.1828 -0.0363 -0.0274 -0.1206 -0.0770 -0.3440 -0.1019 -0.0013 -0.1601 -0.0696 -0.0870 -0.0009 -0.2688 -0.0516 -0.0127 -0.0143 -0.0370 -0.5326 -0.3456 -0.0085 -0.0068 -0.1758 -0.2982 -0.0605 -0.0041 -0.0073 -0.3661 -0.6678 -0.0775
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in vivo ; mir-25 ; antagomir ; cardiac dysfunction ; murine ; myocardium ; heart failure
H-643	-0.2073696404695511	▁in ▁vivo ▁inhibi tion ▁; ▁mi r -25 ▁; ▁anta go mir ▁; ▁spontane ous ▁cardiac ▁dys function ▁; ▁mur ine ▁my o car dium ▁to ▁heart ▁failure
D-643	-0.2073696404695511	in vivo inhibition ; mir-25 ; antagomir ; spontaneous cardiac dysfunction ; murine myocardium to heart failure
P-643	-0.1425 -0.0018 -0.0403 -0.2824 -0.2602 -0.0763 -0.8294 -0.0423 -0.1736 -0.5454 -0.0088 -0.1697 -0.2708 -0.1188 -0.1361 -0.0053 -0.0121 -0.0363 -0.1273 -0.1394 -0.8784 -0.3645 -0.0581 -0.0143 -0.0580 -0.4555 -0.2022 -0.1148 -0.5172 -0.1392
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine ; patients ; dilated cardiomyopathy ; dcm ; heart failure
H-1258	-0.25750795006752014	▁Chinese ▁herbal ▁medicine ▁; CH m ▁; ▁ad ju nc tive ▁treatment ▁; ▁dil ated ▁cardio my o pathy ▁; DC m ▁; ▁heart ▁failure
D-1258	-0.25750795006752014	Chinese herbal medicine ;CHm ; adjunctive treatment ; dilated cardiomyopathy ;DCm ; heart failure
P-1258	-1.0360 -0.0298 -0.0548 -0.0822 -0.7411 -0.4294 -0.1491 -0.4897 -0.0383 -0.0031 -0.1048 -0.2035 -0.2916 -0.1283 -0.0896 -0.0613 -1.0551 -0.4563 -0.0116 -0.1238 -0.3332 -0.3666 -0.2110 -0.0984 -0.0973 -0.1409 -0.1260
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension ; diabetes mellitus ; grade ; systolic ; diastolic murmurs ; apex
H-347	-0.11629793792963028	▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁sy sto lic ▁; ▁dia sto lic ▁mur mur s
D-347	-0.11629793792963028	hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
P-347	-0.4867 -0.0138 -0.0653 -0.4509 -0.0021 -0.0148 -0.3305 -0.0116 -0.0277 -0.0107 -0.2035 -0.0106 -0.0343 -0.0433 -0.1259 -0.0226 -0.1367 -0.1407 -0.0781
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative ; patients ; preoperative ; hypoalbuminemia ; albumin
H-533	-0.490508496761322	▁post operativ e ▁survival ▁; ▁patients ▁; ▁pre operativ e ▁hypo album in emia ▁; ▁album in ▁concentration
D-533	-0.490508496761322	postoperative survival ; patients ; preoperative hypoalbuminemia ; albumin concentration
P-533	-0.8612 -0.0218 -0.0344 -0.4718 -0.1461 -1.5008 -1.2964 -1.0594 -0.0449 -0.0339 -0.0996 -0.1048 -0.1705 -0.2112 -0.1856 -2.1098 -0.1633 -0.2685 -0.9612 -0.0650
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left bundle branch block ; remodeling ; dyssynchronous heart failure ; hf ; heart
H-1147	-0.395021915435791	▁elektri al ▁activa tion ▁; ▁dys syn chron ous ▁heart ▁failure ▁; HF ▁; ▁electro me chan ical ▁behavior ▁; ▁heart
D-1147	-0.395021915435791	elektrial activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
P-1147	-2.8429 -0.0794 -0.0350 -0.1717 -0.1319 -0.0167 -0.0086 -0.0096 -0.2801 -0.8316 -0.1562 -0.2001 -0.0589 -0.2691 -0.0365 -0.0225 -0.0081 -0.0941 -0.8799 -0.3723 -2.3547 -0.1453 -0.0802
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients ; heart failure ; heart ; cardiologists ; cardiovascular ; surgeons ; medical ; patient
H-1822	-0.544498860836029	▁patients ▁; ▁advanced ▁heart ▁failure ▁; heart ▁team ▁; ▁cardio logist s ▁; ▁cardiovascular ▁surge ons
D-1822	-0.544498860836029	patients ; advanced heart failure ;heart team ; cardiologists ; cardiovascular surgeons
P-1822	-2.1838 -1.7652 -0.2199 -0.5440 -0.2740 -0.2774 -1.5009 -0.1281 -0.2591 -0.4183 -0.0524 -0.0594 -0.1626 -0.0459 -0.0927 -0.3150 -1.4075 -0.0948
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex sensitivity ; heart rate variability ; hrv ; renal dnx
H-1376	-0.32841596007347107	▁Baro re flex ▁ sensitiv ity ▁; ▁time ▁domain ▁heart ▁rate ▁variabil ity ▁; HR V ▁; ▁CHF - IN v ▁group ▁; ▁sham - IN v ▁; ▁sham ▁levels ▁; ▁renal ▁DN x
D-1376	-0.32841596007347107	Baroreflex sensitivity ; time domain heart rate variability ;HRV ; CHF-INv group ; sham-INv ; sham levels ; renal DNx
P-1376	-0.0242 -0.0796 -0.0489 -0.3224 -0.0015 -0.4564 -0.1171 -0.0826 -0.0044 -1.3032 -0.2276 -0.0274 -0.6544 -0.2743 -0.2891 -1.8052 -0.1884 -0.0219 -0.0229 -0.7917 -0.4154 -1.1596 -0.0826 -0.0096 -0.0567 -0.5525 -0.3324 -0.1645 -0.7122 -0.7933 -0.3168 -0.0104 -0.1285 -0.0554 -0.2000 -0.0897
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
H-1542	-0.2277652621269226	▁bis phos phon ates ▁; ▁ale ndr onate ▁; ▁et id rona te ▁; ▁risk ▁; ▁heart ▁failure
D-1542	-0.2277652621269226	bisphosphonates ; alendronate ; etidronate ; risk ; heart failure
P-1542	-0.0524 -0.0080 -0.0495 -0.1371 -0.1273 -0.0164 -0.0049 -0.0105 -0.0660 -0.0045 -0.0226 -0.0063 -0.0075 -0.1645 -1.6830 -0.7984 -0.1888 -0.1099 -1.0208 -0.0769
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse ; hospitalization ; physician ; discharge ; patients ; hospitalized ; heart failure
H-206	-0.38606593012809753	▁nurse ▁assessment ▁; ▁cognitive ▁im pair ment ▁; ▁hospital ization ▁; ▁physician ▁; ▁dis charge ▁; ▁el der ly ▁patients ▁hospital ized ▁; ▁heart ▁failure
D-206	-0.38606593012809753	nurse assessment ; cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients hospitalized ; heart failure
P-206	-1.0286 -0.1592 -0.9905 -0.0050 -0.3651 -0.0323 -0.4109 -0.4557 -0.6029 -0.3637 -0.1732 -0.1294 -0.2084 -0.6198 -0.0121 -0.2039 -0.7102 -0.0211 -0.1825 -0.4081 -0.9839 -0.1272 -1.3832 -0.5017 -0.1392 -0.1102 -0.0959
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol ; nonselective β-blocker ; selective β-blocker ; metoprolol ; thromboembolic events ; heart failure
H-1111	-0.3248450458049774	▁car vedi lol ▁; ▁non sel ective ▁β - block er ▁; ▁β - block er ▁met o pro lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure
D-1111	-0.3248450458049774	carvedilol ; nonselective β-blocker ; β-blocker metoprolol ; thromboembolic events ; heart failure
P-1111	-0.0379 -0.0021 -0.0288 -0.2283 -0.5002 -0.0097 -0.0102 -0.0997 -0.0469 -0.1878 -0.1435 -0.2733 -1.8958 -0.0326 -0.1533 -0.1289 -1.0937 -0.1635 -0.0301 -0.1243 -0.2735 -0.5916 -0.9490 -0.8539 -0.2108 -0.0263 -0.7793 -0.5227 -0.5557 -0.2611 -0.2485 -0.1505 -0.1065
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline ; cardiac transplant ; ecct
H-716	-0.45272231101989746	▁cardiac ▁transplant ▁survival ▁; ▁ec CT
D-716	-0.45272231101989746	cardiac transplant survival ; ecCT
P-716	-0.4297 -0.0864 -0.7321 -0.7652 -0.5930 -0.7172 -0.1842 -0.1139
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ; ami ; pna ; mortality
H-1700	-0.6820218563079834	▁ HF ▁; ▁ AMI ▁; ▁p na ▁; ▁mortal ity
D-1700	-0.6820218563079834	HF ; AMI ; pna ; mortality
P-1700	-1.8225 -0.4086 -0.0713 -0.4455 -0.2043 -0.1159 -0.2971 -1.7951 -0.6859 -1.4632 -0.8076 -0.6435 -0.1058
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients ; heart failure ; hf ; evidence ; outcomes ; hf
H-685	-0.8673224449157715	▁heart ▁failure ▁; HF ▁; ▁non - HF ▁population s ▁; ▁dieta ry ▁pattern s ▁; ▁outcome s ▁; ▁ HF
D-685	-0.8673224449157715	heart failure ;HF ; non-HF populations ; dietary patterns ; outcomes ; HF
P-685	-6.3806 -0.1822 -0.2438 -0.0852 -0.9065 -1.6381 -0.0110 -0.0472 -2.1878 -0.1223 -0.3042 -2.0707 -1.0407 -0.2742 -0.1130 -0.3170 -2.4777 -0.0775 -0.6893 -0.4158 -0.1282 -0.1192 -0.1162
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling ; arrhythmia ; ami ; hr variability ; arrhythmia
H-1590	-0.4550977349281311	▁ar rhythm ia ▁substrat e ▁; ▁ AMI ▁; ▁HR ▁variabil ity ▁; ▁ar rhythm ia ▁events
D-1590	-0.4550977349281311	arrhythmia substrate ; AMI ; HR variability ; arrhythmia events
P-1590	-0.4257 -0.0343 -0.5879 -0.0081 -0.0639 -0.1248 -1.8794 -0.0622 -0.1092 -0.1445 -0.0661 -0.2988 -0.3596 -2.8694 -0.2787 -0.5282 -0.6239 -0.1063 -0.0759
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced cardiotoxicity ; resistin ; retn
H-933	-0.318947970867157	▁do xor ubi cin - indu ced ▁cardio toxic ity ▁; ▁Hum - Re t n ▁mi ce ▁; ▁litt er mate ▁control s ▁; ▁human ▁resist in ▁; ▁re t n
D-933	-0.318947970867157	doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate controls ; human resistin ; retn
P-933	-0.0044 -0.0048 -0.0093 -0.7347 -0.0646 -0.0080 -0.0668 -0.0782 -0.3837 -1.1538 -0.1571 -0.1052 -0.0193 -1.6146 -0.0436 -0.0343 -1.8590 -0.2200 -0.0913 -0.0065 -0.0134 -0.0452 -0.6298 -0.0974 -0.2510 -1.4904 -0.1071 -0.0939 -0.5575 -0.4159 -0.2214 -0.0290 -0.1683 -0.0649
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients ; hypertension ; compensated hfpef ; dash ; sodium
H-919	-0.45187851786613464	▁hyper tension ▁; ▁compensa ted ▁H FP EF ▁; ▁DAS h ▁; ▁s rd ▁; ▁so dium ▁; ▁kcal
D-919	-0.45187851786613464	hypertension ; compensated HFPEF ; DASh ; srd ; sodium ; kcal
P-919	-2.5220 -0.0359 -0.0977 -0.0013 -0.0882 -0.6597 -0.3570 -0.4136 -0.1281 -0.1207 -0.0883 -0.5074 -1.0955 -0.7017 -0.4079 -0.0149 -0.0756 -1.6435 -0.3473 -0.1117 -0.0715
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd ; dyssynchronous hf ; remodeling ; insignificantly
H-1154	-0.32172778248786926	▁de rang ed ▁ca (2 +) ▁handling ▁; ▁EM d ▁; ▁dys syn chron ous ▁ HF
D-1154	-0.32172778248786926	deranged ca(2+) handling ; EMd ; dyssynchronous HF
P-1154	-0.6692 -0.0014 -0.0309 -0.9337 -0.1144 -0.0007 -0.0507 -0.1090 -1.9495 -0.7670 -0.3568 -0.0086 -0.0136 -0.0068 -0.3517 -0.1475 -0.1116 -0.3985 -0.0912
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic dysfunction ; pathophysiology ; hfpef ; cardiovascular function
H-1302	-0.20154207944869995	▁dia sto lic ▁dys function ▁; ▁pat ho phy si ology ▁; ▁ HF p EF ▁; ▁non - dia sto lic ▁ab normal ities ▁; ▁cardiovascular ▁function
D-1302	-0.20154207944869995	diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
P-1302	-0.0736 -0.0647 -0.1630 -0.1153 -0.0945 -0.0817 -0.1365 -0.1001 -0.1791 -1.3283 -0.6143 -0.1301 -0.5006 -0.1150 -0.0245 -0.1087 -0.2528 -0.3934 -0.0249 -0.0769 -0.0926 -0.0448 -0.0418 -0.0218 -0.3536 -0.2437 -0.0138 -0.3753 -0.1698 -0.1114
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ; ejection fraction ; cardiac index ; inotropes ; medical ; transplant
H-1997	-0.3046015202999115	▁e je ction ▁ fraction ▁; ▁cardiac ▁index ▁; ▁in o trop es ▁; ▁in ot rope - dependent
D-1997	-0.3046015202999115	ejection fraction ; cardiac index ; inotropes ; inotrope-dependent
P-1997	-0.2540 -0.0388 -0.0283 -0.4486 -0.0027 -0.2792 -0.0486 -0.0046 -0.2936 -0.0246 -0.4207 -0.0376 -0.5238 -0.1575 -0.0092 -0.2193 -0.0259 -0.0881 -0.0224 -3.3566 -0.1124
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density lipoprotein ; hdl ; endothelial cell ; nitric oxide
H-246	-0.38817325234413147	▁hoge - dens ity ▁lipo prote in ▁; HD L ▁; ▁en dot heli al - protec tive ▁effects ▁; ▁en dot heli al ▁cell ▁; ▁ec ▁; ▁ni tric ▁oxid e ▁; NO
D-246	-0.38817325234413147	hoge-density lipoprotein ;HDL ; endothelial-protective effects ; endothelial cell ; ec ; nitric oxide ;NO
P-246	-1.8520 -0.1431 -0.2943 -0.8683 -0.0490 -0.1361 -1.0158 -0.3404 -0.1051 -2.0424 -0.4468 -0.1010 -0.3266 -0.0440 -0.0115 -0.1940 -0.1578 -0.7429 -1.0031 -0.6109 -0.0319 -0.4149 -0.0497 -0.0093 -0.2390 -0.2013 -0.4740 -0.1977 -0.0028 -0.0512 -0.0072 -0.0546 -0.4458 -0.6880 -0.5062 -0.1156
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort study ; saxagliptin ; sitagliptin ; antihyperglycemic agents
H-1840	-0.29449859261512756	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁agents
D-1840	-0.29449859261512756	hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
P-1840	-0.0883 -0.6351 -0.1292 -0.1131 -0.0050 -0.1747 -1.5364 -0.0676 -0.4589 -0.1325 -0.0302 -1.1000 -0.2121 -0.0146 -0.1825 -0.0899 -0.0787 -0.1685 -0.2606 -0.7270 -0.1792 -0.0947
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially expressed genes ; degs ; ischemic heart failure ; healthy ; diagnosis ; heart failure
H-1608	-0.6984042525291443	▁de g s ▁; ▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁healthy ▁control ▁; ▁heart ▁failure
D-1608	-0.6984042525291443	degs ; non-ischemic ; ischemic heart failure ; healthy control ; heart failure
P-1608	-3.9902 -2.0974 -0.0787 -0.2820 -0.4678 -0.0700 -0.0316 -0.1197 -0.6555 -0.1096 -0.0359 -0.2570 -2.2148 -0.0858 -0.9848 -0.3532 -0.4659 -0.2381 -2.3320 -0.1806 -0.1886 -0.1257
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin resistance ; type 2 diabetes ; insulin receptor substrates 1 ; irs1 ; irs2 ; cellular metabolism
H-653	-0.3269805312156677	▁in s ulin ▁resist ance ▁; ▁type ▁2 ▁diabetes ▁; ▁insulin ▁receptor ▁substrat es ▁; IR s 1 ▁; ▁i RS 2 ▁; ▁insulin - signal ing ▁component s ▁; ▁cel lular ▁metabolism
D-653	-0.3269805312156677	insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling components ; cellular metabolism
P-653	-0.4835 -0.3984 -0.0322 -0.2099 -0.0446 -0.1236 -0.0597 -0.1659 -0.0225 -0.0916 -0.0060 -0.0130 -0.0130 -0.1322 -0.3091 -2.1369 -0.1179 -0.4709 -0.1918 -0.5341 -0.4374 -1.1204 -0.5760 -0.0543 -0.1103 -0.0169 -0.0557 -0.6203 -0.3085 -0.9430 -1.0218 -0.0132 -0.0554 -0.4455 -0.1092
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome ; admission ; discharge ; hospitalized ; heart failure ; hf ; nursing outcomes classification ; noc
H-1398	-0.43219423294067383	▁ad mission ▁to ▁dis charge ▁; ▁older ▁adults ▁; ▁heart ▁failure ▁; HF ▁; ▁Nur sing ▁Out com es ▁Classifica tion ▁; NO c
D-1398	-0.43219423294067383	admission to discharge ; older adults ; heart failure ;HF ; Nursing Outcomes Classification ;NOc
P-1398	-2.0640 -0.3218 -0.0984 -0.0276 -0.0223 -0.4029 -1.2165 -0.0980 -2.1431 -0.4654 -0.0997 -0.3200 -0.0776 -0.1544 -0.6154 -0.0401 -0.6344 -0.1117 -0.0179 -0.0449 -0.0740 -0.2705 -0.8295 -0.8253 -0.1569 -0.1049
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp ; phosphomimic ; ser77 ; ser83 ; riα ; proteins ; riα
H-1432	-0.43967610597610474	▁8- flu o - c AMP ▁ binding ▁; ▁wild ▁type ▁; ▁ phos pho mi mic ▁Ser 77 ▁; ▁Ser 83 ▁mu tant ▁; ▁RI α ▁protein s ▁; ▁double ▁mu tant ▁; ▁w t ▁RI α
D-1432	-0.43967610597610474	8-fluo-cAMP binding ; wild type ; phosphomimic Ser77 ; Ser83 mutant ; RIα proteins ; double mutant ; wt RIα
P-1432	-0.1450 -0.2470 -0.2164 -0.0373 -0.0768 -0.0551 -0.7036 -0.0053 -0.1505 -0.1751 -0.0222 -0.0334 -0.0259 -0.0142 -0.0162 -0.1188 -0.3137 -0.7835 -0.1947 -0.0631 -0.6727 -2.5695 -2.5877 -0.1493 -0.0784 -1.7174 -0.0739 -0.2658 -0.0647 -0.1574 -0.9371 -0.1271 -0.0608 -0.1183 -1.1410 -0.2270 -2.8818 -0.1566 -0.1315 -0.0714
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate analysis ; preoperative ; albumin ; mortality ; lvad ; implantation ; hazard ratio ; confidence interval
H-535	-0.3403520882129669	▁pre operativ e ▁album in ▁; ▁mortal ity ▁; ▁l VAD ▁implant ation
D-535	-0.3403520882129669	preoperative albumin ; mortality ; lVAD implantation
P-535	-1.3154 -0.0313 -0.0194 -0.2181 -0.2447 -0.2044 -0.2840 -0.7674 -0.3058 -0.1479 -0.0188 -0.2357 -0.2527 -0.9530 -0.1066
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients ; systolic heart failure ; qrs duration ; crt ; death ; hospitalization ; heart failure ; mortality
H-854	-0.6153447031974792	▁sy sto lic ▁heart ▁failure ▁; ▁QR s ▁; ▁c RT ▁; ▁hospital ization ▁; ▁heart ▁failure
D-854	-0.6153447031974792	systolic heart failure ; QRs ; cRT ; hospitalization ; heart failure
P-854	-0.0645 -0.0552 -0.0555 -0.5766 -0.0929 -0.0970 -0.0286 -1.0393 -0.4391 -0.4819 -2.1802 -0.1897 -3.9421 -0.3886 -0.5319 -0.3201 -0.2190 -0.8712 -0.1180
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox regression models ; propensity score ; oral ; glucocorticoid ; hf ; hospitalisations ; loop diuretics
H-605	-0.19828251004219055	▁co x ▁re gression ▁models ▁; ▁pro pens ity ▁score ▁de cile ▁; ▁oral ▁gluco cor tico id ▁dos age ▁; ▁ HF ▁hospital isation s ▁; ▁loop ▁di ure tics
D-605	-0.19828251004219055	cox regression models ; propensity score decile ; oral glucocorticoid dosage ; HF hospitalisations ; loop diuretics
P-605	-0.0283 -0.0750 -0.0099 -0.0090 -0.4363 -0.1459 -0.0033 -0.0104 -0.5346 -0.0421 -0.2545 -0.0008 -0.0375 -0.0539 -0.0110 -0.3065 -0.2548 -0.1487 -0.7757 -0.0138 -0.1560 -1.3120 -0.0215 -0.1590 -0.0560 -0.0451 -0.1630 -0.0030 -0.0961 -0.8787 -0.2022 -0.2267 -0.0719
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional electrical stimulation ; fes ; exercise capacity ; quality of life ; endothelial function ; chronic heart failure ; systolic function
H-1327	-0.19891676306724548	▁Fun ction al ▁electric al ▁stimul ation ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁stress ▁; ▁en dot heli al ▁function ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁function
D-1327	-0.19891676306724548	Functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; systolic function
P-1327	-0.2272 -0.0052 -0.0084 -0.1832 -0.0064 -0.0586 -0.1873 -0.3522 -0.7816 -0.4509 -0.2268 -0.8836 -0.2225 -0.1243 -0.1151 -0.3374 -0.1816 -0.0297 -0.1426 -0.0261 -0.0026 -0.0538 -0.1092 -0.4589 -0.4242 -0.0780 -0.2525 -0.1088 -0.0466 -0.0590 -0.2079 -0.1425 -0.0696
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis ; patients ; hf ; hospitalization ; all-cause hospitalization ; mortality ; hf ; hospitalization ; death
H-910	-0.5863609313964844	▁dia lys is ▁patients ▁; ▁ HF ▁hospital ization ▁; ▁hospital ization ▁; ▁mortal ity ▁; ▁ HF
D-910	-0.5863609313964844	dialysis patients ; HF hospitalization ; hospitalization ; mortality ; HF
P-910	-0.8498 -0.0561 -0.1497 -0.9084 -0.3489 -1.1469 -0.0823 -0.7886 -0.4031 -0.5444 -1.5430 -0.6405 -0.7730 -0.0873 -0.8890 -0.4465 -0.3273 -0.2126 -1.4189 -0.1111
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse events ; reoperation ; bleeding ; driveline ; infection ; gastrointestinal bleeding ; stroke ; rankin score
H-2003	-0.23844029009342194	▁re opera tion ▁; ▁ble ed ing ▁; ▁drive line ▁infection ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁de bilitat ing ▁stroke
D-2003	-0.23844029009342194	reoperation ; bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
P-2003	-0.3267 -0.2828 -0.2355 -1.0447 -0.0280 -0.4299 -0.1743 -0.2171 -0.0706 -0.0257 -0.0998 -0.1810 -0.0303 -0.1271 -0.3966 -0.0687 -0.0556 -0.6788 -0.1609 -0.1824 -0.0085 -0.0050 -0.0267 -0.1655 -1.0810 -0.0963
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta blockers ; all-cause mortality ; readmissions ; heart failure with reduced ejection fraction ; hfref ; heart rate
H-1936	-0.2717446982860565	▁Beta ▁block ers ▁; ▁mortal ity ▁; ▁read missions ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁heart ▁rate ▁; HR
D-1936	-0.2717446982860565	Beta blockers ; mortality ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
P-1936	-0.4238 -0.3498 -0.0558 -0.2493 -1.2127 -0.5942 -0.0644 -0.0526 -0.0442 -0.8162 -0.1232 -0.0279 -0.1339 -0.4031 -0.0433 -0.0094 -0.1461 -0.0026 -0.1235 -0.1513 -0.0364 -0.2662 -0.0814 -1.3913 -0.2085 -0.5886 -0.0304 -0.1768 -0.0736
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous hf ; electromechanical delay ; emd ; myocyte depolarization ; myofiber shortening
H-1149	-0.21222206950187683	▁dys syn chron ous ▁ HF ▁; ▁electro me chan ical ▁de lay ▁; EM d ▁; ▁my o cy te ▁de po lar ization ▁; ▁my o fi ber
D-1149	-0.21222206950187683	dyssynchronous HF ; electromechanical delay ;EMd ; myocyte depolarization ; myofiber
P-1149	-0.0221 -0.0106 -0.0032 -0.1936 -0.3193 -0.1058 -0.0668 -0.0070 -0.0450 -0.0178 -0.1141 -0.0295 -0.0656 -0.2262 -1.1567 -0.3378 -0.1416 -1.0838 -0.0535 -0.1071 -0.1108 -0.0137 -0.0414 -0.0532 -0.1485 -0.2943 -0.3007 -0.0582 -0.0334 -0.1045 -1.3798 -0.1457
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs morphology ; outcomes ; cardiac resynchronization therapy ; resynchronization-defibrillation for ambulatory heart failure trial ; raft
H-879	-0.28250816464424133	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁re syn chron ization - Def i bril lation ▁; ▁Amb ulator y ▁Heart ▁Fail ure ▁tri al ▁; RAF t
D-879	-0.28250816464424133	QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure trial ;RAFt
P-879	-0.1861 -0.6240 -0.1844 -0.0089 -0.2648 -0.0623 -1.4069 -0.0156 -0.0679 -0.0163 -0.2269 -1.0823 -0.0187 -0.1996 -0.1779 -0.0244 -0.0323 -0.2657 -0.1818 -0.3338 -0.1489 -0.1593 -0.0390 -0.4154 -0.7478 -0.0067 -0.0176 -0.3026 -0.1359 -0.8707 -0.3867 -0.0203 -0.7690 -0.0152 -0.8389 -0.1041 -0.0939
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker ; clinical ; therapeutic
H-1478	-0.33700448274612427	▁bio mark er ▁studies ▁; ▁bio mark er - guide d ▁clinic al ▁trial ▁; ▁multi mark er - based ▁strategy
D-1478	-0.33700448274612427	biomarker studies ; biomarker-guided clinical trial ; multimarker-based strategy
P-1478	-0.6315 -0.1815 -0.0630 -0.3245 -0.2692 -0.0280 -0.1478 -0.0561 -0.0784 -0.0017 -0.0130 -0.1384 -0.0281 -0.2117 -1.2046 -2.2770 -0.4982 -0.0599 -0.1049 -0.0195 -1.1525 -0.1428 -0.1189
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf ; incidence ; liver ; nodularity
H-231	-0.4722113013267517	▁ab normal ▁ liver ▁texture ▁; ▁no du lar ity
D-231	-0.4722113013267517	abnormal liver texture ; nodularity
P-231	-0.8014 -0.0186 -0.2372 -0.6616 -0.8373 -1.5751 -0.0245 -0.0041 -0.1251 -1.0333 -0.2312 -0.1172
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant ; patients ; pd ; hf ; clinical
H-896	-0.4083690941333771	▁transplant ▁in elig ible ▁patients ▁; ▁PD ▁; ▁ HF ▁volume ▁management
D-896	-0.4083690941333771	transplant ineligible patients ; PD ; HF volume management
P-896	-0.4946 -0.0998 -0.0008 -0.1579 -0.2559 -1.0063 -0.4914 -0.3475 -0.6941 -0.0728 -0.0373 -0.0857 -1.8974 -0.0757
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty ; biological phenotype ; physical ; activity
H-1004	-0.5056528449058533	▁fra il ty ▁; ▁bi ological ▁ph eno type ▁; ▁we ak ▁grip ▁strength ▁; ▁physical ▁exhaust ion
D-1004	-0.5056528449058533	frailty ; biological phenotype ; weak grip strength ; physical exhaustion
P-1004	-0.5647 -0.1378 -0.0979 -0.2940 -2.4067 -0.1882 -0.5181 -0.1440 -0.0016 -0.2381 -0.0045 -0.0056 -0.0581 -0.6068 -0.1225 -0.2497 -0.1103 -0.0317 -4.2476 -0.0854
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d ; patients ; ic ; crt-d ; ies
H-109	-0.8235296010971069	▁c RT - d ▁; ▁IE ▁; ▁IC ▁; ▁c RT - d ▁; ▁IE s
D-109	-0.8235296010971069	cRT-d ; IE ; IC ; cRT-d ; IEs
P-109	-1.1656 -1.1665 -0.0528 -0.7873 -0.1119 -2.9921 -0.1380 -0.7471 -0.2320 -0.9874 -1.7374 -0.0630 -0.7139 -0.3530 -2.4254 -0.6669 -0.3799 -0.1033
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds ; discharge ; patients ; heart failure ; outcomes ; driven ; readmissions
H-467	-0.536209762096405	▁ volu me ▁ED s ▁; ▁dis charge ▁patients ▁; ▁heart ▁failure ▁home ▁; ▁low - volu me ▁ED ▁cases ▁; ▁read missions ▁; ▁repeat ▁ED ▁visit s
D-467	-0.536209762096405	volume EDs ; discharge patients ; heart failure home ; low-volume ED cases ; readmissions ; repeat ED visits
P-467	-4.4608 -1.8720 -0.1227 -0.4467 -0.1723 -0.1659 -0.6576 -0.0143 -0.3589 -1.4510 -0.2063 -0.0431 -0.8456 -0.3984 -0.7174 -0.0098 -0.0099 -0.0274 -0.2051 -1.0350 -0.4020 -0.9281 -0.0510 -0.1090 -0.0844 -0.2566 -0.7402 -0.0541 -0.1491 -0.0919
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute right heart failure ; therapy ; refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; ecmo ; cpr ; icu
H-1295	-0.2726403474807739	▁a cute ▁right ▁heart ▁failure ▁; ▁ therapy ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁heart ▁team ▁; ▁extra ▁corpore al ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁c PR ▁; ICU
D-1295	-0.2726403474807739	acute right heart failure ; therapy refractory cardiogenic shock ; heart team ; extra corporeal membrane oxygenation ; ecmo ; cPR ;ICU
P-1295	-0.6901 -0.0025 -0.9681 -0.3022 -0.0381 -0.2740 -0.8263 -0.0060 -0.0129 -0.0116 -0.0970 -0.0497 -0.0398 -0.2957 -0.0214 -0.1876 -1.3203 -0.3269 -0.1143 -0.9194 -0.0206 -0.0088 -0.0228 -0.0554 -0.1631 -0.0899 -0.1597 -0.4265 -0.8433 -0.1839 -0.1312 -0.1883 -0.8332 -0.0504 -0.0840 -0.0502
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report ; patient ; right atrial myxoma ; massive embolism ; pulmonary arteries ; surgically ; right atrial ; pulmonary embolectomy
H-595	-0.2761891782283783	▁right ▁at rial ▁my xo ma ▁; ▁massive ▁e mbol ism ▁; ▁pulmonar y ▁arteri es ▁; ▁right ▁at rial ▁mass ▁remo val ▁; ▁pulmonar y ▁e mbol ecto my
D-595	-0.2761891782283783	right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
P-595	-1.7846 -0.3109 -0.0356 -1.1076 -0.0216 -0.1582 -0.1029 -0.4612 -0.0433 -0.0074 -0.6162 -0.3552 -0.0228 -0.0519 -0.0102 -0.0678 -0.5467 -0.2796 -0.3459 -0.0829 -0.0807 -0.0291 -0.0336 -0.0965 -0.0019 -0.0378 -0.0901 -0.0200 -0.0925 -1.6549 -0.2145 -0.0738
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency room ; undiagnosed ; heart disease ; symptoms ; hf ; surgical palliation
H-201	-0.8630145788192749	▁un diagnos ed ▁heart ▁disease ▁; ▁symptoms ▁; ▁ HF
D-201	-0.8630145788192749	undiagnosed heart disease ; symptoms ; HF
P-201	-3.7767 -0.0092 -0.0143 -0.3532 -0.1656 -0.1021 -1.9487 -0.3424 -1.1617 -0.0319 -2.3579 -0.0922
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart magnetic resonance imaging ; chelation ; patient ; compliance ; heart failure ; arrhythmias
H-745	-0.3767739236354828	▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁patient ▁compliance ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-745	-0.3767739236354828	heart magnetic resonance imaging ; chelation choices ; patient compliance ; heart failure ; arrhythmias
P-745	-1.7970 -0.0393 -0.3660 -0.1078 -0.4319 -0.2957 -0.1014 -0.4061 -0.0091 -0.0154 -0.1950 -0.0836 -0.2005 -0.8994 -0.2658 -0.1323 -2.6195 -0.0904 -0.2820 -0.0079 -0.0516 -0.3821 -0.1898 -0.0732
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection fraction ; ef ; patients ; nyha class iiib ; symptoms ; right ventricular dysfunction
H-897	-0.41734716296195984	▁e je ction ▁ fraction ▁; EF ▁; ▁pre - PD ▁; ▁NY HA ▁class ▁III b ▁; ▁right ▁vent ri cular ▁dys function
D-897	-0.41734716296195984	ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; right ventricular dysfunction
P-897	-0.0761 -0.0742 -0.0278 -0.2479 -0.0029 -0.1252 -0.1651 -0.0917 -0.5077 -0.0089 -0.0227 -0.1577 -2.5712 -0.4277 -0.7574 -0.0769 -0.2606 -1.0489 -2.3364 -0.0956 -0.9673 -0.3439 -0.0519 -0.1904 -0.1155 -0.0994
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs ; early-outgrowth colony-forming units ; eo-cfus ; cells
H-124	-0.3373775780200958	▁c PC s ▁; ▁early - out g row th ▁colon y - form ing ▁unit s ▁; EO - c FU s ▁; ▁circula ting ▁CD 34 ▁; ▁v EG FR 2 ▁; ▁CD 133
D-124	-0.3373775780200958	cPCs ; early-outgrowth colony-forming units ;EO-cFUs ; circulating CD34 ; vEGFR2 ; CD133
P-124	-0.1905 -0.7943 -0.1007 -0.2106 -1.3462 -0.0437 -0.0161 -0.9822 -0.0276 -0.0241 -0.1926 -0.0393 -0.0267 -0.0107 -0.0203 -0.0086 -0.1416 -0.2088 -0.6140 -0.0277 -0.9306 -0.1434 -0.0819 -0.1154 -0.0004 -0.0436 -0.8099 -0.2229 -1.1705 -0.0595 -0.4697 -0.1463 -0.2491 -0.6752 -0.5076 -0.0646 -1.9920 -0.1115
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene expression ; bax ; pacing ; bcl-2 ; mrna ; expression ; heart failure ; bcl-2 ; bax
H-168	-0.4567793309688568	▁Gene ▁expression ▁; ▁Bax ▁; ▁b cl -2 ▁m RNA ▁expression ▁; ▁heart ▁failure ▁; ▁b cl - 2/ Ba x
D-168	-0.4567793309688568	Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
P-168	-1.3784 -0.1111 -0.3749 -0.0051 -0.0934 -0.5034 -0.1209 -0.1226 -0.0033 -0.0379 -0.5695 -0.1485 -2.5274 -0.1051 -0.2726 -1.2437 -0.2206 -0.0384 -0.0219 -2.2575 -0.0387 -0.2311 -0.0799
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl ; hno ; inotropic ; lusitropic ; vasodilator ; in vivo ; camp
H-413	-0.3132591247558594	▁ni tro x yl ▁; ▁h no ▁; ▁donor ▁; ▁Angeli ' s ▁salt ▁; ▁in o tropi c ▁; ▁ lusi tropi c ▁; ▁vaso dila tor ▁effects ▁; ▁c AMP
D-413	-0.3132591247558594	nitroxyl ; hno ; donor ; Angeli's salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
P-413	-0.0023 -0.0231 -0.2810 -0.0800 -0.1286 -1.4377 -0.5588 -0.1286 -1.3651 -0.0450 -0.0018 -3.2574 -0.1023 -0.0054 -0.1182 -0.0850 -0.5334 -0.0032 -0.0710 -0.0842 -0.2940 -0.0031 -0.0068 -0.1079 -0.1183 -0.0031 -0.0016 -0.0206 -0.9546 -0.1998 -0.0134 -0.0198 -0.4959 -0.0997
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy ; anticoagulation ; rate control ; cardiovascular ; complications ; stroke ; cardiovascular death ; acute heart failure ; patients ; atrial fibrillation
H-1643	-0.183623805642128	▁antico ag ulation ▁; ▁rate ▁control ▁; ▁cardiovascular ▁complica tions ▁; stro ke ▁; ▁cardiovascular ▁death ▁; ▁a cute ▁heart ▁failure ▁; ▁at rial ▁fi bril lation ▁; AF
D-1643	-0.183623805642128	anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
P-1643	-0.7826 -0.0692 -0.0697 -0.1130 -0.0327 -0.1612 -0.2301 -0.1884 -0.0243 -0.1759 -0.1436 -0.3436 -0.0377 -0.3221 -0.0193 -0.4241 -0.0696 -0.0089 -0.0039 -0.1693 -0.0551 -0.1852 -0.9189 -0.0380 -0.2285 -0.0157 -0.1218 -0.3915 -0.0847 -0.1863 -0.0776
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence ; clinical ; continuous-flow lvads ; heartmate ii ; hm ii ; heartware ; btt ; dt ; patients
H-309	-0.45752057433128357	▁continuo us - flow ▁l VAD s ▁; ▁he art Mate ▁II ▁; HM ▁II ▁; ▁Heart War e ▁; ▁b t ▁; ▁ DT
D-309	-0.45752057433128357	continuous-flow lVADs ; heartMate II ;HM II ; HeartWare ; bt ; DT
P-309	-2.0229 -0.0354 -0.0601 -0.0259 -1.6675 -0.0418 -0.1170 -0.1761 -0.0748 -0.4878 -0.0729 -0.5431 -0.0473 -0.2024 -1.3910 -0.0554 -1.0563 -0.1340 -0.0321 -0.2043 -0.9652 -0.8942 -0.1483 -0.7290 -0.0980 -0.9330 -0.1375
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients ; baseline ; ef ; ef ; core
H-753	-0.6490598917007446	▁EF ▁; ▁EF ▁; ▁blind ed ▁core ▁laborator y
D-753	-0.6490598917007446	EF ; EF ; blinded core laboratory
P-753	-2.5045 -0.6918 -1.4215 -1.4577 -0.5168 -0.1714 -0.0415 -0.0960 -0.0351 -0.0927 -0.1107
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal muscle ; lean mass ; z-score
H-1499	-0.5928109884262085	▁s kelet al ▁muscle ▁mass ▁; ▁appen di cular ▁lean ▁mass ▁index
D-1499	-0.5928109884262085	skeletal muscle mass ; appendicular lean mass index
P-1499	-2.7333 -0.0244 -0.0354 -0.4324 -0.3337 -0.7812 -1.2724 -0.0472 -0.1458 -1.1083 -0.1431 -0.0333 -1.0807 -0.1282
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash ; mortality ; hf ; nonsignificant
H-693	-0.43335434794425964	▁DAS h ▁die t ▁score s ▁; ▁mortal ity ▁; ▁ HF ▁; ▁Mediterrane an ▁die t ▁score s
D-693	-0.43335434794425964	DASh diet scores ; mortality ; HF ; Mediterranean diet scores
P-693	-0.0579 -0.1603 -1.3358 -0.0503 -0.0181 -0.0487 -0.0985 -1.7958 -0.5204 -0.0709 -2.2144 -0.0815 -0.3043 -0.7062 -0.0817 -1.1191 -0.1663 -0.0134 -0.0557 -0.1211 -0.0799
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality of life ; all-cause mortality ; mortality
H-561	-0.6113016605377197	▁Quality ▁of ▁life ▁; ▁all - ca use ▁mortal ity
D-561	-0.6113016605377197	Quality of life ; all-cause mortality
P-561	-1.1246 -1.2522 -0.8470 -0.4924 -0.7440 -0.0214 -0.0188 -0.0805 -0.0873 -0.8346 -1.7532 -0.0795
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef ; bnp ; bnp ; inhospital ; mortality
H-197	-0.7369697093963623	▁b NP ▁; ▁in hospital ▁mortal ity
D-197	-0.7369697093963623	bNP ; inhospital mortality
P-197	-3.4132 -1.5400 -0.4112 -0.4347 -0.0283 -0.0697 -0.4110 -0.2228 -0.1019
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular diseases ; heart failure ; hf ; incidence ; hf
H-285	-0.2994284927845001	▁cardiovascular ▁disease s ▁; ▁heart ▁failure ▁; HF
D-285	-0.2994284927845001	cardiovascular diseases ; heart failure ;HF
P-285	-0.0608 -0.5833 -0.0602 -0.1149 -0.1209 -0.0967 -0.1277 -0.0977 -1.6490 -0.0831
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart failure ; left ventricular systolic dysfunction ; post hoc analysis
H-402	-0.48874032497406006	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁sy sto lic ▁dys function ▁; ▁BB
D-402	-0.48874032497406006	heart failure ; left ventricular systolic dysfunction ; BB
P-402	-1.9635 -0.2064 -0.3143 -0.8833 -0.0766 -0.9318 -0.1419 -0.0264 -0.0913 -0.1707 -0.0757 -0.1926 -0.4940 -2.0119 -0.1494 -0.0901
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka ; polymorphism ; rs10927887 ; p.arg83gly ; heart failure ; estimated glomerular filtration rate ; renastur
H-1801	-0.4654618799686432	▁CL cn ka ▁poly morph ism ▁; ▁p . ▁ar g 83 g ly ▁; ▁heart ▁failure ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁re NAS tur
D-1801	-0.4654618799686432	CLcnka polymorphism ; p. arg83gly ; heart failure ; glomerular filtration rate ; reNAStur
P-1801	-0.3905 -1.8814 -0.6966 -0.1247 -0.0051 -0.4574 -0.0409 -2.5775 -0.0633 -1.2122 -0.0200 -0.3061 -1.5775 -0.1568 -0.1262 -0.3259 -0.0976 -0.1190 -0.0850 -0.1214 -0.0451 -0.0877 -0.0906 -0.6682 -0.1781 -1.0561 -0.0194 -0.2051 -1.1370 -0.0914
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 ; functional capacity ; outcomes ; ambulatory ; patients ; hf
H-706	-0.6880473494529724	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁ambula tory ▁patients ▁; ▁ HF
D-706	-0.6880473494529724	ST2 ; functional capacity ; ambulatory patients ; HF
P-706	-1.4295 -0.0862 -0.5195 -0.0430 -0.1680 -0.2173 -5.3419 -0.1728 -0.3615 -0.5971 -0.2659 -0.0480 -0.2666 -0.1153
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac vegf expression ; endothelial no synthase activation ; hearts
H-455	-0.4245014190673828	▁cardiac ▁VE GF ▁expression ▁; ▁Akt ▁; ▁en dot heli al ▁no ▁synth ase ▁activa tion ▁; ▁fail ing ▁heart s
D-455	-0.4245014190673828	cardiac VEGF expression ; Akt ; endothelial no synthase activation ; failing hearts
P-455	-1.7398 -0.9441 -0.0333 -0.0369 -0.0936 -0.0108 -0.1089 -0.0164 -0.3363 -0.0169 -0.0040 -1.1934 -0.0364 -0.8907 -0.0030 -0.2697 -0.4846 -2.5329 -0.0587 -0.4645 -0.1504 -0.2470 -0.0909
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene expression ; cardiomyocytes ; jq1 ; drug ; genes
H-1046	-0.35903874039649963	▁Gene ▁expression ▁profil ing ▁; ▁culture d ▁cardio my o cy tes ▁; ▁j q 1 ▁; ▁drug ▁ab roga ted ▁; ▁ phen yle ph rine - indu ced ▁gene s
D-1046	-0.35903874039649963	Gene expression profiling ; cultured cardiomyocytes ; jq1 ; drug abrogated ; phenylephrine-induced genes
P-1046	-3.3894 -0.2571 -0.1553 -0.0434 -0.2719 -0.2623 -0.0294 -0.2463 -0.9070 -0.2645 -0.0830 -0.0581 -0.1579 -1.1995 -0.7455 -0.8129 -0.2125 -0.2230 -0.1940 -0.0081 -0.1657 -0.3170 -0.2368 -0.1114 -0.5256 -0.3315 -0.0278 -0.1226 -0.0022 -0.0653 -0.4401 -0.0698 -0.1930 -0.0774
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced pasp ; right ventricular contractile reserve ; patients ; exercise-induced pasp
H-824	-0.6427888870239258	▁exercise - indu ced ▁PAS p ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pas p
D-824	-0.6427888870239258	exercise-induced PASp ; right ventricular contractile reserve ; pasp
P-824	-2.7978 -0.0402 -0.0271 -0.0299 -0.6118 -1.1148 -0.1187 -1.6655 -0.0198 -0.8639 -0.2835 -0.0148 -0.0596 -0.0062 -0.5629 -3.2328 -0.5189 -0.1812 -0.0637
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene expression profile ; gse9128 ; gene expression omnibus ; non-ischemic heart failure ; ischemic
H-1609	-0.3205038011074066	▁Gene ▁expression ▁profile ▁; ▁g se 91 28 ▁; ▁Gene ▁Express ion ▁Omni bus ▁; ▁non - ische mic ▁heart ▁failure ▁sample s ▁; ▁ ische mic
D-1609	-0.3205038011074066	Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure samples ; ischemic
P-1609	-0.5488 -0.2413 -0.1612 -0.9109 -0.5345 -0.3292 -0.0866 -0.0816 -0.2317 -0.4823 -0.0577 -0.0029 -0.0344 -0.3218 -0.2289 -0.4370 -0.0198 -0.0147 -0.0843 -0.8260 -0.0883 -0.5548 -0.0932 -0.3421 -0.0869 -0.0198 -0.1588 -2.2039 -0.1113
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac ; insulin-resistance ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose
H-1784	-0.1420372575521469	▁cardiac ▁insulin - re si stance ▁; ▁a ac ▁; ▁insulin - stimul ated ▁rates ▁; ▁gly col ysis ▁; ▁gluco se ▁oxid ation ▁; ▁plasma ▁membran e ▁trans location ▁; ▁gluco se ▁transporter
D-1784	-0.1420372575521469	cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
P-1784	-0.0452 -0.3641 -0.0434 -0.3314 -0.2321 -0.0098 -0.1359 -0.9927 -0.2890 -0.2546 -0.0563 -0.0787 -0.0058 -0.0957 -0.0795 -0.3325 -0.0097 -0.0356 -0.0738 -0.1761 -0.0407 -0.0965 -0.0111 -0.0728 -0.2728 -0.0104 -0.0082 -0.0374 -0.0139 -0.1261 -0.3695 -0.0215 -0.0360 -0.0254 -0.2177 -0.1115
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic ; invasively
H-920	-0.3273686468601227	▁post - DAS h ▁; ▁s rd ▁bra chi al ▁; ▁central ▁blood ▁pressure ▁; ▁radi al ▁arterial ▁ton ometr y ▁; ▁cardiovascular ▁function ▁; ▁e cho car dio graphic
D-920	-0.3273686468601227	post-DASh ; srd brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
P-920	-1.6989 -0.0175 -0.0043 -0.0870 -0.6225 -0.9423 -0.5014 -0.5917 -0.0334 -0.0094 -0.2786 -0.8395 -0.4413 -0.4412 -0.0925 -0.2635 -0.0129 -0.0377 -0.3792 -0.0384 -0.1777 -0.1434 -0.0171 -0.6301 -0.2116 -0.0259 -0.0244 -0.0151 -0.1146 -0.2768 -1.4058 -0.1003
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial ; exercise ; outcomes ; heart failure ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-1924	-0.39305129647254944	▁Psycho social ▁Factor s ▁; ▁Exerci se ▁Ad her ence ▁; ▁Heart ▁Fail ure ▁Patient s ▁; ▁Insight s ▁; ▁Heart ▁Fail ure ▁; ▁tri al ▁Investiga ting ▁Out com es ▁; ▁Exerci se ▁Training ▁; HF - ac TION
D-1924	-0.39305129647254944	Psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Insights ; Heart Failure ; trial Investigating Outcomes ; Exercise Training ;HF-acTION
P-1924	-0.8116 -0.0504 -0.5355 -0.0915 -0.1330 -0.1359 -0.0406 -0.4117 -0.3641 -0.2003 -0.1042 -2.3111 -0.1042 -0.8029 -0.1330 -0.0818 -0.3949 -0.0647 -0.0128 -1.1881 -0.5548 -0.1067 -0.5788 -0.3313 -3.1708 -0.0453 -0.0585 -0.0375 -0.2305 -0.0178 -0.0547 -0.3181 -0.2951 -0.0507 -0.2189 -0.3624 -0.2174 -0.0228 -0.6357 -0.9309 -0.2101 -0.0869
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients ; coronary angiography ; diagnosis ; systolic hf ; etiology ; ejection fraction
H-1186	-0.2048695981502533	▁deriva tion ▁co hor t ▁; ▁corona ry ▁ang i ography ▁; ▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology
D-1186	-0.2048695981502533	derivation cohort ; coronary angiography ; systolic HF ; unclear etiology
P-1186	-1.0731 -0.1624 -0.0245 -0.1599 -0.0630 -0.2961 -0.3364 -0.5527 -0.3570 -0.3477 -0.1666 -0.2603 -0.0204 -0.0143 -0.0158 -0.0924 -0.0298 -0.4538 -0.0249 -0.0037 -0.0027 -0.1182 -0.1501 -0.3053 -0.0908
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees ; ea
H-922	-0.32516297698020935	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁ratio ▁e es ▁; ▁e a
D-922	-0.32516297698020935	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ratio ees ; ea
P-922	-0.6270 -0.8843 -0.6448 -0.0890 -0.5351 -0.0950 -0.1544 -1.0758 -0.0489 -0.5739 -0.0431 -0.0280 -0.1878 -0.7305 -0.0959 -0.2742 -0.0247 -0.0868 -0.0137 -0.2984 -0.0607 -0.0568 -0.0120 -0.0145 -0.1064 -0.2465 -0.2749 -0.5153 -0.6825 -0.0427 -1.7150 -0.2078 -0.3267 -0.5166 -0.0912
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic ; rhythm
H-1653	-0.2526824176311493	▁ rhythm ▁control ▁ therapy ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁cat heter ▁ab lation ▁; ▁electro car dio graphic ▁device
D-1653	-0.2526824176311493	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device
P-1653	-0.2269 -0.2551 -0.3394 -0.4982 -0.0140 -0.2693 -1.3083 -0.2891 -0.3443 -0.5261 -0.0191 -0.2089 -0.0133 -0.0797 -0.0406 -0.2457 -0.0225 -0.1932 -0.1088 -0.0012 -0.0050 -0.0223 -0.1736 -0.0156 -0.0243 -0.0894 -0.1627 -0.3081 -1.6362 -0.1397
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells ; angiotensin ii ; angii ; hypoxia ; scn5a ; mrna splicing ; scn5a
H-1083	-0.299297958612442	▁Cell s ▁; ▁ang io ten sin ▁II ▁; Ang II ▁; ▁hypo xia ▁; ▁activa tors ▁; ▁ab normal ▁s cn 5 a ▁m RNA ▁s plic ing ▁; ▁over express ▁s cn 5 a ▁variant s
D-1083	-0.299297958612442	Cells ; angiotensin II ;AngII ; hypoxia ; activators ; abnormal scn5a mRNA splicing ; overexpress scn5a variants
P-1083	-1.5430 -0.1542 -0.4561 -0.1729 -0.3943 -0.0399 -0.9716 -0.6949 -0.1296 -0.1868 -0.3329 -0.0908 -0.0188 -0.0134 -0.1154 -0.0152 -0.0412 -0.2421 -0.3691 -0.0095 -1.0089 -0.3008 -0.1914 -0.5093 -0.0141 -0.0921 -0.1039 -0.1123 -0.0240 -0.1649 -0.2243 -0.0025 -1.2245 -0.3779 -0.2865 -0.5390 -0.1093 -0.2282 -0.3600 -0.1064
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence ; hf with reduced ejection fraction ; hfref ; hf with preserved ejection fraction ; hfpef
H-1488	-0.3755776286125183	▁ HF ▁with ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁treatment ▁; ▁ HF ▁met ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1488	-0.3755776286125183	HF with reduced ejection fraction ;HFrEF ; treatment ; HF met preserved ejection fraction ;HFpEF
P-1488	-1.6929 -0.0550 -2.1476 -0.3090 -0.0099 -0.0213 -0.1160 -0.0213 -0.3510 -0.0053 -0.2447 -0.4356 -0.0743 -0.1186 -0.0699 -1.6850 -0.2124 -1.1911 -0.0840 -1.7831 -0.1814 -0.0407 -0.1641 -0.0452 -0.1114 -0.0391 -0.3791 -0.0062 -0.2370 -0.2704 -0.1601 -0.0791 -0.3601 -0.0679
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal life support ; therapy ; patients ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion ; therapy
H-1298	-0.36050650477409363	▁extra corp o real ▁life ▁support ▁; ▁ brid ging ▁ therapy ▁; ▁ ische mic ▁right ▁heart ▁failure ▁; ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁reper fusion ▁ therapy
D-1298	-0.36050650477409363	extracorporeal life support ; bridging therapy ; ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
P-1298	-0.2943 -0.0052 -0.1096 -0.0052 -0.3827 -0.8525 -0.2846 -0.6057 -0.1371 -0.0109 -0.4757 -0.0069 -0.3267 -4.3535 -0.0648 -0.1247 -1.1162 -0.6098 -0.0606 -0.2632 -0.0049 -0.0047 -0.1252 -0.0396 -0.0935 -0.7734 -0.0351 -0.4207 -0.0017 -0.0060 -0.3745 -0.0079 -0.1817 -0.0983
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart failure ; reduced left ventricular ejection fraction ; fes ; exercise capacity ; quality of life ; endothelial function ; hfpef
H-1332	-0.28383854031562805	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁status ▁; ▁en dot heli al ▁function ▁; ▁ HF p EF
D-1332	-0.28383854031562805	heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
P-1332	-0.3930 -0.0566 -0.0471 -1.3984 -0.0662 -0.6482 -0.3189 -0.0816 -0.1079 -0.0398 -0.4608 -0.0037 -0.1494 -0.8887 -0.6229 -0.1045 -0.7445 -0.1305 -0.0983 -0.7115 -0.0673 -0.1317 -0.0519 -0.1314 -0.0311 -0.0048 -0.1108 -0.2831 -0.9594 -0.2594 -0.0487 -0.3408 -0.0770 -0.0806
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures ; hospitalizations ; noncardiovascular ; diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular ; drugs ; rate-control
H-1240	-0.14343467354774475	▁ex pendi tures ▁; ▁non car dio vas cular ▁diagnose s ▁; ▁implant able ▁cardiac ▁ar rhythm ia ▁devices ▁; ▁non car dio vas cular ▁drugs
D-1240	-0.14343467354774475	expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
P-1240	-1.1895 -0.0393 -0.0611 -0.2527 -0.0994 -0.0139 -0.0616 -0.0793 -0.1690 -0.0707 -0.0255 -0.1541 -0.0413 -0.0287 -0.0041 -0.0139 -0.0196 -0.3427 -0.1183 -0.2282 -0.0257 -0.0163 -0.0638 -0.0754 -0.2114 -0.0485 -0.4756 -0.0865
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.5349124073982239	▁in tub ation ▁rates
D-220	-0.5349124073982239	intubation rates
P-220	-0.0706 -0.0187 -0.2854 -0.7915 -1.9623 -0.0809
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene ; heart failure
H-1541	-0.3728160262107849	▁ra lo xi fen e ▁; ▁mechanism ▁of ▁action ▁; ▁heart ▁failure
D-1541	-0.3728160262107849	raloxifene ; mechanism of action ; heart failure
P-1541	-0.5581 -0.0028 -0.0613 -0.0587 -0.2934 -0.1717 -0.2154 -0.5606 -0.0068 -0.2411 -2.1992 -0.2289 -0.5360 -0.0855
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts ; heart mass ; transgenic
H-1814	-0.5278940200805664	▁heart s ▁; ▁t g t et Men a ▁mi ce ▁; ▁wild - type ▁litt er mates ▁; ▁heart ▁mass ▁; ▁trans ge nic ▁mi ce
D-1814	-0.5278940200805664	hearts ; tgtetMena mice ; wild-type littermates ; heart mass ; transgenic mice
P-1814	-0.6932 -0.0845 -0.2982 -4.2582 -0.0829 -0.0682 -0.1147 -0.4349 -0.0338 -1.4410 -0.3593 -0.2488 -2.7142 -0.0345 -0.0085 -0.0097 -0.0304 -0.0786 -0.2106 -1.9268 -0.2198 -0.1193 -0.0158 -0.0701 -0.4186 -0.8903 -0.2728 -0.1187 -0.0526
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients ; hfref ; exercise ; respiratory gas analysis ; baseline
H-1938	-0.8154067993164062	▁h Fr EF ▁; ▁respirator y ▁gas ▁analysis
D-1938	-0.8154067993164062	hFrEF ; respiratory gas analysis
P-1938	-3.2711 -0.6306 -1.2346 -0.2608 -1.8479 -0.0745 -0.0309 -0.4986 -0.1949 -0.1102
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients ; drugs ; heart failure ; biomedical ; nonprescribing ; patients
H-1126	-0.39029836654663086	▁guide line - re com mend ed ▁drugs ▁; ▁heart ▁failure ▁; ▁chart ▁review ▁; ▁bio medic al ▁reasons ▁; ▁non pre scribi ng
D-1126	-0.39029836654663086	guideline-recommended drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
P-1126	-5.2617 -0.0101 -0.0575 -0.0142 -0.0206 -0.0050 -0.0602 -0.0408 -1.1846 -0.3626 -0.0308 -0.4256 -0.0258 -0.0090 -0.3833 -0.0024 -0.0119 -0.0021 -0.1251 -0.8954 -0.4137 -0.0290 -0.0271 -0.0380 -0.5707 -0.1403
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean mass ; adverse outcome ; adipose tissue ; cardioprotective ; hf
H-1169	-0.3655392825603485	▁fat ▁; ▁lean ▁mass ▁; ▁fat ▁loss ▁; ▁enhance d ▁cata bol ism ▁; ▁adi pose ▁tissu e ▁; ▁cardio protec tive ▁; ▁ HF
D-1169	-0.3655392825603485	fat ; lean mass ; fat loss ; enhanced catabolism ; adipose tissue ; cardioprotective ; HF
P-1169	-4.1200 -0.1274 -0.4163 -0.0652 -0.1475 -1.0890 -0.8896 -0.1592 -0.3398 -0.0097 -0.0142 -0.0937 -0.1867 -0.0421 -0.0018 -0.0120 -0.0065 -0.0662 -0.1065 -0.0207 -0.0411 -0.2659 -0.5769 -0.8822 -0.0709 -0.0455 -0.0727
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
H-97	-0.23460036516189575	▁heart s ▁; ▁fish ▁la cking ▁nu cle olin ▁; ▁cha mber ▁pattern ing ▁; ▁functional ▁deficit s ▁; ▁cardiac ▁loop ing ▁; ▁my o cy te ▁differenti ation
D-97	-0.23460036516189575	hearts ; fish lacking nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
P-97	-0.5013 -0.0599 -0.5002 -0.7358 -0.3936 -0.0219 -1.2916 -0.0034 -0.0145 -0.1539 -1.2987 -0.0018 -0.0429 -0.1191 -0.1170 -0.1744 -0.1437 -0.2193 -0.1034 -0.0685 -0.0012 -0.0231 -0.1783 -0.3035 -0.0293 -0.0363 -0.0388 -0.4321 -0.0795 -0.1101 -0.0758
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients ; chronic hf ; prevalence ; exercise ; hf ; hospitalization ; mortality ; exercise ; training
H-1641	-0.39090996980667114	▁black ▁race ▁; ▁patients ▁; ▁chronic ▁ HF ▁; ▁modifi able ▁risk ▁factors ▁; ▁lower ▁exercise ▁performance ▁; ▁ HF ▁hospital ization ▁; ▁mortal ity ▁; ▁exercise ▁training
D-1641	-0.39090996980667114	black race ; patients ; chronic HF ; modifiable risk factors ; lower exercise performance ; HF hospitalization ; mortality ; exercise training
P-1641	-0.2076 -0.0256 -0.1122 -1.7795 -1.0819 -0.0450 -0.2079 -0.0382 -0.2036 -1.0508 -0.0474 -0.2102 -0.1801 -0.1035 -2.1131 -0.7151 -0.0163 -0.0945 -0.3650 -0.1048 -0.3988 -0.3163 -0.3626 -0.1762 -0.3266 -0.2589 -0.7516 -0.2252 -0.1026 -0.1063
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse event ; acute myocardial infarction ; congestive heart failure ; adverse events
H-4	-0.26853838562965393	▁advers e ▁event ▁rates ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁in - hospital ▁advers e ▁events
D-4	-0.26853838562965393	adverse event rates ; acute myocardial infarction ; congestive heart failure ; in-hospital adverse events
P-4	-1.7777 -0.0286 -0.2900 -0.1545 -0.1548 -0.0314 -0.0145 -1.2096 -0.2092 -0.2915 -0.1350 -0.0191 -0.1645 -0.1184 -0.1030 -0.0066 -0.0664 -0.5416 -0.3243 -0.0637 -1.0083 -0.0589 -0.0407 -0.0026 -0.3219 -0.0424 -0.2902 -0.2305 -0.0877
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages ; cardiomyocytes ; doxorubicin ; in vitro ; resistin ; mrna ; protein expression
H-935	-0.31516313552856445	▁Mac rop hage s ▁; ▁cardio my o cy tes ▁; ▁Hum - re t n ▁mi ce ▁; ▁do xor ubi cin ▁in ▁vi tro ▁; ▁h Re t n ▁; human ▁resist in ▁; ▁m RNA ▁; ▁protein ▁expression
D-935	-0.31516313552856445	Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin in vitro ; hRetn ;human resistin ; mRNA ; protein expression
P-935	-0.5373 -0.0405 -0.0168 -0.0528 -0.0769 -0.0331 -0.3225 -0.1361 -0.0457 -0.0451 -0.1920 -0.5004 -0.0304 -1.9183 -0.1701 -0.0483 -1.3059 -0.4640 -0.9336 -0.4558 -0.0185 -0.0113 -0.2095 -1.5518 -0.0108 -0.0067 -0.1650 -0.0201 -1.7708 -0.0150 -0.0186 -0.1857 -0.3199 -0.0909 -0.0436 -0.5335 -0.0018 -0.0102 -0.8694 -0.0402 -0.1020 -0.1444 -0.0864
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads ; heartmate ii ; thoratec corp ; pleasanton ; calif ; hvad ; heartware ; framingham
H-546	-0.30844905972480774	▁l VAD s ▁; ▁CF ▁devices ▁; ▁Heart Mate ▁II ▁devices ▁; ▁Thor a tec ▁Corp ▁; ▁Ple asan ton ▁; ▁Cali f ▁; ▁h VAD ▁devices ▁; ▁Heart War e ▁in t l ▁; ▁in t l ▁; ▁Fram ing ham ▁; ▁Mass
D-546	-0.30844905972480774	lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD devices ; HeartWare intl ; intl ; Framingham ; Mass
P-546	-0.2540 -0.0169 -0.0923 -0.0839 -0.0592 -0.2693 -0.0284 -1.7537 -0.0240 -0.2787 -0.0907 -0.0479 -0.6783 -0.0373 -0.0017 -0.0247 -0.1347 -0.1730 -0.0016 -0.0029 -1.1970 -0.2865 -0.0036 -0.0136 -0.8854 -0.0949 -0.6804 -0.0458 -1.2955 -0.0676 -0.0121 -0.1610 -0.0188 -0.0082 -0.1311 -2.1793 -0.9210 -0.0142 -0.1005 -0.9198 -0.0136 -0.0039 -0.7120 -0.0486 -0.2565 -0.0645
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma nps ; adiponectin ; baseline ; ffm ; correlate ; nps ; adiponectin ; follow up
H-19	-0.44733765721321106	▁FM ▁; ▁plasma ▁ NP s ▁; ▁total ▁adi pon ect in ▁; ▁FM ▁; ▁f FM ▁; ▁ NP s ▁; ▁adi pon ect in
D-19	-0.44733765721321106	FM ; plasma NPs ; total adiponectin ; FM ; fFM ; NPs ; adiponectin
P-19	-0.5287 -0.1380 -0.3633 -0.6673 -0.0133 -0.0382 -0.1595 -1.8500 -0.0761 -0.0076 -0.3745 -0.8459 -0.5256 -1.1801 -0.1659 -0.5044 -0.9704 -0.2322 -2.2513 -0.1961 -0.0392 -0.1798 -0.0689 -0.0090 -0.3894 -0.4020 -0.2515 -0.0973
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic tone ; parasympathetic tone ; heart rate ; intravenous bolus ; metoprolol ; atropine
H-1378	-0.27720504999160767	▁sympa the tic ▁tone ▁; ▁para sy mpa the tic ▁tone ▁; ▁heart ▁rate ▁response ▁; ▁met o pro lol ▁; ▁a tropi ne
D-1378	-0.27720504999160767	sympathetic tone ; parasympathetic tone ; heart rate response ; metoprolol ; atropine
P-1378	-0.1674 -0.6478 -0.4650 -0.0521 -0.0499 -0.0979 -0.2103 -0.1567 -1.1830 -1.0948 -0.0803 -0.1103 -0.4377 -0.2285 -0.2919 -0.2219 -0.5944 -0.1462 -0.0205 -0.0870 -0.1388 -0.0094 -0.0040 -0.5349 -0.1089 -0.0679
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef ; pathophysiologically ; hf with reduced ef ; hfref ; hfref ; therapy
H-1533	-0.48250681161880493	▁EH ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁reduce d ▁EF ▁; HF r EF ▁; ▁h Fr EF ▁ therapy
D-1533	-0.48250681161880493	EH ; HFpEF ; HF ; reduced EF ;HFrEF ; hFrEF therapy
P-1533	-0.0394 -0.0589 -0.9509 -0.2844 -0.1169 -0.2539 -0.0343 -0.9422 -0.5109 -0.3473 -3.3663 -0.0023 -0.1126 -0.0499 -1.0789 -0.0511 -0.1026 -0.1571 -0.9730 -0.3663 -0.4758 -1.5444 -0.0198 -0.1513 -0.0723
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma ; collected ; hf ; patients ; immunoreactive ; nt-probnp ; c-terminally ; nt-probnp
H-1520	-0.4475439488887787	▁plasma ▁collect ed ▁; ▁ HF ▁patients ▁; ▁immun ore active ▁; ▁NT - pro b NP
D-1520	-0.4475439488887787	plasma collected ; HF patients ; immunoreactive ; NT-probNP
P-1520	-0.7065 -0.0727 -0.3306 -0.3307 -0.7230 -0.0342 -0.3359 -0.1154 -0.0008 -0.3370 -0.0917 -1.3867 -0.7117 -0.0420 -0.0326 -1.1232 -0.1658 -1.8700 -0.0929
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt interval ; ecgs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine ; infusion
H-1438	-0.21434424817562103	▁beat - to - beat ▁ QT ▁interval ▁; ▁e CG s ▁; at rial ▁pa cing ▁; ▁es mol ol ▁; ▁iso pren a line ▁; ▁a tropi ne ▁in fusion
D-1438	-0.21434424817562103	beat-to-beat QT interval ; eCGs ;atrial pacing ; esmolol ; isoprenaline ; atropine infusion
P-1438	-0.0137 -0.0211 -0.0670 -0.0439 -0.1335 -0.4024 -0.1018 -0.0156 -0.2647 -2.1780 -0.4397 -0.0995 -0.5280 -0.5641 -0.0085 -0.0016 -0.0895 -0.0804 -0.4936 -0.0040 -0.0490 -0.1842 -0.0029 -0.0530 -0.0712 -0.0304 -0.3998 -0.0194 -0.0100 -0.5141 -0.0103 -0.0183 -0.2757 -0.0989
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence interval
H-803	-0.5804774761199951	
D-803	-0.5804774761199951	
P-803	-1.0816 -0.0793
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power spectral analysis ; hf ; dnx
H-1377	-0.44579118490219116	▁power ▁spec tral ▁analysis ▁; ▁low - fre quen ncy ▁; high - fre quen ncy ▁; LF ▁; HF ▁; ▁CHF - in v ▁; ▁sham - IN v ▁; ▁sham ▁levels ▁; ▁DN x
D-1377	-0.44579118490219116	power spectral analysis ; low-frequenncy ;high-frequenncy ;LF ;HF ; CHF-inv ; sham-INv ; sham levels ; DNx
P-1377	-0.0937 -2.1362 -0.0047 -0.1944 -0.1359 -0.1431 -0.0515 -0.0295 -1.6912 -0.6012 -0.8208 -1.0843 -0.0956 -0.0402 -1.0580 -0.3995 -0.1642 -0.0348 -1.1826 -0.2560 -0.4765 -0.1214 -0.0582 -0.9518 -0.7638 -0.0684 -0.0440 -0.1470 -1.0371 -0.4822 -0.2160 -0.3028 -0.8531 -0.5668 -0.0494 -0.1037 -0.3456 -0.1346
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ; ventricular-arterial coupling ; patients
H-524	-0.3796420991420746	▁contract ility ▁; ▁vent ri cular - arte rial ▁coup ling
D-524	-0.3796420991420746	contractility ; ventricular-arterial coupling
P-524	-0.0078 -0.1254 -0.1261 -0.0131 -0.5087 -0.1554 -0.0767 -0.0239 -0.0258 -0.3017 -0.6385 -2.8424 -0.0898
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change ; follow-up ; readmissions ; hospital ; follow-up
H-721	-0.6680846810340881	▁follow - up ▁visit s ▁; ▁read missions
D-721	-0.6680846810340881	follow-up visits ; readmissions
P-721	-0.7476 -0.0682 -0.0168 -0.3289 -0.0764 -0.2647 -2.5312 -0.1630 -2.3814 -0.1027
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal pro-b-type natriuretic peptide ; nt-probnp ; misdiagnosis ; heart failure ; hf
H-1511	-0.4234594702720642	▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁mis diagnos is ▁; ▁heart ▁failure ▁; HF
D-1511	-0.4234594702720642	natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
P-1511	-2.0821 -0.4186 -0.2400 -1.4797 -0.9554 -0.0818 -0.2475 -0.1685 -1.1947 -0.0148 -0.0132 -0.3217 -0.1423 -0.3010 -0.1196 -0.0407 -0.1933 -0.7036 -0.2249 -0.1800 -0.5824 -0.1423 -0.1869 -0.1279
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac magnetic resonance postcontrast t1 time ; prognosis ; hfpef ; postcontrast t1 ; biomarker ; hfpef
H-743	-0.49262332916259766	▁cardiac ▁magnetic ▁res on ance ▁; ▁post contra st ▁; ▁h FP EF ▁; ▁bio mark er ▁; ▁h FP EF
D-743	-0.49262332916259766	cardiac magnetic resonance ; postcontrast ; hFPEF ; biomarker ; hFPEF
P-743	-0.0534 -0.0402 -0.2397 -0.1033 -0.1526 -0.6666 -0.7871 -0.0436 -0.0242 -1.6149 -1.1097 -1.0772 -0.3253 -0.2543 -1.1148 -0.1245 -0.0937 -0.1978 -0.9025 -1.5684 -0.6065 -0.1268 -0.1032
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action ; randomized ; patients ; left ventricular ejection fraction ; new york heart association class ii ; hf ; exercise ; training
H-698	-0.5928901433944702	▁ HF - ac TION ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁New ▁York ▁Heart ▁association ▁; ▁IV ▁ HF
D-698	-0.5928901433944702	HF-acTION ; left ventricular ejection fraction ; New York Heart association ; IV HF
P-698	-1.3066 -0.2965 -0.0542 -0.8329 -1.9778 -0.3050 -0.5201 -0.0452 -1.2116 -0.4563 -0.1624 -0.1879 -0.1422 -0.8539 -0.0059 -0.1721 -0.6071 -0.1952 -0.5118 -1.1495 -0.8508 -2.6104 -0.1414 -0.1831 -0.5299 -0.1054
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial dd ; collagen deposition ; titin ; obese ; diabetic ; zsf1 ; heart failure with preserved ejection fraction
H-762	-0.204584538936615	▁my o card ial ▁ DD ▁; ▁collage n ▁de position ▁; ▁titi n ▁modification ▁; ▁obes e ▁; ▁diabet ic ▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-762	-0.204584538936615	myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; preserved ejection fraction
P-762	-0.4925 -0.0451 -0.1503 -0.0678 -0.9692 -0.0078 -0.1726 -0.0033 -0.0851 -0.0121 -0.1427 -0.1115 -0.0195 -0.0375 -0.1229 -0.1358 -0.0678 -0.0201 -0.1581 -0.0183 -0.0243 -1.3429 -0.0271 -0.4076 -0.0060 -0.0387 -1.0174 -0.2565 -0.0339 -0.4132 -0.0061 -0.0283 -0.2648 -0.0143 -0.0314 -0.0253 -0.6967 -0.0034 -0.6258 -0.0798
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac ; jq1 ; bet ; pathological ; cardiac ; gene expression
H-1049	-0.34746959805488586	▁tran scription al ▁analysis ▁; ▁cardiac ▁tissu e ▁; ▁mi ce ▁; ▁ TAC - ▁; ▁sham - opera ted ▁; ▁j q 1 ▁; ▁vehicle ▁; ▁ BET ▁inhibi tion ▁; ▁path ological ▁cardiac ▁gene ▁expression ▁programme
D-1049	-0.34746959805488586	transcriptional analysis ; cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
P-1049	-1.6755 -0.0849 -0.0236 -0.4038 -0.8243 -0.0142 -0.1914 -0.2099 -0.4184 -0.4142 -0.4639 -0.1896 -0.7970 -0.0089 -0.0340 -1.2202 -0.0024 -0.0369 -0.0070 -0.0900 -0.2091 -0.5382 -1.1066 -0.3906 -0.1469 -0.0873 -0.2874 -0.6250 -0.1117 -0.0391 -0.1719 -0.4613 -0.2941 -0.3077 -0.0633 -1.4173 -0.0796 -0.0329 -0.2848 -0.1338
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional hazard models ; negative binomial regression models ; health
H-1624	-0.2683374881744385	▁co x - propor tional ▁hazard ▁models ▁; ▁negative ▁bi nom ial ▁re gression ▁models
D-1624	-0.2683374881744385	cox-proportional hazard models ; negative binomial regression models
P-1624	-0.0531 -0.0289 -0.0111 -0.0087 -0.0606 -0.1551 -0.4289 -0.1326 -0.0148 -0.2563 -0.4133 -0.0372 -0.0251 -0.0045 -0.3872 -2.4778 -0.0664
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic blood pressure ; elevated ; left ventricular ; hypertrophy
H-277	-0.3380633592605591	▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁hyper trop hy ▁; ▁AT ▁; ▁AN ▁; ▁AS ▁; ▁ ANS
D-277	-0.3380633592605591	systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
P-277	-0.5593 -0.0756 -0.0972 -0.4866 -0.3350 -0.1753 -0.8594 -0.0776 -0.5855 -0.2202 -0.3169 -0.2622 -0.8217 -0.1409 -0.0133 -0.4487 -0.3741 -0.2328 -0.3702 -0.1892 -0.3415 -0.1556 -0.2496 -0.5694 -0.0624 -1.0200 -0.0871
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 ; hypertrophy ; fibrosis ; ventricular dysfunction ; gene
H-642	-0.29390043020248413	▁condition al ▁gene - tar get ed ▁hand 2 ▁mi ce ▁; ▁pressure - over load - indu ced ▁hyper trop hy ▁; ▁fibro sis ▁; ▁vent ri cular ▁dys function ▁; ▁fet al
D-642	-0.29390043020248413	conditional gene-targeted hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal
P-642	-0.1208 -0.0078 -1.1451 -0.0786 -0.0433 -0.0361 -0.0409 -0.6864 -0.2134 -1.2415 -0.3081 -0.2885 -0.2014 -0.0546 -0.0493 -0.0874 -0.1490 -0.0242 -0.0553 -0.0952 -0.0107 -0.6767 -0.2183 -0.0020 -0.1580 -0.1663 -0.0012 -0.4448 -0.1897 -0.0295 -0.0369 -0.2975 -0.1390 -0.0140 -3.1390 -0.1303
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission ; nt-probnp ; patients ; acute hf ; diagnosis
H-264	-0.46332848072052	▁cut off ▁value ▁; ▁ad mission ▁NT - pro b NP ▁; ▁patients ▁admit ted ▁to ▁ED ▁; ▁a cute ▁ HF ▁ diagnos is
D-264	-0.46332848072052	cutoff value ; admission NT-probNP ; patients admitted to ED ; acute HF diagnosis
P-264	-1.4187 -0.0601 -0.6555 -0.0884 -0.0719 -0.2399 -1.3270 -0.0233 -0.0092 -0.5048 -0.1001 -0.1336 -3.1655 -0.2246 -0.0979 -0.9443 -0.1710 -0.6543 -0.1966 -0.0055 -0.0979 -0.4551 -1.2258 -0.0951 -0.2410 -0.1654 -0.1374
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak oxygen consumption ; vo2max ; resting hr ; bpm ; p value
H-1943	-0.43308591842651367	▁Peak ▁oxygen ▁consum p tion ▁; VO 2 max ▁; ▁rest ing ▁HR
D-1943	-0.43308591842651367	Peak oxygen consumption ;VO2max ; resting HR
P-1943	-0.3163 -0.9025 -0.2862 -0.0908 -0.4273 -0.2305 -0.1782 -0.0721 -0.0167 -0.2531 -0.6417 -0.0675 -1.1530 -1.7920 -0.0683
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up ; patients ; combined end point ; death ; heart failure ; death ; cardiac transplant
H-1747	-0.656695544719696	heart ▁failure ▁; ▁sud den ▁death ▁; ▁non card iac ▁; ▁cardiac ▁transplant
D-1747	-0.656695544719696	heart failure ; sudden death ; noncardiac ; cardiac transplant
P-1747	-7.2430 -0.1646 -0.9483 -0.0995 -0.0111 -0.4091 -0.1743 -0.0392 -0.0230 -0.0085 -0.3411 -0.0192 -0.1196 -0.1308 -0.1190
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty ; health abc short physical performance battery ; habc battery ; gill index ; hf
H-625	-0.3041189908981323	▁fra il ty ▁; ▁Health ▁ABC ▁Short ▁Physic al ▁Performance ▁Bat tery ▁; ▁h ABC ▁Bat tery ▁; ▁Gill ▁index ▁; ▁incident ▁ HF
D-625	-0.3041189908981323	frailty ; Health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; incident HF
P-625	-0.5527 -0.1437 -0.1854 -0.1106 -1.3544 -0.1339 -0.3596 -0.1912 -0.0065 -0.9634 -0.2176 -0.0050 -0.0412 -0.9442 -0.3755 -0.7166 -0.0040 -0.0763 -0.1081 -0.0071 -0.0749 -0.3300 -0.7786 -0.0667 -0.0881 -0.0718
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic ; cardiac ; cardiac ; gene ; signal transduction ; pathological ; gene expression ; hf
H-1053	-0.34337007999420166	▁epi gene tic ▁readers ▁; ▁cardiac ▁bi ology ▁; ▁cardiac ▁gene ▁control ▁; ▁chr omat in - dependent ▁signal ▁trans duction ▁; ▁path ological ▁gene ▁expression ▁; ▁ HF ▁progression
D-1053	-0.34337007999420166	epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
P-1053	-0.4243 -0.0726 -0.3603 -0.1011 -0.7140 -0.0258 -0.7096 -0.3181 -0.1130 -2.5493 -1.6378 -0.3911 -0.1571 -0.0318 -0.0095 -0.2388 -0.0922 -0.0103 -0.2730 -0.0354 -0.3036 -0.2429 -0.1394 -0.2889 -0.6558 -0.2472 -0.1246 -0.2311 -0.0596 -0.0400 -0.2681 -0.1214
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical ; rule ; patients ; cad ; angiography ; patients ; systolic hf ; cost
H-1193	-0.4346882104873657	▁CAD ▁; ▁ang i ography ▁; ▁sy sto lic ▁ HF
D-1193	-0.4346882104873657	CAD ; angiography ; systolic HF
P-1193	-2.1425 -0.1018 -1.6968 -0.1036 -0.1431 -0.1383 -0.0442 -0.0221 -0.0239 -0.1838 -0.0282 -0.8893 -0.1333
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic response ; heart rate ; exercise ; baseline ; follow-up ; tests ; heart rate ; exercise
H-1176	-0.5861358046531677	▁load - corre cted ▁chr ono tropi c ▁response ▁; ▁heart ▁rate ▁; ▁follow - up ▁tests
D-1176	-0.5861358046531677	load-corrected chronotropic response ; heart rate ; follow-up tests
P-1176	-1.6949 -0.0704 -0.0079 -0.1517 -0.1997 -0.0714 -0.0596 -0.1124 -0.4050 -0.1741 -2.4998 -0.5640 -0.7265 -1.5005 -0.0630 -0.0154 -0.4172 -2.3123 -0.0905
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient ; hospital ; gastrointestinal bleeding ; patient ; ventricular tachycardia ; terminal heart failure
H-1961	-0.22533667087554932	▁gastro inte stin al ▁ble ed ing ▁; ▁ince ssant ▁vent ri cular ▁ta chy car dia ▁storm ▁; ▁terminal ▁heart ▁failure
D-1961	-0.22533667087554932	gastrointestinal bleeding ; incessant ventricular tachycardia storm ; terminal heart failure
P-1961	-1.6687 -0.1085 -0.6753 -0.0270 -0.0221 -0.1668 -0.0973 -0.2471 -0.4284 -0.0076 -0.0248 -0.3125 -0.0825 -0.1397 -0.1361 -0.0331 -0.0139 -0.0014 -0.2009 -0.2829 -0.3471 -0.2127 -0.0874 -0.0842
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous ; revascularization ; angioplasty ; stenting ; clinical ; patients ; randomized ; clinical
H-1601	-0.545932412147522	▁per cuta ne ous ▁re vas cular ization ▁; ▁ang io plast y ▁; ▁sten ting
D-1601	-0.545932412147522	percutaneous revascularization ; angioplasty ; stenting
P-1601	-3.2852 -0.0041 -0.2293 -1.2371 -0.0290 -0.0482 -0.3512 -0.3405 -0.8732 -0.2437 -0.5595 -0.0614 -0.2911 -0.4587 -0.0039 -0.3781 -1.3405 -0.0920
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients ; hf ; t2d ; erc ; vo2max ; maximum oxygen consumption ; skm ; biopsies
H-1251	-0.23264119029045105	▁ HF ▁; ▁t 2 d ▁; ▁ ERC ▁; ▁tre ad m ill ▁testing ▁; VO 2 max ▁; ▁oxygen ▁consum p tion ▁; ▁Sk m ▁bio psi es
D-1251	-0.23264119029045105	HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
P-1251	-1.0866 -0.0575 -0.0448 -0.6958 -0.0127 -0.3221 -0.6692 -1.2441 -0.1678 -0.0811 -0.0108 -0.0023 -0.2192 -0.0713 -0.5735 -0.0231 -0.1706 -0.0262 -0.0149 -0.0948 -0.1540 -0.0431 -0.0481 -0.2340 -0.3844 -0.1854 -0.2493 -0.0412 -0.1203 -0.1514 -0.1739 -0.0711
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild hf ; qrs prolongation ; lvef ; crt ; reverse remodeling ; clinical ; systolic dysfunction
H-758	-0.35836753249168396	▁ HF ▁; ▁QR s ▁prolong ation ▁; ▁LV EF ▁; ▁c RT ▁; ▁rever se ▁remodel ing ▁; ▁LV ▁sy sto lic ▁dys function
D-758	-0.35836753249168396	HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; LV systolic dysfunction
P-758	-0.3752 -0.0493 -0.0543 -0.0118 -1.2094 -0.0122 -0.1832 -0.0827 -0.1614 -0.0719 -0.0190 -0.6759 -1.8180 -0.1795 -0.0220 -0.0075 -0.0078 -0.0175 -0.0976 -3.4457 -0.6707 -0.0496 -0.0565 -0.0554 -0.0693 -0.1954 -0.0772
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients ; rv support ; lvad ; patients ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
H-295	-0.42552244663238525	▁ RV ▁support ▁; ▁l VAD ▁ insertion ▁; ▁cardio ge nic ▁shock ▁; ▁my o card ial ▁in far ction ▁; ▁chronic ▁de com pensa ted ▁heart ▁failure
D-295	-0.42552244663238525	RV support ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
P-295	-1.5805 -0.6489 -2.2157 -0.4319 -0.4850 -0.0105 -1.5216 -0.0060 -0.3901 -0.0608 -0.0519 -1.1930 -0.0469 -0.5694 -0.6703 -0.1563 -0.3856 -0.3532 -0.0264 -0.2053 -0.0836 -0.2905 -0.5016 -0.0122 -0.0813 -0.0274 -0.1806 -0.4056 -0.2070 -0.2259 -0.1661
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up ; patients
H-268	-0.9398425817489624	▁die d ▁; ▁non - sur viv ors
D-268	-0.9398425817489624	died ; non-survivors
P-268	-5.9787 -0.1679 -0.1693 -1.6680 -0.0384 -0.0656 -0.0098 -0.9756 -0.2255 -0.0997
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty ; gill index ; hf
H-628	-0.6049835085868835	▁non - fra il ▁participants ▁; ▁severe ▁fra il ty ▁; HR ▁; ▁Gill ▁index ▁; ▁ HF
D-628	-0.6049835085868835	non-frail participants ; severe frailty ;HR ; Gill index ; HF
P-628	-1.0135 -0.0151 -0.0027 -0.0556 -1.1514 -0.1800 -5.2619 -0.0192 -0.0753 -0.1514 -0.1590 -1.1996 -0.3871 -0.6129 -0.0077 -0.3159 -1.1234 -0.1464 -0.0901 -0.1316
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence ; hf ; ami ; adjusted odds ratio
H-1310	-0.7620512247085571	▁ HF ▁; ▁ AMI
D-1310	-0.7620512247085571	HF ; AMI
P-1310	-1.3976 -0.2541 -0.2440 -1.0108 -0.5017 -1.8434 -0.0827
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic heart failure ; chf ; multisystem disease ; comorbidities ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
H-1357	-0.31041082739830017	▁Chro nic ▁heart ▁failure ▁; CH f ▁; ▁multi system ▁disease ▁; ▁an emia ▁; ▁insulin ▁resist ance ▁; ▁autonomi c ▁dys balance ▁; ▁cardiac ▁cache xia
D-1357	-0.31041082739830017	Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
P-1357	-1.3003 -0.3310 -0.5050 -0.0981 -0.1235 -0.8000 -1.3483 -0.1941 -1.1906 -0.8320 -0.5363 -0.1492 -0.5178 -0.0679 -0.1102 -0.0031 -0.0455 -0.0314 -0.1224 -0.0005 -0.1685 -0.0188 -0.0461 -0.1069 -0.0062 -0.0192 -0.0301 -0.1842 -0.1144
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic ; β-ar ; catecholamine ; infusions ; pde2 ; expression ; camp ; activity ; correlated ; cardiac ; β-ar responsiveness
H-1214	-0.339053750038147	▁Chro nic ▁β - AR ▁stimul ation ▁; ▁cate chol amine ▁in fusion s ▁; ▁rat s ▁; ▁p de 2 ▁expression ▁; ▁c AMP ▁hydro ly tic ▁activity ▁; ▁blu n ted ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.339053750038147	Chronic β-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
P-1214	-3.0889 -0.0479 -0.0569 -0.0160 -0.1724 -0.1106 -0.1495 -1.0515 -0.0128 -0.0149 -0.0815 -0.0308 -0.0046 -0.2196 -0.2929 -0.1195 -0.0530 -1.3413 -0.2128 -1.5105 -0.0446 -0.0402 -0.0719 -0.0179 -0.0349 -0.0153 -0.4953 -1.4545 -0.3522 -0.1706 -0.1440 -0.0780 -0.1994 -0.0056 -0.2390 -0.0231 -0.2001 -0.0895 -1.2457 -0.2654 -0.1260
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic pah ; clinical ; hospitalized ; patients ; acute ; rv decompensation ; pharmacologic ; therapies ; rv failure ; pah
H-1096	-0.36671504378318787	▁chronic ▁P AH ▁; ▁hospital ized ▁patients ▁; ▁ RV ▁de com pensa tion ▁; ▁ pharma c ologic ▁ therapie s ▁; ▁ RV ▁failure ▁management ▁; ▁p AH
D-1096	-0.36671504378318787	chronic PAH ; hospitalized patients ; RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
P-1096	-0.0598 -1.4268 -0.0119 -0.2257 -1.4485 -0.0692 -0.3439 -0.1452 -0.8850 -1.0372 -0.0537 -0.1956 -0.0844 -0.1832 -0.2780 -0.1705 -0.4007 -0.0228 -0.0446 -0.9827 -0.1583 -0.1120 -0.2127 -1.0485 -0.3971 -0.1182 -0.0886 -0.5187 -0.6991 -0.0175 -0.1480 -0.1470
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese ; zsf1 ; heart failure with preserved ejection fraction ; lung ; preserved left ventricular ejection fraction ; left ventricular dd
H-767	-0.32459527254104614	▁obes e ▁; ▁z SF 1 ▁groups ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁lung ▁weight ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁ DD
D-767	-0.32459527254104614	obese ; zSF1 groups ; heart failure ; preserved ejection fraction ; lung weight ; preserved left ventricular ejection fraction ; left ventricular DD
P-767	-0.5478 -0.0227 -1.7926 -0.3951 -0.0683 -1.0539 -0.5357 -0.2269 -1.4226 -0.0605 -0.1822 -0.7389 -0.0149 -0.1407 -0.0487 -0.0881 -0.0402 -0.3011 -0.0073 -0.1214 -0.1494 -0.0995 -0.0476 -0.6292 -0.0123 -0.1884 -0.4156 -0.0675 -0.6327 -0.1113 -0.2145 -0.1260 -0.0932 -0.5145 -0.0065 -0.1269 -0.0464 -0.0308 -0.5430 -0.1340 -1.4450 -0.5171 -0.2262 -0.0949
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine oxidase ; xo ; left ventricular ; myocytes ; volume overload ; vo ; mitral regurgitation ; aortocaval fistula ; acf
H-470	-0.2646511495113373	▁Xan thi ne ▁oxid ase ▁; XO ▁; ▁rat ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁my o cy tes ▁; ▁volume ▁over load ▁; VO ▁; ▁mit ral ▁re gur gi tation ▁; ▁a orto ca val ▁fi stu la ▁; ac f
D-470	-0.2646511495113373	Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ;acf
P-470	-0.0014 -0.0863 -0.3782 -0.0050 -0.1952 -0.2363 -0.0376 -0.1679 -3.4738 -0.9559 -0.1638 -0.0254 -0.3331 -0.1474 -0.1248 -1.0074 -0.1139 -0.2434 -0.0329 -0.0161 -0.0144 -0.4784 -0.0294 -0.0089 -0.0217 -0.1576 -0.1115 -0.1829 -0.0941 -0.0269 -0.0071 -0.0260 -0.0185 -0.0107 -0.0942 -0.0066 -0.0022 -0.0032 -0.0139 -0.0393 -0.0009 -0.1497 -0.5994 -1.3846 -1.0528 -0.0992 -0.0586
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse ; myocardial t1 ; heart failure
H-1055	-0.29236406087875366	▁free - bre a thing ▁puls e ▁se quen nce ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁model ▁; ▁ta chy car dia - indu ced ▁heart ▁failure
D-1055	-0.29236406087875366	free-breathing pulse sequennce ; myocardial t1 ; swine model ; tachycardia-induced heart failure
P-1055	-0.7493 -0.0470 -0.0126 -0.0515 -0.5873 -0.0266 -0.0970 -0.4487 -0.4553 -2.5632 -0.2091 -0.2799 -0.0708 -0.1445 -0.0420 -1.5666 -0.3279 -0.9461 -0.2299 -0.0190 -0.0323 -0.2042 -0.1754 -0.0472 -0.0304 -0.0252 -0.0082 -0.0525 -0.0028 -0.0493 -0.1650 -0.0568 -0.1147 -0.1022
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic ; new york heart association classes ; saf
H-229	-0.8338563442230225	▁ PF ▁co hor t ▁; New ▁York ▁Heart ▁Association ▁classes
D-229	-0.8338563442230225	PF cohort ;New York Heart Association classes
P-229	-2.2944 -0.5091 -0.1309 -0.1194 -0.0595 -0.0587 -0.8568 -0.3312 -1.0297 -0.7364 -1.6750 -2.9726 -0.0664
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians ; patients ; patient ; clinician ; medication ; patient
H-1129	-1.0571212768554688	▁co management ▁; ▁patients
D-1129	-1.0571212768554688	comanagement ; patients
P-1129	-0.2899 -0.0196 -0.5005 -3.2204 -2.2028 -0.1095
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients ; physicians ; mortality ; physicians ; hospitals
H-1727	-0.40792495012283325	▁high - volu me ▁physician s ▁; ▁mortal ity ▁; ▁low - volu me ▁physician s
D-1727	-0.40792495012283325	high-volume physicians ; mortality ; low-volume physicians
P-1727	-2.6925 -0.0348 -0.0361 -0.0589 -0.0893 -0.0816 -0.3005 -0.7743 -1.0172 -0.2383 -0.2238 -0.0341 -0.0379 -0.0190 -0.2388 -0.0907 -1.2892 -0.0857
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western ; administrative ; health ; patients ; hf ; hospitalized ; ami
H-1307	-0.5883475542068481	▁Western ▁Australian ▁link ed ▁administrative ▁health ▁; ▁patients ▁; ▁ HF ▁hospital ized ▁; ▁index ▁; ▁ AMI
D-1307	-0.5883475542068481	Western Australian linked administrative health ; patients ; HF hospitalized ; index ; AMI
P-1307	-0.1294 -0.3062 -2.5597 -0.0461 -0.1926 -0.6362 -1.4507 -2.7609 -0.3336 -0.7937 -0.1874 -1.0031 -0.0447 -0.3811 -0.0195 -0.2469 -0.3385 -0.1118 -0.1267 -0.0981
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report ; connection ; patients ; disease ; healthcare ; conditions ; turkey
H-1825	-2.042933940887451	
D-1825	-2.042933940887451	
P-1825	-3.9891 -0.0967
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective cohort ; eds ; diagnosis ; heart failure
H-463	-1.0095309019088745	▁ diagnos is ▁; ▁heart ▁failure
D-463	-1.0095309019088745	diagnosis ; heart failure
P-463	-3.8960 -1.3437 -0.2273 -1.0087 -0.5703 -0.1478 -0.7624 -0.1199
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome ; prospective ; hospitalized ; hf ; nursing ; outcomes
H-1403	-0.8257092237472534	▁nur sing - sensitiv e ▁outcome ▁measure s ▁; ▁science ▁; ▁effective ▁treatment ▁; ▁older ▁adults ▁hospital ized ▁; ▁ HF
D-1403	-0.8257092237472534	nursing-sensitive outcome measures ; science ; effective treatment ; older adults hospitalized ; HF
P-1403	-5.1378 -0.0241 -0.0469 -0.0006 -0.0384 -0.3175 -0.9253 -0.0448 -0.1783 -2.5417 -0.1529 -3.4322 -0.3833 -0.6094 -0.1311 -0.0647 -0.4659 -0.1094 -1.9545 -0.5176 -0.0524 -1.7413 -0.1211
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas ; rnas ; expression ; genes ; messenger rna ; repression
H-1482	-0.42017391324043274	▁mi RNA s ▁; ▁non co ding ▁ RNA s ▁; ▁ binding ▁; ▁messenger ▁ RNA ▁; ▁degrada tion ▁; ▁translation al ▁re pression
D-1482	-0.42017391324043274	miRNAs ; noncoding RNAs ; binding ; messenger RNA ; degradation ; translational repression
P-1482	-0.6310 -0.0131 -0.0726 -0.5734 -0.4703 -0.0080 -0.1262 -0.1506 -0.0245 -0.0811 -0.3519 -3.2570 -0.9764 -0.6315 -0.4585 -0.1662 -0.0561 -1.6296 -0.6045 -0.2609 -0.4392 -0.0978 -0.0228 -0.0187 -0.0237 -0.1220 -0.0771
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients ; hfpef ; ivabradine ; placebo ; double-blind
H-1173	-0.4824228882789612	▁ HF p EF ▁; ▁i va bra dine ▁; ▁i va bra dine
D-1173	-0.4824228882789612	HFpEF ; ivabradine ; ivabradine
P-1173	-0.6500 -0.3984 -0.0754 -0.3898 -0.1459 -0.0102 -0.0211 -0.2154 -0.0648 -0.6193 -2.4611 -0.0565 -0.3612 -0.0543 -2.1264 -0.0690
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac ; cells ; cardiac ; cells ; cardiac functions ; myocardial infarction
H-1335	-0.3484427332878113	▁Card iac ▁c - K it ▁; ▁cell s ▁isola ted ▁; ▁cardiac ▁ex plant - der i ved ▁cell s ▁; ▁cardiac ▁function s ▁; ▁my o card ial ▁in far ction
D-1335	-0.3484427332878113	Cardiac c-Kit ; cells isolated ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
P-1335	-1.8264 -0.0293 -0.0302 -0.0193 -0.8642 -0.0179 -1.8079 -0.3136 -0.0481 -0.7485 -0.0423 -0.4784 -0.0151 -0.3363 -0.0027 -0.0652 -0.0455 -0.1377 -0.0934 -0.8872 -0.0567 -0.4005 -0.2274 -0.1899 -0.1093 -0.6037 -1.1537 -0.1199 -0.3624 -0.4104 -0.0249 -0.2291 -0.1773 -0.2056 -0.1156
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps ; adverse outcomes ; patients ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
H-1022	-0.6254786849021912	▁p s ▁; ▁pulmonar y ▁e mbol ism ▁; ▁diabetes ▁; ▁che mo therapy
D-1022	-0.6254786849021912	ps ; pulmonary embolism ; diabetes ; chemotherapy
P-1022	-2.7260 -0.2080 -0.3719 -4.7094 -0.0518 -0.1790 -0.0057 -0.6346 -0.0939 -0.0547 -0.4732 -0.1548 -0.0774 -0.0154 -0.1527 -0.0992
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses ; pathophysiology ; hf ; nursing ; medical ; symptoms ; pathophysiologic
H-2022	-0.6796285510063171	▁pat ho phy si ology ▁; HF ▁; ▁medical ▁management ▁; ▁pat ho phy si ologic
D-2022	-0.6796285510063171	pathophysiology ;HF ; medical management ; pathophysiologic
P-2022	-1.5868 -0.3411 -0.2953 -1.1659 -0.3378 -0.1520 -2.6509 -0.1745 -1.2881 -0.1282 -0.3140 -1.3612 -0.1773 -0.5802 -0.7133 -0.0506 -0.8236 -0.0926
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia ; pna
H-1691	-0.38948991894721985	▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia ▁; ▁p NA
D-1691	-0.38948991894721985	heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pNA
P-1691	-5.6099 -0.0574 -0.0747 -0.1003 -0.0321 -0.1449 -0.0047 -0.4694 -0.2362 -0.1426 -0.1843 -0.0113 -0.0745 -0.0645 -0.1030 -0.1688 -0.0545 -0.0067 -0.3642 -0.4487 -0.0602 -0.6289 -0.1650 -0.1410
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
H-1618	-0.25294268131256104	▁mortal ity ▁; ▁health care ▁utiliza tion ▁effects ▁; ▁combinatie d ▁care ▁management ▁; ▁tele health ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁mell itus
D-1618	-0.25294268131256104	mortality ; healthcare utilization effects ; combinatied care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
P-1618	-0.2097 -0.6219 -0.1109 -0.0908 -0.1069 -0.1828 -0.2081 -1.5034 -0.1874 -2.3862 -0.1482 -0.3701 -0.0505 -0.1175 -0.0761 -0.1939 -0.1610 -0.0706 -0.0539 -0.6012 -0.2959 -0.0239 -0.0935 -0.0043 -0.1947 -0.0485 -0.0378 -0.0034 -0.2526 -0.3149 -0.1221 -0.0258 -0.0038 -0.0163 -0.1223 -0.0952
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 ; bets ; chromatin ; downstream signalling ; rna ; polymerase ii ; pol ii
H-1043	-0.32826459407806396	▁inhibi tor ▁J Q 1 ▁; ▁ BET s ▁; ▁chr omat in ▁; ▁down stream ▁signal ling ▁; ▁ RNA ▁poly mera se ▁II ▁; Pol ▁II
D-1043	-0.32826459407806396	inhibitor JQ1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;Pol II
P-1043	-0.3550 -0.0086 -1.4930 -0.7466 -0.4051 -0.3312 -1.1008 -0.7498 -0.2971 -0.7246 -0.0257 -0.0210 -0.2938 -0.1495 -1.1074 -0.0017 -0.0827 -0.1157 -0.4524 -0.2310 -0.0176 -0.0605 -0.0297 -0.0115 -0.0923 -0.2195 -0.4134 -0.1058 -0.1397 -0.0650
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction ; hfpef
H-942	-0.29431623220443726	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF
D-942	-0.29431623220443726	catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hFPEF
P-942	-1.9611 -0.1253 -0.0430 -0.0923 -0.6167 -0.2906 -0.0357 -0.2365 -0.0125 -0.0213 -0.2291 -0.2883 -0.1489 -0.6955 -0.0308 -0.4074 -0.0147 -0.0292 -0.2405 -0.0182 -0.0678 -0.0355 -0.3563 -0.0037 -0.4380 -0.8831 -0.9086 -0.3367 -0.1463 -0.1158
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic ; heart failure with preserved ejection fraction ; hfpef ; patients ; health ; symptoms ; quality of life
H-780	-0.41003918647766113	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-780	-0.41003918647766113	heart failure ; preserved ejection fraction ;HFpEF
P-780	-2.3327 -0.0862 -0.4964 -0.0195 -0.0314 -0.3504 -0.0214 -0.0785 -0.0371 -0.2347 -0.0084 -0.1948 -0.1419 -0.0239 -0.2129 -2.6188 -0.0817
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate cox proportional hazards regression modeling ; hospitalization ; acute coronary syndromes ; coronary interventions ; patients
H-104	-0.3729243874549866	▁co x ▁proportion al ▁hazard s ▁re gression ▁model ing ▁; ▁risk ▁factors ▁; ▁IE ▁; ▁hospital ization ▁; ▁a cute ▁corona ry ▁syndrome s ▁; ▁corona ry ▁intervention s
D-104	-0.3729243874549866	cox proportional hazards regression modeling ; risk factors ; IE ; hospitalization ; acute coronary syndromes ; coronary interventions
P-104	-0.0457 -0.0616 -0.0388 -0.0101 -0.0384 -0.2372 -0.1331 -0.0020 -0.6307 -0.1607 -0.2494 -2.4240 -0.1879 -0.2050 -2.2891 -0.1949 -1.7387 -0.3476 -0.4594 -0.0051 -0.0030 -0.0671 -0.8647 -0.0020 -0.0486 -0.1892 -0.0177 -0.7193 -0.0815 -0.0851 -0.2799 -0.1161
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic adenosine monophosphate ; camp ; cyclic guanosine monophosphate ; cgmp ; hearts
H-1209	-0.36042335629463196	▁di minis hed ▁ cycli c ▁ad enos ine ▁mono phos pha te ▁; ▁c AMP ▁; ▁aug mente d ▁ cycli c ▁gua no sine ▁mono phos pha te ▁; ▁c g MP ▁; ▁fail ing ▁heart s
D-1209	-0.36042335629463196	diminished cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; cgMP ; failing hearts
P-1209	-1.6847 -0.0136 -0.1598 -0.0412 -0.0303 -0.2431 -0.1281 -0.1741 -1.7747 -0.0024 -0.0115 -0.0486 -0.1001 -0.3650 -0.6091 -0.0701 -0.1704 -0.2723 -0.0094 -0.0023 -0.0388 -0.0174 -0.4177 -1.0958 -0.0120 -0.3821 -0.0019 -0.0202 -0.0291 -0.0938 -0.3300 -0.3418 -1.8009 -0.5914 -0.7805 -1.2819 -0.0616 -0.7220 -0.3503 -0.3350 -0.1623
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra ; methotrexate ; tnf antagonist ; non-biological disease modifying antirheumatic drug ; nbdmard
H-604	-0.3340226113796234	▁RA ▁; ▁met ho tre xa te ▁; ▁t NF ▁anta gon ist ▁; ▁non - bi ological ▁disease ▁mod ifying ▁anti r heu matic ▁drug ▁; n b DM ARD
D-604	-0.3340226113796234	RA ; methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug ;nbDMARD
P-604	-0.4858 -0.6130 -0.0327 -0.1291 -0.0174 -0.4156 -0.0431 -0.2207 -2.6740 -0.2044 -0.0395 -0.0013 -0.1081 -0.0825 -0.1735 -0.0228 -0.7094 -0.1255 -0.0834 -0.7302 -0.0080 -0.0240 -0.6576 -0.4933 -0.1080 -0.1509 -0.5851 -1.1704 -0.0020 -0.1392 -0.4450 -0.1723 -0.1550
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal dysfunction ; intestinal ; lead ; chronic ; inflammatory ; catabolic ; anabolic ; cardiac cachexia ; terminal ; chf ; prognosis
H-1360	-0.16451773047447205	▁intestinal ▁dys function ▁; ▁disturb ed ▁intestinal ▁barrier ▁; ▁chronic ▁infla mma tory ▁state ▁; ▁cata bo lic ▁; ana bo lic ▁im balance ▁; ▁cardiac ▁cache xia ▁; ▁CHF
D-1360	-0.16451773047447205	intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
P-1360	-0.1777 -0.3448 -0.0448 -0.0613 -0.0658 -0.0273 -0.1232 -0.1467 -0.1569 -0.3328 -0.0777 -0.2232 -0.0738 -0.4475 -0.0593 -0.0440 -0.0058 -0.0429 -1.6119 -0.0640 -0.0110 -0.0552 -0.3949 -0.0165 -0.0931 -0.0047 -0.0084 -0.0075 -0.0956 -0.2042 -0.1408 -0.1012
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report ; patient ; diagnosis ; ischemic-hypertensive cardiomyiopathy ; angina ; myocardial ischemia ; coronary arteries
H-998	-0.25041887164115906	▁ ische mic - hy per tensi ve ▁cardio my io pathy ▁; ▁ang ina ▁; ▁induc ible ▁my o card ial ▁ ische mia ▁; ▁corona ry ▁arteri es
D-998	-0.25041887164115906	ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
P-998	-0.5642 -0.1477 -0.1698 -0.0414 -0.0445 -0.0372 -0.0878 -0.0245 -0.1370 -0.5957 -1.1910 -0.0899 -0.2135 -1.1929 -0.3567 -0.1338 -0.0035 -0.1285 -0.8211 -0.0807 -0.3018 -0.1279 -0.1215 -0.0465 -0.2727 -0.3441 -0.0309 -0.3455 -0.0111 -0.1074 -0.1548 -0.0876
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate receptor 1 ; s1pr1 ; β1-adrenergic receptor ; β1ar ; g-protein-coupled receptors ; heart
H-1405	-0.4092063009738922	▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁β 1- ad r energi c ▁receptor ▁; β 1 AR ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁heart
D-1405	-0.4092063009738922	sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
P-1405	-0.0016 -1.2397 -0.7352 -3.7833 -1.1792 -0.2413 -0.0091 -0.0755 -0.1120 -0.0194 -0.4462 -0.1786 -0.3025 -0.2721 -1.9793 -0.0401 -0.3319 -0.0979 -0.1722 -0.4653 -0.1227 -0.0213 -0.2914 -0.1601 -0.5540 -0.3528 -0.6951 -0.7262 -0.0368 -0.0108 -0.2000 -0.0526 -0.0060 -0.0075 -0.1280 -0.1380 -0.2275 -0.6200 -0.4682 -0.1542 -0.1219
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal ; correlated ; pcwp ; p values
H-484	-0.8759196400642395	▁e - sept al ▁cor related ▁; ▁pc WP ▁; ▁e / e ' lateral ▁; ▁e / e ' me an
D-484	-0.8759196400642395	e-septal correlated ; pcWP ; e/e'lateral ; e/e'mean
P-484	-0.3078 -4.2408 -0.0066 -0.0131 -1.0992 -0.2525 -0.2393 -0.4313 -0.2891 -0.0968 -0.3860 -1.3415 -0.0464 -4.7919 -0.0183 -0.1297 -0.3526 -1.2593 -0.0776 -4.8651 -0.0606 -0.0460 -0.5500 -0.1205
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-864	-0.2599850594997406	▁in appropria te ▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-864	-0.2599850594997406	inappropriate therapy ; atrial fibrillation ; carvedilol ; metoprolol
P-864	-1.3260 -0.0128 -0.0546 -0.1964 -0.0145 -0.9907 -0.5986 -0.0282 -0.3759 -0.0290 -0.1167 -0.1807 -0.0222 -0.0099 -0.0513 -0.2230 -0.0350 -0.3202 -0.0204 -0.2532 -0.7555 -0.1049
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia ; intravenous ; metoprolol ; cardiac ; sympathetic tone
H-1379	-0.26318222284317017	▁Brad y car dia ▁induc ed ▁; ▁intra ven ous ▁met o pro lol ▁; ▁cardiac ▁sympa the tic ▁tone ▁; ▁CHF - IN v ▁rabbi ts ▁; ▁sham - IN v ▁; ▁CHF - DN x
D-1379	-0.26318222284317017	Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-INv rabbits ; sham-INv ; CHF-DNx
P-1379	-0.0167 -0.1090 -0.0457 -0.0285 -0.5243 -0.1321 -0.4507 -0.0676 -0.0077 -2.3876 -0.0164 -0.1337 -0.0232 -0.2215 -0.0917 -0.0189 -0.0579 -0.3401 -0.9482 -0.0196 -0.4339 -0.4016 -0.0207 -0.8043 -0.3266 -0.0866 -0.1061 -0.2262 -0.0094 -0.0290 -0.5206 -0.2566 -0.3163 -0.1577 -0.0380 -0.2964 -0.3176 -0.1765 -0.0990
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized ; walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; severe heart failure
H-569	-0.526519775390625	▁Nordic ▁walking ▁; ▁standard ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁patients ▁; ▁moderat e ▁to ▁severe ▁heart ▁failure
D-569	-0.526519775390625	Nordic walking ; standard cardiac rehabilitation ; functional capacity ; patients ; moderate to severe heart failure
P-569	-1.3822 -0.6746 -0.0732 -0.4381 -0.0244 -0.0666 -0.2217 -0.6707 -0.1373 -0.3335 -0.2330 -2.6357 -1.4009 -1.7379 -0.0144 -0.2827 -0.0484 -0.3687 -0.0974 -0.1251 -0.0903
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes ; patients ; prescribed ; pharmacological ; discharge ; left ventricular function
H-1849	-0.3772958815097809	▁c PG - re com mend ed ▁ pharma c ological ▁treatment ▁; ▁device ▁consideration ▁; ▁left ▁vent ri cular ▁function ▁assessment
D-1849	-0.3772958815097809	cPG-recommended pharmacological treatment ; device consideration ; left ventricular function assessment
P-1849	-2.1198 -0.3100 -0.0357 -0.0151 -0.0114 -0.0021 -0.0296 -0.0567 -0.1035 -0.0593 -0.3212 -0.7461 -0.1412 -0.3702 -0.1922 -0.1197 -2.8587 -0.0560 -0.8209 -0.1645 -0.2070 -0.0459 -0.1356 -0.1327
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls ; lvef ; prognostic ; clinical ; echocardiographic ; systolic
H-820	-0.36828097701072693	▁g LS ▁; ▁LV EF ▁; ▁sa ▁; ▁CV ▁events ▁; ▁prognos tic ▁benefit ▁; ▁e cho car dio graphic ▁sy sto lic ▁parameter s ▁; ▁AF
D-820	-0.36828097701072693	gLS ; LVEF ; sa ; CV events ; prognostic benefit ; echocardiographic systolic parameters ; AF
P-820	-0.1739 -0.6747 -0.0578 -0.0799 -0.1391 -0.0392 -0.3569 -0.3803 -1.7070 -1.2487 -0.1715 -1.6452 -0.6375 -1.1941 -0.1920 -0.2038 -0.0205 -0.0295 -0.0794 -0.1190 -0.0233 -0.0213 -0.0518 -0.4155 -0.0678 -0.6923 -0.0655 -0.1057 -0.0868
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc ; dapc protein ; sarcomeric microstructure ; skm ; myofibre regeneration
H-1254	-0.4011958837509155	ERC ▁induc ed ▁recovery ▁; ▁DAP c ▁protein ▁levels ▁; ▁sar come ric ▁micro structure ▁; ▁marker s ▁; ▁Sk m ▁growth ▁; different i ation ▁; ▁my o fi bre ▁regenera tion
D-1254	-0.4011958837509155	ERC induced recovery ; DAPc protein levels ; sarcomeric microstructure ; markers ; Skm growth ;differentiation ; myofibre regeneration
P-1254	-1.0317 -1.1062 -0.0609 -0.0413 -0.5397 -1.8256 -1.0074 -0.3052 -0.5348 -0.1451 -0.0031 -0.2118 -0.1660 -0.0047 -0.0799 -0.1449 -2.1459 -0.0192 -0.3590 -0.0733 -0.4956 -1.4127 -0.7970 -0.1976 -0.0522 -0.0660 -0.2424 -0.1707 -0.0319 -0.0183 -0.0305 -0.0806 -0.3701 -0.1934 -0.0772
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas ; expression ; bhlh ; transcription factor ; hand2 ; myocardium ; gene ; heart failure
H-644	-0.24710972607135773	▁signal ling ▁casca des ▁; ▁micro RNA s ▁; ▁b HL h ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁post na tal ▁mamma lian ▁my o car dium ▁; ▁em bry o nic ▁gene ▁programs ▁; ▁heart ▁failure
D-644	-0.24710972607135773	signalling cascades ; microRNAs ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
P-644	-0.2514 -0.1496 -0.0073 -0.0104 -1.4372 -0.0055 -0.0044 -0.0801 -0.2144 -0.2884 -0.0677 -0.0913 -0.0559 -0.0189 -0.0720 -0.6973 -0.2502 -0.1089 -0.2418 -0.0119 -0.4710 -0.0067 -0.0059 -0.1404 -1.2928 -0.0613 -0.0204 -0.0690 -0.2942 -0.4581 -0.0105 -0.0517 -0.5426 -0.6855 -0.1371 -0.8506 -0.0681 -0.3751 -0.1763 -0.1025
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad ; q66p ; rad ; cav1.2 ; cav1.3 ; l-type channel ; isoforms ; heart
H-1674	-0.30261582136154175	▁Rad ▁Q 66 p ▁; ▁inhibi tory ▁actions ▁; ▁Rad ▁on ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁l - type ▁channel ▁iso form s ▁; ▁heart
D-1674	-0.30261582136154175	Rad Q66p ; inhibitory actions ; Rad on cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
P-1674	-0.6471 -0.9914 -0.3088 -0.3500 -0.1927 -0.3201 -0.1304 -0.2774 -0.1510 -0.5693 -0.4871 -0.3222 -0.5451 -0.1742 -0.1725 -0.2964 -0.4116 -0.0860 -0.2236 -0.7406 -0.0183 -0.0039 -0.0285 -0.0113 -0.0442 -0.0676 -0.2722 -1.0563 -0.0829 -0.0957
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef ; lcx ; lad ; stenting ; infarcted ; left ventricle ; lcx ; lad
H-512	-0.43955057859420776	▁EF ▁; LC x ▁model ▁; ▁ LAD ▁; ▁sten ting ▁; ▁in far cted ▁left ▁vent ric le ▁; ▁ LC x ▁; ▁ LAD
D-512	-0.43955057859420776	EF ;LCx model ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
P-512	-0.0373 -0.1309 -1.3069 -1.2746 -0.7849 -0.0400 -0.7739 -0.1939 -0.5473 -0.2675 -0.1495 -0.2585 -0.6544 -0.0107 -0.1729 -0.0302 -0.0394 -0.8302 -0.1933 -0.1790 -1.0910 -0.0749 -1.5641 -0.1744 -0.1686 -0.1790 -1.1002 -0.0800
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv compliance ; lv end-diastolic volume ; lv end-diastolic pressure ; β coefficient
H-1531	-0.7679883241653442	▁EH ▁; ▁LV ▁compliance ▁; ▁CH ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁β ▁co e ffi cient
D-1531	-0.7679883241653442	EH ; LV compliance ; CH ; end-diastolic volume ; LV ; end-diastolic pressure ; β coefficient
P-1531	-0.0796 -0.0746 -1.1524 -1.1892 -0.0524 -5.2793 -0.1223 -4.8442 -0.0555 -0.0247 -0.0886 -0.0488 -0.0670 -0.1297 -2.8663 -0.8107 -2.1166 -0.0554 -0.0405 -0.1630 -0.0489 -0.6523 -0.3340 -0.9097 -0.0274 -0.1722 -0.0179 -0.0186 -1.5030 -0.0946
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva ; surgical ; implantation ; leaflet ; leaflet ; edge-to-edge anastomosis
H-360	-0.2748483121395111	▁m va ▁; ▁sur g ical ▁ring ▁implant ation ▁; ▁le a flet ▁motion ▁; ▁le a flet ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is
D-360	-0.2748483121395111	mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
P-360	-0.1456 -1.6111 -0.1237 -3.3785 -0.0344 -0.1808 -0.0353 -0.1127 -0.1204 -0.1048 -0.0656 -0.0429 -0.0056 -0.2449 -0.1227 -0.1513 -0.0238 -0.0269 -0.9702 -0.0101 -0.3454 -0.0532 -0.0100 -0.0278 -0.1744 -0.0231 -0.0472 -0.0848 -0.0005 -0.2087 -0.4282 -0.0806 -0.0750
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart ; patients ; new york heart association ; nyha ; hospitalized ; hf ; primary outcome ; death ; hf ; hospitalization
H-239	-0.434538334608078	▁h ART ▁; ▁New ▁York ▁Heart ▁Association ▁; NY HA ▁; ▁hospital ized ▁; ▁ HF ▁; ▁self - management ▁counsel ing ▁; ▁death ▁; ▁ HF ▁hospital ization
D-239	-0.434538334608078	hART ; New York Heart Association ;NYHA ; hospitalized ; HF ; self-management counseling ; death ; HF hospitalization
P-239	-2.0804 -0.0666 -0.2754 -1.0289 -0.3446 -0.9859 -0.9441 -0.1221 -0.0962 -1.0529 -0.2063 -1.7913 -0.0756 -0.3326 -0.1757 -0.1458 -0.4829 -0.1349 -0.0370 -0.0094 -0.0247 -0.0414 -0.4459 -0.7919 -0.1196 -0.1613 -0.2648 -0.6823 -0.3558 -0.0970 -0.0973
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in vivo ; cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
H-1783	-0.43653520941734314	▁cardiac ▁function ▁; ▁e cho card i ography ▁; ▁dia sto lic ▁dys function ▁; ▁e / e ▁; ▁sy sto lic ▁dys function ▁; ▁e je ction
D-1783	-0.43653520941734314	cardiac function ; echocardiography ; diastolic dysfunction ; e/e ; systolic dysfunction ; ejection
P-1783	-0.9290 -0.1098 -0.0647 -0.0752 -0.0356 -0.0812 -0.2466 -0.2315 -0.1590 -0.0074 -0.0234 -0.0927 -0.0646 -0.0382 -0.1550 -0.3151 -4.3114 -0.5740 -0.5505 -0.0253 -0.0724 -0.1092 -0.0795 -0.0426 -0.3621 -0.0523 -0.0960 -0.0270 -4.0767 -0.0880
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; hf ; pathogenesis ; hf
H-1038	-0.35115718841552734	▁ BET ▁; ▁bro modo main ▁protein s ▁; BET s ▁; ▁a ce tyl - ly sine ▁reader ▁protein s ▁; ▁ HF
D-1038	-0.35115718841552734	BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF
P-1038	-0.8408 -0.0886 -1.5844 -0.0252 -0.0119 -0.1459 -0.4149 -0.0895 -0.2237 -0.6753 -0.2224 -0.0659 -0.2094 -0.2234 -0.0535 -0.0382 -1.4140 -0.6566 -0.0228 -0.3345 -0.0450 -0.1504 -0.3595 -0.1744 -0.9300 -0.1300
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood transfusions ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
H-42	-0.29795360565185547	▁blood ▁trans fusion s ▁; ▁ir on ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease ▁; ▁trans fusion
D-42	-0.29795360565185547	blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
P-42	-2.7917 -0.0119 -0.0073 -0.1329 -0.2871 -0.0182 -0.0349 -0.2620 -0.0363 -0.1503 -0.2909 -0.2857 -0.6358 -0.2670 -0.2286 -0.0125 -0.1940 -0.7975 -0.3527 -1.3391 -0.0388 -0.0856 -0.0065 -0.1005 -0.6512 -0.2096 -0.0341 -0.0781 -0.0025 -0.3748 -0.2304 -0.3576 -0.4698 -0.0080 -0.0261 -0.0941 -0.1200
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade ; clinical
H-202	-0.4793563187122345	▁Grad ing ▁of ▁re com mend ations ▁assessment ▁; ▁Development ▁and ▁Evalua tion ▁; GRAD e
D-202	-0.4793563187122345	Grading of recommendations assessment ; Development and Evaluation ;GRADe
P-202	-0.4381 -0.1076 -0.6055 -0.7673 -0.0849 -0.0373 -0.0123 -1.8155 -0.2509 -0.9729 -0.5363 -0.9516 -0.1343 -0.2022 -0.0109 -0.1331 -1.5085 -0.0592
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf ; hospitalization
H-563	-0.7084835171699524	▁ HF
D-563	-0.7084835171699524	HF
P-563	-0.8206 -0.2811 -1.6014 -0.1308
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right heart circulatory failure ; disease ; right heart
H-1460	-0.8919950723648071	▁right ▁heart ▁circula tory ▁failure ▁; ▁mechanism s ▁of ▁disease ▁; ▁right ▁heart
D-1460	-0.8919950723648071	right heart circulatory failure ; mechanisms of disease ; right heart
P-1460	-6.6774 -0.6463 -0.0063 -0.0725 -0.0615 -0.6765 -1.2799 -0.0512 -2.0428 -0.6967 -0.3741 -0.3527 -0.2441 -0.0904 -0.1077
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular action potentials ; excitation-contraction ; myocardium
H-1671	-0.35976219177246094	▁volta ge - ga ted ▁ca (2 +) ▁channel s ▁; ▁vent ri cular ▁action ▁potential s ▁; ▁excita tion - con traction ▁; EC ▁; ▁coup ling ▁; ▁my o car dium
D-1671	-0.35976219177246094	voltage-gated ca(2+) channels ; ventricular action potentials ; excitation-contraction ;EC ; coupling ; myocardium
P-1671	-2.4349 -0.0828 -0.0444 -0.0136 -0.0585 -1.6781 -0.3714 -0.0020 -0.0866 -0.1643 -0.3695 -0.0675 -1.1067 -0.4875 -0.0284 -1.2117 -0.1312 -0.2015 -0.1587 -0.2416 -0.0412 -0.0269 -0.0741 -0.2099 -0.7906 -0.5040 -0.0891 -0.1238 -0.7918 -0.3882 -0.0323 -0.0130 -0.1818 -0.2225 -0.1617
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine ; exercise capacity ; left ventricular filling ; patients ; heart failure with preserved ejection fraction ; hfpef
H-1171	-0.18793293833732605	▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁fill ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1171	-0.18793293833732605	ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
P-1171	-0.0277 -0.0197 -0.1115 -0.0798 -0.3828 -1.0816 -0.1650 -0.0509 -0.0213 -0.0148 -0.5246 -0.1161 -0.5991 -0.0232 -0.1095 -0.7457 -0.0348 -0.2303 -0.0088 -0.0162 -0.1396 -0.0072 -0.0502 -0.0222 -0.3123 -0.0039 -0.4671 -0.1816 -0.0570 -0.1779 -0.1245 -0.1067
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; patients ; systolic dysfunction
H-1733	-0.3386583924293518	▁al do ster one ▁anta gon ism ▁; ▁heart ▁failure ▁; ▁al do ster one ▁; ▁neuro hormon e ▁; ▁electro ly tes ▁; ▁heart ▁failure ▁; ▁sy sto lic ▁dys function
D-1733	-0.3386583924293518	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
P-1733	-1.0587 -0.0691 -0.0812 -0.1605 -0.3569 -0.0046 -0.4610 -0.3765 -0.5127 -0.1468 -0.5820 -0.9602 -0.0238 -0.0191 -0.1998 -0.2045 -0.0848 -0.0182 -0.0825 -0.2979 -0.0053 -0.3844 -0.0230 -0.3337 -3.8739 -0.1348 -0.4261 -0.1275 -0.0381 -0.0896 -0.0241 -0.0670 -0.1858 -0.1003
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate analysis ; bnp ; estimated glomerular filtration rate ; hypertension ; transmitral ; e-wave ; diastolic mitral annular velocity
H-1570	-0.29293134808540344	▁b NP ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁hyper tension ▁; ▁transmit ral ▁e - wa ve ▁; ear ly ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1570	-0.29293134808540344	bNP ; glomerular filtration rate ; hypertension ; transmitral e-wave ;early diastolic mitral annular velocity
P-1570	-1.0275 -1.1521 -0.1306 -0.1321 -0.0609 -0.0316 -0.0650 -0.1666 -1.1071 -0.1356 -0.0917 -0.0124 -0.1431 -0.0148 -0.0671 -2.2870 -0.0145 -0.0311 -0.0058 -0.2302 -0.3793 -0.0213 -0.0069 -0.0373 -0.0094 -0.2049 -0.0273 -0.9825 -0.0022 -0.3838 -0.0433 -0.5518 -0.1098
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1 receptors ; neprilysin ; renin-angiotensin-aldosteron ; ras ; vasodilatory ; diuretic ; natriuretic peptides
H-1967	-0.3726794421672821	▁AT 1 ▁receptor s ▁; ▁nepri ly sin ▁block s ▁; ▁re nin - angi oten sin - al do ster on ▁; RAS ▁; ▁vaso dila tory ▁; ▁di ure tic ▁effect ▁; ▁na tri ure tic ▁pe pti des
D-1967	-0.3726794421672821	AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic effect ; natriuretic peptides
P-1967	-1.2135 -0.5056 -0.0133 -0.1881 -0.2732 -0.0119 -0.1723 -1.0259 -0.0793 -0.1294 -0.8468 -0.0608 -0.0848 -0.0179 -0.0007 -0.0466 -1.1494 -0.0809 -0.0174 -0.1788 -0.0289 -0.1648 -0.4467 -0.1230 -0.7901 -1.1426 -0.0048 -0.1085 -0.2227 -0.1211 -0.1926 -1.2925 -0.8728 -0.4761 -0.0031 -0.0579 -0.5998 -1.6593 -0.9659 -0.0943 -0.2857 -0.1581 -0.1172
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade ; halt ; disease ; protein kinase ; pka ; β-adrenergic receptor
H-1425	-0.3996099531650543	▁β - block ade ▁; ▁disease ▁progression ▁; ▁c AMP - dependent ▁protein ▁kina se ▁; ▁p ka ▁; ▁β - ad r energi c ▁receptor ▁activa tion
D-1425	-0.3996099531650543	β-blockade ; disease progression ; cAMP-dependent protein kinase ; pka ; β-adrenergic receptor activation
P-1425	-0.4793 -0.0718 -0.7286 -0.4208 -0.3039 -0.8589 -0.0717 -0.3601 -0.0082 -0.0204 -0.0462 -0.0085 -0.0844 -0.0075 -0.0666 -0.5212 -0.3897 -1.0050 -0.6650 -4.4979 -0.0181 -0.0610 -0.1827 -0.2899 -0.0502 -0.0202 -0.0295 -0.2782 -0.3154 -0.1275
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence ; erythropoiesis-stimulating agent ; therapy ; venous thromboembolism
H-47	-0.5149096846580505	▁er y thro po ies is - stimul ating ▁agent ▁ therapy
D-47	-0.5149096846580505	erythropoiesis-stimulating agent therapy
P-47	-0.5215 -0.0900 -0.2123 -0.4090 -1.2510 -0.1366 -0.1126 -0.0190 -0.2304 -0.0289 -0.5136 -0.0186 -3.5975 -0.0676
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable adjustment ; mortality ; hospitalization ; hazard ratio ; cardiovascular mortality ; hf ; hospitalization
H-1638	-0.3971669375896454	▁black ▁race ▁; ▁mortal ity ▁; hospital ization ▁; haz ard ▁ratio ▁; HR ▁; ▁cardiovascular ▁mortal ity ▁; HF ▁hospital ization
D-1638	-0.3971669375896454	black race ; mortality ;hospitalization ;hazard ratio ;HR ; cardiovascular mortality ;HF hospitalization
P-1638	-0.0048 -0.0905 -0.1101 -0.8780 -0.5277 -0.7271 -0.6182 -0.5454 -0.2525 -0.0095 -0.0039 -0.0024 -0.0827 -1.6845 -0.1813 -0.0215 -0.0411 -0.6232 -0.2290 -0.5363 -1.3675 -0.5301 -0.3148 -0.1500
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous ; chronic myocardial ischemia ; stent ; polytetrafluoroethylene
H-504	-0.41791167855262756	▁per cuta ne ous ▁one - ve sel ▁model ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁sten t ▁co ated ▁; ▁poly te tra flu oro e thy lene ▁tube
D-504	-0.41791167855262756	percutaneous one-vesel model ; chronic myocardial ischemia ; stent coated ; polytetrafluoroethylene tube
P-504	-2.8105 -0.0018 -0.0698 -0.1320 -1.5618 -0.0238 -1.9768 -0.0279 -0.1807 -0.5228 -0.1165 -1.4155 -0.1827 -0.4213 -0.2307 -0.1169 -0.0690 -0.5176 -0.2796 -0.0032 -0.0488 -0.0547 -0.0191 -1.6242 -0.1671 -0.0423 -0.4193 -0.0153 -0.0079 -0.1353 -0.0106 -0.1420 -0.1813 -1.0137 -0.0843
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical ; genetic ; chf ; area under the curve ; auc ; genetic ; auc ; clinical ; auc
H-1456	-0.4761563241481781	▁ clin ical ▁; ▁genetic ▁; ▁CHF ▁predict ive ▁model ▁; ▁cur ve ▁; AU c ▁; ▁genetic ▁; AU c ▁; ▁clinic al
D-1456	-0.4761563241481781	clinical ; genetic ; CHF predictive model ; curve ;AUc ; genetic ;AUc ; clinical
P-1456	-4.2917 -0.0148 -0.1232 -0.1541 -0.0559 -0.1253 -0.0181 -0.6015 -0.0352 -0.2519 -0.1541 -1.9589 -0.0349 -0.1284 -0.0812 -1.5161 -0.0500 -0.0448 -0.1354 -0.0557 -1.1656 -0.2484 -0.0337 -0.0088 -1.0227 -0.0697
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney ; prognostic ; hf index
H-1760	-0.5713285803794861	▁AT ▁; ▁oxygen ▁up take ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score ▁; ▁ HF ▁index
D-1760	-0.5713285803794861	AT ; oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; HF index
P-1760	-3.2451 -0.8689 -2.5721 -1.7647 -0.0570 -0.1093 -0.0599 -0.0494 -0.1188 -0.0772 -0.0078 -1.0988 -0.0233 -0.2429 -0.0155 -0.0227 -0.0975 -0.4393 -1.7494 -0.1991 -0.1228 -0.1150 -0.0842
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart failure ; hf ; tumor necrosis factor ; tnf ; tnf antagonists ; disease ; severe hf
H-601	-0.3833390772342682	▁heart ▁failure ▁; HF ▁; ▁tumor ▁nec rosi s ▁factor ▁; TN F ▁; ▁t NF ▁anta gon ists ▁; ▁ HF
D-601	-0.3833390772342682	heart failure ;HF ; tumor necrosis factor ;TNF ; tNF antagonists ; HF
P-601	-0.2561 -0.0955 -0.1269 -0.0438 -0.1308 -0.1235 -0.1236 -0.0029 -0.0799 -0.0389 -0.3533 -0.0643 -1.0285 -0.7912 -1.9476 -0.0783 -0.1742 -0.0031 -0.1114 -0.2187 -2.8115 -0.3719 -0.1513 -0.0728
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers for medicare and medicaid services ; cms ; hospital ; outcomes ; reported ; mortality ; readmission ; penalties
H-1031	-0.4571130573749542	▁Center s ▁for ▁Medica re ▁and ▁Medica id ▁Services ▁; ▁c MS ▁; ▁hospital ▁quality ▁of ▁care ▁outcome s ▁; ▁risk - standard ized ▁mortal ity ▁; ▁read mission ▁rates ▁; ▁penal ties
D-1031	-0.4571130573749542	Centers for Medicare and Medicaid Services ; cMS ; hospital quality of care outcomes ; risk-standardized mortality ; readmission rates ; penalties
P-1031	-0.7280 -0.0433 -0.3310 -0.0213 -0.0263 -0.4326 -0.0158 -0.0124 -0.2115 -0.3245 -0.2114 -1.2119 -0.7818 -2.6287 -0.3780 -0.9162 -1.0581 -0.3210 -0.0493 -0.3444 -2.3891 -0.0220 -0.0192 -0.0166 -0.0467 -0.3220 -0.2194 -0.3627 -1.0052 -0.2347 -1.0122 -0.0549 -0.0196 -0.1123 -0.1148
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox proportional hazard models ; covariates ; follow-up ; physician ; discharge ; primary outcome ; death ; all-cause readmission
H-1416	-0.2712230384349823	▁co x ▁proportion al ▁hazard ▁models ▁; ▁follow - up ▁; ▁physician ▁; ▁dis charge ▁; ▁death ▁; ▁urgent ▁all - ca use ▁read mission
D-1416	-0.2712230384349823	cox proportional hazard models ; follow-up ; physician ; discharge ; death ; urgent all-cause readmission
P-1416	-0.0402 -0.0161 -0.0182 -0.0037 -0.0244 -0.5996 -0.3112 -0.3604 -0.0422 -0.0055 -0.6192 -0.4109 -0.3860 -0.3605 -0.0274 -0.5239 -1.4102 -0.2008 -0.1032 -0.5455 -0.0179 -0.0028 -0.1846 -0.2635 -0.6925 -0.0700 -0.0825
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate logistic regression analysis ; rule ; cad ; stenosis ; 3-vessel cad ; 2-vessel cad ; left anterior descending artery
H-1187	-0.49909529089927673	▁logistic ▁re gression ▁analysis ▁; ▁severe ▁CAD ▁; ▁diameter ▁sten osis ▁; ▁left ▁main ▁; ▁3- ves sel ▁CAD ▁; ▁2- ves sel ▁CAD ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁arter y
D-1187	-0.49909529089927673	logistic regression analysis ; severe CAD ; diameter stenosis ; left main ; 3-vessel CAD ; 2-vessel CAD ; proximal left anterior descending artery
P-1187	-5.8219 -0.0213 -0.0022 -0.1745 -0.1579 -1.0474 -0.1593 -0.1182 -0.0912 -0.0139 -0.0122 -0.2296 -3.2545 -0.0063 -0.0904 -0.7402 -0.1008 -0.0017 -0.0893 -0.1111 -2.7131 -0.1089 -0.0026 -0.0733 -0.2669 -0.2316 -0.0196 -0.3505 -0.8974 -0.0217 -0.0277 -0.0217 -0.2265 -0.1861 -0.0768
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate ; signal transduction ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
H-1040	-0.3365075886249542	▁signal ▁trans duction ▁casca de ▁; ▁tran scription ▁factors ▁; ▁cardio my o cy tes ▁; ▁tran scription ▁factors ▁; ▁epi gene tic ▁; ▁chr omat in ▁structure
D-1040	-0.3365075886249542	signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
P-1040	-0.3740 -0.0411 -0.8521 -0.0683 -0.0597 -0.2096 -0.2608 -0.0479 -0.4470 -0.3356 -0.1892 -0.6721 -0.3431 -0.0515 -0.0554 -0.3686 -0.4416 -0.0950 -0.4389 -0.2441 -0.6144 -0.1191 -0.6469 -2.2056 -0.0395 -0.0154 -0.2429 -0.2836 -0.1791 -0.1531
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients ; hypertensive hfpef ; dash ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
H-926	-0.15443089604377747	▁hyper tensi ve ▁H FP EF ▁; ▁so dium - re strict ed ▁DAS h ▁die t ▁; ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling
D-926	-0.15443089604377747	hypertensive HFPEF ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
P-926	-0.3404 -0.1223 -0.0130 -0.6172 -0.4710 -0.2272 -0.0545 -0.0044 -0.0159 -0.0038 -0.0152 -0.0079 -0.0197 -0.1348 -0.2125 -0.8439 -0.0226 -0.0954 -0.0109 -0.5349 -0.0529 -0.0155 -0.0312 -0.0206 -0.0863 -0.1113 -0.0146 -0.0993 -0.1057 -0.1236 -0.0086 -0.6575 -0.0856 -0.0817 -0.0369 -0.0255 -0.0560 -0.5321 -0.1771 -0.0878
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular dilatation
H-334	-0.1644599735736847	▁ann ular ▁size ▁re duction ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁di la tation
D-334	-0.1644599735736847	annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
P-334	-0.7604 -0.0004 -0.1653 -0.1107 -0.0109 -0.1290 -0.1254 -0.0727 -0.0008 -0.0149 -0.0126 -0.1004 -0.0223 -0.2343 -0.0996 -0.0132 -0.1382 -0.0304 -0.2199 -0.3749 -0.0412 -0.0544 -0.0028 -0.0329 -0.2101 -1.3054 -0.6196 -0.1147 -0.1117 -0.0124 -0.2120 -0.3094 -0.1127 -0.0386 -0.0378 -0.4063 -0.0383 -0.0164 -0.3591 -0.0963 -0.1937 -0.1490 -0.0090 -0.1841 -0.0965
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized aldactone evaluation study ; symptomatic chronic advanced heart failure ; patients ; aldosterone antagonist ; spironolactone ; mortality ; placebo
H-1735	-0.3398209810256958	▁Rand om ized ▁al da cto ne ▁Evalua tion ▁Study ▁; ▁chronic ▁advanced ▁heart ▁failure ▁patients ▁; ▁al do ster one ▁anta gon ist ▁; ▁spi rono lac tone ▁; ▁mortal ity
D-1735	-0.3398209810256958	Randomized aldactone Evaluation Study ; chronic advanced heart failure patients ; aldosterone antagonist ; spironolactone ; mortality
P-1735	-1.9707 -0.1000 -0.0354 -0.3716 -0.0410 -0.0442 -0.2665 -0.1956 -0.1552 -0.2916 -0.1460 -2.2959 -0.8288 -0.8490 -0.0599 -0.5167 -0.1692 -0.0658 -0.1203 -0.0390 -0.2456 -0.1065 -0.0011 -0.1683 -0.0844 -0.0012 -0.0030 -0.0163 -0.0464 -0.7610 -0.4490 -0.7981 -0.2102 -0.1005
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence ; mortality ; outcomes ; heart failure ; acute myocardial infarction ; patients ; acute myocardial infarction ; western australia
H-1305	-0.8395743370056152	▁incide nce ▁; ▁mortal ity ▁; ▁heart ▁failure ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁Western ▁Australia
D-1305	-0.8395743370056152	incidence ; mortality ; heart failure ; acute myocardial infarction ; Western Australia
P-1305	-5.9625 -0.7245 -0.8588 -0.0401 -0.8673 -1.2213 -0.3558 -0.0827 -0.3805 -0.0903 -0.0157 -2.0649 -0.5339 -0.8676 -0.4605 -0.0229 -0.1888 -0.1747 -0.3609 -3.1134 -0.5404 -0.2215 -0.1613
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf ; hct ; polymorphisms ; genes ; anthracycline ; metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
H-1450	-0.19960618019104004	▁CHF ▁; ▁h CT ▁; ▁poly morph ism s ▁; ▁an thra cycli ne ▁metabolism ▁; ▁ir on ▁home osta sis ▁; ▁anti - oxid ant ▁de fen ce ▁; ▁my o card ial ▁remodel ling
D-1450	-0.19960618019104004	CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
P-1450	-0.0477 -0.3728 -2.0833 -0.4806 -0.0901 -0.4304 -0.0045 -0.1635 -0.1793 -0.1431 -0.1085 -0.0177 -0.0980 -0.6071 -0.0325 -0.0725 -0.1567 -0.0147 -0.2789 -0.0346 -0.0545 -0.0945 -0.0022 -0.0200 -0.0025 -0.0475 -0.0373 -0.0355 -0.3531 -0.1869 -0.2108 -0.0533 -0.4467 -0.1927 -0.0129 -0.0952 -0.2391 -0.0838
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.2631981372833252	▁medication ▁; no nadh er ence
D-559	-1.2631981372833252	medication ;nonadherence
P-559	-0.7341 -0.4510 -1.5318 -2.3094 -0.0509 -2.0052 -2.8932 -0.1300
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological ; diagnostic ; prognostic
H-1278	-0.8478477001190186	▁pat ho phy si ological ▁origin
D-1278	-0.8478477001190186	pathophysiological origin
P-1278	-0.5251 -0.5349 -0.3492 -0.8642 -0.3806 -1.9562 -2.1001 -0.0724
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad ; surgery ; patients ; albumin ; hypoalbuminemia ; surgery
H-534	-0.6110835671424866	▁l VAD ▁; ▁album in ▁levels ▁; ▁hypo album in emia
D-534	-0.6110835671424866	lVAD ; albumin levels ; hypoalbuminemia
P-534	-0.4782 -0.0326 -2.4979 -1.5342 -0.1938 -1.8911 -0.2790 -0.0394 -0.0736 -0.0697 -0.1097 -0.6549 -0.0901
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate model ; creatinine ; hazard ratio ; confidence interval ; mortality
H-717	-0.3930210769176483	▁creati nine ▁; haz ard ▁ratio ▁; ▁post - trans plant ▁mortal ity
D-717	-0.3930210769176483	creatinine ;hazard ratio ; post-transplant mortality
P-717	-0.0525 -0.1379 -0.3465 -0.0443 -0.0022 -0.0031 -0.2929 -3.8024 -0.0298 -0.0791 -0.0178 -0.1003 -0.7609 -0.0845 -0.1411
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death ; patients ; estimated glomerular filtration rate ; odds ratio ; confidence interval
H-977	-0.6009976863861084	▁risk ▁of ▁death ▁; ▁glo mer ular ▁filtr ation ▁rate
D-977	-0.6009976863861084	risk of death ; glomerular filtration rate
P-977	-0.8474 -1.3943 -0.2859 -0.4519 -0.2709 -0.1602 -0.0620 -0.1839 -0.3405 -1.2761 -1.8252 -0.1136
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical ; hm ii ; heartware ; patients ; economic ; hm ii
H-310	-0.4146295189857483	▁scientific ▁literature ▁; ▁ HM ▁II ▁; ▁Heart War e ▁patients ▁; ▁economic ▁evaluation s ▁; HM ▁II ▁; ▁simula tion ▁models
D-310	-0.4146295189857483	scientific literature ; HM II ; HeartWare patients ; economic evaluations ;HM II ; simulation models
P-310	-0.4373 -0.6407 -0.0641 -1.9431 -0.0827 -0.9224 -0.1022 -1.0336 -0.0292 -0.0297 -0.2766 -0.0959 -0.6733 -0.3496 -0.0822 -0.1674 -0.2290 -0.6015 -1.1437 -0.1195 -0.1167 -0.4923 -0.1818 -0.1367
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine ; nesiritide ; renal function ; patients ; acute heart failure ; renal dysfunction
H-72	-0.31059426069259644	▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-72	-0.31059426069259644	dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
P-72	-1.1912 -0.0765 -0.0392 -2.6654 -0.0138 -0.2090 -0.0608 -0.6052 -0.0061 -0.1363 -0.2976 -0.3287 -0.1907 -0.2711 -0.1999 -0.0065 -0.1819 -0.0480 -0.1837 -0.0064 -0.2515 -0.1267 -0.2443 -0.1138
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized ; hr variability ; hr variability ; clinical ; risk stratification ; cardiac ; patients
H-1591	-1.2201769351959229	▁HR ▁variabil ity / tur bul ence ▁; ▁HR ▁variabil ity / tur bul ence ▁; ▁cardiac ▁patients
D-1591	-1.2201769351959229	HR variability/turbulence ; HR variability/turbulence ; cardiac patients
P-1591	-2.5853 -0.0712 -0.8597 -2.6827 -0.1269 -0.4012 -2.7295 -0.4293 -3.1304 -0.0702 -1.2709 -2.8512 -0.3091 -0.3390 -3.2350 -0.6760 -1.7844 -0.5473 -0.1238 -0.1805
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications ; implantation ; lvad therapy ; transplantation ; btt ; dt ; medical therapy
H-313	-0.3867737948894501	▁l VAD ▁ therapy ▁; ▁transplant ation ▁e ligi bility ▁status ▁; ▁device ▁; ▁b t ▁; ▁ DT ▁; ▁medical ▁ therapy
D-313	-0.3867737948894501	lVAD therapy ; transplantation eligibility status ; device ; bt ; DT ; medical therapy
P-313	-2.2177 -0.0163 -1.1463 -0.0119 -0.3343 -0.3017 -0.1403 -0.1538 -0.0067 -0.3237 -0.0247 -0.1505 -0.1391 -0.2989 -1.1693 -0.7294 -0.0499 -1.2859 -0.1619 -0.3928 -0.1135 -0.2421 -0.0238 -0.1333 -0.1017
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical ; artery tonometry ; prospectively ; admission ; patients ; icu ; clinical
H-580	-0.7470618486404419	▁diagnosti c ▁; ▁radi al ▁arter y ▁ton ometr y ▁; ▁p ▁; ▁ ICU
D-580	-0.7470618486404419	diagnostic ; radial artery tonometry ; p ; ICU
P-580	-3.9765 -0.5668 -0.0812 -0.0465 -0.0272 -0.0314 -0.2370 -0.0857 -0.0251 -0.1102 -0.9601 -2.8018 -1.6253 -1.6604 -0.0105 -0.3499 -0.1046
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully magnetically levitated centrifugal-flow chronic lvas ; adverse event ; quality of life ; functional status
H-2006	-0.2794014513492584	▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic ▁l VAS
D-2006	-0.2794014513492584	magnetically levitated centrifugal-flow chronic lVAS
P-2006	-0.9519 -0.0736 -0.0123 -0.0160 -0.1303 -0.1425 -0.8510 -0.0954 -0.0358 -0.0315 -0.2520 -0.6923 -0.1360 -0.7007 -0.0698
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome complex ; scaffold protein ; drives ; kinases ; phosphorylation ; effector molecules
H-995	-0.3430841565132141	▁e RK 1/2 ▁signal ling ▁; ▁signal o some ▁complex ▁; ▁sc af fold ▁protein ▁; ▁kina ses ▁; ▁sequenti al ▁ phos phor y lation
D-995	-0.3430841565132141	eRK1/2 signalling ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
P-995	-0.6751 -0.0205 -0.0783 -0.1897 -0.2220 -0.2714 -0.4349 -0.5277 -0.8216 -0.2846 -0.1159 -0.1943 -0.1852 -0.0647 -0.2062 -0.2645 -0.2892 -0.9482 -0.2595 -0.0375 -0.0142 -0.0895 -0.1418 -1.0883 -0.8898 -0.0370 -1.1458 -0.1089
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast cancer ; patients ; medicare ; diagnosed ; breast cancer ; chemotherapy ; seer-medicare ; texas ; medicare
H-672	-0.3305753469467163	▁breast ▁cancer ▁patients ▁; ▁full ▁Medica re ▁coverage ▁; ▁diagnose d ▁; ▁stage ▁I - III ▁breast ▁cancer ▁; ▁che mo therapy ▁; ▁s EER - Medic are ▁; ▁Texas ▁Cancer ▁Registr y – Medic are ▁database s
D-672	-0.3305753469467163	breast cancer patients ; full Medicare coverage ; diagnosed ; stage I-III breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry–Medicare databases
P-672	-1.2850 -0.2236 -0.2496 -0.2675 -0.1149 -0.0125 -0.0137 -0.0330 -0.2361 -0.9949 -0.0264 -1.6812 -0.6819 -0.4439 -0.0484 -0.0305 -0.0186 -0.0756 -0.2853 -0.4639 -0.1294 -0.0261 -0.3331 -0.3198 -0.0600 -0.0090 -0.1252 -0.1563 -0.0657 -0.1744 -2.0476 -0.2633 -0.0131 -1.1430 -0.1452 -0.1748 -0.3891 -0.1862 -0.1766 -0.0987
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection fraction ; b-type natriuretic peptide ; patients ; hospitalized ; heart failure ; inhospital ; outcomes ; get with the guideline-heart failure registry
H-186	-0.3663453161716461	▁e je ction ▁ fraction ▁; ▁na tri ure tic ▁pe pti de ▁levels ▁; ▁patients ▁hospital ized ▁with ▁heart ▁failure ▁; ▁in hospital ▁outcome s ▁; ▁Guide line - He art ▁Fail ure ▁Registr y
D-186	-0.3663453161716461	ejection fraction ; natriuretic peptide levels ; patients hospitalized with heart failure ; inhospital outcomes ; Guideline-Heart Failure Registry
P-186	-0.5697 -0.0573 -0.0109 -0.1996 -0.0029 -0.0927 -0.2100 -0.3612 -0.3593 -1.0163 -0.4568 -0.0281 -0.0943 -1.1019 -0.2163 -1.4086 -0.2505 -0.0838 -1.2066 -0.2226 -0.0600 -0.3438 -0.0219 -0.0296 -0.1603 -0.0794 -0.3972 -2.0548 -0.0140 -0.0326 -0.9614 -0.4540 -0.1658 -0.4956 -0.3862 -0.0882 -0.1095 -0.1175
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased ; cardiomyocytes ; pde2 ; activity ; cgmp synthesis ; nitric oxide ; donors ; pde2 inhibition ; β-ar responsiveness
H-1215	-0.3306752145290375	▁cardio my o cy tes ▁; ▁p de 2 ▁activity ▁; ▁c g MP ▁synth es is ▁; ▁ni tric ▁oxid e ▁donor s ▁; ▁p de 2 ▁inhibi tion ▁; ▁β - AR ▁responsive ness
D-1215	-0.3306752145290375	cardiomyocytes ; pde2 activity ; cgMP synthesis ; nitric oxide donors ; pde2 inhibition ; β-AR responsiveness
P-1215	-0.6267 -0.9438 -0.2006 -0.0558 -0.0361 -0.1742 -0.6264 -1.2111 -0.0693 -1.0845 -0.1865 -0.0294 -1.4623 -0.3602 -0.0404 -0.0292 -0.1334 -0.5689 -0.0070 -0.0315 -0.0098 -0.0594 -0.0137 -0.0761 -0.2410 -0.3321 -1.1762 -0.0944 -0.1690 -0.1995 -0.3500 -0.0532 -0.0169 -0.2564 -0.0664 -1.3253 -0.1490 -0.1001
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko ; cardiac ; irs1 ; irs2 ; proteins ; heart failure ; cardiac energy metabolism gene expression ; p38α ; mitogen-activated protein kinase ; p38
H-656	-0.30282729864120483	▁l - d ko ▁mi ce ▁; ▁cardiac ▁I RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁heart ▁failure ▁; ▁cardiac ▁energy ▁metabolism ▁; ▁p 38 α ▁mit ogen - activa ted ▁protein ▁kina se
D-656	-0.30282729864120483	l-dko mice ; cardiac IRS1 ; iRS2 proteins ; heart failure ; cardiac energy metabolism ; p38α mitogen-activated protein kinase
P-656	-1.2011 -0.0610 -0.5004 -0.2761 -0.9552 -0.2536 -0.2791 -0.1380 -1.0824 -0.0587 -0.9443 -0.3515 -0.8019 -0.1432 -0.0780 -0.3163 -0.0463 -0.1400 -0.5476 -0.0684 -0.2134 -1.0612 -0.4998 -0.0269 -0.1614 -0.2585 -0.0938 -0.0715 -0.1945 -0.0238 -0.0913 -0.0337 -0.1100 -0.0717 -0.0043 -0.0363 -0.2066 -0.1057
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs ; hdl ; phosphorylation
H-251	-0.3204994797706604	▁EC s ▁; ▁HD L ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁e NOS - Th r ▁; ▁PK c - β II - Ser
D-251	-0.3204994797706604	ECs ; HDL ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser
P-251	-0.8833 -0.3035 -0.1817 -0.1761 -1.7426 -0.1320 -0.0399 -0.0448 -0.2598 -0.8977 -0.1385 -0.1704 -0.0153 -0.0277 -0.0403 -0.1829 -0.7044 -0.0219 -0.0271 -0.0332 -0.9295 -0.0029 -0.2046 -0.1696 -0.5678 -0.0280 -0.0362 -0.4516 -0.0551 -0.0845 -1.5713 -0.1318
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp ; 6-minute walking distance ; peak o2
H-829	-1.1911498308181763	▁pas p
D-829	-1.1911498308181763	pasp
P-829	-1.6904 -0.5717 -2.4118 -0.0908
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts ; patients ; sts ; hh ; sts
H-155	-0.9314950108528137	▁r CT s ▁; ▁s ts ▁; ▁ HH ▁; ▁ HM ▁; ▁s ts ▁; ▁TM
D-155	-0.9314950108528137	rCTs ; sts ; HH ; HM ; sts ; TM
P-155	-2.3326 -0.3582 -0.3509 -0.2671 -1.8387 -1.0240 -0.0879 -2.6010 -0.1876 -0.1044 -1.9212 -0.4610 -0.1501 -2.1643 -1.7795 -0.1576 -1.2705 -0.5235 -0.1184
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular myocytes ; sarcomere ; shortening
H-417	-0.37921443581581116	▁mouse ▁vent ri cular ▁my o cy tes ▁; ▁sar com ere ▁short en ing ▁; ▁ca (2 +) ▁trans ient
D-417	-0.37921443581581116	mouse ventricular myocytes ; sarcomere shortening ; ca(2+) transient
P-417	-0.5959 -0.0194 -0.3373 -0.1217 -1.1350 -0.0741 -0.0397 -0.0620 -0.1850 -0.4769 -0.0839 -0.0397 -0.6310 -0.0334 -0.1540 -0.6123 -3.5155 -0.3015 -0.0010 -0.0095 -0.0598 -0.1646 -0.0687
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative ; alberta ; discharged ; hospital ; diagnosis ; heart failure
H-1415	-0.600354015827179	▁administratie ▁database s ▁; ▁Albert a ▁; ▁dis charge d ▁ali ve ▁; ▁hospital ▁; ▁heart ▁failure
D-1415	-0.600354015827179	administratie databases ; Alberta ; discharged alive ; hospital ; heart failure
P-1415	-3.4158 -0.3832 -0.0771 -0.1866 -1.7968 -0.1102 -0.4021 -0.4429 -0.0302 -0.0143 -0.0615 -0.0234 -1.5410 -0.2050 -0.3661 -2.0517 -0.0991 -0.1217 -0.0779
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart failure ; histologically ; myocardial collagen ; healthy ; heart failure
H-1062	-0.734184980392456	▁animals ▁; ▁heart ▁failure ▁; ▁his t ological ly ▁; ▁my o card ial ▁collage n ▁; ▁tissu e ▁; ▁control ▁; ▁heart ▁failure
D-1062	-0.734184980392456	animals ; heart failure ; histologically ; myocardial collagen ; tissue ; control ; heart failure
P-1062	-3.3165 -0.9369 -0.9709 -0.1548 -0.2521 -4.4052 -0.0315 -0.1421 -0.1427 -0.1485 -0.4421 -0.1416 -0.1945 -0.0933 -0.0250 -0.0811 -0.2789 -0.3032 -0.0386 -0.2922 -4.3290 -0.1176 -1.8489 -0.0839 -0.2344 -0.0833
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates ; crt ; death ; hf ; hospitalization ; hazard ratio ; lvef
H-757	-0.41028791666030884	▁c RT ▁on ▁assign ment ▁; ▁time ▁to ▁death ▁; ▁first ▁ HF ▁hospital ization ▁; haz ard ▁ratio ▁; ▁LV EF
D-757	-0.41028791666030884	cRT on assignment ; time to death ; first HF hospitalization ;hazard ratio ; LVEF
P-757	-0.1676 -1.6604 -1.8981 -0.0648 -0.1098 -0.1235 -1.7190 -0.0290 -0.1265 -0.0690 -1.6330 -0.0672 -0.1588 -0.3013 -0.4617 -0.3111 -0.0141 -0.0049 -0.0023 -0.3898 -0.1213 -0.2957 -0.0474 -0.0705
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor 1 ; s1pr1 ; downregulation ; cardiac ; hypertrophic ; heart failure ; s1pr1 ; cardiac ; gene ; therapy
H-1404	-0.37939584255218506	▁beta 1- ad r energi c ▁receptor ▁; ▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁reciproc al ▁down regul ation ▁; ▁cardiac ▁hyper trop hic ▁response ▁; ▁progression ▁to ▁heart ▁failure ▁; ▁s 1 PR 1 ▁cardiac ▁gene ▁ therapy
D-1404	-0.37939584255218506	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; progression to heart failure ; s1PR1 cardiac gene therapy
P-1404	-0.6817 -0.5468 -0.1871 -0.1428 -0.1820 -0.1079 -0.0064 -0.1107 -0.0033 -0.5996 -0.3572 -3.1248 -1.3044 -0.3525 -0.0032 -0.0285 -0.1141 -0.0075 -0.5020 -0.7830 -0.4344 -1.4243 -1.6795 -0.0236 -0.0040 -0.2002 -0.0760 -0.2038 -0.1923 -0.0105 -0.1581 -0.0054 -0.4550 -0.0582 -0.1268 -0.4069 -0.1933 -0.1383 -0.1068 -0.5156 -0.5546 -0.1862 -0.3785 -1.1538 -0.0551 -0.6497 -0.2330 -0.0129 -0.1150 -0.0723
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative risk ; rr ; heart failure ; bisphophonates ; rr ; confidence interval ; hazard ratio
H-1540	-0.5821008086204529	▁ RR ▁; ▁heart ▁failure ▁; ▁bis pho phon ates ▁; ▁cru de ▁ RR ▁; ▁confidence ▁interval ▁; CI ▁; ▁adjust ed ▁hazard ▁ratio ▁; HR
D-1540	-0.5821008086204529	RR ; heart failure ; bisphophonates ; crude RR ; confidence interval ;CI ; adjusted hazard ratio ;HR
P-1540	-4.3766 -0.1918 -0.2857 -1.5518 -0.1451 -0.1950 -0.5309 -0.0289 -0.1365 -0.5488 -0.4024 -0.0428 -0.0273 -0.5478 -0.0438 -0.3004 -1.7143 -0.0049 -0.2957 -1.5827 -0.3039 -2.2109 -0.0449 -0.0756 -0.0062 -0.4431 -0.4254 -0.3020 -0.1161
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare ; centers for medicare and medicaid services ; clinics ; propensity-score
H-1621	-0.33811768889427185	▁hoog - co st ▁Medica re ▁fee - for - service ▁beneficiar ies ▁; ▁Center s ▁for ▁Medica re ▁; ▁Medica id ▁Services
D-1621	-0.33811768889427185	hoog-cost Medicare fee-for-service beneficiaries ; Centers for Medicare ; Medicaid Services
P-1621	-2.2520 -0.0255 -0.0252 -0.0391 -0.0561 -0.0497 -1.1310 -0.0259 -0.0323 -0.0374 -0.0452 -0.4321 -0.0792 -0.3252 -0.6093 -0.1859 -0.3938 -0.0195 -0.0145 -1.4000 -0.0110 -0.0601 -0.1085 -0.9464 -0.1482
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician ; heart failure ; clinical practice guideline ; cpg ; outcomes ; heart failure ; hf
H-1841	-0.4893268346786499	▁physician ▁ad her ence ▁; ▁guide line ▁recommendations ▁in ▁heart ▁failure ▁; ▁systematic ▁review ▁protocol ▁; ▁Clinic al ▁practice ▁Guide line ▁; CP g ▁; ▁outcome s ▁; ▁heart ▁failure ▁; HF
D-1841	-0.4893268346786499	physician adherence ; guideline recommendations in heart failure ; systematic review protocol ; Clinical practice Guideline ;CPg ; outcomes ; heart failure ;HF
P-1841	-1.1604 -0.0614 -0.1687 -0.3046 -0.7252 -0.1387 -0.0169 -0.3622 -1.2569 -0.3653 -0.0354 -0.3501 -1.9914 -0.0036 -0.0521 -0.0657 -0.6389 -0.0070 -0.5346 -0.7183 -0.0193 -0.1634 -0.3522 -0.7755 -0.2562 -4.3601 -0.0424 -0.6400 -0.3383 -0.0597 -0.2663 -0.1434 -0.1624 -0.1004
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil ; heart failure ; hemodynamic ; mitochondrial dysfunction ; antitumor ; activity
H-967	-0.1513940840959549	▁nic oran dil ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁hem o dynamic ▁perturba tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁ultra struct ural ▁; ▁anti tum or
D-967	-0.1513940840959549	nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; ultrastructural ; antitumor
P-967	-0.0551 -0.0060 -0.0613 -0.1252 -0.0760 -0.0021 -0.0055 -0.5714 -0.0648 -0.0159 -0.0577 -0.3129 -0.0991 -0.2652 -0.0572 -0.0317 -0.3577 -0.0858 -0.0537 -0.0012 -0.0032 -0.0389 -0.1471 -0.0011 -0.1822 -0.0332 -0.0150 -0.0201 -0.0151 -0.1581 -0.0136 -0.0104 -0.0056 -0.9421 -0.0062 -0.3223 -0.0223 -1.5773 -0.0849
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq ; new york heart association class ; patients ; hfpef ; hf with reduced ef
H-788	-0.4803066551685333	▁k cc q ▁summary ▁score s ▁; ▁New ▁York ▁Heart ▁association ▁class ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁EF
D-788	-0.4803066551685333	kccq summary scores ; New York Heart association class ; HFpEF ; HF ; EF
P-788	-1.3380 -0.0939 -1.3431 -0.3824 -0.0607 -0.0670 -0.1073 -0.2465 -0.2349 -1.0479 -1.0031 -0.4709 -0.0569 -0.9542 -0.1948 -0.0929 -0.0800 -0.0594 -0.2526 -0.3384 -0.4668 -2.0291 -0.5330 -0.0735
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm control therapy ; diagnosis ; atrial ; sinus rhythm ; rhythm control ; symptoms ; rate control
H-1646	-0.3241945207118988	▁ Rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁at rial ▁structure ▁; ▁function ▁; ▁sinus ▁ rhythm ▁; ▁de lay ed ▁ rhythm ▁control ▁; ▁rate ▁control
D-1646	-0.3241945207118988	Rhythm control therapy ; AF ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
P-1646	-0.5748 -0.2683 -0.3367 -0.4180 -0.0103 -0.1903 -0.9185 -0.1690 -1.0580 -0.0385 -0.0271 -0.0568 -1.4495 -0.0455 -0.1646 -0.2248 -0.1506 -0.2857 -0.0591 -0.0047 -0.0082 -0.0440 -0.3092 -0.2114 -0.5933 -1.4051 -0.1690 -0.1434 -0.0674
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic ; therapy
H-83	-0.23183710873126984	▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁de con gestion ▁; ▁renal ▁function ▁; ▁di ure tic ▁ therapy
D-83	-0.23183710873126984	acute heart failure ; renal dysfunction ; dopamine ; low-dose nesiritide ; decongestion ; renal function ; diuretic therapy
P-83	-0.3321 -0.0068 -0.2448 -0.0239 -0.1375 -0.0029 -0.0421 -0.0344 -0.2243 -0.5016 -0.0568 -0.0758 -0.6701 -0.0133 -0.0846 -0.0482 -1.3782 -0.0080 -0.0899 -0.1698 -0.5028 -0.0133 -0.0185 -0.1427 -0.0089 -0.1424 -0.6002 -0.0453 -0.4974 -1.1032 -0.3461 -0.0506 -0.1699 -0.0962
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf ; prospective ; dual-energy x-ray absorptiometry ; echocardiography ; blood
H-1161	-0.436091810464859	▁ HF ▁; ▁body ▁composition ▁; ▁s kin fold ▁thi ck ness ▁; ▁dual - ener gy ▁X - ray ▁ab sor pti ometr y ▁; ▁e cho card i ography ▁; ▁blood ▁testing
D-1161	-0.436091810464859	HF ; body composition ; skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
P-1161	-1.3807 -0.3868 -0.1820 -3.3298 -0.2954 -0.1576 -1.4184 -1.9220 -0.0985 -0.3176 -0.0204 -0.8878 -0.2034 -0.0135 -0.0453 -0.1347 -0.0284 -1.9667 -0.0422 -0.2348 -0.0227 -0.2202 -0.1434 -0.0672 -0.2350 -0.1212 -0.0899 -0.0378 -0.2128 -0.3799 -0.2176 -0.2555 -0.0426 -0.2766 -0.1834 -0.1274
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients ; heart failure
H-1744	-1.21540367603302	▁heart ▁failure ▁treatment
D-1744	-1.21540367603302	heart failure treatment
P-1744	-3.0615 -0.2827 -1.5691 -0.9771 -0.1865
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp ; red blood cell transfusion ; hemoglobin ; hemoglobin ; hospitalized ; patients ; coronary heart disease
H-36	-0.5723044872283936	▁a CP ▁; ▁restrict ive ▁red ▁blood ▁cell ▁trans fusion ▁strategy ▁; ▁tri gger ▁hem o glob in ▁thre s hold ▁; ▁hem o glob in ▁levels ▁; ▁hospital ized ▁patients ▁; ▁corona ry ▁heart ▁disease
D-36	-0.5723044872283936	aCP ; restrictive red blood cell transfusion strategy ; trigger hemoglobin threshold ; hemoglobin levels ; hospitalized patients ; coronary heart disease
P-36	-1.1149 -1.1346 -0.3640 -0.2806 -0.0219 -0.1756 -0.3568 -0.5177 -0.0881 -0.0163 -1.9510 -0.1058 -1.2866 -0.0041 -0.4328 -0.8705 -0.5901 -0.9194 -0.2186 -0.0720 -0.3124 -0.1396 -1.2164 -0.5925 -0.4370 -0.5343 -1.3383 -0.5428 -1.8611 -0.0763 -0.5516 -1.2201 -0.0094 -0.9330 -0.2671 -0.8460 -0.1909 -0.1574
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals ; patients ; hospitalized ; heart failure ; hf ; conditions ; acute myocardial infarction ; pneumonia ; conditions
H-1032	-0.5579878687858582	▁hospital s ▁; ▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁pneu monia
D-1032	-0.5579878687858582	hospitals ; heart failure ;HF ; acute myocardial infarction ; pneumonia
P-1032	-4.2853 -0.3539 -0.2061 -4.0453 -0.0691 -0.2403 -0.0370 -0.2223 -0.8775 -0.0015 -0.7615 -0.1315 -0.1279 -0.1740 -0.0078 -0.0320 -0.0703 -0.1750 -0.0018 -0.1214 -0.1985 -0.1359
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted ; interatrial shunt ; clinical ; haemodynamic ; outcomes ; patients ; heart failure with reduced ejection fraction
H-1962	-0.48399972915649414	▁implant ed ▁left - to - right ▁inter at rial ▁shu nt ▁; ▁ha emo dynamic ▁outcome s ▁; ▁heart ▁failure
D-1962	-0.48399972915649414	implanted left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure
P-1962	-4.3299 -0.0514 -0.5652 -0.0136 -0.0479 -0.0471 -0.0443 -0.0428 -0.0207 -0.1233 -0.1367 -0.0935 -0.3404 -0.0647 -0.1052 -0.0010 -0.3677 -0.0748 -0.3652 -0.4659 -0.0458 -3.6661 -0.1189
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1 time ; correlated ; right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
H-742	-0.4273814260959625	▁right ▁vent ri cular - pul mon ary ▁arterial ▁coup ling ▁; pul mon ary ▁vas cular ▁resist ance ▁; ▁right ▁vent ri cular ▁e je ction ▁ fraction
D-742	-0.4273814260959625	right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
P-742	-1.8002 -0.0570 -0.5657 -0.1834 -0.1365 -0.4734 -0.8903 -0.1293 -0.1021 -0.2443 -0.5658 -0.1463 -1.9509 -0.5904 -0.0812 -0.1284 -0.2977 -0.1736 -0.1140 -0.4146 -0.4554 -0.0212 -0.6628 -0.2311 -0.5898 -0.1228 -0.0627 -1.4468 -0.0176 -0.4663 -0.1272
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left ventricular assist devices ; lvads ; chronic end-stage heart failure ; bridge to transplantation ; btt ; patients ; destination therapy ; dt
H-308	-0.3004600703716278	▁le ft ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁chronic ▁end - s tage ▁heart ▁failure ▁; bridge ▁to ▁transplant ation ▁; ▁b t ▁; ▁transplant - ine ligi ble ▁patients ▁; ▁de stin ation ▁ therapy
D-308	-0.3004600703716278	left ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy
P-308	-1.4867 -0.0047 -0.0698 -0.8609 -0.1862 -0.5749 -0.3181 -0.2028 -0.0410 -0.0186 -0.0451 -0.1912 -0.8465 -0.7506 -0.0472 -0.1078 -0.0064 -0.8197 -0.1657 -0.1458 -0.0440 -0.0161 -0.0906 -0.1073 -0.4430 -0.5988 -1.0232 -0.0905 -0.2549 -0.0417 -0.5777 -0.0080 -0.1253 -0.2929 -0.2274 -0.2064 -0.0707 -0.0519 -0.2257 -0.0125 -1.1402 -0.0809
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise ; training ; peak oxygen consumption ; quality of life ; obese ; patients ; heart failure with preserved ejection fraction ; randomized ; clinical
H-1973	-0.30616873502731323	▁Cal o ric ▁re stri ction ▁; ▁aero bic ▁Exerci se ▁Training ▁; ▁Peak ▁o xy gen ▁Consum p tion ▁; ▁Quality ▁of ▁Life ▁; ▁Old er ▁Patient s ▁With ▁Heart ▁Fail ure ▁; ▁Pres er ved ▁e je ction ▁Fra ction
D-1973	-0.30616873502731323	Caloric restriction ; aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Older Patients With Heart Failure ; Preserved ejection Fraction
P-1973	-0.0656 -0.2060 -0.2137 -0.7462 -0.0807 -0.0296 -0.0851 -0.4316 -0.0987 -0.3172 -0.0624 -0.2639 -0.7615 -0.0045 -0.3549 -0.0527 -0.0597 -0.1102 -0.0981 -0.0964 -0.1508 -0.7905 -0.3724 -0.1172 -0.1970 -2.9954 -0.0264 -0.1536 -0.0473 -1.3256 -0.2427 -0.0280 -0.2552 -1.0218 -0.0215 -0.0214 -0.2116 -0.6239 -0.0743 -0.0105 -0.2713 -0.0117 -0.2956 -0.0669
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol ; metoprolol ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-855	-0.2890738248825073	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD it - c RT ▁trial ▁; ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-855	-0.2890738248825073	carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-cRT trial ; Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
P-855	-0.0085 -0.0038 -0.0302 -0.1888 -0.0063 -0.1002 -0.0111 -0.0671 -0.3016 -0.5620 -0.0247 -0.6317 -0.0152 -0.2776 -0.0500 -0.1680 -0.2421 -0.6799 -0.0923 -0.0983 -0.3738 -0.0100 -0.1759 -0.0963 -0.7954 -0.0077 -1.1320 -2.2173 -0.6683 -0.0549 -1.3774 -0.0557 -0.1140 -0.0063 -0.0539 -0.0251 -0.1279 -0.2004 -0.7364 -0.1920 -0.0254 -0.9177 -0.0225 -0.0039 -0.3338 -0.2150 -0.2725 -0.1046
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral ; glucocorticoids ; hf
H-610	-0.6528022885322571	▁Oral ▁gluco cor tico ids ▁; ▁dose - related ▁gradi ent ▁; ▁ HF ▁; ▁HR
D-610	-0.6528022885322571	Oral glucocorticoids ; dose-related gradient ; HF ; HR
P-610	-1.2207 -0.2464 -0.1870 -0.5802 -0.2258 -0.2328 -3.3233 -0.0444 -0.1209 -0.0094 -0.0390 -0.3601 -0.0491 -0.0773 -1.5910 -2.6336 -0.7260 -0.0834
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ; ea ; tac ; placebo
H-523	-0.4546718895435333	▁HR ▁; ▁i va bra dine ▁group ▁; ▁Ea ▁; ▁ TAC
D-523	-0.4546718895435333	HR ; ivabradine group ; Ea ; TAC
P-523	-0.5967 -0.1406 -0.0074 -0.0123 -0.0911 -0.0122 -1.2686 -0.0842 -1.9679 -0.1099 -1.2033 -0.1913 -0.6017 -0.0779
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol ; therapy ; metoprolol ; hazard ratio ; confidence interval
H-862	-0.34099578857421875	▁car vedi lol ▁; ▁in appropria te ▁ therapy ▁; ▁met o pro lol
D-862	-0.34099578857421875	carvedilol ; inappropriate therapy ; metoprolol
P-862	-0.0290 -0.0131 -0.0535 -0.3128 -0.1609 -0.0121 -0.0499 -0.2937 -0.0219 -0.1970 -0.0276 -0.2282 -0.0355 -0.0851 -3.8300 -0.1057
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up ; systemic ; adverse events ; patients ; dcm ; heart failure
H-1265	-0.47535669803619385	▁CH m ▁; ▁ad ju nc tive ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1265	-0.47535669803619385	CHm ; adjunctive treatment ; dCM ; heart failure
P-1265	-3.9677 -0.5941 -0.2799 -0.4160 -0.1399 -0.0020 -0.1304 -0.5400 -0.2123 -0.3319 -0.0708 -0.1675 -0.4378 -0.0801 -0.1491 -0.0862
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone supplementation ; exercise rehabilitation ; health ; outcomes ; patients ; chf ; testosterone
H-1325	-0.585391640663147	▁testosteron e ▁supplement ation ▁; ▁exercise ▁rehabilita tion ▁; ▁CHF ▁; ▁testosteron e ▁status
D-1325	-0.585391640663147	testosterone supplementation ; exercise rehabilitation ; CHF ; testosterone status
P-1325	-0.2640 -0.0495 -0.6670 -0.3548 -0.5065 -1.5453 -0.1133 -0.2718 -0.3961 -1.9461 -0.5729 -2.2056 -0.0369 -0.1302 -0.2229 -0.0834
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change ; peak vo2 ; correlated ; change ; lean body mass ; change ; thigh ; muscle
H-1987	-0.4827478229999542	▁VO 2 ▁; ▁lean ▁body ▁mass ▁; ▁th igh ▁muscle ▁; inter mus cular ▁fat ▁ratio
D-1987	-0.4827478229999542	VO2 ; lean body mass ; thigh muscle ;intermuscular fat ratio
P-1987	-1.8741 -0.0384 -0.1091 -0.5312 -0.5995 -0.2153 -0.1151 -3.0883 -0.1956 -0.1691 -0.5141 -0.0596 -0.2498 -0.1002 -0.3400 -0.0610 -0.2902 -0.1389
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals ; get with the guidelines-heart failure ; hf ; patients ; ef ; ef ; ef ; ef
H-189	-0.4613778591156006	▁Guide lines - He art ▁Fail ure ▁; ▁ HF ▁patients ▁; EF ▁; ▁border line ▁; EF ▁; ▁pres er ved ▁; EF
D-189	-0.4613778591156006	Guidelines-Heart Failure ; HF patients ;EF ; borderline ;EF ; preserved ;EF
P-189	-3.0883 -0.1619 -0.0179 -0.7705 -0.0926 -0.1449 -0.2732 -0.1369 -0.6804 -0.1092 -0.5765 -0.4548 -1.2563 -0.3801 -0.6107 -0.0039 -0.2912 -0.1750 -0.5972 -0.1325 -0.0211 -0.2804 -0.4061 -0.1160 -1.1328 -0.0855
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2017	-0.7108905911445618	▁economic ▁analysis ▁; ▁Patient ▁Management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁; ▁kosten - effect ive ness ▁; ▁disease ▁management ▁programs ▁in ▁heart ▁failure
D-2017	-0.7108905911445618	economic analysis ; Patient Management Interventions in Heart Failure ; kosten-effectiveness ; disease management programs in heart failure
P-2017	-2.6276 -0.9194 -0.6254 -0.6146 -0.8689 -0.2135 -0.0484 -0.6870 -0.3834 -0.2050 -0.7108 -0.6505 -3.5077 -0.0860 -1.4689 -0.1877 -1.1884 -0.8114 -1.2558 -0.0589 -0.2421 -0.4375 -0.3338 -0.0645 -0.1642 -0.1219
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi ; death ; medical ; hospitalization ; hf ; clinic ; outpatients ; hf ; health
H-385	-0.6652156114578247	▁ HF PSI ▁; ▁risk ▁of ▁death ▁; ▁medical ▁hospital ization ▁; ▁ HF ▁clinic ▁out patient s ▁; ▁ HF ▁resources ▁; ▁health ▁systems
D-385	-0.6652156114578247	HFPSI ; risk of death ; medical hospitalization ; HF clinic outpatients ; HF resources ; health systems
P-385	-0.3338 -0.3487 -0.1226 -0.1594 -2.9416 -2.2318 -0.3831 -0.1042 -2.1821 -0.4827 -0.2011 -0.1433 -0.4929 -0.0819 -0.8751 -1.3015 -0.0075 -0.0615 -0.4995 -1.1673 -0.3515 -1.7076 -1.0087 -0.3565 -0.1068 -0.1937 -0.1143
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; hypertrophy ; heart failure
H-1787	-0.22938939929008484	▁cardiac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁oxid ative ▁metabolism ▁; ▁cardiac ▁hyper trop hy ▁; ▁energy ▁deficit ▁; ▁hyper trop hy ▁; ▁heart ▁failure
D-1787	-0.22938939929008484	cardiac insulin-resistance ; mitochondrial oxidative metabolism ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
P-1787	-0.1392 -0.1838 -0.0376 -0.1100 -0.6698 -0.0031 -0.0585 -0.3164 -0.2153 -0.0564 -0.0125 -0.0143 -0.0539 -0.0519 -0.1201 -1.0690 -0.3156 -0.0084 -0.5527 -0.1891 -0.2765 -0.0061 -0.1880 -0.6146 -0.0305 -0.7611 -0.3560 -0.2716 -0.1958 -0.1295 -0.1037
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate cox model ; pasp ; exercise ; peak o2 ; prognostic ; hazard ratio ; peak o2 ; pasp
H-830	-0.9040402770042419	▁co x ▁model ▁analysis ▁; ▁pas p ▁; ▁exercise ▁; ▁ha ard ▁ratio ▁; ▁pe ak ▁o 2 ▁per ▁kilogram ▁; ▁pas p
D-830	-0.9040402770042419	cox model analysis ; pasp ; exercise ; haard ratio ; peak o2 per kilogram ; pasp
P-830	-0.0761 -0.1122 -0.1854 -0.4653 -0.2023 -3.9727 -0.6596 -0.9073 -4.2056 -0.1902 -4.7033 -0.0816 -0.0162 -0.3747 -2.4539 -0.0334 -0.0036 -0.0384 -0.3039 -0.1898 -0.4730 -1.3445 -0.8467 -0.6755 -0.0857
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology ; heart failure with preserved ejection fraction ; hfpef ; myocardial extracellular matrix
H-734	-0.29613831639289856	▁pat ho phy si ology ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF ▁; ▁my o card ial ▁extra cel lular ▁matri x ▁accumula tion
D-734	-0.29613831639289856	pathophysiology ; heart failure ; preserved ejection fraction ; hFPEF ; myocardial extracellular matrix accumulation
P-734	-0.4378 -0.5192 -0.1285 -1.3239 -0.3044 -0.1967 -0.1919 -0.0491 -0.6269 -0.0031 -0.0339 -0.2816 -0.0321 -0.0715 -0.0291 -0.3321 -0.0064 -0.1679 -0.7918 -1.2357 -0.4884 -0.2515 -0.4058 -0.0413 -0.1958 -0.0699 -0.0949 -0.0431 -0.0286 -0.0364 -0.4422 -0.1118 -0.9521 -0.3244 -0.1151
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular ; dilatation
H-338	-0.16538800299167633	▁ann ular ▁size ▁re duction ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁; LV
D-338	-0.16538800299167633	annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
P-338	-0.7881 -0.0003 -0.1605 -0.1141 -0.0100 -0.1313 -0.1489 -0.0782 -0.0008 -0.0140 -0.0146 -0.0974 -0.0228 -0.3120 -0.0892 -0.0145 -0.1409 -0.0299 -0.2096 -0.2543 -0.0431 -0.0516 -0.0026 -0.0324 -0.2039 -1.1313 -0.5528 -0.1006 -0.1122 -0.0116 -0.1650 -0.2618 -0.0862 -0.0321 -0.0321 -0.3434 -0.0132 -0.0153 -0.2164 -0.0387 -0.4287 -0.1088 -0.5617 -0.1004
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ; pvf ; implanted ; cardioverter-defibrillator device
H-1346	-0.2955133616924286	▁breath ing ▁control ▁; ▁cardiac ▁arrest ▁; ▁humans ▁; ▁puls e less ▁vent ri cular ▁fi bril lation ▁; PV F ▁; ▁cardio ver ter - de fi br illa tor ▁device
D-1346	-0.2955133616924286	breathing control ; cardiac arrest ; humans ; pulseless ventricular fibrillation ;PVF ; cardioverter-defibrillator device
P-1346	-0.8353 -0.1022 -0.3847 -0.2826 -0.5846 -0.0193 -0.2387 -1.9831 -0.1507 -0.0127 -0.1170 -0.3279 -0.0220 -0.3011 -0.1480 -0.5441 -0.0523 -0.0507 -0.1671 -0.2822 -1.2122 -0.1179 -0.5020 -0.0104 -0.0883 -0.0349 -0.1078 -0.0436 -0.1501 -0.0728 -0.0393 -0.7687 -0.2076 -0.0858
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad ; rgk ; rem ; rem2 ; rad ; monomeric g proteins ; ventricular action potential ; gain ; cardiac ; l-type channel ; activity
H-1672	-0.30178508162498474	▁r GK ▁; ▁rem ▁; ▁rem 2 ▁; ▁Rad ▁; ▁Gem ▁; Kir ▁; ▁mono me ric ▁g ▁protein s ▁; ▁vent ri cular ▁action ▁potential ▁du ration ▁; ▁EC ▁coup ling ▁; ▁inhibi t ▁cardiac ▁l - type ▁channel ▁activity
D-1672	-0.30178508162498474	rGK ; rem ; rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; ventricular action potential duration ; EC coupling ; inhibit cardiac l-type channel activity
P-1672	-0.6756 -0.3546 -0.0394 -0.3955 -0.7382 -0.1978 -0.0839 -0.0693 -1.1280 -0.1345 -0.6950 -1.0441 -0.2431 -0.2999 -0.0042 -0.0420 -0.0837 -0.4945 -0.1512 -0.0235 -0.1738 -0.0572 -0.8134 -0.2331 -0.0278 -1.4695 -0.0334 -0.0039 -0.0374 -0.1551 -0.0135 -0.0493 -0.8288 -0.6723 -0.0205 -0.0040 -0.9607 -0.0208 -0.0026 -0.0088 -0.2149 -0.1922 -0.0858
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hf ; myocardial infarction
H-1136	-0.32210302352905273	▁a ce tyl cho line ster ase ▁inhibi tor ▁py rido stig mine ▁; ▁sympa t hova gal ▁balance ▁; ▁cardiac ▁remodel ing ▁; ▁cardiac ▁function ▁; ▁ HF ▁; ▁my o card ial ▁in far ction
D-1136	-0.32210302352905273	acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF ; myocardial infarction
P-1136	-0.1278 -2.7839 -0.0644 -0.2007 -0.1861 -0.2374 -0.4584 -0.0495 -0.0306 -0.5466 -0.0099 -0.0008 -0.4705 -0.2867 -0.0202 -0.0744 -0.0555 -0.1222 -0.1481 -0.1071 -0.0032 -0.0475 -0.0135 -0.1320 -0.0228 -0.1774 -0.1599 -1.5127 -0.0672 -0.4328 -1.1462 -0.3048 -0.6836 -0.7594 -0.0335 -0.1765 -0.5913 -0.2150 -0.1022
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac sympathetic activity ; β-blocker
H-1112	-0.34634968638420105	▁cardiac ▁sympa the tic ▁activity ▁; ▁i - meta - i odob enz yl guan i dine ▁; ▁i - mi BG ▁; ▁β - block er
D-1112	-0.34634968638420105	cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
P-1112	-0.6459 -0.2578 -0.5898 -0.7893 -0.3943 -0.2259 -1.3820 -0.5807 -0.0077 -0.0248 -0.1860 -0.0404 -0.2467 -0.6010 -0.0047 -0.1050 -0.0712 -0.1470 -0.4986 -0.1334 -0.7852 -0.7273 -0.6144 -0.1164 -0.0471 -0.2586 -0.1280 -0.2751 -0.1599
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based ; heart disease ; therapies ; patients ; cabg ; sweden
H-971	-0.49195680022239685	▁Swedish ▁Web - system ▁for ▁en han ce ment ▁and ▁Development ▁of ▁e viden ce - based ▁care ▁in ▁Heart ▁disease ▁Evalua ted ▁According ▁to ▁Reco mmende d ▁Therapie s ▁registr y ▁; ▁stockholm
D-971	-0.49195680022239685	Swedish Web-system for enhancement and Development of evidence-based care in Heart disease Evaluated According to Recommended Therapies registry ; stockholm
P-971	-0.3530 -1.3632 -0.0408 -1.0065 -0.5584 -0.2341 -0.0507 -1.7024 -0.0566 -0.2977 -0.5637 -0.3695 -1.0356 -0.0603 -0.4183 -0.0313 -0.0121 -0.9529 -0.4801 -0.3700 -0.1696 -0.7897 -0.1818 -1.4292 -0.0901 -0.0073 -0.0011 -0.0172 -0.1063 -0.0339 -0.0539 -0.0254 -0.4222 -3.0917 -1.2692 -0.0642
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef ; clinical ; reverse remodeling ; death ; hf ; hospitalization ; hazard ratio
H-756	-0.38764262199401855	▁LV EF ▁; ▁clinic al ▁com posit e ▁response ▁; ▁rever se ▁remodel ing ▁parameter s ▁; ▁time ▁to ▁death ▁; ▁ HF ▁hospital ization
D-756	-0.38764262199401855	LVEF ; clinical composite response ; reverse remodeling parameters ; time to death ; HF hospitalization
P-756	-0.0958 -0.1648 -0.0903 -2.5453 -0.0051 -0.0546 -0.0042 -0.0137 -0.1608 -0.1221 -0.0062 -0.0077 -0.0061 -0.0157 -0.0814 -0.0581 -0.1632 -1.6336 -0.0365 -0.1201 -0.0565 -1.9689 -0.1347 -0.6492 -0.5592 -1.6257 -0.0868
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients ; brain natriuretic peptide ; bnp ; bnp ; patients ; bnp ; bnp
H-1569	-0.7009894251823425	▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁b NP ▁; ▁b NP
D-1569	-0.7009894251823425	brain natriuretic peptide ; bNP ; bNP ; bNP
P-1569	-0.4257 -0.0202 -0.2910 -0.3645 -2.3994 -0.8835 -0.2715 -0.4286 -0.2331 -0.7796 -0.2967 -0.5210 -1.1060 -0.3989 -0.8467 -1.0857 -0.3546 -2.5091 -0.1028
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes ; coprimary end points ; end point ; change ; serum cystatin c ; renal function ; end point
H-79	-0.3401792347431183	▁co prima ry ▁end ▁points ▁; ▁cum ul ative ▁urin e ▁volume ▁; ▁de con gestion ▁end ▁point ▁; ▁se rum ▁cyst atin ▁C ▁; ▁en roll ment ▁; ren al ▁function
D-79	-0.3401792347431183	coprimary end points ; cumulative urine volume ; decongestion end point ; serum cystatin C ; enrollment ;renal function
P-79	-0.2431 -0.0290 -0.2981 -1.1989 -0.3504 -0.2162 -0.0466 -0.0241 -0.0280 -0.7935 -0.0888 -0.1153 -0.1538 -0.0368 -0.0149 -0.0343 -1.2815 -0.5183 -0.3824 -0.1510 -0.0510 -0.0149 -0.0696 -1.3697 -0.4735 -0.1925 -0.0297 -0.1877 -0.4935 -0.3989 -0.0451 -0.1083 -2.0278 -0.0988
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse ; longitudinal rv fiber shortening ; pasp ; rv ; in vivo ; rv ; prognosis
H-493	-0.42872029542922974	▁t AP se ▁; long itud in al ▁ RV ▁fiber ▁short en ing ▁; ▁PAS p ▁; force ▁generate d ▁; ▁ RV ▁; ▁in ▁vivo ▁ RV ▁length - force ▁relationship ▁; ▁disc los ing ▁prognos is
D-493	-0.42872029542922974	tAPse ;longitudinal RV fiber shortening ; PASp ;force generated ; RV ; in vivo RV length-force relationship ; disclosing prognosis
P-493	-2.8733 -0.4090 -0.8499 -0.0712 -0.1977 -0.0805 -0.3027 -0.0335 -0.2438 -0.6858 -0.1853 -0.2947 -0.0759 -0.0866 -0.1257 -0.9062 -0.6221 -0.0661 -0.2808 -0.5983 -0.0365 -0.5089 -1.6203 -0.5725 -0.2011 -0.1230 -0.0007 -0.3964 -0.4668 -1.3346 -0.0286 -0.0477 -0.9610 -0.6709 -1.1096 -0.0918 -0.0099 -0.0912 -0.1144 -0.1237 -0.0788
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde ; pde2 ; cgmp ; leading ; camp hydrolysis ; cross talk ; cgmp ; camp signaling
H-1210	-0.35474827885627747	▁p de ▁; ▁p de 2 ▁; ▁c g MP ▁; ▁c AMP ▁hydro lys is ▁; ▁negative ▁cross ▁talk ▁; ▁c g MP ▁; ▁c AMP ▁signal ing
D-1210	-0.35474827885627747	pde ; pde2 ; cgMP ; cAMP hydrolysis ; negative cross talk ; cgMP ; cAMP signaling
P-1210	-0.1259 -0.2435 -1.2145 -0.1181 -0.3053 -0.0388 -0.1096 -0.0404 -2.1479 -0.3899 -0.1093 -0.0192 -0.5847 -0.0119 -0.0126 -0.0426 -0.4027 -1.2138 -0.1293 -0.0496 -0.2786 -0.0033 -2.2222 -0.2720 -0.1474 -0.0036 -0.2223 -0.2359 -0.0860 -0.1294 -0.0868
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal probnp ; nt-probnp ; midregional proanp ; mr-proanp ; adiponectin ; elevated ; chf ; correlated ; bmi
H-14	-0.417564332485199	▁n - termin al ▁pro b NP ▁; NT - pro b NP ▁; ▁mid region al ▁pro AN p ▁; MR - pro AN p ▁; ▁total ▁adi pon ect in ▁; ▁CHF ▁; ▁b mi ▁; ▁FM
D-14	-0.417564332485199	n-terminal probNP ;NT-probNP ; midregional proANp ;MR-proANp ; total adiponectin ; CHF ; bmi ; FM
P-14	-2.7673 -0.0130 -0.0081 -0.0020 -0.0276 -1.6511 -0.2689 -0.0920 -1.7470 -0.0046 -0.0192 -0.9370 -0.1771 -0.0562 -0.0563 -0.0179 -0.0034 -0.0113 -0.4252 -0.7165 -0.0636 -0.2476 -0.0074 -0.0115 -0.5859 -0.5212 -0.1117 -1.3738 -0.0132 -0.0036 -0.1172 -0.3179 -0.1844 -0.0305 -0.1608 -2.7103 -1.1571 -0.1244 -0.2000 -0.0951 -0.0814
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization ; admissions ; patient
H-900	-0.39253920316696167	▁re - hospital ization
D-900	-0.39253920316696167	re-hospitalization
P-900	-0.0788 -0.0752 -0.0241 -0.3095 -1.8020 -0.0655
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides ; szeto-schiller ; ss ; ss20 ; cardiac function ; proteomic remodeling ; signaling pathways
H-870	-0.26966434717178345	▁mito cho ndri al - tar get ed ▁antioxidant ▁; ▁protect ive ▁pe pti des ▁; ▁Sze to - sch iller ▁; SS ▁; ▁cardiac ▁function ▁; ▁prote om ic ▁remodel ing ▁; ▁signal ing ▁path ways
D-870	-0.26966434717178345	mitochondrial-targeted antioxidant ; protective peptides ; Szeto-schiller ;SS ; cardiac function ; proteomic remodeling ; signaling pathways
P-870	-0.2858 -0.1910 -0.1630 -0.0142 -0.0232 -0.0201 -0.0301 -0.0095 -0.0567 -0.1399 -1.3193 -0.0357 -0.3974 -0.1454 -0.1045 -0.3263 -0.0008 -0.0112 -0.0087 -0.7149 -0.0541 -0.3860 -0.5293 -0.5919 -1.6776 -0.0618 -0.2689 -0.0222 -0.1137 -1.1505 -0.0145 -0.0139 -1.1037 -0.0350 -0.0764 -0.0899 -0.0387 -0.2054 -0.0856
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical ; cardiac arrest ; cardiopulmonary resuscitation ; cpr ; diagnosis ; posterior wall infarction ; hospitalized ; cardiac
H-1291	-0.31301939487457275	▁cardiac ▁arrest ▁; ▁cardio pul mon ary ▁res uscita tion ▁; ▁c PR ▁; ▁posterior ▁wall ▁in far ction ▁; ▁cardiac ▁centre
D-1291	-0.31301939487457275	cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
P-1291	-1.9503 -0.0560 -0.1080 -0.0580 -0.2126 -1.4320 -0.2884 -0.1840 -0.0155 -0.3539 -0.1827 -0.3072 -0.2039 -0.2653 -0.0121 -0.2654 -0.0153 -0.0943 -0.0763 -0.6613 -0.0707 -0.4134 -0.1450 -0.1408
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence ; hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorticoid receptor antagonists ; heart failure ; hf
H-1702	-0.3101828098297119	▁hyper kal emia ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁race ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁heart ▁failure ▁; HF
D-1702	-0.3101828098297119	hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
P-1702	-0.4453 -0.1353 -0.1594 -0.4512 -0.2081 -0.1377 -0.8800 -0.6685 -0.2006 -0.0099 -0.0793 -0.0076 -0.2674 -0.2677 -0.1989 -0.1594 -1.3897 -0.1833 -1.0330 -0.8743 -0.1414 -0.0237 -0.1384 -0.0135 -0.3872 -0.3041 -0.2465 -0.1019 -0.5208 -0.0826 -0.1019 -0.1071
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade ; evidence ; acp ; erythropoiesis-stimulating agents ; patients ; anemia ; congestive heart failure ; coronary heart disease
H-37	-0.595079243183136	▁a CP ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease
D-37	-0.595079243183136	aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
P-37	-3.8991 -1.6098 -0.3412 -0.4091 -0.1743 -0.7137 -0.7566 -1.3077 -0.2330 -0.5282 -0.0348 -0.4280 -1.5600 -0.2990 -1.1043 -0.0312 -0.0843 -0.0139 -0.0773 -1.2252 -0.2424 -0.0698 -0.0931 -0.0034 -0.6854 -0.3945 -0.6725 -0.1202 -0.1454
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients ; patients ; type 2 diabetes ; therapy ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; insulin
H-1831	-0.22076621651649475	▁type ▁2 ▁diabetes ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁sul fon yl ure as ▁; ▁long - ac ting ▁insulin ▁products
D-1831	-0.22076621651649475	type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; long-acting insulin products
P-1831	-0.4566 -0.4420 -0.0402 -0.2017 -0.1592 -0.0045 -0.1442 -1.5416 -0.1482 -0.1694 -0.0411 -0.0302 -1.3458 -0.1131 -0.0264 -0.0106 -0.0461 -0.0678 -0.0993 -0.2669 -0.0090 -0.0584 -0.1529 -0.0271 -0.1250 -0.2627 -0.0142 -0.0073 -0.0105 -0.0192 -0.8641 -0.2636 -0.1164
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr ; scn5a ; ventricular systolic hf ; human induced pluripotent stem cell-derived cardiomyocytes ; hipsc-cms
H-1082	-0.240017369389534	▁u PR ▁; ▁s cn 5 a ▁; ▁vent ri cular ▁sy sto lic ▁ HF ▁tissu e ▁sample s ▁; ▁human ▁induc ed ▁pluri potent ▁stem ▁cell - der i ved ▁cardio my o cy tes ▁; hi PS c - CM s
D-1082	-0.240017369389534	uPR ; scn5a ; ventricular systolic HF tissue samples ; human induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
P-1082	-1.6601 -1.0310 -0.0635 -0.1291 -0.1882 -0.2153 -0.1946 -0.1733 -0.1765 -0.7596 -0.1498 -0.0113 -0.0298 -0.0236 -0.2729 -0.3125 -0.1368 -0.0620 -0.2032 -0.0860 -0.1056 -1.9910 -0.0150 -0.0188 -0.0041 -0.0002 -0.0003 -0.1254 -0.0593 -0.0393 -0.0571 -0.0841 -0.0639 -0.7708 -0.2283 -0.0167 -0.0479 -0.2731 -0.2038 -0.2523 -0.3925 -0.0238 -0.0279 -0.0331 -0.2360 -0.0912
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory ; patients ; heart failure ; hf ; reduced ejection fraction ; renin-angiotensin system ; ras ; β-blockers ; all-cause mortality ; readmissions
H-175	-0.3230915069580078	▁ambula tory ▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁e je ction ▁ fraction ▁; ▁r EF ▁; ▁re nin - angi oten sin ▁system ▁; RAS ▁; ▁β - block ers
D-175	-0.3230915069580078	ambulatory patients ; heart failure ;HF ; ejection fraction ; rEF ; renin-angiotensin system ;RAS ; β-blockers
P-175	-1.8862 -0.0773 -0.3054 -1.0549 -0.2698 -0.0353 -0.2087 -0.0320 -0.0768 -0.8619 -0.0409 -0.0127 -0.3143 -0.0042 -0.1961 -1.0480 -0.0976 -0.0394 -0.0013 -0.3265 -0.0317 -0.0020 -0.0907 -0.4870 -0.0495 -0.5277 -0.1235 -0.2885 -0.0287 -0.0122 -0.0475 -0.0242 -2.2701 -0.1124
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial ; cochrane effective practice and organisation of care taxonomy
H-1847	-0.3044475317001343	▁co ch rane ▁Effective ▁practice ▁; ▁Organisation ▁of ▁Care ▁Tax ono my
D-1847	-0.3044475317001343	cochrane Effective practice ; Organisation of Care Taxonomy
P-1847	-0.3139 -0.0673 -0.0285 -0.1005 -0.7031 -0.1132 -1.0758 -0.0466 -0.2313 -0.7053 -0.0220 -0.5444 -0.2254 -0.0853
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd ; chf ; crf ; icc ; kappa coefficients
H-802	-0.37384578585624695	▁co PD ▁; ▁CHF ▁; ▁c RF ▁; ▁ICC ▁; ▁ka ppa ▁co ef fici ents
D-802	-0.37384578585624695	coPD ; CHF ; cRF ; ICC ; kappa coefficients
P-802	-1.1534 -1.5835 -0.1500 -0.0058 -0.2034 -0.1316 -0.6411 -0.4648 -0.1019 -1.0603 -0.0033 -0.0497 -0.0653 -0.0059 -0.0219 -0.7816 -0.1796 -0.1261
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients ; stable heart failure ; left ventricular ejection fraction ; training ; training
H-1913	-0.508940577507019	▁stable ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁aero bic ▁training ▁; ▁dynamic ▁resist ance ▁training ▁; ▁lower ▁lim bs
D-1913	-0.508940577507019	stable heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
P-1913	-4.5255 -0.3778 -0.0937 -0.0945 -0.4661 -0.0460 -0.8260 -0.3267 -0.0767 -0.1203 -0.0399 -1.4473 -0.0156 -0.2770 -0.1204 -0.0889 -0.7664 -1.1059 -0.7591 -0.1597 -0.0568 -0.8744 -0.3037 -0.0890 -0.0165 -0.9167 -0.1609 -0.0986
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient ; implantable cardioverter-defibrillator ; implant ; change ; clinical
H-1865	-0.4106864333152771	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant
D-1865	-0.4106864333152771	implantable cardioverter-defibrillator deactivation ; implant
P-1865	-2.2889 -0.0441 -0.3886 -0.0186 -0.1740 -0.0459 -0.0682 -0.1288 -0.5235 -0.0715 -0.0436 -0.0999 -0.0432 -0.3774 -0.6524 -0.2793 -2.0444 -0.0999
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients ; heart failure ; myocardial function ; dilated ; contracting ; ventricles ; aetiologies
H-987	-0.4892130196094513	▁heart ▁failure ▁; ▁my o card ial ▁function ▁; ▁dil ated ▁poor ly ▁contract ing ▁vent ric les
D-987	-0.4892130196094513	heart failure ; myocardial function ; dilated poorly contracting ventricles
P-987	-2.9502 -0.1097 -0.1013 -1.7907 -0.1543 -0.4075 -0.3231 -0.0863 -0.1622 -1.1261 -0.0250 -1.0715 -0.1198 -0.0016 -0.0209 -0.0197 -0.5942 -0.3896 -0.2451 -0.0855
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients ; implantable cardioverter-defibrillator ; patients ; implantable cardioverter-defibrillator
H-1866	-0.2702619135379791	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁preference s ▁; ▁di stress ing ▁implant able ▁cardio ver ter - de fi br illa tor ▁shock s
D-1866	-0.2702619135379791	implantable cardioverter-defibrillator deactivation preferences ; distressing implantable cardioverter-defibrillator shocks
P-1866	-1.2637 -0.0398 -0.2699 -0.0165 -0.1513 -0.0319 -0.0741 -0.2015 -0.5733 -0.0607 -0.0501 -0.0914 -0.0543 -0.4285 -0.8392 -0.0906 -0.6077 -1.6004 -0.0079 -0.0520 -0.3219 -0.0488 -0.3910 -0.0241 -0.2225 -0.0447 -0.0602 -0.2085 -0.3124 -0.0974 -0.0388 -0.5157 -0.1443 -0.3988 -0.1253
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global left ventricular longitudinal systolic strain ; gls ; left ventricular ; cardiovascular ; atrial fibrillation
H-809	-0.2945464253425598	▁global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁g LS ▁; ▁left ▁vent ri cular ▁mechanic s ▁; ▁cardiovascular ▁; CV ▁; ▁at rial ▁fi bril lation ▁; AF
D-809	-0.2945464253425598	global left ventricular longitudinal systolic strain ; gLS ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
P-809	-0.0584 -0.3180 -0.0515 -0.4302 -0.2188 -0.0112 -0.0683 -0.0104 -0.0220 -0.0466 -0.0298 -0.0291 -0.2308 -0.1121 -0.5663 -0.1111 -0.9990 -0.0415 -0.6898 -0.2561 -0.5816 -0.0301 -0.1253 -1.0795 -0.2326 -0.0073 -0.0943 -3.0940 -0.0112 -0.2232 -0.0160 -0.0706 -0.4653 -0.0697 -0.1195 -0.0823
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad ; q65p ; murine ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type rad
H-1675	-0.5105563402175903	▁mouse ▁Rad ▁Q 65 p ▁; ▁mur ine ▁equivalent ▁; ▁human ▁Rad ▁Q 66 p ▁; ▁l - type ▁current s ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁channel s ▁; ▁wild - type ▁Rad
D-1675	-0.5105563402175903	mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; l-type currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
P-1675	-0.0451 -1.1233 -1.6943 -0.1858 -0.5006 -0.0797 -0.0187 -1.0295 -0.1088 -0.2271 -0.9256 -1.5204 -0.6306 -0.2059 -0.3126 -0.2079 -4.3264 -0.0312 -0.0042 -0.0245 -0.1098 -1.1589 -0.5250 -0.3467 -0.2571 -0.1467 -0.8798 -0.2255 -0.0729 -0.8106 -0.0930 -0.2201 -0.1359 -0.0214 -0.0067 -0.5084 -0.6014 -0.0787
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient ; mi ; hazard ratios ; hf
H-1108	-0.8451194763183594	▁MI ▁; ▁hazard ▁ratio s ▁; ▁ HF
D-1108	-0.8451194763183594	MI ; hazard ratios ; HF
P-1108	-2.0685 -1.0007 -0.9772 -0.0359 -0.2627 -0.3586 -2.5191 -0.9581 -0.1093 -0.1611
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare ; patients ; acute ; hospital ; hf ; ami ; pna
H-1693	-0.6605234146118164	▁Medica re ▁; ▁older ▁patients ▁; ▁a cute ▁care ▁hospital ▁; ▁ HF ▁; ▁ AMI ▁; ▁p NA
D-1693	-0.6605234146118164	Medicare ; older patients ; acute care hospital ; HF ; AMI ; pNA
P-1693	-2.2139 -0.0384 -0.4117 -1.5799 -0.2979 -0.5482 -0.2002 -0.0173 -0.6998 -0.1642 -0.1451 -1.7819 -0.3420 -0.1559 -0.9080 -1.8082 -0.3759 -0.1274 -1.8282 -0.1042 -0.1228
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular events ; baseline ; sst2 ; metoprolol succinate
H-404	-0.5414637923240662	▁cardio vas cular ▁events ▁; ▁s st 2 ▁status ▁; ▁BB ▁dose ▁; ▁met o pro lol ▁suc cina te
D-404	-0.5414637923240662	cardiovascular events ; sst2 status ; BB dose ; metoprolol succinate
P-404	-3.4934 -0.2281 -0.2737 -0.6619 -0.3970 -0.0139 -1.3054 -0.1098 -0.1372 -0.1260 -3.4394 -0.4006 -0.1256 -0.1053 -0.2162 -0.0295 -0.4959 -0.0516 -0.0220 -0.0433 -0.1804 -0.0560
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt ; nt-probnp ; aric ; hf ; aucs ; nris
H-289	-0.24388858675956726	▁c t n t ▁; ▁NT - pro b NP ▁; ▁a RIC ▁ HF ▁model ▁; AU c s ▁; ▁continuo us ▁NR Is
D-289	-0.24388858675956726	ctnt ; NT-probNP ; aRIC HF model ;AUcs ; continuous NRIs
P-289	-0.0053 -0.1372 -0.0310 -0.2425 -0.0349 -0.0763 -0.0160 -0.0094 -0.5840 -0.1820 -0.0630 -0.0974 -0.5551 -0.1035 -0.2308 -0.2822 -0.2685 -0.2110 -1.0670 -0.1190 -0.2081 -0.3449 -0.0038 -0.0192 -0.6547 -0.9578 -0.0806
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf ; hf with reduced ef ; hf with preserved ef ; change ; hf ; mi
H-1109	-0.51023930311203	▁ HF ▁; ▁ HF ▁; ▁EF ▁; ▁ HF ▁; ▁ HF ▁; ▁pres er ved ▁EF ▁; ▁ HF ▁; ▁MI ▁; ▁pre vention ▁strategie s
D-1109	-0.51023930311203	HF ; HF ; EF ; HF ; HF ; preserved EF ; HF ; MI ; prevention strategies
P-1109	-0.7546 -0.4380 -0.1449 -1.6212 -0.0813 -0.1892 -2.2121 -0.0648 -0.5503 -0.1094 -0.1710 -1.9838 -0.1130 -0.2435 -0.5163 -0.0097 -0.1412 -0.1772 -0.1764 -1.0653 -0.5900 -0.1642 -2.1222 -0.9749 -0.3680 -0.0080 -0.0593 -0.0394 -0.1392 -0.0790
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl ; nyha-iiib ; phosphorylation ; phosphorylation ; hdl ; healthy
H-255	-0.476340115070343	▁EC ▁; ▁HD L ▁; NY ha - III b ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁ phos phor y lation ▁; ▁e NOS - Th r ▁; ▁HD L
D-255	-0.476340115070343	EC ; HDL ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDL
P-255	-1.0439 -0.1838 -0.7691 -2.0403 -0.0931 -0.2637 -0.8579 -0.0461 -0.0564 -0.0072 -0.2170 -0.5054 -0.1834 -0.7960 -0.9096 -0.0981 -0.3425 -0.0509 -0.0096 -0.0454 -0.0867 -1.3757 -0.3739 -0.2574 -1.1801 -0.8334 -0.1342 -0.3650 -0.0729 -0.0123 -0.0446 -0.7463 -0.0042 -0.8542 -0.4150 -1.8853 -0.7993 -0.1413
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol ; von willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
H-1118	-0.2145988941192627	▁car vedi lol ▁; ▁von ▁Will e brand ▁factor ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1118	-0.2145988941192627	carvedilol ; von Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
P-1118	-0.2643 -0.0198 -0.1264 -0.2829 -1.2086 -1.2277 -0.0833 -0.0266 -0.0939 -0.0958 -0.0570 -0.1715 -0.0312 -0.2060 -0.3659 -0.3541 -0.0903 -0.0944 -0.1144 -0.4223 -0.0410 -0.0202 -0.0735 -0.0379 -0.0109 -0.1775 -0.0969
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart failure ; hf ; hypertensive heart disease ; hhd ; pathophysiology ; therapeutic ; hhd ; stable ; phenotypes
H-274	-0.3819628059864044	▁mouse ▁heart ▁failure ▁; HF ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁h HD ▁; ▁pat ho phy si ology ▁; ▁ therapeut ic ▁target s ▁; ▁h HD
D-274	-0.3819628059864044	mouse heart failure ;HF ; hypertensive heart disease ; hHD ; pathophysiology ; therapeutic targets ; hHD
P-274	-0.0081 -0.5927 -0.0230 -0.0988 -0.0381 -0.1482 -0.4383 -0.0642 -0.0332 -0.8235 -0.3416 -0.1041 -0.9431 -0.7715 -0.3511 -1.7359 -0.0481 -0.1187 -0.7168 -0.2107 -0.0477 -1.3718 -0.0517 -0.2352 -0.1826 -0.0567 -0.2103 -0.6698 -0.8704 -0.4686 -0.0661
2021-01-18 17:54:53 | INFO | fairseq.logging.progress_bar | :    101 / 142 wps=223
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic reticular ; protein ; phospholamban ; infarcted ; hearts ; metoprolol
H-1551	-0.22484278678894043	▁sar co plas mic ▁reti cular ▁; SR ▁; ▁ca (2 +) - up take ▁; ▁protein ▁content ▁; ▁SR ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁in far cted ▁heart s ▁; ▁met o pro lol
D-1551	-0.22484278678894043	sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein content ; SR ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
P-1551	-0.0065 -0.0867 -0.5580 -1.0754 -0.0049 -0.1813 -0.2211 -0.0876 -0.3063 -0.2891 -0.1607 -0.0015 -0.0250 -0.0421 -0.1378 -0.0876 -0.2899 -0.8989 -0.0603 -0.0344 -1.8742 -0.1442 -0.0025 -0.0134 -0.0265 -0.0930 -0.1894 -0.0325 -0.0451 -0.5508 -0.2852 -0.1479 -0.0124 -0.0548 -0.7867 -0.2188 -0.0660 -0.2713 -0.0523 -0.0838 -0.0442 -0.1806 -0.0983 -0.0641
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug ; patients ; chronic obstructive pulmonary disease ; copd ; chronic heart failure ; chf ; chronic renal failure ; crf
H-794	-0.49187952280044556	▁Time d ▁Up ▁& ▁Go ▁; ▁tu g ▁; ▁advanced ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; co PD ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁chronic ▁renal ▁failure ▁; CR F
D-794	-0.49187952280044556	Timed Up & Go ; tug ; advanced chronic obstructive pulmonary disease ;coPD ; chronic heart failure ;CHf ; chronic renal failure ;CRF
P-794	-1.8345 -0.0533 -0.7083 -1.1179 -0.9301 -0.1811 -0.7159 -1.2643 -0.2372 -1.9515 -0.1307 -0.3011 -0.0637 -0.1393 -0.0032 -0.0537 -0.2337 -0.0841 -0.7834 -0.5475 -0.0503 -0.0345 -0.2004 -0.0269 -0.1014 -0.7521 -0.9616 -0.0386 -0.0662 -0.0342 -0.1233 -0.2775 -1.6521 -1.7400 -0.1698 -0.1444
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise ; intramuscular testosterone supplementation ; patients ; chronic heart failure ; chf ; testosterone ; collected ; health ; outcomes
H-1317	-0.6089540123939514	▁in mus cular ▁testosteron e ▁supplement ation ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁low ▁testosteron e ▁status
D-1317	-0.6089540123939514	inmuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status
P-1317	-5.8348 -0.0975 -0.0706 -0.1392 -0.0381 -0.7363 -0.1806 -0.1694 -2.1227 -0.4493 -0.0375 -0.1594 -0.6612 -0.8785 -0.0814 -0.2510 -0.0529 -0.0502 -0.1419 -0.5467 -0.0887
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients ; hospitalized ; hf ; preserved lvef ; mortality ; patients ; lvef ; lvef ; mortality
H-117	-0.5824350714683533	▁patients ▁hospital ized ▁; ▁ HF ▁; ▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF
D-117	-0.5824350714683533	patients hospitalized ; HF ; LVEF ; long-term mortality ; LVEF
P-117	-2.1981 -1.3884 -0.1483 -0.3414 -0.4022 -0.0267 -0.1105 -2.1831 -0.1515 -0.1409 -1.2858 -0.0812 -0.1083 -0.0569 -0.5621 -0.3169 -0.1806 -0.0626 -1.8249 -0.0782
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls ; left ventricular ejection fraction ; lvef ; systolic mitral annulus velocity ; multivariate models
H-818	-0.4124961793422699	▁g LS ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF ▁; ▁sy sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁sa ▁; ▁CV ▁events
D-818	-0.4124961793422699	gLS ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; CV events
P-818	-0.2094 -0.7935 -0.8585 -1.3336 -0.0672 -0.9143 -0.3806 -0.2127 -0.1396 -0.2388 -0.6514 -0.0242 -0.2224 -0.1515 -0.1829 -0.0591 -0.0031 -0.0306 -0.0353 -0.2221 -0.0723 -1.8182 -0.1335 -0.5288 -0.0271 -0.2115 -0.1593 -0.5231 -1.2583 -1.3605 -0.2804 -0.0958
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart failure ; hf ; plasma b-type natriuretic peptide ; bnp ; preserved ejection fraction ; ef ; hf
H-187	-0.43144461512565613	▁heart ▁failure ▁; HF ▁; ▁plasma ▁; ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁reduce d ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; EF ▁; ▁ HF ▁studies ▁; ▁sex
D-187	-0.43144461512565613	heart failure ;HF ; plasma ; natriuretic peptide ; bNP ; reduced ; preserved ejection fraction ;EF ; HF studies ; sex
P-187	-0.4574 -0.0874 -0.1497 -0.1799 -0.1110 -0.0854 -1.0663 -0.1161 -0.2381 -0.4953 -2.2984 -0.5071 -0.0991 -0.3341 -0.3048 -0.8679 -0.5043 -0.2169 -2.2978 -0.0055 -1.3112 -0.0059 -0.0572 -0.2076 -0.0257 -0.0738 -0.0164 -0.2404 -0.0018 -0.3783 -0.1129 -0.2005 -0.2924 -0.1740 -0.9221 -0.7510 -0.2156 -1.3296 -0.0874
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm ; telemonitoring ; implanted ; medical ; structured telephone support ; sts ; human-to-human contact ; hh ; human-to-machine interface
H-153	-0.3806498944759369	▁RM ▁; ▁home ▁tele monitor ing ▁; TM ▁; ▁implant ed ▁monitoring ▁devices ▁; ▁medical ▁support ▁; ▁structure d ▁telephone ▁support ▁; ST s ▁; ▁human - to - human ▁contact ▁; HH ▁; ▁human - to - machine ▁interface ▁; HM
D-153	-0.3806498944759369	RM ; home telemonitoring ;TM ; implanted monitoring devices ; medical support ; structured telephone support ;STs ; human-to-human contact ;HH ; human-to-machine interface ;HM
P-153	-1.0019 -0.5339 -1.3348 -1.2211 -0.1105 -0.0476 -0.3621 -0.9710 -0.4656 -0.0243 -0.0885 -0.0063 -0.3369 -0.5125 -0.7016 -1.0489 -0.3466 -2.2274 -0.0042 -0.0754 -0.5989 -0.2791 -1.3482 -0.4764 -0.1716 -0.7889 -0.0180 -0.0183 -0.0910 -0.0101 -0.0046 -0.2963 -0.0538 -0.2019 -0.0979 -0.0220 -0.0306 -0.0254 -0.0542 -0.0014 -0.4091 -0.0640 -0.1852 -0.0804
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox regression analysis ; patients ; beta-blockers ; beta-blockers ; primary endpoint ; therapy ; antitachycardia pacing ; atp ; shock therapy
H-859	-0.20620644092559814	▁co x ▁re gression ▁analysis ▁; ▁beta - block ers ▁; ▁beta - block ers ▁; ▁in appropria te ▁ therapy ▁; ▁anti ta chy car dia ▁pa cing ▁; ▁a TP ▁; ▁shock ▁ therapy
D-859	-0.20620644092559814	cox regression analysis ; beta-blockers ; beta-blockers ; inappropriate therapy ; antitachycardia pacing ; aTP ; shock therapy
P-859	-0.1774 -0.0885 -0.0248 -0.0055 -0.1777 -0.3457 -1.9782 -0.0485 -0.2330 -0.0311 -0.1087 -1.0773 -0.0416 -0.2064 -0.0373 -0.1932 -0.0645 -0.0026 -0.0512 -0.0987 -0.0142 -0.1187 -0.0076 -0.5786 -0.1511 -0.0303 -0.0095 -0.0047 -0.0816 -0.1509 -0.6327 -0.2636 -0.2989 -0.0120 -0.2491 -0.0138 -0.1190 -0.1078
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically ; legal ; decisions
H-1680	-0.5902685523033142	▁et h ically ▁complex ▁situations ▁; ▁pediatr ics ▁; ▁families ▁; ▁religious ▁belief s ▁; ▁life - s usta ining ▁treatment
D-1680	-0.5902685523033142	ethically complex situations ; pediatrics ; families ; religious beliefs ; life-sustaining treatment
P-1680	-0.1434 -0.0721 -0.3546 -1.4902 -0.9055 -0.2998 -0.0095 -0.1810 -0.2044 -1.5883 -0.5716 -0.2543 -0.4025 -0.0926 -0.1707 -2.0715 -0.0466 -0.5763 -0.3094 -0.5832 -0.4478 -2.7255 -0.0755
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient ; prescribing ; medications ; medical
H-1122	-0.5765411257743835	▁context ual ▁factors ▁; ▁patient ▁preference s ▁; ▁priorit ies ▁; ▁guide line - re com mend ed ▁medication s
D-1122	-0.5765411257743835	contextual factors ; patient preferences ; priorities ; guideline-recommended medications
P-1122	-5.1922 -0.0433 -0.2811 -0.2287 -0.7461 -0.0276 -0.0767 -0.1307 -0.4984 -0.1707 -0.2528 -2.4666 -0.0170 -0.0454 -0.0161 -0.0677 -0.0296 -0.0522 -0.0738 -0.0432 -2.1397 -0.0844
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost ; patient ; rhythm-control ; rate-control
H-1241	-1.0603113174438477	▁cost ▁; ▁ rhythm - control
D-1241	-1.0603113174438477	cost ; rhythm-control
P-1241	-1.1176 -0.5233 -0.3431 -1.2424 -0.2790 -0.0182 -4.7425 -0.2164
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left ventricular ejection fraction ; egfr
H-393	-0.5308928489685059	▁media n ▁age ▁; ▁women ▁; ▁media n ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁media n ▁e G FR
D-393	-0.5308928489685059	median age ; women ; median left ventricular ejection fraction ; median eGFR
P-393	-1.4265 -0.0494 -0.4332 -0.1219 -1.6535 -0.1681 -0.9581 -0.0248 -1.1190 -0.0605 -0.9167 -0.3497 -0.1746 -0.1448 -0.1872 -0.8664 -0.0122 -0.4436 -0.6880 -0.0161 -0.0740 -2.2570 -0.1022 -0.8952 -0.1296
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf ; hazard ratios ; body mass index ; obese
H-1773	-0.39740055799484253	▁fit ▁; ▁un fit ▁; ▁c RF ▁; ▁hazard ▁ratio s ▁; ▁fit ▁; ▁un fit ▁; ▁over weight ▁body ▁mass ▁index ▁; ▁obes e ▁men
D-1773	-0.39740055799484253	fit ; unfit ; cRF ; hazard ratios ; fit ; unfit ; overweight body mass index ; obese men
P-1773	-0.0391 -0.4098 -0.0054 -0.0405 -0.0928 -0.2178 -0.1087 -1.5810 -0.5628 -0.0127 -0.3614 -0.2328 -1.8913 -0.1191 -0.0286 -0.0265 -0.8844 -0.1923 -0.1556 -1.9191 -0.2361 -0.0123 -0.9223 -0.3278 -0.0579 -0.4800 -0.1120 -0.0973
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary outcome ; patients ; crt ; hazard ratio ; confidence interval
H-852	-0.6437610387802124	▁c RT ▁; ▁control ▁group ▁; ▁hazard ▁ratio ▁; ▁95% ▁confidence ▁interval ▁; CI
D-852	-0.6437610387802124	cRT ; control group ; hazard ratio ; 95% confidence interval ;CI
P-852	-0.4019 -2.0633 -1.2004 -2.1158 -1.1294 -0.2033 -0.0265 -0.0037 -0.3897 -0.7230 -0.0291 -0.0062 -0.7477 -1.0390 -0.1133 -0.1078
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi ; blood urea nitrogen ; b-type natriuretic peptide ; new york heart association class ; diabetes ; atrial fibrillation ; all-cause hospitalization
H-382	-0.28240537643432617	▁ HF PSI ▁model ▁; ▁blood ▁u rea ▁nit rogen ▁; ▁na tri ure tic ▁pe pti de ▁; ▁New ▁York ▁Heart ▁association ▁class ▁; ▁diabetes ▁status ▁; ▁at rial ▁fi bril lation ▁; flu tter
D-382	-0.28240537643432617	HFPSI model ; blood urea nitrogen ; natriuretic peptide ; New York Heart association class ; diabetes status ; atrial fibrillation ;flutter
P-382	-0.7269 -0.2875 -0.7018 -0.6258 -0.0612 -0.0764 -0.0389 -0.2099 -0.0825 -0.0215 -0.0643 -0.1230 -0.1844 -0.2233 -1.5432 -0.2793 -0.0608 -0.1750 -0.0627 -0.1084 -0.1457 -0.8932 -0.8919 -0.6834 -0.0352 -0.0271 -0.1078 -0.0590 -0.5037 -0.0174 -0.0666 -0.0174 -0.0526 -1.1787 -0.0596 -0.0208 -0.2438 -0.0705
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare patient safety monitoring system ; mpsms ; adverse event ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
H-2	-0.3381027281284332	▁Medica re ▁Patient ▁Safety ▁Monitor ing ▁system ▁; MP SMS ▁; ▁advers e ▁event ▁rates ▁; ▁patients ▁hospital ized ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁pneu monia ▁; ▁surgery
D-2	-0.3381027281284332	Medicare Patient Safety Monitoring system ;MPSMS ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
P-2	-0.0454 -0.0098 -0.2128 -0.2481 -1.9248 -0.0150 -0.4737 -0.2592 -0.5140 -0.5524 -0.5615 -1.1021 -0.0247 -0.3235 -0.5078 -0.4836 -0.9718 -0.5371 -0.1047 -1.2151 -0.0387 -0.0023 -0.9613 -0.1894 -0.2590 -0.1620 -0.0119 -0.0785 -0.0624 -0.1367 -0.0049 -0.0364 -0.6044 -0.1892 -0.0344 -0.1517 -0.0101 -0.1384 -0.7968 -0.0861 -0.0847 -0.0737
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells ; functional capacity ; cells ; peak vo2
H-127	-0.7560645341873169	▁CD 34 + ve g FR 2 + ▁cell s ▁; ▁functional ▁capacity ▁; ▁10- cell ▁; ▁CD 34 + ve g FR 2 + ▁cell s ▁; ▁VO 2
D-127	-0.7560645341873169	CD34+vegFR2+ cells ; functional capacity ; 10-cell ; CD34+vegFR2+ cells ; VO2
P-127	-2.0870 -0.1279 -1.3188 -0.1766 -1.3908 -0.6609 -0.2702 -1.0733 -0.2093 -0.0783 -0.2751 -0.2428 -0.3499 -0.0678 -3.2178 -0.1630 -0.5503 -1.4375 -0.1857 -1.3756 -0.3382 -1.2709 -1.1477 -0.1688 -0.9285 -0.3725 -0.0753 -0.3475 -3.9348 -0.1833 -0.0944 -0.0737
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients ; heart failure and reduced ejection fraction ; patient
H-659	-0.7456896901130676	▁in patient s ▁with ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-659	-0.7456896901130676	inpatients with heart failure ; reduced ejection fraction
P-659	-6.3252 -0.0372 -0.0366 -2.5243 -0.6133 -0.0257 -0.1558 -0.2821 -0.0058 -0.0086 -0.0800 -0.0104 -0.2518 -0.0036 -1.4429 -0.1277
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality rate ; patients ; hf ; hf ; case-fatality rate
H-1311	-0.386481910943985	▁cru de ▁28- day ▁case - fat ality ▁rate ▁; ▁concurrent ▁ HF ▁; ▁concurrent ▁ HF
D-1311	-0.386481910943985	crude 28-day case-fatality rate ; concurrent HF ; concurrent HF
P-1311	-1.2015 -0.0286 -0.4727 -0.1790 -0.6557 -0.0515 -0.0142 -0.0256 -0.5239 -0.1654 -1.0437 -0.1581 -0.0566 -0.3959 -0.2917 -0.2920 -0.2053 -1.4947 -0.0870
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame ; chf ; anthracycline ; stem cell ; allogeneic ; autologous ; follow-up
H-1453	-0.7119699120521545	▁CHF ▁; ▁an thra cycli ne ▁exposure ▁; ▁stem ▁cell ▁source ▁; allo gene ic
D-1453	-0.7119699120521545	CHF ; anthracycline exposure ; stem cell source ;allogeneic
P-1453	-2.2650 -0.4476 -5.1756 -0.1304 -0.1259 -0.3754 -0.1525 -0.1655 -0.0005 -0.2109 -0.1944 -0.3445 -0.0010 -0.1016 -0.1892 -2.1504 -0.0730
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting tension ; fpassive ; muscle ; kcl-ki ; titin ; titin ; extracellular matrix ; fpassive
H-765	-0.30546197295188904	▁Rest ing ▁tension ▁; F pass ive ▁; sar com ere ▁length ▁relations ▁; ▁muscle ▁strip s ▁; ▁k c l - KI ▁treatment ▁; ▁titi n ▁; ▁extra cel lular ▁matri x ▁; ▁f pass ive
D-765	-0.30546197295188904	Resting tension ;Fpassive ;sarcomere length relations ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; fpassive
P-765	-2.0868 -0.1092 -0.0400 -0.2681 -1.7921 -0.0719 -0.0468 -1.2492 -0.4227 -0.0149 -0.0145 -0.2362 -0.5072 -0.3810 -0.9465 -0.0570 -0.0236 -0.2816 -0.8711 -0.2778 -0.0291 -0.0090 -0.0316 -0.1493 -0.2399 -0.0793 -0.0146 -0.1092 -0.0290 -0.0198 -0.0068 -0.0033 -0.0294 -0.6696 -0.5882 -0.0303 -0.0280 -0.0965 -0.0519
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart failure ; myocardial infarction ; mi ; β-adrenoceptor blockade ; infarcted ; metoprolol
H-1547	-0.2334732562303543	▁rever si bility ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction ▁; MI ▁; ▁β - ad re no cept or ▁block ade ▁; ▁in far cted ▁rat s ▁; ▁met o pro lol
D-1547	-0.2334732562303543	reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
P-1547	-0.2801 -0.5986 -0.2610 -0.6735 -0.4517 -0.0563 -0.3029 -0.4714 -0.1757 -0.4667 -0.2769 -0.0454 -0.1791 -0.0698 -0.2027 -1.3930 -0.1221 -0.0400 -0.0091 -0.0189 -0.0498 -0.0730 -0.2761 -0.0673 -0.1206 -0.0880 -0.1764 -0.0089 -0.0545 -0.5822 -0.0468 -0.0444 -0.4869 -0.0232 -0.0964 -0.0270 -0.2250 -0.5065 -0.0579
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training ; exercise capacity ; muscle ; quality of life ; cardiac ; nt-probnp ; inflammatory ; il6 ; hscrp ; biomarkers
H-1922	-0.3085041046142578	▁aero bic ▁; ▁resist ance ▁training ▁; ▁aug mente d ▁feedback ▁; ▁exercise ▁capacity ▁; ▁muscle ▁strength ▁; ▁cardiac ▁; NT - pro b NP ▁; ▁infla mma tory ▁; IL 6 ▁; ▁h s cr p
D-1922	-0.3085041046142578	aerobic ; resistance training ; augmented feedback ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ;IL6 ; hscrp
P-1922	-0.0186 -0.2654 -0.4353 -0.0242 -0.0816 -1.5907 -0.5497 -0.6875 -0.0095 -0.0021 -0.0396 -0.1414 -0.5263 -0.1651 -0.0969 -0.0762 -0.2062 -0.1556 -0.8625 -0.1709 -1.3405 -0.0097 -0.6160 -0.5908 -0.1527 -0.1352 -0.0887 -0.1611 -0.0589 -0.1433 -1.2189 -0.1526 -0.2989 -0.0027 -0.0118 -0.1647 -0.2958 -0.3715 -0.1122
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital ; readmission ; all-cause readmission ; acr ; potential preventable readmission ; ppr ; medicare ; medicaid ; readmission ; cms
H-135	-0.44783177971839905	▁hospital ▁performance ▁; ▁read mission ▁metri cs ▁; ▁all - ca use ▁read mission ▁; ▁a cr ▁; ▁Potential ▁Prev en table ▁Read mission ▁; ▁p PR ▁; ▁Center s ▁for ▁Medica re ▁; ▁Medica id ▁; ▁c MS
D-135	-0.44783177971839905	hospital performance ; readmission metrics ; all-cause readmission ; acr ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid ; cMS
P-135	-4.4193 -0.1535 -0.1492 -0.3197 -1.0714 -0.7509 -0.6197 -0.3737 -1.5505 -0.0133 -0.0018 -0.1160 -0.4476 -0.5192 -0.1785 -0.1345 -0.2348 -0.0469 -0.3050 -0.2895 -0.0451 -0.1084 -0.4924 -0.2446 -0.1044 -0.0324 -0.3015 -0.0878 -0.4498 -0.0790 -0.3503 -0.0157 -0.0056 -0.6913 -0.0200 -0.0085 -0.9352 -1.2543 -1.1788 -0.1561 -0.1048
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive heart failure ; correlation coefficient
H-218	-0.6654148697853088	▁con ges tive ▁heart ▁failure ▁visit s ▁; ▁ED ▁visit s
D-218	-0.6654148697853088	congestive heart failure visits ; ED visits
P-218	-0.6639 -0.0364 -0.5861 -0.7329 -0.1373 -1.5690 -0.0535 -0.2923 -0.8583 -1.2997 -0.0547 -2.2863 -0.0797
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise ; rehabilitation ; walking ; minnesota quality of life ; exercise
H-1882	-1.575907826423645	▁m ▁; ▁Minnesota ▁; ▁quality ▁of ▁life
D-1882	-1.575907826423645	m ; Minnesota ; quality of life
P-1882	-6.0189 -0.9834 -1.6690 -1.3788 -1.9537 -0.7777 -0.7667 -0.5421 -0.0929
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine vasopressin ; avp ; physiologic ; chf ; avp ; vasopressin receptor antagonist ; therapy ; therapeutic ; chf
H-637	-0.39394935965538025	▁argi nine ▁vaso press in ▁; ▁a VP ▁; ▁physio logic ▁process es ▁; ▁CHF ▁in hib i tion ▁; ▁a VP ▁; ▁vaso press in ▁receptor ▁anta gon ist ▁ therapy ▁; ▁CHF
D-637	-0.39394935965538025	arginine vasopressin ; aVP ; physiologic processes ; CHF inhibition ; aVP ; vasopressin receptor antagonist therapy ; CHF
P-637	-2.3187 -0.3232 -0.1842 -0.0941 -0.5605 -0.3348 -0.2522 -0.1744 -0.2629 -0.7193 -0.1866 -2.2950 -0.0934 -0.3399 -0.0046 -2.1902 -0.0047 -0.1640 -0.1272 -0.8626 -0.2433 -0.2151 -0.1426 -0.0289 -0.0572 -0.2461 -0.0144 -0.0292 -0.0012 -0.1456 -0.6735 -0.0144 -0.3713 -0.0697 -0.3070 -0.1301
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; β-blockers ; patients ; heart failure and reduced ejection fraction
H-661	-0.5660099983215332	▁patients ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-661	-0.5660099983215332	patients ; angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
P-661	-6.4141 -0.8577 -2.1631 -0.3877 -0.0724 -1.7756 -0.2953 -0.0199 -0.0355 -0.1565 -0.1375 -0.0506 -0.0463 -0.6238 -0.5422 -0.1543 -0.1096 -0.7443 -0.0167 -0.3634 -0.0308 -0.1859 -0.0307 -0.0301 -0.1367 -0.0447 -0.2601 -2.9380 -0.1548 -0.2489 -0.9139 -0.0625 -0.0413 -0.4346 -0.0067 -0.3343 -0.1218
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies ; medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; risk stratification ; patient ; heart failure ; therapies ; disease
H-1205	-0.2737053334712982	▁medication ▁; ▁physical ▁ therapy ▁; ▁implant able ▁de fi br illa tors ▁; ▁circula tory ▁support ▁; ▁transplant ation ▁; ▁heart ▁failure
D-1205	-0.2737053334712982	medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure
P-1205	-1.4360 -0.1193 -0.0243 -0.1844 -0.0054 -0.1855 -0.0852 -0.0201 -0.0154 -0.0413 -0.2105 -0.0639 -0.1348 -0.2161 -0.0001 -0.0317 -0.1151 -0.2894 -0.0456 -0.0585 -0.2690 -1.5579 -0.0476 -1.5724 -0.1132
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary approaches to stop hypertension ; dash ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hfpef
H-918	-0.24712324142456055	▁so dium - re strict ed ▁dieta ry ▁approach es ▁; ▁stop ▁hyper tension ▁die t ▁; DAS h ▁; ▁s rd ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁H FP EF
D-918	-0.24712324142456055	sodium-restricted dietary approaches ; stop hypertension diet ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
P-918	-0.0159 -0.0218 -0.0046 -0.0145 -0.0136 -0.0149 -0.6514 -1.0723 -1.6590 -0.1038 -0.5753 -1.2118 -0.1781 -0.0143 -0.7265 -0.0384 -0.0683 -0.0093 -0.1529 -0.1802 -0.8213 -0.7244 -0.1389 -0.1230 -0.0120 -0.6452 -0.0555 -0.0228 -0.0174 -0.0125 -0.0502 -0.1069 -0.0143 -0.1964 -0.0636 -0.1274 -0.0049 -0.6124 -0.0594 -0.0605 -0.0239 -0.0125 -0.0124 -0.1785 -0.2022 -0.1473 -0.1006 -0.0222 -1.2630 -0.1375 -0.2108 -0.1171 -0.0737
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right ventricular pacing ; gene expressions ; bax ; bcl-2 ; caspase-3 ; rtq-pcr ; interventricular septum ; biopsies ; heart failure
H-166	-0.22502325475215912	▁rapid ▁right ▁vent ri cular ▁pa cing ▁; ▁Bax ▁; ▁b cl -2 ▁; ▁Cas pas e -3 ▁; ▁RT Q - PC r ▁; ▁interven tri cular ▁sept um ▁bio psi es ▁; ▁beag le ▁dog s ▁; ▁heart ▁failure
D-166	-0.22502325475215912	rapid right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTQ-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
P-166	-0.3812 -1.1607 -0.0463 -0.4353 -0.1354 -0.0113 -0.0789 -0.1288 -0.9908 -0.0709 -0.1752 -0.1199 -0.1558 -0.1197 -0.0101 -0.0108 -0.0287 -0.1692 -0.1561 -0.6202 -1.4635 -0.0257 -0.9499 -0.0884 -0.1527 -0.0069 -0.1032 -0.0478 -0.0120 -0.0039 -0.0058 -0.0272 -0.0653 -0.2031 -0.0091 -0.0214 -0.2081 -0.0336 -0.6040 -0.3063 -0.1744 -0.0923 -0.0662
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; bax ; caspase 3 ; expression
H-961	-0.29753679037094116	▁rat s ▁; ▁heart s ▁; ▁cas pas e -3 ▁activity ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁cy to ch rom e ▁c ▁; ▁b cl 2 ▁; ▁Bax ▁; ▁cas pas e ▁3 ▁expression
D-961	-0.29753679037094116	rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
P-961	-0.9614 -0.0597 -0.2293 -4.1671 -0.0359 -0.1375 -2.1838 -0.0267 -0.1327 -0.1721 -0.7972 -0.0561 -0.1390 -0.0101 -0.0988 -0.1351 -0.4674 -0.1681 -0.0104 -0.0086 -0.5192 -0.0115 -0.0603 -0.0249 -0.2415 -0.1306 -0.0151 -0.0422 -0.0008 -0.0568 -0.1674 -0.1380 -0.2017 -0.0240 -0.0377 -0.0691 -0.0015 -0.0713 -0.0438 -0.0454 -0.1543 -0.9599 -0.1717 -0.1164 -0.0874
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol ; carvedilol ; sympathetic activity ; von willebrand factor
H-1119	-0.45579099655151367	▁met o pro lol ▁; ▁car vedi lol ▁; ▁sympa the tic ▁activity ▁; ▁von ▁Will e brand ▁factor
D-1119	-0.45579099655151367	metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor
P-1119	-0.0293 -0.1606 -0.0100 -0.1107 -0.1332 -0.0015 -0.0547 -0.1034 -0.3129 -0.0825 -0.3827 -0.5664 -0.6197 -0.2329 -1.8283 -1.6954 -0.0711 -0.1103 -0.0538 -2.9006 -0.1118
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute hf ; relax-ahf ; astronaut ; pronto ; patient ; patients ; end points
H-1017	-0.3258306682109833	▁a cute ▁ HF ▁trial s ▁; ▁RELA X - a HF ▁; ▁ AST RON AUT ▁; ▁PR ONTO
D-1017	-0.3258306682109833	acute HF trials ; RELAX-aHF ; ASTRONAUT ; PRONTO
P-1017	-0.1256 -0.0133 -0.2434 -0.1407 -1.1798 -0.0464 -0.0800 -0.0650 -0.6129 -0.0053 -0.4130 -0.6992 -0.0517 -0.4373 -0.3089 -0.4214 -0.0147 -0.0800 -0.4309 -0.0083 -1.6898 -0.1006
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized ; hf ; international classification of diseases ; clinical ; principal ; discharge ; diagnosis
H-1832	-0.28140926361083984	▁hospital ized ▁ HF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision ▁; ▁Clinic al ▁Modifica tion ▁code s ▁; ▁dis charge ▁ diagnos is
D-1832	-0.28140926361083984	hospitalized HF ; international Classification of Diseases ; Ninth revision ; Clinical Modification codes ; discharge diagnosis
P-1832	-1.8257 -0.0637 -0.2496 -0.1235 -0.1418 -0.3313 -0.0644 -0.0392 -0.1455 -0.0554 -0.0110 -0.1925 -0.0071 -0.0089 -0.9691 -0.0227 -0.1280 -0.3917 -0.0027 -0.0587 -0.1341 -0.0262 -0.0627 -0.5237 -1.4616 -0.0631 -1.1805 -0.0956 -0.1958 -0.0668 -0.0811
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
H-1959	-0.5468013286590576	▁Pul mon ary ▁cap illa ry ▁we dge ▁pressure ▁; ▁h g ▁; SD ▁; ▁pulmonar y ▁arterial ▁pressure ▁; ▁pulmonar y ▁resist ance
D-1959	-0.5468013286590576	Pulmonary capillary wedge pressure ; hg ;SD ; pulmonary arterial pressure ; pulmonary resistance
P-1959	-0.4462 -0.8136 -0.2391 -0.3518 -0.1725 -0.1602 -0.2112 -0.1559 -0.4600 -0.1755 -3.7947 -0.1543 -0.1171 -1.3698 -0.3863 -3.6831 -0.0343 -0.0112 -0.5112 -0.2549 -0.0031 -0.0963 -0.2189 -0.1527 -0.1730 -0.0700
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad ; q65p ; movement ; wild-type rad ; q65p ; l-type channel ; rgk proteins
H-1676	-0.5822920799255371	▁Rad ▁Q 65 p ▁; ▁ga ting ▁movement ▁; ▁channel s ▁; ▁wild - type ▁Rad ▁; ▁Q 65 p ▁substitut ion ▁; ▁l - type ▁channel ▁inhibi tion ▁; ▁r GK ▁protein s
D-1676	-0.5822920799255371	Rad Q65p ; gating movement ; channels ; wild-type Rad ; Q65p substitution ; l-type channel inhibition ; rGK proteins
P-1676	-0.6552 -1.8679 -0.3082 -0.7556 -0.2061 -2.3839 -0.0197 -0.3212 -0.1990 -6.1734 -0.1143 -0.1474 -0.1043 -0.0128 -0.0031 -0.6117 -0.0911 -1.5455 -0.1053 -0.6526 -1.2518 -0.0115 -0.1174 -2.0295 -0.0216 -0.0035 -0.0417 -0.0164 -0.2489 -0.2062 -0.2727 -0.0932 -0.1031 -0.0493 -0.1429 -0.0744
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 ; heart failure ; proteomics ; actin cytoskeleton ; ss20 ; mitochondrial ; metabolic pathways
H-876	-0.45575231313705444	▁heart ▁failure ▁; ▁prote o mics ▁; ▁act in ▁cy tos kelet on ▁path ways ▁; ▁SS 20 ▁; ▁mito cho ndri al ▁; ▁metabol ic ▁path ways
D-876	-0.45575231313705444	heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
P-876	-4.6483 -0.3978 -0.2042 -1.9691 -0.3958 -0.0072 -1.2426 -0.0655 -0.0499 -0.4924 -0.2913 -0.0513 -0.0578 -0.5791 -0.0545 -0.6086 -0.1798 -0.1731 -0.6786 -0.0403 -0.1599 -0.0483 -0.0143 -0.2937 -0.0254 -0.1836 -0.3288 -0.0969 -0.2182 -0.1162
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic insufficiency ; mechanical circulatory support ; continuous flow ; left ventricular assist devices ; lvads ; pulsatile devices
H-542	-0.18060076236724854	▁a or tic ▁insu ffi cie ncy ▁; AI ▁; ▁mechanic al ▁circula tory ▁support ▁; ▁continuo us ▁flow ▁; CF ▁; ▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁pulsa tile ▁devices
D-542	-0.18060076236724854	aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
P-542	-0.0748 -0.0509 -0.8964 -0.0416 -0.3641 -1.2063 -0.0613 -0.1943 -0.5088 -0.2249 -0.1861 -0.0051 -0.0019 -0.1327 -0.1885 -0.1458 -0.0190 -0.0346 -0.0220 -0.0765 -0.1557 -0.0825 -0.0301 -0.0306 -0.3876 -0.0891 -0.3056 -0.1933 -0.1841 -0.0591 -0.0076 -0.0657 -0.3076 -0.0273 -0.0134 -0.1547 -0.2299 -0.1031
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration ; pyridostigmine ; coronary artery ligation ; cardiac ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hf
H-1145	-0.1626557558774948	▁py rido stig mine ▁; ▁corona ry ▁arter y ▁liga tion ▁; ▁cardiac ▁va gal ▁; ▁sympa the tic ▁tone ▁; ▁cardiac ▁remodel ing ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ HF
D-1145	-0.1626557558774948	pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
P-1145	-0.2916 -0.0064 -0.0012 -0.1739 -0.1583 -0.0474 -0.2445 -0.0327 -0.0910 -0.0712 -0.4303 -0.2430 -0.5917 -0.0083 -0.0193 -0.0754 -0.0281 -0.1742 -0.4524 -0.0136 -0.1019 -0.0448 -0.0062 -0.0187 -0.1131 -0.0417 -0.0203 -0.4816 -0.1353 -0.0376 -0.0976 -0.1966 -0.6942 -0.1042 -0.5393 -0.0679
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge ; patients ; follow-up ; physician ; physician
H-1418	-0.9512004256248474	▁follow - up ▁visit s
D-1418	-0.9512004256248474	follow-up visits
P-1418	-4.6964 -0.1200 -0.0139 -0.5629 -0.0845 -1.0913 -0.0894
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life expectancy ; heart failure ; patients ; disease ; terminal heart failure
H-1665	-0.8861660361289978	▁heart ▁failure ▁; ▁re frac tory ▁; ▁terminal ▁heart ▁failure
D-1665	-0.8861660361289978	heart failure ; refractory ; terminal heart failure
P-1665	-5.8647 -0.1806 -0.3067 -2.4522 -0.0154 -0.0943 -0.2952 -0.0846 -0.9498 -0.1670 -0.1106 -0.1128
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart failure ; discharges ; university of connecticut health center ; patients ; follow-up
H-723	-0.6393966674804688	▁heart ▁failure ▁dis charge s ▁; ▁University ▁of ▁Connect i cut ▁health ▁Center
D-723	-0.6393966674804688	heart failure discharges ; University of Connecticut health Center
P-723	-3.4474 -0.1238 -0.9053 -0.0289 -0.0574 -0.2519 -0.8227 -0.0322 -0.5487 -0.0102 -0.0490 -0.8601 -0.6941 -1.6738 -0.0855
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes ; patients ; new york heart association ; nyha ; heart failure ; eplerenone ; placebo ; heart failure ; medicines ; emphasis-hf
H-1229	-0.6583977937698364	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁Class ▁II ▁Heart ▁Fail ure ▁; ▁e pler en one ▁; ▁Place bo ▁; ▁standard ▁Heart ▁Fail ure ▁Medicine s ▁; EMP ha SIS - HF ▁Study
D-1229	-0.6583977937698364	New York Heart association ;NYha ; Class II Heart Failure ; eplerenone ; Placebo ; standard Heart Failure Medicines ;EMPhaSIS-HF Study
P-1229	-4.6995 -1.1483 -2.9189 -0.7117 -0.0550 -0.2154 -0.9942 -0.1595 -1.5251 -0.1250 -0.6893 -0.1784 -0.7760 -0.2024 -0.3897 -0.0175 -0.0888 -0.2978 -0.0694 -0.2670 -0.0043 -0.0620 -2.0773 -0.6859 -0.1378 -0.6775 -0.0846 -0.0474 -0.1423 -0.0677 -1.5880 -1.0151 -0.0236 -0.2183 -1.2617 -0.6241 -0.1142
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; ivc occlusion ; bivp ; ste ; rs
H-324	-0.23242922127246857	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁base ▁; ▁mid pap illa ry ▁; ▁ap ex ▁; ▁IV c ▁oc clusi on ▁; ▁Bi VP ▁; ▁ STE ▁analysis ▁; ▁twist ▁; ▁ap ical ▁; ▁bas al ▁rota tions ▁; ▁CS ▁; ▁RS
D-324	-0.23242922127246857	echocardiograms ; left ventricular base ; midpapillary ; apex ; IVc occlusion ; BiVP ; STE analysis ; twist ; apical ; basal rotations ; CS ; RS
P-324	-0.2878 -0.0239 -0.0825 -0.1702 -0.0023 -0.1201 -0.2254 -0.0636 -0.0258 -0.4703 -0.0470 -0.1761 -0.1134 -0.0751 -0.1024 -0.0432 -0.1679 -0.1675 -0.2252 -0.0733 -0.3468 -0.5963 -0.5155 -0.0010 -0.0003 -0.0314 -0.1044 -0.5741 -0.0405 -0.3878 -2.9133 -0.8236 -0.3073 -0.1829 -0.1068 -0.1524 -0.3290 -0.0214 -0.3955 -0.0066 -0.0028 -0.0023 -0.0152 -0.1571 -0.0975 -0.2056 -0.0133 -0.3216 -0.0738
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence ; drugs ; drugs ; raas ; renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
H-1490	-0.19812481105327606	▁drugs ▁; ▁RA as ▁; ▁direct ▁re nin ▁inhibi tors ▁; ▁neutral ▁en dop ep tida se ▁inhibi tors ▁; ▁vaso pe pti das e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers
D-1490	-0.19812481105327606	drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
P-1490	-1.4521 -0.1381 -0.4695 -0.3188 -0.1163 -0.0023 -0.0099 -1.1586 -0.0290 -0.0472 -0.1031 -0.0371 -0.0089 -0.0559 -0.4502 -0.0048 -0.0168 -0.0140 -0.0621 -0.1101 -0.0028 -0.1376 -0.1795 -0.6939 -0.0591 -0.0378 -0.1308 -0.1557 -0.3865 -0.1232 -0.0272 -0.2690 -0.0046 -0.1411 -0.0234 -0.2339 -0.1198
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute heart failure ; hf ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
H-1015	-0.2178899198770523	▁a cute ▁heart ▁failure ▁; HF ▁; ▁ pharma c ologic ▁studies ▁; ▁calci um - sensi t izing ▁agents ▁; ▁anta gon ists ▁; ▁en do the lin ▁; ▁vaso press in ▁; ▁ad enos ine
D-1015	-0.2178899198770523	acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
P-1015	-0.0823 -0.0168 -0.5171 -0.0653 -0.1933 -0.0690 -0.2006 -0.5924 -0.2693 -0.0561 -0.0771 -0.1683 -0.2637 -0.2645 -0.0050 -0.0459 -0.0157 -1.2989 -0.0121 -0.4567 -0.1274 -0.7359 -0.0026 -0.3946 -0.2199 -0.0074 -0.0183 -0.1027 -0.6351 -0.1092 -0.0003 -0.0149 -0.1668 -0.1759 -0.0057 -0.0172 -0.8179 -0.1725 -0.1034
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in vivo ; hf ; phenylephrine ; haemodynamic ; surgical ; transverse aortic constriction ; tac ; jq1 ; pathological ; cardiac hypertrophy
H-1047	-0.3201134204864502	▁ HF ▁induc ed ▁in ▁mi ce ▁; ▁ phen yle ph rine ▁; ▁ha emo dynamic ▁stress ▁; ▁sur g ical ▁method ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁j q 1 ▁; ▁cardiac ▁hyper trop hy
D-1047	-0.3201134204864502	HF induced in mice ; phenylephrine ; haemodynamic stress ; surgical method ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
P-1047	-1.6862 -0.1320 -0.3819 -0.1154 -0.8482 -0.0705 -0.1667 -0.9184 -0.2289 -0.0664 -0.1926 -0.0825 -0.0345 -0.1155 -0.0007 -0.0182 -0.0008 -0.1076 -0.0608 -0.6862 -0.1698 -0.0600 -0.1581 -1.0974 -0.0001 -0.0964 -0.0213 -0.1023 -0.9558 -0.0239 -0.2454 -0.0268 -0.3879 -0.0238 -0.5942 -0.5298 -0.9209 -0.5326 -0.9026 -0.2713 -0.3252 -0.0068 -0.8470 -0.1359 -0.0558
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; fontan
H-1502	-0.2614709436893463	▁mus cle ▁aero bic ▁capacity ▁; ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis ▁; ▁Font an ▁adults
D-1502	-0.2614709436893463	muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan adults
P-1502	-0.5990 -0.1091 -0.0320 -0.1075 -0.2268 -0.1088 -0.4667 -0.0103 -0.0384 -0.2600 -0.1724 -0.0270 -0.2092 -0.5910 -0.8437 -0.0276 -0.0361 -0.4071 -0.5510 -0.4117 -0.0344 -0.0266 -0.3948 -0.7733 -0.0723
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
H-1117	-0.39040490984916687	▁i - mi BG ▁cardiac ▁was hout ▁; ▁car vedi lol ▁; ▁met o pro lol ▁treatment ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1117	-0.39040490984916687	i-miBG cardiac washout ; carvedilol ; metoprolol treatment ; β2-adrenergic receptor haplotype
P-1117	-0.0947 -0.8091 -0.3428 -3.6069 -0.1863 -2.3029 -0.1330 -0.2086 -0.0134 -0.0192 -0.0599 -0.2954 -0.0159 -0.2483 -0.0252 -0.2276 -1.0217 -0.4320 -0.2506 -0.1330 -0.1083 -0.0960 -0.4682 -0.0543 -0.0562 -0.1126 -0.0435 -0.0088 -0.1987 -0.1390
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute myocardial infarction ; ami ; incidence ; deaths ; heart failure ; hf ; ami
H-1306	-0.5389840602874756	▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁cardiac ▁failure ▁; HF ▁; ▁complicat ing ▁ AMI
D-1306	-0.5389840602874756	acute myocardial infarction ;AMI ; cardiac failure ;HF ; complicating AMI
P-1306	-2.2526 -0.0330 -1.6786 -0.2016 -0.3934 -0.3012 -0.0325 -0.0926 -0.0878 -0.2143 -0.9263 -0.2195 -4.4954 -0.1729 -0.1775 -0.0893 -0.2510 -0.2191 -0.0469 -0.1864 -0.0822 -0.1618 -0.0807
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; cardiac metabolic gene expression ; atp
H-655	-0.5227357745170593	▁h - d ko ▁; ▁vent ri cular ▁mass ▁; ▁cardiac ▁apo pto sis ▁; ▁fibro sis ▁; ▁Akt → for k head ▁box ▁; ▁o -1 ▁signal ing ▁; ▁cardiac ▁metabol ic ▁; ▁ATP
D-655	-0.5227357745170593	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt→forkhead box ; o-1 signaling ; cardiac metabolic ; ATP
P-655	-1.8872 -0.1079 -0.4056 -0.3455 -0.7686 -0.2807 -0.8944 -0.3115 -0.1262 -0.0235 -0.1137 -0.0841 -0.0858 -0.2866 -0.2801 -0.0033 -0.0475 -0.4143 -2.0692 -2.9390 -0.1126 -0.0406 -0.6294 -0.0841 -0.5420 -0.5218 -0.8420 -0.2488 -0.0512 -0.1145 -0.5113 -0.0309 -0.1446 -1.5691 -1.0730 -1.2589 -0.0916
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck stent ; implanted ; lad ; circumflex artery ; lcx ; lcx ; lad
H-505	-0.2421310395002365	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁; LAD ▁; ▁proxima l ▁circum flex ▁arter y ▁; LC X ▁; ▁proxima l ▁ LC X ▁; ▁mid ▁ LAD
D-505	-0.2421310395002365	bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCX ; proximal LCX ; mid LAD
P-505	-0.0302 -0.0429 -0.0111 -0.0408 -0.0887 -0.1852 -1.4640 -0.0219 -0.1817 -0.2170 -0.0138 -0.0119 -0.1498 -0.1036 -0.0801 -0.0298 -0.0338 -0.0087 -0.0095 -0.0264 -0.2068 -0.3160 -0.2814 -0.7021 -0.1300 -0.2264 -0.0190 -0.1700 -0.0570 -0.8342 -0.1820 -0.5062 -0.1256 -0.0446 -2.0660 -0.0987
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized ; heart failure ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
H-1827	-0.4856678247451782	▁post marketing ▁; ▁hospital ized ▁heart ▁failure ▁; h HF ▁; ▁di pe pti dy l ▁pep tida se -4 ▁; ▁d PP -4 ▁; ▁anti hy per gly ce mic ▁agents
D-1827	-0.4856678247451782	postmarketing ; hospitalized heart failure ;hHF ; dipeptidyl peptidase-4 ; dPP-4 ; antihyperglycemic agents
P-1827	-0.6199 -0.0524 -0.4888 -2.7434 -0.1203 -0.9798 -0.1939 -0.1654 -0.9695 -0.3089 -0.0732 -0.0641 -0.0104 -0.0363 -3.2289 -1.6240 -0.0073 -0.0340 -0.1279 -0.0597 -0.2219 -0.1719 -0.5700 -0.0486 -0.7467 -0.4596 -0.2936 -0.0410 -0.1140 -0.1896 -0.5118 -0.9029 -0.2141 -0.1188
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox modeling ; heart failure patient severity index ; hfpsi ; university of michigan ; hf ; clinic ; primary outcome
H-380	-0.29324713349342346	▁quality ▁improvement ▁database ▁; ▁multi vari able ▁co x ▁model ing ▁; ▁Heart ▁Fail ure ▁Patient ▁Sever ity ▁index ▁; HF PSI ▁; ▁University ▁of ▁Michigan ▁ HF ▁clinic ▁; UM ▁co hor t
D-380	-0.29324713349342346	quality improvement database ; multivariable cox modeling ; Heart Failure Patient Severity index ;HFPSI ; University of Michigan HF clinic ;UM cohort
P-380	-0.8952 -0.0292 -0.1444 -0.0337 -0.0597 -0.0224 -0.0197 -0.1472 -0.1035 -0.0806 -0.0504 -0.0689 -0.6258 -0.2366 -0.4464 -0.1364 -0.3331 -0.4854 -0.2404 -0.1190 -0.7499 -0.2519 -0.0564 -0.4404 -0.0174 -0.0073 -1.1223 -0.7666 -0.3847 -0.2576 -0.9212 -0.2832 -0.2641 -0.0343 -0.6330 -0.0885
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 ; healthy ; cardiomyocytes ; camp ; inotropic effect ; acute ; β-ar ; contractility
H-1216	-0.24106371402740479	▁p de 2 ▁over expression ▁; ▁healthy ▁cardio my o cy tes ▁; ▁c AMP ▁levels ▁; ▁ca 2 ▁; ▁in o tropi c ▁effect ▁; ▁β - AR ▁stimul ation ▁; ▁bas al ▁contract ility
D-1216	-0.24106371402740479	pde2 overexpression ; healthy cardiomyocytes ; cAMP levels ; ca2 ; inotropic effect ; β-AR stimulation ; basal contractility
P-1216	-0.4874 -0.2909 -0.0589 -0.0277 -0.0168 -0.2329 -0.3304 -0.0969 -0.3880 -0.1694 -0.0597 -0.0652 -0.0969 -0.0049 -0.0285 -0.5430 -0.0692 -1.5419 -0.0736 -1.2166 -0.7992 -0.2887 -0.0094 -0.0749 -0.1209 -0.1502 -0.2134 -0.0094 -0.2209 -0.1471 -0.2524 -0.5815 -0.0096 -0.0140 -0.0068 -0.1839 -0.1795 -0.1001
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp ; shock therapy
H-863	-0.3947094678878784	▁in appropria te ▁ATP ▁; ▁in appropria te ▁shock ▁ therapy
D-863	-0.3947094678878784	inappropriate ATP ; inappropriate shock therapy
P-863	-0.2518 -0.0113 -0.0725 -0.5864 -0.1004 -1.4116 -0.0307 -0.0428 -0.7185 -0.1595 -0.0150 -1.6154 -0.1152
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac resynchronization therapy ; crt ; patients ; heart failure ; hf ; outcomes ; crt ; dialysis ; reported
H-904	-0.45639142394065857	▁Card iac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure ▁; HF
D-904	-0.45639142394065857	Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF
P-904	-0.9216 -0.1270 -0.0302 -0.0599 -0.0094 -0.7324 -0.7459 -0.0246 -0.1610 -0.7387 -1.9826 -0.1974 -0.5223 -0.0482 -0.0389 -0.1352 -0.0529 -0.4620 -0.9448 -0.3975 -0.0928 -0.4004 -0.0747 -2.4106 -0.0988
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ; hf ; mortality ; cardiovascular ; hf ; mortality
H-1766	-0.39801397919654846	▁cardio re spira tory ▁fitness ▁; cr f ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁; HF ▁; ▁mortal ity ▁; ▁cardiovascular ▁risk ▁factors ▁; ▁ HF ▁mortal ity ▁; ▁fit ▁; ▁un fit ▁men
D-1766	-0.39801397919654846	cardiorespiratory fitness ;crf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
P-1766	-0.6162 -0.0434 -0.1324 -0.0877 -0.5059 -0.1151 -1.5880 -1.1837 -0.0611 -0.0210 -0.0950 -0.0024 -0.0737 -0.5436 -0.1527 -0.3103 -0.4386 -0.8308 -0.7893 -0.4098 -0.2491 -0.0234 -0.4652 -0.2323 -0.1605 -0.6239 -0.2502 -0.2059 -0.3461 -0.3345 -0.1915 -1.9848 -0.0020 -0.0155 -1.2000 -0.3005 -0.1401
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; eplerenone ; patients ; hospitalization ; heart failure
H-1221	-0.3430733382701874	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁EM PHA SIS - HF ▁; ▁e pler en one ▁in ▁Mil d ▁Patient s ▁Hospital ization ▁; ▁Sur v I val ▁Study ▁in ▁Heart ▁Fail ure
D-1221	-0.3430733382701874	eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone in Mild Patients Hospitalization ; SurvIval Study in Heart Failure
P-1221	-0.1454 -0.3333 -0.2161 -0.9811 -0.1540 -0.3926 -0.1736 -0.0913 -0.0682 -0.0783 -0.1292 -0.2582 -0.3516 -0.0234 -0.1997 -0.0167 -0.0385 -0.9405 -0.1192 -0.1255 -0.1519 -0.6967 -3.5208 -0.6817 -0.0078 -0.0650 -0.0538 -0.2051 -0.4500 -0.1725 -0.1977 -0.0554 -0.7772 -0.0090 -0.1118 -0.5133 -0.2357 -0.0815 -0.9253 -0.1703 -0.1469
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart rate ; cardiac ; patients ; patients ; acute myocardial infarction ; ami ; patients ; congestive heart failure ; chf ; left ventricular ; dysfunction
H-1585	-0.35446280241012573	▁Heart ▁rate ▁; HR ▁; ▁variabil ity ▁; ▁cardiac ▁patients ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁left ▁vent ri cular ▁; LV
D-1585	-0.35446280241012573	Heart rate ;HR ; variability ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
P-1585	-0.8287 -0.3396 -0.4575 -0.1396 -0.4891 -1.7970 -0.7627 -0.1879 -0.0103 -0.2505 -0.2138 -1.0348 -0.0143 -1.0600 -0.2710 -0.2836 -0.4268 -0.0259 -0.1588 -0.1326 -0.3395 -0.1092 -0.2483 -0.1569 -0.0762 -0.8018 -0.2600 -0.0509 -0.1191 -0.3329 -1.0403 -0.0478 -0.0114 -0.0292 -0.4047 -0.0790 -0.3927 -0.0386 -0.6435 -0.1121
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular cardiomyocytes ; chronic ; insulin ; irs1 ; irs2 ; proteins ; insulin ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
H-657	-0.21780869364738464	▁ne ona tal ▁rat ▁vent ri cular ▁cardio my o cy tes ▁; ▁chronic ▁insulin ▁exposure ▁; ▁i RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁insulin ▁action ▁; ▁activa tion ▁; ▁cardiac ▁dys function ▁; ▁insulin ▁resist ance ▁; ▁type ▁2 ▁diabetes
D-657	-0.21780869364738464	neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; activation ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
P-657	-0.1218 -0.0033 -0.0095 -0.0813 -0.0560 -0.4753 -0.2076 -0.1392 -0.9631 -0.1681 -0.0480 -0.0643 -0.2258 -0.1789 -0.2684 -0.0630 -0.1231 -1.0768 -0.0247 -0.6340 -0.3004 -0.7084 -0.1557 -0.0505 -0.1968 -0.0331 -0.1730 -0.5478 -0.1097 -0.3916 -0.2074 -0.0795 -0.6435 -0.5355 -0.0454 -0.0157 -0.1426 -0.0153 -0.1065 -0.0253 -0.1636 -0.0215 -0.1104 -0.0231 -0.1673 -0.1171
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms ; left ventricular ; midpapillary ; atrioventricular delay ; avd ; interventricular delay ; vvd ; ste ; circumferential strain ; radial strain ; rs
H-323	-0.28240618109703064	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁mid pap illa ry ▁level ▁; ▁at rio ven tri cular ▁de lay ▁; AV d ▁; ▁interven tri cular ▁de lay ▁; VV d ▁; ▁ STE ▁analysis ▁; ▁circum fer ential ▁strain ▁; CS ▁; ▁radi al ▁strain ▁; RS
D-323	-0.28240618109703064	echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ;AVd ; interventricular delay ;VVd ; STE analysis ; circumferential strain ;CS ; radial strain ;RS
P-323	-0.7500 -0.0329 -0.1250 -0.1969 -0.0050 -0.2177 -0.2443 -0.0573 -0.0324 -0.6667 -0.1758 -0.6297 -0.1736 -0.1685 -0.3481 -0.2335 -0.1197 -0.4595 -0.0750 -0.0111 -1.5018 -0.2181 -0.0359 -0.0314 -0.2008 -0.2942 -0.7104 -0.0550 -0.0028 -0.4762 -0.0666 -0.0224 -0.0841 -0.2662 -0.9584 -0.3847 -0.1114 -2.1552 -0.3149 -0.2357 -0.4073 -0.1671 -0.0669 -0.1508 -0.0148 -0.2394 -0.3898 -0.1225 -0.0105 -0.0189 -0.0421 -0.7096 -0.0121 -0.2760 -0.0558
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients ; new york heart association ; nyha ; functional class ; hf ; ejection fractions ; chronic ; stable ; guideline-directed medical therapy ; gdmt ; united states ; canada ; europe
H-1870	-0.2416311353445053	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁functional ▁class ▁III ▁ HF ▁; ▁e je ction ▁ fraction s ▁; ▁chronic ▁stable ▁guide line - direct ed ▁medical ▁ therapy ▁; GD MT
D-1870	-0.2416311353445053	New York Heart association ;NYha ; functional class III HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
P-1870	-1.0016 -0.4182 -1.2168 -0.8246 -0.1284 -0.1519 -1.1122 -0.0825 -0.0257 -0.0419 -0.1853 -0.1468 -0.1270 -0.0480 -0.0106 -0.0350 -0.0145 -0.1198 -0.0008 -0.0768 -0.0800 -0.0885 -0.1958 -0.5838 -0.0108 -0.0291 -0.0018 -0.0571 -0.0723 -0.1308 -0.0174 -0.1454 -0.0655 -0.9551 -0.4410 -0.0561
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients ; qrs ; hazard ratio ; primary outcome ; patients ; qrs ; hazard ratio
H-889	-0.43360596895217896	▁non - LB bb ▁; ▁QR s ▁; ▁hazard ▁ratio
D-889	-0.43360596895217896	non-LBbb ; QRs ; hazard ratio
P-889	-0.3186 -0.0166 -0.0522 -0.9205 -0.0753 -0.0221 -1.0087 -0.5782 -0.4546 -0.0174 -1.6241 -0.1148
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous hf ; myofiber shortening ; septum ; myofiber shortening ; stretch ; wall
H-1155	-0.3758356273174286	▁ab normal ▁Ca (2 +) ▁handling ▁; ▁dys syn chron ous ▁ HF ▁; ▁my o fi ber ▁short en ing ▁veloci ty ▁; ▁sept um ▁; ▁my o fi ber ▁short en ing ▁; ▁stretch ▁rate ▁; ▁lateral ▁wall
D-1155	-0.3758356273174286	abnormal Ca(2+) handling ; dyssynchronous HF ; myofiber shortening velocity ; septum ; myofiber shortening ; stretch rate ; lateral wall
P-1155	-3.2424 -0.0102 -1.1099 -0.0304 -0.0012 -0.0724 -0.6449 -0.0100 -0.0133 -0.0046 -0.2842 -0.2389 -0.1665 -0.1749 -1.8135 -0.1032 -0.0299 -0.1412 -0.4698 -0.0587 -0.1428 -0.6969 -0.0978 -0.2154 -0.1455 -0.0058 -0.1367 -1.6991 -0.0691 -0.0270 -0.1134 -0.6600 -0.0572 -0.1625 -0.3891 -0.1166 -0.5752 -0.7275 -0.1881 -0.6842 -0.1432 -0.1120
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics ; proteomics ; transverse aortic constriction ; tac ; heart failure ; signaling pathway ; ingenuity pathway analysis
H-871	-0.39925798773765564	▁label - free ▁shot gun ▁prote o mics ▁; ▁global ▁prote o mics ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC - indu ced ▁heart ▁failure
D-871	-0.39925798773765564	label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC-induced heart failure
P-871	-0.9475 -0.0195 -0.0337 -0.0519 -0.0287 -1.4109 -0.4135 -0.0060 -0.4959 -0.5136 -0.3218 -0.3712 -0.0042 -0.6178 -0.0015 -0.1334 -0.0164 -0.1269 -1.1213 -0.0263 -0.9243 -0.0287 -0.2653 -0.3138 -2.2653 -0.0035 -0.0253 -0.0902 -0.0662 -1.6469 -0.0852
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells ; transforming growth factor-β ; tgf-β ; epithelial ; mesenchymal ; transition ; expression ; pluripotency markers
H-1342	-0.3355051279067993	▁c - K it + ▁cell s ▁; ▁transform ing ▁growth ▁factor - β ▁; ▁t GF - β ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker s ▁; ▁sham s
D-1342	-0.3355051279067993	c-Kit+ cells ; transforming growth factor-β ; tGF-β ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
P-1342	-0.4174 -0.0431 -3.2277 -0.0337 -0.3553 -0.1297 -0.1043 -0.4545 -1.4697 -0.0238 -1.1323 -0.1115 -0.1431 -0.0230 -0.4410 -0.8123 -0.2396 -0.0272 -0.0141 -0.6608 -0.7904 -0.0310 -0.0380 -0.0063 -0.7141 -0.0292 -0.1296 -0.1109 -0.8917 -0.0574 -0.0774 -0.0558 -0.3124 -0.2612 -0.0339 -0.0271 -0.0756 -0.0304 -0.5548 -0.0086 -0.0866 -0.1406 -0.0998
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka ; change ; riiα ; cα ; expression ; riiα ; ser96 ; cα ; thr197 ; phosphorylation ; hf
H-1428	-0.43612030148506165	▁p ka ▁sub un its ▁; ▁type ▁II ▁regulator y ▁; RI i α ▁; ▁cata ly tic ▁; ▁c α ▁; ▁sub un it ▁expression ▁; ▁r II α ▁; Ser 96) ▁; ▁c α ▁; ▁ phos phor y lation ▁; HF
D-1428	-0.43612030148506165	pka subunits ; type II regulatory ;RIiα ; catalytic ; cα ; subunit expression ; rIIα ;Ser96) ; cα ; phosphorylation ;HF
P-1428	-0.3252 -0.4865 -2.6304 -0.1355 -0.0242 -0.1022 -0.2376 -0.1544 -0.0896 -0.0664 -0.1154 -1.3865 -0.2566 -0.0403 -0.0930 -0.0119 -0.1890 -0.3425 -0.3858 -0.7794 -0.1990 -0.3900 -2.8190 -0.0245 -0.0226 -0.0983 -0.1728 -0.2338 -0.8731 -0.1496 -0.1151 -0.9350 -0.0511 -0.2647 -0.2103 -0.1188 -0.0925 -1.9804 -0.1258 -0.5234 -0.3992 -0.0915 -0.3131 -1.7463 -0.1623 -0.0966
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients ; hfref ; left ventricular ejection fraction ; hfpef ; left ventricular ejection fraction ; β-blocker ; hf ; hospitalization
H-178	-0.4753752648830414	▁h Fr EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF p EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ RAS - ▁; ▁β - block er ▁dose ▁changes ▁; ▁index ▁ HF
D-178	-0.4753752648830414	hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; β-blocker dose changes ; index HF
P-178	-0.9492 -0.2698 -0.3871 -0.4891 -0.0300 -0.0709 -1.3616 -0.9199 -0.2428 -0.1973 -0.3261 -0.8174 -0.0162 -0.1784 -0.5552 -0.1804 -0.1164 -0.0681 -0.4531 -0.0719 -0.0658 -1.7593 -0.9222 -0.2978 -0.3758 -0.5094 -0.8703 -0.0375 -0.6431 -1.0856 -0.3347 -0.0567 -1.3134 -0.0160 -0.0715 -0.0671 -0.0346 -0.7905 -2.6898 -0.5475 -0.0270 -0.2422 -0.0938 -0.7102 -0.1291
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross talk ; g-protein-coupled receptors ; physiological ; significance ; regulation ; hearts ; chronic ; β-adrenergic receptor ; postischemic heart failure
H-1410	-0.257594496011734	▁g - prote in - co up led ▁receptor s ▁; ▁reciproc al ▁regula tion ▁; ▁mouse ▁heart s ▁; ▁β - ad r energi c ▁receptor ▁stimul ation ▁; ▁post ische mic ▁heart ▁failure
D-1410	-0.257594496011734	g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor stimulation ; postischemic heart failure
P-1410	-0.6301 -0.0641 -0.0462 -0.3191 -0.0461 -0.0068 -0.0311 -0.2760 -0.0906 -0.2841 -0.4725 -1.8619 -0.0096 -0.3846 -0.2007 -0.1854 -0.0503 -0.2418 -0.0460 -0.2825 -0.9219 -0.0295 -0.1307 -0.1635 -0.3007 -0.0367 -0.0253 -0.6848 -0.2107 -0.1138 -0.0419 -0.0305 -0.2345 -0.6747 -0.1368 -0.1797 -0.0857
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric remodeling ; concentric hypertrophy ; left ventricular ; remodeling ; heart failure with preserved ejection fraction ; hfpef ; eccentric hypertrophy ; patients
H-1524	-0.21868596971035004	▁concentr ic ▁remodel ing ▁; CR ▁; ▁concentr ic ▁hyper trop hy ▁; CH ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁remodel ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁ecce n tric ▁hyper trop hy ▁; EH
D-1524	-0.21868596971035004	concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
P-1524	-0.0081 -0.0478 -0.1354 -0.0329 -0.1892 -1.3462 -0.0838 -0.0104 -0.0427 -0.1221 -0.0224 -0.3669 -0.3214 -0.5744 -0.2056 -0.1798 -0.0352 -0.3922 -0.1785 -0.2541 -0.0639 -0.2137 -1.9322 -0.0085 -1.0136 -0.4931 -0.0258 -0.5486 -0.0108 -0.0181 -0.1695 -0.0135 -0.0566 -0.0258 -0.3536 -0.0038 -0.2216 -0.0674 -0.0362 -0.1451 -0.0503 -0.0036 -0.0114 -0.0558 -0.1280 -0.0130 -0.3574 -0.2083 -0.0289 -0.2230 -0.1030
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise ; exercise
H-1989	-1.1976958513259888	▁weight ▁; SD ▁; ▁die t ▁group ▁; SD
D-1989	-1.1976958513259888	weight ;SD ; diet group ;SD
P-1989	-2.1233 -0.3779 -1.3615 -0.4622 -1.3440 -0.0718 -1.1439 -0.3610 -3.8573 -1.9343 -0.1376
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv dysfunction ; hazard ratio ; confidence interval ; cachexia ; hazard ratio ; multivariate analyses
H-1166	-0.41701582074165344	▁ RV ▁dys function ▁; haz ard ▁ratio ▁; ▁confidence ▁interval ▁; CI ▁; ▁cache xia ▁; haz ard ▁ratio
D-1166	-0.41701582074165344	RV dysfunction ;hazard ratio ; confidence interval ;CI ; cachexia ;hazard ratio
P-1166	-2.8627 -0.8806 -0.3194 -0.0339 -0.1254 -0.3568 -0.0052 -0.0747 -0.2810 -0.5377 -0.0085 -0.1836 -0.6782 -0.2327 -0.0139 -0.1854 -0.5608 -0.3979 -0.0125 -0.0489 -1.2165 -0.1580
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients ; resting hr ; follow-up ; baseline ; vo2max ; patients ; resting hr ; p value
H-1945	-1.1682493686676025	▁rest ing ▁HR ▁; ▁VO 2 max
D-1945	-1.1682493686676025	resting HR ; VO2max
P-1945	-1.4936 -0.1440 -0.3939 -0.4681 -4.4352 -0.1147 -0.0264 -3.3081 -0.1304
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β ; cell ; phenotype ; in vitro ; cardiac progenitor function ; cell ; clinical
H-1344	-0.3331414759159088	▁t GF - β ▁inhibi tion ▁; ▁c - K it + ▁cell ▁ph eno type ▁; ▁function ▁in ▁vi tro ▁; ▁cardiac ▁pro gen itor ▁function ▁; ▁cell ▁exp an sion ▁protocol s
D-1344	-0.3331414759159088	tGF-β inhibition ; c-Kit+ cell phenotype ; function in vitro ; cardiac progenitor function ; cell expansion protocols
P-1344	-1.7866 -0.5694 -0.0237 -0.0421 -0.1228 -0.3452 -0.1010 -0.0256 -0.0677 -1.8612 -0.0105 -0.4412 -0.1991 -0.7116 -0.0562 -0.0019 -0.1317 -0.7690 -0.9767 -0.0080 -0.0037 -0.3343 -0.0909 -0.1457 -0.0709 -0.0498 -0.1134 -0.1327 -0.1231 -0.0265 -0.1396 -1.5432 -0.3963 -0.1201 -0.3812 -0.0704
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp ; inflammatory ; biomarkers ; hscrp ; il6 ; patients ; hscrp
H-1920	-0.3351859152317047	▁NT - pro b NP ▁; ▁infla mma tory ▁bio mark ers ▁; ▁h s cr p ▁; ▁IL ▁6 ▁; ▁h s cr p
D-1920	-0.3351859152317047	NT-probNP ; inflammatory biomarkers ; hscrp ; IL 6 ; hscrp
P-1920	-0.0629 -0.0474 -0.4973 -0.7082 -0.1891 -0.0806 -0.1605 -0.2023 -0.2545 -0.0282 -0.0543 -0.0695 -0.1738 -0.2486 -0.0087 -0.1863 -0.4454 -0.1115 -0.4925 -2.1630 -0.9191 -0.5013 -0.0101 -0.1853 -0.2626 -0.8694 -0.1178
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets ; in vitro ; neurohormonally ; heart disease ; nanomolar ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological ; gene induction
H-1044	-0.20953546464443207	▁ BET s ▁; ▁neuro hormon ally ▁induc ed ▁heart ▁disease ▁; ▁na nomo lar ▁dos es ▁; ▁j q 1 ▁; ▁ phen yle ph rine - media ted ▁hyper trop hy ▁; ▁cardio my o cy tes ▁; ▁path ological ▁gene ▁in duction
D-1044	-0.20953546464443207	BETs ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
P-1044	-1.4820 -0.1085 -0.1417 -0.3011 -0.2145 -0.0132 -0.1118 -0.0281 -0.0507 -0.8874 -0.3463 -0.1826 -0.0423 -0.0024 -0.0662 -0.1222 -0.0052 -0.1956 -0.3429 -1.0894 -0.7188 -0.3388 -0.8526 -0.0163 -0.0642 -0.0932 -0.0122 -0.0380 -0.0290 -0.0153 -0.0165 -0.0028 -0.4434 -0.1482 -0.0286 -0.2307 -0.1054 -0.0164 -0.0225 -0.3419 -0.0067 -0.1542 -0.0625 -0.0202 -0.0044 -0.2458 -0.0852
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat ; functional status ; quality of life ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; patients ; nyha functional class iii ; hf
H-1878	-0.3891083002090454	▁BAT ▁; ▁functional ▁status ▁; ▁exercise ▁capacity ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁burde n ▁; ▁heart ▁failure ▁hospital ization s ▁; ▁GD MT - tre ated ▁NY HA ▁functional ▁class ▁III ▁ HF
D-1878	-0.3891083002090454	BAT ; functional status ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; burden ; heart failure hospitalizations ; GDMT-treated NYHA functional class III HF
P-1878	-0.0392 -0.3937 -2.9362 -0.0542 -0.0788 -0.7427 -0.2131 -0.0884 -1.6660 -0.0140 -0.0277 -0.0028 -0.0218 -0.0337 -0.0546 -0.0394 -0.0145 -0.1700 -0.3120 -1.1079 -0.5843 -0.0525 -0.0943 -0.1181 -2.5654 -0.0164 -0.4736 -0.1892 -0.0578 -0.5316 -0.4520 -0.0934 -0.1379 -0.7563 -1.0567 -0.0958 -0.0005 -0.1262 -0.4821 -0.3773 -0.7132 -0.1162 -0.7798 -0.1513 -0.0431 -0.1334 -0.0792
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated ; p70s6k ; pkc-βii ; hdl ; nyha-iiib ; malondialdehyde ; bound ; hdl ; nyha-iiib ; hdl ; healthy
H-257	-0.5078426003456116	▁activa tion ▁; ▁p 70 s 6 k ▁; ▁PK c - β II ▁; ▁malo ndi alde hy de ▁; ▁ bound ▁to ▁HD L ▁; NY ha - III b ▁; ▁HD L ▁; health y
D-257	-0.5078426003456116	activation ; p70s6k ; PKc-βII ; malondialdehyde ; bound to HDL ;NYha-IIIb ; HDL ;healthy
P-257	-1.3110 -0.2085 -0.1209 -0.1177 -0.1868 -0.4294 -0.1788 -1.8696 -0.0752 -0.0075 -0.6096 -0.0279 -0.0140 -0.2195 -0.0406 -2.1040 -0.0387 -0.0159 -0.4082 -0.0881 -0.2457 -3.6534 -0.0527 -0.8399 -0.3146 -1.4615 -0.1286 -0.2721 -1.0480 -0.0866 -0.4432 -0.0142 -0.2727 -0.4128 -1.3132 -0.5575 -0.9288 -0.0140 -0.0963 -0.0860
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change ; exercise ; exercise
H-1986	-0.8073603510856628	▁ ML HF ▁total ▁score ▁; ▁exercise ▁; ▁die t
D-1986	-0.8073603510856628	MLHF total score ; exercise ; diet
P-1986	-0.5790 -0.0474 -0.4233 -4.7113 -0.0884 -0.1301 -0.5078 -0.1031 -0.6073 -0.0558 -2.3368 -0.0980
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx ; dnx
H-1374	-0.6447253823280334	▁non pa ce ▁; ▁non - DN x ▁; ▁s ham - I nner vat ed ▁; ▁s ham - in v ▁; ▁non pa ce ▁DN x ▁; ▁s ham - DN x ▁; ▁pace ▁non - DN x ▁; ▁cm f - in v ▁; ▁pace ▁; ▁DN x ▁; CH f - DN x
D-1374	-0.6447253823280334	nonpace ; non-DNx ; sham-Innervated ; sham-inv ; nonpace DNx ; sham-DNx ; pace non-DNx ; cmf-inv ; pace ; DNx ;CHf-DNx
P-1374	-0.4745 -0.0760 -0.2473 -0.4088 -0.0994 -0.1401 -0.8405 -0.7479 -0.2622 -2.1587 -0.1774 -0.0246 -2.4388 -0.0001 -0.0231 -0.0717 -0.2418 -1.9377 -0.2218 -0.0254 -0.3970 -0.4357 -0.4395 -0.1495 -0.0686 -0.0806 -1.2676 -0.1265 -0.1494 -1.9244 -0.1130 -0.0343 -3.0672 -0.2624 -0.1102 -0.1407 -0.6696 -0.0430 -0.9361 -0.3002 -0.1186 -3.0030 -2.3746 -0.0378 -0.3347 -0.2114 -0.1561 -1.1605 -1.2459 -0.7231 -0.1205 -0.2532 -3.8266 -1.2849 -0.0292 -0.9408 -0.4033 -0.3649 -0.1165
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc battery ; hf ; health abc hf model ; death
H-629	-0.7538977265357971	▁h ABC ▁Bat tery ▁score ▁; ▁ HF ▁risk ▁; ▁health ▁ABC ▁; ▁ HF ▁model ▁; ▁SD ▁decrease ▁; ▁score ▁; ▁control led ▁for ▁death ▁; ▁competi ng ▁risk
D-629	-0.7538977265357971	hABC Battery score ; HF risk ; health ABC ; HF model ; SD decrease ; score ; controlled for death ; competing risk
P-629	-2.2574 -0.3605 -1.0975 -0.0105 -0.0657 -0.0492 -0.5246 -0.0749 -1.4776 -0.0891 -1.2242 -0.0672 -1.6943 -0.4635 -0.1046 -0.5144 -0.0922 -1.1737 -3.3834 -0.8236 -1.7418 -0.3034 -2.2247 -0.3292 -0.8931 -0.1404 -0.6730 -1.3004 -0.0170 -0.2231 -0.6556 -0.0751
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection fraction ; patients ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
H-1010	-0.4446927309036255	▁e je ction ▁ fraction ▁; ▁fra il ▁; ▁bi ological ▁ph eno type ▁; ▁risk ▁of ▁death ▁; ▁fra il ty ▁; ▁deficit ▁index
D-1010	-0.4446927309036255	ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
P-1010	-2.8576 -0.0369 -0.0071 -0.4208 -0.0021 -0.1538 -0.0634 -0.0270 -0.1838 -0.9557 -0.1989 -0.4228 -0.0311 -0.0019 -0.1596 -1.0944 -1.6542 -0.4297 -0.7755 -0.1042 -0.0501 -0.2334 -0.3069 -0.0826 -0.0127 -1.6598 -0.0806
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin ; hgb ; hrqol ; hrqol ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-836	-0.3582910895347595	▁hem o glob in ▁; ▁h gb ▁; ▁HR Qo L ▁; ▁HR Qo L ▁; ▁patients ▁in ▁Heart ▁Fail ure ▁; ▁tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - AC TION
D-836	-0.3582910895347595	hemoglobin ; hgb ; HRQoL ; HRQoL ; patients in Heart Failure ; trial Investigating Outcomes of Exercise Training ;HF-ACTION
P-836	-0.4123 -0.1054 -0.0691 -0.4659 -0.1867 -1.2654 -0.0382 -0.0755 -0.3108 -0.0137 -0.9953 -0.0579 -0.9558 -0.0098 -0.8145 -0.0814 -1.1629 -0.4935 -0.3143 -0.0587 -0.2075 -0.2651 -3.2360 -0.0320 -0.0946 -0.0185 -0.0989 -0.0211 -0.0336 -0.5167 -0.0973 -0.0165 -0.1988 -0.2669 -0.0955 -0.0137 -0.8216 -0.2023 -0.1215 -0.0866
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial fibrillation ; congestive heart failure ; health care ; expenditures ; patients ; québec ; randomized ; rhythm ; rate-control
H-1234	-0.48733580112457275	▁At rial ▁Fi bril lation ▁; ▁con ges tive ▁Heart ▁Fail ure ▁trial ▁; ▁health ▁care ▁ex pendi tures ▁; ▁patients ▁; ▁Québec ▁; ▁ rhythm ▁; ▁rate - control ▁treatment ▁strategie s
D-1234	-0.48733580112457275	Atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; patients ; Québec ; rhythm ; rate-control treatment strategies
P-1234	-0.8793 -0.0054 -0.4518 -0.0297 -0.0331 -0.4404 -0.0940 -0.0924 -0.9347 -0.3646 -0.1929 -0.9685 -0.9952 -0.1475 -1.0685 -2.0386 -0.0764 -0.0177 -0.1152 -0.2555 -1.4809 -0.8397 -0.0353 -0.3334 -0.2259 -0.2160 -0.4006 -0.0455 -0.1748 -0.0104 -0.6963 -1.8261 -0.0679 -1.3566 -0.1457
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart failure ; patient ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
H-1668	-0.39315521717071533	▁heart ▁failure ▁; ▁my o card ial ▁is cha emia ▁; ▁ta chy - ▁; ▁bra dy ar rhythm ias ▁; ▁val vu lar ▁re gur gi tation ▁; ▁pulmonar y ▁e mbol ism ▁; ▁infection ▁; ▁renal ▁dys function
D-1668	-0.39315521717071533	heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
P-1668	-6.2883 -0.1048 -0.2142 -1.0984 -0.0844 -0.4330 -0.1625 -0.2933 -0.0196 -0.1286 -0.1747 -0.2093 -0.0523 -0.0258 -2.2877 -0.0079 -0.8597 -0.0323 -0.0272 -0.2732 -0.1370 -0.0784 -0.0505 -0.0740 -0.0097 -0.0912 -0.0504 -0.0399 -0.1932 -0.0009 -0.0584 -0.0681 -0.0041 -0.6278 -0.2020 -1.3292 -0.3262 -0.0004 -0.0413 -0.0413 -0.2060 -0.1054
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report ; calcineurin ; nfat ; mir-25 ; expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dhand ; hand2 ; diseased ; myocardium
H-640	-0.3260573148727417	▁calci ne uri n ▁; ▁n fat ▁signal ling ▁; ▁mi R -25 ▁expression ▁integrat e ▁; ▁heli x - loop - heli x ▁; ▁b HL h ▁; ▁tran scription ▁factor ▁d HAND ▁; ▁hand ▁; ▁disease d ▁human ▁; ▁mouse ▁my o car dium
D-640	-0.3260573148727417	calcineurin ; nfat signalling ; miR-25 expression integrate ; helix-loop-helix ; bHLh ; transcription factor dHAND ; hand ; diseased human ; mouse myocardium
P-640	-0.0113 -0.2760 -0.0153 -0.1062 -0.7387 -2.5302 -0.0989 -0.2001 -0.1197 -0.0802 -0.4511 -0.9299 -0.0189 -0.1072 -0.5873 -0.0249 -0.1399 -0.0206 -0.1738 -0.0251 -0.0034 -0.0967 -0.0081 -0.2333 -0.2662 -0.9386 -0.1178 -0.1540 -0.1592 -0.0053 -0.0048 -0.0102 -0.1928 -0.7707 -0.1157 -0.6803 -1.3298 -1.7387 -0.0028 -0.0844 -0.1996 -0.0374 -1.3134 -0.0429 -0.0103 -0.0922 -0.2857 -0.1014
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise ; correlated ; psss ; btes ; exercise ; psss ; btes
H-1929	-0.8958069086074829	▁Exerci se ▁time ▁; ▁PS SS ▁; ▁b tes ▁; ▁exercise ▁time ▁; ▁PS SS ▁; ▁b tes
D-1929	-0.8958069086074829	Exercise time ; PSSS ; btes ; exercise time ; PSSS ; btes
P-1929	-3.3788 -0.0540 -1.2655 -0.1430 -0.7244 -0.3089 -0.0724 -1.5627 -0.2512 -0.5685 -2.4487 -1.2089 -0.2720 -2.1170 -0.4514 -0.1797 -2.3184 -0.2864 -0.2229 -0.0813
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp ; admission ; sensitivity ; specificity ; confidence interval ; area under the curve
H-269	-0.4440729022026062	▁NT - pro b NP ▁cut off ▁point ▁; ▁ sensitiv ity ▁; ▁confidence ▁interval
D-269	-0.4440729022026062	NT-probNP cutoff point ; sensitivity ; confidence interval
P-269	-0.4388 -0.0180 -0.0228 -0.4505 -0.4593 -0.2495 -0.0621 -0.8028 -0.2266 -2.6389 -0.0325 -0.4755 -0.2191 -0.6298 -0.0458 -0.7079 -0.0694
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic ; r-r interval ; hr variability ; short-term fractal scaling exponent ; prognostic
H-1588	-0.27773910760879517	▁prognos tic ▁power ▁; ▁r - r ▁interval ▁os cilla tions ▁; ▁non - line ar ▁HR ▁variabil ity ▁; ▁fra c tal ▁scal ing ▁ex ponent
D-1588	-0.27773910760879517	prognostic power ; r-r interval oscillations ; non-linear HR variability ; fractal scaling exponent
P-1588	-0.5828 -0.5797 -0.0692 -0.1562 -0.2170 -0.0779 -0.9759 -0.0037 -0.8924 -0.0329 -0.0959 -0.1667 -0.6502 -0.0148 -0.0033 -0.0039 -0.2495 -0.0326 -0.2117 -0.4449 -1.0795 -0.0534 -0.0321 -0.3917 -0.0314 -0.4602 -0.0512 -0.4106 -0.0830
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic function ; diastolic filling formalism ; relaxation ; doppler mitral inflow velocity ; e-wave
H-921	-0.22689038515090942	▁dia sto lic ▁function ▁; ▁dia sto lic ▁fill ing ▁formal ism ▁; ▁relax ation ▁; vis co ela stic ▁; ▁passiv e ▁; sti ff ness ▁; ▁do pp ler ▁mit ral ▁in flow ▁veloci ty ▁; ▁e - wa ve
D-921	-0.22689038515090942	diastolic function ; diastolic filling formalism ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
P-921	-0.0741 -0.0229 -0.0099 -0.0983 -0.1439 -0.1505 -0.0401 -0.0299 -0.7872 -0.0284 -0.7989 -0.2025 -0.0760 -0.0821 -0.0391 -0.7869 -0.0329 -0.0084 -0.0026 -0.0087 -0.1783 -0.0569 -0.0206 -1.4191 -1.1266 -0.0632 -0.5932 -0.1858 -0.6944 -0.0104 -0.9647 -0.1107 -0.0364 -0.0374 -0.0388 -0.1190 -0.0451 -0.2202 -0.2127 -0.0152 -0.0689 -0.0502 -0.2009 -0.0913
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart failure ; hf ; patients ; spontaneous ventricular tachycardia ; hf ; patients ; spontaneous vt ; hearts
H-1437	-0.4868601858615875	▁heart ▁failure ▁; HF ▁; ▁spontane ous ▁vent ri cular ▁ta chy car dia ▁; HF VT ▁; ▁ HF ▁patients ▁; ▁spontane ous ▁ VT ▁; HF VT ▁; ▁structura lly ▁normal ▁heart s ▁; ▁h Nor m
D-1437	-0.4868601858615875	heart failure ;HF ; spontaneous ventricular tachycardia ;HFVT ; HF patients ; spontaneous VT ;HFVT ; structurally normal hearts ; hNorm
P-1437	-0.9955 -0.1169 -0.1838 -0.0837 -0.2647 -2.7713 -0.2168 -0.0394 -1.0283 -0.2598 -0.4205 -0.2583 -0.0692 -0.0150 -0.0652 -0.3457 -0.6147 -0.1471 -0.6440 -0.1378 -0.8395 -0.4268 -0.1149 -0.1232 -0.2420 -0.0439 -0.0724 -0.2449 -0.4940 -0.3021 -4.5679 -0.0103 -0.1259 -0.1259 -0.0458 -0.1914 -2.1663 -0.7856 -0.0244 -0.2575 -0.0789
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; estimated glomerular filtration rate ; lvef
H-819	-0.18639664351940155	▁g LS ▁; ▁co x ▁model ▁; ▁chronic ▁heart ▁failure ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁prior ▁stroke ▁score ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁LV EF ▁; ▁sa
D-819	-0.18639664351940155	gLS ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa
P-819	-0.2116 -0.7019 -0.1315 -0.0907 -0.0300 -0.0354 -0.2435 -0.0737 -0.1910 -0.0395 -0.1481 -0.0369 -0.0151 -0.0900 -0.0759 -0.0607 -0.0049 -0.0392 -0.0186 -0.0535 -0.0283 -0.0609 -0.0305 -0.0986 -0.0968 -0.1802 -0.0881 -0.0142 -0.0800 -0.0808 -0.5686 -2.4750 -0.0576
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient ; vad ; patients ; ventricular assist device ; ecmo ; patients ; extracorporeal membrane oxygenation ; ecmo ; vad ; patients ; ecmo ; vad
H-1387	-0.6788300275802612	▁vent ri cular ▁assist ▁device ▁support ▁; ▁ec mo ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁membran e ▁support ▁; ▁ec mo ▁; ▁ VAD
D-1387	-0.6788300275802612	ventricular assist device support ; ecmo ; extracorporeal membrane oxygenation membrane support ; ecmo ; VAD
P-1387	-0.6429 -0.6788 -0.0773 -0.7108 -0.1970 -1.6192 -0.0617 -0.8268 -1.6138 -0.8269 -0.1721 -0.0479 -0.2505 -0.0963 -0.0338 -0.0422 -0.3108 -0.2406 -0.0422 -0.0875 -2.5944 -0.2842 -1.2738 -1.9484 -0.7179 -2.7562 -0.1975 -1.1613 -0.1734
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic events ; ies ; patients ; ischemic cardiomyopathy ; ic ; cardiac resynchronization therapy ; defibrillator ; crt-d
H-102	-0.3489115834236145	▁ ische mic ▁events ▁; IE s ▁; ▁ ische mic ▁cardio my o pathy ▁; IC ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁c RT - d
D-102	-0.3489115834236145	ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; cRT-d
P-102	-1.3687 -0.0539 -0.4107 -0.5842 -0.2132 -1.0107 -0.0382 -0.2274 -1.0039 -0.0481 -0.1699 -0.1518 -1.2988 -0.6637 -0.0309 -0.1994 -0.8181 -0.2225 -0.0214 -0.0257 -0.0153 -0.0135 -0.3511 -0.8122 -0.0086 -0.3661 -0.0249 -0.0114 -0.0279 -0.0527 -0.0453 -0.1584 -0.3448 -0.9382 -0.0376 -0.7707 -0.6031 -0.1156
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart failure ; disease ; evidence-based ; health care
H-2016	-0.8265658020973206	▁cost - effect ive ness ▁; ▁heart ▁failure ▁disease ▁management ▁programs ▁; ▁evidence - based ▁treatment s
D-2016	-0.8265658020973206	cost-effectiveness ; heart failure disease management programs ; evidence-based treatments
P-2016	-1.6875 -0.1166 -0.0279 -0.2576 -2.3182 -0.4474 -0.5509 -0.1227 -0.6150 -0.2612 -1.7380 -0.5760 -5.3445 -0.0124 -0.0029 -0.4030 -0.0955 -1.0335 -0.0940
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin ; heart failure ; murine ; resistin ; transgenic ; retn ; gene ; resistin
H-930	-0.48043590784072876	▁human ▁resist in ▁in ▁heart ▁failure ▁; ▁human ized ▁mouse ▁; ▁mur ine ▁resist in ▁; ▁trans ge nic ▁; ▁Ret n ▁gene ▁; ▁h um - re t n ▁mi ce ▁; ▁bas al ▁; ▁ inflammation - stimul ated ▁resist in ▁; ▁humans
D-930	-0.48043590784072876	human resistin in heart failure ; humanized mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin ; humans
P-930	-2.9753 -1.5826 -0.1923 -0.5058 -0.1852 -0.0249 -0.2002 -2.6618 -0.1378 -0.5526 -1.3223 -0.0190 -0.9775 -0.1398 -0.2270 -0.0804 -0.0423 -0.0190 -0.0516 -0.1496 -1.2992 -0.0070 -0.2827 -0.0807 -0.7886 -0.0074 -0.0073 -1.8433 -0.0331 -0.0035 -0.5314 -0.2407 -0.4671 -0.7785 -0.0021 -0.6459 -0.0627 -0.0142 -0.0363 -0.0049 -0.1706 -0.1931 -0.1211 -2.2392 -0.4680 -0.1157 -0.0895
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients ; angiotensin-converting enzyme inhibitors ; angiotensin receptors blockers ; β-blockers
H-1745	-0.44012027978897095	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor s ▁block ers ▁; ▁β - block ers ▁; ▁devices
D-1745	-0.44012027978897095	angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers ; devices
P-1745	-3.7341 -0.5687 -0.1141 -1.9725 -0.2255 -0.0238 -0.0394 -0.2016 -0.1369 -0.0503 -0.0434 -0.4768 -0.8264 -0.0186 -0.0535 -0.7428 -0.0117 -0.1141 -1.1449 -0.0611 -0.2508 -0.0247 -0.0228 -0.1258 -0.0524 -0.9822 -0.2650 -0.3446 -0.1350
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ; tac
H-1815	-0.31877538561820984	▁t g t et Men a ▁mi ce ▁; ▁cardiac ▁injury ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁heart ▁di la tation ▁; ▁hyper trop hy ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC
D-1815	-0.31877538561820984	tgtetMena mice ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
P-1815	-4.5083 -0.2902 -0.0545 -0.1756 -0.7886 -0.0555 -1.4263 -0.6774 -0.1852 -0.0697 -0.0562 -0.1985 -0.2664 -0.0201 -0.0167 -0.2537 -0.0020 -0.1415 -0.1945 -0.0003 -0.0159 -0.2309 -0.0289 -0.1116 -0.1172 -0.4121 -0.2351 -0.1352 -0.0053 -0.1985 -0.0467 -0.0062 -0.4487 -0.1468 -0.0003 -0.1184 -0.0188 -0.1165 -0.7725 -0.0127 -0.2127 -0.0605 -1.6175 -0.0356 -0.0994 -0.0785
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation for ambulatory heart failure trial ; implantable ; primary end point ; all-cause mortality ; heart failure ; hospitalization
H-882	-0.446041464805603	▁re syn chron ization - Def i bril lation ▁; ▁Amb ulator y ▁Heart ▁Fail ure ▁tri al ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - c RT ▁; ▁cardiovascular ver ter ▁de fi br illa tor - c RT
D-882	-0.446041464805603	resynchronization-Defibrillation ; Ambulatory Heart Failure trial ; implantable cardioverter defibrillator-cRT ; cardiovascularverter defibrillator-cRT
P-882	-0.1255 -0.0139 -0.0251 -0.3083 -0.0544 -0.1935 -0.1231 -0.2267 -0.0199 -1.3328 -0.7820 -0.0097 -0.0227 -0.2234 -0.1356 -0.7980 -0.4475 -0.0429 -0.1593 -0.0439 -0.0310 -0.0921 -0.0119 -0.0531 -0.0386 -0.0472 -0.1267 -0.0346 -0.0186 -0.1026 -1.0794 -1.7554 -0.5029 -2.1076 -3.7512 -0.0537 -0.0556 -0.0310 -0.1276 -0.0572 -0.0171 -0.0709 -1.1008 -2.3332 -1.7397 -0.0901
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart failure ; patients ; italy ; confirmatory factor analysis ; cfa ; schfi v.6.2 ; self-care maintenance ; self-care management ; self-care confidence
H-1505	-0.3861519992351532	▁heart ▁failure ▁patients ▁; ▁Italy ▁; ▁confirma tory ▁factor ▁analysis ▁; ▁c fa ▁; ▁ SCH FI ▁; Sel f - Car e ▁Main ten ance ▁; ▁Self - Car e ▁management ▁; ▁Self - Car e ▁Confi den ce
D-1505	-0.3861519992351532	heart failure patients ; Italy ; confirmatory factor analysis ; cfa ; SCHFI ;Self-Care Maintenance ; Self-Care management ; Self-Care Confidence
P-1505	-2.0666 -0.1009 -0.4933 -0.1811 -0.2526 -0.1824 -0.0111 -0.0097 -0.0166 -0.0908 -0.1070 -0.3121 -0.9150 -0.1080 -0.8036 -0.7043 -1.7320 -0.1838 -0.7373 -0.4369 -0.0477 -1.7393 -0.0315 -0.1304 -0.0505 -0.0958 -0.0772 -0.1231 -0.0252 -1.2623 -0.0245 -0.8208 -0.1283 -0.1200 -0.0208 -1.1957 -0.0330 -0.3094 -0.0454 -0.2299 -0.1664 -0.0962
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional status ; 6-mwt ; nyha class ; patients ; hfpef ; hfref ; prescribed ; therapy ; patients ; hfpef ; death ; hf ; hospitalization
H-244	-0.5091891288757324	▁functional ▁status ▁; ▁w t ▁; ▁NY ha ▁class ▁; ▁patients ▁; ▁ HF p EF ▁; ▁h Fr EF ▁; ▁ therapy ▁; ▁ HF p EF ▁; ▁ HF ▁hospital ization
D-244	-0.5091891288757324	functional status ; wt ; NYha class ; patients ; HFpEF ; hFrEF ; therapy ; HFpEF ; HF hospitalization
P-244	-0.1167 -0.0243 -0.0697 -1.4057 -0.0169 -0.0779 -0.1026 -0.3972 -0.4254 -0.0939 -0.6084 -0.7175 -0.1484 -0.1530 -0.0385 -0.1115 -0.0487 -1.5662 -0.2064 -0.2314 -0.1240 -1.6954 -1.3115 -0.1403 -0.9040 -0.2085 -0.0860 -0.0707 -0.1424 -2.1924 -0.2581 -3.4533 -0.4292 -0.1603 -0.0853
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; follow-up ; mortality ; ischemic cardiomyopathy
H-69	-0.19500280916690826	▁renal ▁dys function ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i CD ▁shock s ▁; ▁mortal ity ▁; ▁ ische mic ▁cardio my o pathy
D-69	-0.19500280916690826	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
P-69	-0.0087 -0.0101 -0.0208 -0.0489 -0.0097 -0.1692 -0.0436 -0.1680 -0.0029 -0.0958 -0.3758 -0.0588 -0.0506 -0.0831 -0.0081 -0.0346 -0.0128 -0.0510 -0.0807 -0.0918 -0.1427 -0.0906 -0.1672 -0.0435 -0.5427 -0.2607 -0.0658 -0.0838 -0.0565 -0.5369 -0.0082 -0.2393 -0.4915 -0.3083 -0.0131 -0.0369 -0.3345 -1.0501 -0.5649 -0.0586 -0.5452 -0.0143 -0.1236 -0.0340 -0.4911 -0.1688 -0.0475 -1.5058 -0.1040
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold proteins ; cardiac remodelling ; field ; therapeutic
H-996	-0.43588483333587646	▁Raf - MEK 1/2 - er k 1/2 ▁sc af fold ▁protein s ▁; ▁cardiac ▁remodel ling
D-996	-0.43588483333587646	Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
P-996	-0.0157 -0.0479 -0.0069 -0.1256 -0.0317 -0.9103 -0.1542 -0.1675 -1.3984 -0.3682 -0.0383 -0.4699 -0.0562 -0.3298 -2.4609 -0.0177 -0.0604 -1.5663 -0.0561
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients ; chf ; testosterone ; exercise ; testosterone ; placebo
H-1318	-0.6629467010498047	▁CHF ▁; ▁SD ▁testosteron e ▁levels ▁; ▁n mol / L
D-1318	-0.6629467010498047	CHF ; SD testosterone levels ; nmol/L
P-1318	-0.0938 -0.1880 -0.6223 -0.1558 -0.0353 -1.1063 -0.3324 -0.1476 -0.0060 -1.4404 -0.5119 -3.9146 -0.0637
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional ms ; lv dilatation ; heart failure ; hf ; functional ms ; hf ; prolapse ; degenerative mitral valve
H-341	-0.2838703989982605	▁functional ▁MS ▁; ▁LV ▁di la tation ▁; ▁treatment ▁for ▁heart ▁failure ▁; HF ▁; ▁LV ▁; ▁functional ▁MS ▁; ▁ HF ▁; ▁MR ▁; ▁de genera tive ▁mit ral ▁val ve
D-341	-0.2838703989982605	functional MS ; LV dilatation ; treatment for heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
P-341	-0.0348 -0.0559 -0.0658 -0.8894 -0.2044 -0.0554 -0.0019 -0.0872 -1.5584 -1.2195 -0.2142 -0.0142 -0.1548 -0.4835 -0.0579 -0.2393 -0.5241 -0.0563 -0.1554 -0.2071 -0.9204 -0.1830 -0.0977 -0.6664 -0.1772 -0.7750 -0.0015 -0.0937 -0.0350 -0.0228 -0.0291 -0.0382 -0.2730 -0.0590
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new york heart association class ; kccq ; symptom ; spearman correlations ; 2-way anova ; patients ; hf with reduced ef ; hfpef
H-783	-0.37411436438560486	▁New ▁York ▁Heart ▁association ▁class ▁; ▁k cc q ▁over all ▁Summa ry ▁; ▁Total ▁Symptom ▁domain s ▁; ▁Spe ar man ▁corre lation s ▁; ▁2- way ▁a NOVA ▁; ▁patients ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-783	-0.37411436438560486	New York Heart association class ; kccq overall Summary ; Total Symptom domains ; Spearman correlations ; 2-way aNOVA ; patients ; HF ; EF ; HFpEF
P-783	-1.6671 -0.3513 -1.1514 -0.5556 -0.9901 -0.0662 -0.4196 -0.0423 -0.9319 -0.8136 -0.0321 -0.0462 -0.0861 -0.1612 -0.8727 -0.4402 -0.2507 -0.0502 -0.3256 -0.0248 -0.0019 -0.0136 -0.0129 -0.0048 -0.0280 -0.1337 -1.9319 -0.0753 -0.3142 -0.0011 -0.1760 -0.2984 -1.2171 -0.4188 -0.1562 -0.3431 -1.4062 -0.0833 -0.1241 -0.1411 -0.0442 -0.0722 -0.1212 -0.0624
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; patients ; heart failure ; medications ; medical
H-1130	-0.5459827184677124	▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure
D-1130	-0.5459827184677124	angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
P-1130	-4.7632 -1.3215 -0.0883 -0.5990 -0.0336 -0.0474 -0.0845 -0.0562 -0.1483 -0.2198 -0.0722 -0.7682 -0.8601 -0.1606 -0.9452 -0.4582 -0.0292 -0.1323 -1.7961 -0.1135 -0.2374 -0.0524 -0.0418 -0.1531 -0.0868 -0.6845 -1.2324 -0.1505 -0.8560 -0.1871
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang ii infusion ; ang ii infusion ; uninephrectomy ; ang ii infusion ; salt loading ; ang ii infusion ; uninephrectomy ; salt loading
H-276	-0.6165280342102051	▁c 57 b ▁; ▁in fusion ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion ▁; ▁salt ▁load ing ▁; ▁as ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁salt ▁load ing ▁; ANS
D-276	-0.6165280342102051	c57b ; infusion ; ANG II infusion ; uninephrectomy ; ANG II infusion ; salt loading ; as ; ANG II infusion ; uninephrectomy ; salt loading ;ANS
P-276	-1.4346 -0.7789 -1.2148 -0.2109 -3.2072 -0.0358 -0.1642 -2.2398 -0.9235 -0.0108 -0.0117 -0.0981 -0.1558 -1.1290 -1.8623 -0.1114 -0.0584 -0.9425 -0.1324 -2.3104 -1.2615 -0.0136 -0.0177 -0.1013 -0.0602 -0.0150 -0.0233 -0.2105 -1.7051 -0.5514 -1.2617 -1.0838 -0.0162 -0.0134 -0.1332 -0.0228 -1.0183 -1.7554 -0.1554 -0.1988 -0.9848 -0.2271 -0.1051 -0.0471 -0.0267 -0.7301 -0.9287 -0.4093 -0.0997
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral blood flow velocity ; tissue doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcwp ; patients ; decompensated systolic heart failure ; hf
H-480	-0.3045753240585327	▁early ▁transmit ral ▁blood ▁flow ▁veloci ty ▁; ▁tissu e ▁; ▁do pp ler ▁; ▁early ▁dia sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁; ▁pc WP ▁; ▁de com pensa ted ▁sy sto lic ▁heart ▁failure ▁; HF
D-480	-0.3045753240585327	early transmitral blood flow velocity ; tissue ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcWP ; decompensated systolic heart failure ;HF
P-480	-1.8792 -0.4409 -0.2737 -0.7247 -0.0579 -1.3518 -0.0221 -0.8191 -0.4465 -0.0975 -0.4017 -0.6007 -0.0041 -0.4152 -1.0568 -1.4965 -0.0439 -0.0867 -0.0151 -0.1982 -0.0270 -1.8467 -0.0953 -0.2766 -0.0104 -0.0556 -0.0318 -0.0106 -0.0274 -0.0208 -0.0919 -0.0196 -0.0588 -0.1465 -0.1175 -0.1675 -0.8229 -0.0756 -0.0943 -0.0062 -0.0085 -0.0784 -0.0052 -0.0478 -0.0536 -0.2401 -0.0687 -0.3269 -0.0387 -0.1689 -0.0612
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic ; lv ejection fraction ; lv strain ; strain ; systole ; diastolic ; lv strain rate ; diastole ; transmitral flow ; patients ; sinus rhythm ; follow-up
H-951	-0.3102555274963379	▁sy sto lic ▁indice s ▁; LV ▁e je ction ▁ fraction ▁; ▁LV ▁strain ▁; stra in ▁rate ▁; ▁sy stol e ▁; ▁dia sto lic ▁indice s ▁; ▁LV ▁strain ▁rate ▁; ▁dia stol e ▁; ▁early ▁transmit ral ▁flow ▁; ▁sinus ▁ rhythm
D-951	-0.3102555274963379	systolic indices ;LV ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow ; sinus rhythm
P-951	-1.6580 -0.0894 -0.0077 -0.0779 -0.0135 -0.0672 -0.0751 -0.1274 -0.0581 -0.0136 -0.1511 -0.0030 -0.0786 -0.0810 -0.4089 -1.2618 -0.4203 -0.0400 -0.0724 -0.3229 -0.1416 -0.1033 -0.2833 -0.1439 -0.0239 -0.1238 -0.0087 -0.0789 -0.0103 -0.0557 -3.6889 -1.0283 -0.1037 -0.1698 -0.1448 -0.0277 -0.2668 -0.6881 -0.5374 -0.1810 -0.1343 -0.1665 -1.0168 -0.1378 -0.1017 -0.1318 -0.2826 -0.0831
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak vo2 ; exercise
H-1984	-1.1989672183990479	▁pe ak ▁VO 2 ▁; ▁exercise ▁; ▁body ▁mass
D-1984	-1.1989672183990479	peak VO2 ; exercise ; body mass
P-1984	-5.5981 -0.0148 -0.4399 -0.0603 -0.2918 -2.2085 -0.2618 -1.8446 -0.1479 -2.1730 -0.1478
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard ratios ; confidence interval ; hf ; hf
H-1107	-0.5871078968048096	▁age - ▁and ▁sex - ad just ed ▁risk ▁; ▁hazard ▁ratio s ▁; ▁confidence ▁interval ▁; CI ▁; ▁early - ons et ▁ HF
D-1107	-0.5871078968048096	age- and sex-adjusted risk ; hazard ratios ; confidence interval ;CI ; early-onset HF
P-1107	-1.8416 -0.0479 -2.9580 -1.0319 -0.0407 -0.0133 -0.0049 -0.0427 -0.4172 -0.2547 -0.8034 -0.0405 -0.1753 -0.1750 -2.1430 -0.0044 -0.2106 -1.6143 -0.1396 -0.6635 -0.0663 -0.1860 -0.0409 -0.4121 -0.1475 -2.2768 -0.0998
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami ; patient ; hospital ; hospital compare ; p-value
H-1698	-0.4879069924354553	▁ AMI ▁patient ▁; ▁hospital ▁; ▁best ▁quin tile ▁; ▁performance ▁; ▁hospital ▁Compar e
D-1698	-0.4879069924354553	AMI patient ; hospital ; best quintile ; performance ; hospital Compare
P-1698	-0.6692 -0.0401 -0.9544 -0.2143 -0.3524 -0.5227 -0.7100 -0.0806 -0.0042 -0.8111 -0.7134 -0.1454 -1.0063 -0.2628 -0.0125 -1.6839 -0.1111
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass spectrometry ; c-terminally ; nt-probnp ; physiological ; proteolysis
H-1517	-0.4972843825817108	▁Mass ▁spec tro met ry ▁; ▁circula ting ▁NT - pro b NP ▁; ▁physio logic al ▁prote ol ysis ▁; ▁le u 3- G ly 4 ▁; ▁pro 6 - G ly 7
D-1517	-0.4972843825817108	Mass spectrometry ; circulating NT-probNP ; physiological proteolysis ; leu3-Gly4 ; pro6-Gly7
P-1517	-0.2300 -0.7253 -0.1462 -0.0304 -2.5421 -0.1611 -0.2644 -0.0435 -0.7719 -0.0197 -0.0441 -1.0626 -0.1598 -0.2320 -0.0134 -0.1872 -0.0073 -0.0618 -0.1716 -0.1389 -0.3914 -0.2211 -0.0022 -0.1870 -1.9098 -0.0786 -0.9772 -0.3790 -0.2130 -2.1497 -0.0169 -2.4832 -0.0927 -0.4529 -1.2517 -0.0824
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt ; nt-probnp ; report ; ctnt ; nt-probnp ; clinical ; hf
H-292	-0.2980203330516815	▁c t n t ▁; ▁NT - pro b NP ▁; ▁laborator y ▁report ▁; ▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF ▁predict ion ▁model
D-292	-0.2980203330516815	ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF prediction model
P-292	-0.4580 -0.1358 -0.0431 -0.3324 -0.0605 -0.5578 -0.0344 -0.0193 -0.7117 -0.1639 -0.1510 -0.5986 -0.0515 -0.0312 -0.2692 -0.0254 -0.2206 -0.0218 -0.3793 -0.0666 -1.3741 -0.0388 -0.0538 -0.5503 -0.2004 -0.2932 -0.5577 -0.5737 -0.8007 -0.0203 -0.7307 -0.1892 -0.1197
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef ; patients ; new york heart association class ii ; ejection fraction ; fes ; placebo
H-1329	-0.786931574344635	▁ HF p EF ▁patients ▁; ▁New ▁York ▁Heart ▁Association ▁class ▁II ▁; ▁e je ction ▁ fraction
D-1329	-0.786931574344635	HFpEF patients ; New York Heart Association class II ; ejection fraction
P-1329	-0.2255 -0.6698 -0.0887 -0.2646 -0.5748 -0.1072 -3.8590 -0.3619 -0.9403 -0.7055 -1.1944 -0.2455 -0.1780 -3.9583 -0.0988 -0.0228 -0.4582 -0.0034 -1.6954 -0.0864
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left ventricular ; systolic pressure ; ejection fraction ; fractional shortening ; cardiac output ; lv end-diastolic pressure ; mi ; metoprolol
H-1548	-0.2510690987110138	▁de press ed ▁left ▁vent ri cular ▁; LV ▁; ▁sy sto lic ▁pressure ▁; ▁pressure ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁cardiac ▁output ▁; ▁LV ▁end - dia sto lic ▁pressure ▁; ▁MI ▁animals ▁; ▁met o pro lol
D-1548	-0.2510690987110138	depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV end-diastolic pressure ; MI animals ; metoprolol
P-1548	-0.0337 -0.0076 -0.0389 -0.1028 -0.0479 -0.4572 -0.0945 -0.2287 -0.2645 -0.2482 -0.0162 -0.1050 -0.0783 -0.4313 -0.0903 -0.5603 -0.7838 -0.0322 -0.0419 -0.0175 -0.2244 -0.0032 -0.1017 -0.6314 -0.0007 -0.0213 -0.0618 -0.0318 -0.0690 -0.0841 -0.0848 -0.0030 -0.1722 -0.1168 -3.0938 -0.0179 -0.0091 -0.0533 -0.0195 -0.2628 -0.1519 -2.2466 -0.5892 -0.4087 -0.0164 -0.0588 -0.0178 -0.1554 -0.0992 -0.0661
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction ; clinical ; carotid ; baroreflex activation therapy ; bat ; heart failure ; hf
H-1867	-0.4389145076274872	▁bar ore flex ▁Activ ation ▁Therapy ▁; ▁Heart ▁Fail ure ▁With ▁a ▁Red u ced ▁e je ction ▁Fra ction ▁; ▁caro tid ▁baro re flex ▁activa tion ▁ therapy ▁; BAT ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1867	-0.4389145076274872	baroreflex Activation Therapy ; Heart Failure With a Reduced ejection Fraction ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
P-1867	-3.4012 -0.3737 -0.1293 -0.7595 -0.0514 -0.0767 -0.2133 -1.2851 -0.1831 -0.4599 -1.6822 -0.1180 -0.3136 -0.0157 -0.6473 -0.3789 -0.0218 -0.0075 -0.4540 -0.0039 -0.3518 -2.4658 -0.0376 -0.8390 -0.6444 -0.0726 -0.0118 -0.2663 -0.7712 -0.0154 -0.0853 -0.1740 -0.0910 -0.3370 -0.1498 -0.0592 -0.4205 -0.0170 -0.1043 -0.0666
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome ; hazard ratio
H-1748	-1.0403121709823608	▁en roll ment ▁; ▁ha ard ▁ratio ▁; HR
D-1748	-1.0403121709823608	enrollment ; haard ratio ;HR
P-1748	-1.8489 -0.0320 -0.4754 -1.8689 -5.3000 -0.0745 -0.0085 -0.1210 -0.1478 -1.3992 -0.1673
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf ; blood glucose ; obesity ; systemic hypertension ; rheumatic fever ; disease
H-1793	-0.32988113164901733	▁ HF ▁; ▁raised ▁blood ▁gluco se ▁levels ▁; ▁obes ity ▁; ▁to ba cco ▁; ▁system ic ▁hyper tension ▁; SH ▁; ▁rhe u matic ▁fe ver ▁; ▁Cha gas ' ▁disease ▁; ▁c ' d
D-1793	-0.32988113164901733	HF ; raised blood glucose levels ; obesity ; tobacco ; systemic hypertension ;SH ; rheumatic fever ; Chagas' disease ; c'd
P-1793	-1.3621 -0.0251 -0.1766 -0.3050 -0.2385 -0.0067 -0.0264 -0.3080 -0.0652 -0.1725 -0.8932 -0.0851 -0.0032 -0.3116 -0.0204 -0.1152 -0.6898 -0.1610 -0.0449 -0.0052 -0.0796 -0.1159 -0.0269 -0.0052 -0.0192 -0.0907 -0.0315 -0.0151 -0.0744 -1.1739 -0.0035 -2.4406 -0.0894 -0.1403 -1.1452 -1.5980 -0.1796 -0.4998 -0.1207
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard ratios ; crf ; obese ; body mass index
H-1772	-0.6176943182945251	▁c RF ▁; ▁over weight ▁; ▁obes e ▁body ▁mass ▁index
D-1772	-0.6176943182945251	cRF ; overweight ; obese body mass index
P-1772	-2.3259 -1.5472 -0.5159 -1.1717 -0.1493 -0.1794 -0.0428 -0.0494 -0.8808 -0.1904 -0.0200 -0.8274 -0.1299
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq ; patients ; hfpef ; log rank ; ef
H-789	-0.7993512153625488	▁k cc q ▁; ▁patients ▁; ▁ HF p EF ▁; log ▁rank ▁; ▁EF
D-789	-0.7993512153625488	kccq ; patients ; HFpEF ;log rank ; EF
P-789	-2.8042 -0.0561 -1.5141 -0.5733 -2.0831 -1.2936 -0.3191 -0.0838 -0.0231 -0.3629 -0.3139 -2.0037 -0.6509 -0.4930 -0.7008 -0.1814 -0.1320
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline ; egfr ; egfr ; egfr ; hypertension ; diuretics ; esrd
H-395	-0.5512544512748718	▁e g FR ▁group ▁II ▁; ▁e g FR ▁group ▁III ▁; ▁e g FR ▁group ▁IV ▁; ▁un control led ▁hyper tension ▁; ▁di ure tics ▁; ▁age ▁; ▁ES RD
D-395	-0.5512544512748718	egFR group II ; egFR group III ; egFR group IV ; uncontrolled hypertension ; diuretics ; age ; ESRD
P-395	-0.1278 -1.3260 -0.1414 -0.9159 -1.7669 -0.0757 -0.0360 -1.2104 -0.1554 -0.6375 -0.9046 -0.0839 -0.0294 -1.2640 -0.1374 -0.7590 -1.0401 -0.1290 -0.0021 -0.0046 -0.3885 -0.0999 -0.0283 -0.1340 -1.5317 -0.6510 -0.1828 -0.3003 -2.9782 -0.4031 -0.9369 -0.1843 -0.0742 -0.1023
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial ; phosphodiesterase-2 ; pde2 ; heart failure ; hf ; beta-adrenergic receptor ; β-ar ; healthy ; diseased ; cardiomyocytes
H-1208	-0.3221288025379181	▁my o card ial ▁ phos pho dies tera se -2 ▁; ▁p de 2) ▁; ▁heart ▁failure ▁; HF ▁; ▁p de 2- media ted ▁effects ▁; ▁beta - ad r energi c ▁receptor ▁; β - AR ▁; ▁cardio my o cy tes
D-1208	-0.3221288025379181	myocardial phosphodiesterase-2 ; pde2) ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
P-1208	-0.5821 -0.0743 -0.2832 -0.3728 -0.2990 -0.0203 -0.4093 -2.0186 -0.0245 -0.2873 -0.4734 -0.1953 -0.1517 -0.5844 -1.5880 -0.2677 -0.5349 -0.0268 -0.2783 -0.0531 -0.1562 -0.1442 -0.5759 -0.0125 -0.2712 -0.0229 -0.1988 -0.8008 -0.0725 -0.0250 -0.0434 -0.1329 -0.6246 -0.1133 -0.0058 -0.3615 -0.1516 -0.0102 -0.2385 -0.6179 -0.7139 -0.7017 -0.1230 -0.0818 -0.1067 -0.1869 -0.1212
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart failure ; patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator ; carvedilol ; atp ; shock therapy ; metoprolol
H-866	-0.2102702260017395	▁heart ▁failure ▁patients ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁; ▁car vedi lol ▁; ▁ATP ▁; ▁shock ▁ therapy ▁; ▁met o pro lol
D-866	-0.2102702260017395	heart failure patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
P-866	-1.1186 -0.0703 -0.6737 -0.2445 -0.0230 -0.0274 -0.0440 -0.0145 -0.4290 -1.2219 -0.0218 -0.3080 -0.0088 -0.0372 -0.3006 -0.1080 -0.0850 -0.1615 -0.0743 -0.0185 -0.1267 -0.0153 -0.0958 -0.0407 -0.0966 -0.0541 -0.4072 -0.1335 -0.0760 -0.4834 -0.1584 -0.0010 -0.0040 -0.0233 -0.1826 -1.6714 -0.1764 -0.0271 -0.2652 -0.0085 -0.3360 -0.0061 -0.0659 -0.0180 -0.0812 -0.2419 -0.0955
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich cocoa ; skm ; mitochondrial structure ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; murphy ; naviaux ; hogan ; ceballos ; maisel ; henry
H-1245	-0.20651403069496155	▁e pica tech in - rich ▁coco a ▁; ▁Sk m ▁mito cho ndri al ▁structure ▁; ▁ta ub ▁; ▁Ram i rez - s anche z ▁; ▁ci ar aldi ▁; ▁per kin s ▁; ▁Murphy ▁; ▁na vi aux ▁; ▁Hoga n ▁; ▁ce ball os ▁; ▁Mais el ▁; ▁Henry
D-1245	-0.20651403069496155	epicatechin-rich cocoa ; Skm mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
P-1245	-1.3509 -0.0183 -0.0957 -0.1153 -0.0562 -0.0057 -0.0414 -0.0108 -0.1559 -1.2518 -0.5265 -0.0882 -0.3988 -0.2758 -0.0101 -0.2144 -0.0951 -0.4512 -0.0143 -0.1487 -0.9291 -0.0101 -0.0097 -0.0071 -1.5374 -0.0020 -0.0065 -0.1150 -0.0117 -0.0029 -0.0005 -0.0753 -0.8081 -0.2621 -0.0057 -0.0552 -0.4501 -0.0527 -0.0085 -0.0088 -0.0053 -0.1116 -0.0111 -0.0091 -0.1148 -0.0200 -0.1019 -0.0355 -0.1284 -0.4187 -0.0020 -0.5065 -0.0148 -0.1159 -0.0792
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up ; death ; readmission ; patients ; physician ; physicians
H-1420	-0.8930251598358154	▁follow - up ▁visit s ▁; ▁death ▁; ▁urgent ▁read mission
D-1420	-0.8930251598358154	follow-up visits ; death ; urgent readmission
P-1420	-1.0141 -0.0785 -0.0105 -1.1384 -0.0683 -0.4180 -4.7342 -0.2029 -0.0862 -1.2804 -0.7836 -1.7111 -0.0830
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena overexpression ; tac ; surgery ; mena ; cardiac hypertrophy ; cardiac
H-1816	-0.4558066129684448	▁men a ▁over expression ▁; ▁ TTA / t g t et Men a ▁mi ce ▁; ▁ TAC ▁surgery ▁; ▁cardiac ▁hyper trop hy ▁; ▁ TTA / t g t et Men a ▁; ▁post - TAC ▁cardiac ▁functional ▁deteriora tion
D-1816	-0.4558066129684448	mena overexpression ; TTA/tgtetMena mice ; TAC surgery ; cardiac hypertrophy ; TTA/tgtetMena ; post-TAC cardiac functional deterioration
P-1816	-1.0970 -0.1956 -0.1013 -0.0102 -0.0828 -2.1850 -0.0258 -1.7050 -0.3108 -0.2345 -0.1052 -0.0974 -0.2866 -0.0340 -1.1296 -0.1825 -0.0836 -1.8461 -0.0343 -0.2095 -0.1257 -0.4503 -0.2604 -0.0060 -0.3576 -0.2066 -1.1140 -0.0312 -1.1247 -0.2567 -0.0958 -0.0552 -0.0310 -0.4915 -0.0219 -0.8295 -3.1458 -0.0090 -0.1980 -0.1563 -0.2510 -0.5090 -0.6221 -0.1131 -0.0923
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography ; lv end-diastolic volume ; mitral valve opening ; mva
H-357	-0.30463555455207825	▁e cho card i ography ▁; ▁LV ▁end - dia sto lic ▁volume ▁; ▁disappear ance ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁m VA ▁; ▁pressure ▁gradi ent
D-357	-0.30463555455207825	echocardiography ; LV end-diastolic volume ; disappearance ; MR ; mitral valve opening ; mVA ; pressure gradient
P-357	-0.0492 -0.0575 -0.1112 -0.2756 -0.1809 -0.1227 -1.9943 -1.8921 -0.0201 -0.0102 -0.0453 -0.0245 -0.0789 -0.1292 -0.7776 -0.0218 -0.3692 -0.0172 -0.2155 -0.0362 -0.0146 -0.0159 -0.0282 -0.1048 -0.3527 -0.1121 -0.8153 -0.1935 -0.7803 -0.0051 -0.0270 -1.1161 -0.0581
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd ; diuretic ; hf ; outcomes ; clinical ; hospitalizations ; pdrelated ; complications
H-901	-0.38684672117233276	▁PD ▁; ▁di ure tic ▁re frac tory ▁severe - end - s tage ▁ HF
D-901	-0.38684672117233276	PD ; diuretic refractory severe-end-stage HF
P-901	-2.5376 -0.1435 -0.1975 -0.1521 -0.7364 -0.0150 -0.0116 -0.1645 -0.5204 -0.0718 -0.2673 -0.0382 -0.1004 -0.0044 -0.1661 -0.0758 -1.6980 -0.0628
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial ; glycolysis
H-1785	-0.21667033433914185	▁ATP ▁production ▁rates ▁; ▁mito cho ndri al ▁oxid ation ▁; ▁gluco se ▁; ▁lac tate ▁; ▁fa tty ▁acid s ▁; ▁my o card ial ▁gly col ysis
D-1785	-0.21667033433914185	ATP production rates ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
P-1785	-0.1048 -1.4130 -0.4055 -0.3685 -0.1710 -0.2757 -0.1226 -0.0060 -0.0148 -0.1322 -0.1568 -0.0132 -0.0471 -0.2086 -0.0019 -0.0286 -0.1607 -0.0151 -0.0421 -0.0105 -0.0508 -0.2104 -0.7942 -0.0967 -0.3440 -0.5483 -0.0546 -0.0442 -0.0474 -0.7356 -0.0918
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients ; eplerenone ; potassium ; potassium ; hospitalization ; hyperkalemia ; medication ; adverse events
H-1226	-0.5174333453178406	▁e pler en one ▁; ▁po tas s ium ▁; ▁po tas s ium
D-1226	-0.5174333453178406	eplerenone ; potassium ; potassium
P-1226	-0.1299 -0.0220 -0.0790 -0.5997 -0.1721 -0.8072 -0.2849 -0.2110 -0.2843 -0.1448 -1.1197 -0.3773 -0.1405 -0.4647 -3.3376 -0.1042
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient ; new york heart association class iii ; heart failure ; hf ; left ventricular ejection fraction ; periodic breathing ; pb ; report
H-1347	-0.43720725178718567	▁New ▁York ▁Heart ▁Association ▁class ▁III ▁heart ▁failure ▁; HF ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁permanent ▁periodic ▁breath ing ▁; ▁p b
D-1347	-0.43720725178718567	New York Heart Association class III heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ; pb
P-1347	-3.0035 -0.4706 -1.2024 -0.8035 -0.3698 -0.0402 -0.4740 -0.1362 -0.1257 -0.3317 -0.0898 -0.7332 -0.0261 -0.0369 -0.7292 -0.2721 -0.0477 -0.0727 -0.0141 -0.7997 -0.0032 -0.3292 -1.0831 -0.0527 -0.3693 -0.0469 -0.1936 -0.2910 -1.2570 -0.0782 -0.0703
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation ; bottleneck stent ; lad ; lcx ; myocardial ischemia ; stent ; ischemic heart failure ; stent ; therapeutic
H-514	-0.26255035400390625	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁ LAD ▁; ▁ LC X ▁; ▁por cine ▁model ▁; ▁rever sible ▁my o card ial ▁ ische mia ▁; open ▁sten t ▁; ▁ ische mic ▁heart ▁failure ▁; ▁sten t
D-514	-0.26255035400390625	bottleneck stent ; proximal LAD ; LCX ; porcine model ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
P-514	-1.0414 -0.0489 -0.0077 -0.0332 -0.0904 -0.2213 -0.0365 -0.0092 -0.1264 -0.0159 -0.0896 -0.7007 -0.0407 -1.0986 -0.1558 -2.1512 -0.0531 -0.0247 -0.4218 -0.0003 -0.0012 -0.5615 -0.2032 -0.2132 -0.1175 -0.1191 -0.0466 -0.3991 -0.1069 -0.1708 -0.0295 -0.0533 -0.0898 -0.1692 -0.0186 -0.0478 -0.2100 -0.0388 -0.2548 -1.6987 -0.0387 -0.2638 -0.0700
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium ; spironolactone ; aas
H-1705	-0.44560888409614563	▁Po tas s ium ▁; ▁spi rono lac tone ▁; ▁non - AA s ▁; ▁AA s
D-1705	-0.44560888409614563	Potassium ; spironolactone ; non-AAs ; AAs
P-1705	-1.6594 -0.0637 -0.1219 -0.0618 -0.2101 -0.0535 -0.0210 -0.0497 -0.0546 -0.1430 -2.0149 -0.0122 -0.0272 -0.0515 -0.1615 -0.7966 -0.1447 -2.7240 -0.0953
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese ; body mass index ; chronic ; stable ; hfpef
H-1978	-0.6307998299598694	▁obes e ▁participants ▁; SD ▁; ▁body ▁mass ▁index ▁; ▁chronic ▁; ▁stable ▁H FP EF
D-1978	-0.6307998299598694	obese participants ;SD ; body mass index ; chronic ; stable HFPEF
P-1978	-2.0784 -0.0708 -1.3382 -0.1162 -1.2037 -0.1080 -0.1746 -0.0984 -0.0047 -0.1654 -2.3434 -0.6353 -0.1560 -2.0334 -0.2512 -0.1937 -0.2752 -0.1078
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic ; vegf pathway ; intravenously ; injected ; adenoviral ; vegf receptor ; adenovirus
H-456	-0.3526594638824463	▁pro angi ogen ic ▁effects ▁; ▁B ▁; ▁activa tion ▁; ▁VE GF ▁path way ▁; ▁rat s ▁; ▁intra ven ously ▁inject ed ▁; ▁a den ovi ral ▁ve ctor ▁; ▁de co y ▁VE GF ▁receptor ▁; ▁ad - f lk ▁; ▁control ▁ade no virus ▁; ▁ad - c
D-456	-0.3526594638824463	proangiogenic effects ; B ; activation ; VEGF pathway ; rats ; intravenously injected ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; control adenovirus ; ad-c
P-456	-0.0884 -0.0109 -0.0656 -0.3024 -0.5127 -0.3322 -1.2202 -0.7818 -0.3896 -0.1340 -1.3307 -0.4707 -0.0247 -0.0637 -0.0640 -0.1897 -0.4849 -0.0358 -0.3011 -1.5964 -0.0153 -0.3567 -0.0074 -0.2719 -1.0963 -0.0068 -0.0642 -0.0969 -0.0621 -0.4557 -0.0043 -0.5549 -0.0062 -0.0002 -0.0191 -1.3012 -0.0624 -0.0075 -0.1300 -0.5855 -0.0316 -0.3926 -0.0087 -0.0928 -1.0618 -0.0204 -0.0207 -0.0036 -0.1831 -0.7235 -0.0192 -0.2576 -2.6409 -0.0829
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical ; post-lvad ai ; aortic valve ; leaflet ; bioprosthetic aortic valve replacement ; functional capacity ; lvad ; patients ; symptomatic
H-552	-0.366543173789978	▁post - ▁l VAD ▁AI ▁; ▁a or tic ▁val ve ▁over se wing ▁; ▁le a flet ▁repair ▁; ▁bio pro sthetic ▁a or tic ▁val ve ▁replace ment ▁; ▁CF ▁l VAD ▁patients
D-552	-0.366543173789978	post- lVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD patients
P-552	-2.4102 -0.0098 -1.6331 -0.0162 -0.3233 -0.8675 -0.0264 -0.0445 -0.5961 -0.2006 -0.0503 -0.0426 -0.0736 -0.1060 -0.0926 -0.0031 -0.0197 -0.0054 -0.0425 -0.0267 -0.0016 -0.0128 -0.0043 -0.2025 -0.0311 -0.4390 -0.2064 -0.0654 -0.2972 -0.1543 -0.2080 -0.7206 -0.6651 -0.0158 -1.1422 -2.7276 -0.0780
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced pulmonary artery systolic pressure ; pasp ; stress doppler echocardiography ; right ventricular contractile reserve ; patients ; pulmonary hypertension ; right heart failure
H-822	-0.25438278913497925	▁exercise - indu ced ▁pulmonar y ▁arter y ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁stress ▁; ▁do pp ler ▁e cho card i ography ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension ▁; ▁right ▁heart ▁failure
D-822	-0.25438278913497925	exercise-induced pulmonary artery systolic pressure ;PASp ; stress ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
P-822	-2.5326 -0.0420 -0.0174 -0.0450 -0.0121 -0.0594 -0.1617 -0.0785 -0.3584 -0.1036 -0.1020 -0.2447 -0.3156 -0.2944 -0.6365 -0.1772 -0.7391 -0.3620 -0.8591 -0.0035 -0.3568 -0.0507 -0.1760 -0.2075 -0.1106 -0.1994 -0.1526 -0.3544 -0.0123 -0.6629 -0.1554 -0.0134 -0.0272 -0.0055 -0.1274 -0.1488 -0.0479 -0.1440 -0.0121 -0.1389 -0.4743 -0.1478 -0.2799 -0.2103 -0.0865
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline ; embase ; healthstar ; cinahl ; cochrane library ; campbell collaboration ; joanna briggs institute evidence based practice ; centre for reviews and dissemination ; evidence based practice centres
H-1844	-0.40458041429519653	▁med line ▁; EMBA se ▁; ▁HE al th STAR ▁; ▁c INA HL ▁; ▁co ch rane ▁Library ▁; ▁Campbell ▁Col labora tion ▁; ▁Joan na ▁Brig gs ▁institut ▁; ▁e viden ce ▁Base d ▁practice ▁; ▁Centre ▁for ▁Review s ▁and ▁Disse mination ▁; ▁e viden ce ▁Base d ▁practice
D-1844	-0.40458041429519653	medline ;EMBAse ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institut ; evidence Based practice ; Centre for Reviews and Dissemination ; evidence Based practice
P-1844	-1.6495 -0.2740 -0.1112 -0.8555 -0.7591 -0.0628 -0.9269 -0.2728 -0.6464 -1.1010 -0.0979 -0.4530 -0.7176 -0.3688 -0.0956 -0.0179 -0.0102 -0.0028 -0.0754 -0.0450 -0.0007 -0.2951 -0.0321 -0.0208 -0.0614 -0.0217 -0.1748 -0.0607 -0.0246 -0.4331 -1.6606 -1.2599 -0.0140 -0.0690 -1.1767 -0.0031 -0.7614 -1.7216 -0.5584 -0.2600 -0.5744 -0.0122 -0.3929 -0.0021 -0.0193 -0.2837 -0.3731 -0.0284 -0.1610 -0.6350 -0.0025 -1.2195 -0.8848 -0.1052
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods study ; health care ; systolic heart failure ; prescribed ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
H-1123	-0.444225549697876	▁sy sto lic ▁heart ▁failure ▁; ▁β - block er ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block er
D-1123	-0.444225549697876	systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
P-1123	-4.3200 -0.0704 -0.0610 -0.5669 -0.1895 -0.1771 -0.5671 -0.0207 -0.1494 -0.1331 -0.0724 -2.7831 -0.4756 -0.1388 -0.5260 -0.0452 -0.0322 -0.0340 -0.0493 -0.0533 -0.0278 -0.1050 -0.3754 -0.7060 -0.1624 -0.9029 -0.1913 -0.0457 -0.0323 -1.0676 -0.2081 -0.2604 -0.1097
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ; angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
H-647	-0.27371758222579956	▁heart ▁failure ▁; ▁neuro - hormon al ▁system ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁in tolerance ▁; ▁beta ▁receptor ▁block ers ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists
D-647	-0.27371758222579956	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
P-647	-3.4747 -0.1798 -0.2050 -0.0922 -0.0392 -0.0098 -0.0143 -0.0784 -0.2246 -1.2451 -0.2174 -0.0711 -0.8132 -0.0490 -0.0591 -0.0491 -0.0761 -0.0615 -0.2254 -0.1614 -0.0284 -0.1225 -0.6093 -0.0247 -0.2418 -0.0219 -0.1058 -0.4983 -0.1954 -0.0552 -0.4808 -0.1073 -0.0643 -0.1222 -0.1091 -0.1188 -0.4550 -0.6651 -0.0134 -0.1684 -0.1940 -0.0073 -0.2524 -0.0212 -0.1021 -0.0075 -0.0716 -0.9801 -0.5354 -0.0805 -0.0036 -0.0692 -0.0010 -1.0611 -0.2743 -0.1130
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest ; rs ; rs synchrony ; ste ; noninvasive ; rvpo ; rs synchrony ; strain ; bivp
H-330	-0.4486989378929138	▁open ▁che st ▁model ▁; ▁twist ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁ STE ▁; ▁non in va sive ▁sur roga tes ▁; ▁ RV PO ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁Bi VP ▁; ▁CO
D-330	-0.4486989378929138	open chest model ; twist ; RS ; RS synchrony ; CS ; STE ; noninvasive surrogates ; RVPO ; RS synchrony ; CS ; BiVP ; CO
P-330	-0.0073 -0.0563 -0.0094 -0.0583 -0.0305 -0.0001 -0.0741 -0.0297 -0.2266 -0.1262 -0.0016 -0.0990 -0.0862 -0.2950 -0.2240 -1.8314 -1.3420 -0.0991 -4.0831 -0.1021 -0.0273 -0.1278 -0.1000 -0.0014 -0.0051 -0.1521 -2.5845 -0.7693 -0.3401 -0.0375 -0.6395 -0.0030 -0.1384 -0.0469 -0.3030 -0.1233 -2.4144 -0.1034 -0.4137 -1.5211 -0.1109 -0.1008
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse ; pasp ; tapse ; pasp ; cox regression ; kaplan-meier analyses ; tapse ; pasp
H-498	-0.5283726453781128	▁T AP se ▁; ▁PAS p ▁; ▁t AP se - to - PAS p ▁ratio ▁; TA PS e ▁; PAS p ▁; ▁co x ▁re gression ▁; ▁ka plan - me ier ▁analyse s ▁; ▁t AP se ▁; ▁pas p
D-498	-0.5283726453781128	TAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe ;PASp ; cox regression ; kaplan-meier analyses ; tAPse ; pasp
P-498	-2.4877 -0.1369 -0.9352 -0.2086 -0.7360 -1.0553 -0.1398 -2.0265 -0.2242 -0.5667 -0.0283 -0.0768 -0.0271 -1.1084 -0.9740 -0.1432 -0.1171 -1.0408 -0.4441 -0.3864 -0.7693 -0.7800 -0.6934 -0.3652 -0.0654 -0.0618 -0.0079 -0.0019 -0.1164 -0.5792 -0.0189 -0.0129 -0.4536 -0.0475 -0.3324 -0.0996 -0.3567 -2.7172 -0.2416 -0.5470 -0.1871 -1.0341 -0.4315 -0.9017 -0.0914
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom ; cpet ; patients ; chf ; patients ; exercise ; exercise ; patients ; exercise ; rehabilitation
H-1880	-0.879328727722168	▁symptom ▁limited ▁; ▁c PET ▁; ▁CHF ▁; ▁control ▁; ▁exercise ▁; ▁exercise
D-1880	-0.879328727722168	symptom limited ; cPET ; CHF ; control ; exercise ; exercise
P-1880	-0.8261 -0.4324 -2.0330 -0.3140 -0.1153 -0.1386 -0.0439 -0.4263 -3.4716 -0.3383 -0.3802 -0.4430 -1.2577 -2.8895 -0.0799
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart failure ; hf ; mrna splicing ; cardiac ; scn5a ; endoplasmic reticulum
H-1080	-0.19760943949222565	▁Human ▁heart ▁failure ▁; HF ▁; ▁m RNA ▁s plic ing ▁; ▁volta ge - ga ted ▁cardiac ▁na + ▁channel ▁α - sub un it ▁; ▁s cn 5 a ▁; ▁en co ding ▁tru nca ted ▁; ▁non function al ▁channel s ▁; ▁en do plas mic ▁reti culum
D-1080	-0.19760943949222565	Human heart failure ;HF ; mRNA splicing ; voltage-gated cardiac na+ channel α-subunit ; scn5a ; encoding truncated ; nonfunctional channels ; endoplasmic reticulum
P-1080	-2.0254 -0.3253 -0.0768 -0.1211 -0.1827 -0.1139 -0.0238 -0.0293 -0.1530 -0.0227 -0.0336 -0.1294 -0.0298 -0.0222 -0.0366 -0.0179 -0.0958 -0.0273 -0.9476 -0.6040 -0.0921 -0.5639 -0.0093 -0.0037 -0.0297 -0.0208 -0.1679 -0.1741 -0.2222 -0.2690 -0.3095 -0.1416 -0.2353 -0.0371 -0.0479 -0.0364 -0.0135 -0.0104 -0.8234 -0.7245 -0.0041 -0.0034 -0.0659 -0.0203 -0.2327 -0.1217 -0.0852 -0.0834 -0.6993 -0.0027 -0.0012 -0.1252 -0.0778
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart failure ; diagnosis ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; disease
H-988	-0.43219295144081116	▁pa e dia tric ▁heart ▁failure ▁; ▁my o card itis ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure ▁; ▁cel lular ▁response s ▁; ▁heart ▁failure ▁; ▁an thra cycli ne ▁treated ▁sur viv ors ▁; ▁child hood ▁malign ant ▁disease
D-988	-0.43219295144081116	paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular responses ; heart failure ; anthracycline treated survivors ; childhood malignant disease
P-988	-0.1380 -0.0730 -0.1048 -0.3649 -1.1751 -0.1146 -0.2915 -2.5099 -0.1766 -0.5493 -0.2412 -0.2848 -0.0320 -0.0565 -0.0527 -0.4503 -0.1352 -0.0261 -0.1759 -1.5382 -0.0454 -0.5281 -2.7315 -0.0052 -0.0500 -0.0300 -1.1286 -0.3169 -0.0570 -0.1698 -0.0669 -0.0145 -0.1092 -0.2777 -1.2114 -1.3379 -0.0003 -0.0888 -0.5012 -0.4490 -0.4545 -0.0215 -0.1205 -0.2910 -1.2626 -0.1207
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; clinical ; evidence-based ; medications ; costs ; outcomes
H-2010	-0.8350865840911865	▁Tools ▁for ▁Economic ▁Analys is ▁of ▁Patient ▁Management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁; ▁kosten - ef ective ness ▁model
D-2010	-0.8350865840911865	Tools for Economic Analysis of Patient Management Interventions in Heart Failure ; kosten-efectiveness model
P-2010	-1.6439 -0.5567 -1.7089 -1.5731 -0.1344 -1.0699 -0.1580 -0.7901 -0.1278 -0.0431 -0.3027 -0.3590 -0.1857 -0.5232 -1.3209 -2.5486 -0.1088 -2.0074 -0.0249 -0.5313 -0.9155 -2.5083 -0.0648
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic peptides ; nps ; b-type np ; n-terminal pro-b-type np ; diagnosis ; acute heart failure ; patients ; emergency department ; acute dyspnea
H-1020	-0.2881213128566742	▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁b - type ▁ NP ▁; ▁n - termin al ▁pro - b - type ▁ NP ▁; ▁a cute ▁heart ▁failure ▁; ▁Emer gen cy ▁Department ▁; ED ▁; ▁a cute ▁dys pne a
D-1020	-0.2881213128566742	natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-b-type NP ; acute heart failure ; Emergency Department ;ED ; acute dyspnea
P-1020	-0.0065 -0.2528 -0.5462 -2.2559 -0.5482 -0.2018 -0.3978 -0.2041 -0.0825 -0.1981 -0.0538 -2.2320 -0.0225 -0.0098 -0.2848 -0.0224 -0.0608 -1.0560 -0.0237 -0.0032 -0.0021 -0.0608 -0.0096 -1.2997 -0.0166 -0.0031 -0.0787 -0.0190 -0.1800 -0.4075 -0.0242 -0.2801 -0.0366 -0.1264 -0.2587 -0.1040 -0.0335 -0.1629 -0.1703 -1.0456 -0.3296 -0.0353 -0.0077 -0.1238 -0.0049 -0.1113 -0.3234 -0.1113
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak oxygen consumption ; peak vo2 ; exercise ; exercise oscillatory ventilation ; eov ; partial pressure of end-tidal co2 ; petco2 ; gain ; cardiopulmonary exercise testing
H-1275	-0.33064883947372437	▁pe ak ▁oxygen ▁consum p tion ▁; pe ak ▁VO 2 ▁; ven ▁; ▁v co 2 ▁s lope ▁; ▁exercise ▁os cilla tory ▁ventilation ▁; ▁e OV ▁; ▁parti al ▁pressure ▁; ▁end - ti dal ▁CO 2 ▁; PET co 2 ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-1275	-0.33064883947372437	peak oxygen consumption ;peak VO2 ;ven ; vco2 slope ; exercise oscillatory ventilation ; eOV ; partial pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
P-1275	-0.6438 -0.0030 -0.2260 -0.0841 -0.0962 -0.3629 -0.1050 -1.8492 -0.0039 -0.1597 -1.4235 -0.0685 -1.7672 -1.0966 -0.1817 -0.6021 -0.0386 -0.0483 -0.0163 -0.0979 -0.1518 -0.4279 -0.0055 -0.0335 -0.0047 -0.1201 -0.1347 -0.0773 -0.0638 -1.1039 -0.0029 -0.0703 -0.1750 -0.9181 -0.0195 -0.0136 -0.0119 -0.4809 -0.0504 -0.0728 -0.0407 -0.6296 -1.2069 -0.2914 -0.0648 -0.0879 -0.3891 -0.2252 -0.8490 -0.3245 -0.1820 -0.0899
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective cohort study ; denmark ; bisphosphonates ; raloxifene
H-1536	-0.7288537621498108	▁Denmark ▁; ▁bis phos phon ates ▁; ▁ra lo xi fen e
D-1536	-0.7288537621498108	Denmark ; bisphosphonates ; raloxifene
P-1536	-6.0608 -0.1662 -0.5068 -0.0172 -0.0765 -0.4020 -0.2964 -0.3427 -0.0149 -0.0905 -0.1186 -0.2839 -1.7339 -0.0936
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension ; lv dilatation ; lv dysfunction ; mitral valve ; organic ; lesion ; systolic ; diastolic tethering ; etiology
H-365	-0.2750418186187744	▁hyper tension ▁; ▁LV ▁di la tation ▁; ▁LV ▁dys function ▁; ▁MR ▁; ▁MS ▁; ▁mit ral ▁val ve ▁; ▁ closure ▁; ▁opening ▁; ▁organic ▁les ion ▁; ▁sy sto lic ▁; ▁dia sto lic ▁te ther ing ▁; ▁MR ▁; ▁MS
D-365	-0.2750418186187744	hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; closure ; opening ; organic lesion ; systolic ; diastolic tethering ; MR ; MS
P-365	-0.5535 -0.0106 -0.0295 -0.2718 -0.1447 -0.0650 -0.0038 -0.0789 -0.0205 -0.0082 -0.0152 -0.0339 -0.5927 -0.0539 -2.4365 -1.0142 -0.0859 -0.0123 -0.0628 -0.0310 -0.2190 -3.3422 -0.0269 -0.1566 -0.8542 -0.1958 -0.9355 -0.0531 -0.0093 -0.1375 -0.0046 -0.0098 -0.0046 -0.1611 -0.0012 -0.0261 -0.0110 -0.0053 -0.1144 -0.0121 -0.1075 -0.4607 -0.1365 -0.0296 -0.0597 -0.0523
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; patients ; diuretic ; therapy ; serum sodium ; systolic function
H-1196	-0.38910046219825745	▁to lv ap tan ▁; ▁severe ▁hypo na trem ia ▁; ▁Japan ▁; ▁con ges tive ▁heart ▁failure ▁patients ▁; ▁optimal ▁di ure tic ▁ therapy ▁; ▁so dium ▁levels ▁; ▁sy sto lic ▁function
D-1196	-0.38910046219825745	tolvaptan ; severe hyponatremia ; Japan ; congestive heart failure patients ; optimal diuretic therapy ; sodium levels ; systolic function
P-1196	-0.0641 -0.1986 -0.1899 -0.0227 -0.1153 -2.5990 -0.0688 -0.4753 -0.0385 -0.3799 -0.1108 -3.5835 -0.1200 -0.3504 -0.1090 -0.4208 -0.2059 -0.0272 -0.6557 -0.1202 -0.1087 -0.3659 -0.8904 -0.5636 -0.3978 -0.0155 -0.3984 -0.6801 -0.0057 -0.2364 -0.1072 -0.0009 -0.0221 -0.0471 -0.4100 -0.2278 -0.0635
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal ; strain ; left ventricle ; echocardiographic ; patients ; baseline ; echocardiography ; crt ; follow-up ; echocardiograms
H-429	-0.35806018114089966	▁longitud in al ▁strain ▁; ▁left ▁vent ric le ▁; ▁e cho car dio graphic ▁measure ments ▁; ▁patients ▁; ▁base line ▁e cho card i ography ▁; ▁c RT ▁; ▁follow - up ▁e cho card i ogram s
D-429	-0.35806018114089966	longitudinal strain ; left ventricle ; echocardiographic measurements ; patients ; baseline echocardiography ; cRT ; follow-up echocardiograms
P-429	-1.4382 -0.1547 -0.0143 -0.0925 -0.5608 -0.1042 -0.1293 -0.9147 -0.4928 -0.1410 -0.1044 -0.0288 -0.0286 -0.1487 -0.1641 -0.9300 -0.2800 -0.2593 -3.7208 -0.1328 -0.5724 -0.0038 -0.0342 -0.0566 -0.2337 -0.4056 -0.2422 -0.2396 -0.3381 -1.4209 -0.1561 -0.0199 -0.0436 -0.0147 -0.0964 -0.0594 -0.2096 -0.5904 -0.0115 -0.2244 -0.1598 -0.0655
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating factor ; paf ; metabolic ; enzymes ; follow-up ; patients ; diagnosed ; heart failure ; hf ; healthy
H-1267	-0.542847216129303	▁plate let - activa ting ▁factor ▁; PA f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure ▁; HF
D-1267	-0.542847216129303	platelet-activating factor ;PAf ; metabolic enzymes ; heart failure ;HF
P-1267	-0.7305 -0.3941 -0.1196 -0.0928 -0.2042 -0.0547 -0.2954 -1.2648 -1.5689 -0.1363 -0.0238 -0.0879 -0.0437 -0.0465 -0.3382 -3.2953 -0.1405 -0.5036 -1.2640 -0.7282 -0.0666
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute care surgery ; acs ; consultations ; oht ; transplantation ; medical therapy ; intravenous ; inotropes ; ventricular assist devices ; vads
H-1281	-0.25261610746383667	▁a cute ▁care ▁surgery ▁; AC s ▁; ▁o HT ▁; ▁transplant ation ▁; ▁medical ▁ therapy ▁; ▁m t ▁; ▁intra ven ous ▁in o trop es ▁; ▁vent ri cular ▁assist ▁devices ▁; VAD s
D-1281	-0.25261610746383667	acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
P-1281	-0.0083 -0.0160 -1.2888 -0.0745 -0.1681 -1.1374 -0.4510 -0.2047 -0.2519 -0.7100 -0.2385 -0.2543 -0.0929 -0.3188 -0.1254 -0.1446 -0.0065 -0.1127 -0.3849 -0.7363 -0.0879 -0.0388 -0.0054 -0.8313 -0.0057 -0.1952 -0.0243 -0.2073 -0.0951 -0.0023 -0.3296 -0.0761 -0.2328 -0.0475 -0.3850 -0.0071 -0.3080 -0.1616 -0.0853
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients ; hfpef ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1178	-0.4542982578277588	▁i va bra dine ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁response ▁; ▁exercise ▁; ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1178	-0.4542982578277588	ivabradine ; left ventricular filling pressure response ; exercise ; diastolic mitral flow velocity ; early diastolic mitral annular velocity
P-1178	-2.9350 -0.0455 -0.1844 -0.0630 -0.1432 -1.6881 -0.0191 -0.6430 -0.0757 -0.8772 -0.0287 -0.2370 -0.9182 -0.4080 -1.7328 -0.3196 -0.9901 -0.0570 -0.0095 -0.2463 -0.0263 -1.4620 -0.5594 -0.0644 -0.2684 -0.4332 -0.0188 -0.0939 -0.0684 -0.3385 -0.0748 -1.4258 -0.0009 -0.0911 -0.0820 -0.1081 -0.0715
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone system ; raas ; hfref ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpef
H-1489	-0.27094581723213196	▁re nin - angi oten sin - al do ster one ▁system ▁; RA as ▁; ▁h Fr EF ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁al do ster one ▁block ade ▁; ▁ HF p EF
D-1489	-0.27094581723213196	renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
P-1489	-0.0056 -0.2314 -0.0424 -0.0052 -0.0531 -1.2132 -0.0713 -0.0265 -0.2130 -0.0522 -0.3126 -0.0433 -0.3054 -0.2443 -0.4410 -0.1050 -4.6162 -0.6061 -0.3470 -0.1099 -0.3482 -0.2485 -0.0502 -0.8388 -0.0809 -0.0060 -0.0152 -0.0399 -0.0114 -0.0323 -0.0085 -0.1300 -0.1015 -0.1069 -0.2346 -0.0470 -0.3964 -0.2044 -0.2081 -0.0363 -0.0711 -0.0172 -0.0402 -0.0253 -0.1413 -0.2136 -0.1187 -0.3721 -0.3871 -0.2595 -0.0542 -0.5708 -0.1044 -0.0657
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission ; lvet ; patients ; outcome ; tonometric
H-583	-0.521895706653595	▁l VET ▁; ▁un favor able ▁outcome
D-583	-0.521895706653595	lVET ; unfavorable outcome
P-583	-0.4883 -0.8757 -0.3651 -0.3388 -0.0080 -0.0749 -0.2271 -2.1774 -0.1418
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart rate ; blood pressure ; renal function ; spironolactone ; ras blockers ; β-blockers
H-182	-0.36437949538230896	▁heart ▁rate ▁; ▁blood ▁pressure ▁; ▁renal ▁function ▁; ▁spi rono lac tone ▁; ▁ RAS ▁block ers ▁; ▁β - block ers
D-182	-0.36437949538230896	heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
P-182	-3.1992 -0.1262 -0.1500 -0.1535 -0.3504 -0.1085 -0.0141 -0.0840 -0.1246 -0.0018 -0.0043 -0.0267 -0.0137 -0.3274 -0.7068 -0.0988 -0.5668 -0.0268 -0.1840 -1.9962 -0.0538 -0.0953 -0.0682 -0.5235 -0.1049
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac ; β-adrenoceptor blockade ; heart failure ; reverse ; cardiac remodeling ; elevated ; plasma catecholamines
H-1553	-0.17333248257637024	▁cardiac ▁performance ▁; ▁β - ad re no cept or ▁block ade ▁; ▁heart ▁failure ▁; ▁SR ▁ca (2 +) - pump ▁function ▁; ▁rever se ▁cardiac ▁remodel ing ▁; ▁plasma ▁cate chol amine s
D-1553	-0.17333248257637024	cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
P-1553	-0.9638 -0.0259 -0.0970 -0.0219 -0.0182 -0.0364 -0.1171 -0.1110 -0.3205 -0.0721 -0.2228 -0.2448 -0.2003 -0.5137 -0.1226 -0.2888 -0.2088 -0.9188 -0.1960 -0.0021 -0.0198 -0.0183 -0.3182 -0.1487 -0.2183 -0.0037 -0.0134 -0.0086 -0.0243 -0.3600 -0.0502 -0.0524 -0.0086 -0.0697 -0.1555 -0.1573 -0.0833
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate ratio ; confidence interval ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; therapy ; confidence interval ; β-blockers ; therapy
H-666	-0.5731709003448486	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁ therapy ▁; ▁β - block ers ▁ therapy
D-666	-0.5731709003448486	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; β-blockers therapy
P-666	-6.6429 -0.9351 -0.0516 -1.2714 -0.2117 -0.0099 -0.0231 -0.0709 -0.0624 -0.0483 -0.0314 -0.2427 -0.6959 -0.0324 -0.0932 -0.3120 -0.0198 -0.4726 -0.0349 -1.8110 -0.0231 -0.4426 -1.6564 -0.0386 -0.1276 -0.0352 -1.0386 -0.0424 -0.5263 -0.1911
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 ; congestive heart failure ; phenotypes ; mitochondrial ; tac ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
H-874	-0.36757928133010864	▁SS 31 ▁; ▁con ges tive ▁heart ▁failure ▁ph eno type s ▁; ▁mito cho ndri al ▁damage ▁; TAC ▁; ▁mito cho ndri al ▁prote ome ▁changes ▁; ▁mito cho ndri al ▁; ▁non mi to cho ndri al ▁protein ▁changes
D-874	-0.36757928133010864	SS31 ; congestive heart failure phenotypes ; mitochondrial damage ;TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
P-874	-0.3986 -0.5159 -1.0809 -0.0410 -0.1167 -1.0340 -0.8892 -0.1050 -0.5759 -0.0239 -0.0034 -0.0593 -0.1041 -0.0209 -0.4317 -0.3003 -0.0155 -0.9898 -1.2796 -0.9140 -0.1979 -0.5787 -0.2382 -0.2640 -0.0140 -0.1546 -0.0402 -1.4658 -0.5785 -0.4123 -0.1970 -0.1990 -0.0118 -0.4082 -0.3141 -0.0718 -0.0243 -0.2252 -0.1206 -0.0081 -0.1685 -1.2684 -0.2534 -0.0592
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar ; atpase ; activity ; mrna ; phospholamban ; α-myosin heavy chain ; mrna ; β-myosin heavy chain ; metoprolol
H-1552	-0.254223108291626	▁my o fi bril lar ▁ca (2 +) - stimul ated ▁ATP ase ▁activity ▁; ▁m RNA ▁levels ▁; ▁SR ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁α - my os in ▁heavy ▁chain ▁; ▁m RNA ▁level ▁; ▁β - my os in ▁heavy ▁chain ▁; ▁met o pro lol
D-1552	-0.254223108291626	myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA level ; β-myosin heavy chain ; metoprolol
P-1552	-1.8390 -0.1367 -0.0318 -0.0328 -0.1711 -1.1330 -0.1936 -0.0034 -0.0128 -0.0230 -0.0859 -1.3883 -0.7982 -0.4266 -0.1552 -0.0041 -0.0205 -0.5455 -0.1197 -0.1491 -1.0008 -0.1509 -0.0020 -0.0238 -0.0400 -0.1373 -0.3234 -0.0529 -0.0735 -0.6504 -0.2061 -0.1690 -0.0844 -0.0132 -0.1060 -0.0718 -0.2933 -0.1849 -0.0074 -0.4587 -0.0078 -0.0662 -0.3910 -0.1449 -0.7496 -0.0140 -0.1429 -0.1011 -0.1960 -0.2309 -0.0159 -0.6146 -0.0261 -0.1053 -0.0575 -0.2575 -0.1866 -0.1170
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl ; healthy ; hdl ; healthy ; patients ; chf-nyha-iii ; hdl ; nyha-iiib ; patients ; chf-nyha-ii ; hdl ; nyha-ii
H-250	-0.596920907497406	▁HD L ▁; ▁healthy ▁control s ▁; HD L ▁; ▁CHF - NY ha - III ▁; HD L ▁; NY ha - III b ▁; ▁ET ▁; ▁CHF - NY ha - II ▁; HD L ▁; NY ha - II
D-250	-0.596920907497406	HDL ; healthy controls ;HDL ; CHF-NYha-III ;HDL ;NYha-IIIb ; ET ; CHF-NYha-II ;HDL ;NYha-II
P-250	-1.0730 -1.9400 -0.1511 -1.8345 -0.6365 -0.0548 -0.0996 -0.3908 -1.5762 -0.1396 -1.1155 -0.0455 -0.0219 -1.1032 -0.0626 -0.0977 -0.2145 -0.7843 -1.7348 -0.3041 -0.8540 -0.9651 -0.0250 -0.1856 -0.0514 -0.2762 -1.6891 -0.3979 -0.4147 -0.0459 -0.0563 -0.9903 -0.0295 -0.2496 -0.1356 -1.0506 -2.2660 -0.5998 -0.7193 -0.9255 -0.0367 -0.4620 -0.3725 -0.0857
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized ; coronary microembolization-induced hf ; cxl-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
H-420	-0.3020411431789398	▁an est ized ▁dog s ▁; ▁corona ry ▁micro e mbol ization - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁vent ri cular ▁end - dia sto lic ▁pressure ▁; ▁my o card ial ▁oxygen ▁consum p tion ▁; ▁e je ction ▁ fraction ▁; ▁maximal ▁vent ri cular ▁power ▁index
D-420	-0.3020411431789398	anestized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
P-420	-1.3043 -0.0772 -2.0796 -0.5632 -0.0236 -1.2463 -0.0144 -0.1766 -0.0099 -0.2046 -0.0043 -0.2545 -0.1556 -0.0040 -0.0280 -0.1721 -0.1237 -0.0700 -1.0611 -0.0716 -0.1274 -0.0720 -0.7840 -0.2379 -0.0320 -0.7416 -0.1080 -1.5223 -0.0538 -0.0161 -0.0455 -0.0279 -0.1661 -0.0814 -0.4219 -0.0510 -0.3026 -0.1839 -0.1812 -0.0821 -0.0299 -0.4294 -0.1350 -0.0215 -0.0420 -0.0231 -0.9424 -0.0039 -0.1497 -0.9891 -0.0343 -0.8573 -0.2559 -0.0390 -0.0469 -0.2470 -0.0863
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard error of measurement ; mdc ; mdc
H-805	-0.5752821564674377	▁m DC ▁; ▁m DC ▁; ▁95% ▁confidence ▁level ▁; ▁m DC 95%
D-805	-0.5752821564674377	mDC ; mDC ; 95% confidence level ; mDC95%
P-805	-0.3404 -0.4504 -0.2189 -0.9644 -0.4473 -0.5786 -2.3930 -0.0260 -0.0230 -0.1802 -0.0253 -0.4583 -1.5431 -0.8772 -0.1030
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline ; heart failure ; t1-mapping ; administration ; administration
H-1061	-1.1627980470657349	▁heart ▁failure ▁; ▁t 1- ma pping ▁values ▁; ▁contrast ▁agent
D-1061	-1.1627980470657349	heart failure ; t1-mapping values ; contrast agent
P-1061	-3.7291 -0.2543 -0.8869 -3.8806 -0.1764 -0.1411 -0.0114 -1.9846 -0.2017 -2.0373 -0.0140 -1.7012 -0.0978
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies ; hf ; idiopathic dilated cardiomyopathy ; ischemic ; valvular
H-1794	-0.407007098197937	▁ HF ▁; ▁la ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁c ' d ▁; ▁ ische mic ▁; ▁SH ▁; ▁val vu lar ▁; ▁alcohol
D-1794	-0.407007098197937	HF ; la ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
P-1794	-1.3122 -0.5079 -0.4726 -0.7577 -1.3301 -1.1110 -0.0441 -0.0131 -0.1499 -0.1187 -0.0999 -0.3186 -0.8958 -0.2668 -0.0133 -0.1202 -0.1820 -2.6496 -0.1622 -0.0780 -0.0831 -0.0220 -0.0330 -0.1577 -0.5303 -0.2819 -0.0146 -0.0019 -0.0532 -0.2972 -0.1604 -1.0941 -0.0986
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 ; functional capacity ; clinical ; outcomes ; ambulatory ; patients ; hf ; heart failure ; outcomes ; exercise ; training ; hf-action ; randomized ; exercise ; training ; hf
H-697	-0.36568644642829895	▁ST 2 ▁levels ▁; ▁functional ▁capacity ▁; ▁ambula tory ▁patients ▁; ▁ HF ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - AC TION ▁; ▁exercise ▁training ▁; ▁ HF
D-697	-0.36568644642829895	ST2 levels ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; controlled trial Investigating Outcomes of Exercise Training ;HF-ACTION ; exercise training ; HF
P-697	-0.1735 -0.1176 -1.3037 -0.1423 -0.0148 -0.1387 -0.1196 -0.4034 -0.0835 -0.2645 -0.6395 -0.2070 -0.1055 -0.2965 -1.0106 -0.0784 -0.2089 -0.2497 -1.5535 -0.1125 -0.4598 -0.0235 -0.0941 -0.0300 -0.2137 -0.0738 -0.0442 -0.9705 -0.2223 -0.0372 -0.2046 -0.2115 -0.8925 -0.0229 -1.1731 -0.3229 -0.3151 -1.9066 -0.1411 -0.7553 -0.3212 -0.2221 -0.1283 -0.0802
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ; exercise rehabilitation ; patient ; chronic heart failure ; chf ; clinical ; cardiopulmonary exercise testing ; cpet ; exercise rehabilitation ; china
H-1879	-0.6144588589668274	▁cardio pul mon ary ▁exercise ▁testing ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; CH F ▁; ▁Card io P ul mon ary ▁Exerci se ▁Test ing ▁; ▁c PET ▁; ▁exercise ▁rehabilita tion ▁; ▁China
D-1879	-0.6144588589668274	cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ;CHF ; CardioPulmonary Exercise Testing ; cPET ; exercise rehabilitation ; China
P-1879	-0.1154 -0.2715 -1.1844 -0.2345 -0.9879 -0.4165 -0.2478 -2.1387 -0.2048 -0.2334 -0.3676 -0.7424 -2.7156 -0.0501 -0.4649 -0.1052 -0.1522 -2.0001 -1.4667 -0.1526 -1.0374 -0.1247 -1.9236 -0.0839 -0.7433 -0.0647 -0.5188 -0.0729 -1.1390 -0.0243 -0.1148 -0.2773 -0.1352 -0.1943 -0.6093 -0.1064 -0.1841 -1.3898 -1.8179 -0.2579 -0.1213
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ; ischemic hf ; pathogenesis ; nyha functional class iv ; estimated glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
H-1704	-0.21391496062278748	▁ ische mic ▁ HF ▁path ogen es is ▁; ▁NY HA ▁functional ▁class ▁IV ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁heart ▁rate ▁; ▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁my o card ial ▁in far ction
D-1704	-0.21391496062278748	ischemic HF pathogenesis ; NYHA functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
P-1704	-1.4445 -0.0285 -0.0377 -0.1011 -0.1696 -0.5535 -0.0784 -0.0299 -0.2408 -0.0855 -0.2191 -0.3159 -0.0402 -0.0654 -0.1303 -0.1739 -0.0290 -0.0519 -0.0264 -0.0596 -0.1079 -0.5707 -0.1105 -0.4082 -0.4397 -0.0623 -0.1179 -0.0065 -0.0484 -0.0211 -0.0013 -0.0047 -0.0803 -1.4332 -0.1070 -0.2107 -0.2671 -0.0246 -0.1189 -0.1921 -0.6555 -0.1144
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action ; randomized ; exercise ; training ; patients ; hf ; left ventricular ejection fractions ; hrqol ; kansas city cardiomyopathy questionnaire ; kccq ; baseline
H-837	-0.34407439827919006	▁ HF - ac TION ▁; ▁exercise ▁training ▁; ▁patients ▁; ▁ HF ▁; ▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction s ▁; ▁HR Qo L ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁k cc q
D-837	-0.34407439827919006	HF-acTION ; exercise training ; patients ; HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
P-837	-0.9604 -0.0727 -0.0197 -0.4594 -1.1688 -0.1723 -1.2844 -0.1820 -0.2947 -1.1073 -0.9790 -0.8828 -0.0142 -0.1129 -0.5191 -0.8700 -0.0758 -0.7334 -0.3687 -0.0694 -0.1501 -0.0557 -0.4438 -0.0018 -0.0400 -0.0875 -0.0666 -0.0026 -0.4645 -0.0531 -0.0069 -0.1200 -0.5221 -0.0398 -0.0346 -1.1053 -0.0955 -0.0808 -0.0047 -0.2051 -0.3544 -0.1541 -0.9056 -0.0669 -0.0748
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt ; systolic dysfunction ; outcomes ; resynchronization reverses remodeling in systolic left ventricular dysfunction ; reverse ; patients ; left ventricular ; ejection fraction ; lvef
H-752	-0.3308391571044922	▁c RT ▁; ▁sy sto lic ▁dys function ▁; ▁re syn chron ization ▁re ve rse s ▁re model ing ▁; ▁sy sto lic ▁left ▁v ▁en tri cular ▁dys function ▁; ▁re vers e ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; LV EF
D-752	-0.3308391571044922	cRT ; systolic dysfunction ; resynchronization reverses remodeling ; systolic left v entricular dysfunction ; reverse ; left ventricular ;LV ; ejection fraction ;LVEF
P-752	-0.3361 -2.3844 -0.1844 -0.1901 -0.0206 -0.0842 -0.1128 -0.0475 -0.0848 -0.3362 -0.0402 -0.0095 -0.2918 -0.0317 -0.6521 -0.0898 -0.0156 -0.4866 -0.5560 -0.0187 -1.1708 -0.6458 -0.0072 -0.0176 -0.1958 -0.0555 -0.9732 -1.0493 -0.1175 -0.0394 -0.0707 -0.1270 -1.1614 -0.9665 -0.1848 -0.2853 -0.8907 -0.0127 -0.2091 -0.0551 -0.1633 -0.4600 -1.5310 -0.0260 -0.0576 -0.0208 -0.3870 -0.0092 -0.2851 -0.0363 -0.1485 -0.1089 -0.0921
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated glomerular filtration rate ; egfr ; type 2 diabetes ; cholesterol ; ldl-cholesterol ; clcnka ; genotype
H-1803	-0.35806041955947876	▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR ▁; ▁type ▁2 ▁diabetes ▁; ▁total ▁cholesterol ▁; ▁l DL - ch olesterol ▁; ▁CL cn ka ▁ gg ▁geno type
D-1803	-0.35806041955947876	glomerular filtration rate ; egFR ; type 2 diabetes ; total cholesterol ; lDL-cholesterol ; CLcnka gg genotype
P-1803	-0.1455 -0.1804 -0.0697 -0.2725 -0.2664 -0.5842 -0.1756 -0.0732 -1.7182 -0.2044 -0.1309 -1.6849 -0.1241 -0.0144 -0.0682 -0.1436 -0.0622 -0.1415 -0.3400 -0.3673 -0.0674 -0.3032 -0.0016 -0.2047 -0.0682 -1.6502 -0.6854 -0.3679 -0.9930 -0.3776 -0.0023 -0.2433 -0.0837
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography ; lv end-diastolic dimension ; lv end-diastolic pressure ; wall stress ; lung ; acf
H-474	-0.43140867352485657	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight ▁; ▁un tre ated ▁A CF ▁groups ▁; ▁sham ▁group
D-474	-0.43140867352485657	echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; untreated ACF groups ; sham group
P-474	-0.1457 -0.0419 -0.2287 -0.3176 -0.1384 -0.1216 -2.3190 -1.5646 -0.6547 -0.0423 -0.0335 -0.1052 -0.0899 -0.9034 -0.0365 -0.0598 -1.1681 -1.2198 -0.9216 -0.0489 -0.0377 -0.1259 -0.0537 -0.3135 -0.7197 -0.5691 -0.1765 -0.1145 -0.2920 -0.0983 -0.0804 -1.1208 -0.0018 -0.1109 -1.2007 -0.1326 -0.8123 -0.2669 -0.0097 -1.4740 -0.1524 -0.0947
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic ; patients ; auc ; auc
H-488	-1.1575559377670288	▁e - lateral ▁; ▁diagnosti ▁performance ▁; ▁s ' lateral ▁; ▁a UC
D-488	-1.1575559377670288	e-lateral ; diagnosti performance ; s'lateral ; aUC
P-488	-0.9348 -5.7472 -0.2311 -0.2463 -2.8259 -0.1368 -0.2037 -0.0825 -3.0451 -0.0519 -0.2617 -0.2625 -0.9365 -2.2269 -0.1704
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients ; follow-up ; patients ; spironolactone ; hospitalization ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval
H-443	-0.7003219723701477	▁spi rono lac tone ▁; ▁risk ▁; ▁hospital ization
D-443	-0.7003219723701477	spironolactone ; risk ; hospitalization
P-443	-0.2798 -0.0105 -0.0230 -0.0330 -0.3936 -1.6781 -1.5621 -0.1760 -0.6781 -2.7036 -0.1656
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control ; patients ; cardiac ; driven ; cardioversions ; costs ; antiarrhythmic drugs ; cad ; patient ; confidence interval ; patient
H-1239	-0.5494505763053894	▁Rate - control ▁patients ▁; ▁cardiac ▁procedure s ▁; ▁cardio version s ▁; ▁kosten ▁; ▁anti ar rhythm ic ▁drugs ▁; CAD ▁; ▁ci
D-1239	-0.5494505763053894	Rate-control patients ; cardiac procedures ; cardioversions ; kosten ; antiarrhythmic drugs ;CAD ; ci
P-1239	-2.3954 -0.3216 -0.0078 -0.6348 -0.4730 -0.4859 -0.1501 -0.0423 -0.1869 -0.5909 -0.0344 -0.0957 -0.1616 -1.7203 -0.3189 -0.0739 -0.0917 -0.0772 -0.1908 -0.0999 -0.2901 -0.9544 -0.3642 -3.1999 -1.2104 -0.1136
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients ; bundle branch morphology ; diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin ii receptor blocker
H-906	-0.25517538189888	▁diabetes ▁mell itus ▁; ▁cardio my o pathy ▁origin ▁; ▁β - block er ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin ▁II ▁receptor ▁block er
D-906	-0.25517538189888	diabetes mellitus ; cardiomyopathy origin ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
P-906	-3.2284 -0.0040 -0.0317 -0.1360 -0.0060 -0.3919 -0.3283 -0.0281 -0.3010 -0.1391 -0.0573 -0.0167 -0.1247 -0.0789 -0.0780 -0.5578 -0.2346 -0.0879 -0.7627 -0.1132 -0.0108 -0.0273 -0.0360 -0.0415 -0.0399 -0.0196 -0.0324 -0.0810 -0.2585 -0.2514 -0.0901 -0.4540 -0.5026 -0.0081 -0.2880 -0.1005 -0.6205 -0.1281
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone post myocardial infarction heart failure efficacy and survival study ; ephesus ; post-myocardial infarction ; patients ; heart failure ; mortality ; hospitalizations ; patients ; randomized ; aldosterone antagonist ; eplerenone
H-1737	-0.47896328568458557	▁e pler en one ▁; ▁post ▁my o card ial ▁in far ction ▁; ▁Heart ▁failure ▁Ef fica cy ▁; ▁SU rvi val ▁Study ▁; EP HE SUS ▁; ▁post - my o card ial ▁in far ction ▁patients ▁; ▁heart ▁failure ▁; ▁al do ster one ▁anta gon ist ▁e pler en one
D-1737	-0.47896328568458557	eplerenone ; post myocardial infarction ; Heart failure Efficacy ; SUrvival Study ;EPHESUS ; post-myocardial infarction patients ; heart failure ; aldosterone antagonist eplerenone
P-1737	-0.2363 -0.0055 -0.1332 -0.3147 -1.5754 -0.6910 -1.2084 -0.3891 -0.8202 -0.4468 -0.0369 -0.1760 -0.0908 -0.9083 -2.3368 -0.0437 -1.0487 -0.0318 -0.0309 -0.1888 -1.0119 -0.0171 -0.0104 -0.2991 -0.1002 -4.1242 -1.6680 -0.2225 -0.0698 -0.0163 -0.0451 -0.3734 -0.2203 -1.1197 -0.4128 -0.0283 -0.1995 -0.0627 -0.7727 -1.0757 -0.3904 -0.0632 -0.5163 -1.4287 -0.0270 -0.0216 -0.1561 -0.0625 -0.0005 -0.1649 -0.1702 -0.0202 -0.0526 -0.8803 -0.1822 -0.1222
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol ; metoprolol ; endpoint ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-856	-0.2862534821033478	▁car vedi lol ▁; ▁met o pro lol ▁; ▁in appropria te ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD it - c r ▁; Mul ti center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁With ▁Card iac ▁re syn chron ization ▁Therapy
D-856	-0.2862534821033478	carvedilol ; metoprolol ; inappropriate implantable cardioverter-defibrillator therapy ; MADit-cr ;Multicenter Automatic Defibrillator Implantation With Cardiac resynchronization Therapy
P-856	-0.0690 -0.0118 -0.0448 -0.1365 -0.0087 -0.0650 -0.0117 -0.0662 -0.1219 -0.1931 -0.0010 -0.0328 -0.0655 -0.0197 -0.5853 -0.0157 -0.1644 -0.0373 -0.1608 -0.1407 -0.4914 -0.0867 -0.0725 -0.4792 -0.0099 -0.0746 -0.0748 -1.6410 -0.0060 -1.2987 -3.1325 -0.0835 -1.1469 -0.2490 -0.0281 -0.2012 -0.0415 -0.1662 -0.0185 -0.1110 -0.0252 -0.1103 -0.1644 -1.4019 -0.1291 -0.0277 -0.9777 -0.0221 -0.0071 -0.3618 -0.2673 -0.2302 -0.0817
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence interval ; heart ; mortality ; death
H-1749	-0.9008857011795044	▁risk ▁re duction ▁; HR ▁; ▁95% ▁confidence ▁interval
D-1749	-0.9008857011795044	risk reduction ;HR ; 95% confidence interval
P-1749	-1.1429 -0.2146 -0.0309 -0.1808 -0.2281 -0.2216 -3.4159 -0.0767 -0.0069 -4.3024 -0.0888
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash ; clinic ; brachial systolic pressure ; central end-systolic pressure
H-924	-0.5996495485305786	▁DAS h ▁; ▁s rd ▁; ▁bra chi al ▁sy sto lic ▁pressure ▁; ▁central ▁end - sy sto lic ▁pressure
D-924	-0.5996495485305786	DASh ; srd ; brachial systolic pressure ; central end-systolic pressure
P-924	-0.0090 -0.1056 -0.6577 -0.5824 -0.8453 -0.2827 -1.0308 -0.0461 -0.0757 -0.0249 -0.1015 -0.1159 -0.3377 -0.1214 -3.4953 -2.4122 -0.1090 -1.2042 -0.0856 -0.0476 -0.4040 -1.5935 -0.1038
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients ; hf ; obese ; body mass index ; idiopathic-dilated cardiomyopathy
H-558	-0.36708658933639526	▁ HF ▁; ▁obes e ▁; ▁body ▁mass ▁index ▁; ▁black ▁et hni city ▁; ▁ idio pathi c - dila ted ▁cardio my o pathy
D-558	-0.36708658933639526	HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
P-558	-1.4762 -0.0983 -0.2785 -0.5128 -0.0896 -0.1242 -0.9161 -0.1891 -0.0055 -0.3805 -3.0991 -0.0253 -0.0930 -0.3731 -0.0754 -0.2556 -0.0531 -0.0543 -0.3883 -0.1289 -0.0020 -0.0554 -0.1131 -0.9163 -0.2624 -0.0289 -0.1912 -0.0921
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause mortality ; hospitalization ; hf ; lvef ; patients ; heart failure survey ; israel
H-113	-0.7344798445701599	▁all - ca use ▁mortal ity ▁; ▁hospital ization ▁; ▁ HF ▁; ▁LV EF ▁; ▁cardiac ▁Fail ure ▁Survey ▁; ▁IS ra el
D-113	-0.7344798445701599	all-cause mortality ; hospitalization ; HF ; LVEF ; cardiac Failure Survey ; ISrael
P-113	-5.3964 -0.0253 -0.0400 -0.3520 -0.0296 -1.0925 -0.1999 -2.0577 -0.4584 -0.3279 -0.1737 -0.1029 -0.1491 -0.0311 -0.1508 -0.0778 -4.2596 -0.6783 -0.9254 -0.2084 -0.6838 -1.4474 -0.0535 -0.0154 -0.0776 -0.0818
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients ; left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography ; followed up
H-1743	-0.43851691484451294	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁world ▁health ▁Organization ▁criteri a ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁negative ▁corona ry ▁ang i ography
D-1743	-0.43851691484451294	left ventricular ejection fraction ; world health Organization criteria ; idiopathic dilated cardiomyopathy ; negative coronary angiography
P-1743	-5.0165 -0.0454 -0.8162 -0.2604 -0.0688 -0.0940 -0.0449 -0.5636 -0.0040 -0.2015 -0.9840 -1.3561 -0.4907 -0.4021 -0.1070 -0.4735 -0.0925 -0.0037 -0.0447 -0.1970 -0.1038 -0.1513 -0.1093 -1.2767 -0.4416 -0.0385 -0.0609 -0.0167 -0.1622 -0.7100 -0.2589 -0.2631 -0.2001 -0.1894 -0.0989
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european society of cardiology ; hfpef ; symptoms ; heart failure ; preserved lv ejection fraction ; non-dilated left ventricle ; evidence ; diastolic dysfunction ; lv relaxation ; lv diastolic stiffness ; elevated ; lv filling pressures
H-27	-0.33104240894317627	▁ europe se ▁society ▁of ▁Card i ology ▁guidelines ▁; ▁h FP EF ▁; ▁heart ▁failure ▁; ▁pres er ved ▁LV ▁e je ction ▁ fraction ▁; ▁non - dila ted ▁left ▁vent ric le ▁; ▁dia sto lic ▁dys function ▁; impa i red ▁LV ▁relax ation ▁; ▁LV ▁dia sto lic ▁sti ff ness ▁; ▁LV ▁fill ing ▁pressure s
D-27	-0.33104240894317627	europese society of Cardiology guidelines ; hFPEF ; heart failure ; preserved LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
P-27	-1.5869 -0.0102 -0.0202 -1.9510 -0.2111 -1.1781 -0.0604 -0.1741 -0.7011 -0.2531 -1.5543 -1.4259 -0.2907 -0.1028 -1.0239 -0.0260 -0.0664 -1.9310 -0.0093 -0.0973 -0.0543 -0.0487 -0.0326 -0.0075 -0.4902 -0.0016 -0.1646 -1.2685 -0.0104 -0.0002 -0.0078 -0.0194 -0.0198 -0.5851 -0.1611 -0.1145 -0.0197 -0.0225 -0.0253 -0.0601 -0.0137 -0.0497 -2.2727 -0.0315 -0.0040 -0.0099 -0.0986 -0.0332 -0.0277 -0.5801 -0.3986 -0.0438 -0.0290 -0.0100 -0.0869 -0.6128 -0.1318 -0.3781 -0.1243 -0.0129 -0.1041 -0.0815 -0.2065 -0.0577
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars ; s1pr1s ; myocyte ; camp ; report ; receptors ; g-protein-coupled receptor ; kinase-2
H-1408	-0.3801872134208679	▁β 1 AR s ▁; ▁s 1 PR 1 s ▁; ▁my o cy te ▁; ▁c AMP ▁production ▁; ▁receptor s ▁; ▁regulator y ▁; ▁g - prote in - co up led ▁receptor ▁kina se -2
D-1408	-0.3801872134208679	β1ARs ; s1PR1s ; myocyte ; cAMP production ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
P-1408	-3.2103 -1.1343 -0.3449 -0.2988 -0.2513 -0.4359 -0.3518 -0.1616 -1.3349 -0.2021 -0.2110 -0.5782 -0.0893 -0.0655 -0.0379 -0.0953 -0.2069 -0.0606 -0.2550 -0.3313 -1.7994 -0.2955 -0.2371 -0.3805 -0.0225 -1.1607 -0.5759 -0.0511 -0.0430 -0.0883 -0.0232 -0.0080 -0.0121 -0.1857 -0.0180 -0.0490 -0.0177 -0.2326 -0.2587 -0.0918
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up ; paf-cpt ; paf ; lyso-paf-at ; downregulated ; paf-ah ; lp-pla2 ; elevated
H-1270	-0.6771915555000305	▁pa f - c pt ▁; ▁PA f ▁; ▁lys o - pa f - AT ▁; ▁pa f - AH ▁; ▁l p - PLA 2
D-1270	-0.6771915555000305	paf-cpt ; PAf ; lyso-paf-AT ; paf-AH ; lp-PLA2
P-1270	-3.1871 -0.9970 -0.0780 -0.4223 -1.2972 -0.0719 -1.1701 -1.9356 -0.8037 -0.6528 -0.0458 -0.0241 -0.6083 -0.8246 -0.2494 -0.9308 -0.1829 -3.3426 -1.2369 -0.0854 -0.3979 -0.1969 -0.2399 -0.0121 -0.0213 -0.0042 -0.0708 -0.4316 -0.1172
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients ; heart failure ; ejection fraction ; cardiac rehabilitation ; walking ; exercise
H-570	-0.43920278549194336	▁heart ▁failure ▁; me an ▁e je ction ▁ fraction ▁; ▁cardiac ▁rehabilita tion ▁; ▁Nordic ▁walking
D-570	-0.43920278549194336	heart failure ;mean ejection fraction ; cardiac rehabilitation ; Nordic walking
P-570	-2.8483 -0.1066 -0.1560 -0.8235 -0.0825 -0.0123 -0.0770 -0.0139 -0.2478 -0.0018 -0.1502 -1.2056 -0.0417 -0.3224 -0.7200 -0.4367 -0.5887 -0.4212 -0.0885
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
H-1836	-0.5423420667648315	▁d RS - stra t ified ▁hazard ▁ratio s ▁; ▁ci ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁ci ▁; ▁si tag lip tin ▁; ▁sul fon yl ure as ▁; ▁insulin
D-1836	-0.5423420667648315	dRS-stratified hazard ratios ; ci ; sitagliptin ; pioglitazone ; ci ; sitagliptin ; sulfonylureas ; insulin
P-1836	-0.4451 -0.3941 -0.0362 -0.0088 -0.0270 -0.0358 -0.3577 -0.0636 -0.0930 -0.1620 -1.6478 -0.5507 -1.6816 -0.1095 -0.1418 -1.9703 -0.7539 -0.2469 -0.0603 -0.0984 -0.0795 -0.1082 -1.1841 -0.5965 -1.5657 -0.1842 -0.1263 -1.9034 -0.5662 -0.1291 -0.0161 -0.0914 -0.2567 -0.0528 -0.1680 -4.4436 -0.1308 -0.1218
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal muscle ; t-score ; fontan ; sarcopenic range muscle wasting ; t-score ; clinically ; t-score
H-1501	-0.6766343116760254	▁skelet al ▁muscle ▁mass ▁; ▁t - s core ▁; ▁Font an ▁; ▁sar co pen ic ▁range ▁; ▁muscle ▁was ting ▁; ▁t - s core
D-1501	-0.6766343116760254	skeletal muscle mass ; t-score ; Fontan ; sarcopenic range ; muscle wasting ; t-score
P-1501	-0.1332 -0.0120 -0.4865 -0.3228 -0.7291 -1.1294 -0.0537 -0.0815 -0.1614 -0.1205 -6.0879 -0.0222 -0.2403 -1.1642 -0.0268 -0.1469 -0.6501 -0.0097 -1.3479 -1.5846 -1.8758 -0.1009 -0.2685 -1.4539 -0.0315 -0.0676 -0.1582 -1.0886 -0.0667
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise ; testosterone ; baseline ; peak oxygen uptake ; beck depression inventory ; leg ; medical outcomes study short-form ; quality of life ; exercise ; placebo
H-1323	-0.33415481448173523	▁testosteron e ▁group ▁; ▁oxygen ▁up take ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁leg ▁strength ▁; ▁Medical ▁Out com es ▁Study ▁Short - Form ▁quality ▁of ▁life ▁domain s
D-1323	-0.33415481448173523	testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes Study Short-Form quality of life domains
P-1323	-0.5763 -0.0356 -0.7770 -0.1288 -0.4663 -1.5218 -0.0620 -0.0685 -0.0520 -0.2887 -0.0265 -0.4265 -0.0540 -0.0211 -0.1076 -0.2554 -0.3172 -0.1346 -0.4329 -0.2442 -0.0386 -0.0161 -0.3680 -0.2336 -0.0204 -0.2581 -0.0843 -0.4600 -0.2786 -0.8518 -0.0639 -2.2417 -0.1149
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker ; uptitrations ; composite end-point ; all-cause mortality ; hf ; readmissions ; hfref ; hazard ratio ; confidence interval
H-181	-0.5769514441490173	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁all - ca use ▁mortal ity ▁; ▁ HF ▁read missions ▁; ▁h Fr EF ▁; haz ard ▁ratio ▁; HR
D-181	-0.5769514441490173	RAS- ; β-blocker uptitrations ; all-cause mortality ; HF readmissions ; hFrEF ;hazard ratio ;HR
P-181	-1.0484 -0.0110 -0.0423 -2.3179 -0.0241 -0.0268 -0.0877 -0.0226 -3.3071 -0.1246 -0.7158 -0.1992 -0.2989 -2.9187 -0.0103 -0.0063 -0.0781 -0.0223 -0.8199 -0.0523 -0.2955 -0.1568 -1.6093 -0.2046 -0.1633 -0.7086 -0.3311 -0.8566 -0.1964 -0.3664 -0.0073 -0.0037 -0.1029 -1.6853 -1.8390 -0.1091
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients ; heart failure ; outcomes ; exercise ; training ; hf-action ; exercise ; perceived social support score ; psss ; barriers to exercise score ; btes
H-1927	-0.43252110481262207	▁Heart ▁Fail ure ▁; ▁tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - ac TION ▁; ▁social ▁support ▁; ▁barrier s ▁to ▁exercise ▁score ▁; ▁b tes
D-1927	-0.43252110481262207	Heart Failure ; trial Investigating Outcomes of Exercise Training ;HF-acTION ; social support ; barriers to exercise score ; btes
P-1927	-2.0942 -0.2452 -0.1927 -0.2039 -1.6974 -0.0396 -0.1851 -0.0412 -0.2527 -0.0538 -0.0204 -0.5141 -0.3214 -0.0344 -0.2401 -0.3007 -0.2770 -0.0154 -0.4755 -1.0625 -0.2417 -1.1275 -0.2966 -0.2176 -0.6273 -0.0183 -0.0517 -0.1579 -0.8137 -0.3542 -2.0807 -0.1764 -0.1914 -0.0834
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable analysis ; st2 ; death ; hospitalization ; hazard ratio ; cardiovascular death ; hf ; hospitalization ; hazard ratio ; all-cause mortality ; hazard ratio ; hazard ratios
H-703	-0.5016748309135437	▁ST 2 ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; haz ard ▁ratio ▁; ▁all - ca use ▁mortal ity ▁; ▁hazard ▁ratio s ▁; ▁log 2
D-703	-0.5016748309135437	ST2 ; cardiovascular death ; HF hospitalization ;hazard ratio ; all-cause mortality ; hazard ratios ; log2
P-703	-1.1276 -0.2037 -0.4156 -2.4537 -0.6500 -0.0706 -0.4341 -0.1057 -0.5691 -0.8491 -0.1659 -0.1971 -0.0120 -0.0323 -0.4015 -0.9048 -0.0248 -0.0046 -0.0516 -0.0086 -1.0738 -0.3373 -2.5239 -0.0792 -0.3171 -0.8589 -0.0246 -0.1708 -0.8305 -0.1517
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients ; new york heart association class i ; fontan ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dxa ; calf ; muscle ; magnetic resonance spectroscopy ; healthy
H-1495	-0.31248506903648376	▁New ▁York ▁Heart ▁association ▁; ▁Font an ▁adults ▁; ▁cardio pul mon ary ▁exercise ▁testing ▁; ▁lean ▁mass ▁quant ification ▁; ▁dual ▁x - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁cal f ▁muscle ▁; ▁magnetic ▁res on ance ▁spec tros copy
D-1495	-0.31248506903648376	New York Heart association ; Fontan adults ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
P-1495	-2.0491 -0.5273 -1.9824 -0.7745 -0.9766 -0.4507 -0.0301 -0.2465 -0.1205 -0.0027 -0.2954 -1.0062 -0.2826 -0.2638 -0.4959 -0.1103 -0.0023 -0.1466 -0.1078 -0.0734 -0.1878 -0.0478 -0.0402 -0.0448 -0.1441 -0.0237 -0.2719 -0.3283 -0.1079 -0.2095 -0.2407 -0.1732 -0.0742 -0.0559 -0.0110 -0.0076 -0.0368 -0.1234 -0.2000 -0.1569 -0.1940 -0.2704 -0.3618 -0.0205 -0.6414 -0.6989 -0.0690
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo ; dopamine ; nesiritide ; bolus ; diuretic ; therapy ; renal function ; patients ; acute heart failure ; renal dysfunction
H-73	-0.4970126450061798	▁dop amine ▁; ▁nesi riti de ▁; ▁di ure tic ▁ therapy ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-73	-0.4970126450061798	dopamine ; nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
P-73	-2.8756 -0.0833 -0.0988 -3.5130 -0.0031 -0.0742 -0.0878 -2.2235 -0.4399 -0.5854 -0.3651 -0.0186 -0.2324 -0.0508 -0.5565 -0.4797 -0.1022 -0.0067 -0.1031 -0.0388 -0.2976 -0.0049 -0.1747 -0.2000 -0.2154 -0.0911
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized ; crt ; patients ; new york heart association class iii ; heart failure ; left ventricular ejection fraction ; qrs duration ; echocardiographic ; evidence ; left ventricular dyssynchrony
H-847	-0.5573131442070007	▁c RT ▁; ▁New ▁York ▁Heart ▁association ▁class ▁III ▁; ▁IV ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁; ▁QR s ▁; ▁e cho car dio graphic ▁; ▁left ▁vent ri cular ▁dys syn chron y
D-847	-0.5573131442070007	cRT ; New York Heart association class III ; IV heart failure ; left ventricular ejection ; QRs ; echocardiographic ; left ventricular dyssynchrony
P-847	-1.5977 -3.0847 -0.1692 -2.5119 -0.7832 -0.8366 -1.0145 -1.4084 -0.1130 -0.4612 -2.3934 -0.3008 -0.1101 -0.0919 -0.0403 -0.0464 -0.8767 -0.2105 -0.1747 -0.1115 -0.0419 -0.9953 -0.0265 -0.5760 -0.7851 -0.1103 -0.0208 -0.0258 -0.0693 -0.1177 -0.8935 -0.2191 -0.0743 -1.2554 -0.3727 -0.0905 -0.0276 -0.0027 -0.4574 -0.2531 -0.0983
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients ; left ventricular ; ejection fraction ; stable hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
H-482	-0.16388404369354248	▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁right - side d ▁cardiac ▁cat heter ization ▁; ▁trans t hora cic ▁e cho card i ography ▁; ▁transmit ral ▁flow ▁veloci ties ▁; ▁mit ral ▁ann ulus ▁veloci ties ▁; ▁sy stol e ▁; ▁dia stol e
D-482	-0.16388404369354248	left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
P-482	-0.1136 -0.0724 -0.4662 -0.1157 -0.1880 -0.0674 -0.1466 -0.2050 -0.0240 -0.0141 -0.4966 -0.0052 -0.1589 -1.3245 -0.2870 -0.1137 -1.0753 -0.0281 -0.1413 -0.0193 -0.0096 -0.2652 -0.0071 -0.2955 -0.0685 -0.0012 -0.0843 -0.0071 -0.0212 -0.0779 -0.1132 -0.1024 -0.1211 -0.1507 -0.1257 -0.0086 -0.2154 -0.0699 -0.4187 -0.0096 -0.0827 -0.0770 -0.0282 -0.1484 -0.0281 -0.3593 -0.0056 -0.1370 -0.0555 -0.0053 -0.2363 -0.1890 -0.0081 -0.0082 -0.3496 -0.3227 -0.0641
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients ; acute coronary syndromes ; patients ; stable ; cad ; bnp ; nt-probnp ; cad ; prognostic ; clinical ; outcome
H-1367	-0.4365021884441376	▁a cute ▁corona ry ▁syndrome s ▁; ▁CAD ▁; ▁b NP ▁; ▁NT - pro b NP ▁levels ▁; ▁CAD
D-1367	-0.4365021884441376	acute coronary syndromes ; CAD ; bNP ; NT-probNP levels ; CAD
P-1367	-0.1030 -0.0048 -0.0878 -0.6183 -0.0031 -0.0517 -0.3362 -0.9763 -0.7566 -3.1255 -0.2007 -0.1269 -0.2226 -0.0339 -0.0057 -0.5672 -0.1386 -1.1783 -0.3368 -0.1801 -0.4313 -0.1176
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline ; patients ; hf ; lyso-paf-at ; paf-cpt ; paf ; paf-ah ; lp-pla2
H-1269	-0.5113416910171509	▁ HF ▁; ▁lys o - pa f - AT ▁; ▁PA f - c pt ▁; ▁PA f ▁levels ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1269	-0.5113416910171509	HF ; lyso-paf-AT ; PAf-cpt ; PAf levels ; PAf-AH ; lp-PLA2
P-1269	-1.3046 -0.0443 -0.1880 -0.5508 -0.0309 -0.0342 -0.8166 -0.9021 -0.1349 -0.6657 -0.0814 -1.0630 -1.3709 -0.0547 -0.9251 -1.1795 -0.1009 -0.7390 -1.5204 -1.7148 -0.1079 -1.1756 -0.9929 -0.0437 -0.1777 -0.1563 -0.2018 -0.0123 -0.0271 -0.0019 -0.0505 -0.3910 -0.1138
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical therapy ; patients ; redo sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; patients ; transcatheter aortic valve procedure ; surgery ; aortic valve
H-549	-0.23541006445884705	▁redo ▁ster no to my ▁; ▁a or tic ▁val ve ▁procedure s ▁; ▁bio pro sthetic ▁val ve ▁replace ment ▁; ▁da cro n ▁patch ▁ closure ▁; ▁a or tic ▁val ve ▁repair s ▁; ▁trans cat heter ▁a or tic ▁val ve ▁procedure ▁; ▁open ▁surgery ▁; ▁a or tic ▁val ve ▁replace ment
D-549	-0.23541006445884705	redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
P-549	-2.1231 -0.4775 -0.0392 -0.0986 -1.0551 -0.2766 -0.0085 -0.0253 -0.9770 -0.2306 -0.0491 -0.4492 -0.1658 -0.1538 -0.0019 -0.0455 -0.0150 -0.3458 -0.0454 -0.9065 -0.1637 -0.1450 -0.3061 -0.0024 -0.0099 -0.0137 -0.1497 -0.0019 -0.1347 -0.0143 -0.0261 -0.3400 -0.1028 -0.0860 -0.3505 -0.1575 -0.2713 -0.0031 -0.0531 -0.0014 -0.1077 -0.0315 -0.7040 -0.1143 -0.0570 -0.3393 -0.2743 -0.1161 -0.0659 -0.4058 -0.0150 -0.0206 -0.6731 -0.1201 -0.1166 -0.3319 -0.2446 -0.2369 -0.0918
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma n-terminal pro-b-type natriuretic peptide ; nt-probnp ; patients ; acute heart failure ; hf ; admission ; emergency department
H-263	-0.37102165818214417	▁cut off ▁value ▁; ▁plasma ▁N - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁a cute ▁heart ▁failure ▁; HF ▁; ▁emergency ▁department ▁; ED
D-263	-0.37102165818214417	cutoff value ; plasma N-terminal pro-b-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ;ED
P-263	-2.0126 -0.0647 -1.0964 -0.0721 -0.0554 -2.3035 -0.0165 -0.0133 -0.0045 -0.0348 -0.0143 -1.0669 -0.0268 -0.0018 -0.0043 -0.3387 -0.4515 -1.5107 -0.8028 -0.0928 -0.1532 -0.1551 -0.5788 -0.0057 -0.0081 -0.3426 -0.1266 -0.2565 -1.1794 -0.0456 -0.2194 -0.0630 -0.1698 -0.2879 -0.4533 -0.3324 -0.0275 -0.5228 -0.1265 -0.0806 -0.0927
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac troponin t ; ctnt ; n-terminal pro-b-type natriuretic peptide ; nt-probnp ; biomarkers ; hf ; hf ; atherosclerosis risk in communities ; aric
H-286	-0.2832590639591217	▁cardiac ▁trop onin ▁T ▁; ▁c t n t ▁; ▁high - sensitiv ity ▁as say ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁bio mark ers ▁; ▁incident ▁ HF ▁; ▁ HF ▁risk ▁predict ion ▁; ▁Ath eros cle rosi s ▁Risk ▁in ▁Communi ties ▁; ARI c
D-286	-0.2832590639591217	cardiac troponin T ; ctnt ; high-sensitivity assay ; n-terminal pro-b-type natriuretic peptide ;NT-probNP ; biomarkers ; incident HF ; HF risk prediction ; Atherosclerosis Risk in Communities ;ARIc
P-286	-0.0076 -0.0403 -0.0501 -1.4447 -0.1615 -0.6686 -0.0464 -0.0124 -0.3022 -0.1537 -2.8251 -0.0099 -0.0005 -0.2222 -0.0179 -0.0137 -0.0540 -1.3293 -0.0118 -0.0377 -0.0024 -0.0672 -0.0104 -1.2405 -0.0161 -0.0019 -0.0018 -0.2587 -0.2281 -1.2835 -0.4042 -0.1658 -0.2097 -0.1616 -1.0525 -0.0047 -0.0099 -0.2977 -0.1121 -0.0833 -0.1359 -0.0248 -0.0469 -0.1572 -0.0434 -0.1865 -0.0826 -0.0662 -0.7901 -0.1239 -1.3929 -0.5317 -0.0156 -0.0885 -0.0431 -0.0421 -0.4833 -0.0637 -0.0192 -0.0964 -0.2845 -0.1506 -0.0046 -0.2758 -0.0436 -0.8256 -0.1262 -0.0954
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body mass index ; fat mass ; fat-free mass
H-1167	-1.0482405424118042	▁body ▁mass ▁index ▁; HR ▁per ▁kg / m ▁; ▁fat ▁mass ▁; ▁fat - free ▁mass ▁index
D-1167	-1.0482405424118042	body mass index ;HR per kg/m ; fat mass ; fat-free mass index
P-1167	-3.9641 -0.7663 -0.0264 -0.3234 -1.9308 -2.8046 -0.1625 -1.2575 -0.1253 -1.1040 -2.8847 -1.9305 -0.7737 -1.8283 -0.2772 -0.1120 -0.2380 -0.0493 -0.2894 -0.1168
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile range ; body mass index ; interquartile range ; copd ; chf ; crf
H-797	-0.7333669662475586	▁men ▁; inter quart ile ▁range ▁; ▁media n ▁body ▁mass ▁index ▁; inter quart ile ▁range ▁; ▁COP d ▁; ▁CHF ▁; ▁c RF
D-797	-0.7333669662475586	men ;interquartile range ; median body mass index ;interquartile range ; COPd ; CHF ; cRF
P-797	-5.7554 -0.1733 -1.6288 -0.0756 -0.0075 -0.0273 -0.3130 -1.0158 -0.0179 -0.6913 -0.2229 -0.0135 -0.3359 -0.9150 -0.0499 -0.0061 -0.0313 -0.2702 -4.3235 -1.9044 -0.1070 -0.0188 -0.3262 -0.3580 -0.8151 -0.1857 -0.2116
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse remodeling ; ejection fraction ; mortality ; all-cause hospitalizations ; hf ; hospitalizations ; dialysis ; patients
H-911	-0.3972713053226471	▁rever se ▁remodel ing ▁; ▁e je ction ▁ fraction ▁; ▁mortal ity ▁; ▁ HF ▁hospital ization s ▁; ▁di al ysis ▁patients
D-911	-0.3972713053226471	reverse remodeling ; ejection fraction ; mortality ; HF hospitalizations ; dialysis patients
P-911	-0.1307 -0.0430 -0.0335 -0.0293 -0.1340 -0.0149 -0.0453 -0.0193 -0.2631 -0.0032 -0.1672 -0.3743 -0.9347 -0.2365 -3.7060 -0.5489 -1.2660 -0.6841 -0.1098 -0.2853 -0.3359 -0.0158 -0.0454 -0.6988 -0.1235 -0.0804
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates ; lv contractility ; lvef ; β coefficient ; confidence interval ; systolic blood pressure ; end-systolic volume ; β coefficient
H-1530	-0.9152213931083679	▁EH ▁; ▁LV ▁contract ility ▁; ▁CH ▁; ▁LV EF ▁; ▁confidence ▁interval ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁end - sy sto lic ▁volume
D-1530	-0.9152213931083679	EH ; LV contractility ; CH ; LVEF ; confidence interval ; systolic blood pressure ; end-systolic volume
P-1530	-0.2927 -0.0636 -2.0647 -0.0287 -0.0122 -0.0778 -5.2090 -0.1945 -1.2601 -0.4193 -0.0682 -7.4287 -0.0271 -0.0458 -1.6117 -0.0372 -0.0467 -0.2921 -0.2581 -0.3571 -2.6385 -0.0481 -0.4355 -0.2170 -0.0939 -0.0855 -2.2002 -0.1120
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography ; dilated lv ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mva
H-348	-0.31383073329925537	▁e cho card i ography ▁; ▁dil ated ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁m L / m 2 ▁; ▁LV ▁e je ction ▁ fraction ▁; ▁mild ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁MS ▁; ▁m VA ▁; ▁pressure ▁gradi ent
D-348	-0.31383073329925537	echocardiography ; dilated LV ; end-diastolic volume index ; mL/m2 ; LV ejection fraction ; mild MR ; mitral valve opening ; MS ; mVA ; pressure gradient
P-348	-0.4025 -0.0260 -0.2304 -0.2761 -0.1076 -0.0803 -1.8853 -0.0689 -0.3132 -0.1094 -0.7343 -0.0190 -0.0166 -0.0372 -0.0095 -0.0267 -0.0346 -0.0908 -2.2465 -0.4960 -2.0390 -0.1751 -0.0180 -0.0580 -0.7849 -0.2826 -0.0345 -0.0118 -0.4717 -0.0031 -0.0995 -0.3319 -0.0122 -0.1113 -0.2014 -0.0099 -0.0320 -0.0332 -0.0899 -0.1432 -0.2576 -0.2369 -0.1432 -1.0888 -0.1524 -0.3555 -0.0036 -0.0183 -1.2127 -0.0682
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind ; clinical ; renal optimization strategies evaluation ; rose ; hospitalized ; patients ; acute heart failure ; renal dysfunction ; estimated glomerular filtration rate ; randomized ; admission
H-74	-0.3491472601890564	▁re nal ▁Optim ization ▁strategie s ▁Evalua tion ▁; ROS e ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁glo mer ular ▁filtr ation ▁rate
D-74	-0.3491472601890564	renal Optimization strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate
P-74	-3.9995 -0.2052 -0.5539 -0.2483 -0.7213 -0.0095 -0.3678 -0.1707 -0.2025 -0.0672 -0.1087 -0.2529 -0.4043 -0.0047 -0.2125 -0.0457 -0.1450 -0.0026 -0.0517 -0.0764 -0.2730 -0.0136 -0.0838 -0.0254 -0.0687 -0.1339 -0.6308 -0.9464 -0.0992
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets ; signal transduction ; pol ii ; transcription factor ; hf ; pathogenesis ; nuclear factor of activated t cells ; nfat ; nuclear factor-κb ; nf-κb ; transcription factor ; gata4
H-1051	-0.2973335385322571	▁ BET s ▁; ▁chr omat in - media ted ▁signal ▁trans duction ▁; ▁Pol ▁II ▁; ▁co - activa ting ▁tran scription ▁factor ▁network s ▁; ▁ HF ▁path ogen es is ▁; ▁nuclear ▁factor ▁of ▁activa ted ▁T ▁cell s ▁; ▁n FAT ▁; ▁nuclear ▁factor - κ b ▁; NF - κ b ▁; ▁tran scription ▁factor
D-1051	-0.2973335385322571	BETs ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; nFAT ; nuclear factor-κb ;NF-κb ; transcription factor
P-1051	-1.9825 -0.3641 -0.3153 -0.2912 -0.0937 -0.0041 -0.2852 -0.0436 -0.0362 -0.0764 -0.1192 -0.0096 -0.1526 -1.0321 -0.9422 -0.0996 -0.2287 -1.2763 -0.0081 -0.0111 -0.0440 -0.0369 -0.0513 -0.0417 -0.8321 -0.0880 -0.2114 -0.5085 -0.2963 -0.1265 -0.1025 -0.0415 -0.1347 -0.1640 -0.0162 -0.0267 -1.0138 -0.0011 -0.0278 -0.6151 -0.1161 -0.0218 -0.1897 -1.6115 -0.1562 -0.0358 -0.0662 -0.0755 -0.2106 -0.3194 -0.3756 -0.0596 -0.5609 -0.0508 -0.2371 -0.2835 -0.1907 -0.0649 -0.1430 -0.0565 -1.7426 -0.1144
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes ; mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
H-33	-0.3264867663383484	▁mortal ity ▁; ▁hospital ization ▁; ▁exercise ▁ tolerance ▁; ▁quality ▁of ▁life ▁; ▁cardiovascular ▁events ▁; ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁ex ace rb ation ▁; ▁ar rhythm ia ▁; ▁cardiac ▁death ▁; ▁hyper tension ▁; ▁ve nous ▁ thro mbol ic ▁events ▁; ▁ ische mic ▁cerebro vas cular ▁events
D-33	-0.3264867663383484	mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thrombolic events ; ischemic cerebrovascular events
P-33	-5.5618 -0.6493 -0.0331 -0.1619 -0.3299 -0.0315 -0.0950 -0.0625 -0.0005 -0.0292 -0.4793 -0.2764 -0.4029 -0.0726 -0.0290 -0.2524 -0.0904 -0.5422 -0.1116 -0.2124 -0.1361 -0.0194 -0.1130 -0.0736 -0.1343 -0.0074 -0.0803 -0.4200 -0.3246 -0.0484 -0.3529 -0.0180 -0.0022 -0.1280 -0.1721 -0.0034 -0.0305 -0.8370 -0.1423 -0.0157 -0.3615 -0.2636 -0.4932 -0.0171 -0.0797 -0.2434 -0.0380 -0.1473 -0.1210 -0.7400 -1.2239 -0.7203 -0.2575 -0.3020 -0.0154 -0.1867 -0.0479 -0.0367 -0.4038 -1.7325 -0.2225 -0.1050
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular mortality ; multivariable adjustment ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-562	-0.7192996144294739	▁all - ca use ▁; ▁cardiovascular ▁mortal ity
D-562	-0.7192996144294739	all-cause ; cardiovascular mortality
P-562	-2.3325 -0.0482 -0.0194 -0.0940 -0.4836 -0.0070 -0.0567 -1.3173 -2.7397 -0.0946
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus ; diabetes ; patients ; diabetes ; peak vo2 ; patients ; diabetes ; eo-cfus ; peak vo2
H-128	-0.880115807056427	▁interaction ▁effect ▁; ▁ EO - c FU s ▁; ▁diabetes ▁; ▁patients ▁without ▁diabetes ▁; ▁10- EO - c FU ▁; ▁ EO - c FU ▁; ▁VO 2
D-128	-0.880115807056427	interaction effect ; EO-cFUs ; diabetes ; patients without diabetes ; 10-EO-cFU ; EO-cFU ; VO2
P-128	-2.9949 -0.0156 -0.1222 -0.8786 -0.1510 -0.0360 -1.3007 -0.5460 -0.2682 -0.2455 -0.0415 -0.1358 -4.1643 -0.9224 -0.0282 -0.0886 -2.5049 -0.0544 -0.0450 -1.4802 -0.1441 -0.3830 -4.0241 -0.2311 -0.0400 -1.3498 -0.3439 -1.2696 -3.5516 -0.0940 -0.5946 -0.1139
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting ; video edge detection ; epifluorescence microscopy ; myocardial tissues ; cardiomyocytes ; hf
H-1212	-0.31163933873176575	▁immun o blo tting ▁; ▁radio en zy matic - ▁; ▁fluor esc ence ▁res on ance ▁; ▁energy ▁transfer - based ▁as say s ▁; ▁video ▁edge ▁det ection ▁; ▁epi flu o resc ence ▁micro s copy ▁; ▁l - type ▁ca 2 ( +) ▁; ▁my o card ial ▁tissu es ▁; ▁isola ted ▁cardio my o cy tes ▁; ▁experimental ▁ HF
D-1212	-0.31163933873176575	immunoblotting ; radioenzymatic- ; fluorescence resonance ; energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2(+) ; myocardial tissues ; isolated cardiomyocytes ; experimental HF
P-1212	-0.1910 -0.1201 -0.0234 -0.2784 -0.0810 -0.0390 -0.3000 -0.1810 -0.1971 -0.1548 -1.8380 -0.0043 -1.3332 -0.8704 -0.1484 -0.0641 -0.3705 -1.3744 -0.7968 -0.1264 -0.0834 -0.0232 -0.0384 -0.0291 -0.0946 -0.1126 -0.2512 -0.0289 -0.1539 -0.0854 -0.1152 -0.0670 -0.0165 -0.2503 -0.0843 -0.6149 -0.0148 -0.0625 -0.2218 -0.1340 -0.5717 -0.0117 -0.0031 -0.7557 -0.0344 -2.5260 -0.0029 -1.0580 -0.7083 -0.0407 -0.1322 -0.1404 -0.0220 -0.0438 -0.0586 -0.2992 -0.0099 -0.0136 -0.4284 -0.1475 -0.0893 -0.0257 -0.1232 -2.4439 -0.2431 -0.1284 -0.0904 -0.0649
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east ; early treatment of atrial fibrillation for stroke prevention trial ; randomize ; patients ; stroke ; rhythm control therapy ; prospective ; randomized ; outcome
H-1649	-0.5556820034980774	▁e ast ▁; ▁At rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁tri al ▁; ▁AF ▁at ▁risk ▁; ▁stroke ▁; CHA 2 DS 2 VAS c ▁score ▁; ▁guide line - manda ted ▁usual ▁care ▁; ▁early ▁ rhythm ▁control ▁ therapy
D-1649	-0.5556820034980774	east ; Atrial fibrillation ; Stroke prevention trial ; AF at risk ; stroke ;CHA2DS2VASc score ; guideline-mandated usual care ; early rhythm control therapy
P-1649	-0.5517 -0.2909 -0.0730 -4.4993 -0.0283 -0.1910 -0.0119 -0.0300 -0.6804 -0.4703 -0.0480 -0.0728 -0.0050 -0.6621 -0.0118 -0.3679 -0.3471 -2.6527 -0.0465 -1.0517 -0.1951 -0.4405 -1.7600 -0.0630 -1.2780 -0.1406 -0.1686 -0.1044 -0.4278 -0.5308 -4.1188 -0.0030 -0.0658 -0.0024 -0.0223 -0.1391 -0.7271 -0.0700 -1.8220 -0.0269 -0.0936 -0.1287 -0.3463 -0.0112 -0.6999 -0.0828
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes ; exercise capacity ; peak oxygen consumption ; vo2 ; co-primary outcome ; qol ; minnesota ; heart failure ; heart ; qol ; co-primary outcome
H-1980	-0.5198803544044495	▁Exerci se ▁capacity ▁; ▁pe ak ▁oxygen ▁consum p tion ▁; VO 2 ▁; ▁m L / kg / min ▁; ▁Q OL ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁; ML HF ▁; ▁heart ▁failure - related ▁Q OL
D-1980	-0.5198803544044495	Exercise capacity ; peak oxygen consumption ;VO2 ; mL/kg/min ; QOL ; Minnesota Living with Heart Failure ;MLHF ; heart failure-related QOL
P-1980	-1.5382 -0.0930 -0.0865 -0.1386 -1.8619 -0.0086 -0.2634 -0.0629 -0.0598 -0.3390 -0.0989 -0.2072 -0.0655 -0.1837 -0.1749 -1.4964 -0.6520 -0.4296 -0.5560 -0.0891 -0.0701 -1.3809 -0.2791 -0.0865 -0.0599 -0.0901 -0.4919 -0.1919 -0.2048 -1.1230 -0.1361 -0.9729 -0.5300 -0.5009 -5.4537 -0.2937 -0.2164 -0.0536 -0.6865 -0.3063 -0.2026 -0.0988
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic ; mitochondrial-targeted peptide ; ss31 ; mitochondrial function ; tac ; clinical ; mitochondrial-targeted peptide ; drugs ; heart failure
H-878	-0.3134002089500427	▁ TAC - indu ced ▁prote om ic ▁altera tions ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁SS 31 ▁; ▁per tur bed ▁mito cho ndri al ▁function ▁; ▁ TAC ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁drugs ▁; ▁heart ▁failure
D-878	-0.3134002089500427	TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
P-878	-0.7905 -0.0355 -0.0501 -0.0261 -0.1552 -0.0694 -0.0818 -0.3014 -0.4591 -0.1301 -0.1578 -0.3418 -0.6719 -0.4938 -0.0310 -0.0528 -0.0862 -0.0593 -0.0156 -0.8751 -0.0986 -0.1447 -0.5573 -0.2071 -0.1849 -0.1820 -0.0113 -0.4928 -0.3191 -0.5168 -0.2214 -0.0134 -0.1276 -0.2507 -2.0255 -0.1978 -0.1172 -1.2160 -0.2711 -0.9258 -0.0316 -0.0454 -0.1170 -0.0727 -0.0128 -1.4067 -0.0646 -0.0860 -0.2874 -0.3441 -1.2298 -0.1003 -0.0889 -0.0707
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients ; left ventricular ejection fraction ; patients ; hf ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; epidemic ; medical ; financial costs
H-55	-0.6005739569664001	▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁patients ▁; ▁ HF ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁hospital ▁; ▁physician s ▁; ▁a cute ▁; ▁out patient ▁setting s
D-55	-0.6005739569664001	low left ventricular ejection fraction ; patients ; HF ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient settings
P-55	-2.4741 -1.1391 -0.1659 -1.0099 -0.6881 -0.1653 -0.1809 -0.0655 -0.7636 -0.0048 -0.1136 -0.4164 -1.2110 -1.4697 -0.0318 -1.3520 -0.8404 -0.0167 -0.2857 -0.1240 -0.0833 -1.1458 -0.4681 -0.1598 -0.1561 -0.0756 -0.5541 -0.0049 -0.3318 -0.5460 -0.1639 -0.2583 -0.0328 -0.4885 -3.2284 -0.0009 -0.7844 -0.2236 -0.0058 -1.2865 -0.0210 -3.1845 -0.1018
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf ; patients ; hfref ; left ventricular ; ejection fraction ; hfpef ; echo-doppler ; n-terminal pro-brain-type natriuretic peptide ; adverse events
H-494	-0.3502786159515381	▁ HF ▁patients ▁; HF r EF ▁; ▁pres er ved ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁e cho - D opp ler ▁studies ▁; ▁n - termin al ▁pro - bra in - type ▁na tri ure tic ▁pe pti de ▁assessment
D-494	-0.3502786159515381	HF patients ;HFrEF ; preserved left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; n-terminal pro-brain-type natriuretic peptide assessment
P-494	-0.8914 -0.0914 -0.5401 -0.3596 -2.0515 -1.1848 -0.1117 -0.0659 -1.3567 -0.0207 -0.2666 -0.1561 -0.0576 -0.7719 -0.1254 -0.2329 -0.2461 -0.3135 -0.0386 -0.0432 -0.0161 -0.2220 -0.0042 -0.1275 -0.1549 -0.7551 -0.1342 -0.1157 -0.0936 -0.0277 -0.0151 -0.7106 -0.0137 -0.3398 -0.0824 -0.0871 -2.3091 -0.0066 -0.0115 -0.0026 -0.0236 -0.0142 -0.1414 -0.0317 -0.0128 -0.0013 -0.0121 -0.0896 -0.3348 -2.0227 -0.9052 -0.0739 -0.1613 -0.8790 -0.6368 -0.1199
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds ; comorbidities ; hospitalized ; adjusted odds ratio ; aor ; confidence interval ; eds ; aor
H-464	-0.5946446061134338	▁low - volu me ▁ED s ▁; ▁como rbi di ties ▁; ▁hospital ized ▁; ▁medium ▁; ▁adjust ed ▁odds ▁ratio ▁; ▁a OR
D-464	-0.5946446061134338	low-volume EDs ; comorbidities ; hospitalized ; medium ; adjusted odds ratio ; aOR
P-464	-1.2680 -0.0400 -0.0186 -0.0709 -0.4844 -0.0879 -0.2513 -1.9021 -0.0009 -0.1269 -0.0531 -0.1904 -0.4990 -0.4834 -0.2754 -0.3017 -0.3102 -5.2278 -0.0381 -0.0178 -0.0182 -0.1188 -0.4914 -0.0906 -2.9788 -0.1151
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients ; cardiac transplant ; ecct ; patients ; diabetes mellitus ; chronic kidney disease ; estimated glomerular filtration rate
H-715	-0.2711549997329712	▁cardiac ▁transplant ▁; ▁EC CT ▁patients ▁; ▁diabetes ▁mell itus ▁; ▁chronic ▁ki dne y ▁disease ▁; ▁glo mer ular ▁filtr ation ▁rate
D-715	-0.2711549997329712	cardiac transplant ; ECCT patients ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
P-715	-0.1251 -0.0561 -0.1789 -0.8343 -0.2427 -0.9415 -0.2993 -0.2355 -0.0009 -0.0172 -0.1339 -0.1603 -0.0221 -0.1885 -0.0776 -0.3107 -0.1252 -0.0354 -0.0869 -0.0208 -0.1538 -0.2485 -1.3841 -0.7600 -0.1399
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc battery ; health abc hf risk model ; change ; c-index ; net-reclassification-improvement ; hf
H-631	-0.44634881615638733	▁h ABC ▁Bat tery ▁score s ▁; ▁Health ▁ABC ▁ HF ▁Risk ▁model ▁; ▁discrimina tion ▁; ▁c - index ▁; net - re class ification - improv ement ▁; ▁ HF
D-631	-0.44634881615638733	hABC Battery scores ; Health ABC HF Risk model ; discrimination ; c-index ;net-reclassification-improvement ; HF
P-631	-1.7476 -0.5872 -0.4199 -0.0056 -0.1658 -0.0283 -0.0889 -1.2569 -0.0800 -0.8272 -0.0707 -1.1632 -0.4821 -0.1500 -0.4282 -0.7321 -0.1720 -0.2559 -0.0622 -0.0107 -0.1926 -2.4772 -0.0279 -0.2085 -0.0444 -0.1992 -0.0977 -0.0117 -0.4915 -0.3090 -0.6327 -1.4862 -0.1916 -0.0709
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi ; rmsea ; self-care maintenance ; cfi ; rmsea ; self-care management ; cfi ; rmsea ; self-care confidence
H-1507	-0.576435387134552	▁c fi ▁; ▁RM se a ▁; ▁Self - Car e ▁Main ten ance ▁Scal e ▁; ▁c fi ▁; ▁RM se a ▁; ▁Self - Car e ▁management ▁Scal e ▁; ▁c fi ▁; ▁RM se a ▁; ▁Self - Car e ▁Confi den ce ▁scale
D-1507	-0.576435387134552	cfi ; RMsea ; Self-Care Maintenance Scale ; cfi ; RMsea ; Self-Care management Scale ; cfi ; RMsea ; Self-Care Confidence scale
P-1507	-1.6726 -1.3833 -0.0259 -1.1343 -0.7419 -0.4149 -0.0249 -0.7265 -0.0516 -1.8798 -0.1250 -1.1953 -0.2406 -0.2050 -0.1787 -0.0338 -0.0179 -0.1926 -1.5551 -0.0216 -0.8055 -0.6565 -0.3608 -0.0285 -0.4672 -0.0706 -1.9270 -0.1105 -0.4449 -0.3956 -0.0182 -0.0331 -0.5194 -2.0687 -0.0388 -1.5768 -0.6484 -0.3989 -0.0645 -0.6850 -0.0698 -2.0422 -0.1411 -1.3630 -0.1738 -0.3831 -0.5859 -0.1937 -0.1528
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients ; bat ; patients ; quality-of-life ; nyha functional class ; change
H-1876	-0.6182246208190918	▁BAT ▁; ▁quality - of - life ▁score ▁; ▁NY HA ▁functional ▁class ▁ranking
D-1876	-0.6182246208190918	BAT ; quality-of-life score ; NYHA functional class ranking
P-1876	-0.0767 -0.5066 -3.8006 -0.1118 -0.0305 -0.2306 -0.2836 -0.1618 -0.3369 -2.0421 -0.9010 -0.2024 -0.1044 -0.5151 -0.4582 -0.1295
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients ; preoperative ; hypoalbuminemia ; postoperative ; albumin ; hypoalbuminemia ; albumin ; lvad
H-537	-0.4253791868686676	▁hypo album in emia ▁; ▁post operativ e ▁normal ization ▁; ▁album in ▁levels ▁; ▁hypo album in emia ▁; ▁de cre as ing ▁album in ▁levels ▁; ▁l VAD
D-537	-0.4253791868686676	hypoalbuminemia ; postoperative normalization ; albumin levels ; hypoalbuminemia ; decreasing albumin levels ; lVAD
P-537	-2.7334 -0.1356 -0.2102 -0.0575 -0.1075 -0.1227 -0.1192 -0.0705 -1.3882 -0.5594 -0.8582 -0.1999 -0.2415 -0.3844 -0.2220 -0.7536 -0.1606 -0.2324 -0.1167 -0.1479 -1.3999 -0.0278 -0.1235 -0.1308 -0.9586 -0.2436 -0.7204 -0.3116 -0.1435 -0.0146 -0.6392 -0.0771
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization ; confidence interval ; acute myocardial infarction ; ami ; complications ; kidney infection ; urinary tract infection ; uti ; complications
H-1717	-0.5343354940414429	▁re hospital ization ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁ki dne y ▁infection ▁; ▁urin ary ▁tract ▁infection ▁; UTI
D-1717	-0.5343354940414429	rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
P-1717	-4.0678 -0.0102 -0.3968 -0.1665 -1.7895 -0.0193 -0.9647 -0.2073 -0.2656 -0.1937 -0.0237 -0.0673 -0.2014 -0.2133 -0.2148 -0.3181 -4.6092 -0.3569 -0.0343 -0.1260 -0.0595 -0.0021 -0.0905 -0.1037 -0.1291 -0.5468 -0.0071 -0.1805 -0.1301
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients ; heart failure ; hf ; ischemic ; nonischemic cardiomyopathies ; pharmacological ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
H-54	-0.27468064427375793	▁patients ▁with ▁heart ▁failure ▁; HF ▁; ▁ ische mic ▁; ▁non ische mic ▁cardio my o pathi es ▁; ▁ pharma c ological ▁arma ment arium ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cardiac ▁transplant ation ▁; ▁left ▁; ▁vent ri cular ▁assist ▁devices
D-54	-0.27468064427375793	patients with heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; ventricular assist devices
P-54	-2.7180 -1.8937 -0.6616 -0.0426 -0.2081 -0.0614 -0.1013 -0.9266 -0.0379 -0.0751 -0.4792 -0.0606 -0.0533 -0.2834 -0.1322 -0.5785 -0.2985 -0.0196 -0.1832 -0.2325 -0.9201 -0.0867 -0.0371 -0.1746 -0.0395 -0.0261 -0.0004 -0.0763 -0.1146 -0.0167 -0.3115 -0.0111 -0.1010 -0.0399 -0.0617 -0.2439 -0.0519 -0.1590 -0.1507 -0.0084 -0.0233 -0.0111 -0.0040 -0.3164 -0.5955 -0.0099 -0.1282 -0.0356 -0.0226 -0.0827 -0.1674 -0.0455 -1.1535 -1.2587 -0.2875 -0.0635 -0.2477 -0.1331 -0.1525 -0.0635
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf ; catheterization ; central venous pressure ; svr ; cardiac index
H-230	-1.5319569110870361	▁ SAF ▁; ▁ PF ▁; ▁ PF ▁; ▁centrale ▁ve nous ▁pressure ▁; ▁h g ▁; ▁s VR ▁index ▁; ▁dyn ▁s / cm (5) ▁; ▁cardiac ▁index
D-230	-1.5319569110870361	SAF ; PF ; PF ; centrale venous pressure ; hg ; sVR index ; dyn s/cm(5) ; cardiac index
P-230	-2.5840 -0.0923 -0.7164 -2.1557 -0.1179 -1.3881 -5.4099 -0.4178 -1.4920 -6.9966 -2.7598 -0.4404 -0.8519 -0.3364 -4.2539 -0.2798 -0.2007 -0.6134 -0.4807 -0.0551 -0.3834 -6.2401 -0.6526 -3.4356 -1.0726 -1.1202 -1.8459 -0.5247 -0.0512 -0.3511 -0.1706
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission ; bnp ; reduced ef ; preserved ef ; bnp ; ef
H-193	-0.9187960624694824	▁women ▁; ▁ad mission ▁media n ▁; ▁b NP ▁levels ▁; ▁reduce d ▁EF ▁; ▁pres er ved ▁EF ▁; ▁media n ▁b NP ▁; ▁women ▁; ▁men ▁; ▁EF
D-193	-0.9187960624694824	women ; admission median ; bNP levels ; reduced EF ; preserved EF ; median bNP ; women ; men ; EF
P-193	-3.2728 -0.1604 -2.0719 -0.9201 -0.0424 -0.0167 -1.5363 -0.9530 -0.3863 -2.1427 -0.1234 -2.2909 -0.0120 -0.4324 -0.0709 -2.1985 -0.0330 -0.1911 -0.8749 -0.1580 -2.0208 -0.0054 -1.1664 -0.3327 -0.1192 -3.5110 -0.4293 -0.3323 -0.2813 -0.8496 -2.3327 -0.1331
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart failure ; admission ; heart transplantation ; lv assist device ; death ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval ; ischemic ; functional class
H-435	-0.4551013112068176	▁heart ▁failure ▁ad mission ▁; ▁heart ▁transplant ation ▁; LV ▁assist ▁device ▁; ▁death ▁; haz ard ▁ratio
D-435	-0.4551013112068176	heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
P-435	-2.2531 -0.2320 -0.5293 -0.2154 -0.0705 -0.6466 -0.1819 -0.1671 -0.2764 -0.1201 -0.2844 -0.1226 -0.1662 -0.2351 -0.2656 -0.2099 -0.0071 -0.0984 -2.8942 -0.1261
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv ejection fraction ; shortening ; systolic elastance ; contractile efficiency ; acf ; acf ; allopurinol ; cardiomyocytes ; extracellular flux analyzer
H-475	-0.1460399627685547	▁e je ction ▁ fraction ▁; ▁veloci ty ▁; ▁circum fer ential ▁short en ing ▁; ▁sy sto lic ▁elastan ce ▁; ▁contract ile ▁efficiency ▁; ▁a cf ▁; ▁allo puri nol ▁rat s ▁; ▁o 2 ▁consum p tion ▁rate ▁; ▁isola ted ▁cardio my o cy tes ▁; ▁extra cel lular ▁flux ▁anal y zer
D-475	-0.1460399627685547	ejection fraction ; velocity ; circumferential shortening ; systolic elastance ; contractile efficiency ; acf ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
P-475	-0.3641 -0.0454 -0.0181 -0.2747 -0.0026 -0.0734 -0.2754 -0.0385 -0.7458 -0.0065 -0.4911 -0.1760 -0.0572 -0.0549 -0.0873 -0.1137 -0.2027 -0.0173 -0.0113 -0.0183 -0.3391 -0.0503 -0.0017 -0.0344 -0.1412 -0.0490 -0.3406 -1.0597 -0.0200 -0.1523 -0.0033 -0.0858 -0.0380 -0.0218 -0.1452 -0.8821 -0.0362 -0.0172 -0.1042 -0.1706 -0.2034 -0.0631 -0.5150 -0.0058 -0.0088 -0.3707 -0.0966 -0.0280 -0.0301 -0.1284 -0.0043 -0.0192 -0.0028 -0.0009 -0.0822 -0.0824 -0.0225 -0.1278 -0.0574
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively ; patients ; hfpef ; lv hypertrophy ; lvh ; relative wall thickness ; rwt ; lvh ; rwt ; lvh ; rwt ; lvh ; rwt
H-1526	-0.4119735658168793	▁ HF p EF ▁; ▁LV ▁structure ▁; ▁normal ▁ge ometr y ▁; ▁LV ▁hyper trop hy ▁; LV h ▁; ▁relative ▁wall ▁thi ck ness ▁; RW t ▁; ▁CR ▁; ▁LV h ▁; ▁r w t
D-1526	-0.4119735658168793	HFpEF ; LV structure ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rwt
P-1526	-1.0205 -0.1433 -0.0326 -0.1887 -0.1790 -1.0596 -1.5506 -0.1788 -0.8164 -0.0551 -0.0609 -0.1983 -0.0476 -0.9105 -0.6409 -0.0168 -0.3261 -0.0479 -0.3272 -0.7317 -0.0277 -0.2379 -0.3741 -0.1183 -0.0110 -0.6988 -0.1195 -0.2413 -0.0371 -0.0651 -0.1658 -0.0274 -1.1219 -0.4762 -0.0249 -0.1147 -0.1367 -0.1286 -3.7118 -0.1076
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 ; angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist ; valsartan ; hypertension ; heart failure with preserved ejection fraction ; outcomes ; heart failure with reduced ejection fraction
H-1463	-0.40459227561950684	▁ang io ten sin ▁receptor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁nepri ly sin ▁inhibi tor ▁pro drug ▁; ▁ang io ten sin ▁receptor ▁anta gon ist ▁val sar tan ▁; ▁hyper tension ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1463	-0.40459227561950684	angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction
P-1463	-3.0518 -0.9212 -0.1451 -1.5971 -0.0151 -1.1577 -0.0209 -0.2127 -0.7170 -0.0212 -0.0171 -0.1682 -0.0241 -0.1631 -0.9408 -0.0308 -0.0215 -0.5218 -0.8524 -0.1969 -0.9814 -0.0375 -0.0217 -0.8043 -0.0179 -0.0444 -0.9474 -0.2832 -0.0848 -0.7805 -0.0108 -0.0956 -0.0013 -0.1993 -0.1620 -0.0958 -0.0088 -0.1553 -0.0894 -0.0132 -0.1871 -2.1933 -0.0256 -1.1769 -0.3848 -0.0136 -0.2716 -0.0153 -0.0893 -0.0210 -0.2952 -0.0039 -1.4143 -0.1251
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood pressure ; mitral valve plasty ; degenerative mr ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; physio ring 30 ; edwards lifesciences ; irvine
H-343	-0.1633678823709488	▁blood ▁pressure ▁; ▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁p 3 ▁pro lapse ▁; ▁chor dal ▁rup tures ▁; ▁tri ang ular ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is ▁; ▁ring ▁ann ulo plast y ▁; ▁Ph y sio ▁Ring ▁; Ed ward s ▁Life science s ▁; ▁Ir vine
D-343	-0.1633678823709488	blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ;Edwards Lifesciences ; Irvine
P-343	-0.1061 -0.0490 -0.0598 -0.6328 -0.0152 -0.0459 -0.0195 -0.0510 -0.1924 -0.1414 -0.0037 -0.0025 -0.1182 -0.0322 -0.1588 -0.4966 -0.0475 -0.0182 -0.0142 -0.3700 -0.0111 -0.0286 -0.0082 -0.0169 -0.1009 -0.0021 -0.0055 -0.0010 -0.0414 -0.0048 -0.1392 -0.0109 -0.0073 -0.0368 -0.2648 -0.0131 -0.0381 -0.0327 -0.0006 -0.2753 -0.0972 -0.1093 -0.0020 -0.0832 -0.0519 -0.0228 -0.0749 -0.1246 -0.2936 -0.0048 -0.0050 -1.1978 -0.6713 -1.5679 -0.0017 -0.0021 -0.5115 -0.0087 -0.0025 -0.3397 -0.7853 -0.0009 -0.8273 -0.0552
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes ; incremental shuttle walk test ; peak oxygen uptake ; muscular ; echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory ; beck depression inventory ; health-related quality of life ; minnesota living with heart failure questionnaire ; medical outcomes study short-form
H-1320	-0.2949272692203522	▁shu ttle ▁walk ▁test ▁; ▁oxygen ▁up take ▁; ▁muscular ▁strength ▁; ▁e cho car dio graphic ▁measure s ▁; ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s ▁; ▁depression ▁; ▁be ck ▁de pression ▁in ven tory ▁; ▁health - related ▁quality ▁of ▁life ▁; Min nes ota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Medical
D-1320	-0.2949272692203522	shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic measures ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; health-related quality of life ;Minnesota Living with Heart Failure Questionnaire ; Medical
P-1320	-0.2599 -0.0002 -0.1623 -0.1606 -0.1009 -0.6062 -1.5418 -0.0540 -0.1091 -0.0212 -0.8980 -0.0731 -0.0070 -0.0200 -0.0236 -0.0733 -0.1488 -1.1040 -0.0223 -0.0979 -1.0744 -0.1770 -0.2147 -1.0994 -0.7982 -0.0782 -0.1619 -0.0890 -0.0051 -0.1732 -0.0577 -0.0443 -0.0275 -0.0745 -0.0615 -0.0949 -0.2442 -0.0084 -0.1372 -0.1220 -0.3703 -0.1147 -0.0198 -0.3473 -2.3821 -0.0230 -0.0641 -0.2059 -0.6476 -0.5419 -0.3714 -0.3851 -0.3545 -0.0220 -0.1755 -0.3892 -0.2234 -0.0769 -0.5653 -0.0720 -0.0085 -0.2921 -0.1157 -1.0539 -0.1207
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction term analysis ; lvef ; patients ; patients ; mortality ; lvef ; p value
H-116	-0.7113130688667297	▁inter action ▁term ▁analysis ▁; ▁severe ly ▁reduce d ▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁pres er ved ▁; ▁severe ly ▁reduce d ▁LV EF
D-116	-0.7113130688667297	interaction term analysis ; severely reduced LVEF ; long-term mortality ; preserved ; severely reduced LVEF
P-116	-5.5772 -0.0937 -0.0055 -0.1931 -0.2973 -3.2199 -0.1187 -0.4369 -0.0142 -0.2113 -0.0641 -0.1401 -5.9281 -0.0829 -0.1037 -0.0549 -0.5948 -0.2734 -0.4566 -0.0859 -0.2525 -0.2628 -0.7780 -0.0581 -0.3980 -0.0087 -0.2476 -0.0660 -1.2322 -0.0835
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto ; zsf1 ; obese ; zsf1 ; obese ; zsf1 ; followed up ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
H-763	-0.5237606167793274	▁w star - k yo to ▁; ▁lean ▁Z SF ▁; ▁obes e ▁Z SF 1 ▁; ▁obes e ▁Z SF ▁; ▁z SF 1 ▁; ▁high - fat ▁die t ▁; ▁metabol ic ▁; ▁renal ▁; ▁e cho car dio graphic ▁evaluation s ▁; ▁hem o dynamic ally
D-763	-0.5237606167793274	wstar-kyoto ; lean ZSF ; obese ZSF1 ; obese ZSF ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically
P-763	-1.5742 -0.7974 -0.0177 -3.5841 -0.1664 -0.0202 -0.1284 -0.0326 -2.0635 -0.1523 -1.0955 -0.0875 -0.0191 -1.2843 -0.2332 -1.8815 -0.1180 -0.1306 -0.0233 -1.0283 -0.3020 -1.5884 -1.7341 -0.4718 -1.5168 -0.4885 -0.1974 -0.0162 -0.0517 -0.4331 -0.0460 -0.3586 -0.6890 -0.0197 -0.1586 -0.0017 -0.2538 -0.0105 -0.0137 -0.0169 -0.0557 -0.2178 -1.5735 -0.0820 -0.1686 -0.1599 -0.0378 -0.0023 -0.1725 -1.3579 -0.0772
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; patients
H-384	-0.7641814351081848	▁ka plan - me ier ▁cur ves ▁; ▁log - rank ▁testing ▁; ▁risk ▁strat ification ▁; ▁patients ▁; ▁UM / VA / VA - RT ▁co hor ts
D-384	-0.7641814351081848	kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; UM/VA/VA-RT cohorts
P-384	-0.6331 -0.0040 -0.0183 -0.8624 -0.1776 -0.3037 -1.3815 -0.1762 -0.1131 -0.0395 -0.0365 -0.7426 -0.2433 -1.9660 -0.3877 -0.4415 -0.2241 -5.1741 -0.2415 -1.6624 -0.8541 -0.5753 -1.4545 -1.5708 -0.1752 -1.9392 -0.5958 -0.1488 -0.2008 -1.1968 -0.1493
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate cox regression analyses ; hypertension ; sinus rhythm ; hazard ratio ; confidence interval
H-950	-0.549610435962677	▁multi varia te ▁co x ▁re gression ▁analyse s ▁; ▁AF ▁type ▁; ▁lack ▁of ▁hyper tension ▁; ▁sinus ▁ rhythm ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁ci
D-950	-0.549610435962677	multivariate cox regression analyses ; AF type ; lack of hypertension ; sinus rhythm ;hazard ratio ;HR ; confidence interval ; ci
P-950	-2.2057 -0.0283 -0.0941 -0.0946 -0.2141 -0.0591 -0.0121 -0.4911 -0.1541 -0.3412 -0.3052 -0.1668 -0.0615 -3.8945 -0.2852 -0.1611 -0.0212 -0.0956 -1.6087 -0.1187 -0.1487 -0.2218 -0.0527 -0.0031 -0.0014 -0.1021 -1.7230 -0.4052 -1.6446 -0.0033 -0.1294 -1.4809 -2.2592 -0.0984
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients ; chronic ; hf-ref ; nyha functional class ii ; egfr ; potassium ; eplerenone ; hyperkalemia
H-1228	-0.36978763341903687	▁chronic ▁ HF - re f ▁; ▁NY HA ▁functional ▁class ▁II ▁; ▁e G FR ▁; ▁po tas s ium ▁; ▁e pler en one ▁; ▁hyper kal emia ▁; ▁w RF
D-1228	-0.36978763341903687	chronic HF-ref ; NYHA functional class II ; eGFR ; potassium ; eplerenone ; hyperkalemia ; wRF
P-1228	-0.2629 -0.1667 -0.2184 -0.0224 -1.2496 -1.2244 -0.1104 -0.2402 -0.4978 -0.0391 -0.0353 -0.4121 -0.2197 -0.1608 -2.4243 -0.0820 -0.0517 -0.9322 -0.2346 -0.0855 -0.0879 -0.1694 -0.1160 -0.1233 -0.0340 -0.3368 -0.6446 -1.9541 -0.0744 -0.0819 -0.1744 -0.0463 -0.2452 -0.0817 -0.1026
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm ; dual energy x-ray absorptiometry ; dxa ; patients ; chronic heart failure ; chf ; non-cachectic chf ; myocardial
H-12	-0.3252602219581604	▁f FM ▁; ▁FM ▁; ▁body ▁fat ▁distribution ▁; ▁dual ▁energy ▁X - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁non - dia be tic ▁patients ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; cc ▁; ▁non - ca che ctic ▁CHF ▁; ▁my o card ial ▁in far ction - bo th
D-12	-0.3252602219581604	fFM ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; non-cachectic CHF ; myocardial infarction-both
P-12	-0.4512 -0.7301 -0.1585 -2.1897 -0.1277 -0.2378 -0.3199 -0.1050 -0.1688 -0.0345 -0.2166 -1.4943 -0.0857 -0.3690 -0.0640 -0.4713 -0.3785 -0.2210 -0.3240 -0.4260 -0.3019 -0.0603 -0.1610 -0.6174 -0.0240 -0.0023 -0.0510 -0.1439 -0.2582 -1.0325 -0.0373 -0.2292 -0.0466 -0.1465 -1.8237 -0.7996 -0.0447 -1.0398 -0.1458 -1.2727 -0.0148 -0.0011 -0.0180 -0.0120 -0.0062 -0.1096 -0.9016 -0.0823 -0.1602 -0.1070 -0.0152 -0.0564 -0.0859 -0.1706 -0.0132 -0.0373 -0.1896 -0.0721
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline ; drug ; spironolactone ; combined end point ; death ; hospitalization ; hf ; hazard ratio ; confidence interval ; aas ; hazard ratio ; confidence interval ; p value
H-1707	-0.5819110870361328	▁spi rono lac tone ▁; ▁end ▁point ▁of ▁death ▁; ▁hospital ization ▁; ▁ HF ▁; haz ard ▁ratio ▁; ▁AA s
D-1707	-0.5819110870361328	spironolactone ; end point of death ; hospitalization ; HF ;hazard ratio ; AAs
P-1707	-0.8606 -0.0093 -0.0368 -0.0672 -0.2036 -4.3312 -0.4851 -1.5988 -0.4184 -0.1521 -0.1239 -0.4646 -0.1669 -0.8807 -0.0914 -0.1734 -1.3962 -0.0092 -0.0409 -0.2920 -0.2225 -0.1194 -1.7094 -0.1123
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective study ; patients ; invasively ; diagnosed ; pulmonary arterial hypertension ; inoperable ; chronic thromboembolic pulmonary hypertension ; right ventricular ; pump ; stable ; pulmonary arterial hypertension ; medication ; noninvasive ; stress echocardiography ; cardiopulmonary exercise testing
H-823	-0.23123307526111603	▁pulmonar y ▁arterial ▁hyper tension ▁; ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y ▁hyper tension ▁; ▁im pair ed ▁right ▁vent ri cular ▁pump ▁function ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁medication ▁; ▁stress ▁e cho card i ography ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-823	-0.23123307526111603	pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump function ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise testing
P-823	-1.0766 -0.0371 -0.0065 -0.1698 -0.0189 -0.0410 -0.0061 -0.0147 -0.1358 -0.0278 -0.0998 -0.0613 -1.0921 -0.0326 -0.0085 -0.2187 -0.0115 -0.0830 -0.2470 -0.0339 -0.0901 -2.1824 -0.0012 -0.0065 -0.4959 -0.0224 -0.6228 -0.0610 -0.4117 -0.7644 -0.1432 -0.1735 -0.0307 -0.0041 -0.1662 -0.0212 -0.3278 -0.3000 -0.1151 -0.0147 -0.0245 -0.1352 -0.1205 -0.2648 -0.0883 -0.0043 -0.1121 -0.2151 -0.2130 -0.2474 -1.1876 -0.1921 -0.0728
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular death ; hf ; hospitalization ; randomization ; btes ; btes ; cardiovascular death ; hf ; hospitalization ; exercise ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-1930	-0.37922823429107666	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁b tes ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁exercise ▁group ▁; haz ard ▁ratio
D-1930	-0.37922823429107666	cardiovascular death ; HF hospitalization ; btes ; cardiovascular death ; HF hospitalization ; exercise group ;hazard ratio
P-1930	-0.1100 -0.3513 -0.1088 -0.0942 -0.0872 -0.4871 -0.4782 -0.2204 -1.3709 -0.3189 -0.0686 -0.2211 -0.3257 -0.0692 -0.0524 -0.1245 -0.5461 -0.4702 -0.1300 -1.1610 -1.3529 -0.4479 -0.1588 -0.0074 -0.0313 -1.3477 -0.0973
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients ; hospitalized ; death ; all-cause readmission ; aor ; eds ; aor
H-466	-0.6216837763786316	▁index ▁ED ▁visit ▁; ▁low - volu me ▁ED ▁cases ▁; ▁death / all - ca use ▁read mission ▁; ▁medium ▁; ▁a OR ▁; ▁high - volu me ▁ED s
D-466	-0.6216837763786316	index ED visit ; low-volume ED cases ; death/all-cause readmission ; medium ; aOR ; high-volume EDs
P-466	-0.1255 -0.9758 -1.7815 -0.1653 -0.3592 -0.0267 -0.0231 -0.0428 -0.9135 -0.9643 -0.2346 -4.9697 -2.3573 -0.4027 -0.0713 -0.0104 -0.0407 -0.4157 -0.8241 -0.1970 -0.3046 -0.3395 -0.2080 -0.1465 -0.2792 -2.2928 -0.0393 -0.0500 -0.0255 -0.8078 -0.1346 -0.8739 -0.1125
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients ; implantable cardioverter-defibrillator ; implantation ; engage ; patients ; decisions ; implantable cardioverter-defibrillator
H-1863	-0.44886597990989685	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1863	-0.44886597990989685	implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator deactivation
P-1863	-0.6248 -0.0376 -0.3518 -0.0313 -0.2700 -0.0445 -0.0638 -0.4217 -0.9112 -0.1117 -0.0588 -0.1090 -0.1194 -0.7192 -0.7171 -1.4978 -3.3135 -0.4528 -0.0250 -0.2339 -0.0390 -0.0477 -0.2452 -0.6628 -0.1070 -0.0425 -0.2035 -0.2549 -0.8409 -1.2565 -0.0999
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac magnetic resonance ; t1 time ; hazard ratio ; confidence interval ; left atrial area ; hazard ratio ; confidence interval ; pulmonary vascular resistance ; hazard ratio ; confidence interval ; cardiac events
H-739	-0.57004314661026	▁Card iac ▁magnetic ▁res on ance ▁; ▁left ▁at rial ▁area ▁; haz ard ▁ratio ▁; ▁95% ▁confidence ▁interval ▁; ▁pulmonar y ▁vas cular ▁resist ance ▁; haz ard ▁ratio
D-739	-0.57004314661026	Cardiac magnetic resonance ; left atrial area ;hazard ratio ; 95% confidence interval ; pulmonary vascular resistance ;hazard ratio
P-739	-0.8173 -0.0537 -0.1060 -0.4215 -0.3282 -0.6106 -0.7283 -3.5610 -0.5875 -0.0913 -0.8382 -0.1651 -1.1727 -0.0063 -0.0741 -0.2922 -1.9617 -0.1740 -0.0358 -0.3648 -0.1570 -0.0655 -0.1128 -0.2906 -0.9062 -0.1400 -0.4869 -1.6720 -0.0135 -0.1835 -1.6965 -0.1268
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively ; followed up ; hf ; patients ; systolic ; left ventricular ejection fraction ; hf ; stable ; clinical ; conditions ; new york heart association class i ; clinical ; echocardiographic ; cardiopulmonary exercise test
H-1755	-0.31981825828552246	▁ HF ▁unit s ▁; ▁sy sto lic ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁New ▁York ▁Heart ▁Association ▁class ▁I ▁to ▁III ▁; ▁e cho car dio graphic ▁; ▁cardio pul mon ary ▁exercise
D-1755	-0.31981825828552246	HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart Association class I to III ; echocardiographic ; cardiopulmonary exercise
P-1755	-0.7867 -0.9516 -0.2295 -0.0583 -0.1715 -0.0324 -0.0154 -0.0050 -0.1354 -0.6921 -0.0225 -0.0398 -0.5244 -0.2282 -0.1100 -0.0786 -0.0663 -0.6172 -0.0026 -0.1722 -0.2867 -0.3740 -0.0939 -0.6026 -0.1566 -0.5162 -0.9295 -0.7621 -0.9659 -0.5375 -0.0166 -0.4109 -0.1780 -0.0154 -0.0126 -0.0613 -0.0626 -0.0750 -0.0156 -0.0919 -0.2687 -0.1993 -0.5060 -2.2337 -0.0794
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients ; end stage heart failure ; abcd classification ; american college of cardiology ; acc ; american heart association ; aha ; new york heart association ; nyha ; heart disease ; symptoms ; heart failure ; physical ; medical treatment
H-1666	-0.668046772480011	▁end ▁stage ▁heart ▁failure ▁; ▁ABC d ▁classifica tion ▁; ▁American ▁college ▁of ▁Card i ology ▁; ▁a cc ▁; American ▁Heart ▁association ▁; AHA ▁; ▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁structura l ▁heart ▁disease ▁; ▁heart ▁failure
D-1666	-0.668046772480011	end stage heart failure ; ABCd classification ; American college of Cardiology ; acc ;American Heart association ;AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure
P-1666	-4.5367 -0.0619 -1.8071 -0.2776 -0.2031 -0.2881 -0.3723 -0.1002 -0.0664 -0.0670 -1.4557 -0.6231 -0.2230 -1.5555 -0.1203 -0.1237 -0.0674 -0.1257 -0.0531 -0.1309 -0.4272 -1.5362 -0.7004 -0.1316 -1.2768 -0.0237 -1.4774 -0.3092 -1.2878 -0.8690 -0.1442 -0.0741 -0.9958 -0.4211 -2.4906 -0.2370 -0.4308 -0.5192 -0.1405 -2.0690 -0.1741 -0.6354 -0.0962
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva ; continuity equation ; lv end-diastolic volume ; lv end-systolic volume ; mitral filling flow ; mva ; mitral filling flow ; continuous wave doppler echocardiography ; mitral valve plasty
H-345	-0.2845124304294586	▁m va ▁; ▁continu ity ▁e qu ation ▁; LV ▁end - dia sto lic ▁volume ▁; ▁LV ▁end - sy sto lic ▁volume ▁; ▁mit ral ▁fill ing ▁flow ▁volume ▁; ▁m VA ▁; ▁veloci ty ▁time ▁integral ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁continuo us ▁wa ve ▁; ▁do pp ler ▁e cho card i ography ▁; ▁MR ▁; ▁mit ral ▁val ve ▁plast y
D-345	-0.2845124304294586	mva ; continuity equation ;LV end-diastolic volume ; LV end-systolic volume ; mitral filling flow volume ; mVA ; velocity time integral ; mitral filling flow ; continuous wave ; doppler echocardiography ; MR ; mitral valve plasty
P-345	-0.5486 -1.6331 -0.1748 -2.9338 -0.1118 -0.0302 -0.0485 -0.2754 -0.1015 -1.0955 -2.1802 -0.0187 -0.0787 -0.0744 -0.0136 -0.0439 -0.0465 -0.4802 -0.8438 -0.0155 -0.7389 -0.0396 -0.0123 -0.0676 -0.0498 -0.1531 -0.0398 -0.1891 -0.0287 -0.2321 -0.1929 -0.0784 -0.1047 -1.3256 -0.1458 -0.0657 -0.0033 -0.2819 -0.0515 -0.1943 -0.0441 -0.0228 -0.1710 -0.0201 -0.1338 -0.1727 -0.1340 -0.0089 -0.0025 -0.0049 -1.3949 -0.3733 -0.0117 -0.2602 -0.0388 -0.0193 -0.0513 -0.1042 -0.1032 -0.1437 -0.0609 -1.1293 -0.0711 -0.0140 -0.0652 -0.0287 -0.1069 -0.3382 -0.0593 -0.0834
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance ; rm ; all-cause mortality ; sts ; hh ; cri ; cri ; cri
H-157	-0.7131112813949585	▁stati tis tical ▁significa nce ▁; ▁RM ▁; ▁all - ca use ▁mortal ity ▁; ▁s ts ▁ HH ▁; ▁cred ible ▁interval ▁; ▁c r I ▁; ▁TM
D-157	-0.7131112813949585	statitistical significance ; RM ; all-cause mortality ; sts HH ; credible interval ; crI ; TM
P-157	-3.1024 -0.2284 -0.0696 -1.5632 -0.7449 -0.1809 -0.2207 -0.2464 -2.0179 -0.0150 -0.0045 -0.0346 -0.0162 -0.5989 -0.1212 -0.2624 -0.8818 -0.7538 -0.0702 -0.0975 -1.8009 -0.0744 -0.0034 -0.1290 -0.6309 -0.0392 -2.3418 -0.1476 -1.1729 -4.4632 -0.0727
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi ; hf ; clinic ; outcomes ; hfpsi ; outcomes ; tracking ; patients ; hfpsi
H-381	-0.4764343202114105	▁ HF PSI ▁; ▁Ann ▁ar bor ▁Veteran s ' ▁Affairs ▁ HF ▁clinic ▁; ▁va ▁co hor t ▁; ▁ HF PSI ▁; ▁va - RT ▁co hor t ▁; ▁va ▁patients ▁; ▁ HF PSI
D-381	-0.4764343202114105	HFPSI ; Ann arbor Veterans' Affairs HF clinic ; va cohort ; HFPSI ; va-RT cohort ; va patients ; HFPSI
P-381	-0.7459 -0.9958 -0.1927 -0.1052 -0.0184 -0.2425 -0.0057 -0.3101 -0.0093 -3.5731 -0.0147 -0.9841 -0.6065 -0.3173 -0.0405 -0.6095 -0.3489 -0.1418 -0.0144 -0.0703 -0.7116 -0.8020 -0.3410 -0.1939 -0.6857 -0.1940 -1.0676 -0.1323 -0.2667 -0.0154 -0.1397 -1.4859 -0.4569 -0.2603 -0.8170 -0.4324 -0.2769 -0.8719 -0.0828
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas ; spironolactone ; hyperkalemia ; potassium ; hypokalemia ; potassium
H-1706	-0.3668655753135681	▁AA s ▁; ▁spi rono lac tone ▁dose ▁; ▁hyper kal emia ▁; po tas s ium
D-1706	-0.3668655753135681	AAs ; spironolactone dose ; hyperkalemia ;potassium
P-1706	-0.7618 -0.2077 -0.2928 -0.3983 -0.0136 -0.0579 -0.0481 -0.0675 -0.0858 -0.7228 -0.1137 -0.0668 -0.2348 -0.5203 -0.2845 -0.1494 -0.3029 -2.5147 -0.1269
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate analysis ; patients ; preserved lvef ; mortality ; patients ; lvef ; hazard ratio ; lvef ; preserved lvef
H-115	-0.5285922288894653	▁pres er ved ▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF ▁; haz ard ▁ratio ▁; HR ▁; ▁pres er ved ▁LV EF
D-115	-0.5285922288894653	preserved LVEF ; long-term mortality ; LVEF ;hazard ratio ;HR ; preserved LVEF
P-115	-4.5595 -0.0616 -0.2619 -0.5461 -0.1238 -0.1224 -2.4295 -0.0924 -0.0931 -0.0740 -0.7011 -0.1398 -1.3418 -0.1385 -0.2356 -0.0728 -0.0031 -0.0006 -0.1268 -0.4832 -0.4937 -0.8296 -0.0469 -0.4834 -0.2592 -0.1920 -0.7901 -0.0981
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients ; hfpef ; primary outcome ; odds ratio ; nyha class iii ; 6-minute walk test ; 6-mwt ; feet ; prescribed ; medications
H-242	-0.8608149290084839	▁ HF p EF ▁; ▁male ▁gender ▁; odd s ▁ratio ▁; ▁ny ha ▁class ▁III ▁; ▁w t ▁; ▁ad her ence ▁; ▁medication s
D-242	-0.8608149290084839	HFpEF ; male gender ;odds ratio ; nyha class III ; wt ; adherence ; medications
P-242	-0.9397 -0.0479 -0.0346 -0.2692 -0.1890 -5.1713 -0.1635 -0.0743 -0.0112 -0.0080 -0.0019 -0.0515 -2.5222 -0.1989 -0.4228 -0.2696 -0.2149 -4.3955 -0.6981 -0.7729 -4.8260 -0.2352 -0.1368 -1.0473 -1.0120 -0.0881 -0.2018 -0.0987
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived pulmonary arterial systolic pressure ; pasp ; right ventricular ; rv ; tricuspid annular plane systolic excursion ; tapse ; diastole ; end-systole ; clinical ; follow-up ; heart failure ; hf ; patients ; cardiac
H-492	-0.2832779884338379	▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁right ▁vent ri cular ▁; ▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; TA PS e ▁; ▁dia stol e ▁; ▁end - sy stol e ▁; ▁heart ▁failure ▁; HF ▁; ▁cardiac ▁risk
D-492	-0.2832779884338379	pulmonary arterial systolic pressure ;PASp ; right ventricular ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
P-492	-0.4276 -0.0412 -0.0125 -0.0264 -0.0336 -0.0839 -0.1537 -0.0893 -0.2011 -0.9463 -0.0509 -0.2938 -0.0179 -0.3464 -0.1023 -0.1583 -2.2888 -0.0465 -0.0089 -0.0453 -0.0042 -0.2677 -0.0054 -0.0557 -0.0677 -0.2409 -0.0058 -0.1289 -0.9626 -0.5276 -1.1457 -0.0297 -0.0304 -0.0065 -0.2110 -0.6903 -0.1214 -0.0381 -0.4523 -0.0245 -0.0701 -0.2243 -2.0170 -0.0545 -0.0836 -0.0539 -0.4881 -0.1584 -0.7370 -0.0854 -0.0837
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad ; diabetes ; odds ratio ; electrocardiographic q waves ; left bundle branch block ; odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; odds ratio
H-1190	-0.2822363078594208	▁severe ▁CAD ▁; ▁diabetes ▁; ▁electro car dio graphic ▁Q ▁wa ves ▁; ▁left ▁bund le ▁bran ch ▁block ▁; ▁non dia bete s ▁risk ▁factors ▁; ▁dys li pide mia ▁; ▁hyper tension ▁; ▁to ba cco
D-1190	-0.2822363078594208	severe CAD ; diabetes ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco
P-1190	-1.0492 -0.1281 -0.0371 -0.1257 -0.0572 -0.0183 -0.0194 -0.0246 -0.0558 -1.4831 -0.0058 -0.2720 -0.0727 -0.0243 -0.0115 -0.1925 -0.0111 -0.0425 -0.2690 -0.1889 -1.1365 -0.0750 -0.0499 -0.0144 -2.0012 -0.2392 -0.1666 -0.0667 -0.0362 -0.0105 -0.2290 -0.1005 -0.0254 -0.0088 -0.1275 -0.0200 -0.3428 -0.2333 -2.1669 -0.1504
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area under the receiver operating characteristic curve ; auc ; pcwp ; confidence interval ; septal ; p values
H-485	-0.685559093952179	▁receive r ▁operating ▁character istic ▁cur ve ▁; AU c ▁; ▁e / e ▁; ▁ratio s ▁; ▁pc WP ▁; ▁confidence ▁interval ▁; CI ▁; ▁e / e ▁; sept al ▁; ▁ec / e lateral ▁; ▁e / eme an
D-485	-0.685559093952179	receiver operating characteristic curve ;AUc ; e/e ; ratios ; pcWP ; confidence interval ;CI ; e/e ;septal ; ec/elateral ; e/emean
P-485	-1.9844 -0.0129 -0.3166 -0.2106 -0.0695 -0.9723 -0.0589 -0.1380 -0.1517 -1.6451 -0.0326 -1.6646 -0.7280 -0.0310 -0.9801 -1.2122 -0.0580 -0.0430 -0.1150 -0.9160 -0.3257 -0.6750 -0.0082 -0.0371 -2.0301 -0.0402 -0.7020 -1.9291 -0.0672 -6.0831 -0.0260 -0.0039 -0.0818 -1.6704 -1.8431 -0.1070 -0.1897 -0.3768 -1.0908 -1.3035 -0.0380 -0.0189 -0.0731 -0.1035
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients ; coronary artery disease ; hypertension ; trastuzumab ; administration ; chf
H-680	-0.7480676770210266	▁tras tuz um ab - tre ated ▁patients ▁; ▁corona ry ▁arter y ▁disease ▁; HR ▁; ▁hyper tension ▁; HR ▁; ▁week ly ▁tras tuz um ab ▁; ▁CHF
D-680	-0.7480676770210266	trastuzumab-treated patients ; coronary artery disease ;HR ; hypertension ;HR ; weekly trastuzumab ; CHF
P-680	-0.5401 -0.0282 -0.0098 -1.5978 -0.4494 -0.0225 -0.5263 -0.5840 -0.1564 -2.8128 -0.3697 -0.0109 -0.1409 -0.3091 -0.0814 -1.3445 -0.1485 -2.0982 -0.0163 -0.1313 -3.4582 -0.4514 -2.5807 -0.1705 -0.4020 -0.0135 -0.0133 -1.0113 -2.0474 -2.1846 -0.1060 -0.1213
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef ; clinical ; crt ; crt ; systolic volume index ; lv mass
H-754	-0.5516862273216248	▁LV EF ▁; ▁clinic al ▁com posit e ▁response ▁; ▁c RT ▁ON ▁; ▁c RT ▁OFF ▁; ▁LV ▁end ▁sy sto lic ▁volume ▁index ▁; ▁LV ▁mass
D-754	-0.5516862273216248	LVEF ; clinical composite response ; cRT ON ; cRT OFF ; LV end systolic volume index ; LV mass
P-754	-1.8189 -0.1979 -0.0543 -1.5331 -0.0054 -0.0451 -0.0030 -0.0146 -0.1930 -0.1366 -0.2663 -0.6488 -1.3987 -0.3112 -0.2785 -1.1521 -0.3514 -0.1554 -1.1990 -2.6299 -0.0529 -0.0272 -0.0566 -0.0601 -0.0282 -0.1740 -2.3948 -0.9583 -0.3346 -0.0707
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β signaling ; tgf-β receptor type i ; cell ; yield ; epithelial ; mesenchymal ; transition ; pluripotency marker ; nanog ; cell ; cells ; in vitro
H-1343	-0.19661524891853333	▁t GF - β ▁signal ing ▁; ▁inhibi ting ▁T GF - β ▁receptor ▁type ▁I ▁; ▁s mad ▁; ▁small - mo le cule ▁inhibi tors ▁; ▁c - K it + ▁cell ▁yi eld ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker ▁na nog ▁; ▁c - K it + ▁cell ▁differenti ation ▁; ▁cardio my o cy te - like ▁cell s
D-1343	-0.19661524891853333	tGF-β signaling ; inhibiting TGF-β receptor type I ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
P-1343	-1.6638 -0.1187 -0.0399 -0.1033 -0.1516 -0.0919 -0.1758 -0.2159 -0.3283 -1.0856 -0.0327 -0.0588 -0.1970 -0.0626 -0.1931 -1.1255 -0.1599 -0.0947 -0.0286 -0.6535 -0.0553 -0.0204 -0.0842 -0.1899 -0.0519 -0.0143 -0.0883 -0.0667 -0.0249 -0.0372 -0.7955 -0.0199 -0.2959 -0.0925 -0.0023 -0.0003 -0.0864 -0.0535 -0.0225 -0.0257 -0.0060 -0.6525 -0.0166 -0.1647 -0.0749 -0.8877 -0.0194 -0.0396 -0.0285 -0.0734 -0.0758 -0.0276 -0.0114 -0.0302 -0.2414 -0.0050 -0.3160 -0.0251 -0.0179 -0.5108 -0.0190 -0.3111 -0.1618 -0.1415 -0.0894 -0.5018 -0.0094 -0.4701 -0.1232 -0.0411 -0.0408 -0.2787 -0.2479 -0.1115 -0.0427 -0.6399 -0.0756
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients ; hfref ; diuretics ; co-morbidities ; 6-mwt ; feet ; nyha class iii
H-243	-0.7363284826278687	▁h Fr EF ▁; ▁di ure tics ▁; ▁co - mor bid ities ▁; ▁w ha ▁class ▁III
D-243	-0.7363284826278687	hFrEF ; diuretics ; co-morbidities ; wha class III
P-243	-1.9526 -0.4504 -0.9735 -0.0816 -1.0012 -1.2650 -0.4746 -0.1706 -0.0598 -0.0340 -0.0346 -0.0657 -0.8192 -0.2472 -3.3240 -0.8731 -0.5926 -0.5405 -1.6593 -0.1070
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery ; hf ; postoperative ; echocardiography ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mitral valve area ; mva
H-344	-0.3112640976905823	▁ HF ▁; ▁post operativ e ▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁LV ▁; ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁pres er ved ▁mit ral ▁val ve ▁opening ▁; ▁mit ral ▁val ve ▁area ▁; ▁m VA ▁; ▁mean ▁pressure ▁gradi ent
D-344	-0.3112640976905823	HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; preserved mitral valve opening ; mitral valve area ; mVA ; mean pressure gradient
P-344	-2.0619 -0.0776 -0.2664 -0.9507 -0.1130 -0.0178 -0.0707 -0.0774 -0.1244 -0.2584 -0.1442 -0.0825 -1.5196 -0.1087 -0.4750 -0.0260 -0.0250 -0.0272 -0.0112 -0.0314 -0.0160 -0.0777 -2.1260 -0.5293 -0.5631 -0.0592 -0.0127 -0.4855 -0.0022 -0.0935 -0.0223 -0.0540 -0.8615 -0.0208 -0.1452 -0.0324 -0.0472 -0.0428 -0.0244 -0.0766 -0.1338 -0.0694 -0.0388 -0.0341 -0.0230 -1.2117 -0.1632 -0.0346 -1.6605 -0.3289 -0.8256 -0.1591 -0.0107 -0.0112 -0.9204 -0.0441
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients ; systolic heart failure ; ejection fraction ; randomized ; placebo ; ivabradine ; shift ; systolic heart failure treatment with the if inhibitor ivabradine trial ; patients ; placebo ; ivabradine ; echocardiographic
H-519	-0.3302856385707855	▁sy sto lic ▁heart ▁failure ▁; ej ection ▁ fraction ▁; ▁i va bra dine ▁; ▁SHI ft ▁; ▁sy sto lic ▁Heart ▁Fail ure ▁Treatment ▁; ▁If ▁in hib itor ▁i va bra dine ▁tri al ▁; ▁i va bra dine ▁; ▁i va bra dine ▁; ▁e cho car dio graphic ▁sub stu dy
D-519	-0.3302856385707855	systolic heart failure ;ejection fraction ; ivabradine ; SHIft ; systolic Heart Failure Treatment ; If inhibitor ivabradine trial ; ivabradine ; ivabradine ; echocardiographic substudy
P-519	-0.2942 -0.0356 -0.0444 -0.8245 -0.0712 -0.1046 -3.1141 -0.0055 -0.0612 -0.0021 -0.2455 -0.3046 -0.1598 -0.3997 -0.2141 -0.0971 -0.0622 -0.5748 -0.0836 -0.1499 -0.0098 -0.0278 -0.6081 -0.3122 -0.3408 -0.1700 -0.5658 -1.2543 -0.4242 -0.0021 -0.0049 -0.8427 -0.0302 -0.1491 -0.0365 -0.2960 -0.0144 -0.1380 -0.1679 -0.0479 -0.4187 -0.0606 -0.9911 -0.9594 -0.0963 -0.7400 -0.0784 -1.1135 -0.8485 -0.0151 -0.0226 -0.1072 -0.4658 -0.3430 -0.0009 -0.4276 -0.1131 -0.0630
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard ratios ; multivariate regression ; tapse ; pasp ; hazard ratio ; tapse ; new york heart association functional class
H-499	-1.0913093090057373	▁Hazard ▁ratio s ▁; ▁t AP se ▁; ▁pas p ▁; haz ard ▁ratio ▁; ▁t AP se ▁; ▁p b ▁; ▁New ▁York ▁Heart ▁Association ▁functional ▁class
D-499	-1.0913093090057373	Hazard ratios ; tAPse ; pasp ;hazard ratio ; tAPse ; pb ; New York Heart Association functional class
P-499	-1.5155 -0.0242 -0.2843 -0.1746 -4.1760 -0.3656 -1.8140 -1.0157 -2.4533 -0.2017 -0.0908 -0.8359 -0.0153 -0.0169 -0.1348 -3.9598 -0.6781 -1.3380 -0.1007 -2.8988 -3.8416 -0.0748 -1.5687 -0.2108 -1.1229 -1.0101 -0.2516 -0.1365 -2.2936 -0.1349
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal function ; the chronic kidney disease epidemiology collaboration ; patients ; estimated glomerular filtration rate ; egfr
H-390	-0.5239946842193604	▁Ren al ▁function ▁; ▁Chro nic ▁Kid ney ▁Disease ▁Epidemi ology ▁Col labora tion ▁e qu ation ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR
D-390	-0.5239946842193604	Renal function ; Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; egFR
P-390	-1.8043 -0.0394 -0.0744 -0.3261 -0.0541 -0.2997 -0.0798 -1.0899 -0.1975 -0.1991 -0.2382 -2.3134 -0.0116 -0.0601 -1.0200 -0.0334 -0.4623 -0.2012 -0.4576 -0.4093 -0.1003 -0.1572 -0.2510 -0.4102 -0.4698 -0.1105 -1.6749 -0.8987 -2.1064 -0.1693
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective ; randomized ; paradigm-hf ; chronic heart failure ; systolic dysfunction ; lv ef ; functional class ; nyha ; elevated ; bnp ; nt-pro bnp ; primary endpoint ; cardiovascular death ; hospitalization ; heart failure ; arni ; lcz696 ; sacubiltril ; valsartan
H-1968	-0.3829379975795746	▁para DIG m - HF ▁; ▁stabil ized ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; LV ▁EF ▁; ▁functional ▁class ▁NY HA ▁II - III ▁; ▁b NP ▁; ▁b NP ▁; ▁car dio vas cular ▁death ▁; ▁hospital ization ▁for ▁heart ▁failure ▁; ▁ar ni ▁; ▁sa cubi lt ril ▁; ▁val sar tan
D-1968	-0.3829379975795746	paraDIGm-HF ; stabilized chronic heart failure ; systolic dysfunction ;LV EF ; functional class NYHA II-III ; bNP ; bNP ; cardiovascular death ; hospitalization for heart failure ; arni ; sacubiltril ; valsartan
P-1968	-1.6891 -1.1573 -0.6085 -0.0240 -0.1357 -0.3141 -2.8183 -0.0599 -0.2237 -0.5219 -0.0780 -0.8833 -0.0137 -0.0182 -0.1093 -0.0093 -0.0131 -0.1337 -0.0594 -0.5353 -0.1046 -0.1088 -0.0401 -0.1192 -0.3435 -0.1279 -0.0219 -0.0068 -0.2214 -1.2343 -0.3870 -0.1498 -3.1639 -0.6143 -0.1064 -0.9499 -0.0502 -0.1050 -0.1412 -0.3426 -0.0635 -0.0881 -0.3807 -1.3349 -0.1586 -0.0627 -0.3668 -0.4905 -0.7512 -0.0630 -0.7123 -0.0047 -0.0153 -0.0760 -0.1309 -0.0603 -0.0519 -0.0203 -0.3270 -0.0733
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv reverse remodeling ; lv end-diastolic dimension ; longitudinal ; strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial ; right ventricular fractional area ; change
H-432	-0.665954053401947	▁rever se ▁remodel ing ▁; ▁pre - c RT ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁index ▁; ▁global ▁longitud in al ▁strain ▁; ▁left ▁vent ric le ▁; ▁left ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁end - dia sto lic ▁area ▁index ▁; ▁right ▁at rial ▁area ▁; ▁right ▁vent ri cular
D-432	-0.665954053401947	reverse remodeling ; pre-cRT LV ; end-diastolic dimension index ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial area ; right ventricular
P-432	-1.9820 -0.0212 -0.0279 -0.0263 -0.1111 -3.3471 -0.0036 -0.9845 -1.2541 -2.0308 -0.7071 -4.3837 -0.0379 -0.0247 -0.3331 -0.0700 -0.6411 -0.0693 -0.3242 -0.1407 -0.8239 -0.0048 -0.0405 -0.0076 -0.0839 -0.3622 -0.0345 -0.1844 -1.0109 -0.3466 -0.1405 -0.0510 -1.1252 -0.0930 -0.7546 -0.2059 -0.9657 -0.1034 -0.6819 -0.1274 -4.0686 -0.0425 -0.0186 -0.2069 -0.0851 -1.6386 -0.9701 -0.1864 -0.3982 -1.7138 -0.0837 -0.8023 -0.6929 -0.6630 -0.1754 -0.8530 -0.2589 -2.6794 -0.0855
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia ; outcomes ; african americans ; aas ; new york heart association ; nyha ; hf ; left ventricular dysfunction ; randomized ; spironolactone ; titrated ; placebo ; randomized aldactone evaluation study ; rales
H-1703	-0.3873693346977234	▁hyper kal emia ▁; ▁African ▁American s ▁; ▁non - AA s ▁; ▁white ▁; ▁New ▁York ▁Heart ▁Association ▁; NY ha ▁; ▁class ▁III ▁; ▁IV ▁ HF ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁spi rono lac tone ▁; ▁al da cto ne ▁Evalua tion ▁Study ▁; RAL es
D-1703	-0.3873693346977234	hyperkalemia ; African Americans ; non-AAs ; white ; New York Heart Association ;NYha ; class III ; IV HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
P-1703	-0.5181 -0.1559 -0.1286 -0.0848 -1.2880 -0.3609 -0.0858 -0.0444 -1.3403 -0.0199 -0.0736 -0.0090 -0.0263 -0.6254 -0.1715 -2.4632 -0.1578 -0.7102 -0.8656 -0.1004 -0.1204 -1.2221 -0.1020 -2.4773 -0.0220 -0.2447 -0.7286 -0.0862 -0.0341 -0.0489 -0.0067 -0.0170 -0.7703 -0.1296 -0.0137 -0.0685 -0.0895 -0.0060 -0.0019 -0.0094 -0.0103 -0.1712 -3.0121 -0.0413 -0.0237 -0.2752 -0.5173 -0.1021 -0.5192 -0.2842 -0.0020 -0.3184 -0.1364 -0.0757
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; irs1 ; irs2 ; heart-specific irs1 and irs2 gene double-knockout ; h-dko ; liver-specific irs1 and irs2 double-knockout ; l-dko
H-654	-0.45954829454421997	▁i RS 1 ▁; ▁i RS 2 ▁in ▁the ▁heart ▁; ▁hyper insu line mia ▁; ▁my o card ial ▁insulin ▁resist ance ▁; ▁cel lular ▁dys function ▁; ▁i RS 2 ▁; ▁i RS 2 ▁; ▁i RS 1 ▁; ▁i RS 2 ▁double - k no ckou t ▁; ▁l - d ko
D-654	-0.45954829454421997	iRS1 ; iRS2 in the heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS2 ; iRS1 ; iRS2 double-knockout ; l-dko
P-654	-0.4353 -0.1563 -1.0864 -0.4471 -0.4084 -0.4057 -0.1585 -3.2287 -1.0264 -0.2789 -0.1097 -0.2348 -0.0066 -0.1069 -1.1090 -0.2551 -0.2815 -0.1229 -0.3662 -0.3297 -0.0584 -0.2493 -0.0563 -0.1372 -0.2733 -0.0078 -0.0219 -0.0242 -0.2092 -0.4664 -0.0540 -1.2565 -0.2547 -0.5210 -0.2036 -0.6711 -0.3878 -1.2823 -0.2890 -2.3988 -0.2084 -0.7325 -0.3539 -0.2635 -1.5392 -0.0570 -0.6025 -0.0522 -0.0447 -0.0029 -0.1875 -0.8631 -0.0462 -0.6360 -0.3512 -0.7517 -0.1252
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; diagnostic ; stable ; coronary artery disease ; b-type natriuretic peptide ; bnp ; nt-probnp ; ventricular cardiomyocytes ; ventricular ; wall stress ; myocardial ischemia
H-1364	-0.5344154238700867	▁na tri ure tic ▁pe pti de ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁stable ▁corona ry ▁arter y ▁disease ▁; ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁n - termin al ▁fragment ▁; nt - pro b NP ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁vent ri cular ▁wall ▁stress ▁; ▁my o card ial ▁ ische mia
D-1364	-0.5344154238700867	natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; stable coronary artery disease ; natriuretic peptide ; bNP ; n-terminal fragment ;nt-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
P-1364	-1.4209 -0.9076 -0.6993 -1.7984 -1.0419 -0.1880 -0.3523 -0.0942 -2.6912 -0.0134 -0.0089 -0.0028 -0.3195 -0.0229 -1.5644 -0.0464 -0.0129 -0.0746 -0.4363 -0.4959 -2.2013 -1.4536 -0.3499 -0.1950 -0.1232 -2.0823 -0.1984 -0.6795 -0.0472 -0.2248 -0.3113 -0.4926 -0.3226 -0.7767 -0.5175 -2.1059 -1.7322 -0.2447 -0.3667 -0.1299 -0.6379 -0.6206 -0.1398 -1.7788 -0.0057 -0.0132 -0.0011 -0.1751 -0.1209 -2.6034 -0.0056 -0.0082 -0.3901 -0.9029 -0.2423 -0.0172 -0.5273 -0.2470 -0.2180 -0.3689 -0.1586 -0.0516 -0.0681 -0.2048 -0.0110 -0.8368 -0.3521 -0.8089 -0.1645 -0.1033 -1.0075 -0.1161 -0.3954 -0.4544 -0.2256 -0.0662 -0.9767 -0.3015 -0.1442
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range ; interquartile range
H-665	-0.4277825951576233	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁inter quart ile ▁range ▁; ▁β - block ers
D-665	-0.4277825951576233	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; β-blockers
P-665	-5.6230 -0.7632 -0.0488 -1.4025 -0.1097 -0.0122 -0.0237 -0.0486 -0.0564 -0.0452 -0.0231 -0.1711 -0.8156 -0.0565 -0.0735 -0.3647 -0.0146 -0.6125 -0.0335 -0.5110 -0.0199 -0.0098 -0.0058 -0.1519 -0.6827 -0.4968 -0.0210 -0.1153 -0.0429 -0.7610 -0.1447
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ; ivabradine ; change ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; correlates ; exercise capacity ; therapy ; ivabradine ; correlated ; peak oxygen uptake
H-1177	-0.6594615578651428	▁i va bra dine ▁; ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁early ▁dia sto lic ▁mit ral ▁mit ral ▁ann ular ▁veloci ty ▁; ▁exercise ▁capacity ▁; ▁i va bra dine ▁; ▁oxygen ▁up take
D-1177	-0.6594615578651428	ivabradine ; diastolic mitral flow velocity ; early diastolic mitral mitral annular velocity ; exercise capacity ; ivabradine ; oxygen uptake
P-1177	-0.2849 -0.0277 -0.1642 -0.1191 -0.1566 -5.4983 -0.0719 -0.0222 -0.3641 -0.0508 -2.4277 -0.3874 -0.0347 -0.1618 -0.7119 -0.0132 -0.0391 -0.0272 -0.2508 -0.0675 -2.6271 -0.0919 -2.5115 -0.0040 -0.0626 -0.0260 -0.2392 -2.9581 -0.1980 -0.1732 -0.1892 -0.0409 -0.2150 -0.1384 -0.1753 -3.0510 -2.4051 -0.1683 -0.0967 -0.1262
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence ; transfusion ; mortality ; relative risk ; mortality ; patients ; acute coronary syndrome
H-45	-0.7007474899291992	▁liberal ▁trans fusion ▁protocol s ▁; ▁short - term ▁mortal ity ▁rates ▁; ▁aggressiv e ▁protocol s ▁; ▁relative ▁risk ▁; ▁trial ▁; ▁a cute ▁corona ry ▁syndrome
D-45	-0.7007474899291992	liberal transfusion protocols ; short-term mortality rates ; aggressive protocols ; relative risk ; trial ; acute coronary syndrome
P-45	-0.4353 -0.0425 -0.1054 -0.6254 -0.0866 -0.2498 -5.1276 -0.1186 -0.1899 -0.2220 -0.8146 -0.4521 -0.2829 -0.1651 -0.0281 -0.0588 -0.0490 -0.2658 -2.9164 -0.2043 -0.4704 -3.1290 -3.4600 -0.2893 -0.0067 -0.0333 -0.5840 -0.0021 -0.4729 -0.1345
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death ; readmission ; patients ; physician ; hazard ratio ; confidence interval ; physician ; follow-up ; patients ; follow-up
H-1419	-0.6193544268608093	▁risk ▁; ▁un plan ned ▁read mission ▁; ▁familiar ▁physician ▁; ▁adjust ed ▁hazard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; CI ▁; ▁un fa milia r ▁physician
D-1419	-0.6193544268608093	risk ; unplanned readmission ; familiar physician ; adjusted hazard ratio ;HR ; confidence interval ;CI ; unfamiliar physician
P-1419	-2.3174 -0.8642 -0.4573 -0.0226 -0.0811 -0.9947 -0.6138 -0.5508 -3.1287 -0.1860 -0.1229 -2.9102 -0.0114 -0.0394 -0.0017 -0.0810 -0.5899 -0.1540 -0.4188 -0.0033 -0.1009 -0.6564 -0.3724 -0.0592 -0.0791 -0.0074 -0.0117 -0.0855 -3.5554 -0.1035
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek ; human embryonic kidney ; cells ; β1ar ; s1pr1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1pr1 agonist ; s1pr1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
H-1409	-0.5575670003890991	▁h ek ▁; human ▁em bry o nic ▁ki dne y ▁; ▁cell s ▁over express ing ▁; ▁β 1 AR ▁; ▁s 1 PR 1 ▁; ▁β 1 AR ▁down regul ation ▁; ▁sp hing os ine -1 - phos pha te ▁; ▁s 1 PR 1 ▁ago nist ▁; ▁iso prot eren ol ▁; ▁β - ad r energi c ▁receptor ▁ago nist
D-1409	-0.5575670003890991	hek ;human embryonic kidney ; cells overexpressing ; β1AR ; s1PR1 ; β1AR downregulation ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; β-adrenergic receptor agonist
P-1409	-1.6116 -0.5184 -0.1470 -0.6747 -0.0687 -0.0275 -0.0971 -0.5083 -0.0207 -0.4133 -0.0481 -0.1922 -4.2562 -0.0548 -0.1116 -0.0274 -0.0317 -0.5947 -0.2670 -1.1130 -0.5439 -0.1826 -0.8533 -0.7327 -0.4680 -2.4995 -0.9683 -2.7338 -0.9523 -1.1923 -2.1157 -0.2886 -0.2766 -0.2685 -0.1856 -0.7309 -0.2353 -2.3935 -1.1312 -0.1387 -0.0078 -0.0180 -0.0587 -0.1047 -0.8405 -0.1919 -0.3792 -1.3928 -0.9373 -0.0816 -0.3768 -0.7204 -0.0263 -0.0308 -0.1506 -0.1215 -0.3275 -0.0320 -0.0481 -0.1889 -0.7686 -0.0993 -0.0360 -0.0613 -0.0322 -0.5297 -0.1190
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline ; training ; 6-minute walked distance ; quality of life ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; symptoms ; beck depression inventory ; zung self-rated depression scores ; b-type natriuretic peptide ; endothelial function ; flow-mediated dilatation ; left ventricular diastolic function
H-1330	-0.19737392663955688	▁kan sas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁ depressiv e ▁symptoms ▁; ▁be ck ▁de pression ▁in ven tory ▁; ▁z ung ▁self - rat ed ▁depression ▁score s ▁; ▁na tri ure tic ▁pe pti de ▁; ▁en dot heli al ▁function ▁; flow - media ted ▁di la tation ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function
D-1330	-0.19737392663955688	kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
P-1330	-1.3457 -0.0005 -0.5349 -0.8537 -0.0221 -0.0398 -1.0015 -0.1592 -0.3797 -0.0113 -0.0421 -0.0078 -0.1503 -0.3650 -0.2910 -0.0890 -0.3149 -0.1713 -0.0159 -0.0862 -0.1569 -0.0036 -0.0253 -0.2156 -0.0545 -0.1580 -0.0024 -0.2292 -0.1066 -0.5092 -0.0621 -0.0062 -0.0427 -0.4459 -0.2160 -0.2816 -0.0015 -0.0046 -0.0030 -0.0464 -0.2821 -0.0317 -0.1964 -0.0281 -0.0794 -0.3212 -0.5231 -0.6619 -0.0668 -0.1176 -0.0795 -0.0301 -0.2111 -0.0315 -0.0027 -0.2902 -0.0936 -0.4324 -0.0268 -0.0343 -0.0981 -0.0504 -0.0667 -0.0127 -0.2327 -0.0629 -0.0391 -0.4460 -0.1860 -0.0515 -0.0192 -0.0887 -1.0818 -0.2775 -0.0959
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds ratios ; confidence intervals ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; patients ; estimated glomerular filtration rate ; nonsignificant ; acute kidney injury
H-976	-0.27224332094192505	▁Odd s ▁ratio s ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁diabetes ▁mell itus ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁stroke
D-976	-0.27224332094192505	Odds ratios ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke
P-976	-2.8687 -0.0624 -0.1263 -0.0663 -0.4695 -0.8401 -0.3702 -0.3200 -2.3549 -0.0146 -0.1901 -0.0065 -0.0624 -0.1340 -0.0443 -0.0246 -0.4580 -0.2753 -0.0533 -0.0533 -0.0320 -0.3921 -0.0041 -0.0941 -0.0325 -0.0008 -0.0059 -0.0821 -0.0087 -0.0164 -0.0182 -0.0100 -0.1146 -0.0505 -0.1486 -0.0840 -0.4164 -0.0857 -0.1616 -0.1161 -0.0101 -0.0788 -0.0647 -0.0833 -0.2081 -0.0294 -0.1070 -0.0511 -2.2419 -0.0685
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic function ; ea ; ventricular-arterial coupling ; ees ; ea
H-925	-0.8153783082962036	▁dia sto lic ▁function ▁; ▁ec b ▁; ▁vent ri cular - arte rial ▁coup ling
D-925	-0.8153783082962036	diastolic function ; ecb ; ventricular-arterial coupling
P-925	-0.4350 -0.2149 -0.0633 -0.1406 -0.2067 -4.0585 -3.0164 -0.3237 -1.5381 -0.9042 -0.0886 -0.1732 -0.0304 -0.0470 -0.6129 -0.4853 -2.1840 -0.1538
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard ratios ; disease risk score ; drs ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
H-1835	-0.720710277557373	▁disease ▁risk ▁score ▁; ▁d RS - stra t ified ▁analyse s ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁ci ▁; ▁sax ag lip tin ▁; ▁pi og lita zone ▁; ▁sax ag lip tin ▁; ▁sul fon yl ure as ▁; ▁sax ag lip tin ▁; ▁insulin
D-1835	-0.720710277557373	disease risk score ; dRS-stratified analyses ; saxagliptin ; sitagliptin ; ci ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
P-1835	-2.0881 -0.9159 -0.0550 -0.2017 -0.1785 -0.1021 -4.2326 -0.0066 -0.0113 -0.0147 -0.0624 -0.0451 -0.2279 -2.3983 -0.0219 -0.5464 -1.8852 -0.6310 -1.1749 -0.3028 -0.1713 -1.8295 -0.2307 -1.5047 -0.8740 -0.5907 -0.0215 -0.6370 -1.8666 -0.6084 -2.4485 -0.0397 -0.0738 -0.0917 -0.1446 -1.1879 -0.0290 -0.5919 -2.1367 -0.6826 -0.1781 -0.0150 -0.0879 -0.4194 -0.0790 -0.2849 -2.8648 -0.0476 -0.6842 -2.2412 -0.8464 -0.0572 -0.1281 -0.1216
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients ; revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline ; electrocardiogram
H-106	-0.34085091948509216	▁i ▁; ▁re vas cular ization ▁; co ron ary ▁arter y ▁by pass ▁surgery ▁; ▁hazard ▁ratio ▁; HR ▁; ▁per cuta ne ous ▁corona ry ▁intervention ▁; ▁HR ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁bund le ▁bran ch ▁block ▁pattern ▁; ▁base line ▁electro card i ogram ▁; ▁IE
D-106	-0.34085091948509216	i ; revascularization ;coronary artery bypass surgery ; hazard ratio ;HR ; percutaneous coronary intervention ; HR ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram ; IE
P-106	-1.7891 -0.8894 -0.1415 -0.0188 -0.0915 -0.2473 -0.1762 -0.9088 -0.2051 -0.2652 -0.0423 -0.0773 -0.7691 -0.2324 -0.0415 -0.2305 -0.0481 -0.0013 -0.0479 -1.6929 -0.1058 -0.0432 -0.0005 -0.0836 -0.1642 -0.0743 -0.4292 -0.0824 -0.1494 -1.0234 -0.1760 -0.0809 -0.0119 -0.0374 -0.1281 -0.1974 -0.1685 -2.2612 -0.0038 -0.0498 -0.0717 -0.0478 -0.2315 -0.1942 -0.1264 -0.3322 -0.0063 -0.0116 -0.0790 -0.1693 -0.0156 -0.2202 -3.0887 -0.8650 -0.1001
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical ; biomedical ; relative risk ; confidence interval ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1262	-0.5027877688407898	▁bio medic al ▁treatment ▁; ▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1262	-0.5027877688407898	biomedical treatment ; biomedical treatment ; CHm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
P-1262	-0.0036 -0.0468 -0.0038 -0.6134 -0.4727 -0.0870 -0.0390 -0.0040 -0.7430 -0.2485 -1.6335 -0.5120 -0.1558 -4.2276 -0.0301 -0.6040 -0.1885 -0.4382 -0.1234 -0.0716 -0.7264 -0.0137 -0.1240 -1.2580 -0.0309 -0.6085 -0.1391 -0.2300 -0.0463 -0.0427 -1.2243 -0.4022 -1.8916 -0.1105
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective ; randomized ; crossover study ; outcome ; stable heart failure ; patients ; left ventricular ejection fraction ; homozygous ; haplotype ; β2-receptor ; randomized ; carvedilol ; metoprolol
H-1114	-0.33058667182922363	▁open - label ▁cross over ▁study ▁; ▁stable ▁heart ▁failure ▁patients ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ar g 16 / ▁g l n 27 ▁; ▁g ly 16 / ▁g lu 27 ▁ha plo type ▁; ▁β 2- recept or ▁; ▁car vedi lol ▁; ▁met o pro lol
D-1114	-0.33058667182922363	open-label crossover study ; stable heart failure patients ; left ventricular ejection fraction ; arg16/ gln27 ; gly16/ glu27 haplotype ; β2-receptor ; carvedilol ; metoprolol
P-1114	-2.2235 -0.0598 -0.0422 -0.2695 -0.0105 -1.6860 -0.4058 -2.4467 -0.2871 -0.0549 -0.4131 -0.1135 -1.0494 -0.0188 -0.0417 -0.7230 -0.2561 -0.0615 -0.1216 -0.0410 -0.6961 -0.0039 -0.1532 -0.3891 -0.0226 -0.0412 -1.4677 -0.5399 -0.1123 -0.0075 -0.1679 -0.0526 -0.2209 -0.3689 -0.0266 -0.9467 -1.0929 -0.4756 -0.5792 -0.0214 -0.0104 -0.0203 -0.0362 -0.0522 -0.0129 -0.0072 -0.0216 -0.2024 -0.0997 -0.0094 -0.1601 -0.0934 -0.0162 -0.0616 -0.0329 -0.4642 -0.0872 -0.0744
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients ; death ; hospitalization ; aor ; aor ; aor ; aor
H-465	-0.8912131190299988	▁low - volu me ▁ED ▁cases ▁; ▁death ▁; hospital ization ▁; ED ▁visit ▁; ▁a OR ▁; ▁high - volu me ▁ED ▁cases ▁; ▁a OR
D-465	-0.8912131190299988	low-volume ED cases ; death ;hospitalization ;ED visit ; aOR ; high-volume ED cases ; aOR
P-465	-1.8618 -0.0443 -0.0284 -0.0692 -1.3921 -1.0089 -0.3019 -3.4870 -1.8846 -0.2506 -0.5901 -0.8631 -1.8955 -1.8786 -0.4049 -0.6071 -0.1487 -0.4054 -2.9648 -0.0504 -0.0817 -0.0433 -2.0251 -1.6595 -0.7064 -0.2613 -0.2860 -0.5265 -0.1179
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health buddy program ; all-cause mortality ; hazard ratio ; confidence interval ; inpatient ; admissions ; baseline
H-1625	-0.3707447052001953	▁Health ▁Budd y ▁Program ▁; ▁risk - ad just ed ▁all - ca use ▁mortal ity ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; CI ▁; ▁in patient ▁ad missions
D-1625	-0.3707447052001953	Health Buddy Program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; confidence interval ;CI ; inpatient admissions
P-1625	-3.1561 -0.1416 -0.0324 -0.8573 -0.2138 -2.7023 -0.0303 -0.0114 -0.0030 -0.0351 -0.1399 -0.0236 -0.0068 -0.1374 -0.0194 -0.4694 -0.2086 -0.0134 -0.0045 -0.0004 -0.3020 -0.1329 -0.1000 -0.0773 -0.0037 -0.2049 -0.2679 -0.5639 -0.8923 -0.0361 -0.1331 -0.1170 -1.4777 -0.0899
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted hazard ratios ; dash
H-691	-0.7668103575706482	▁multi vari able - ad just ed ▁hazard ▁ratio s ▁; ▁
D-691	-0.7668103575706482	multivariable-adjusted hazard ratios ;
P-691	-0.4138 -0.0498 -0.1662 -0.1041 -0.0148 -0.0091 -0.0613 -0.4467 -0.0273 -0.1166 -0.2059 -3.7620 -4.5908
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt ; nt-probnp ; report ; aric ; hf ; systolic blood pressure ; antihypertensive medication ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hf ; area under the receiver operating characteristic curve ; auc ; integrated discrimination improvement ; net reclassification improvement ; nri
H-287	-0.20984332263469696	▁c t n t ▁; ▁NT - pro b NP ▁; labora tory ▁report ▁; ▁a RIC ▁ HF ▁model ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁anti hy per tensi ve ▁medication ▁use ▁; ▁smoking ▁; ▁diabetes ▁; ▁body ▁mass ▁index ▁; ▁corona ry ▁heart ▁disease ▁; ▁heart ▁rate ▁; ▁receive r ▁operating ▁character istic ▁cur ve ▁; AU C ▁; ▁discrimina tion ▁improvement ▁; ▁net ▁re class ification ▁improvement ▁; ▁n RI
D-287	-0.20984332263469696	ctnt ; NT-probNP ;laboratory report ; aRIC HF model ; systolic blood pressure ; antihypertensive medication use ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; receiver operating characteristic curve ;AUC ; discrimination improvement ; net reclassification improvement ; nRI
P-287	-0.0218 -0.0457 -0.0637 -0.1514 -0.0419 -0.0277 -0.0149 -0.0088 -0.3524 -0.2651 -0.1706 -1.2553 -0.0104 -0.0071 -0.2704 -0.2331 -0.4040 -0.6373 -0.3852 -1.2553 -0.0298 -0.0524 -0.0254 -0.0383 -0.0589 -0.1340 -0.0774 -0.0109 -0.4121 -0.0313 -0.0192 -0.0043 -0.0191 -1.1797 -0.0382 -0.1888 -0.0417 -0.0291 -0.0349 -0.0825 -0.0450 -0.0028 -0.0254 -0.0426 -0.1262 -0.0912 -0.2274 -0.0451 -0.2725 -0.1960 -0.1527 -1.4642 -0.0036 -0.0578 -0.0347 -0.0106 -0.1535 -0.0168 -0.1286 -0.3703 -2.0051 -0.0326 -0.2177 -0.0924 -0.2779 -0.0647 -0.0019 -0.0094 -0.0185 -0.0953 -0.6215 -0.1938 -0.3531 -0.0666 -0.2519 -0.0486
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; patients ; heart failure and reduced ejection fraction ; hf-ref ; new york heart association ; nyha ; functional class ; estimated glomerular filtration rate ; egfr ; serum potassium
H-1222	-0.29051321744918823	▁e pler en one ▁; ▁hyper kal emia ▁; ▁worse ning ▁renal ▁function ▁; ▁w RF ▁; ▁EM PHA SIS - HF ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF - re f ▁; ▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e ▁g FR ▁; ▁se rum ▁po tas s ium
D-1222	-0.29051321744918823	eplerenone ; hyperkalemia ; worsening renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart association ;NYHA ; glomerular filtration rate ; e gFR ; serum potassium
P-1222	-0.2254 -0.1026 -0.1184 -0.6459 -0.0948 -0.1727 -0.1533 -0.0239 -0.0430 -0.5452 -0.0385 -0.0082 -0.0335 -0.1150 -0.3973 -0.1816 -0.1056 -0.7295 -0.0263 -0.3457 -0.0126 -0.0931 -0.0498 -1.9624 -0.1001 -0.0425 -0.1645 -0.0049 -0.0036 -0.0753 -0.0070 -0.1349 -0.0026 -0.0644 -2.4908 -0.0257 -0.6846 -0.9563 -0.0204 -0.9336 -0.0788 -0.3942 -0.9599 -0.0676 -0.1515 -0.5538 -0.1286 -0.0065 -0.1217 -0.0343 -0.0508 -0.1037 -0.1808 -0.1429 -0.1047 -2.0288 -0.2073 -0.3986 -0.1248 -0.0962 -0.3993 -0.3094 -0.1549 -0.1421 -0.2248 -0.0729
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide ; nesiritide ; placebo ; change ; cystatin c ; nesiritide ; placebo
H-81	-1.045431137084961	▁low - dos e ▁nesi riti de ▁; ▁cum ul ative ▁urin e ▁volume ▁; nesi riti de ▁; ▁m L ▁; ▁place bo ▁; ▁cyst atin ▁c ▁level ▁; nesi riti de
D-81	-1.045431137084961	low-dose nesiritide ; cumulative urine volume ;nesiritide ; mL ; placebo ; cystatin c level ;nesiritide
P-81	-4.6078 -0.0854 -0.7896 -0.2291 -0.8631 -0.0250 -0.2130 -0.2717 -2.0176 -0.0149 -0.0202 -1.0471 -0.2079 -0.0546 -0.1761 -1.2846 -0.0826 -0.3475 -0.3888 -8.1848 -1.4843 -0.0560 -3.4406 -0.0128 -0.2831 -0.5010 -0.1010 -1.7498 -0.0776 -0.1141 -2.8366 -0.0910 -0.2429 -4.5293 -0.1587
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking ; functional capacity ; 6mwt ; physical ; activity ; symptoms ; hospital anxiety and depression scale
H-572	-0.9198603630065918	▁Nordic ▁walking ▁; ▁functional ▁capacity ▁; ▁kw t ▁; ▁self - report ed ▁physical ▁activity ▁; ▁right ▁grip ▁strength ▁; ▁ depressiv e ▁symptoms ▁; Hospital ▁an xie ty ▁and ▁de pression ▁Scal e ▁score
D-572	-0.9198603630065918	Nordic walking ; functional capacity ; kwt ; self-reported physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety and depression Scale score
P-572	-2.2702 -1.2230 -0.1254 -0.0744 -0.1644 -0.1344 -6.4430 -0.0707 -0.0594 -3.1908 -0.0343 -0.0162 -0.0235 -0.1833 -0.1746 -0.2309 -6.3303 -0.4150 -1.3198 -0.2302 -3.6924 -0.3768 -0.0903 -1.1044 -0.2851 -0.5860 -0.9827 -0.0377 -0.0840 -1.6800 -0.1361 -0.1834 -0.4215 -0.0105 -0.4694 -1.0501 -0.1307
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients ; hyperkalemia ; patients ; diabetes ; egfr ; systolic blood pressure ; potassium ; hyperkalemia ; leading ; hospitalization ; hospitalization ; primary outcome ; hospitalization ; hf ; cardiovascular mortality
H-1225	-0.6266365647315979	▁hyper kal emia ▁; ▁w RF ▁; ▁diabetes ▁; ▁e G FR ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁h g ▁; po tas s ium ▁; ▁hyper kal emia ▁; ▁w r ▁; ▁cardiovascular ▁mortal ity
D-1225	-0.6266365647315979	hyperkalemia ; wRF ; diabetes ; eGFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; wr ; cardiovascular mortality
P-1225	-1.0551 -0.1749 -0.1063 -0.0516 -0.0853 -0.7207 -0.1070 -0.1187 -0.0525 -0.0260 -1.7303 -0.0483 -0.0509 -0.1756 -0.0319 -0.0480 -0.1481 -0.2670 -0.1453 -5.1960 -0.1375 -0.1848 -2.6864 -0.1397 -0.0706 -0.1627 -0.0688 -3.3699 -0.2577 -0.0972 -0.2633 -1.9434 -2.2927 -0.7182 -1.1859 -0.0207 -0.3380 -0.0911 -0.0707
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf ; biosynthetic enzymes ; lyso-paf acetyltransferase ; lyso-paf-at ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; paf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-ah ; lipoprotein-associated phospholipase a2 ; lp-pla2 ; leukocytes
H-1268	-0.4708564281463623	▁PA F ▁; ▁bio syn the tic ▁enzym es ▁; lys o - pa f ▁a ce tyl transfer ase ▁; lys o - pa f - at ▁; ▁di thi oth rei tol ▁; ▁d t ▁; ▁cd p ▁; ▁cho line ▁; ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁; ▁cho line phos pho transfer ase ▁; ▁p f - c pt ▁; ▁cata bo lic ▁iso en zy mes ▁; ▁pa f - ace tyl hydro lase ▁; ▁p f - AH ▁; ▁lipo prote in - as soci ated ▁ phos pho lipa se ▁A 2 ▁; ▁l p - PLA 2]
D-1268	-0.4708564281463623	PAF ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-at ; dithiothreitol ; dt ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase A2 ; lp-PLA2]
P-1268	-1.2529 -1.3521 -0.2472 -0.0142 -0.0251 -0.6895 -1.2938 -0.0373 -0.0605 -0.1369 -0.0984 -0.0482 -0.0489 -0.5115 -1.6026 -0.2598 -1.8234 -0.9620 -0.0409 -1.3719 -0.1277 -0.2075 -0.0279 -0.0342 -0.2029 -1.4244 -0.5993 -1.0077 -0.1284 -0.1654 -0.1274 -0.6261 -0.0574 -0.5406 -0.0986 -1.6071 -1.1264 -0.5691 -0.9652 -0.3579 -0.6038 -1.6899 -0.0373 -2.0460 -0.9353 -0.0448 -0.1277 -0.2733 -0.0831 -0.6077 -0.1080 -0.0363 -0.0512 -0.0062 -0.0349 -0.0690 -0.0310 -0.0991 -1.2128 -0.9417 -0.0405 -0.3604 -0.5088 -0.4005 -0.8850 -0.1201 -1.1003 -2.0708 -0.0428 -1.1497 -1.3268 -0.1518 -0.0844 -0.0134 -0.0059 -0.0040 -0.0959 -0.0946 -0.6505 -0.1079 -2.6468 -1.1948 -0.0327 -0.1381 -0.1848 -0.0498 -0.1813 -0.1074 -1.6979 -1.8364 -0.0322 -0.1651 -0.0525 -0.0078 -0.0627 -0.1416 -0.0585 -0.0217 -0.0003 -0.2605 -0.1244 -0.0806 -0.0616 -0.1078 -0.4605 -1.8738 -0.0232 -0.2808 -0.0394 -0.0126 -0.0452 -0.0028 -1.2797 -0.6576 -0.0939
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine ; baseline ; follow-up ; exercise capacity ; mets ; mets ; peak oxygen uptake ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1175	-0.7414543628692627	▁i va bra dine ▁group ▁; ▁follow - up ▁exercise ▁capacity ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁early ▁dia sto lic ▁mit ral
D-1175	-0.7414543628692627	ivabradine group ; follow-up exercise capacity ; peak oxygen uptake ; early diastolic mitral flow velocity ; early diastolic mitral
P-1175	-0.0066 -0.0178 -0.1390 -0.0400 -1.2566 -0.1656 -0.5314 -0.0365 -0.0043 -0.7151 -0.3681 -0.1461 -4.1959 -0.0052 -0.7043 -1.4096 -0.0916 -0.1966 -5.2674 -0.0131 -0.1259 -0.0317 -0.3866 -0.0914 -1.7233 -0.6042 -0.0409 -0.2697 -1.1246 -0.0191 -0.1265 -0.0622 -0.3073 -0.0852 -6.2978 -0.0851
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate analysis ; chf ; odds ratio ; chest ; hypertension ; genes ; rac2 ; doxorubicin efflux transporter ; abcc2
H-1455	-0.816650390625	▁CHF ▁; ▁o ds ▁Ra tio ▁; ▁o ds ▁Ra tio ▁; ▁h CT ▁che st ▁radi ation ▁; ▁hyper tension ▁; ▁r 130 58 338 ▁; ▁gene s ▁co ding ▁; ▁ NAD ( p h - oxid ase ▁sub un it ▁ RAC 2 ▁; ▁h bf ▁; ▁do xor ubi cin ▁ eff lux ▁transporter ▁ABC c
D-1455	-0.816650390625	CHF ; ods Ratio ; ods Ratio ; hCT chest radiation ; hypertension ; r13058338 ; genes coding ; NAD(ph-oxidase subunit RAC2 ; hbf ; doxorubicin efflux transporter ABCc
P-1455	-0.8583 -0.2286 -1.8782 -0.0350 -0.8483 -0.1274 -0.1149 -1.7604 -2.3659 -2.6053 -0.3001 -0.0756 -3.9386 -2.4821 -0.6562 -0.0411 -0.0378 -0.2255 -0.0687 -0.1774 -0.0253 -0.1630 -2.8705 -2.2824 -0.7070 -0.7007 -0.0748 -3.1825 -0.0329 -0.0146 -0.0589 -0.2108 -0.5375 -0.0032 -2.5250 -1.8781 -2.8119 -0.3156 -0.0123 -1.6780 -0.0243 -0.0446 -0.0544 -0.4948 -0.0701 -0.1720 -0.0454 -2.6131 -2.1513 -0.0621 -1.2747 -0.0199 -0.0074 -0.1229 -0.2250 -0.0224 -0.0494 -0.0254 -0.5368 -1.5028 -2.0808 -0.1225
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline ; follow-up ; nyha classification ; patients ; patient ; change ; patient ; quality of life ; duke activity status index ; kansas city cardiomyopathy questionnaire ; 6 min walk test
H-1958	-0.7781451940536499	▁NY ha ▁classifica tion ▁; ▁class ▁III ▁; ▁class ▁III ▁; ▁class ▁I ▁; ▁patient ▁; ▁quality ▁of ▁life ▁; ▁Duke ▁Activ ity ▁Status ▁index ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁walk ▁test ▁distance ▁; SD
D-1958	-0.7781451940536499	NYha classification ; class III ; class III ; class I ; patient ; quality of life ; Duke Activity Status index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance ;SD
P-1958	-1.3043 -0.8161 -0.3260 -0.1616 -0.1149 -0.9497 -1.2931 -0.5674 -0.3346 -2.7692 -0.3793 -0.9788 -0.6416 -0.1659 -2.8053 -0.1290 -1.4016 -0.2694 -0.5101 -0.1312 -0.0665 -0.4090 -0.1475 -0.9892 -0.8205 -0.0946 -1.4558 -0.5436 -1.2367 -0.0501 -0.0511 -1.1742 -0.1987 -0.5042 -0.0104 -0.5442 -3.6603 -0.1803 -0.7772 -0.6437 -2.9024 -0.8024 -0.1486
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo ; dopamine ; dopamine ; placebo ; change ; cystatin c ; dopamine ; placebo
H-80	-0.9656221270561218	▁low - dos e ▁dop amine ▁; ▁cum ul ative ▁urin e ▁volume ▁; dop amine
D-80	-0.9656221270561218	low-dose dopamine ; cumulative urine volume ;dopamine
P-80	-3.7813 -0.0533 -0.5332 -0.2351 -0.3083 -0.1018 -0.1804 -1.9486 -0.0184 -0.0211 -1.0709 -0.1995 -0.0553 -0.1258 -1.5773 -0.0804 -6.9090 -0.1816
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard ratio ; confidence interval ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; new york heart association class ; atrial fibrillation ; congestive hf ; mortality
H-66	-0.6892285943031311	▁ha ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁ci ▁; ▁base line ▁glo mer ular ▁filtr ation ▁rate ▁; HR ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; HR ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁h ▁; ▁in appropria te ▁i CD ▁shock s ▁; ▁New ▁York ▁Heart ▁association ▁; ▁at rial ▁fi bril lation ▁; ▁con ges tive ▁ HF
D-66	-0.6892285943031311	haard ratio ;HR ; confidence interval ; ci ; baseline glomerular filtration rate ;HR ; chronic obstructive pulmonary disease ; diabetes ;HR ; peripheral vascular disease ; left ventricular ejection fraction ; h ; inappropriate iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF
P-66	-3.4848 -0.0263 -0.0092 -0.0560 -1.8801 -0.0711 -2.4950 -0.0119 -0.0692 -0.8316 -0.7359 -0.4068 -0.0166 -0.2844 -0.1519 -0.0417 -0.0866 -0.1153 -0.5940 -0.1315 -1.9762 -0.2750 -6.8535 -0.3609 -0.0514 -0.0654 -0.0022 -0.1201 -0.3577 -0.0872 -0.5037 -0.0917 -4.5631 -0.2613 -2.6647 -0.0358 -0.1221 -0.0369 -0.2007 -0.2030 -0.2250 -0.1204 -2.7237 -0.0211 -0.6901 -0.3098 -0.0521 -0.0618 -0.0230 -0.3611 -0.0058 -0.1814 -5.4445 -0.3842 -2.8493 -0.0040 -0.0179 -1.1844 -0.5217 -0.0118 -0.0247 -0.1033 -4.4390 -0.1629 -0.6791 -0.7579 -1.6136 -0.2564 -0.0591 -0.0508 -0.0144 -0.0684 -0.0686 -0.0147 -0.0529 -0.3886 -0.0870 -0.0463 -0.6225 -0.1027
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable analysis ; end point ; peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
H-1761	-0.7239950299263	▁pe ak ▁oxygen ▁up take ▁; ▁hazard ▁ratio ▁; ▁h ▁; ▁confidence ▁interval ▁; ▁ci ▁; ▁ventilator y ▁efficiency ▁s lope ▁; ▁HR ▁; ▁hem o glob in ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁HR =0 0.9 48 ▁; ▁renal ▁function ▁; ▁renal ▁disease ▁; ▁so dium
D-1761	-0.7239950299263	peak oxygen uptake ; hazard ratio ; h ; confidence interval ; ci ; ventilatory efficiency slope ; HR ; hemoglobin ; left ventricular ejection fraction ; HR=00.948 ; renal function ; renal disease ; sodium
P-1761	-2.2423 -0.0065 -0.3068 -1.9223 -0.1168 -0.0606 -0.1525 -0.0037 -0.0340 -4.0205 -0.4929 -0.0692 -0.0098 -0.0396 -1.1120 -1.0959 -0.3033 -0.0644 -0.0384 -0.0850 -0.0266 -0.0484 -4.9264 -1.0031 -0.5993 -0.1277 -0.1458 -0.4872 -0.1172 -3.3698 -0.0161 -0.8369 -0.4610 -0.0751 -0.0520 -0.0261 -0.4619 -0.0103 -0.1059 -3.2783 -2.3604 -1.2740 -1.0469 -0.0300 -0.0655 -0.7775 -0.0971 -0.3449 -0.8867 -0.1233 -0.0796 -0.1354 -3.3955 -0.1274
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute walked distance ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; beck depression inventory ; flow-mediated dilatation ; fes ; placebo ; b-type natriuretic peptide ; mitral
H-1331	-0.4232277572154999	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁summary ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁z ung ▁; ▁flow - media ted ▁di la tation ▁diameter ▁; ▁f es ▁group ▁; ▁na tri ure tic ▁pe pti de
D-1331	-0.4232277572154999	Kansas City Cardiomyopathy Questionnaire summary ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes group ; natriuretic peptide
P-1331	-1.1645 -0.7048 -1.5454 -0.0291 -0.0441 -0.6646 -0.1326 -0.9849 -0.0046 -1.0087 -0.0548 -0.3871 -0.1501 -0.2866 -0.2132 -0.0712 -0.4265 -0.1515 -0.0119 -0.1217 -0.1819 -0.2437 -0.0309 -0.3827 -0.0895 -0.0306 -0.0972 -0.6645 -0.7268 -0.1794 -0.1632 -0.0190 -0.0745 -0.1306 -0.0341 -0.0849 -0.0098 -0.0071 -0.1038 -1.4563 -1.3383 -1.6089 -0.0895 -0.8219 -0.0910 -0.5575 -0.8229 -0.8156 -0.0334 -0.1183 -2.7440 -0.0981
2021-01-18 17:56:12 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-18 17:56:12 | INFO | fairseq_cli.generate | Translated 2,024 sentences (38,552 tokens) in 188.3s (10.75 sentences/s, 204.77 tokens/s)
2021-01-18 17:56:12 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 47.62, 66.5/52.5/43.8/36.7 (BP=0.979, ratio=0.979, syslen=38552, reflen=39387)
